FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Bohnert, KM Sripada, RK Mach, J McCarthy, JF AF Bohnert, Kipling M. Sripada, Rebecca K. Mach, Jennifer McCarthy, John F. TI Same-Day Integrated Mental Health Care and PTSD Diagnosis and Treatment Among VHA Primary Care Patients With Positive PTSD Screens SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COLLABORATIVE CARE; RANDOMIZED-TRIAL; MEDICAL HOME; DEPRESSION; VETERANS; SERVICES; INITIATION; OUTCOMES; ACCESS AB Objective: The study examined whether same-day integrated mental health services are associated with increased diagnosis and treatment initiation among primary care patients with positive posttraumatic stress disorder (PTSD) screens. Methods: Data were from a national sample of Veterans Health Administration (VHA) primary care patients with a positive PTSD screen (N=21,427). Patients were assessed for PTSD diagnosis and treatment initiation on the screening day and <= 7 days, <= 12 weeks, <= 6 months, and <= 1 year after screening positive. The service setting on screening day was categorized as primary care only, same-day primary care-mental health integration (PC-MHI), or same-day specialty mental health care. Multivariable generalized estimating equations logistic regression was used to estimate associations between category of screening day services and diagnosis and treatment initiation, with adjustment for demographic characteristics, prior psychiatric diagnoses, prior VHA service utilization, and PTSD screen score. Results: Of the 21,427 patients with positive PTSD screens, 10,809 (50.4%) received a diagnosis within one year of screening positive. Same-day PC-MHI services were associated with greater odds of PTSD diagnosis, both on the same day as (odds ratio [OR]= 2.23) and one year (OR=1.67) after screening positive compared with primary care-only services (p<.001). Among those who received a diagnosis on the same day as their positive screen, same-day PC-MHI services were associated with increased odds of initiating PTSD treatment (OR=3.39) within 12 weeks of diagnosis, compared with primary care only (p<.001). Conclusions: Same-day integrated mental health services may help facilitate PTSD diagnosis and treatment initiation after a positive screen. C1 [Bohnert, Kipling M.; Sripada, Rebecca K.] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Bohnert, Kipling M.; Sripada, Rebecca K.; Mach, Jennifer; McCarthy, John F.] US Dept Vet Affairs, SMITREC, Ann Arbor, MI 48105 USA. [Bohnert, Kipling M.; Sripada, Rebecca K.; McCarthy, John F.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Bohnert, KM (reprint author), US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI 48105 USA.; Bohnert, KM (reprint author), US Dept Vet Affairs, SMITREC, Ann Arbor, MI 48105 USA.; Bohnert, KM (reprint author), Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. EM kiplingb@med.umich.edu OI Sripada, Rebecca/0000-0002-2844-3458 FU VA Health Services Research & Development Career Development Award [CDA 11-245]; SMITREC Advanced Fellowship Program in Mental Illness Research and Treatment from the VA Office of Academic Affiliations FX Study analyses were conducted as part of the VA National Primary Care-Mental Health Integration Evaluation (Dr. Mach and Dr. McCarthy). Dr. Bohnert is supported by a VA Health Services Research & Development Career Development Award (CDA 11-245). Dr. Sripada is supported by the SMITREC Advanced Fellowship Program in Mental Illness Research and Treatment from the VA Office of Academic Affiliations. NR 28 TC 1 Z9 1 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2016 VL 67 IS 1 BP 94 EP 100 DI 10.1176/appi.ps.201500035 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DO4SX UT WOS:000377775000016 PM 26423103 ER PT J AU Cunningham, KF Beeson, GC Beeson, CC McDermott, PJ AF Cunningham, Kathryn F. Beeson, Gyda C. Beeson, Craig C. McDermott, Paul J. TI Increased expression of estrogen-related receptor beta during adaptation of adult cardiomyocytes to sustained hypoxia SO AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE LA English DT Article DE Cardiomyocyte; hypoxia; estrogen-related receptor; estrogen-related receptor beta; peroxisome proliferator-activated receptor gamma coactivator-1 ID ELECTRICALLY STIMULATED CONTRACTION; PROMOTES CARDIAC MITOCHONDRIAL; ACID-BINDING PROTEIN; ERR-ALPHA; GENE-EXPRESSION; TRANSCRIPTIONAL NETWORK; PGC-1 COACTIVATORS; FELINE CARDIOCYTES; GAMMA; HEART AB Estrogen-related Receptors (ERR) are members of the steroid hormone receptor superfamily of transcription factors that regulate expression of genes required for energy metabolism including mitochondrial biogenesis, fatty acid oxidation and oxidative phosphorylation. While ERR alpha and EPP gamma isoforms are known to share a wide array of target genes in the adult myocardium, the function of ERR beta has not been characterized in cardiomyocytes. The purpose of this study was to determine the role of ERR beta in regulating energy metabolism in adult cardiomyocytes in primary culture. Adult feline cardiomyocytes were electrically stimulated to contract in either hypoxia (0.5% O-2) or normoxia (21% O-2). As compared to baseline values measured in normoxia, ERR beta mRNA levels increased significantly after 8 hours of hypoxia and remained elevated over 24 h. Conversely, ERR beta mRNA decreased to normoxic levels after 4 hours of reoxygenation. Hypoxia increased expression of the alpha and beta isoforms of Peroxisome Proliferator-Activated Receptor. Coactivator-1 (PGC-1) mRNA by 6-fold and 3-fold, respectively. Knockdown of ERR beta expression via adenoviral-mediated delivery of ERR beta shRNA blocked hypoxia-induced increases in PGC-1 beta mRNA, but not PGC-1 alpha mRNA. Loss of ERR beta had no effect on mtDNA content as measured after 24 h of hypoxia. To determine whether loss of ERR beta affected mitochondrial function, oxygen consumption rates (OCR) were measured in contracting versus quiescent cardiomyocytes in normoxia. OCR was significantly lower in contracting cardiomyocytes expressing ERR beta shRNA than scrambled shRNA controls. Maximal OCR also was reduced by ERR beta knockdown. In conclusion: 1) hypoxia increases in ERR beta mRNA expression in contracting cardiomyocytes; 2) ERR beta is required for induction of the PGC-1 beta isoform in response to hypoxia; 3) ERR beta expression is required to sustain OCR in normoxic conditions. C1 [Cunningham, Kathryn F.; McDermott, Paul J.] Med Univ S Carolina, Dept Med, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. [Beeson, Gyda C.; Beeson, Craig C.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [McDermott, Paul J.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP McDermott, PJ (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, 301 Strom Thurmond Bldg,114 Doughty St,MSC 773, Charleston, SC 29425 USA. EM mcdermp@musc.edu FU NHLBI NIH HHS [T32 HL007260] NR 41 TC 0 Z9 0 U1 0 U2 0 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 2160-200X J9 AM J CARDIOVASC DIS JI Am. J. Cardiovasc. Dis. PY 2016 VL 6 IS 2 BP 46 EP 54 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DO3JQ UT WOS:000377678300004 PM 27335690 ER PT J AU Gallagher, RM AF Gallagher, Rollin M. TI Pain Medicine and Oxford University Press: Building a Scholarly Pain Community Together SO PAIN MEDICINE LA English DT Editorial Material C1 [Gallagher, Rollin M.] Univ Penn, Philadelphia VA Med Ctr, Pain Med, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Philadelphia VA Med Ctr, Pain Med, Philadelphia, PA 19104 USA. EM rgallagher@mail.med.upenn.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JAN PY 2016 VL 17 IS 1 BP 1 EP 2 DI 10.1093/pm/pnv049 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DI8DD UT WOS:000373730500001 PM 26768182 ER PT J AU DiNapoli, EA Craine, M Dougherty, P Gentili, A Kochersberger, G Morone, NE Murphy, JL Rodakowski, J Rodriguez, E Thielke, S Weiner, DK AF DiNapoli, Elizabeth A. Craine, Michael Dougherty, Paul Gentili, Angela Kochersberger, Gary Morone, Natalia E. Murphy, Jennifer L. Rodakowski, Juleen Rodriguez, Eric Thielke, Stephen Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult - Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment. Part V: Maladaptive Coping SO PAIN MEDICINE LA English DT Review DE Aged; Assessment; Maladaptive Coping; Chronic Pain; Elderly; Low Back Pain; Primary Care; Chronic Low Back Pain ID FEAR-AVOIDANCE BELIEFS; BEHAVIORAL TREATMENT; PERSISTENT PAIN; DISABILITY; DEPRESSION; STRATEGIES; IMPACT; EXPERIENCE; MANAGEMENT; DEMENTIA AB Objective. As part of a series of articles designed to deconstruct chronic low back pain (CLBP) in older adults, this article focuses on maladaptive copinga significant contributor of psychological distress, increased pain, and heightened disability in older adults with CLBP. Methods. A modified Delphi technique was used to develop a maladaptive coping algorithm and table providing the rationale for the various components of the algorithm. A seven-member content expert panel and a nine-member primary care panel were involved in the iterative development of the materials. While the algorithm was developed keeping in mind resources available within the Veterans Health Administration (VHA) facilities, panelists were not exclusive to the VHA, and therefore, materials can be applied in both VHA and civilian settings. The illustrative clinical case was taken from one of the contributors' clinical practice. Results. We present a treatment algorithm and supporting table to be used by providers treating older adults who have CLBP and engage in maladaptive coping strategies. A case of an older adult with CLBP and maladaptive coping is provided to illustrate the approach to management. Conclusions. To promote early engagement in skill-focused treatments, providers can routinely evaluate pain coping strategies in older adults with CLBP using a treatment algorithm. C1 [DiNapoli, Elizabeth A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Craine, Michael] VA Eastern Colorado Healthcare Syst, Denver, CO USA. [Craine, Michael] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO 80202 USA. [Dougherty, Paul; Kochersberger, Gary] Canandaigua VA Med Ctr, Canandaigua, NY USA. [Dougherty, Paul] New York Chiropract Coll, Seneca Falls, NY USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [DiNapoli, Elizabeth A.; Kochersberger, Gary] Univ Rochester, Div Geriatr, Rochester, NY USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Murphy, Jennifer L.] James A Haley Vet Hosp, Tampa, FL USA. [Murphy, Jennifer L.] Univ S Florida, Tampa, FL USA. [Rodakowski, Juleen] Univ Pittsburgh, Dept Occupat Therapy, Pittsburgh, PA USA. [Rodriguez, Eric; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Thielke, Stephen] Puget Sound VA Med Ctr, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Thielke, Stephen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. RP Weiner, DK (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.; Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov OI Rodakowski, Juleen/0000-0002-6397-8124 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. NR 43 TC 2 Z9 2 U1 2 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JAN PY 2016 VL 17 IS 1 BP 64 EP 73 DI 10.1093/pm/pnv055 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DI8DD UT WOS:000373730500011 PM 26768183 ER PT J AU Miller, MB Borsari, B Fernandez, AC Yurasek, AM Hustad, JTP AF Miller, Mary Beth Borsari, Brian Fernandez, Anne C. Yurasek, Ali M. Hustad, John T. P. TI Drinking Location and Pregaming as Predictors of Alcohol Intoxication Among Mandated College Students SO SUBSTANCE USE & MISUSE LA English DT Article DE Alcohol; college students; drinking; location; pregaming ID DESCRIPTIVE NORMS; INJUNCTIVE NORMS; BINGE DRINKING; CONSUMPTION; PREVENTION; OUTCOMES; MISPERCEPTIONS; INTERVENTIONS; VALIDATION; BEHAVIOR AB Background: Both drinking location and pregaming have been associated with heavy alcohol use among college students, yet the manner by which they uniquely contribute to alcohol intoxication remains unclear. Objective: The current study examined the unique utility of drinking location and pregaming in predicting alcohol intoxication among college students who violated campus alcohol policy. Method: Eietween 2011 and 2012, mandated college students who reported drinking prior to heir referral events (N = 212, 41% female, 80% White, A4 =19.4 y) completed a computerized assessment of drinking location arid related behaviors as part of larger research trial Chi-squared statistics, tests, one-way analyses of covariance, and regression were used to examine study aims. Results: Parcipants were most likely (44%) to report drinking in off-campus housing prior to the referral event, and approximately half (47%) reported pregaming. Alcohol intoxication on the night of the referral event differed significantly as a function of both drinking location and pregaming, but pregaming did not moderate the association between drinking location arid alcohol intoxication among marl dated students. Female birth sex, pregaming, arid drinking at either fraternities or off-campus housng predicted greater levels of alcohol intoxication on the night of the referral incident, while drinking n a residence hall/dorm predicted lovver intoxication. Fonclusions/fmportance: Drinking location and pregaming are distinct predictors of alcohol intoxication among mandated college students. Future n e veritions may benefitfrom targeting both where arid how college students consume alcohol C1 [Miller, Mary Beth; Borsari, Brian; Fernandez, Anne C.; Yurasek, Ali M.] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Borsari, Brian] San Francisco VA Med Ctr, Mental Hlth & Behav Sci Serv, San Francisco, CA USA. [Hustad, John T. P.] Penn State Univ, Coll Med, Dept Med & Publ Hlth Sci, Hershey, PA USA. RP Miller, MB (reprint author), Brown Univ, Ctr Alcohol & Addict Studies, Dept Behav & Social Sci, Box G-S121-5, Providence, RI 02912 USA. EM mary_miller@brown.edu FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [R01-AA015518, 01-AA017874]; VISN1 Career Development Award [V1CDA2012-18]; National Institute on Drug Abuse (NIDA) [T32 DA016184]; National Center for Advancing Translational Sciences (NCATS); National Institutes of Health (NIH) [UL1 TR000127, KL2 TR000126] FX Brian Borsari's contribution to this manuscript was supported by National Institute on Alcohol Abuse and Alcoholism (NIAAA) Grants R01-AA015518 and 01-AA017874 and VISN1 Career Development Award V1CDA2012-18. Anne Fernandez's and Ali Yurasek's contributions to this manuscript were supported by the National Institute on Drug Abuse (NIDA) grant T32 DA016184. John Hustad's contribution was supported by the National Center for Advancing Translational Sciences (NCATS) and the National Institutes of Health (NIH) through Grants UL1 TR000127 and KL2 TR000126 to Lawrence Sinoway. The contents of this article do not represent the views of the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 39 TC 2 Z9 2 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1082-6084 EI 1532-2491 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2016 VL 51 IS 8 BP 983 EP 992 DI 10.3109/10826084.2016.1152496 PG 10 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA DN8AR UT WOS:000377301800004 PM 27070480 ER PT J AU Yurasek, A Miller, MB Mastroleo, N Lazar, V Borsari, B AF Yurasek, Ali Miller, Mary Beth Mastroleo, Nadine Lazar, Vanessa Borsari, Brian TI Pregaming, Drinking Duration, and Movement as Unique Predictors of Alcohol Use and Cognitions Among Mandated College Students SO SUBSTANCE USE & MISUSE LA English DT Article DE Pregaming; duration of drinking; movement; event-related cognitions; mandated college students; alcohol ID EVENT-LEVEL ASSOCIATIONS; RISK-FACTORS; CONSUMPTION; ADOLESCENTS; AGGRESSION; MOTIVATION; HEALTH; TRENDS; PARTY AB Background: Pregaming is a common phenomenon among college students and is associated with increased risks such as heavy drinking, alcohol-related consequences, and violating campus alcohol policies. However, the mechanism by which pregaming increases student risk is unclear. Objectives: The current study aimed to delineate, the role of personal endorsement of pregaming; duration of an entire drinking episode on the night of an alcohol violation, and movement from one ()cation to another in predicting alcohol use and violation-related cognitions. Methods: Participants (N = 113) were college students who had received an alcohol violation. Hierarchical multiple regressions were conducted to investigate the predictive value of pregaming endorsement, duration of drinking, and movement on drinking behaviors (number of drinks consumed and estimated blood alcohol content (eBAC)] on the night of the alcohol violation as well as violation-related cognitions (responsibility, aversiveness). Results: Pregaming and duration of drinking were significant predictors of alcohol consumption and eBAC on the night of the violation, whereas movement was not, Duration of the drinking episode was significantly related to increased perceived responsibility for the alcohol violation. Conclusions/importance: Self-reported pregaming and the duration of the drinking episode appear to be better targets than movement for prevention and intervention efforts addressing pregaming on college campuses. Interventions should continue focusing on reducing pregaming and its associated consequences, especially for those who report a longer duration of drinking following a pregaming episode C1 [Yurasek, Ali; Miller, Mary Beth; Lazar, Vanessa] Brown Univ, Sch Publ Hlth, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Mastroleo, Nadine] Binghamton Univ, Community & Publ Affairs Dept, Binghamton, NY USA. [Borsari, Brian] San Francisco VA Med Ctr, Mental Hlth & Behav Sci Serv, San Francisco, CA USA. [Borsari, Brian] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Yurasek, A (reprint author), Brown Univ, Dept Publ Hlth, Ctr Alcohol & Addict Studies, 121 South Main St, Providence, RI 02906 USA. EM ali_yurasek@brown.edu FU National Institute on Alcohol Abuse and Alcoholism [R01 AA015518] FX This work was supported by the National Institute on Alcohol Abuse and Alcoholism [Grant number R01 AA015518]. NR 37 TC 2 Z9 2 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1082-6084 EI 1532-2491 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2016 VL 51 IS 8 BP 993 EP 1001 DI 10.3109/10826084.2016.1152491 PG 9 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA DN8AR UT WOS:000377301800005 PM 27070369 ER PT J AU Silbert, LC Dodge, HH Lahna, D Promjunyakul, NO Austin, D Mattek, N Erten-Lyons, D Kaye, JA AF Silbert, Lisa C. Dodge, Hiroko H. Lahna, David Promjunyakul, Nutta-on Austin, Daniel Mattek, Nora Erten-Lyons, Deniz Kaye, Jeffrey A. TI Less Daily Computer Use is Related to Smaller Hippocampal Volumes in Cognitively Intact Elderly SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; assessment of cognitive disorders/dementia; cognitive aging; MRI; volumetric MRI ID ALZHEIMERS-DISEASE; IMPAIRMENT AB Background: Computer use is becoming a common activity in the daily life of older individuals and declines over time in those with mild cognitive impairment (MCI). The relationship between daily computer use (DCU) and imaging markers of neurodegeneration is unknown. Objective: The objective of this study was to examine the relationship between average DCU and volumetric markers of neurodegeneration on brain MRI. Methods: Cognitively intact volunteers enrolled in the Intelligent Systems for Assessing Aging Change study underwent MRI. Total in-home computer use per day was calculated using mouse movement detection and averaged over a one-month period surrounding the MRI. Spearman's rank order correlation (univariate analysis) and linear regression models (multivariate analysis) examined hippocampal, gray matter (GM), white matter hyperintensity (WMH), and ventricular cerebral spinal fluid (vCSF) volumes in relation to DCU. A voxel-based morphometry analysis identified relationships between regional GM density and DCU. Results: Twenty-seven cognitively intact participants used their computer for 51.3 minutes per day on average. Less DCU was associated with smaller hippocampal volumes (r= 0.48, p = 0.01), but not total GM, WMH, or vCSF volumes. After adjusting for age, education, and gender, less DCU remained associated with smaller hippocampal volume (p = 0.01). Voxel-wise analysis demonstrated that less daily computer use was associated with decreased GM density in the bilateral hippocampi and temporal lobes. Conclusions: Less daily computer use is associated with smaller brain volume in regions that are integral to memory function and known to be involved early with Alzheimer's pathology and conversion to dementia. Continuous monitoring of daily computer use may detect signs of preclinical neurodegeneration in older individuals at risk for dementia. C1 [Silbert, Lisa C.; Dodge, Hiroko H.; Lahna, David; Promjunyakul, Nutta-on; Austin, Daniel; Mattek, Nora; Erten-Lyons, Deniz; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, NIA Layton Aging & Alzheimers Dis Ctr, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Dodge, Hiroko H.; Austin, Daniel; Mattek, Nora; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, NIA Oregon Ctr Aging & Technol ORCATECH, Portland, OR 97239 USA. [Dodge, Hiroko H.] Univ Michigan, Dept Neurol, Michigan Alzheimers Dis Ctr, Ann Arbor, MI USA. [Silbert, Lisa C.; Erten-Lyons, Deniz; Kaye, Jeffrey A.] Portland VA Med Ctr, Portland, OR USA. RP Silbert, LC (reprint author), Oregon Hlth & Sci Univ, NIA Layton Aging & Alzheimers Dis Ctr, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM silbertl@ohsu.edu FU NIH [1RO1AG036772, P30 AG008017, P30 AG024978, RO1 AG024059, R01 AG042191] FX This study was sponsored by the NIH (1RO1AG036772, P30 AG008017, P30 AG024978; RO1 AG024059; R01 AG042191). NR 16 TC 2 Z9 2 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 52 IS 2 BP 713 EP 717 DI 10.3233/JAD-160079 PG 5 WC Neurosciences SC Neurosciences & Neurology GA DN1PU UT WOS:000376838700027 PM 26967228 ER PT J AU McAllister, T Zafonte, R Jain, S Flashman, L George, M Grant, G He, F Lohr, J Andaluz, N Summerall, L Paulus, M Raman, R Stein, M AF McAllister, Thomas Zafonte, Ross Jain, Sonia Flashman, Laura George, Mark Grant, Gerald He, Feng Lohr, James Andaluz, Norberto Summerall, Lanier Paulus, Martin Raman, Rema Stein, Murray TI Randomized placebo-controlled trial of methylphenidate or galantamine for persistent emotional and cognitive symptoms associated with TBI and PTSD SO BRAIN INJURY LA English DT Meeting Abstract C1 [McAllister, Thomas] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Zafonte, Ross] Spaulding Rehabil Hosp, Boston, MA USA. [Jain, Sonia; He, Feng; Lohr, James; Raman, Rema; Stein, Murray] Univ Calif San Diego, San Diego, CA 92103 USA. [Flashman, Laura] Geisel Sch Med Dartmouth, Lebanon, NH USA. [George, Mark; Summerall, Lanier] Ralph H Johnson VAMC, Charleston, SC USA. [Grant, Gerald] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Andaluz, Norberto] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Paulus, Martin] Laureate Inst Brain Res, Tulsa, OK USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0306 BP 594 EP 595 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200260 ER PT J AU Pape, T Rosenow, J Herrold, A Harton, B Patil, V Guernon, A AF Pape, Therea Rosenow, Joshua Herrold, Amy Harton, Brett Patil, Vijaya Guernon, Ann TI Neurobiological model for use of rTMS plus amantadine as a treatment to modulate and shape neural repair for persons in states of disordered consciousness SO BRAIN INJURY LA English DT Meeting Abstract C1 [Pape, Therea; Herrold, Amy; Harton, Brett] US Dept Vet Affairs, Hines, VA USA. [Pape, Therea; Rosenow, Joshua; Herrold, Amy; Harton, Brett] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Patil, Vijaya] Hines VA & Loyola Stritch Sch Med, Hines, IL USA. [Guernon, Ann] Hines VA & Marianjoy Rehabil Hosp, Hines, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0357 BP 615 EP 616 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200308 ER PT J AU Pape, T Harton, B Bhaumik, D Guernon, A Mallinson, T AF Pape, Theresa Harton, Brett Bhaumik, Dulal Guernon, Ann Mallinson, Trudy TI Functional connectivity of networks supporting arousal and awareness: VS versus MCS and clinically meaningful gain from VS and MCS SO BRAIN INJURY LA English DT Meeting Abstract C1 [Pape, Theresa] US Dept Vet Affairs, Hines, VA USA. [Pape, Theresa] Northwestern Univ, Feinberg Sch Med, Hines, IL USA. [Harton, Brett; Bhaumik, Dulal; Guernon, Ann] Hines VA, Hines, IL USA. [Bhaumik, Dulal] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Guernon, Ann] Marianjoy Rehabil Hosp, Hines, IL USA. [Mallinson, Trudy] George Washington Univ, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0380 BP 625 EP 626 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200331 ER PT J AU McAllister, T Temkin, N Dikmen, S Flashman, L Pagulayan, K Cissell, S Duncan, C Thomas, E Grant, G Summerall, L Stein, M AF McAllister, Thomas Temkin, Nancy Dikmen, Sureyya Flashman, Laura Pagulayan, Kathleen Cissell, Shadha Duncan, Connie Thomas, Elissa Grant, Gerald Summerall, Lanier Stein, Murray TI The structured assessment for evaluation of TBI (SAFE-TBI): A new instrument for assessing previous exposure to TBI SO BRAIN INJURY LA English DT Meeting Abstract C1 [McAllister, Thomas] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Temkin, Nancy; Dikmen, Sureyya; Pagulayan, Kathleen] Univ Washington, Sch Med, Seattle, WA USA. [Flashman, Laura] Geisel Sch Med Dartmouth, Dartmouth, NS, Lebanon. [Cissell, Shadha; Stein, Murray] Univ Calif San Diego, San Diego, CA 92103 USA. [Duncan, Connie] Uniform Serv Univ Hlth Sci, Bethesda, MD USA. [Thomas, Elissa] Madigan Army Med Ctr, Tacoma, WA 98431 USA. [Grant, Gerald] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Summerall, Lanier] Ralph Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0603 BP 714 EP 715 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200519 ER PT J AU Byoj, L Duff, M Turkstra, L AF Byoj, Lindsey Duff, Melissa Turkstra, Lyn TI Emotion recognition of older and younger adults with traumatic brain injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Byoj, Lindsey] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Duff, Melissa] Univ Iowa, Iowa City, IA USA. [Turkstra, Lyn] Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0624 BP 722 EP 723 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200537 ER PT J AU Strigo, I Simmons, A AF Strigo, Irina Simmons, Alan TI Avoiding pain: Compromised pain processing after combat trauma SO BRAIN INJURY LA English DT Meeting Abstract C1 [Strigo, Irina] San Francisco VA Med Ctr, San Francisco, CA USA. [Strigo, Irina] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Simmons, Alan] San Diego Vet Healthcare Syst, San Diego, CA USA. [Simmons, Alan] Univ Calif San Diego, San Diego, CA 92103 USA. RI strigo, irina/L-9882-2016 OI strigo, irina/0000-0002-8799-716X NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0625 BP 723 EP 723 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200538 ER PT J AU Bhaumik, D Bhaumik, R Pape, T AF Bhaumik, Dulal Bhaumik, Runa Pape, Theresa TI Statistical methods for analysing advanced imaging data for traumatic brain injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Bhaumik, Dulal; Bhaumik, Runa] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Bhaumik, Dulal; Bhaumik, Runa] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. [Pape, Theresa] US Dept Vet Affairs, Hines, VA USA. [Pape, Theresa] Northwestern Univ, Feinberg Sch Med, Hines, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0634 BP 726 EP 727 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200546 ER PT J AU Mallinson, T Pape, T Guernon, A AF Mallinson, Trudy Pape, Theresa Guernon, Ann TI Identifying patterns of clinically meaningful recovery of NBF in persons in states of disordered consciousness due to TBI SO BRAIN INJURY LA English DT Meeting Abstract C1 [Mallinson, Trudy] George Washington Univ, Washington, DC USA. [Pape, Theresa] US Dept Vet Affairs, Hines, VA USA. [Pape, Theresa] Northwestern Univ, Feinberg Sch Med, Hines, IL USA. [Guernon, Ann] Hines VA & Marianjoy Rehabil Hosp, Hines, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 5-6 MA 0633 BP 726 EP 726 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DM5KP UT WOS:000376388200545 ER PT J AU Coleman, RR Starr, PA Katz, M Glass, GA Volz, M Khandhar, SM Ostrem, JL AF Coleman, Robert R. Starr, Philip A. Katz, Maya Glass, Graham A. Volz, Monica Khandhar, Suketu M. Ostrem, Jill L. TI Bilateral Ventral Intermediate Nucleus Thalamic Deep Brain Stimulation in Orthostatic Tremor SO STEREOTACTIC AND FUNCTIONAL NEUROSURGERY LA English DT Article DE Orthostatic tremor; Deep brain stimulation; Tremor; Ventral intermediate nucleus; Outcome; Surgical treatment; Thalamic stimulation AB Background: Orthostatic tremor (OT) is characterized by high-frequency leg tremor when standing still, resulting in a sense of imbalance, with limited treatment options. Ventral intermediate (Vim) nucleus thalamic deep brain stimulation (DBS) has been reported as beneficial in a few cases. Objective: To report clinical outcomes, lead locations, and stimulation parameters in 2 patients with severe medication-refractory OT treated with Vim DBS. Methods: The patients underwent surface electromyography (EMG) to confirm the OT diagnosis. Outcomes were measured as change in tolerated standing time at the last follow-up. Lead locations were quantified using postoperative MRI. Results: Vim DBS was well tolerated and resulted in improvement in standing time (patient 1: 50 s at baseline to 15 min 16 months after surgery; patient 2: 34 s at baseline to 4.2 min 7 months after surgery). Postoperative surface EMG for patient 1 demonstrated a delayed onset of tremor, lower-amplitude tremor, and periods of quiescence, but an unchanged tremor frequency. Conclusion: These cases provide further support for Vim DBS to improve standing time in severe medication-refractory OT. The location of the effective thalamic target for OT does not differ from the effective target for essential tremor. (C) 2016 S. Karger AG, Basel C1 [Coleman, Robert R.; Katz, Maya; Glass, Graham A.; Volz, Monica; Ostrem, Jill L.] Univ Calif San Francisco, Neurol, San Francisco, CA 94143 USA. [Starr, Philip A.] Univ Calif San Francisco, Neurosurg, San Francisco, CA 94143 USA. [Coleman, Robert R.; Starr, Philip A.; Katz, Maya; Glass, Graham A.; Ostrem, Jill L.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. [Khandhar, Suketu M.] Kaiser Fdn Hosp, Neurol, Sacramento, CA USA. RP Coleman, RR (reprint author), Univ Calif San Francisco, 1635 Divisadero St,Suite 520-530, San Francisco, CA 94115 USA. EM robert.coleman@ucsf.edu NR 12 TC 2 Z9 2 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1011-6125 EI 1423-0372 J9 STEREOT FUNCT NEUROS JI Stereotact. Funct. Neurosurg. PY 2016 VL 94 IS 2 BP 69 EP 74 DI 10.1159/000444127 PG 6 WC Neurosciences; Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA DM7WQ UT WOS:000376571100001 PM 27002536 ER PT J AU Nguyen, VHV Wong, BM Shen, DD Woo, DT Vu, AV Lie, JD AF Nguyen, Viet-Huong V. Wong, Bonnie M. Shen, Diana D. Woo, Denny T. Vu, Amanda V. Lie, Janette D. TI Early Management of Acute Ischemic Stroke: Focus on IV tPA and Timely Reperfusion SO US PHARMACIST LA English DT Article AB Alteplase (Activase), an intravenous (IV) tissue plasminogen activator (tPA), is the only FDA-approved thrombolytic agent for acute ischemic stroke (AIS). Recently updated American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Early Management of Patients with Acute Ischemic Stroke and revisions to Activase labeling have expanded the time window eligibility for tPA treatment and have loosened contraindications surrounding tPA treatment. These changes should promote increased utilization of tPA in AIS, resulting in more instances of timely reperfusion and reduction of neurologic sequelae. C1 [Nguyen, Viet-Huong V.] Chapman Univ, Sch Pharm, Dept Pharm Practice, Pharm Practice, Irvine, CA USA. [Wong, Bonnie M.; Shen, Diana D.; Woo, Denny T.; Vu, Amanda V.] Univ So Calif, Sch Pharm, Los Angeles, CA USA. [Wong, Bonnie M.; Shen, Diana D.; Woo, Denny T.; Vu, Amanda V.] Vet Affairs Greater Los Angeles Healthcare Syst, Pharm VA Learning Opportun Residency VALOR, Los Angeles, CA USA. [Lie, Janette D.] Vet Affairs Greater Los Angeles Healthcare Syst, Pharm Educ & Training, Los Angeles, CA USA. RP Nguyen, VHV (reprint author), Chapman Univ, Sch Pharm, Dept Pharm Practice, Pharm Practice, Irvine, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU JOBSON PUBLISHING LLC PI NEW YORK PA 100 AVE OF THE AMERICAS, NEW YORK, NY 10013-1678 USA SN 0148-4818 EI 2331-3501 J9 US PHARM JI US Pharm. PD JAN PY 2016 VL 41 IS 1 BP HS9 EP HS12 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DN0KC UT WOS:000376751800004 ER PT J AU Chen, H Ding, P Geng, Z Zhou, XH AF Chen, Hua Ding, Peng Geng, Zhi Zhou, Xiao-Hua TI Semiparametric Inference of the Complier Average Causal Effect with Nonignorable Missing Outcomes SO ACM TRANSACTIONS ON INTELLIGENT SYSTEMS AND TECHNOLOGY LA English DT Article DE Experimentation; Measurement; Theory; Causal inference; instrumental variable; missing not at random; noncompliance; outcome-dependent missing; principal stratification ID RANDOMIZED EXPERIMENTS; PRINCIPAL STRATIFICATION; TREATMENT-NONCOMPLIANCE; ENCOURAGEMENT DESIGN; CLINICAL-TRIALS; IDENTIFIABILITY; LIKELIHOOD AB Noncompliance and missing data often occur in randomized trials, which complicate the inference of causal effects. When both noncompliance and missing data are present, previous papers proposed moment and maximum likelihood estimators for binary and normally distributed continuous outcomes under the latent ignorable missing data mechanism. However, the latent ignorable missing data mechanism may be violated in practice, because the missing data mechanism may depend directly on the missing outcome itself. Under noncompliance and an outcome-dependent nonignorable missing data mechanism, previous studies showed the identifiability of complier average causal effect for discrete outcomes. In this article, we study the semiparametric identifiability and estimation of complier average causal effect in randomized clinical trials with both all-or-none noncompliance and outcome-dependent nonignorable missing continuous outcomes, and propose a two-step maximum likelihood estimator in order to eliminate the infinite dimensional nuisance parameter. Our method does not need to specify a parametric form for the missing data mechanism. We also evaluate the finite sample property of our method via extensive simulation studies and sensitivity analysis, with an application to a double-blinded psychiatric clinical trial. C1 [Chen, Hua] Inst Appl Phys & Computat Math, POB 8009, Beijing 100088, Peoples R China. [Ding, Peng] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA. [Geng, Zhi] Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98101 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Biostat Unit, Seattle, WA 98101 USA. RP Chen, H (reprint author), Inst Appl Phys & Computat Math, POB 8009, Beijing 100088, Peoples R China.; Ding, P (reprint author), Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA.; Geng, Z (reprint author), Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China.; Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98101 USA.; Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Biostat Unit, Seattle, WA 98101 USA. EM chen_hua@iapcm.ac.cn; pengdingpku@gmail.com; zhigeng@pku.edu.cn; azhou@uw.edu FU NSFC [11101045, 11021463, 10931002, 11171365]; CAEP [2012A0201011, 2013A0101004]; Department of Veterans Affairs HSRD RCS Award [05-196] FX Chen's research was supported in part by NSFC 11101045, CAEP 2012A0201011 and CAEP 2013A0101004. Geng's research was supported by NSFC 11021463, 10931002, and 11171365. Zhou's research was supported in part by the Department of Veterans Affairs HSR&D RCS Award 05-196. It does not necessarily represent the views of the VA HSR&D Service. NR 21 TC 0 Z9 0 U1 1 U2 1 PU ASSOC COMPUTING MACHINERY PI NEW YORK PA 2 PENN PLAZA, STE 701, NEW YORK, NY 10121-0701 USA SN 2157-6904 EI 2157-6912 J9 ACM T INTEL SYST TEC JI ACM Trans. Intell. Syst. Technol. PD JAN PY 2016 VL 7 IS 2 SI SI AR 19 DI 10.1145/2668135 PG 15 WC Computer Science, Artificial Intelligence; Computer Science, Information Systems SC Computer Science GA DJ8FB UT WOS:000374446800007 ER PT J AU Winter, L Moriarty, HJ Robinson, K Piersol, CV Vause-Earland, T Newhart, B Iacovone, DB Hodgson, N Gitlin, LN AF Winter, Laraine Moriarty, Helene J. Robinson, Keith Piersol, Catherine V. Vause-Earland, Tracey Newhart, Brian Iacovone, Delores Blazer Hodgson, Nancy Gitlin, Laura N. TI Efficacy and acceptability of a home-based, family-inclusive intervention for veterans with TBI: A randomized controlled trial SO BRAIN INJURY LA English DT Article DE Community reintegration; family; in-home service; rehabilitation; traumatic brain injury; veterans ID TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; COMMUNITY REINTEGRATION; SERVICE MEMBERS; NEUROREHABILITATION PROGRAM; OLDER-ADULTS; CAREGIVER; MILITARY; OUTCOMES; INTEGRATION AB Objective: Traumatic brain injury (TBI) often undermines community re-integration, impairs functioning and produces other symptoms. This study tested an innovative programme for veterans with TBI, the Veterans' In-home Programme (VIP), delivered in veterans' homes, involving a family member and targeting the environment (social and physical) to promote community re-integration, mitigate difficulty with the most troubling TBI symptoms and facilitate daily functioning. Setting: Interviews and intervention sessions were conducted in homes or by telephone. Participants: Eighty-one veterans with TBI at a VA polytrauma programme and a key family member. Design: This was a 2-group randomized controlled trial. Control-group participants received usual-care enhanced by two attention-control telephone calls. Follow-up interviews occurred up to 4 months after baseline interview. Main measures: VIP's efficacy was evaluated using measures of community re-integration, target outcomes reflecting veterans' self-identified problems and self-rated functional competence. Results: At follow-up, VIP participants had significantly higher community re-integration scores and less difficulty managing targeted outcomes, compared to controls. Self-rated functional competence did not differ between groups. In addition, VIP's acceptability was high. Conclusion: A home-based, family-inclusive service for veterans with TBI shows promise for improving meaningful outcomes and warrants further research and clinical application. C1 [Winter, Laraine] Philadelphia Res & Educ Fdn, Philadelphia, PA 19104 USA. [Winter, Laraine; Moriarty, Helene J.] Dept Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA 19104 USA. [Moriarty, Helene J.] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA. [Robinson, Keith; Newhart, Brian; Iacovone, Delores Blazer] Dept Vet Affairs Med Ctr, Med Rehabil Serv, Philadelphia, PA 19104 USA. [Robinson, Keith] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Piersol, Catherine V.; Vause-Earland, Tracey] Thomas Jefferson Univ, Sch Hlth Profess, Philadelphia, PA 19107 USA. [Hodgson, Nancy; Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Ctr Innovat Care Aging, Baltimore, MD USA. RP Winter, L (reprint author), Philadelphia Res & Educ Fdn, Philadelphia VA Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM laraine.winter@gmail.com NR 69 TC 2 Z9 2 U1 5 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 4 BP 373 EP 387 DI 10.3109/02699052.2016.1144080 PG 15 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DK1BF UT WOS:000374646200002 PM 26983578 ER PT J AU Li, H McSharry, M Clambey, E Nguyen, T McNamee, E Weiser-Evans, M Nemenoff, R AF Li, Howard McSharry, Maria Clambey, Eric Nguyen, Teresa McNamee, Eoin Weiser-Evans, Mary Nemenoff, Raphael TI Non-small cell lung cancer cells induce PD-L1 expression in the tumor microenvironment in an orthotopic mouse model of lung cancer SO CANCER IMMUNOLOGY RESEARCH LA English DT Meeting Abstract C1 [Li, Howard] Denver VA Med Ctr, Denver, CO USA. [McSharry, Maria; Clambey, Eric; Nguyen, Teresa; McNamee, Eoin; Weiser-Evans, Mary; Nemenoff, Raphael] Univ Colorado, Anschutz Med Campus, Aurora, CO USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2326-6066 EI 2326-6074 J9 CANCER IMMUNOL RES JI Cancer Immunol. Res. PD JAN PY 2016 VL 4 IS 1 SU S MA A122 DI 10.1158/2326-6074.CRICIMTEATIAACR15-A122 PG 2 WC Oncology; Immunology SC Oncology; Immunology GA DL2SB UT WOS:000375484400265 ER PT J AU Jiang, X Pu, H Mao, L Xia, J Wang, G Zhang, H Wu, Y Shi, Y Hu, X Gao, Y Chen, J AF Jiang, X. Pu, H. Mao, L. Xia, J. Wang, G. Zhang, H. Wu, Y. Shi, Y. Hu, X. Gao, Y. Chen, J. TI Poststroke EPA/DHA Treatment Combined With Dietary Supplementation of Omega-3 Polyunsaturated Fatty Acids Promotes Long-Term Neurological Recovery After Transient Cerebral Ischemia SO CELL TRANSPLANTATION LA English DT Meeting Abstract CT 23rd Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair (ASNTR) CY APR 29-30, 2016 CL Clearwater, FL SP Amer Soc Neural Therapy & Repair C1 [Jiang, X.; Pu, H.; Mao, L.; Xia, J.; Wang, G.; Zhang, H.; Wu, Y.; Shi, Y.; Hu, X.; Chen, J.] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA. [Jiang, X.; Pu, H.; Wang, G.; Hu, X.; Gao, Y.; Chen, J.] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Jiang, X.; Pu, H.; Wang, G.; Hu, X.; Gao, Y.; Chen, J.] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Hu, X.; Chen, J.] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 NR 0 TC 0 Z9 0 U1 0 U2 1 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 EI 1555-3892 J9 CELL TRANSPLANT JI Cell Transplant. PY 2016 VL 25 IS 4 BP 762 EP 763 PG 2 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA DK2BB UT WOS:000374718500056 ER PT J AU Shi, Y Zhang, L Pu, H Mao, L Hu, X Jiang, X Xu, N Stetler, RA Lealc, RK Keep, RF Chen, J AF Shi, Y. Zhang, L. Pu, H. Mao, L. Hu, X. Jiang, X. Xu, N. Stetler, R. A. Lealc, R. K. Keep, R. F. Chen, J. TI Rapid Endothelial Cytoskeletal Reorganization Enables Early Blood Brain Barrier Disruption and Long-Term Ischemic/Reperfusion Brain Injury SO CELL TRANSPLANTATION LA English DT Meeting Abstract CT 23rd Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair (ASNTR) CY APR 29-30, 2016 CL Clearwater, FL SP Amer Soc Neural Therapy & Repair C1 [Shi, Y.; Zhang, L.; Pu, H.; Mao, L.; Hu, X.; Jiang, X.; Xu, N.; Stetler, R. A.; Chen, J.] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA. [Shi, Y.; Zhang, L.; Hu, X.; Stetler, R. A.; Chen, J.] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Lealc, R. K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Keep, R. F.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 EI 1555-3892 J9 CELL TRANSPLANT JI Cell Transplant. PY 2016 VL 25 IS 4 BP 772 EP 772 PG 1 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA DK2BB UT WOS:000374718500086 ER PT J AU Matthews, AM Fu, RW Dana, T Chou, R AF Matthews, Annette M. Fu, Rongwei Dana, Tracy Chou, Roger TI Intranasal or transdermal nicotine for the treatment of postoperative pain SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID SYSTEMATIC REVIEWS; MANAGEMENT; ANALGESIA; PATCH; SMOKING; NAUSEA; TRIAL; METAANALYSIS; EXPERIENCES; SURGERY AB Background Acute pain frequently occurs after surgical procedures. Nicotine has been explored as an adjunctive medication for management of postoperative pain. Objectives To assess the effect of transdermal or intranasal nicotine administration on postoperative pain, opioid analgesic use, and opioid-related adverse events. Search methods We searched MEDLINE (1966 to 20 March 2014), the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 3), EMBASE (1980 to 20 March 2014), and also databases of ongoing trials (www.controlled-trials.com/ and http://clinicaltrials.gov/). We re-ran the search on 28 April 2015. We will assess the one study of interest when we update the review. Selection criteria We included randomized, placebo-controlled clinical trials that evaluated the effects of perioperative (pre-, intra-, or postoperative) administration of nicotine on postoperative pain, opioid use, and opioid-related adverse events. We excluded all other studies. Data collection and analysis Two authors independently screened all titles and abstracts for eligibility and documented reasons for exclusion. In case of disagreement, a third author decided on the inclusion or exclusion of a trial report. When additional information was needed in order to decide if a trial should be included, one of the authors contacted the corresponding author of the trial in question. Main results Nine trials (666 participants) evaluated nicotine for postoperative pain. Nicotine may reduce postoperative pain scores at 24 hours by a small amount compared with placebo (eight trials, mean difference -0.88 on a 0 to 10 scale, 95% confidence interval (CI) -1.58 to 0.18; low quality evidence). The effect on pain at one hour and 12 hours postoperatively was less certain (very low quality evidence). Statistical heterogeneity was substantial and not adequately explained by stratification of trials according to type of surgical procedure, smoking status, mode of nicotine administration, timing of administration, or assessed risk of bias. Excluding one trial at high risk of bias resulted in similar findings. The effect of nicotine on postoperative opioid use was uncertain due to small number of participants in the studies. Nicotine probably increases the risk of postoperative nausea (seven trials, RR 1.24, 95% CI 1.03 to 1.50; moderate quality evidence). Three trials assessed sedation but the effect is very uncertain due to the very low quality of evidence. We found no evidence that nicotine increased the risk of vomiting (seven studies, risk difference (RD) 0.03, 95% CI -0.04 to 0.09; low quality evidence). The results from one single small trial were insufficient to establish whether nicotine led to an earlier hospital discharge (very low quality evidence). Authors' conclusions Based on evidence of generally low quality, nicotine may reduce postoperative pain at 24 hours compared with placebo, but the effects were relatively small (less than 1 point on a 10 point pain scale) and there was substantial heterogeneity in the results of our analyses. Nicotine does not appear to reduce postoperative use of opioids or opioid-related adverse events but probably increases the risk of nausea. More research is needed to determine the effectiveness of nicotine for postoperative pain and to understand the optimal timing, dose, and method of delivery of nicotine. C1 [Matthews, Annette M.] Portland VA Med Ctr, Dept Behav Hlth & Neurosci, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. [Matthews, Annette M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Matthews, Annette M.; Dana, Tracy; Chou, Roger] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Fu, Rongwei] Oregon Hlth & Sci Univ, Dept Publ Hlth, Portland, OR 97201 USA. [Fu, Rongwei] Oregon Hlth & Sci Univ, Dept Prevent Med, Portland, OR 97201 USA. [Fu, Rongwei] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA. [Chou, Roger] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. RP Matthews, AM (reprint author), Portland VA Med Ctr, Dept Behav Hlth & Neurosci, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM Annette.Matthews@va.gov FU Oregon Health & Science University Human Investigations Program, USA; National Center for Research Resources/National Center for Advancing Translational Sciences (NCRR/NCATS) [UL1RR024140]; Veterans Affairs Clinical Sciences Research and Development (CSR&D) Career Development Award, USA FX Internal sources; Oregon Health & Science University Human Investigations Program, USA.; A draft of this protocol was first developed as part of a course on systematic reviews that was sponsored by National Center for Research Resources/National Center for Advancing Translational Sciences (NCRR/NCATS)-funded Clinical and Translational Science Award (CTSA) grant (UL1RR024140).; External sources; Veterans Affairs Clinical Sciences Research and Development (CSR&D) Career Development Award, USA. Awarded to Annette M. Matthews, MD. NR 38 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2016 IS 1 AR CD009634 DI 10.1002/14651858.CD009634.pub2 PG 125 WC Medicine, General & Internal SC General & Internal Medicine GA DJ7PV UT WOS:000374404200040 PM 26756459 ER PT J AU Benmansour, S Adeniji, OS Privratsky, AA Frazer, A AF Benmansour, Saloua Adeniji, Opeyemi S. Privratsky, Anthony A. Frazer, Alan TI Effects of Long-Term Treatment with Estradiol and Estrogen Receptor Subtype Agonists on Serotonergic Function in Ovariectomized Rats SO NEUROENDOCRINOLOGY LA English DT Article DE Estradiol; Estrogen receptor agonists; Antidepressant; Forced swim test; Signaling pathways ID CENTRAL-NERVOUS-SYSTEM; FORCED SWIM TEST; OBJECT MEMORY CONSOLIDATION; DEPRESSIVE-LIKE BEHAVIOR; SIGNAL-REGULATED KINASE; BETA MESSENGER-RNA; ER-BETA; ANTIDEPRESSANT TREATMENTS; HIPPOCAMPAL-FORMATION; SYNAPTIC PLASTICITY AB Acute estradiol treatment was reported to slow the clearance of serotonin via activation of estrogen receptors (ER)beta and/or GPR30 and to block the ability of a selective serotonin reuptake inhibitor (SSRI) to slow serotonin clearance via activation of ER alpha. In this study, the behavioral consequences of longer-term treatments with estradiol or ER subtype-selective agonists and/or an SSRI were examined in the forced swim test (FST). Ovariectomized rats were administered the following for 2 weeks: estradiol, ER beta agonist (diarylpropionitrile, DPN), GPR30 agonist (G1), ER alpha agonist (PPT), and/or the SSRI sertraline. Similar to sertraline, longer-term treatment with estradiol, DPN or G1 induced an antidepressant-like effect. By contrast, PPT did not, even though it blocked the antidepressant-like effect of sertraline. Uterus weights, used as a peripheral measure of estrogenic activity, were increased by estradiol and PPT but not DPN or G1 treatment. A second part of this study investigated, using Western blot analyses in homogenates from hippocampus, whether these behavioral effects are accompanied by changes in the activation of specific signaling pathways and/or TrkB. Estradiol and G1 increased phosphorylation of Akt, ERK and TrkB. These effects were similar to those obtained after treatment with sertraline. Treatment with DPN increased phosphorylation of ERK and TrkB, but it did not alter that of Akt. Treatment with PPT increased phosphorylation of Akt and ERK without altering that of TrkB. In conclusion, activation of at least TrkB and possibly ERK may be involved in the antidepressant- like effect of estradiol, ER beta and GPR30 agonists whereas Akt activation may not be necessary. (C) 2015 S. Karger AG, Basel C1 [Benmansour, Saloua; Adeniji, Opeyemi S.; Privratsky, Anthony A.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol MC 7764, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Frazer, Alan] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Benmansour, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol MC 7764, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM benmansour@uthscsa.edu FU NARSAD; Department of Veterans Affairs; National Institute of Mental Health [MH090386] FX This research was supported by funds from NARSAD, the Department of Veterans Affairs and the National Institute of Mental Health (MH090386). NR 75 TC 3 Z9 3 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 IS 3-4 BP 269 EP 281 DI 10.1159/000437268 PG 13 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA DL6RO UT WOS:000375766500009 PM 26159182 ER PT J AU Moghadam-Kia, S Oddis, CV Aggarwal, R AF Moghadam-Kia, Siamak Oddis, Chester V. Aggarwal, Rohit TI Approach to asymptomatic creatine kinase elevation SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Article ID HYPER-CK-EMIA; STATIN-INDUCED MYOPATHY; MUSCLE BIOPSY; IDIOPATHIC HYPERCKEMIA; PERSISTENT HYPERCKEMIA; LARGE POPULATION; RHABDOMYOLYSIS; HYPOTHYROIDISM; DYSTROPHY; MUTATION AB How to manage a patient who has an elevated serum creatine kinase (CK) level but no or insignificant muscle-related signs and symptoms is a clinical conundrum. The authors provide a systematic approach, including repeat testing after a period of rest, defining higher thresholds over which pursuing a diagnosis is worthwhile, and evaluating for a variety of nonneuromuscular causes. They also outline a workup for neuromuscular causes. C1 [Moghadam-Kia, Siamak; Oddis, Chester V.] Univ Pittsburgh, Sch Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15261 USA. [Moghadam-Kia, Siamak] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Aggarwal, Rohit] Univ Pittsburgh, Sch Med, Div Rheumatol & Clin Immunol, Med, Pittsburgh, PA 15261 USA. RP Aggarwal, R (reprint author), Univ Pittsburgh, Dept Med, Div Rheumatol & Clin Immunol, 3601 5th Ave,Suite 2B, Pittsburgh, PA 15261 USA. EM aggarwalr@upmc.edu FU NIAID NIH HHS [T32 AI089443] NR 37 TC 0 Z9 1 U1 0 U2 1 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 EI 1939-2869 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD JAN PY 2016 VL 83 IS 1 BP 37 EP 42 DI 10.3949/ccjm.83a.14120 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DK3TL UT WOS:000374840200010 PM 26760521 ER PT J AU Wylie, KP Smucny, J Legget, KT Tregellas, JR AF Wylie, Korey P. Smucny, Jason Legget, Kristina T. Tregellas, Jason R. TI Targeting Functional Biomarkers in Schizophrenia with Neuroimaging SO CURRENT PHARMACEUTICAL DESIGN LA English DT Article DE Biomarkers; functional magnetic resonance imaging; fMRI; nicotine; alpha7 nicotinic receptor; functional connectivity; SPEM ID PURSUIT EYE-MOVEMENTS; DEFAULT-MODE NETWORK; CNS DRUG DEVELOPMENT; ACETYLCHOLINE-RECEPTOR; PHARMACOLOGICAL FMRI; TRACKING DYSFUNCTION; NICOTINIC RECEPTORS; LEADING SACCADES; BRAIN NETWORKS; MOUSE MODEL AB Many of the most debilitating symptoms for psychiatric disorders such as schizophrenia remain poorly treated. As such, the development of novel treatments is urgently needed. Unfortunately, the costs associated with high failure rates for investigational compounds as they enter clinical trials has led to pharmaceutical companies downsizing or eliminating research programs needed to develop these drugs. One way of increasing the probability of success for investigational compounds is to incorporate alternative methods of identifying biological targets in order to more effectively screen new drugs. A promising method of accomplishing this goal for psychiatric drugs is to use functional magnetic resonance imaging (fMRI). fMRI investigates neural circuits, shedding light on the biology that generates symptoms such as hallucinations. Once identified, relevant neural circuits can be targeted with pharmacologic interventions and the response to these drugs measured with fMRI. This review describes the early use of fMRI in this context, and discusses the alpha7 nicotinic receptor agonist 3-(2,4-dimethoxybenzylidene) anabaseine (DMXB-A), as an example of the potential value of fMRI for psychiatric drug development. C1 [Wylie, Korey P.; Smucny, Jason; Legget, Kristina T.; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Dept Psychiat, Denver, CO USA. [Smucny, Jason] Univ Colorado Anschutz Med Campus, Neurosci Program, Denver, CO USA. [Tregellas, Jason R.] Denver Vet Affairs Med Ctr, Res Serv, Denver, CO USA. RP Wylie, KP (reprint author), Anschutz Med Campus, Dept Psychiat, Bldg 500,Mail Stop F546,13001 East 17th Pl, Aurora, CO 80045 USA. EM Korey.Wylie@ucdenver.edu OI Smucny, Jason/0000-0001-5656-7987; Legget, Kristina/0000-0002-2948-506X FU Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service; National Institutes of Health [R01MH102224, R01DK103691, K01DK100445]; Brain and Behavior Research Foundation FX This work was supported by the Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service, the National Institutes of Health grants R01MH102224, R01DK103691, K01DK100445 and the Brain and Behavior Research Foundation. NR 80 TC 1 Z9 1 U1 3 U2 6 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 EI 1873-4286 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PY 2016 VL 22 IS 14 BP 2117 EP 2123 DI 10.2174/1381612822666160127113912 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DK7ZV UT WOS:000375146900014 PM 26818860 ER PT J AU Dai, XM Busby-Whitehead, J Forman, DE Alexander, KP AF Dai, Xuming Busby-Whitehead, Jan Forman, Daniel E. Alexander, Karen P. TI Stable ischemic heart disease in the older adults SO JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Article DE Aging; Coronary artery disease; Older adults; Risk assessment; Stable ischemic heart disease ID CORONARY-ARTERY-DISEASE; ELDERLY-PATIENTS; ASSOCIATION; TIME; OCTOGENARIANS; TRIAL C1 [Dai, Xuming] Univ N Carolina, Div Cardiol, Chapel Hill, NC USA. [Busby-Whitehead, Jan] Univ N Carolina, Ctr Aging & Hlth, Div Geriatr Med, Chapel Hill, NC USA. [Forman, Daniel E.] Univ Pittsburgh, Sect Geriatr Cardiol, VA Pittsburgh Healthcare Syst, Med Ctr,Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Alexander, Karen P.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. RP Alexander, KP (reprint author), Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. EM karen.alexander@duke.edu NR 20 TC 0 Z9 0 U1 1 U2 1 PU SCIENCE PRESS PI BEIJING PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA SN 1671-5411 J9 J GERIATR CARDIOL JI J. Geriatr. Cardiol. PY 2016 VL 13 IS 2 BP 109 EP 114 PG 6 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA DK2WV UT WOS:000374776000002 PM 27168734 ER PT J AU Silva, CGDE Franklin, BA Forman, DE Araujo, CGS AF de Souza e Silva, Christina G. Franklin, Barry A. Forman, Daniel E. Araujo, Claudio Gil S. TI Influence of age in estimating maximal oxygen uptake SO JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Article DE Aging; Cardiopulmonary exercise testing; Error of measurement ID CYCLE ERGOMETRY EQUATION; ALL-CAUSE MORTALITY; HEALTHY-MEN; CARDIAC REHABILITATION; EXERCISE; HEART; EFFICIENCY; DISEASE; WOMEN; METAANALYSIS AB Objective To assess the influence of age on the error of estimate (EE) of maximal oxygen uptake (VO(2)max) using sex and population specific-equations in cycle ergometer exercise testing, since estimated VO(2)max is associated with a substantial EE, often exceeding 20%, possibly due to intrinsic variability of mechanical efficiency. Methods 1850 adults (68% men), aged 18 to 91 years, underwent maximal cycle ergometer cardiopulmonary exercise testing. Cardiorespiratory fitness (CRF) was assessed relative to sex and age [younger (18 to 35 years), middle-aged (36 to 60 years) and older (>60 years)]. VO(2)max [mL.(kg.min)(-1)] was directly measured by assessment of gas exchange and estimated using sex and population specific-equations. Measured and estimated values of VO(2)max and related EE were compared among the three age-and sex-specific groups. Results Directly measured VO(2)max of men and women were 29.5 +/- 10.5 mL.(kg.min)(-1) and 24.2 +/- 9.0 mL.(kg.min)(-1) (P < 0.01). EE [mL.(kg.min)(-1)] and percent errors (%E) for men and women had similar values, 0.5 +/- 3.2 and 0.4 +/- 2.9 mL.(kg.min)(-1), and -0.8 +/- 13.1% and -1.7 +/- 15.4% (P > 0.05), respectively. EE and %E for each age-group were, respectively, for men: younger = 1.9 +/- 4.1 mL.(kg.min)(-1) and 3.8 +/- 10.5%, middle-aged = 0.6 +/- 3.1 mL.(kg.min)(-1) and 0.4 +/- 10.3%, older = -0.2 +/- 2.7 mL.(kg.min)(-1) and -4.2 +/- 16.6% (P < 0.01); and for women: younger = 1.2 +/- 3.1 mL.(kg.min)(-1) and 2.7 +/- 10.0%, middle-aged = 0.7 +/- 2.8 mL.(kg.min)(-1) and 0.5 +/- 11.1%, older = -0.8 +/- 2.3 mL.(kg.min)(-1) and -9.5 +/- 22.4% (P < 0.01). Conclusion VO(2)max were underestimated in younger age-groups and were overestimated in older age groups. Age significantly influences the magnitude of the EE of VO(2)max in both men and women and should be considered when CRF is estimated using population specific equations, rather than directly measured. C1 [de Souza e Silva, Christina G.; Araujo, Claudio Gil S.] Univ Fed Rio de Janeiro, Heart Inst Edson Saad & Med Sch, Rio De Janeiro, RJ, Brazil. [de Souza e Silva, Christina G.; Araujo, Claudio Gil S.] CLINIMEX, Exercise Med Clin, Rua Siqueira Campos 93-101, BR-22031070 Rio De Janeiro, RJ, Brazil. [Franklin, Barry A.] William Beaumont Hosp, Prevent Cardiol & Cardiac Rehabil, Royal Oak, MI 48072 USA. [Forman, Daniel E.] Univ Pittsburgh, Sect Geriatr Cardiol, Geriatr Res Educ & Clin Ctr, Med Ctr,VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Araujo, CGS (reprint author), CLINIMEX, Exercise Med Clin, Rua Siqueira Campos 93-101, BR-22031070 Rio De Janeiro, RJ, Brazil. EM cgaraujo@iis.com.br RI Araujo, Claudio/A-7027-2008 OI Araujo, Claudio/0000-0001-6679-6695 FU CNPq; FAPERJ FX Partial financial support for this study was provided by CNPq and FAPERJ. NR 37 TC 1 Z9 1 U1 0 U2 1 PU SCIENCE PRESS PI BEIJING PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA SN 1671-5411 J9 J GERIATR CARDIOL JI J. Geriatr. Cardiol. PY 2016 VL 13 IS 2 BP 126 EP 131 PG 6 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA DK2WV UT WOS:000374776000005 ER PT J AU Kearns, WD Fozard, JL Ray, RD Scott, S Jasiewicz, JM Craighead, JD Pagano, CV AF Kearns, William D. Fozard, James L. Ray, Roger D. Scott, Steven Jasiewicz, Jan M. Craighead, Jeffrey D. Pagano, Craig V. TI Movement Path Tortuosity Predicts Compliance With Therapeutic Behavioral Prompts in Patients With Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE location aware technology; memory prompting and spatial disorientation; movement path tortuosity; traumatic brain injury ID PAGING SYSTEM; MEMORY; PEOPLE; TRIAL; ADULTS AB Objective: Rehabilitation of patients with traumatic brain injury typically includes therapeutic prompts for keeping appointments and adhering to medication regimens. Level of cognitive impairment may significantly affect a traumatic brain injury victim's ability to benefit from text-based prompting. We tested the hypothesis that spatial disorientation as measured by movement path tortuosity during ambulation would be associated with poorer compliance with automated prompts by veterans actively being treated for traumatic brain injury. Setting: Clinical polytrauma center. Participants: Ten (1 female) veteran patients mean age = 35.4 (SD = 12.4) years. Design: Small group correlational study without random assignment. Main Measures: Fractal Dimension, a measure of movement path tortuosity derived from a GPS logging device used to record casual outdoor ambulation at the start of the study. Compliance with smart home machine-generated therapeutic prompts received during rehabilitation at the James A. Haley Veterans Administration Hospital Polytrauma Transitional Rehabilitation Program. A patient was compliant with a prompt if they transited from where the prompt was presented to the prescribed destination (both within the Polytrauma Transitional Rehabilitation Program) within 30 minutes. Noncompliance was failure to appear at the destination within the allotted time. Results: Fractal dimension was significantly inversely related to overall prompt compliance (r = -0.603, n = 10, P = .032; 1-tailed). Conclusions: The findings support the hypothesis that increased spatial disorientation adversely impacts compliance with automated prompts throughout therapy. The results are consistent with previous studies linking elevated path tortuosity to cognitive impairment and increased risk for falls in assisted living facility residents. C1 [Kearns, William D.] Univ S Florida, Coll Behav & Community Sci, Dept Rehabil & Mental Hlth Counseling, 13301 N Bruce B Downs Blvd,MHC 1601, Tampa, FL 33612 USA. [Fozard, James L.] Univ S Florida, Coll Behav & Community Sci, Sch Aging Studies, Tampa, FL 33612 USA. [Ray, Roger D.] Rollins Coll, Dept Psychol, Winter Pk, FL 32789 USA. [Scott, Steven; Pagano, Craig V.] US Dept Vet Affairs, James A Haley Vet Adm Hosp, Phys Med & Rehabil Serv, Tampa, FL USA. [Jasiewicz, Jan M.; Craighead, Jeffrey D.] US Dept Vet Affairs, James A Haley Vet Adm Hosp, Ctr Innovat Disabil & Rehabil Res CINDRR, Tampa, FL USA. RP Kearns, WD (reprint author), Univ S Florida, Coll Behav & Community Sci, Dept Rehabil & Mental Hlth Counseling, 13301 N Bruce B Downs Blvd,MHC 1601, Tampa, FL 33612 USA. EM Kearns@usf.edu RI Kearns, William/F-9810-2015 OI Kearns, William/0000-0002-0241-814X FU US Department of Defense [W81XWH-11-1-0634] FX This research was supported by the US Department of Defense under award number W81XWH-11-1-0634 to Dr Paul Sanberg "Battlefield-Related Injury Translational Research, Post-Traumatic Disease, and Disability Veterans Injury Translational Research, Post-Traumatic Disease, and Disability Veterans Re-Integration." NR 23 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD JAN-FEB PY 2016 VL 31 IS 1 BP E20 EP E27 DI 10.1097/HTR.0000000000000126 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DK9CN UT WOS:000375228000003 PM 25931182 ER PT J AU Moriarty, HJ Robinson, JP Bunting-Perry, L Bradway, CW AF Moriarty, Helene J. Robinson, Joanne P. Bunting-Perry, Lisette Bradway, Christine W. TI Cognitive, Affective, and Behavioral Dimensions of the Lower Urinary Tract Symptom Experience in Men With Parkinson's Disease SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Article DE lower urinary tract symptoms; military veterans; Parkinson's disease; symptom experience; urinary incontinence ID QUALITY-OF-LIFE; VOIDING DYSFUNCTION; INCONTINENCE; DEPRESSION; MANAGEMENT; IMPACT; ADULTS; WOMEN; STATE AB OBJECTIVE: Lower urinary tract symptoms (LUTS) in persons with Parkinson's disease (PD) have received little research attention. To address this gap in our knowledge, we examined the LUTS experience in men with PD, guided by The Theory of Unpleasant Symptoms. METHODS: A qualitative design was used to explore the LUTS experience in this population. Participants were recruited from a Veterans' Affairs PD Center. Maximum variation sampling was used to select diverse participants for audiotaped open-ended interviews. Additional data sources included field notes collected during interviews and observation of a PD support group. The template organizing analytic approach was used to code transcribed interviews and field notes. RESULTS: Cognitive, affective, and behavioral dimensions of the LUTS experience were identified. Participants attributed LUTS to aging, medications, and effects of motor symptoms on their ability to respond to the urge to void. There was little awareness of the neurologic contributions of PD to LUTS, and most viewed LUTS as "something that you have to put up with." Negative effects of LUTS on self-identity were noted, which jeopardized relationships, intimacy, participation in social activities, and travel. Affective responses to LUTS, particularly embarrassment, had a profound impact on quality of life. Behavioral strategies to manage LUTS focused on "being prepared to go when you need to go" and consisted mostly of trial-and-error efforts. CONCLUSION: Misconceptions about LUTS among men with PD may result in underreporting, missed opportunities for professional assistance, and diminished health-related quality of life. Future research should focus on developing and testing nursing interventions to address cognitive, affective, and behavioral aspects of the LUTS experience in men with PD. C1 [Moriarty, Helene J.] Villanova Univ, Coll Nursing, 800 Lancaster Ave, Villanova, PA 19085 USA. [Moriarty, Helene J.] Dept Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA 19104 USA. [Robinson, Joanne P.] Rutgers State Univ, Sch Nursing, Camden, NJ 08102 USA. [Bunting-Perry, Lisette] Univ Delaware, Sch Nursing, Newark, DE 19716 USA. [Bunting-Perry, Lisette] Dept Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Bradway, Christine W.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Moriarty, HJ (reprint author), Villanova Univ, Coll Nursing, 800 Lancaster Ave, Villanova, PA 19085 USA. EM Helene.moriarty@villanova.edu FU Hollister Grant for Continence Nursing from the Wound Ostomy Continence Nursing Society's Center for Clinical Investigation FX The project described was funded by the Hollister Grant for Continence Nursing, from the Wound Ostomy Continence Nursing Society's Center for Clinical Investigation. The research team thanks the veterans with Parkinson's disease who gave of themselves and their time to share their stories and take part in this study. NR 43 TC 2 Z9 2 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1071-5754 EI 1528-3976 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD JAN-FEB PY 2016 VL 43 IS 1 BP 80 EP 87 DI 10.1097/WON.0000000000000165 PG 8 WC Nursing SC Nursing GA DK9EO UT WOS:000375233800012 PM 26727686 ER PT J AU Milburn, E Warren, T Dickey, MW AF Milburn, Evelyn Warren, Tessa Dickey, Michael Walsh TI World knowledge affects prediction as quickly as selectional restrictions: evidence from the visual world paradigm SO LANGUAGE COGNITION AND NEUROSCIENCE LA English DT Article DE Language comprehension; plausibility; eye tracking; sentence processing; prediction ID ANTICIPATORY EYE-MOVEMENTS; LANGUAGE COMPREHENSION; EVENT KNOWLEDGE; TIME-COURSE; INTEGRATION; VERBS; VIOLATIONS; MODELS AB There has been considerable debate regarding the question of whether linguistic knowledge and world knowledge are separable and used differently during processing or not (Hagoort et al, 2004). Integration of word meaning and world knowledge in language comprehension (Matsuki et al, 2011). Event-based plausibility immediately influences on-line language comprehension (Paczynski et al, 2012). Multiple influences of semantic memory on sentence processing: Distinct effects of semantic relatedness on violations of real-world event/state knowledge and animacy selection restrictions (Warren et al, 2007). Investigating effects of selectional restriction violations and plausibility violation severity on eye movements in reading. Previous investigations into this question have provided mixed evidence as to whether violations of selectional restrictions are detected earlier than violations of world knowledge. We report a visual world eye-tracking study comparing the timing of facilitation contributed by selectional restrictions vs. world knowledge. College-aged adults (n=36) viewed photographs of natural scenes while listening to sentences. Participants anticipated upcoming direct objects similarly regardless of whether facilitation was provided by only world knowledge or a combination of selectional restrictions and world knowledge. These results suggest that selectional restrictions are not available earlier in comprehension than world knowledge. C1 [Milburn, Evelyn; Warren, Tessa] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Milburn, Evelyn; Warren, Tessa] Univ Pittsburgh, Learning Res & Dev Ctr, Pittsburgh, PA USA. [Dickey, Michael Walsh] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Milburn, E (reprint author), Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.; Milburn, E (reprint author), Univ Pittsburgh, Learning Res & Dev Ctr, Pittsburgh, PA USA. EM eam115@pitt.edu FU National Institutes of Health [R01DC011520] FX This research was supported by the National Institutes of Health under grant R01DC011520 to the second and third authors. NR 29 TC 0 Z9 0 U1 2 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 2327-3798 EI 2327-3801 J9 LANG COGN NEUROSCI JI Lang. Cogn. Neurosci. PY 2016 VL 31 IS 4 BP 536 EP 548 DI 10.1080/23273798.2015.1117117 PG 13 WC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology, Experimental SC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology GA DK5VO UT WOS:000374989100017 PM 27148555 ER PT J AU Ni, A Yang, T Mesnard-Hoaglin, NA Gutierrez, R Stubbs, EB McGuire, SO Sanders, VM Jones, KJ Foecking, EM Xin, JP AF Ni, Allen Yang, Tao Mesnard-Hoaglin, Nichole A. Gutierrez, Rafael Stubbs, Evan B., Jr. McGuire, Susan O. Sanders, Virginia M. Jones, Kathryn J. Foecking, Eileen M. Xin, Junping TI Th17 Cell Response in SOD1(G93A) Mice following Motor Nerve Injury SO MEDIATORS OF INFLAMMATION LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; REGULATORY T-LYMPHOCYTES; MEDIATE NEUROPROTECTION; THERAPEUTIC-STRATEGIES; ALS; INFLAMMATION; AXOTOMY; SERUM AB An increased risk of ALS has been reported for veterans, varsity athletes, and professional football players. The mechanism underlying the increased risk in these populations has not been identified; however, it has been proposed that motor nerve injury may trigger immune responses which, in turn, can accelerate the progression of ALS. Accumulating evidence indicates that abnormal immune reactions and inflammation are involved in the pathogenesis of ALS, but the specific immune cells involved have not been clearly defined. To understand how nerve injury and immune responses may contribute to ALS development, we investigated responses of CD4(+) T cell after facial motor nerve axotomy (FNA) at a presymptomatic stage in a transgenic mouse model of ALS (B6SJL SOD1(G93A)). SOD1(G93A) mice, compared with WT mice, displayed an increase in the basal activation state of CD4(+) T cells and higher frequency of Th17 cells, which were further enhanced by FNA. In conclusion, SOD1(G93A) mice exhibit abnormal CD4(+) T cell activation with increased levels of Th17 cells prior to the onset of neurological symptoms. Motor nerve injury exacerbates Th17 cell responses and may contribute to the development of ALS, especially in those who carry genetic susceptibility to this disease. C1 [Ni, Allen; Gutierrez, Rafael; Xin, Junping] Loyola Univ Chicago, Oncol Res Inst, Maywood, IL 60153 USA. [Ni, Allen; Mesnard-Hoaglin, Nichole A.; Stubbs, Evan B., Jr.; McGuire, Susan O.; Foecking, Eileen M.; Xin, Junping] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. [Yang, Tao] Gansu Prov Chinese Tradit Med Hosp, Dept Brain Dis, Lanzhou 730050, Gansu, Peoples R China. [Stubbs, Evan B., Jr.] Loyola Univ Chicago, Stritch Sch Med, Dept Ophthalmol, Maywood, IL 60153 USA. [Sanders, Virginia M.] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. [Jones, Kathryn J.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA. [Jones, Kathryn J.] Roudebush VA Hosp, Res & Dev Serv, Indianapolis, IN 46202 USA. [Foecking, Eileen M.] Loyola Univ, Ctr Med, Dept Otolaryngol, Maywood, IL 60153 USA. [Xin, Junping] Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Maywood, IL 60153 USA. RP Xin, JP (reprint author), Loyola Univ Chicago, Oncol Res Inst, Maywood, IL 60153 USA.; Xin, JP (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.; Xin, JP (reprint author), Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Maywood, IL 60153 USA. EM researchtreg@gmail.com FU Muscular Dystrophy Association [MDA202906]; NIH [NIH 40433, R21-CA181970]; Leukemia Research Foundation; Gansu Chinese Medicine Administration [GZK-2014-11] FX This work was supported by a grant from Muscular Dystrophy Association (MDA202906 to Junping Xin) and partially by NIH grant (NIH 40433 to Kathryn J. Jones and Virginia M. Sanders). Junping Xin was also supported in part by grants from NIH (R21-CA181970) and the Leukemia Research Foundation (New Investigator Award, 8th Annual George Richard Memorial Grant). Tao Yang was supported by a grant from Gansu Chinese Medicine Administration (GZK-2014-11). The authors thank Ms. Patricia Simms and Ms. Ashley Hess for assistance with FACS analysis and Drs. Jiwang Zhang, James Walter, Gwendolyn L. Kartje, William Wolf, Keith Fargo, Haiyan Chen, and Cynthia Pervan for ongoing professional support and collaborations, as well as scientific suggestions and discussions. NR 16 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 0962-9351 EI 1466-1861 J9 MEDIAT INFLAMM JI Mediat. Inflamm. PY 2016 AR 6131234 DI 10.1155/2016/6131234 PG 7 WC Cell Biology; Immunology SC Cell Biology; Immunology GA DL0GN UT WOS:000375310500001 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Design of Clinical Trials in Acute Kidney Injury: Lessons from the Past and Future Directions SO SEMINARS IN NEPHROLOGY LA English DT Review DE Acute kidney injury; clinical trial; prevention; treatment ID CONTRAST-INDUCED NEPHROPATHY; ACUTE-RENAL-FAILURE; ATRIAL-NATRIURETIC-PEPTIDE; GROWTH-FACTOR-I; RADIOCONTRAST-INDUCED NEPHROPATHY; RANDOMIZED-CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; ACUTE TUBULAR-NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; MELANOCYTE-STIMULATING HORMONE AB Acute kidney injury (AKI) is a common condition with multiple etiologies and variable clinical findings and pathologic manifestations. AKI is associated with serious adverse clinical outcomes, including the development of de novo chronic kidney disease, accelerated progression of pre-existing chronic kidney disease, end-stage kidney disease, and increased mortality. Past research has advanced our understanding of the pathophysiology, epidemiology, and outcomes of AKI significantly, however, little progress has been made in the development of evidence-based interventions for its prevention and treatment. In this review, we discuss key considerations in the design of clinical trials in AKI and highlight significant methodologic limitations that precluded many past studies from determining the effectiveness of preventive and therapeutic strategies for this common and serious condition. Published by Elsevier Inc. C1 [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Sect,VA Pittsburgh Healthcare Syst,Renal El, Pittsburgh, PA 15213 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Dept Med, Renal Sect, Renal Electrolyte Div, 7 East,Room 120 111F-U,Univ Dr Div, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 89 TC 1 Z9 1 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0270-9295 EI 1558-4488 J9 SEMIN NEPHROL JI Semin. Nephrol. PD JAN PY 2016 VL 36 IS 1 BP 42 EP 52 DI 10.1016/j.semnephrol.2016.01.004 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DK4TZ UT WOS:000374914500006 PM 27085734 ER PT J AU Hossein-nezhad, A Fatemi, RP Ahmad, R Peskind, ER Zabetian, CP Hu, SC Shi, M Wahlestedt, C Zhang, J Faghihi, MA AF Hossein-nezhad, Arash Fatemi, Roya Pedram Ahmad, Rili Peskind, Elaine R. Zabetian, Cyrus P. Hu, Shu-Ching Shi, Min Wahlestedt, Claes Zhang, Jing Faghihi, Mohammad Ali TI Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease SO JOURNAL OF PARKINSONS DISEASE LA English DT Article DE Parkinson disease; RNA sequencing; cerebrospinal fluid; biomarkers; long noncoding RNA ID LARGE GENE LISTS; ALPHA-SYNUCLEIN; NONCODING RNAS; BIOMARKERS; SUSCEPTIBILITY; GENERATION; NDUFV2; MIRNA AB Background: Parkinson's disease (PD) is a debilitating neurological disorder for which prognostic and diagnostic biomarkers are lacking. Cerebrospinal fluid (CSF) is an accessible body fluid that comes into direct contact with the central nervous system (CNS) and acts as a nuclease-free repository where RNA transcripts shed by brain tissues can reside for extended periods of time. Objective: We studied the RNA species present in the CSF of PD patients to identify novel diagnostic biomarkers. Methods: Small volumes of CSF from 27 PD patients and 30 healthy age-and sex-matched controls were used for RNA extraction followed by next-generation sequencing (RNA-seq) using the Illumina platform. CSF contains a number of fragmented RNA species that were individually sequenced and analyzed. Comparing PD to control subjects, we observed a pool of dysregulated sequencing tags that were further analyzed and validated by quantitative real-time PCR (qRT-PCR). Results: A total of 201 differentially expressed sequencing tags (DETs), including 92 up-regulated and 109 down-regulated DETs were identified. We validated the following DETs by real time PCR in the patient samples: Dnmt1, Ezh2, CCR3, SSTR5, PTPRC, UBC, NDUFV2, BMP7, SCN9, SCN9 antisense (AC010127.3), and long noncoding RNAs AC079630 and UC001lva. 4 (close to the LRRK2 gene locus), as potential PD biomarkers. Conclusions: The CSF is a unique environment that contains many species of RNA. Our work demonstrates that CSF can potentially be used to identify biomarkers for the detection and tracking of disease progression and evaluation of therapeutic outcomes. C1 [Hossein-nezhad, Arash; Fatemi, Roya Pedram; Ahmad, Rili; Wahlestedt, Claes; Faghihi, Mohammad Ali] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA. [Faghihi, Mohammad Ali] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. [Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. RP Faghihi, MA (reprint author), 1501 NW 10th Ave,Biomed Res Bldg,Room 508, Miami, FL 33136 USA. EM mfaghihi@med.miami.edu OI Hossein-nezhad, Arash/0000-0003-2847-4737 FU NIH [P50NS071674, U01 NS082137, P50 NS062684, P50 NIA AG05136] FX NIH grants P50NS071674 supporting AH and part of MAF as well as sequencing costs, U01 NS082137 (to JZ), P50 NS062684 (PANUC), and P50 NIA AG05136 (to EP). NR 39 TC 2 Z9 2 U1 1 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1877-7171 EI 1877-718X J9 J PARKINSON DIS JI J. Parkinsons Dis. PY 2016 VL 6 IS 1 BP 109 EP 117 DI 10.3233/JPD-150737 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DK0YL UT WOS:000374638600011 PM 26889637 ER PT J AU Pandhi, N Schumacher, JR Thorpe, CT Smith, MA AF Pandhi, Nancy Schumacher, Jessica R. Thorpe, Carolyn T. Smith, Maureen A. TI Cross-sectional study examining whether the extent of first-contact access to primary care differentially benefits those with certain personalities to receive preventive services SO BMJ OPEN LA English DT Article DE PRIMARY CARE; PREVENTIVE MEDICINE ID 5-FACTOR MODEL; INFLUENZA VACCINATION; UNITED-STATES; OLDER-ADULTS; PREDICTORS; MAMMOGRAPHY; VALIDATION; OBSERVERS; TRAITS; HEALTH AB Objective The extent of first-contact access to primary care (ie, easy availability when needed) is associated with receiving recommended preventive services. Whether this access benefits patients at risk of preventive services underutilisation, such as those with certain personality characteristics, is unclear. Setting Secondary analysis of the 2003-2006 round of the Wisconsin Longitudinal Study. Participants 6975 respondents who reported a usual provider whose specialty was internal medicine or family medicine. Those reporting not visiting a medical provider in the past 12months, and those who were uninsured were excluded. Primary outcome measures Receiving mammography, cholesterol testing and influenza vaccination. Adjusted predicted probabilities (aPP) of receiving these services were analysed stratified by personality characteristics overall, and if significant, then interacted with first-contact access. Results Lower conscientiousness as compared with higher conscientiousness predicted less of all 3 preventive services; mammography (aPP 80%; 95% CI (77% to 83%) vs aPP 85%; (95% CI 82% to 87%)), cholesterol testing (88%; (85% to 90%) vs 93% (91% to 94%), and influenza vaccination (62%; (59% to 64%) vs 66%; (63% to 68%)). Lower agreeableness as compared with higher agreeableness predicted less mammography (77%; (73% to 81%) vs 84%; (82% to 87%)) and less influenza vaccination (59%; (56% to 62%) vs 65%; (63% to 68%)). Lower extraversion predicted less cholesterol testing (88%; (86% to 91%) vs (92%; (90% to 94%)). Lower openness to experience predicted less influenza vaccination (59%; (56% to 63%) vs (68%; (65% to 70%)). For agreeableness, these differences in receiving preventive services did not persist when first-contact access to primary care was present. Conclusions Certain personality characteristics predicted receiving less preventive care services. For those with less agreeableness, improved first-contact access to primary care mitigated this effect. If these results are replicated in other studies, primary care offices seeking to improve population health through receiving preventive services should prioritise increasing their first-contact accessibility. C1 [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, Madison, WI USA. [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Dept Populat Hlth Sci, Madison, WI USA. [Schumacher, Jessica R.; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Philadelphia, PA USA. [Thorpe, Carolyn T.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. RP Pandhi, N (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, Madison, WI USA.; Pandhi, N (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Dept Populat Hlth Sci, Madison, WI USA. EM nancy.pandhi@fammed.wisc.edu FU Clinical and Translational Science Award (CTSA) programme; National Center for Research Resources (NCRR) [1UL1RR025011]; National Center for Advancing Translational Sciences (NCATS) [9U54TR000021]; National Institute on Aging Mentored Clinical Scientist Research Career Development Award [1 K08 AG029527]; University of Wisconsin Carbone Cancer Center (UWCCC) Support Grant from the National Cancer Institute [P30 CA014520]; UW School of Medicine and Public Health from the Wisconsin Partnership Program FX This work was supported by the Clinical and Translational Science Award (CTSA) programme, previously through the National Center for Research Resources (NCRR) grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021. The content is solely the responsibility of the authors, and does not necessarily represent the official views of the NIH, the Department of Veterans Affairs or the USA government. In addition, NP was supported by a National Institute on Aging Mentored Clinical Scientist Research Career Development Award, grant number 1 K08 AG029527. This project was also supported by the University of Wisconsin Carbone Cancer Center (UWCCC) Support Grant from the National Cancer Institute, grant number P30 CA014520. Additional support was provided by the UW School of Medicine and Public Health from the Wisconsin Partnership Program. NR 38 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 3 AR e009738 DI 10.1136/bmjopen-2015-009738 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DJ2RH UT WOS:000374052300039 PM 26951211 ER PT J AU Gray, NE Zweig, JA Kawamoto, C Quinn, JF Copenhaver, PF AF Gray, Nora E. Zweig, Jonathan A. Kawamoto, Colleen Quinn, Joseph F. Copenhaver, Philip F. TI STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-beta Toxicity SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Amyloid-beta toxicity; mitochondrial dysfunction; neuroprotection; selective estrogen receptor modulator ID TRANSGENIC MOUSE MODEL; INDUCED NEURONAL DEATH; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY; PRECURSOR PROTEIN; OXIDATIVE STRESS; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; BIOENERGETIC DEFICITS; COGNITIVE IMPAIRMENT AB Because STX is a selective ligand for membrane estrogen receptors, it may be able to confer the beneficial effects of estrogen without eliciting the deleterious side effects associated with activation of the nuclear estrogen receptors. This study evaluates the neuroprotective properties of STX in the context of amyloid-beta (A beta) exposure. MC65 and SH-SY5Y neuroblastoma cell lines, as well as primary hippocampal neurons from wild type (WT) and Tg2576 mice, were used to investigate the ability of STX to attenuate cell death, mitochondrial dysfunction, dendritic simplification, and synaptic loss induced by A beta. STX prevented A beta-induced cell death in both neuroblastoma cell lines; it also normalized the decrease in ATP and mitochondrial gene expression caused by A beta in these cells. Notably, STX also increased ATP content and mitochondrial gene expression in control neuroblastoma cells (in the absence of A beta). Likewise in primary neurons, STX increased ATP levels and mitochondrial gene expression in both genotypes. In addition, STX treatment enhanced dendritic arborization and spine densities in WT neurons and prevented the diminished outgrowth of dendrites caused by A beta exposure in Tg2576 neurons. These data suggest that STX can act as an effective neuroprotective agent in the context of A beta toxicity, improving mitochondrial function as well as dendritic growth and synaptic differentiation. In addition, since STX also improved these endpoints in the absence of A beta, this compound may have broader therapeutic value beyond Alzheimer's disease. C1 [Gray, Nora E.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. [Zweig, Jonathan A.; Kawamoto, Colleen; Copenhaver, Philip F.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. [Quinn, Joseph F.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr PADRECC, Portland, OR USA. RP Gray, NE (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM grayn@ohsu.edu FU Department of Veterans Affairs Merit Review grant; NIH [NS078363, AG025525, P30 NS061800]; OHSU School of Medicine Faculty Innovation Fund FX This work was funded by a Department of Veterans Affairs Merit Review grant awarded to J. Quinn, and by NIH grants NS078363 and AG025525 awarded to P. Copenhaver. The authors thank Dr. Martin Kelly for providing his expertise and the STX used in this study, and Dr. Gary Banker and Ms. Barbara Smoody for their support of our experiments with primary hippocampal neurons. We also wish to thank Ms. Jenna Fisk for her assistance with image acquisition in some of our studies. Dr. Doris Kretzschmar provided critical input on this manuscript. We gratefully acknowledge Dr. Stefanie Kaech and Ms. Aurelie Snyder for their invaluable assistance with the confocal imaging analysis that was performed in the Advanced Light Microscopy Core, Jungers Center, OHSU. Confocal imaging was supported in part by NIH P30 NS061800, and by the OHSU School of Medicine Faculty Innovation Fund (to P. Copenhaver). MC65 cells were generously provided by Randy Woltjer, MD, PhD. NR 92 TC 1 Z9 2 U1 2 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 51 IS 2 BP 391 EP 403 DI 10.3233/JAD-150756 PG 13 WC Neurosciences SC Neurosciences & Neurology GA DJ5IJ UT WOS:000374240000007 PM 26890746 ER PT J AU Gurubhagavatula, I Patil, S Meoli, A Olson, R Sullivan, S Berneking, M Watson, NF AF Gurubhagavatula, Indira Patil, Susheel Meoli, Amy Olson, Ryan Sullivan, Shannon Berneking, Michael Watson, Nathaniel F. CA Amer Acad Sleep Med TI Sleep Apnea Evaluation of Commercial Motor Vehicle Operators SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material C1 [Gurubhagavatula, Indira] Univ Penn, Med Ctr, Div Sleep Med, Occupat Sleep Med, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Sleep Med Clin, Philadelphia, PA USA. [Patil, Susheel] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Meoli, Amy] Penn State Hershey Sleep Res & Treatment Ctr, Hummelstown, PA USA. [Olson, Ryan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Sullivan, Shannon] Stanford Univ, Div Sleep Med, Dept Psychiat, Palo Alto, CA 94304 USA. [Berneking, Michael] Concentra, Grand Rapids, MI USA. [Watson, Nathaniel F.] Univ Washington, UW Med Sleep Ctr, Seattle, WA 98195 USA. Amer Acad Sleep Med, Sleep & Transportat Safety Awareness Task Force, Darien, IL 60561 USA. RP Gurubhagavatula, I (reprint author), Amer Acad Sleep Med, Sleep & Transportat Safety Awareness Task Force, 2510 N Frontage Rd, Darien, IL 60561 USA. NR 11 TC 0 Z9 0 U1 2 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 3 BP 285 EP 286 AR PII jc-00060-16 DI 10.5664/jcsm.5560 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA DJ3XI UT WOS:000374139600001 PM 26857051 ER PT J AU Primeau, M Gershon, A Talbot, L Cotto, I Lotspeich, L Hardan, A Hallmayer, J O'Hara, R AF Primeau, Michelle Gershon, Anda Talbot, Lisa Cotto, Isabelle Lotspeich, Linda Hardan, Antonio Hallmayer, Joachim O'Hara, Ruth TI Individuals with Autism Spectrum Disorders Have Equal Success Rate But Require Longer Periods of Systematic Desensitization than Control Patients to Complete Ambulatory Polysomnography SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE autism spectrum disorder; polysomnography; pediatric; methodology ID RESPIRATORY INDICATIONS; PRACTICE PARAMETERS; YOUNG-CHILDREN; SLEEP-APNEA; FEASIBILITY; EVENTS; BRAIN AB Study Objectives: Polysomnography (PSG) is the gold standard for the assessment of sleep, yet the extensive apparatus required for monitoring with PSG can be difficult to tolerate, particularly in children. Clinical populations, such as those with anxiety or tactile sensitivity, may have even greater difficulty tolerating the PSG equipment. This study evaluated an innovative protocol for obtaining full PSG in individuals diagnosed autism spectrum disorders (ASD) or developmental delay (DD), as well as typically developing controls (TD). The primary aim was to assess whether this protocol was equally successful for obtaining PSG between these groups. Methods: One hundred sixty-one individuals were recruited for participation; 93 with a diagnosis of ASD, 23 with a diagnosis of DD, and 45 TD. The participants and families were instructed on a procedure of systematic desensitization to the ambulatory PSG equipment; PSG was performed in the home of the participant. Results: PSG was successfully attained in 144 (89.4%) participants. There was no difference in completion rate by diagnosis (p = 0.1), though younger age (p = 0.018) and duration of desensitization (p = 0.024) did predict PSG failure. Further, it was found that individuals with ASD took longer to desensitize to the equipment (16.08 d), than those with DD (8.04 d) or TD (0.98 d). Conclusions: Systematic desensitization to PSG equipment, in combination with PSG completed in the home, allows for individuals with ASD to be equally successful in completing PSG, though they do take longer to acclimate to the equipment. C1 [Primeau, Michelle] Palo Alto Med Fdn, Dept Sleep Med, Sunnyvale, CA 94087 USA. [Primeau, Michelle; Gershon, Anda; Cotto, Isabelle; Lotspeich, Linda; Hardan, Antonio; Hallmayer, Joachim; O'Hara, Ruth] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Talbot, Lisa; O'Hara, Ruth] San Francisco VA Med Ctr, San Francisco, CA USA. [Hardan, Antonio; Hallmayer, Joachim] Stanford Univ, Dept Psychiat & Behav Sci, Child & Adolescent Psychiat, Stanford, CA 94305 USA. [O'Hara, Ruth] Dept Vet Affairs, MIRECC, VISN Sierra Pacific Network 21, Palo Alto, CA USA. RP Primeau, M (reprint author), Palo Alto Med Fdn, 1309 S Mary Ave Ste 200, Sunnyvale, CA 94087 USA. EM primeamm@pamf.org FU Roche FX This was not an industry supported study. Dr. Hardan has recieved research support from Roche and has consulted for Integragen. The other authors have indicated no financial conflicts of interest. NR 32 TC 0 Z9 0 U1 2 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 3 BP 357 EP 362 AR PII jc-00448-14 DI 10.5664/jcsm.5584 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA DJ3XI UT WOS:000374139600013 PM 26564388 ER PT J AU Kuhn, E Weiss, BJ Taylor, KL Hoffman, JE Ramsey, KM Manber, R Gehrman, P Crowley, JJ Ruzek, JI Trockel, M AF Kuhn, Eric Weiss, Brandon J. Taylor, Katherine L. Hoffman, Julia E. Ramsey, Kelly M. Manber, Rachel Gehrman, Philip Crowley, Jill J. Ruzek, Josef I. Trockel, Mickey TI CBT-I Coach: A Description and Clinician Perceptions of a Mobile App for Cognitive Behavioral Therapy for Insomnia SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Cognitive behavioral therapy for insomnia; Diffusion of Innovations; mobile apps; sleep problems ID RANDOMIZED CONTROLLED-TRIAL; COMPARATIVE METAANALYSIS; PERSISTENT INSOMNIA; BREAST-CANCER; DISSEMINATION; INTERVENTIONS; RESTRICTION; EFFICACY; OUTCOMES; MHEALTH AB Study Objectives: This paper describes CBT-I Coach, a patient-facing smartphone app designed to enhance cognitive behavioral therapy for insomnia (CBT-I). It presents findings of two surveys of U. S. Department of Veterans Affairs (VA) CBT-I trained clinicians regarding their perceptions of CBT-I Coach before it was released (n = 138) and use of it two years after it was released (n = 176). Methods: VA-trained CBT-I clinicians completed web-based surveys before and two years after CBT-I Coach was publicly released. Results: Prior to CBT-I Coach release, clinicians reported that it was moderately to very likely that the app could improve care and a majority (87.0%) intended to use it if it were available. Intention to use the app was predicted by smartphone ownership (beta = 0.116, p < 0.05) and perceptions of relative advantage to existing CBT-I practices (beta = 0.286, p < 0.01), compatibility with their own needs and values (beta = 0.307, p < 0.01), and expectations about the complexity of the app (beta = 0.245, p < 0.05). Two years after CBT-I Coach became available, 59.9% of participants reported using it with patients and had favorable impressions of its impact on homework adherence and outcomes. Conclusions: Findings suggest that before release, CBT-I Coach was perceived to have potential to enhance CBT-I and address common adherence issues and clinicians would use it. These results are reinforced by findings two years after it was released suggesting robust uptake and favorable perceptions of its value. C1 [Kuhn, Eric; Weiss, Brandon J.; Taylor, Katherine L.; Hoffman, Julia E.; Ramsey, Kelly M.; Crowley, Jill J.; Ruzek, Josef I.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Kuhn, Eric; Weiss, Brandon J.; Manber, Rachel; Ruzek, Josef I.; Trockel, Mickey] Stanford Univ, Stanford, CA 94305 USA. [Gehrman, Philip] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Gehrman, Philip] Univ Penn, Philadelphia, PA 19104 USA. RP Kuhn, E (reprint author), VA Natl Ctr PTSD, D&T Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Eric.Kuhn@va.gov RI Emchi, Karma/Q-1952-2016 FU Merck Inc. FX This was not an industry supported study. Julia E. Hoffman is a consultant to Otsuka Pharmaceuticals. Rachel Manber receives royalties from New Harbinger Press. Philip Gehrman has received grant/research support from Merck Inc. The other authors have indicated no financial conflicts of interest. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 41 TC 3 Z9 3 U1 2 U2 11 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 4 BP 597 EP 606 AR PII jc-00087-15 DI 10.5664/jcsm.5700 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DJ3XM UT WOS:000374140000019 PM 26888586 ER PT J AU Tong, GE Kumar, S Chong, KC Shah, N Wong, MJ Zimmet, JM Wang, ZJ Yee, J Fu, YJ Yeh, BM AF Tong, Gregory E. Kumar, Sant Chong, Karen C. Shah, Nikita Wong, Margaret J. Zimmet, Jeffrey M. Wang, Zhen Jane Yee, Judy Fu, Yanjun Yeh, Benjamin M. TI Risk of contrast-induced nephropathy for patients receiving intravenous vs. intra-arterial iodixanol administration SO ABDOMINAL RADIOLOGY LA English DT Article DE Contrast-induced nephropathy; Intra-arterial; Intravenous; Renal; CT; Cardiac catheterization ID ACUTE KIDNEY INJURY; PERCUTANEOUS CORONARY INTERVENTIONS; INDUCED NEPHROTOXICITY; METAANALYSIS; OSMOLALITY; FREQUENCY; ANEMIA; MEDIA AB Purpose: To compare the incidence of contrast-induced nephropathy (CIN) for intravenous vs. intra-arterial administration of iodixanol, compared to non-administration. Methods: We retrospectively identified 650 patients who had intravenous iodixanol-enhanced CT, 695 with intra-arterial iodixanol cardiac catheterization, 651 with unenhanced CT, and those who also had baseline and follow-up serum creatinine within 5 days of the exam. From the medical records, we recorded the gender, age, baseline and follow-up serum creatinine/eGFR; underlying renal injury risk factors; indication for imaging; contrast material administration volume, concentration, and route of administration; and use of pre-imaging prophylactic measures for CIN. Univariate and multivariate models were used to determine predictors of CIN. Results: Baseline eGFR was lower for patients undergoing unenhanced CT than intravenous or intra-arterial patients (68 vs. 74.6 and 72.2, respectively, p < 0.01) and not different between intravenous and intra-arterial patients (p = 0.735). Simple logistic regression did not show a difference in the rate of CIN in patients who received intravenous vs. intra-arterial iodixanol (28 of 650, 4%, vs. 28 of 695, 4%, respectively, p = 0.798), nor a higher rate of CIN than seen with unenhanced CT (45 of 651, 7%, p = 0.99 and p = 0.98 by one-sided t test). Multivariate regression modeling showed that only elevated baseline creatinine or decreased eGFR and low hematocrit/hemoglobin were associated with CIN incidence (odds ratio 1.28 and 2.5; p < 0.023 and < 0.006, respectively). Conclusions: Elevation in serum creatinine due to intravenous and intra-arterial iodixanol administration is infrequent and is not more common than after unenhanced CT scans. C1 [Tong, Gregory E.; Kumar, Sant; Chong, Karen C.; Shah, Nikita; Wong, Margaret J.; Wang, Zhen Jane; Yee, Judy; Fu, Yanjun; Yeh, Benjamin M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0628,M-372,505 Parnassus Ave, San Francisco, CA 94143 USA. [Zimmet, Jeffrey M.] San Francisco VA Med Ctr, Div Cardiol, 4150 Clement Ave, San Francisco, CA 94121 USA. RP Yeh, BM (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0628,M-372,505 Parnassus Ave, San Francisco, CA 94143 USA. EM ben.yeh@ucsf.edu FU General Electric Healthcare; NIH [1R21EB013816, 1R01EB015476]; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI [UL1 TR000004] FX This study was supported by grants from General Electric Healthcare, NIH Grant Numbers 1R21EB013816 and 1R01EB015476, and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR000004. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of General Electric Healthcare or the NIH. NR 22 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 2366-004X EI 2366-0058 J9 ABDOM RADIOL JI Abdom. Radiol. PD JAN PY 2016 VL 41 IS 1 BP 91 EP 99 DI 10.1007/s00261-015-0611-9 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DJ3MK UT WOS:000374109400012 PM 26830615 ER PT J AU Dzierzewski, JM Wallace, DM Wohlgemuth, WK AF Dzierzewski, Joseph M. Wallace, Douglas M. Wohlgemuth, William K. TI Adherence to Continuous Positive Airway Pressure in Existing Users: Self-Efficacy Enhances the Association between Continuous Positive Airway Pressure and Adherence SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE adherence; continuous positive airway pressure; CPAP; moderation; self-efficacy; sleep apnea ID OBSTRUCTIVE SLEEP-APNEA; QUALITY-OF-LIFE; CPAP ADHERENCE; US VETERANS; THERAPY; RISK; POPULATION; DEPRESSION; DISORDER; GENDER AB Study Objectives: Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a common sleep disorder associated with a myriad of sequelae. OSAHS is effectively treated with continuous positive airway pressure (CPAP) therapy. However, fewer than 50% of patients are compliant with their CPAP therapy prescriptions. The current study sought to explore an integrated, biopsychological approach to CPAP adherence among experienced CPAP users. Methods: We performed a retrospective, cross-sectional analysis of a cohort of veterans with a diagnosis of OSAHS (n = 191) who were prescribed CPAP therapy and returned for adherence download at the Miami VA Sleep Clinic. The relationships between biomedical characteristics (e.g., CPAP pressure, self-reported sleepiness, and change in sleep efficiency) and psychological factors (e.g., self-efficacy beliefs and psychological diagnoses) and objectively measured CPAP use were examined to determine whether psychological factors moderated the relationships between biomedical characteristics and CPAP adherence. Results: Hierarchical regression analyses predicting CPAP adherence (adjusting for time since CPAP prescription, age, education, prescribed CPAP pressure, daytime sleepiness, changes in sleep efficiency with CPAP, and psychiatric conditions) revealed the following: (1) CPAP self-efficacy and CPAP pressure were positively related to adherence, and (2) CPAP self-efficacy moderates the relationship between CPAP pressure and CPAP adherence. Conclusions: There was no relationship between CPAP pressure and adherence in individuals with low self-efficacy beliefs. However, for individuals with high self-efficacy beliefs, there was a significant positive relationship between CPAP pressure and adherence. Self-efficacy beliefs appear to be a prime target for focused interventions aimed at improving CPAP adherence among those individuals with higher pressure prescriptions. C1 [Dzierzewski, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Dzierzewski, Joseph M.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, 16111 Plummer St 11E, North Hills, CA 91343 USA. [Wallace, Douglas M.; Wohlgemuth, William K.] Univ Miami, Miller Sch Med, Sleep Med Div, Dept Neurol, Miami, FL 33136 USA. [Wallace, Douglas M.] Bruce W Carter VA Med Ctr, Neurol Serv, Miami, FL USA. RP Dzierzewski, JM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.; Dzierzewski, JM (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, 16111 Plummer St 11E, North Hills, CA 91343 USA. EM Joseph.Dzierzewski@va.gov FU UCLA Claude Pepper Center [5P30AG028748]; UCLA CTSI [UL1TR000124]; VA Advanced Geriatrics Fellowship FX This work was performed at the Bruce W. Carter VA Medical Center. Joseph M Dzierzewski was supported by UCLA Claude Pepper Center (5P30AG028748), UCLA CTSI (UL1TR000124), and VA Advanced Geriatrics Fellowship. The authors have indicated no financial conflicts of interest. NR 44 TC 2 Z9 2 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 2 BP 169 EP 176 DI 10.5664/jcsm.5478 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DJ3XB UT WOS:000374138900005 PM 26350607 ER PT J AU Weiner, MW Gorriz, JM Ramirez, J Castiglioni, I AF Weiner, Michael W. Gorriz, Juan M. Ramirez, Javier Castiglioni, Isabella TI Statistical Signal Processing in the Analysis, Characterization and Detection of Alzheimer's Disease SO CURRENT ALZHEIMER RESEARCH LA English DT Editorial Material C1 [Weiner, Michael W.] Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St 114M, San Francisco, CA 94121 USA. [Gorriz, Juan M.; Ramirez, Javier] Univ Granada, Dept Signal Theory Networking & Commun, Fuentenueva S-N, E-18071 Granada, Spain. [Castiglioni, Isabella] CNR, Inst Mol Bioimaging & Physiol, Rome, Italy. RP Gorriz, JM; Ramirez, J (reprint author), Univ Granada, Dept Signal Theory Networking & Commun, Fuentenueva S-N, E-18071 Granada, Spain.; Castiglioni, I (reprint author), CNR, Inst Mol Bioimaging & Physiol, Rome, Italy. EM gorriz@ugr.es; javierrp@ugr.es; isabella.castiglioni@ibfm.cnr.it RI Ramirez, Javier/B-1836-2012 OI Ramirez, Javier/0000-0002-6229-2921 NR 23 TC 1 Z9 1 U1 0 U2 3 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1567-2050 EI 1875-5828 J9 CURR ALZHEIMER RES JI Curr. Alzheimer Res. PY 2016 VL 13 IS 5 BP 466 EP 468 DI 10.2174/156720501304160325180321 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DI4GP UT WOS:000373458700001 PM 27025774 ER PT J AU Solak, S Acar, YA Uysal, E AF Solak, Suleyman Acar, Yahya Ayhan Uysal, Emin TI Bladder herniation into inguinal canal: an important differential diagnosis of inguinal hernia SO CUKUROVA MEDICAL JOURNAL LA English DT Letter ID URINARY-BLADDER; INGUINOSCROTAL HERNIATION; INCIDENTAL DEMONSTRATION; BONE-SCAN; SCROTUM C1 [Solak, Suleyman; Uysal, Emin] Bagcilar Training & Res Hosp, Dept Emergency Med, Istanbul, Turkey. [Acar, Yahya Ayhan] San Francisco VA Med Ctr, Dept Anaesthesiol, San Francisco, CA USA. RP Acar, YA (reprint author), San Francisco VA Med Ctr, Dept Anaesthesiol, San Francisco, CA USA. EM yahya_acar@yahoo.com NR 19 TC 0 Z9 0 U1 1 U2 1 PU CUKUROVA UNIV, FAC MEDICINE PI ADANA PA YAYIN VE DOKUMENTASYON KURULU, BALCALI, ADANA, 01330, TURKEY SN 0250-5150 J9 CUKUROVA MED J JI Cukurova Med. J. PY 2016 VL 41 IS 1 BP 191 EP 192 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DH9PS UT WOS:000373128700034 ER PT J AU Millstein, RA Hoerster, KD Rosenberg, DE Nelson, KM Reiber, G Saelens, BE AF Millstein, Rachel A. Hoerster, Katherine D. Rosenberg, Dori E. Nelson, Karin M. Reiber, Gayle Saelens, Brian E. TI Individual, Social, and Neighborhood Associations With Sitting Time Among Veterans SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE sedentary behavior; physical functioning; health behaviors; mental health ID PHYSICAL-ACTIVITY QUESTIONNAIRE; TELEVISION VIEWING TIME; SEDENTARY BEHAVIOR; OLDER-ADULTS; US ADULTS; HEALTH; DEPRESSION; WALKABILITY; OUTCOMES; WOMEN AB Background: Sedentary behavior is an increasingly recognized health risk factor, independent of physical activity. Although several correlates of sedentary behavior are known, little research has identified them among U.S. veterans, a population that faces disproportionate chronic disease burden. Methods: A survey was mailed to 1997 randomly selected veterans at a large urban Veterans Affairs medical center in 2012 and remailed in 2013 to nonresponders, resulting in a 40% response rate. We examined individual-, social-, and neighborhood-level factors in association with self-reported sitting time. Factors correlated with sitting time at P < .05 were included in a multiple linear regression model. Results: In the multivariate model, higher depression (B = 7.8), body mass index (B = 5.1), functional impairment (B = 4.2), and self-rated health (B = 68.5) were significantly associated with higher sitting time, and leisure time physical activity (B = -0.10) and being employed (B = -71.3) were significantly associated with lower sitting time. Conclusions: Individual-level, but not social- and neighborhood-level, variables were associated with sitting time in this population. This study identified individual-level targets for reducing sitting time and improving overall health among veterans. C1 [Millstein, Rachel A.] Univ Calif San Diego, San Diego Joint Doctoral Program Clin Psychol, San Diego State Univ, San Diego, CA 92103 USA. [Millstein, Rachel A.; Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Mental Hlth Serv, Seattle Div, Seattle, WA USA. [Hoerster, Katherine D.; Saelens, Brian E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rosenberg, Dori E.] Grp Hlth Res Inst, Seattle, WA USA. [Rosenberg, Dori E.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Nelson, Karin M.] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev & Gen Internal Med Serv, Seattle Div, Seattle, WA USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. [Reiber, Gayle] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Serv, Seattle Div, Seattle, WA USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Saelens, Brian E.] Seattle Childrens Res Inst, Seattle, WA USA. RP Millstein, RA (reprint author), Univ Calif San Diego, San Diego Joint Doctoral Program Clin Psychol, San Diego State Univ, San Diego, CA 92103 USA.; Millstein, RA (reprint author), VA Puget Sound Healthcare Syst, Mental Hlth Serv, Seattle Div, Seattle, WA USA. EM rmillstein@gmail.com FU US Department of Veterans Affairs; VA Puget Sound, Seattle Division Mental Illness Research, Education, and Clinical Center (MIRECC); Health Services Research and Development (HSR&D) Center of Excellence FX The authors would like to acknowledge Carol Malte, Linda Guerrero, David Tice, Marie Lutton, and Jeff Rodenbaugh, all from VA Puget Sound Healthcare System, Seattle Division, for their important contributions to this study. Ms Malte identified the survey sample using VA administrative data. Ms Guerrero, Mr Tice, and Ms Lutton helped to coordinate the survey mailing. Ms Lutton performed data entry, and Mr Rodenbaugh performed the study analyses. This material is based upon work supported by the US Department of Veterans Affairs, including local funds from the VA Puget Sound, Seattle Division Mental Illness Research, Education, and Clinical Center (MIRECC) and the Health Services Research and Development (HSR&D) Center of Excellence. NR 41 TC 0 Z9 0 U1 2 U2 5 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD JAN PY 2016 VL 13 IS 1 BP 30 EP 35 DI 10.1123/jpah.2014-0369 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DH4QH UT WOS:000372770000005 PM 25831556 ER PT J AU Jarcho, JM Feier, NA Labus, JS Naliboff, B Smith, SR Hong, JY Colloca, L Tillisch, K Mandelkern, MA Mayer, EA London, ED AF Jarcho, Johanna M. Feier, Natasha A. Labus, Jennifer S. Naliboff, Bruce Smith, Suzanne R. Hong, Jui-Yang Colloca, Luana Tillisch, Kirsten Mandelkern, Mark A. Mayer, Emeran A. London, Edythe D. TI Placebo analgesia: Self-report measures and preliminary evidence of cortical dopamine release associated with placebo response SO NEUROIMAGE-CLINICAL LA English DT Article DE Placebo effect; Pain; PET; [F-18]fallypride; Ventrolateral prefrontal cortex ID TRANSCRANIAL MAGNETIC STIMULATION; REFERENCE TISSUE MODEL; CHRONIC PAIN; PREFRONTAL CORTEX; PARKINSONS-DISEASE; C-11 RACLOPRIDE; INDIVIDUAL-DIFFERENCES; CLINICAL IMPORTANCE; OPIOID ACTIVITY; HEALTH-CARE AB Placebo analgesia is measured by self-report, yet current, expected, and recalled efficacy may be differentially related to brain function. Here we used a human thermal pain model to compare self-reports of expected, concurrent, and recalled efficacy of a topical placebo analgesic, and tested associations of the three measures of efficacy with changes in dopamine D2/D3 receptor availability in brain using [F-18] fallypride with positron emission tomography (PET). Participants (15 healthy women) were assessed on three test days. The first test day included a laboratory visit, during which the temperature needed to evoke consistent pain was determined, placebo analgesia was induced via verbal and experience-based expectation, and the placebo response was measured. On two subsequent test days, PET scans were performed in Control and Placebo conditions, respectively, in counterbalanced order. During Visit 1, concurrent and recalled placebo efficacy were unrelated; during the Placebo PET visit, expected and recalled efficacy were highly correlated (rho = 0.68, p = 0.005), but concurrent efficacy was unrelated to expected or recalled efficacy. Region of interest analysis revealed dopamine D2/D3 receptor availability was lower in left ventrolateral prefrontal cortex in the Placebo condition (p < 0.001, uncorrected), and greater change in this measure was associated with higher levels of recalled analgesic efficacy (rho = 0.58, p = 0.02). These preliminary findings underscore the need to consider how self-reported symptom improvement is assessed in clinical trials of analgesics and suggest that dopaminergic activity in the ventrolateral prefrontal cortex may promote recalled efficacy of placebo. (C) 2015 The Authors. Published by Elsevier Inc. C1 [Jarcho, Johanna M.; Feier, Natasha A.; Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, Los Angeles, CA 90095 USA. [Jarcho, Johanna M.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY USA. [Feier, Natasha A.] McGill Univ, Fac Dent, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada. [Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.; London, Edythe D.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. [Labus, Jennifer S.; Naliboff, Bruce; Smith, Suzanne R.; Hong, Jui-Yang; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, PAIN, Los Angeles, CA USA. [Colloca, Luana] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA. [Colloca, Luana] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Tillisch, Kirsten; Mandelkern, Mark A.; London, Edythe D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, CHS 42-210 MC737818,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM emayer@ucla.edu OI Jarcho, Johanna/0000-0001-9075-6968 FU Intramural Research Program at National Institute of Mental Health, National Institutes of Health [F31-DA021951, T32-MH017140] FX This work was supported in part by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health Grants F31-DA021951, T32-MH017140 (JMJ), and endowments from the Thomas P and Katherine K Pike Chair of Addiction Studies (EDL) and an endowment from the Marjorie Green Trust. NR 54 TC 2 Z9 2 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 10 BP 107 EP 114 DI 10.1016/j.nicl.2015.11.009 PG 8 WC Neuroimaging SC Neurosciences & Neurology GA DI0LX UT WOS:000373189000012 PM 26759785 ER PT J AU Messamore, E Yao, JK AF Messamore, Erik Yao, Jeffrey K. TI Phospholipid, arachidonate and eicosanoid signaling in schizophrenia SO OCL-OILSEEDS AND FATS CROPS AND LIPIDS LA English DT Review DE Phospholipids; arachidonic acid; eicosanoids; niacin-induced flushing, endophenotype marker; schizophrenia ID NIACIN SKIN FLUSH; CEREBRAL-BLOOD-FLOW; OPTICAL REFLECTION SPECTROSCOPY; MAGNETIC-RESONANCE-SPECTROSCOPY; POLYUNSATURATED FATTY-ACIDS; PLACEBO-CONTROLLED TRIAL; CELL MEMBRANE DYNAMICS; NICOTINIC-ACID; PROSTAGLANDIN D-2; TOPICAL NIACIN AB This paper reviews the potential role of arachidonic acid in the pathophysiology of schizophrenia. We discuss how abnormal levels of arachidonic acid may arise, and how dysregulation of signaling molecules derived from it have the potential to disrupt not only dopamine signaling, but numerous other physiological processes associated with the illness. Pharmacological doses of niacin stimulate the release of arachidonic acid; and arachidonic acid-derived molecules in turn dilate blood vessels in the skin. A blunted skin flush response to niacin is reliably observed among patients with schizophrenia. The niacin response abnormality may thus serve as a biomarker to identify a physiological subtype of schizophrenia associated with defective arachidonic acid-derived signaling. C1 [Messamore, Erik] Univ Cincinnati, Cincinnati, OH USA. [Messamore, Erik] Lindner Ctr Hope, Cincinnati, OH USA. [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Yao, Jeffrey K.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst Clin, Dept Psychiat, Pittsburgh, PA 15213 USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.; Yao, JK (reprint author), Univ Pittsburgh, Med Ctr, Western Psychiat Inst Clin, Dept Psychiat, Pittsburgh, PA 15213 USA.; Yao, JK (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA. EM jkyao@pitt.edu NR 95 TC 0 Z9 0 U1 2 U2 4 PU EDP SCIENCES S A PI LES ULIS CEDEX A PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A, FRANCE SN 1258-8210 EI 2257-6614 J9 OCL OILS FAT CROP LI JI OCL Oilseed.Fats Crops Lipids PD JAN-FEB PY 2016 VL 23 IS 1 AR D112 DI 10.1051/ocl/2015054 PG 8 WC Agronomy SC Agriculture GA DH9WB UT WOS:000373145600007 ER PT J AU Handtke, V Wolff, H Williams, BA AF Handtke, Violet Wolff, Hans Williams, Brie A. TI The pains of imprisonment: challenging aspects of pain management in correctional settings SO PAIN MANAGEMENT LA English DT Editorial Material DE ethics; jail; pain; prison; vulnerable patients ID PRISON HEALTH-CARE; PREVALENCE; INMATES C1 [Handtke, Violet] Univ Basel, Inst Biomed Eth, Bernoullistr 28, CH-4056 Basel, Switzerland. [Wolff, Hans] Univ Hosp Geneva, Div Correct Med & Psychiat, Geneva, Switzerland. [Wolff, Hans] Univ Geneva, Fac Med, CH-1211 Geneva 4, Switzerland. [Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Handtke, V (reprint author), Univ Basel, Inst Biomed Eth, Bernoullistr 28, CH-4056 Basel, Switzerland. EM v.handtke@unibas.ch NR 19 TC 0 Z9 0 U1 2 U2 3 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-1869 EI 1758-1877 J9 PAIN MANAG JI Pain Manag. PY 2016 VL 6 IS 2 BP 133 EP 136 DI 10.2217/pmt.15.62 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA DH7TB UT WOS:000372995600008 PM 26915436 ER PT J AU Dicianno, BE Morgan, A Lieberman, J Rosen, L AF Dicianno, Brad E. Morgan, Amy Lieberman, Jenny Rosen, Lauren TI Rehabilitation Engineering & Assistive Technology Society (RESNA) position on the application of wheelchair standing devices: 2013 current state of the literature SO ASSISTIVE TECHNOLOGY LA English DT Article DE mobility limitation; rehabilitation; standing position; wheelchairs ID SPINAL-CORD-INJURY; WHOLE-BODY VIBRATION; SPASTIC CEREBRAL-PALSY; BONE-MINERAL DENSITY; WEIGHT-BEARING; ORTHOSTATIC HYPOTENSION; CHILDREN; PROGRAMS; MOBILITY; INDIVIDUALS AB This article, approved by the Rehabilitation Engineering & Assistive Technology Society of North America Board of Directors on December 23, 2013, shares typical clinical applications and provides evidence from the literature supporting the use of wheelchair standers. C1 [Dicianno, Brad E.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400,Bakery Sq, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.] Univ Pittsburgh, Sch Med, Dept PM&R, Pittsburgh, PA USA. [Morgan, Amy] Permobil Inc, Lebanon, TN USA. [Lieberman, Jenny] Mt Sinai Hosp, Dept Rehabil, New York, NY 10029 USA. [Rosen, Lauren] St Josephs Childrens Hosp Tampa, Mot Anal Ctr, Tampa, FL USA. RP Dicianno, BE (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400,Bakery Sq, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu NR 44 TC 0 Z9 0 U1 4 U2 7 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 EI 1949-3614 J9 ASSIST TECHNOL JI Assist. Technol. PY 2016 VL 28 IS 1 BP 57 EP 62 DI 10.1080/10400435.2015.1113837 PG 6 WC Rehabilitation SC Rehabilitation GA DH0KY UT WOS:000372474300009 PM 26910615 ER PT J AU Primack, BA Carroll, MV Weiss, PM Shihadeh, AL Shensa, A Farley, ST Fine, MJ Eissenberg, T Nayak, S AF Primack, Brian A. Carroll, Mary V. Weiss, Patricia M. Shihadeh, Alan L. Shensa, Ariel Farley, Steven T. Fine, Michael J. Eissenberg, Thomas Nayak, Smita TI Systematic Review and Meta-Analysis of Inhaled Toxicants from Waterpipe and Cigarette Smoking SO PUBLIC HEALTH REPORTS LA English DT Article ID HIGH-SCHOOL-STUDENTS; POLYCYCLIC AROMATIC-HYDROCARBONS; US UNIVERSITY-STUDENTS; PIPE TOBACCO SMOKING; MAINSTREAM SMOKE; CARBON-MONOXIDE; NARGHILE WATERPIPE; HOOKAH USE; VOLATILE ALDEHYDES; NICOTINE EXPOSURE AB Objective. Waterpipe tobacco smoking (WTS) is an emerging trend worldwide. To inform public health policy and educational programming, we systematically reviewed the biomedical literature to compute the inhaled smoke volume, nicotine, tar, and carbon monoxide (CO) associated with a single WTS session and a single cigarette. Methods. We searched seven biomedical bibliographic databases for controlled laboratory or natural environment studies designed to mimic human tobacco consumption. Included studies quantified the mainstream smoke of a single cigarette and/or single WTS session for smoke volume, nicotine, tar, and/or CO. We conducted meta-analyses to calculate summary estimates for the inhalation of each unique substance for each mode of tobacco consumption. We assessed between-study heterogeneity using chi-squared and I-squared statistics. Results. Sufficient data from 17 studies were available to derive pooled estimates for inhalation of each exposure via each smoking method. Two researchers working independently abstracted measurement of smoke volume in liters, and nicotine, tar, and CO in milligrams. All numbers included in meta analyses matched precisely between the two researchers (100% agreement, Cohen's kappa=1.00). Whereas one WTS session was associated with 74.1 liters of smoke inhalation (95% confidence interval [CI] 38.2, 110.0), one cigarette was associated with 0.6 liters of smoke (95% CI 0.5, 0.7). One WTS session was also associated with higher levels of nicotine, tar, and CO. Conclusions. One WTS session consistently exposed users to larger smoke volumes and higher levels of tobacco toxicants compared with one cigarette. These computed estimates may be valuable to emphasize in prevention programming. C1 [Primack, Brian A.; Shensa, Ariel; Farley, Steven T.] Univ Pittsburgh, Sch Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. [Carroll, Mary V.] Squirrel Hill Hlth Ctr, Pittsburgh, PA USA. [Weiss, Patricia M.] Univ Pittsburgh Hlth Sci Lib Syst, Pittsburgh, PA USA. [Shihadeh, Alan L.] Amer Univ Beirut, Beirut, Lebanon. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Eissenberg, Thomas] Virginia Commonwealth Univ, Richmond, VA USA. [Nayak, Smita] Swedish Ctr Res & Innovat, Swedish Hlth Serv, Seattle, WA USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu OI Shihadeh, Alan/0000-0001-6387-8564; Weiss, Patricia/0000-0002-5434-391X FU National Cancer Institute [R01-CA140150] FX The authors acknowledge receipt of funding from the National Cancer Institute (R01-CA140150). The fenders played no role in the conception, data collection, writing, or approval of this manuscript. NR 49 TC 9 Z9 10 U1 4 U2 9 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JAN-FEB PY 2016 VL 131 IS 1 BP 76 EP 85 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DG9HD UT WOS:000372392500014 PM 26843673 ER PT J AU Genes, N Kim, MS Thum, FL Rivera, L Beato, R Song, C Soriano, J Kannry, J Baumlin, K Hwang, U AF Genes, Nicholas Kim, Min Soon Thum, Frederick L. Rivera, Laura Beato, Rosemary Song, Carolyn Soriano, Jared Kannry, Joseph Baumlin, Kevin Hwang, Ula TI Usability Evaluation of a Clinical Decision Support System for Geriatric ED Pain Treatment SO APPLIED CLINICAL INFORMATICS LA English DT Article DE Clinical decision support systems; decision support techniques; aged; acute pain; medical record systems; computerized; man-machine systems ID HEALTH INFORMATION-TECHNOLOGY; EMERGENCY-DEPARTMENT PATIENTS; RANDOMIZED-CONTROLLED-TRIAL; POSTOPERATIVE PAIN; ORDER ENTRY; CARE; IMPACT; ADHERENCE; INTERVENTIONS; MEDICATION AB Background: Older adults are at risk for inadequate emergency department (ED) pain care. Unrelieved acute pain is associated with poor outcomes. Clinical decision support systems (CDSS) hold promise to improve patient care, but CDSS quality varies widely, particularly when usability evaluation is not employed. Objective: To conduct an iterative usability and redesign process of a novel geriatric abdominal pain care CDSS. We hypothesized this process would result in the creation of more usable and favorable pain care interventions. Methods: Thirteen emergency physicians familiar with the Electronic Health Record (EHR) in use at the study site were recruited. Over a 10-week period, 17 1-hour usability test sessions were conducted across 3 rounds of testing. Participants were given 3 patient scenarios and provided simulated clinical care using the EHR, while interacting with the CDSS interventions. Quantitative System Usability Scores (SUS), favorability scores and qualitative narrative feedback were collected for each session. Using a multi-step review process by an interdisciplinary team, positive and negative usability issues in effectiveness, efficiency, and satisfaction were considered, prioritized and incorporated in the iterative redesign process of the CDSS. Video analysis was used to determine the appropriateness of the CDS appearances during simulated clinical care. Results: Over the 3 rounds of usability evaluations and subsequent redesign processes, mean SUS progressively improved from 74.8 to 81.2 to 88.9; mean favorability scores improved from 3.23 to 4.29 (1 worst, 5 best). Video analysis revealed that, in the course of the iterative redesign processes, rates of physicians' acknowledgment of CDS interventions increased, however most rates of desired actions by physicians (such as more frequent pain score updates) decreased. Conclusion: The iterative usability redesign process was instrumental in improving the usability of the CDSS; if implemented in practice, it could improve geriatric pain care. The usability evaluation process led to improved acknowledgement and favorability. Incorporating usability testing when designing CDSS interventions for studies may be effective to enhance clinician use. C1 [Genes, Nicholas; Thum, Frederick L.; Rivera, Laura; Beato, Rosemary; Song, Carolyn; Baumlin, Kevin] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA. [Kim, Min Soon] Univ Missouri, Sch Med, Dept Hlth Management & Informat, Columbia, MO USA. [Kim, Min Soon] Univ Missouri, Inst Informat, Columbia, MO USA. [Soriano, Jared; Kannry, Joseph] Mt Sinai Hlth Syst, Informat Technol, New York, NY USA. [Kannry, Joseph] Icahn Sch Med Mt Sinai, Div Gen Internal Med, New York, NY 10029 USA. [Hwang, Ula] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Hwang, Ula] James J Peters VAMC, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Genes, N (reprint author), Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA. EM nicholas.genes@mountsinai.org NR 35 TC 0 Z9 0 U1 2 U2 3 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 1869-0327 J9 APPL CLIN INFORM JI Appl. Clin. Inform. PY 2016 VL 7 IS 1 BP 128 EP 142 DI 10.4338/ACI-2015-08-RA-0108 PG 15 WC Medical Informatics SC Medical Informatics GA DG4SQ UT WOS:000372063200010 PM 27081412 ER PT J AU Taylor, RL Cruickshank, MN Karimi, M Ng, HL Quail, E Kaufman, KM Harley, JB Abraham, LJ Tsao, BP Boackle, SA Ulgiati, D AF Taylor, Rhonda L. Cruickshank, Mark N. Karimi, Mahdad Ng, Han Leng Quail, Elizabeth Kaufman, Kenneth M. Harley, John B. Abraham, Lawrence J. Tsao, Betty P. Boackle, Susan A. Ulgiati, Daniela TI Focused transcription from the human CR2/CD21 core promoter is regulated by synergistic activity of TATA and Initiator elements in mature B cells SO CELLULAR & MOLECULAR IMMUNOLOGY LA English DT Article DE B cells; core promoter; CR2/CD21; molecular biology; transcription factor ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; COMPLEMENT RECEPTOR 2; HUMAN LYMPHOCYTES-B; GENOME-WIDE ANALYSIS; GENE-EXPRESSION; PLASMA-CELL; FACTOR E2A; CR-2 GENE; T-CELLS; C3D AB Complement receptor 2 (CR2/CD21) is predominantly expressed on the surface of mature B cells where it forms part of a coreceptor complex that functions, in part, to modulate B-cell receptor signal strength. CR2/CD21 expression is tightly regulated throughout B-cell development such that CR2/CD21 cannot be detected on pre-B or terminally differentiated plasma cells. CR2/CD21 expression is upregulated at B-cell maturation and can be induced by IL-4 and CD40 signaling pathways. We have previously characterized elements in the proximal promoter and first intron of CR2/CD21 that are involved in regulating basal and tissue-specific expression. We now extend these analyses to the CR2/CD21 core promoter. We show that in mature B cells, CR2/CD21 transcription proceeds from a focused TSS regulated by a non-consensus TATA box, an initiator element and a downstream promoter element. Furthermore, occupancy of the general transcriptional machinery in pre-B versus mature B-cell lines correlate with CR2/CD21 expression level and indicate that promoter accessibility must switch from inactive to active during the transitional B-cell window. C1 [Taylor, Rhonda L.; Ng, Han Leng; Abraham, Lawrence J.; Ulgiati, Daniela] Univ Western Australia, Ctr Genet Origins Hlth & Dis, Sch Pathol & Lab Med, Crawley, WA 6009, Australia. [Taylor, Rhonda L.; Karimi, Mahdad; Quail, Elizabeth] Univ Western Australia, Sch Chem & Biochem, Biochem & Mol Biol, Crawley, WA 6009, Australia. [Cruickshank, Mark N.] Univ Western Australia, Telethon Kids Inst, Crawley, WA 6009, Australia. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Tsao, Betty P.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA. [Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO USA. RP Ulgiati, D (reprint author), Univ Western Australia, Sch Pathol & Lab Med, 35 Stirling Highway, Crawley, WA 6009, Australia. EM daniela.ulgiati@uwa.edu.au FU National Health and Medical Research Council of Australia [303206]; Lupus Research Institute; Alliance for Lupus Research; National Institutes of Health [R01AI070983, K24 AI078004, P01AI083194, P01AR049084, R37AI024717, U01HG006828]; US Department of Veterans Affairs FX This study was generously supported by the National Health and Medical Research Council of Australia (303206 to DU and LJA), the Lupus Research Institute (to SAB), the Alliance for Lupus Research (to SAB, DU and BPT), National Institutes of Health (R01AI070983 to SAB, DU and BPT, K24 AI078004 to SAB, and P01AI083194, P01AR049084, R37AI024717 and U01HG006828 to JBH) and the US Department of Veterans Affairs (to JBH). The authors declare that there is no conflict of interest. NR 62 TC 0 Z9 0 U1 0 U2 0 PU CHIN SOCIETY IMMUNOLOGY PI BEING PA 5 DONGDAN SANTIAO, DONGCHEN DISTRICT, BEING, 100005, PEOPLES R CHINA SN 1672-7681 EI 2042-0226 J9 CELL MOL IMMUNOL JI Cell. Mol. Immunol. PD JAN PY 2016 VL 13 IS 1 SI SI BP 119 EP 131 DI 10.1038/cmi.2014.138 PG 13 WC Immunology SC Immunology GA DG3UQ UT WOS:000371996300013 PM 25640655 ER PT J AU Zamboanga, BL Tomaso, CC Cloutier, RM Blumenthal, H Kenney, SR Borsari, B AF Zamboanga, Byron L. Tomaso, Cara C. Cloutier, Renee M. Blumenthal, Heidemarie Kenney, Shannon R. Borsari, Brian TI Drinking Game Participation Among High School and Incoming College Students A Narrative Review SO JOURNAL OF ADDICTIONS NURSING LA English DT Review DE college transition; adolescents; incoming college students; drinking games; alcohol use; high school students ID RANDOMIZED CONTROLLED-TRIAL; ILLICIT DRUG-USE; ALCOHOL-USE; HEAVY-DRINKING; MOTIVES; RISK; INTERVENTION; TRANSITION; BEHAVIORS; 1ST-YEAR AB The transition from high school to college has been characterized as a potentially vulnerable period because of decreased parental supervision and increased autonomy. This transition can increase risk for participation in high-risk behaviors such as drinking games (DGs), which are a social drinking activity that encourages intoxication and are associated with negative alcohol-related consequences. To date, there has not been a narrative review of DG research that examines this activity among high schoolers and incoming college students specifically, and thus, the current review bridges this gap. Findings indicate that DG participation is consistently linked to negative consequences (e.g., passing out, becoming sick) and other high-risk behaviors, such as prepartying (drinking before going to a social event). In addition, DG participation is linked to demographic (e.g., age, gender), psychological (e.g., personality, alcohol cognitions), and contextual/cultural factors (e.g., the college drinking culture). These findings have implications for current prevention and intervention efforts and suggest promising directions for future research. C1 [Zamboanga, Byron L.; Tomaso, Cara C.] Smith Coll, Northampton, MA 01063 USA. [Cloutier, Renee M.; Blumenthal, Heidemarie] Univ N Texas, Denton, TX 76203 USA. [Kenney, Shannon R.] Brown Univ, Providence, RI 02912 USA. [Borsari, Brian] San Francisco VA Med Ctr, San Francisco, CA USA. [Borsari, Brian] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Zamboanga, BL; Tomaso, CC (reprint author), Smith Coll, Dept Psychol, Northampton, MA 01063 USA. EM bzamboan@smith.edu; ctomaso@smith.edu FU National Institute on Alcohol Abuse and Alcoholism [R01-AA017427]; VISN1 Career Development Award [V1CDA2012-18] FX Brian Borsari's contribution to this manuscript was supported by National Institute on Alcohol Abuse and Alcoholism Grant R01-AA017427 and VISN1 Career Development Award V1CDA2012-18. The contents of this manuscript do not represent the views of the National Institute on Alcohol Abuse and Alcoholism, the Department of Veterans Affairs, or the United States Government. Byron L. Zamboanga and Cara C. Tomaso contributed equally to the writing of this manuscript. NR 54 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1088-4602 EI 1548-7148 J9 J ADDICT NURS JI J. Addict. Nurs. PD JAN-MAR PY 2016 VL 27 IS 1 BP 24 EP 31 DI 10.1097/JAN.0000000000000108 PG 8 WC Substance Abuse; Nursing SC Substance Abuse; Nursing GA DG6RV UT WOS:000372214700004 PM 26950839 ER PT J AU Merrick, DT Gao, DX Miller, YE Keith, RL Baron, AE Feser, W Kennedy, TC Blatchford, PJ Braudrick, S Hirsch, FR Heasley, L Bunn, PA Franklin, WA AF Merrick, Daniel T. Gao, Dexiang Miller, York E. Keith, Robert L. Baron, Anna E. Feser, William Kennedy, Timothy C. Blatchford, Patrick J. Braudrick, Sarah Hirsch, Fred R. Heasley, Lynn Bunn, Paul A., Jr. Franklin, Wilbur A. TI Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma SO CANCER PREVENTION RESEARCH LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; WHITE-LIGHT BRONCHOSCOPY; LUNG-CANCER; PREINVASIVE LESIONS; AUTOFLUORESCENCE BRONCHOSCOPY; IN-SITU; PRENEOPLASTIC LESIONS; FACTOR RECEPTOR; NATURAL COURSE; FOLLOW-UP AB Bronchial dysplasia (BD), a presumed precursor of pulmonary squamous cell carcinoma (SCC), rarely progresses to invasive cancer. A high-risk cohort at the University of Colorado provided an opportunity to directly sample airway epithelium at mapped sites on successive bronchoscopies. We have hypothesized that persistent dysplastic lesions showing a similar or higher level of dysplasia on follow-up biopsy, are associated with increased risk for the development of SCC. Endoscopic biopsies from 188 high-risk subjects were histologically classified according to the current WHO classification for BD using a numeric histology score ranging from 1 to 8 representing normal bronchial mucosa through invasive lung cancer. Differences in follow-up histology scores were compared between sites classified by clinical, histologic, and immunohistochemical variables. Subjects with a higher frequency of sites that persist or progress to high-grade dysplasia (>37.5% persist/progress, N = 35 versus <37.5% persist/progress, N = 114) show a significant association with development of incident invasive SCC (adjusted HR, 7.84; 95% confidence interval, 1.56-39.39), and those with incident lung SCC have adjusted mean follow-up histology scores 1.55 U higher than in subjects without lung cancer. Current smoking, elevated Ki67 growth fraction, histologic features of angiogenic squamous dysplasia (ASD) and higher histology score in baseline biopsies are significantly associated with increased follow-up histology scores. These results show that persistent BD is associated with the development of invasive SCC. Furthermore, increased expression of Ki67, the presence of angiogenic change and degree of baseline atypia are associated with persistence of BD. (C)2015 AACR. C1 [Merrick, Daniel T.; Hirsch, Fred R.; Franklin, Wilbur A.] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA. [Gao, Dexiang; Blatchford, Patrick J.] Univ Colorado, Dept Pediat, Anschutz Med Campus, Aurora, CO 80045 USA. [Miller, York E.; Keith, Robert L.] Denver Vet Affairs Med Ctr, Dept Med, Div Pulm Med, Denver, CO USA. [Miller, York E.; Keith, Robert L.; Kennedy, Timothy C.] Univ Colorado, Dept Med, Div Pulm Med, Anschutz Med Campus, Aurora, CO 80045 USA. [Baron, Anna E.; Feser, William] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Heasley, Lynn] Univ Colorado, Dept Craniofacial Biol, Anschutz Med Campus, Aurora, CO 80045 USA. [Bunn, Paul A., Jr.] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80045 USA. RP Merrick, DT (reprint author), Univ Colorado, Mail Stop 8104,12801 East 17th Ave,Room 5114, Aurora, CO 80045 USA. EM dan.merrick@ucdenver.edu FU Lung Specialized Programs of Research Excellence [P50 CA058187]; Cancer Center Support grant [P30 CA046934] FX This study was supported by Lung Specialized Programs of Research Excellence P50 CA058187 and Cancer Center Support grant P30 CA046934 (all authors received P30 CA046934) NR 36 TC 3 Z9 3 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD JAN PY 2016 VL 9 IS 1 BP 96 EP 104 DI 10.1158/1940-6207.CAPR-15-0305 PG 9 WC Oncology SC Oncology GA DG3XY UT WOS:000372005700013 PM 26542061 ER PT J AU Loewenstein, G Price, J Volpp, K AF Loewenstein, George Price, Joseph Volpp, Kevin TI Habit formation in children: Evidence from incentives for healthy eating SO JOURNAL OF HEALTH ECONOMICS LA English DT Article DE Habit formation; Incentives; School lunch; Field experiments ID INTRINSIC MOTIVATION; EXERCISE; TRIAL AB We present findings from a field experiment conducted at 40 elementary schools involving 8000 children and 400,000 child-day observations, which tested whether providing short-run incentives can create habit formation in children. Over a 3- or 5-week period, students received an incentive for eating a serving of fruits or vegetables during lunch. Relative to an average baseline rate of 39%, providing small incentives doubled the fraction of children eating at least one serving of fruits or vegetables. Two months after the end of the intervention, the consumption rate at schools remained 21% above baseline for the 3 week treatment and 44% above baseline for the 5-week treatment. These findings indicate that short-run incentives can produce changes in behavior that persist after incentives are removed. (C) 2015 Elsevier B.V. All rights reserved. C1 [Loewenstein, George] Carnegie Mellon Univ, Social & Decis Sci, Pittsburgh, PA 15213 USA. [Price, Joseph] Brigham Young Univ, 162 FOB, Provo, UT 84602 USA. [Volpp, Kevin] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Volpp, Kevin] Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Davis, CA USA. [Volpp, Kevin] Penn Med Ctr Innovat, Philadelphia, PA USA. [Volpp, Kevin] Univ Penn, Perelman Sch Med, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Wharton Sch, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. RP Price, J (reprint author), Brigham Young Univ, 162 FOB, Provo, UT 84602 USA. EM joseph_price@byu.edu FU USDA Economic Research Service [59-5000-1-0034] FX The authors are grateful to the USDA Economic Research Service for research funding (grant # 59-5000-1-0034) and for the many BYU undergraduates and PTA parents that helped as research assistants on the project. This paper has benefitted from the helpful comments by Sandy Black, Dan Hamermesh, Patrick Nolen, Devin Pope, Bob Slonim, Coady Wing, Jingsan Zhu and seminar participants at the Cornell University, Harris School, University of Illinois at Chicago, University of Sydney, UT-Austin, Iowa State, University of Utah, University of Oregon, University of Iowa, and Brigham Young University. NR 22 TC 1 Z9 1 U1 5 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-6296 EI 1879-1646 J9 J HEALTH ECON JI J. Health Econ. PD JAN PY 2016 VL 45 BP 47 EP 54 DI 10.1016/j.jhealeco.2015.11.004 PG 8 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DG1PU UT WOS:000371840800004 PM 26717440 ER PT J AU Haidar, G Crespo, M Maximous, S Lendermon, E Clancy, CJ Nguyen, MH AF Haidar, G. Crespo, M. Maximous, S. Lendermon, E. Clancy, C. J. Nguyen, M. H. TI Invasive Tracheobronchial Aspergillosis in a Lung Transplant Recipient Receiving Belatacept as Salvage Maintenance Immunosuppression: A Case Report SO TRANSPLANTATION PROCEEDINGS LA English DT Article ID ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; COSTIMULATION BLOCKADE; PHASE-III; CYCLOSPORINE; REGIMENS; PATIENT; BENEFIT AB Introduction. The association between belatacept, a CD28 costimulation blocker, and invasive mycoses is unclear. Case Report. We describe a patient who initiated belatacept 3 years after lung transplantation and developed invasive tracheobronchial aspergillosis, a disease encountered almost exclusively within the first 6 months after transplantation. Conclusions. Belatacept may have played a causative role. Until more data are available, belatacept should be used cautiously after lung transplantation. C1 [Haidar, G.; Crespo, M.; Maximous, S.; Lendermon, E.; Clancy, C. J.; Nguyen, M. H.] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15213 USA. [Clancy, C. J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Haidar, G (reprint author), Univ Pittsburgh, Med Ctr, 3601 Fifth Ave,Suite 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. EM haidarg@upmc.edu NR 22 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0041-1345 EI 1873-2623 J9 TRANSPL P JI Transplant. Proc. PD JAN-FEB PY 2016 VL 48 IS 1 BP 275 EP 278 DI 10.1016/j.transproceed.2016.01.003 PG 4 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DG1TG UT WOS:000371849800051 PM 26915884 ER PT J AU Ahluwalia, SC Schreibeis-Baum, H Prendergast, TJ Reinke, LF Lorenz, KA AF Ahluwalia, Sangeeta C. Schreibeis-Baum, Hannah Prendergast, Thomas J. Reinke, Lynn F. Lorenz, Karl A. TI NURSES AS INTERMEDIARIES: HOW CRITICAL CARE NURSES PERCEIVE THEIR ROLE IN FAMILY MEETINGS SO AMERICAN JOURNAL OF CRITICAL CARE LA English DT Article ID OF-LIFE CARE; PATIENT OUTCOMES; PALLIATIVE CARE; COMMUNICATION; END; UNIT; PHYSICIANS; PERSPECTIVES; ICU; PERCEPTIONS AB Background Nurses' involvement in family meetings in the intensive care unit is central to supporting consistent communication and shared understanding within the care team and with patients and patients' family members. Evidence suggests the existence of major barriers to the effective participation and contribution of nurses during family meetings. Objectives To characterize the nature and extent of nurses' involvement in family meetings in the intensive care unit, including identifying barriers to nurses' participation and opportunities for involvement. Methods Meetings with focus groups of nurses at a Veterans Affairs medical intensive care unit were recorded, transcribed, and qualitatively analyzed by using the constant comparative method. Results Thirty critical care nurses participated in 6 focus groups. Three major themes describing nurses' involvement in family meetings were identified: nurses can play multiple roles in supporting conduct in family meetings, nurses face critical barriers to fully realizing these roles, and nurses end up as intermediaries in family meetings. Subthemes pertained to being well positioned to act as the patient's advocate, yet feeling undervalued and underempowered to contribute important information in family meetings, often resulting in mixed messages about care preferences, prognosis, or goals of care that nurses did not feel able to address during the meeting. Conclusion Nurses are positioned to play essential roles in family meetings, but their full involvement remains unrealized. Communication training and greater attention to nurses' empowerment and to facilitating the nurse-physician relationship in the context of family meetings most likely would increase appropriate involvement of nurses in the meetings. C1 [Ahluwalia, Sangeeta C.] RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. [Ahluwalia, Sangeeta C.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA. [Schreibeis-Baum, Hannah; Lorenz, Karl A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Prendergast, Thomas J.] Oregon Hlth & Sci Univ, Med, Portland, OR USA. [Prendergast, Thomas J.] Portland VA Med Ctr, Pulm & Crit Care Med, Portland, OR USA. [Reinke, Lynn F.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Reinke, Lynn F.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Lorenz, Karl A.] Univ Calif Los Angeles, Sch Med, Med, Los Angeles, CA 90024 USA. RP Ahluwalia, SC (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM sahluwal@rand.org FU National Palliative Care Research Center; Implementation Research Institute, George Warren Brown School of Social Work, Washington University, St Louis, Missouri, through the National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative FX Dr Ahluwalia was supported by a career development award from the National Palliative Care Research Center. The preparation of this article was supported in part by the Implementation Research Institute, George Warren Brown School of Social Work, Washington University, St Louis, Missouri, through the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative. NR 31 TC 2 Z9 2 U1 2 U2 12 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 1062-3264 EI 1937-710X J9 AM J CRIT CARE JI Am. J. Crit. Care PD JAN 1 PY 2016 VL 25 IS 1 BP 33 EP 38 DI 10.4037/ajcc2016653 PG 6 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA DF3FL UT WOS:000371229200011 PM 26724291 ER PT J AU Fan, VS Gharib, SA Martin, TR Wurfel, MM AF Fan, Vincent S. Gharib, Sina A. Martin, Thomas R. Wurfel, Mark M. TI COPD disease severity and innate immune response to pathogen-associated molecular patterns SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE chronic obstructive pulmonary disease; innate immunity; inflammation; chronic bronchitis; toll-like receptors ID OBSTRUCTIVE PULMONARY-DISEASE; TOLL-LIKE RECEPTORS; TUMOR-NECROSIS-FACTOR; AIRWAY INFLAMMATION; SYSTEMIC INFLAMMATION; ALVEOLAR MACROPHAGES; BRONCHIAL LAVAGE; HUMAN MONOCYTES; EXPRESSION; CYTOKINES AB The airways of COPD patients are often colonized with bacteria leading to increased airway inflammation. This study sought to determine whether systemic cytokine responses to microbial pathogen-associated molecular patterns (PAMPs) are increased among subjects with severe COPD. In an observational cross-sectional study of COPD subjects, PAMP-induced cytokine responses were measured in whole blood ex vivo. We used PAMPs derived from microbial products recognized by toll-like receptors 1, 2, 4, 5, 6, 7, and 8. Patterns of cytokine response to PAMPs were assessed using hierarchical clustering. One-sided Student's t-tests were used to compare PAMP-induced cytokine levels in blood from patients with and without severe COPD, and for subjects with and without chronic bronchitis. Of 28 male patients, 12 had moderate COPD (FEV1 50%-80%) and 16 severe COPD (FEV1,50%); 27 participants provided data on self-reported chronic bronchitis, of which 15 endorsed chronic bronchitis symptoms and 12 did not. Cytokine responses to PAMPs in severe COPD were generally lower than in subjects with milder COPD. This finding was particularly strong for PAMP-induced interleukin (IL)-10, granulocyte colony stimulating factor, and IL-1 beta. Subjects with chronic bronchitis showed higher PAMP-induced IL-1RA responses to most of the PAMPs evaluated. COPD patients with more severe disease demonstrated a diminished cytokine response to PAMPs, suggesting that chronic colonization with bacteria may dampen the systemic innate immune response. C1 [Fan, Vincent S.; Martin, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Fan, Vincent S.; Gharib, Sina A.; Martin, Thomas R.; Wurfel, Mark M.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA 98195 USA. [Gharib, Sina A.] Univ Washington, Computat Med Core, Ctr Lung Biol, Seattle, WA 98195 USA. RP Fan, VS (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, 1660 S Columbian Way, Seattle, WA 98108 USA. EM vfan@u.washington.edu FU United States Department of Veterans Affairs Health Services Research and Development Program [02-170-2]; National Institute of Allergy and Infectious Diseases [U54 AI057141] FX Angela Horn assisted in recruitment, study visits, and data management for the study. This work was supported by Career Development Award, Award # 02-170-2, from the United States Department of Veterans Affairs Health Services Research and Development Program, as well as a grant by the National Institute of Allergy and Infectious Diseases (Award # U54 AI057141). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 45 TC 3 Z9 4 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2016 VL 11 BP 467 EP 477 DI 10.2147/COPD.S94410 PG 11 WC Respiratory System SC Respiratory System GA DF5GK UT WOS:000371379600001 PM 27019597 ER PT J AU Brummel-Smith, K Butler, D Frieder, M Gibbs, N Henry, M Koons, E Loggers, E Porock, D Reuben, DB Saliba, D Scanlon, WJ Tabbush, V Tinetti, M Tumlinson, A Vladeck, BC Kogan, AC Mosqueda, L Wilber, K Goodwin, C Lundebjerg, NE Mikhailovich, A Aiello, SE AF Brummel-Smith, Kenneth Butler, Dawn Frieder, Miryam Gibbs, Nancy Henry, Maureen Koons, Eileen Loggers, Elizabeth Porock, Davina Reuben, David B. Saliba, Debra Scanlon, William J. Tabbush, Victor Tinetti, Mary Tumlinson, Anne Vladeck, Bruce C. Kogan, Alexis Coulourides Mosqueda, Laura Wilber, Kate Goodwin, Carol Lundebjerg, Nancy E. Mikhailovich, Anna Aiello, Susan E. CA Amer Geriatrics Soc Expert Panel TI Person-Centered Care: A Definition and Essential Elements SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE person-centered care; patient-centered care; care delivery; care quality; care coordination AB Improving healthcare safety, quality, and coordination, as well as quality of life, are important aims of caring for older adults with multiple chronic conditions and/or functional limitations. Person-centered care is an approach to meeting these aims, but there are no standardized, agreed-upon parameters for delivering such care. The SCAN Foundation charged a team from the American Geriatrics Society (AGS) in collaboration with a research and clinical team from the Keck School of Medicine of the University of Southern California to provide the evidence base to support a definition of person-centered care and its essential elements. An interprofessional panel of experts in person-centered care principles and practices that the AGS convened developed this statement. C1 [Brummel-Smith, Kenneth] Amer Geriat Soc, 40 Fulton St 18th Floor, New York, NY 10038 USA. [Brummel-Smith, Kenneth] Florida State Univ, Coll Med, Tallahassee, FL 32306 USA. [Butler, Dawn] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA. [Frieder, Miryam] Avalere Hlth, Washington, DC USA. [Gibbs, Nancy] So Calif Permanente Med Grp, Pasadena, CA USA. [Henry, Maureen] NCQA, Washington, DC USA. [Henry, Maureen] Univ Utah, Coll Nursing, Salt Lake City, UT USA. [Koons, Eileen] Huntington Hosp Senior Care Network, Pasadena, CA USA. [Loggers, Elizabeth] Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Loggers, Elizabeth] Seattle Canc Care Alliance, Seattle, WA USA. [Porock, Davina] Lehman Coll, Bronx, NY USA. [Reuben, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [Saliba, Debra] Univ Calif Los Angeles, Jewish Home Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, Debra] VA Greater Angeles Healthcare Syst, Geriat Res, Educ & Clin Ctr, Los Angeles, CA USA. [Saliba, Debra] RAND Hlth, Santa Monica, CA USA. [Scanlon, William J.] Natl Hlth Policy Forum, Washington, DC USA. [Tabbush, Victor] Univ Calif Los Angeles, Anderson Sch Management, Los Angeles, CA USA. [Tinetti, Mary] Yale Univ, Sch Med, New Haven, CT USA. [Tumlinson, Anne] Anne Tumlinson Innovat LLC, Washington, DC USA. [Vladeck, Bruce C.] Nexera Inc, New York, NY USA. [Kogan, Alexis Coulourides; Mosqueda, Laura] Univ So Calif, Family Med & Geriat, Keck Sch Med, Los Angeles, CA USA. [Wilber, Kate] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA USA. [Goodwin, Carol; Lundebjerg, Nancy E.; Mikhailovich, Anna] Writing & Editorial Serv, New York, NY USA. [Goodwin, Carol; Lundebjerg, Nancy E.; Mikhailovich, Anna] Amer Geriat Soc, 40 Fulton St 18th Floor, New York, NY USA. [Aiello, Susan E.] Provided Editorial Serv, Indianapolis, IN USA. RP Goodwin, C (reprint author), Writing & Editorial Serv, New York, NY USA.; Goodwin, C (reprint author), Amer Geriat Soc, 40 Fulton St 18th Floor, New York, NY USA. EM CGoodwin@americangeriatrics.org FU TSF FX This work was supported by a grant from TSF. Gretchen E. Alkema, PhD, Victoria R. Ballesteros, MA, Megan Burke, MSW, Megan Juring, Lynn Palin, MSW, Rene Seidel, Dipl. Soz. Paed. (FH), and Erin Westphal, MS, The SCAN Foundation, Long Beach, CA, and Sean Dryden, PerryUndem Research/Communication, Washington, DC, participated in the expert panel meeting. NR 4 TC 13 Z9 14 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2016 VL 64 IS 1 BP 15 EP 18 DI 10.1111/jgs.13866 PG 4 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FQ UT WOS:000371157900003 ER PT J AU Singh, JA Ramachandran, R AF Singh, Jasvinder A. Ramachandran, Rekha TI Time trends in total ankle arthroplasty in the USA: a study of the National Inpatient Sample SO CLINICAL RHEUMATOLOGY LA English DT Article DE Ankle arthroplasty; Outcomes; Sex; Time trends; Utilization ID UNITED-STATES; KNEE ARTHROPLASTY; SHOULDER ARTHROPLASTY; TOTAL HIP; OPEN APPENDECTOMY; NIS DATABASE; FOLLOW-UP; OUTCOMES; REPLACEMENT; SURGERY AB The objective of this study was to assess the time trends in utilization, clinical characteristics, and outcomes of patients undergoing total ankle arthroplasty (TAA) in the USA. We used the Nationwide Inpatient Sample (NIS) data from 1998 to 2010 to examine time trends in the utilization rates of TAA. We used the Cochran Armitage test for trend to assess time trends across the years and the analysis of variance (ANOVA), Wilcoxon test, or chi-squared test (as appropriate) to compare the first (1998-2000) and the last time periods (2009-2010). TAA utilization rate increased significant from 1998 to 2010: 0.13 to 0.84 per 100,000 overall, 0.14 to 0.88 per 100,000 in females, and from 0.11 to 0.81 per 100,000 in males (p<0.0001 for each comparison for time trends). Compared to the 1998-2000 period, those undergoing TAA in 2009-2010 were older (41 % fewer patients <50 years, p<0.0001), less likely to have rheumatoid arthritis as the underlying diagnosis (55 % fewer patients, p=0.0001), more likely to have Deyo-Charlson index of 2 or more (197 % more, p=0.0010), and had a shorter length of stay at 2.5 days (17 % reduction, p<0.0001). Mortality was rare ranging from 0 to 0.6 % and discharge to inpatient facility ranged 12.6-14.1 %; we noted no significant time trends in either (p>0.05). The utilization rate of TAA increased rapidly in the USA from 1998 to 2010, but post-arthroplasty mortality rate was stable. Underlying diagnosis and medical comorbidity changed over time and both can impact outcomes after TAA. Further studies should examine how the outcomes and complications of TAA have evolved over time. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. EM Jasvinder.md@gmail.com FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient Centered Outcomes Research Institute (PCORI) [CE-1304-6631]; VA Medical Center at Birmingham, AL, USA FX JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110; the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891; the National Institute of Aging (NIA) U01 AG018947; the National Cancer Institute (NCI) U10 CA149950; and research contract CE-1304-6631 from Patient Centered Outcomes Research Institute (PCORI). JAS is also supported through the use of resources and facilities at the VA Medical Center at Birmingham, AL, USA. NR 25 TC 4 Z9 4 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0770-3198 EI 1434-9949 J9 CLIN RHEUMATOL JI Clin. Rheumatol. PD JAN PY 2016 VL 35 IS 1 BP 239 EP 245 DI 10.1007/s10067-014-2703-2 PG 7 WC Rheumatology SC Rheumatology GA DE7MM UT WOS:000370821000029 PM 24907036 ER PT J AU Miedema, MD Huguelet, J Virani, SS AF Miedema, Michael D. Huguelet, Joseph Virani, Salim S. TI Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity SO CURRENT ATHEROSCLEROSIS REPORTS LA English DT Review DE Aspirin; Primary prevention; Cardiovascular disease ID LOW-DOSE ASPIRIN; RANDOMIZED-CONTROLLED-TRIALS; ACUTE MYOCARDIAL-INFARCTION; PLACEBO-CONTROLLED TRIAL; RISK-FACTORS; EVENTS; CORONARY; METAANALYSIS; SECONDARY; STROKE AB Aspirin remains one of the most extensively studied cardiovascular medications in the history of medicine. However, despite multiple, well-designed, large randomized controlled trials evaluating the potential of aspirin to prevent cardiovascular events in individuals without known cardiovascular disease (CVD), the role of aspirin in primary prevention is currently unclear. The initial aspirin trials included largely low-risk individuals with primary outcomes mostly focused on myocardial infarction (MI) and stroke, and showed a significant reduction in these CVD outcomes, especially MI. The more recently conducted trials have focused on older, higher CVD risk populations with high rates of lipid-lowering and antihypertensive medications use. These studies have used broader CVD outcomes as their primary end points and have failed to show a significant benefit of aspirin therapy in primary prevention. The exact reasons for the lack of efficacy in these recent trials are unclear but may be related to low rate of atherothrombotic events relative to other CVD events in the populations studied. Four large randomized controlled trials are currently underway which should provide some clarity in determining the optimal use of aspirin in the primary prevention of CVD. C1 [Miedema, Michael D.] Minneapolis Heart Inst, Minneapolis, MN USA. [Miedema, Michael D.] Minneapolis Heart Inst Fdn, 920 E 28th St, Minneapolis, MN 55414 USA. [Huguelet, Joseph] Abbott NW Hosp, Minneapolis, MN 55407 USA. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Sect Cardiovasc Res, Houston, TX 77030 USA. RP Miedema, MD (reprint author), Minneapolis Heart Inst, Minneapolis, MN USA.; Miedema, MD (reprint author), Minneapolis Heart Inst Fdn, 920 E 28th St, Minneapolis, MN 55414 USA. EM mdm307@mail.harvard.edu OI Virani, Salim/0000-0001-9541-6954 NR 38 TC 0 Z9 0 U1 0 U2 1 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1523-3804 EI 1534-6242 J9 CURR ATHEROSCLER REP JI Curr. Atheroscleros. Rep. PD JAN PY 2016 VL 18 IS 1 AR 4 DI 10.1007/s11883-015-0555-0 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DE7JF UT WOS:000370811300003 PM 26753770 ER PT S AU Lyamin, OI Korneva, SM Rozhnov, VV Mukhametov, LM AF Lyamin, Oleg I. Korneva, Svetlana M. Rozhnov, Viatcheslav V. Mukhametov, Lev M. BE Popper, AN Hawkins, A TI Cardiorespiratory Responses to Acoustic Noise in Belugas SO EFFECTS OF NOISE ON AQUATIC LIFE II SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 3rd International Conference on the Effects of Noise on Aquatic Life CY AUG, 2013 CL Budapest, HUNGARY SP Fisheries Joint Management Comm, Natl Oceanog & Atmospher Adm, Natl Sci Fdn, NAVFAC, Off Naval Res, Off Naval Res Global, Acoust Soc Amer, Aquat Noise Trust, Discovery Sound Sea, Co Biologists, Univ Maryland, Coll Chem & Life Sci, Ctr Comparat & Evolutionary Biol Hearing DE Noise; Beluga; Heart rate; Breathing; Stress ID DOLPHIN TURSIOPS-TRUNCATUS AB To date, most research on the adverse effects of anthropogenic noise on marine mammals has focused on auditory and behavioral responses. Other responses have received little attention and are often ignored. In this study, the effect of acoustic noise on heart rate was examined in captive belugas. The data suggest that (1) heart rate can be used as a measure of physiological response (including stress) to noise in belugas and other cetaceans, (2) cardiac response is influenced by parameters of noise and adaptation to repeated exposure, and (3) cetacean calves are more vulnerable to the adverse effect of noise than adults. C1 [Lyamin, Oleg I.; Rozhnov, Viatcheslav V.; Mukhametov, Lev M.] Russian Acad Sci, AN Severtsov Inst Ecol & Evolut, Moscow 119071, Russia. [Lyamin, Oleg I.; Korneva, Svetlana M.; Mukhametov, Lev M.] Utrish Dolphinarium Ltd, Moscow 119071, Russia. [Lyamin, Oleg I.] Sepulveda Res Corp, VA Greater Los Angeles Healthcare Syst, Neurobiol Res 15A03, 16111 Plummer St, North Hills, CA 91343 USA. RP Lyamin, OI (reprint author), Russian Acad Sci, AN Severtsov Inst Ecol & Evolut, Moscow 119071, Russia.; Lyamin, OI (reprint author), Utrish Dolphinarium Ltd, Moscow 119071, Russia.; Lyamin, OI (reprint author), Sepulveda Res Corp, VA Greater Los Angeles Healthcare Syst, Neurobiol Res 15A03, 16111 Plummer St, North Hills, CA 91343 USA. EM olyamin@ucla.edu; s_korneva@list.ru; rozhnov.v@gmail.com; lev.mukhametov@gmail.com RI Varghese, Ann/P-7833-2016 FU Russian Geographical Society; Utrish Dolphinarium Ltd. FX The study was funded by the Russian Geographical Society and supported by Utrish Dolphinarium Ltd. We thank the colleagues from Dr. A. Supin's laboratory (A. N. Severtsov Institute of Ecology and Evolutions, Moscow, Russia) for assistance with the presentation of noises and Dr. P. Kosenko (Utrish Dolphinarium Ltd., Moscow, Russia) for technical support. NR 14 TC 0 Z9 0 U1 9 U2 13 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-1-4939-2981-8; 978-1-4939-2980-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 875 BP 665 EP 672 DI 10.1007/978-1-4939-2981-8_80 PG 8 WC Environmental Sciences; Marine & Freshwater Biology SC Environmental Sciences & Ecology; Marine & Freshwater Biology GA BE2TA UT WOS:000370000900081 PM 26611017 ER PT J AU Jaoude, WA Tiu, B Strieter, N Maloney, JD AF Jaoude, Wassim Abi Tiu, Brian Strieter, Nicole Maloney, James D. TI Thoracoscopic native lung pneumonectomy after single lung transplant: initial experience with 2 cases SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Editorial Material CT CHEST Annual Meeting CY OCT 29, 2013 CL Chicago, IL DE Lung-other; Experimental thoracic surgery ID COMPLICATIONS AB Single lung transplants (SLTs) leave in place a diseased lung, a potential source of complications. Native lung pneumonectomy is occasionally indicated. We present 2 cases of native lung complications (NLCs) managed with video-assisted thoracoscopic surgery (VATS) pneumonectomy at our institution, a procedure never reported in this context before. Case 1 involves a 59-year old gentleman with refractory, invasive pulmonary aspergillosis of the native lung, 5 years after SLT for idiopathic pulmonary fibrosis. Case 2 involves a 66-year old gentleman with alpha-1 antitrypsin deficiency who developed severe haemoptysis and intraparenchymal haemorrhage in the native lung 12 years after SLT. AVATS pneumonectomy was performed in both cases because we believed it would facilitate wound healing and hasten recovery in immunosuppressed patients. Our short-term results align with this hypothesis. We conclude that VATS pneumonectomy is a feasible, adequate and safe procedure in this patient population; larger series are needed to draw definitive conclusions. C1 [Jaoude, Wassim Abi; Maloney, James D.] Univ Wisconsin Hosp & Clin, Div Cardiothorac Surg, Thorac Surg Sect, Madison, WI 53792 USA. [Tiu, Brian] Suny Downstate Med Ctr, Dept Surg, 450 Clarkson Ave, Brooklyn, NY 11203 USA. [Strieter, Nicole; Maloney, James D.] William S Middleton Mem Vet Adm Med Ctr, Div Cardiothorac Surg, Thorac Surg Sect, Madison, WI USA. RP Tiu, B (reprint author), Suny Downstate Med Ctr, Dept Surg, 450 Clarkson Ave, Brooklyn, NY 11203 USA. EM brian.tiu@downstate.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 EI 1873-734X J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD JAN PY 2016 VL 49 IS 1 BP 352 EP 354 DI 10.1093/ejcts/ezv075 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DE9SR UT WOS:000370979800095 ER PT J AU Calverley, PM Postma, DS Anzueto, AR Make, BJ Eriksson, G Peterson, S Jenkins, CR AF Calverley, Peter M. Postma, Dirkje S. Anzueto, Antonio R. Make, Barry J. Eriksson, Goeran Peterson, Stefan Jenkins, Christine R. TI Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE anti-inflammatories; bronchodilator effect; chronic obstructive pulmonary disease; predictors; risk assessment; risk factors ID OBSTRUCTIVE PULMONARY-DISEASE; METERED-DOSE INHALER; LUNG-FUNCTION; FLUTICASONE PROPIONATE; CLINICAL-TRIAL; HEALTH-STATUS; SALMETEROL; EFFICACY; OUTCOMES; BUDESONIDE/FORMOTEROL AB Background: Early treatment response markers, for example, improvement in forced expiratory volume in 1 second (FEV1) and St George's Respiratory Questionnaire (SGRQ) total score, may help clinicians to better manage patients with chronic obstructive pulmonary disease (COPD). We investigated the prevalence of clinically important improvements in FEV1 and SGRQ scores after 2-month budesonide/formoterol or formoterol treatment and whether such improvements predict subsequent improvements and exacerbation rates. Methods: This post hoc analysis is based on data from three double-blind, randomized studies in patients with moderate-to-very-severe COPD receiving twice-daily budesonide/formoterol or formoterol alone for 6 or 12 months. Prebronchodilator FEV1 and SGRQ total score were measured before treatment and at 2 and 12 months; COPD exacerbation rates were measured during months 2-12. Responders were defined by >= 100 mL improvement in prebronchodilator FEV1 and >= 4-point decrease in SGRQ total score. Results: Overall, 2,331 and 1,799 patients were included in the 0-2- and 0-12-month responder analyses, respectively, and 2,360 patients in the 2-12-month exacerbation rate analysis. At 2 months, 35.1% of patients were FEV1 responders and 44.3% were SGRQ responders. The probability of response was significantly greater with budesonide/formoterol than with formoterol or placebo for both parameters. Two-month responders had a greater chance of 12-month response than 2-month nonresponders for both FEV1 (odds ratio, 5.57; 95% confidence interval, 4.14-7.50) and SGRQ (odds ratio, 3.87; 95% confidence interval, 2.83-5.31). Two-month response in FEV1 (P<0.001), but not SGRQ (P=0.11), was associated with greater reductions in exacerbation risk. Conclusion: Early FEV1 and SGRQ treatment responses relate to their changes at 12 months. FEV1 response, but not SGRQ response, at 2 months predicts the risk of a future COPD exacerbation in some, but not all patients. This is potentially useful in clinical practice, although more sensitive and specific markers of favorable treatment response are required. C1 [Calverley, Peter M.] Aintree Univ Hosp NHS Fdn Trust, Pulm & Rehabil Res Grp, Liverpool L9 7AL, Merseyside, England. [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Gronigen Res Inst Asthma, Dept Pulm Med & TB, Groningen, Netherlands. [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, COPD, Groningen, Netherlands. [Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. [Anzueto, Antonio R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Make, Barry J.] Univ Colorado, Natl Jewish Hlth, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA. [Eriksson, Goeran] Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden. [Peterson, Stefan] StatMind AB, Lund, Sweden. [Jenkins, Christine R.] Univ Sydney, Concord Clincal Sch, George Inst Global Hlth, Sydney, NSW 2006, Australia. RP Calverley, PM (reprint author), Aintree Univ Hosp NHS Fdn Trust, Inst Ageing & Chron Dis, Dept Clin Sci, Lower Lane, Liverpool L9 7AL, Merseyside, England. EM pmacal@liverpool.ac.uk FU AstraZeneca FX This analysis was funded by AstraZeneca. Anna Mett and Shaun Foley of in Science Communications, Springer Healthcare, provided medical writing assistance, funded by AstraZeneca. The authors thank Malin Fageras of AstraZeneca R&D, Gothenburg, Sweden, and Thomas Similowski, of Groupe Hospitalier Pitie-Salpetriere, Paris, France, for their assistance with the development of this manuscript. Anders Persson of AstraZeneca R&D, Gothenburg, Sweden, performed additional statistical analyses. NR 30 TC 1 Z9 1 U1 0 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2016 VL 11 BP 381 EP 390 DI 10.2147/COPD.S93303 PG 10 WC Respiratory System SC Respiratory System GA DE9RK UT WOS:000370975600001 PM 26952309 ER PT J AU Burgess, DJ Gravely, AA Nelson, DB Bair, MJ Kerns, RD Higgins, DM Farmer, MM Partin, MR AF Burgess, Diana J. Gravely, Amy A. Nelson, David B. Bair, Matthew J. Kerns, Robert D. Higgins, Diana M. Farmer, Melissa M. Partin, Melissa R. TI Association between pain outcomes and race and opioid treatment: Retrospective cohort study of Veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE blacks; chronic pain; Department of Veterans Affairs; disparities; opioids; pain outcomes; pain treatment effectiveness; race; survey; Veterans ID CHRONIC NONCANCER PAIN; UNITED-STATES; PRIMARY-CARE; RACIAL-DIFFERENCES; HEALTH-CARE; PATIENT SATISFACTION; AFRICAN-AMERICAN; POPULATION; OSTEOARTHRITIS; MANAGEMENT AB We examined whether pain outcomes (pain interference, perceived pain treatment effectiveness) vary by race and then whether opioid use moderates these associations. These analyses are part of a retrospective cohort study among 3,505 black and 46,203 non-Hispanic, white Department of Veterans Affairs (VA) patients with diagnoses of chronic musculoskeletal pain who responded to the 2007 VA Survey of Healthcare Experiences of Patients (SHEP). We used electronic medical record data to identify prescriptions for pharmacologic pain treatments in the year after diagnosis (Pain Diagnosis index visit) and before the SHEP index visit (the visit that made one eligible to complete the SHEP); pain outcomes came from the SHEP. We found no significant associations between race and pain interference or perceived effectiveness of pain treatment. VA patients with opioid prescriptions between the Pain Diagnosis index visit and the SHEP index visit reported greater pain interference on the SHEP than those without opioid prescriptions during that period. Opioid prescriptions were not associated with perceived treatment effectiveness for most patients. Findings raise questions about benefits of opioids for musculoskeletal pain and point to the need for alternative treatments for addressing chronic noncancer pain. C1 [Burgess, Diana J.; Gravely, Amy A.; Nelson, David B.; Partin, Melissa R.] Minneapolis Dept Vet Affairs VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Burgess, Diana J.; Nelson, David B.; Partin, Melissa R.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Bair, Matthew J.] Richard L Roudebush VA Med Ctr, VA Hlth Serv Res & Dev, Ctr Hlth Informat & Commun, Indianapolis, IN USA. [Bair, Matthew J.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Bair, Matthew J.] Regenstrief Inst Inc, Indianapolis, IN USA. [Kerns, Robert D.; Higgins, Diana M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Kerns, Robert D.; Higgins, Diana M.] Yale Univ, Sch Med, New Haven, CT USA. [Higgins, Diana M.; Farmer, Melissa M.] VA Greater Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, VA Hlth Serv Res & Dev Serv, Sepulveda, CA USA. RP Higgins, DM (reprint author), Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, One Vet Dr, Minneapolis, MN 55419 USA. EM Diana.Burgess@va.gov FU VA Health Services Research and Development Service (HSRD) [IIR 07-071]; VA HSR&D Research Career Scientist [RCS 10-185]; Merit Review Entry Program award MRP [04-41-1] FX This material was based on work supported by three awards from VA Health Services Research and Development Service (HSR&D): investigator initiated research IIR 07-071 (D.J.B.), VA HSR&D Research Career Scientist award RCS 10-185 (M.R.P.), and Merit Review Entry Program award MRP 04-41-1 (D.J.B.). NR 48 TC 0 Z9 0 U1 1 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2016 VL 53 IS 1 BP 13 EP 24 DI 10.1682/JRRD.2014.10.0252 PG 12 WC Rehabilitation SC Rehabilitation GA DE9WS UT WOS:000370991200005 PM 26933921 ER PT J AU Costa-Mallen, P Zabetian, CP Agarwal, P Hu, SC Yearout, D Samii, A Leverenz, JB Roberts, JW Checkoway, H AF Costa-Mallen, Paola Zabetian, Cyrus P. Agarwal, Pinky Hu, Shu-Ching Yearout, Dora Samii, Ali Leverenz, James B. Roberts, John W. Checkoway, Harvey TI Response to the letter "Haptoglobin phenotype and Parkinson disease risk" by Delanghe et al. SO PARKINSONISM & RELATED DISORDERS LA English DT Letter DE Haptoglobin polymorphism; Parkinson disease; Heterosis C1 [Costa-Mallen, Paola] Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA USA. [Zabetian, Cyrus P.; Yearout, Dora; Samii, Ali] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Zabetian, Cyrus P.; Hu, Shu-Ching; Samii, Ali] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Agarwal, Pinky] Evergreen Hlth, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Leverenz, James B.] Cleveland Clin, Neurol Inst, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Checkoway, Harvey] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. RP Costa-Mallen, P (reprint author), Bastyr Univ, Res Inst, 14500 Juanita Dr NE, Kenmore, WA USA. EM pcostamallen@bastyr.edu FU BLRD VA [I01 BX000531]; NIEHS NIH HHS [R01 ES010750]; NINDS NIH HHS [R01 NS065070, P50 NS062684, R21 NS070202] NR 5 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD JAN PY 2016 VL 22 BP 110 EP 111 DI 10.1016/j.parkreldis.2015.10.021 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA DE8JU UT WOS:000370883100020 PM 26708126 ER PT J AU Hetzenecker, A Escourrou, P Kuna, ST Series, F Lewis, K Birner, C Pfeifer, M Arzt, M AF Hetzenecker, Andrea Escourrou, Pierre Kuna, Samuel T. Series, Frederic Lewis, Keir Birner, Christoph Pfeifer, Michael Arzt, Michael TI Treatment of sleep apnea in chronic heart failure patients with auto-servo ventilation improves sleep fragmentation: a randomized controlled trial SO SLEEP MEDICINE LA English DT Article DE Heart failure; Sleep disordered breathing; Auto-servo ventilation; Sleep quality; NT-pro BNP ID POSITIVE AIRWAY PRESSURE; CHEYNE-STOKES RESPIRATION; PROGNOSTIC IMPACT; ADAPTIVE SERVOVENTILATION; HYPOPNEA SYNDROME; WRIST ACTIGRAPHY; PREVALENCE; DIAGNOSIS; SYMPTOMS; EPIDEMIC AB Background: Impaired sleep efficiency is independently associated with worse prognosis in patients with chronic heart failure (CHF). Therefore, a test was conducted on whether auto-servo ventilation (ASV, biphasic positive airway pressure [BiPAP]-ASV, Philips Respironics) reduces sleep fragmentation and improves sleep efficiency in CHF patients with central sleep apnea (CSA) or obstructive sleep apnea (OSA). Methods: In this multicenter, randomized, parallel group trial, a study was conducted on 63 CHF patients (age 64 +/- 10 years; left ventricular ejection fraction 29 +/- 7%) with CSA or OSA (apnea-hypopnea Index, AHI 47 +/- 18/h; 46% CSA) referred to sleep laboratories of the four participating centers. Participants were randomized to either ASV (n = 32) or optimal medical treatment alone (control, n = 31). Results: Polysomnography (PSG) and actigraphy at home (home) with centralized blinded scoring were obtained at baseline and 12 weeks. ASV significantly reduced sleep fragmentation (total arousal indexpsc: -16.4 +/- 20.6 vs.-0.6 13.2/h, p = 0.001; sleep fragmentation index(home):-7.6 +/- 15.6 versus 4.3 +/- 13.9/h, p = 0.003, respectively) and significantly increased sleep efficiency assessed by actigraphy (SEhome) compared to controls (2.3 +/- 10.1 vs.-2.1 +/- 6.9%, p = 0.002). Effects of ASV on sleep fragmentation and efficiency were similar in patients suffering from OSA and CSA. Conclusions: At home, ASV treatment modestly improves sleep fragmentation as well as sleep efficiency in CHF patients having either CSA or OSA. (C) 2015 Elsevier B.V. All rights reserved. C1 [Hetzenecker, Andrea; Birner, Christoph; Pfeifer, Michael; Arzt, Michael] Univ Hosp Regensburg, Dept Internal Med 2, Regensburg, Germany. [Hetzenecker, Andrea; Pfeifer, Michael] Donaustauf Hosp, Ctr Pneumol, Donaustauf, Germany. [Escourrou, Pierre] Hop Antoine Beclere, Ctr Med Sommeil, Clamart, France. [Kuna, Samuel T.] Univ Penn, Perleman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Series, Frederic] Univ Laval, IUCPQ, Ctr Rech, Quebec City, PQ, Canada. [Lewis, Keir] Prince Philip Hosp, Dept Resp Med, Llanelli, Wales. [Lewis, Keir] Swansea Coll Med, Swansea, W Glam, Wales. [Pfeifer, Michael] Hosp Order St John God Regensburg, Clin Pulmonol, Regensburg, Germany. RP Arzt, M (reprint author), Univ Hosp Regensburg, Ctr Sleep Med, Dept Internal Med 2, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany. EM michael.arzt@ukr.de NR 41 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 EI 1878-5506 J9 SLEEP MED JI Sleep Med. PD JAN PY 2016 VL 17 BP 25 EP 31 DI 10.1016/j.sleep.2015.08.020 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DE8OX UT WOS:000370897100006 PM 26847970 ER PT J AU George, MD Baker, JF AF George, Michael D. Baker, Joshua F. TI y The Obesity Epidemic and Consequences for Rheumatoid Arthritis Care SO CURRENT RHEUMATOLOGY REPORTS LA English DT Article DE Rheumatoid arthritis; Obesity; Adiposity ID BODY-MASS INDEX; RADIOGRAPHIC JOINT DAMAGE; TUMOR-NECROSIS-FACTOR; LONG-TERM CHANGES; RISK-FACTORS; DISEASE-ACTIVITY; AUTOIMMUNE-DISEASES; CARDIOVASCULAR RISK; ALCOHOL-CONSUMPTION; GENERAL-POPULATION AB With the prevalence of obesity increasing dramatically worldwide over the past several decades, an increasing body of literature has examined the impact of obesity in the context of rheumatoid arthritis (RA). Epidemiologic studies suggest that obesity may be associated with a modestly increased risk for the development of RA, although these studies have shown conflicting results. Among patients with established RA, obesity has been observed to be associated with greater subjective measures of disease activity and poor treatment response, but also with a decreased risk of joint damage and lower mortality. A comprehensive evaluation of the influence of obesity on the measurement of disease, response to therapies, and long-term prognosis is critical in order to understand these observations. This review therefore focuses on recent observations, potential explanations for these findings, and implications for clinicians and investigators caring for and studying patients with RA. C1 [George, Michael D.; Baker, Joshua F.] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP George, MD (reprint author), Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. EM michael.george@uphs.upenn.edu FU Veterans Affairs Clinical Science Research & Development Career Development Award [IK2 CX000955] FX Dr. Baker would like to acknowledge funding through a Veterans Affairs Clinical Science Research & Development Career Development Award (IK2 CX000955). The contents of this work do not represent the views of the Department of the Veterans Affairs or the United States Government. NR 78 TC 1 Z9 1 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3774 EI 1534-6307 J9 CURR RHEUMATOL REP JI Curr. Rheumatol. Rep. PD JAN PY 2016 VL 18 IS 1 AR 6 DI 10.1007/s11926-015-0550-z PG 9 WC Rheumatology SC Rheumatology GA DD9HE UT WOS:000370235500006 PM 26739963 ER PT J AU May, P Garrido, MM Cassel, JB Kelley, AS Meier, DE Normand, C Stefanis, L Smith, TJ Morrison, RS AF May, Peter Garrido, Melissa M. Cassel, J. Brian Kelley, Amy S. Meier, Diane E. Normand, Charles Stefanis, Lee Smith, Thomas J. Morrison, R. Sean TI Palliative Care Teams' Cost-Saving Effect Is Larger For Cancer Patients With Higher Numbers Of Comorbidities SO HEALTH AFFAIRS LA English DT Article ID OF-LIFE DISCUSSIONS; RESEARCH PRIORITIES; AMERICAN SOCIETY; CONSULTATION; HEALTH; PREFERENCES; DEATH; END; BENEFICIARIES; OUTCOMES AB Patients with multiple serious conditions account for a high proportion of health care spending. Such spending is projected to continue to grow substantially as a result of increased insurance eligibility, the ever-rising cost of care, the continued use of nonbeneficial high-intensity treatments at the end of life, and demographic changes. We evaluated the impact of palliative care consultation on hospital costs for adults with advanced cancer, excluding those with dementia. We found that compared to usual care, the receipt of a palliative care consultation within two days of admission was associated with 22 percent lower costs for patients with a comorbidity score of 2-3 and with 32 percent lower costs for those with a score of 4 or higher. Earlier consultation was also found to be systematically associated with a larger cost-saving effect for all subsamples defined by multimorbidity. Given ongoing workforce shortages, targeting early specialist palliative care to hospitalized patients with advanced cancer and higher numbers of serious concurrent conditions could improve care while complementing strategies to curb the growth of health spending. C1 [May, Peter] Univ Dublin Trinity Coll, Ctr Hlth Policy & Management, Dublin, Ireland. [May, Peter; Garrido, Melissa M.; Kelley, Amy S.; Meier, Diane E.; Morrison, R. Sean] Icahn Sch Med Mt Sinai, Geriatr & Palliat Med, New York, NY 10029 USA. [Garrido, Melissa M.; Stefanis, Lee] James J Peters Vet Affairs VA Med Ctr, Bronx, NY USA. [Cassel, J. Brian] Virginia Commonwealth Univ, Hematol Oncol & Palliat Care, Richmond, VA 23284 USA. [Meier, Diane E.] Icahn Sch Med Mt Sinai, Ctr Adv Palliat Care, New York, NY 10029 USA. [Normand, Charles] Univ Dublin Trinity Coll, Hlth Policy & Management, Dublin, Ireland. [Smith, Thomas J.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Palliat Med, Baltimore, MD USA. [Morrison, R. Sean] Icahn Sch Med Mt Sinai, Natl Palliat Care Res Ctr, New York, NY 10029 USA. RP May, P (reprint author), Univ Dublin Trinity Coll, Ctr Hlth Policy & Management, Dublin, Ireland. EM mayp2@tcd.ie RI May, Peter/B-2107-2017 OI May, Peter/0000-0001-8501-6500 FU National Cancer Institute (NCI); National Institute of Nursing Research [5R01CA116227-04]; health economics fellowship from the Health Research Board of Ireland; NCI [P30 CA 006973]; Veterans Affairs Health Services Research and Development Career Development Award [CDA 11-201/CDP 12-255]; National Institute on Aging (NIA) [1K23AG040774-01A1]; National Institutes of Health [5K24AG022345]; NIA; Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai [5P30AG028741]; National Palliative Care Research Center FX An early version of these results was presented at the Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association, Philadelphia, Pennsylvania, February 26, 2015. The study was funded by the National Cancer Institute (NCI) and the National Institute of Nursing Research (Project No. 5R01CA116227-04). The study sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. All authors are independent of the study sponsors. Peter May is sponsored by a health economics fellowship from the Health Research Board of Ireland and by the NCI. Melissa Garrido is supported by a Veterans Affairs Health Services Research and Development Career Development Award (Award No. CDA 11-201/CDP 12-255). Amy Kelley was supported by the National Institute on Aging (NIA; Grant No. 1K23AG040774-01A1). Thomas Smith is supported by a grant from the NCI to the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University (Grant No. P30 CA 006973). Sean Morrison received a Midcareer Investigator Award in Patient-Oriented Research from the National Institutes of Health (Award No. 5K24AG022345) during the course of this work. This work was supported by the NIA, the Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai (Grant No. 5P30AG028741), and the National Palliative Care Research Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. The authors thank Robert Arnold, Phil Santa Emma, Mary Beth Happ, Tim Smith, and David Weissman for their contributions to the Palliative Care for Cancer project. NR 42 TC 8 Z9 8 U1 3 U2 5 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN PY 2016 VL 35 IS 1 BP 44 EP 53 DI 10.1377/hlthaff.2015.0752 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DD1PV UT WOS:000369694700007 PM 26733700 ER PT J AU Townsend, RR Rosendorff, C Nichols, WW Edwards, DG Chirinos, JA Fernhall, B Cushman, WC AF Townsend, Raymond R. Rosendorff, Clive Nichols, Wilmer W. Edwards, David G. Chirinos, Julio A. Fernhall, Bo Cushman, William C. TI American Society of Hypertension position paper: central blood pressure waveforms in health and disease SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Augmentation index; central arterial pressure; pulse pressure augmentation; pulse wave analysis ID CENTRAL AORTIC PRESSURE; LEFT-VENTRICULAR AFTERLOAD; CENTRAL PULSE PRESSURE; ARTERY FUNCTION EVALUATION; MOVING AVERAGE METHOD; SYSTOLIC PRESSURE; NONINVASIVE EVALUATION; CARDIOVASCULAR EVENTS; REFLECTION MAGNITUDE; AUGMENTATION INDEX AB A number of devices are available which noninvasively estimate central aortic blood pressure using a variety of approaches such as tonometry or oscillometry. In this position paper, we discuss how the central pressure waveform is generated and measured, how central pressure waveforms appear in health and disease, the predictive value of central blood pressure measurements, the effects of interventions on waveforms, and areas of future need in this field of clinical and research endeavor. (C) 2016 American Society of Hypertension. All rights reserved. C1 [Townsend, Raymond R.; Chirinos, Julio A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Rosendorff, Clive] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Dept Med, Bronx, NY USA. [Nichols, Wilmer W.] Univ Florida, Coll Med, Dept Med, Div Med, Gainesville, FL USA. [Nichols, Wilmer W.] Univ Florida, Dept Med, Div Cardiovasc Med, Gainesville, FL USA. [Edwards, David G.] Univ Delaware, Coll Hlth Sci, Dept Kinesiol & Appl Physiol, Newark, DE USA. [Fernhall, Bo] Univ Illinois, Coll Appl Hlth Sci, Dept Kinesiol & Nutr, Chicago, IL USA. [Cushman, William C.] Univ Tennessee, Coll Med, Vet Affairs Med Ctr, Dept Med Serv, Memphis, TN USA. RP Townsend, RR (reprint author), Univ Penn, Renal Electrolyte & Hypertens Div, Perelman Sch Med, 122 Founders Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM townsend@exchange.upenn.edu FU NIH; Fukuda Denshi; American College of Radiology Network; Department of Homeland Security; National Multiple Sclerosis Society; Merck; Eli Lilly FX R.R.T. received grants from NIH and Fukuda Denshi. D.G.E. received grants from NIH. J.A.C. received grants from NIH, American College of Radiology Network, and Fukuda Denshi. B.F. received grants from NIH, Department of Homeland Security, and the National Multiple Sclerosis Society. W.C.C. received grants from NIH, Merck, and Eli Lilly. NR 83 TC 3 Z9 3 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD JAN PY 2016 VL 10 IS 1 BP 22 EP 33 DI 10.1016/j.jash.2015.10.012 PG 12 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DE2OM UT WOS:000370466600007 PM 26612106 ER PT J AU McClatchey, PM Keller, AC Bouchard, R Knaub, LA Reusch, JEB AF McClatchey, P. Mason Keller, Amy C. Bouchard, Ron Knaub, Leslie A. Reusch, Jane E. B. TI Fully automated software for quantitative measurements of mitochondrial morphology SO MITOCHONDRION LA English DT Article DE Mitochondria; Morphology; Microscopy; Image processing ID CELL-DEATH; DYNAMICS; FISSION; NEURONS; DISEASE; CALCIUM; FIBROBLASTS; DYSFUNCTION; ACTIVATION; INCREASES AB Mitochondria undergo dynamic changes in morphology in order to adapt to changes in nutrient and oxygen availability, communicate with the nucleus, and modulate intracellular calcium dynamics. Many recent papers have been published assessing mitochondrial morphology endpoints. Although these studies have yielded valuable insights, contemporary assessment of mitochondrial morphology is typically subjective and qualitative, precluding direct comparison of outcomes between different studies and likely missing many subtle effects. In this paper, we describe a novel software technique for measuring the average length, average width, spatial density, and intracellular localization of mitochondria from a fluorescent microscope image. This method was applied to distinguish baseline characteristics of Human Umbilical Vein Endothelial Cells (HUVECs), primary Goto-Kakizaki rat aortic smooth muscle cells (GK SMCs), primary Wistar rat aortic smooth muscle cells (Wistar SMCs), and SH-SY5Ys (human neuroblastoma cell line). Consistent with direct observation, our algorithms found SH-SY5Ys to have the greatest mitochondria] density, while HUVECs were found to have the longest mitochondria. Mitochondrial morphology responses to temperature, nutrient, and oxidative stressors were characterized to test algorithm performance. Large morphology changes recorded by the software agreed with direct observation, and subtle but consistent morphology changes were found that would not otherwise have been detected. Endpoints were consistent between experimental repetitions (R = 0.93 for length, R = 0.93 for width, R = 0.89 for spatial density, and R = 0.74 for localization), and maintained reasonable agreement even when compared to images taken with compromised microscope resolution or in an alternate imaging plane. These results indicate that the automated software described herein allows quantitative and objective characterization of mitochondrial morphology from fluorescent microscope images. Published by Elsevier B.V. and Mitochondria Research Society. C1 [McClatchey, P. Mason; Keller, Amy C.; Knaub, Leslie A.; Reusch, Jane E. B.] Univ Colorado Anschutz Med Campus, Div Endocrinol, Aurora, CO USA. [McClatchey, P. Mason; Keller, Amy C.; Bouchard, Ron; Knaub, Leslie A.; Reusch, Jane E. B.] Denver VA Med Ctr, Dept Med, Denver, CO USA. [McClatchey, P. Mason; Reusch, Jane E. B.] Univ Colorado Anschutz Med Campus, Dept Bioengn, Aurora, CO USA. [Reusch, Jane E. B.] Univ Colorado, Sch Med, Ctr Womens Hlth Res, Aurora, CO USA. RP Reusch, JEB (reprint author), Univ Colorado Anschutz Med Campus, Div Endocrinol, Aurora, CO USA. EM jane.reusch@ucdenver.edu FU VA Merit, Denver Research Institute [NIH-5T32HL007171, NIH-5P01HL014985, CCTSI-UL1RR025780]; Center for Women's Health Research; Department of Bioengineering; National Cancer Institute Cancer Center Support Grant [P30CA046934] FX Sources of funding for this study were provided by VA Merit, Denver Research Institute, NIH-5T32HL007171 (ACK), NIH-5P01HL014985 (ACK), CCTSI-UL1RR025780 (JEBR), the Center for Women's Health Research (JEBR), and the Department of Bioengineering (PMM). Flow Cytometry is supported through a National Cancer Institute Cancer Center Support Grant (P30CA046934). NR 41 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD JAN PY 2016 VL 26 BP 58 EP 71 DI 10.1016/j.mito.2015.12.003 PG 14 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA DE6UC UT WOS:000370768100007 PM 26688338 ER PT J AU Duong, TQ Watts, LT AF Duong, Timothy Q. Watts, Lora T. TI A brief report on MRI investigation of experimental traumatic brain injury SO NEURAL REGENERATION RESEARCH LA English DT Article DE MRI; traumatic brain injury; magnetic resonance imaging; diffusion tensor imaging; cerebral blood flow ID VETERANS AB Traumatic brain injury is a major cause of death and disability. This is a brief report based on a symposium presentation to the 2014 Chinese Neurotrauma Association Meeting in San Francisco, USA. It covers the work from our laboratory in applying multimodal MRI to study experimental traumatic brain injury in rats with comparisons made to behavioral tests and histology. MRI protocols include structural, perfusion, manganese-enhanced, diffusion-tensor MRI, and MRI of blood-brain barrier integrity and cerebrovascular reactivity. C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Res Imaging Inst, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Res Imaging Inst, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu NR 17 TC 1 Z9 1 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1673-5374 EI 1876-7958 J9 NEURAL REGEN RES JI Neural Regen. Res. PD JAN PY 2016 VL 11 IS 1 BP 15 EP 17 DI 10.4103/1673-5374.169604 PG 3 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA DD7ZF UT WOS:000370142800003 PM 26981069 ER PT J AU Fujikawa, DG Pais, ES Aviles, ER Hsieh, KC Bashir, MT AF Fujikawa, Denson G. Pais, Emil S. Aviles, Ernesto R., Jr. Hsieh, Kung-Chiao Bashir, Muhammad Tariq TI Methamphetamine-induced neuronal necrosis: the role of electrographic seizure discharges SO NEUROTOXICOLOGY LA English DT Article DE Electrographic seizures; Excitotoxicity; Methamphetamine; Mouse; Necrosis; Apoptosis ID INTERNUCLEOSOMAL DNA CLEAVAGE; ELECTRON-MICROSCOPIC FINDINGS; INDUCED STATUS EPILEPTICUS; HYPOGLYCEMIC BRAIN-DAMAGE; TEMPORAL EVOLUTION; APOPTOTIC NEURODEGENERATION; RAT-BRAIN; DEATH; DEGENERATION; FRAGMENTATION AB We have evidence that methamphetamine (METH)-induced neuronal death is morphologically necrotic, not apoptotic, as is currently believed, and that electrographic seizures may be responsible. We administered 40 mg/kg i.p. to 12 male C57BL/6 mice and monitored EEGs continuously and rectal temperatures every 15 min, keeping rectal temperatures <41.0 degrees C. Seven of the 12 mice had repetitive electrographic seizure discharges (RESDs) and 5 did not. The RESDs were often not accompanied by behavioral signs of seizures-i.e., they were often not accompanied by clonic forelimb movements. The 7 mice with RESDs had acidophilic neurons (the H&E light-microscopic equivalent of necrotic neurons by ultrastructural examination) in all of 7 brain regions (hippocampal CA1, CA2, CA3 and hilus, amygdala, piriform cortex and entorhinal cortex), the same brain regions damaged following generalized seizures, 24 h after METH administration. The 5 mice without RESDs had a few acidophilic neurons in 4 of the 7 brain regions, but those with RESDs had significantly more in 6 of the 7 brain regions. Maximum rectal temperatures were comparable in mice with and without RESDs, so that cannot explain the difference between the two groups with respect to METH-induced neuronal death. Our data show that METH-induced neuronal death is morphologically necrotic, that EEGs must be recorded to detect electrographic seizure activity in rodents without behavioral evidence of seizures, and that RESDs may be responsible for METH-induced neuronal death. Published by Elsevier Inc. C1 [Fujikawa, Denson G.; Pais, Emil S.; Aviles, Ernesto R., Jr.; Hsieh, Kung-Chiao; Bashir, Muhammad Tariq] VA Greater Los Angeles Healthcare Syst, Sepulveda VA Ambulatory Care Ctr & Nursing Home, Expt Neurol Lab, North Hills, CA USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Mail Code 151B4,16111 Plummer St, North Hills, CA 91343 USA. EM dfujikaw@ucla.edu FU VA Merit Review grant [I01-BX001858]; VA Greater Los Angeles Research and Development Service; Sepulveda Research Corporation Various Donors Fund; UCLA Department of Neurology Academic Enrichment Fund FX Our study was supported by a VA Merit Review grant (I01-BX001858), the VA Greater Los Angeles Research and Development Service, the Sepulveda Research Corporation Various Donors Fund and the UCLA Department of Neurology Academic Enrichment Fund. Dr. Jeffrey Gornbein, a UCLA biomathematical statistician, provided expert assistance in the statistical analysis of data. NR 28 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X EI 1872-9711 J9 NEUROTOXICOLOGY JI Neurotoxicology PD JAN PY 2016 VL 52 BP 84 EP 88 DI 10.1016/j.neuro.2015.11.001 PG 5 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA DE6TW UT WOS:000370767500009 PM 26562800 ER PT J AU Soleymani, T Daniel, S Garvey, WT AF Soleymani, T. Daniel, S. Garvey, W. T. TI Weight maintenance: challenges, tools and strategies for primary care physicians SO OBESITY REVIEWS LA English DT Review DE Maintenance; obesity; primary care; weight loss ID DIABETES-PREVENTION-PROGRAM; LIFE-STYLE INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; COMPLICATIONS-CENTRIC APPROACH; CARDIOVASCULAR RISK-FACTORS; OBSTRUCTIVE SLEEP-APNEA; ALL-CAUSE MORTALITY; BARIATRIC SURGERY; CONTROL REGISTRY AB Obesity is recognized as a chronic disease and one of the major healthcare challenges facing us today. Weight loss can be achieved via lifestyle, pharmacological and surgical interventions, but weight maintenance remains a lifetime challenge for individuals with obesity. Guidelines for the management of obesity have highlighted the role of primary care providers (PCPs). This review examines the long-term outcomes of clinical trials to identify effective weight maintenance strategies that can be utilized by PCPs. Because of the broad nature of the topic, a structured PubMed search was conducted to identify relevant research articles, peer-reviewed reviews, guidelines and articles published by regulatory bodies. Trials have demonstrated the benefit of sustained weight loss in managing obesity and its comorbidities. Maintaining 5-10% weight loss for >= 1 year is known to ameliorate many comorbidities. Weight maintenance with lifestyle modification although challenging - is possible but requires long-term support to reinforce diet, physical activity and behavioural changes. The addition of pharmacotherapy to lifestyle interventions promotes greater and more sustained weight loss. Clinical evidence and recently approved pharmacotherapy has given PCPs improved strategies to support their patients with maintenance of weight loss. Further studies are needed to assess the translation of these strategies into clinical practice. C1 [Soleymani, T.; Daniel, S.; Garvey, W. T.] Univ Alabama Birmingham, Dept Nutr Sci, 1720 Second Ave South, Birmingham, AL 35294 USA. [Soleymani, T.; Garvey, W. T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1720 Second Ave South, Birmingham, AL 35294 USA. EM garveyt@uab.edu FU Novo Nordisk A/S; Diabetes Research Center at the University of Alabama at Birmingham - National Institutes of Health [DK-079626] FX WTG acts as guarantor and takes responsibility for the content of the article. Editorial assistance was provided by Dr Ian Seymour from AXON Communications, and funded by Novo Nordisk A/S. The authors acknowledge the support of the Diabetes Research Center at the University of Alabama at Birmingham, funded by an award from the National Institutes of Health (DK-079626). NR 129 TC 1 Z9 1 U1 7 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1467-7881 EI 1467-789X J9 OBES REV JI Obes. Rev. PD JAN PY 2016 VL 17 IS 1 BP 81 EP 93 DI 10.1111/obr.12322 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD8EZ UT WOS:000370159500007 PM 26490059 ER PT J AU Little, EC Camp, ER Wang, C Watson, PM Watson, DK Cole, DJ AF Little, E. C. Camp, E. R. Wang, C. Watson, P. M. Watson, D. K. Cole, D. J. TI The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells SO ONCOGENESIS LA English DT Article ID EPITHELIAL-MESENCHYMAL TRANSITION; ACTIVATOR RECEPTOR UPAR; SM-LIKE PROTEIN; HIGH-RISK GROUP; PLASMINOGEN-ACTIVATOR; DUCTAL ADENOCARCINOMA; GENE-EXPRESSION; LUNG-CANCER; STEM-CELLS; GEMCITABINE AB The cancer-associated Sm-like (CaSm) oncogene is overexpressed in 87% of human pancreatic tumor samples and CaSm knockdown has demonstrated therapeutic efficacy in murine models of pancreatic cancer. Evidence indicates that CaSm modulates messenger RNA degradation; however, its target genes and the mechanisms by which CaSm promotes pancreatic cancer remain largely unknown. Here, we demonstrate that the CaSm overexpression alters several hallmarks of cancer-including transformation, proliferation, chemoresistance and metastasis. Doxycycline-induced CaSm expression enhanced proliferation and both anchorage-dependent and -independent growth of the human Panc-1 cells in vitro. CaSm induction decreased gemcitabine-induced cytotoxicity and altered the expression of apoptotic regulation genes, including Bad, E2F1 and Bcl-X-L. CaSm-overexpressing Panc-1 cells were twofold more migratory and fourfold more invasive than the driver controls and demonstrated characteristics of epithelial-to-mesenchymal transition such as morphological changes and decreased E-cadherin expression. CaSm induction resulted in changes in RNA expression of metastasis-associated genes such as MMP1, SerpinB5, uPAR and Slug. Using a murine model of metastatic pancreatic cancer, injection of CaSm-induced Panc-1 cells resulted in a higher abundance of hepatic metastatic lesions. Overall, CaSm overexpression contributed to a more aggressive cancer phenotype in Panc-1 cells, further supporting the use of CaSm as a therapeutic target against pancreatic cancer. C1 [Little, E. C.; Cole, D. J.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Little, E. C.; Camp, E. R.; Wang, C.; Watson, P. M.; Watson, D. K.; Cole, D. J.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Camp, E. R.; Wang, C.; Cole, D. J.] Med Univ S Carolina, Dept Surg, 114 Doughty St,BM 241,MSC 295, Charleston, SC 29425 USA. [Camp, E. R.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Watson, P. M.; Watson, D. K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Watson, D. K.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, 114 Doughty St,BM 241,MSC 295, Charleston, SC 29425 USA. EM campe@musc.edu FU National Institutes of Health [R01CA123159, K08CA142904]; South Carolina Clinical and Translational Research through NIH [UL1TR000062]; Hollings Cancer Center Medical University of South Carolina [POCA138313] FX This work was supported by funding from the National Institutes of Health (R01CA123159 (DJC, DKW) and K08CA142904 (ERC)) and the South Carolina Clinical and Translational Research through NIH grant number UL1TR000062. We thank the MUSC Hollings Cancer Center Tissue Biorepository and the Flow Cytometry core facilities for their assistance. The shared resources are supported in part by the Hollings Cancer Center Medical University of South Carolina Support Grant (POCA138313) NR 42 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2157-9024 J9 ONCOGENESIS JI Oncogenesis PD JAN PY 2016 VL 5 AR e182 DI 10.1038/oncsis.2015.45 PG 10 WC Oncology SC Oncology GA DE2TP UT WOS:000370480200003 PM 26751936 ER PT J AU Janke-Stedronsky, SR Greenawalt, DS Stock, EM Tsan, JY MacCarthy, AA MacCarthy, DJ Copeland, LA AF Janke-Stedronsky, Shonda R. Greenawalt, David S. Stock, Eileen M. Tsan, Jack Y. MacCarthy, Andrea A. MacCarthy, Daniel J. Copeland, Laurel A. TI Association of Parental Status and Diagnosis of Posttraumatic Stress Disorder Among Veterans of Operations Iraqi and Enduring Freedom SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE posttraumatic stress disorder; parenting; gender; veterans ID MALE VIETNAM VETERANS; MENTAL-HEALTH; OEF/OIF VETERANS; RISK-FACTORS; DEPLOYMENT; PTSD; COMBAT; AFGHANISTAN; RESILIENCE; FEMALE AB Research indicates that concerns about disruption of family relationships during military service may be associated with greater posttraumatic stress symptomatology. The current study sought to extend previous findings by examining the relative odds of a posttraumatic stress disorder (PTSD) diagnosis among Operations Enduring and Iraqi Freedom (OEF/OIF) veterans with dependent children versus veterans without dependent children. Administrative databases were queried to identify 36,334 OEF/OIF veterans with dependent children seeking care in the Veterans Health Administration (VA) during fiscal years 2006-2009. These veterans were matched 1: 1 on age, gender, and demobilization date to veterans without dependent children (N = 72,668). In unconditional analyses, OEF/OIF veterans with dependent children versus those without were significantly more likely to incur a PTSD diagnosis (44% vs. 28%). After controlling for demographic variables, mental health utilization, and other serious mental illness, OEF/OIF veterans with dependent children were about 40% more likely to carry a diagnosis of PTSD. The association was stronger for men than for women. It may be of value for clinicians to consider parental status when assessing and treating veterans with PTSD. In-depth study of OEF/OIF veterans is needed to determine whether disruption of family relationships leads to increased psychological stress or parents are more likely than nonparents to seek VA mental health services for PTSD symptoms. C1 [Janke-Stedronsky, Shonda R.] Univ Texas Austin, Southwestern Residency Programs, Seton Healthcare Network, Dept Psychiat, Austin, TX 78712 USA. [Greenawalt, David S.] Albany Stratton Vet Affairs Med Ctr, Albany, NY USA. [Stock, Eileen M.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Internal Med, Temple, TX USA. [Stock, Eileen M.; Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA. [Stock, Eileen M.; Copeland, Laurel A.] Baylor Scott & White Hlth, Temple, TX USA. [Tsan, Jack Y.] Cent Texas Vet Hlth Care Syst, Psychol Serv, Austin, TX USA. [MacCarthy, Andrea A.; MacCarthy, Daniel J.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Coll Med, Internal Med, Temple, TX USA. RP Copeland, LA (reprint author), Ctr Appl Hlth Res, 2102 Birdcreek Dr, Temple, TX 76502 USA. EM LaurelACopeland@gmail.com OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs; Central Texas Veterans Health Care System; VHA HSRD [IIR-09-335]; Baylor Scott & White Health, Temple, Texas FX This research was supported by Department of Veterans Affairs, Central Texas Veterans Health Care System, and VHA HSR&D Award IIR-09-335 (Laurel A. Copeland, PI), with additional support from Baylor Scott & White Health, Temple, Texas. The views are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 43 TC 1 Z9 1 U1 3 U2 6 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD JAN PY 2016 VL 8 IS 1 BP 72 EP 79 DI 10.1037/tra0000014 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DD8KW UT WOS:000370176400010 PM 25793320 ER PT J AU Baird, SO Hopkins, LB Medina, JL Rosenfield, D Powers, MB Smits, JAJ AF Baird, Scarlett O. Hopkins, Lindsey B. Medina, Johnna L. Rosenfield, David Powers, Mark B. Smits, Jasper A. J. TI Distress Tolerance as a Predictor of Adherence to a Yoga Intervention: Moderating Roles of BMI and Body Image SO BEHAVIOR MODIFICATION LA English DT Article DE yoga; adherence; intervention; distress tolerance; predictors ID PERCEIVED STRESS QUESTIONNAIRE; REDUCING ANXIETY SENSITIVITY; PHYSICAL-ACTIVITY; PANIC DISORDER; DISCOMFORT INTOLERANCE; SHAPE QUESTIONNAIRE; FUTURE-RESEARCH; EXERCISE; WOMEN; EFFICACY AB This study tested whether distress tolerance, body image, and body mass index (BMI) predicted adherence to a yoga intervention. Participants were 27 women who participated in a yoga intervention as part of a randomized controlled trial. Attendance and distress tolerance were assessed weekly, and body image and BMI were measured at baseline. Multilevel modeling revealed a three-way interaction of distress tolerance, BMI, and body image (p < .001). For participants with few body image concerns, distress tolerance was positively associated with adherence regardless of BMI (p = .009). However, for those with poor body image, increases in distress tolerance were associated with increases in adherence among overweight participants (p < .001) but lower adherence among obese participants (p = .007). Distress tolerance may be implicated in adherence to a yoga intervention, although its effects may be dependent on body image concerns, BMI, and their interaction. Research and clinical implications are discussed. C1 [Baird, Scarlett O.] Univ Texas Austin, Clin Psychol Program, Austin, TX 78712 USA. [Baird, Scarlett O.; Medina, Johnna L.; Powers, Mark B.; Smits, Jasper A. J.] Univ Texas Austin, Austin, TX 78712 USA. [Powers, Mark B.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Hopkins, Lindsey B.] San Francisco VA Med Ctr, San Francisco, CA USA. [Rosenfield, David] So Methodist Univ, Fac, Dallas, TX 75275 USA. RP Baird, SO (reprint author), Univ Texas Austin, Mental Hlth Res Inst, Dept Psychol, Austin, TX 78712 USA. EM scarlett.baird@utexas.edu OI Hopkins, Lindsey/0000-0002-0577-2961; Powers, Mark/0000-0001-7898-073X FU Pure Action, Inc., Austin, Texas, USA FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Portions of this research were funded by a grant from Pure Action, Inc., Austin, Texas, USA, a 501c3 nonprofit organization. NR 54 TC 1 Z9 1 U1 5 U2 11 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-4455 EI 1552-4167 J9 BEHAV MODIF JI Behav. Modificat. PD JAN-MAR PY 2016 VL 40 IS 1-2 SI SI BP 199 EP 217 DI 10.1177/0145445515612401 PG 19 WC Psychology, Clinical SC Psychology GA DD5ZC UT WOS:000370002500011 PM 26530475 ER PT J AU Williams, JS Lynch, CP Voronca, D Egede, LE AF Williams, Joni S. Lynch, Cheryl P. Voronca, Delia Egede, Leonard E. TI Health locus of control and cardiovascular risk factors in veterans with type 2 diabetes SO ENDOCRINE LA English DT Article DE Health locus of control; Diabetes; Diabetes outcomes; Cardiovascular disease risk factors; Quality of life; Veterans ID QUALITY-OF-LIFE; PERCEIVED CONTROL; SELF-MANAGEMENT; VALIDATION; DISEASE; RELIABILITY; POPULATION; DEPRESSION; ADHERENCE; VALIDITY AB Perceptions of control impact outcomes in veterans with chronic disease. The purpose of this study was to examine the association between control orientation and clinical and quality of life (QOL) outcomes in male veterans with type 2 diabetes (T2DM). Cross-sectional study of 283 male veterans from a primary care clinic in the southeastern US. Health locus of control (LOC) was the main predictor and assessed using the Multidimensional Health LOC Scale. Clinical outcomes were glycosylated hemoglobin A1c (HbA1c), systolic and diastolic blood pressure, and low-density lipoprotein cholesterol (LDL-C). Physical (PCS) and mental (MCS) health component scores for QOL were assessed using the Veterans RAND 12-Item Health Survey. Unadjusted and adjusted multivariate analyses were performed to assess associations between LOC and outcomes. Unadjusted analyses showed internal LOC associated with HbA1c (beta = 0.036; 95 % CI 0.001, 0.071), external LOC: powerful others inversely associated with LDL-C (beta = -0.794; 95 % CI -1.483, -0.104), and external LOC: chance inversely associated with MCS QOL (beta = -0.418; 95 % CI -0.859, -0.173). These associations remained significant when adjusting for relevant covariates. Adjusted analyses also demonstrated a significant relationship between external LOC: chance and PCS QOL (beta = 0.308; 95 % CI 0.002, 0.614). In this sample of male veterans with T2DM, internal LOC was significantly associated with glycemic control, and external was significantly associated with QOL and LDL-C, when adjusting for relevant covariates. Assessments of control orientation should be performed to understand the perceptions of patients, thus better equipping physicians with information to maximize care opportunities for veterans with T2DM. C1 [Lynch, Cheryl P.; Egede, Leonard E.] Vet Affairs Med Ctr, Ralph H Johnson Dept, HEROIC, Charleston, SC 29403 USA. [Williams, Joni S.; Lynch, Cheryl P.; Voronca, Delia; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Vet Affairs Med Ctr, Ralph H Johnson Dept, HEROIC, Charleston, SC 29403 USA.; Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. EM stromjl@musc.edu; lynchcp@musc.edu; voronca@musc.edu; egedel@musc.edu FU VHA Health Services Research and Development (HSRD) program [TRP 04-038] FX This study was supported by Grant #TRP 04-038 (PI: Leonard Egede) funded by the VHA Health Services Research and Development (HSR&D) program. NR 37 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-008X EI 1559-0100 J9 ENDOCRINE JI Endocrine PD JAN PY 2016 VL 51 IS 1 BP 83 EP 90 DI 10.1007/s12020-015-0677-8 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD6WH UT WOS:000370064800011 PM 26148703 ER PT J AU Milanesi, A Lee, JW Kim, NH Liu, YY Yang, A Sedrakyan, S Kahng, A Cervantes, V Tripuraneni, N Cheng, SY Perin, L Brent, GA AF Milanesi, Anna Lee, Jang-Won Kim, Nam-Ho Liu, Yan-Yun Yang, An Sedrakyan, Sargis Kahng, Andrew Cervantes, Vanessa Tripuraneni, Nikita Cheng, Sheue-yann Perin, Laura Brent, Gregory A. TI Thyroid Hormone Receptor alpha Plays an Essential Role in Male Skeletal Muscle Myoblast Proliferation, Differentiation, and Response to Injury SO ENDOCRINOLOGY LA English DT Article ID GROWTH-PLATE CHONDROCYTES; INSULIN-RESISTANCE; SATELLITE CELLS; SOLEUS MUSCLE; GENE; MYOD; MICE; EXPRESSION; MUTATION; MOUSE AB Thyroid hormone plays an essential role in myogenesis, the process required for skeletal muscle development and repair, although the mechanisms have not been established. Skeletal muscle develops from the fusion of precursor myoblasts into myofibers. We have used the C2C12 skeletal muscle myoblast cell line, primary myoblasts, and mouse models of resistance to thyroid hormone (RTH) alpha and beta, to determine the role of thyroid hormone in the regulation of myoblast differentiation. T-3, which activates thyroid hormone receptor (TR) alpha and beta, increased myoblast differentiation whereas GC1, a selective TR beta agonist, was minimally effective. Genetic approaches confirmed that TR alpha plays an important role in normal myoblast proliferation and differentiation and acts through the Wnt/beta-catenin signaling pathway. Myoblasts with TR alpha knockdown, or derived from RTH-TR alpha PV (a frame-shift mutation) mice, displayed reduced proliferation and myogenic differentiation. Moreover, skeletal muscle from the TR alpha 1PV mutant mouse had impaired in vivo regeneration after injury. RTH-TR beta PV mutant mouse model skeletal muscle and derived primary myoblasts did not have altered proliferation, myogenic differentiation, or response to injury when compared with control. In conclusion, TR alpha plays an essential role in myoblast homeostasis and provides a potential therapeutic target to enhance skeletal muscle regeneration. C1 [Milanesi, Anna; Liu, Yan-Yun; Yang, An; Brent, Gregory A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Lee, Jang-Won; Kim, Nam-Ho; Kahng, Andrew; Cervantes, Vanessa] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA. [Sedrakyan, Sargis; Tripuraneni, Nikita; Perin, Laura] Univ So Calif, Childrens Hosp Los Angeles, Dept Urol, Los Angeles, CA 90027 USA. [Cheng, Sheue-yann] NCI, Bethesda, MD 20892 USA. RP Milanesi, A; Brent, GA (reprint author), VA Greater Angeles Healthcare Syst, Dept Med, 111,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM amilanesi@mednet.ucla.edu; gbrent@mednet.ucla.edu FU National Institutes of Health (NIH) Grant [1K08DK097295]; NIH [RO1DK98576]; NIH/National Center for Advancing Translational Science University of California, Los Angeles, Clinical and Translational Science Institute [UL1TR000124] FX This work was supported by National Institutes of Health (NIH) Grant No. 1K08DK097295 (to A.M.), and NIH RO1DK98576 (to G.A.B.). The research described was supported by NIH/National Center for Advancing Translational Science University of California, Los Angeles, Clinical and Translational Science Institute Grant No. UL1TR000124. NR 61 TC 5 Z9 5 U1 2 U2 4 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2016 VL 157 IS 1 BP 4 EP 15 DI 10.1210/en.2015-1443 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD5KM UT WOS:000369962600002 PM 26451739 ER PT J AU Tascau, L Gardner, T Anan, H Yongpravat, C Cardozo, CP Bauman, WA Lee, FY Oh, DS Tawfeek, HA AF Tascau, Liana Gardner, Thomas Anan, Hussein Yongpravat, Charlie Cardozo, Christopher P. Bauman, William A. Lee, Francis Y. Oh, Daniel S. Tawfeek, Hesham A. TI Activation of Protein Kinase A in Mature Osteoblasts Promotes a Major Bone Anabolic Response SO ENDOCRINOLOGY LA English DT Article ID ENGINEERED G(S)-COUPLED RECEPTOR; PARATHYROID-HORMONE RESISTANCE; SYMPATHETIC-NERVOUS-SYSTEM; MESSENGER-RNA EXPRESSION; MCCUNE-ALBRIGHT-SYNDROME; ELEMENT-BINDING PROTEIN; HUMAN FIBROUS DYSPLASIA; MESENCHYMAL STEM-CELLS; OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN AB Protein kinase A(PKA) regulates osteoblast cell function in vitro and is activated by important bone mass modulating agents. We determined whether PKA activation in osteoblasts is sufficient to mediate a bone anabolic response. Thus, a mouse model conditionally expressing a constitutively active PKA (CA-PKA) in osteoblasts (CA-PKA-OB mouse) was developed by crossing a 2.3-kb alpha 1 (I)-collagen promoter-Cre mouse with a floxed-CA-PKA mouse. Primary osteoblasts from the CA-PKA-OB mice exhibited higher basal PKA activity than those from control mice. Microcomputed tomographic analysis revealed that CA-PKA-OB female mice hadan 8.6-fold increase in femoral but only 1.16-fold increase in lumbar 5 vertebral bone volume/total volume. Femur cortical thickness and volume were also higher in the CA-PKA-OB mice. In contrast, alterations in many femoral microcomputed tomographic parameters in male CA-PKA-OB mice were modest. Interestingly, the 3-dimensional structure model index was substantially lower both in femur and lumbar 5 of male and female CA-PKA-OB mice, reflecting an increase in the plate to rod-like structure ratio. In agreement, femurs from female CA-PKA-OB mice had greater load to failure and were stiffer compared with those of control mice. Furthermore, the CA-PKA-OB mice had higher levels of serum bone turnover markers and increased osteoblast and osteoclast numbers per total tissue area compared with control animals. In summary, constitutive activation of PKA in osteoblasts is sufficient to increase bone mass and favorably modify bone architecture and improve mechanical properties. PKA activation in mature osteoblasts is, therefore, an important target for designing anabolic drugs for treating diseases with bone loss. C1 [Cardozo, Christopher P.; Bauman, William A.; Tawfeek, Hesham A.] James J Peters VA Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, 130 West Kingsbridge Rd,Room 3F-12, Bronx, NY 10468 USA. [Gardner, Thomas; Yongpravat, Charlie; Lee, Francis Y.] Columbia Univ, Ctr Orthopaed Res, New York, NY 10029 USA. [Oh, Daniel S.] Columbia Univ, Coll Dent Med, New York, NY 10029 USA. [Tascau, Liana] Columbia Univ, Dept Mol Med, New York, NY 10029 USA. [Cardozo, Christopher P.; Bauman, William A.; Tawfeek, Hesham A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Cardozo, Christopher P.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [Anan, Hussein] Temple Univ, Sacred Heart Hosp, Allentown, PA 16102 USA. RP Tawfeek, HA (reprint author), James J Peters VA Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, 130 West Kingsbridge Rd,Room 3F-12, Bronx, NY 10468 USA. EM HeshamA.Tawfeek@va.gov FU Department of Veterans Affairs Rehabilitation Research and Development Service [B9212C] FX This work was supported in part by the Department of Veterans Affairs Rehabilitation Research and Development Service Grant B9212C (to W.A.B.). NR 93 TC 1 Z9 1 U1 1 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2016 VL 157 IS 1 BP 112 EP 126 DI 10.1210/en.2015-1614 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD5KM UT WOS:000369962600018 PM 26488807 ER PT J AU Smith, K Firth, K Smeeding, S Wolever, R Kaufman, J Delgado, R Bellanti, D Xenalcis, L AF Smith, Katherine Firth, Kimberly Smeeding, Sandra Wolever, Ruth Kaufman, Joanna Delgado, Roxana Bellanti, Dawn Xenalcis, Lea TI GUIDELINES FOR CREATING, IMPLEMENTING, AND EVALUATING MIND-BODY PROGRAMS IN A MILITARY HEALTHCARE SETTING SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING LA English DT Article DE Mind-body skills; Empowerment; Guidelines; Program evaluation; Healthcare; Military healthcare ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; CENTERED MEDICAL HOME; ALTERNATIVE MEDICINE; MINDFULNESS MEDITATION; VETERANS-IMPLICATIONS; INTEGRATIVE MEDICINE; PEER SUPPORT; CHRONIC PAIN AB Research suggests that the development of mind-body skills can improve individual and family resilience, particularly related to the stresses of illness, trauma, and caregiving. To operationalize the research evidence that mind body skills help with health and recovery, Samueli Institute, in partnership with experts in mind body programming, created a set of guidelines for developing and evaluating mind-body programs for service members, veterans, and their families. The Guidelines for Creating, Implementing, and Evaluating Mind-Body Programs in a Military Healthcare Setting outline key strategies and issues to consider when developing, implementing, and evaluating a mind body focused family empowerment approach in a military healthcare setting. Although these guidelines were developed specifically for a military setting, most of the same principles can be applied to the development of programs in the civilian setting as well. The guidelines particularly address issues unique to mind-body programs, such as choosing evidence-based modalities, licensure and credentialing, safety and contraindications, and choosing evaluation measures that capture the holistic nature of these types of programs. The guidelines are practical, practice-based guidelines, developed by experts in the fields of program development and evaluation, mind-body therapies, patient- and family-centered care, as well as, experts in military and veteran's health systems. They provide a flexible framework to create mind body family empowerment programs and describe important issues that program developers and evaluators are encouraged to address to ensure the development of the most impactful, successful, evidence-supported programs possible. C1 [Smith, Katherine; Firth, Kimberly; Delgado, Roxana; Bellanti, Dawn; Xenalcis, Lea] Samueli Inst, Optimal Healing Environm, 1737 King St,Suite 600, Alexandria, VA 22314 USA. [Firth, Kimberly] NIA, NIH, Bethesda, MD 20892 USA. [Smeeding, Sandra] San Francisco VA Med Ctr, San Francisco, CA USA. [Wolever, Ruth] Duke Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA. [Wolever, Ruth] Duke Integrat Med, Durham, NC USA. [Wolever, Ruth] Vanderbilt Hlth Coaching, Osher Ctr Integrat Med Vanderbilt, Nashville, TN USA. [Wolever, Ruth] Vanderbilt Univ Sch Med, Phys Med & Rehabil, Nashville, TN USA. [Wolever, Ruth] Vanderbilt Univ Sch Med, Dept Psychiat, Nashville, TN USA. [Wolever, Ruth] Vanderbilt Sch Nursing, Nashville, TN USA. [Kaufman, Joanna] Inst Patient & Family Centered Care, Bethesda, MD USA. [Smeeding, Sandra] Salt Lake City VA Healthcare Syst, Integrat Hlth Clin & Program, Salt Lake City, UT USA. [Wolever, Ruth] Duke Sch Med, Durham, NC USA. [Wolever, Ruth] Duke Integrat Med, Durham, NC USA. RP Smith, K (reprint author), Samueli Inst, Optimal Healing Environm, 1737 King St,Suite 600, Alexandria, VA 22314 USA. EM ksmith@siib.org FU US Army Medical Research and Materiel Command, United States [W81XWH-11-1-0759] FX This work is supported by the US Army Medical Research and Materiel Command, United States, under Award no. W81XWH-11-1-0759. The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. NR 102 TC 0 Z9 0 U1 5 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-8307 EI 1878-7541 J9 EXPLORE-NY JI Explore-J Sci. Heal. PD JAN-FEB PY 2016 VL 12 IS 1 BP 18 EP 33 DI 10.1016/j.explore.2015.10.002 PG 16 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DD1LG UT WOS:000369682600007 PM 26686476 ER PT J AU Steward, J Holt, CL Pollio, DE Austin, EL Johnson, N Gordon, AJ Kertesz, SG AF Steward, Jocelyn Holt, Cheryl L. Pollio, David E. Austin, Erika L. Johnson, Nancy Gordon, Adam J. Kertesz, Stefan G. TI Priorities in the primary care of persons experiencing homelessness: convergence and divergence in the views of patients and provider/experts SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE homeless persons; patient-centered care; primary care; provider perspectives ID DECISION-MAKING; PATIENTS WANT; PREFERENCES; QUALITY AB Purpose: Homeless individuals face unique challenges in health care. Several US initiatives seeking to advance patient-centered primary care for homeless persons are more likely to succeed if they incorporate the priorities of the patients they are to serve. However, there has been no prior research to elicit their priorities in primary care. This study sought to identify aspects of primary care important to persons familiar with homelessness based on personal experience or professional commitment, and to highlight where the priorities of patients and professionals dedicated to their care converge or diverge. Methods: This qualitative exercise asked 26 homeless patients and ten provider/experts to rank 16 aspects of primary care using a card sort. Patient-level respondents (n= 26) were recruited from homeless service organizations across all regions of the USA and from an established board of homeless service users. Provider/expert-level respondents (n= 10) were recruited from veteran and non-veteran-focused homeless health care programs with similar geographic diversity. Results: Both groups gave high priority to accessibility, evidence-based care, coordination, and cooperation. Provider/experts endorsed patient control more strongly than patients. Patients ranked information about their care more highly than provider/experts. Conclusion: Accessibility and the perception of care based on medical evidence represent priority concerns for homeless patients and provider/experts. Patient control, a concept endorsed by experts, is not strongly endorsed by homeless patients. Understanding how to assure fluid communication, coordination, and team member cooperation could represent more worthy targets for research and quality improvement in this domain. C1 [Steward, Jocelyn] Clayton State Univ, Dept Hlth Care Management, Morrow, GA USA. [Holt, Cheryl L.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Pollio, David E.] Univ Alabama Birmingham, Dept Social Work, Birmingham, AL USA. [Austin, Erika L.; Johnson, Nancy; Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA. [Austin, Erika L.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL USA. [Gordon, Adam J.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. Birmingham VA Med Ctr, Hlth Serv Res & Dev Program, Birmingham, AL 35233 USA. RP Kertesz, SG (reprint author), Birmingham VA Med Ctr, Hlth Serv Res & Dev Program, 700 South 19th St, Birmingham, AL 35233 USA. EM skertesz@uabmc.edu FU Department of Veterans Affairs, Health Services Research and Development Branch, Merit Award [07-969] FX This study is sponsored by the Department of Veterans Affairs, Health Services Research and Development Branch, Merit Award 07-969. Opinions expressed within this manuscript are those of the authors alone and do not represent positions of the Veterans Health Administration or any entity within the US federal government. NR 21 TC 0 Z9 0 U1 3 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2016 VL 10 BP 153 EP 158 DI 10.2147/PPA.S75477 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DD7EA UT WOS:000370085300001 PM 26929607 ER PT S AU Pujol-Lereis, LM Schafer, N Kuhn, LB Rohrer, B Pauly, D AF Pujol-Lereis, Luciana M. Schaefer, Nicole Kuhn, Laura B. Rohrer, Baerbel Pauly, Diana BE Rickman, CB LaVail, MM Anderson, RE Grimm, C Hollyfield, J Ash, J TI Interrelation Between Oxidative Stress and Complement Activation in Models of Age-Related Macular Degeneration SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 16th International Symposium on Retinal Degeneration (RD) CY JUL 13-18, 2014 CL Pacific Grove, CA DE Oxidative stress; Complement system; Age-related macular degeneration; Oxidation-specific epitopes; Alternative pathway; Cigarette smoke model; Light-damage model; CEP-immunization model; Sodium iodate-treatment model; Knock-out mice models ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H DEFICIENCY; CHOROIDAL NEOVASCULARIZATION; PHOTORECEPTOR DEGENERATION; REGULATORY PROTEINS; CIGARETTE-SMOKE; RPE CELLS; MICE; EXPRESSION; COMPONENT AB Millions of individuals older than 50-years suffer from age-related macular degeneration (AMD). Associated with this multifactorial disease are polymorphisms of complement factor genes and a main environmental risk factoroxidative stress. Until now the linkage between these risk factors for AMD has not been fully understood. Recent studies, integrating results on oxidative stress, complement activation, epidemiology and ocular pathology suggested the following sequence in AMD-etiology: initially, chronic oxidative stress results in modification of proteins and lipids in the posterior of the eye; these tissue alterations trigger chronic inflammation, involving the complement system; and finally, invasive immune cells facilitate pathology in the retina. Here, we summarize the results for animal studies which aim to elucidate this molecular interplay of oxidative events and tissue-specific complement activation in the eye. C1 [Schaefer, Nicole; Pauly, Diana] Univ Hosp Regensburg, Dept Ophthalmol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany. [Rohrer, Baerbel] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Ophthalmol, Charleston, SC 29401 USA. [Rohrer, Baerbel] Res Serv, Charleston, SC 29401 USA. [Pujol-Lereis, Luciana M.; Kuhn, Laura B.] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany. RP Pauly, D (reprint author), Univ Hosp Regensburg, Dept Ophthalmol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany. EM Luciana.pujol@klinik.uni-regensburg.de; Nicole.schafer@klinik.uni-regensburg.de; laura.kuhn@stud.uni-regensburg.de; rohrer@musc.edu; Diana.Pauly@klinik.uni-regensburg.de OI Pujol Lereis, Luciana Mercedes/0000-0002-7009-2743 NR 33 TC 4 Z9 4 U1 5 U2 14 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-17121-0; 978-3-319-17120-3 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 854 BP 87 EP 93 DI 10.1007/978-3-319-17121-0_13 PG 7 WC Medicine, Research & Experimental; Ophthalmology SC Research & Experimental Medicine; Ophthalmology GA BE2OL UT WOS:000369715400013 PM 26427398 ER PT S AU Beeson, C Lindsey, C Nasarre, C Bandyopadhyay, M Perron, N Rohrer, B AF Beeson, Craig Lindsey, Chris Nasarre, Cecile Bandyopadhyay, Mausumi Perron, Nathan Rohrer, Baerbel BE Rickman, CB LaVail, MM Anderson, RE Grimm, C Hollyfield, J Ash, J TI Small Molecules that Protect Mitochondrial Function from Metabolic Stress Decelerate Loss of Photoreceptor Cells in Murine Retinal Degeneration Models SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 16th International Symposium on Retinal Degeneration (RD) CY JUL 13-18, 2014 CL Pacific Grove, CA DE Mitochondria; Respirometry; Glycolysis; Neuroprotectant; ATP ID OXIDATIVE STRESS; RETINITIS-PIGMENTOSA; MECHANISMS; DEATH; APOPTOSIS; SURVIVAL; ENERGY; OXYGEN AB One feature common to many of the pathways implicated in retinal degeneration is increased metabolic stress leading to impaired mitochondrial function. We found that exposure of cells to calcium ionophores or oxidants as metabolic stressors diminish maximal mitochondrial capacity. A library of 50,000 structurally diverse "drug-like" molecules was screened for protection against loss of calcium-induced loss of mitochondrial capacity in 661W rod-derived cells and C6 glioblastomas. Initial protective hits were then tested for protection against IBMX-induced loss of mitochondrial capacity as measured via respirometry. Molecules that protected mitochondria were then evaluated for protection of rod photoreceptor cells in retinal explants from rd1 mice. Two of the molecules attenuated loss of photoreceptor cells in the rd1 model. In the 661W cells, exposure to calcium ionophore or tert-butylhydroperoxide caused mitochondrial fragmentation that was blocked with the both compounds. Our studies have identified molecules that protect mitochondria and attenuate loss of photoreceptors in models of retinal degeneration suggesting that they could be good leads for development of therapeutic drugs for treatment of a wide variety of retinal dystrophies. C1 [Beeson, Craig; Lindsey, Chris] MitoChem Therapeut Inc, 280 Calhoun St,MSC140, Charleston, SC 29403 USA. [Beeson, Craig; Lindsey, Chris] Med Univ S Carolina, Dept Drug Discovery, Charleston, SC 29425 USA. [Beeson, Craig; Lindsey, Chris] Med Univ S Carolina, Dept Biomed Sci, Charleston, SC 29425 USA. [Nasarre, Cecile; Bandyopadhyay, Mausumi; Perron, Nathan; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC 29401 USA. RP Beeson, C (reprint author), MitoChem Therapeut Inc, 280 Calhoun St,MSC140, Charleston, SC 29403 USA.; Beeson, C (reprint author), Med Univ S Carolina, Dept Drug Discovery, Charleston, SC 29425 USA.; Beeson, C (reprint author), Med Univ S Carolina, Dept Biomed Sci, Charleston, SC 29425 USA. EM beesonc@musc.edu; lindseyc@musc.edu; nassarre@musc.edu; e-bandyom@musc.edu; perron@musc.edu; rohrer@musc.edu NR 15 TC 0 Z9 0 U1 0 U2 5 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-17121-0; 978-3-319-17120-3 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 854 BP 449 EP 454 DI 10.1007/978-3-319-17121-0_60 PG 6 WC Medicine, Research & Experimental; Ophthalmology SC Research & Experimental Medicine; Ophthalmology GA BE2OL UT WOS:000369715400060 PM 26427445 ER PT S AU Rohrer, B Bandyopadhyay, M Beeson, C AF Rohrer, Baebel Bandyopadhyay, Mausumi Beeson, Craig BE Rickman, CB LaVail, MM Anderson, RE Grimm, C Hollyfield, J Ash, J TI Reduced Metabolic Capacity in Aged Primary Retinal Pigment Epithelium (RPE) is Correlated with Increased Susceptibility to Oxidative Stress SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 16th International Symposium on Retinal Degeneration (RD) CY JUL 13-18, 2014 CL Pacific Grove, CA DE Retinal pigment epithelium; Mitochondria; ATP production; Oxidative stress ID MACULAR DEGENERATION; CELLS; COMPLEMENT AB One of the affected tissues in age-related macular degeneration (AMD) is the retinal pigment epithelium (RPE), a tissue that consists of terminally differentiated cells and that accumulates damage over time. In all tissues, mitochondria (mt), which play an essential role in both cell health (energy) and death (initiator of apoptosis), undergo an aging process through the accumulation of mtDNA damage, changes in mitochondrial dynamics, a reduction in biogenesis, and mitophagy, leading to an overall reduction in mitochondrial energy production and other non-energy-related functions. Here we have compared energy metabolism in primary human RPE cells isolated from aborted fetus or aged donor eyes and grown as stable monolayers. H2O2 treatment resulted in the generation of reactive oxygen species and superoxide, an effect that was significantly augmented by age. Mitochondrial metabolism, as analyzed by Seahorse respirometry, revealed reduced mitochondrial oxygen consumption (ATP production) at baseline and a complete loss of reserve capacity in aged cells. Likewise, glycolysis was blunted in aged cells. Taken together, these studies showed that RPE cells derived from aged donor eyes are more susceptible to oxidative stress, and exhibit a loss in mitochondrial respiratory reserve capacity and a reduction in glycolysis. These data suggest that while old cells may have sufficient energy at rest, they cannot mount a stress response requiring additional ATP and reducing agents. In summary, these data support the hypothesis that mitochondria or energy metabolism is a valid target for therapy in AMD. C1 [Rohrer, Baebel; Bandyopadhyay, Mausumi] Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI614, Charleston, SC 29425 USA. [Beeson, Craig] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 167 Ashley Ave,SEI614, Charleston, SC 29425 USA. [Rohrer, Baebel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI614, Charleston, SC 29425 USA. EM rohrer@musc.edu FU National Institutes of Health [R01EY019320]; Veterans Affairs [I01 RX000444]; Foundation Fighting Blindness; Research to Prevent Blindness FX This work was supported in part by the National Institutes of Health (R01EY019320), Veterans Affairs (I01 RX000444), Foundation Fighting Blindness, and an unrestricted grant to MUSC from Research to Prevent Blindness. The authors have no financial conflicts of interest. NR 12 TC 5 Z9 5 U1 0 U2 3 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-17121-0; 978-3-319-17120-3 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 854 BP 793 EP 798 DI 10.1007/978-3-319-17121-0_106 PG 6 WC Medicine, Research & Experimental; Ophthalmology SC Research & Experimental Medicine; Ophthalmology GA BE2OL UT WOS:000369715400106 PM 26427491 ER PT J AU Byrne, T Montgomery, AE Fargo, JD AF Byrne, Thomas Montgomery, Ann Elizabeth Fargo, Jamison D. TI Unsheltered Homelessness Among Veterans: Correlates and Profiles SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE Homelessness; Veterans; Serious mental illness; Substance use disorders; Latent class analysis ID STREET OUTREACH; HEALTH; CARE; INDIVIDUALS; SERVICES; ACCESS; ADULTS AB We identified correlates of unsheltered status among Veterans experiencing homelessness and described distinct subgroups within the unsheltered homeless Veteran population using data from a screening instrument for homelessness that is administered to all Veterans accessing outpatient care at a Veterans Health Administration (VHA) facility. Correlates of unsheltered homelessness included male gender, white race, older age, lower levels of VHA eligibility, substance use disorders, frequent use of VHA inpatient and infrequent use of VHA outpatient services, and residing in the West. We identified six distinct subgroups of unsheltered Veterans; the tri-morbid frequent users represented the highest need group, but the largest group was comprised of Veterans who made highly infrequent use of VHA healthcare services. Differences between sheltered and unsheltered Veterans and heterogeneity within the unsheltered Veteran population should be considered in targeting housing and other interventions. C1 [Byrne, Thomas] Boston Univ, Sch Social Work, 264 Bay State Rd, Boston, MA 02215 USA. [Byrne, Thomas; Montgomery, Ann Elizabeth; Fargo, Jamison D.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. [Fargo, Jamison D.] Utah State Univ, Dept Psychol, 2810 Old Main Hill, Logan, UT 84322 USA. RP Byrne, T (reprint author), Boston Univ, Sch Social Work, 264 Bay State Rd, Boston, MA 02215 USA.; Byrne, T (reprint author), US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. EM tbyrne@bu.edu; Ann.montgomery@va.gov; Jamison.fargo@usu.edu NR 22 TC 1 Z9 1 U1 3 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0010-3853 EI 1573-2789 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD JAN PY 2016 VL 52 IS 2 BP 148 EP 157 DI 10.1007/s10597-015-9922-0 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DC7UX UT WOS:000369427100004 PM 26289119 ER PT J AU De Luca, SM Blosnich, JR Hentschel, EAW King, E Amen, S AF De Luca, Susan M. Blosnich, John R. Hentschel, Elizabeth A. W. King, Erika Amen, Sally TI Mental Health Care Utilization: How Race, Ethnicity and Veteran Status are Associated with Seeking Help SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE Veteran; Mental health; Mental health treatment utilization; Racial/ethnic disparities ID AFGHANISTAN VETERANS; CLINICAL-OUTCOMES; SERVICES; IRAQ; DIAGNOSES; ATTITUDES; MILITARY; BARRIERS; SOLDIERS; MEMBERS AB As veterans disproportionately experience higher rates of mental illness than civilians, conflicting results surround the impact of race/ethnicity on treatment utilization. This study utilized the CDC's Texas Behavioral Risk Factor Surveillance System data, a random-digit dialed telephone survey of non-institutionalized adults. A subset of Texas respondents (n = 8563) were asked questions related to mental health treatment, stigma, help-seeking attitudes and emotional support. While no differences were found in health care utilization between non-Hispanic white veterans and non-veterans, there were distinct patterns among racial/ethnic minority veterans and non-veterans. Black and Latino non-veterans reported significantly lower health care utilization compared to non-Hispanic white non-veterans. Among veterans, there were no differences in reported utilization rates comparing non-Hispanic whites and Latinos and also non-Hispanic whites and Blacks. Our study adds to the literature by examining health care utilization among a diverse group of veterans by focusing on Veterans Administration (VA) and non-VA services to veterans. C1 [De Luca, Susan M.; King, Erika] Univ Texas Austin, Sch Social Work, 1925 San Jacinto Blvd,Stop D3500, Austin, TX 78712 USA. [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Hlth Serv Res, Univ Dr C 151C-U,Bldg 30, Pittsburgh, PA 15240 USA. [Hentschel, Elizabeth A. W.] Univ Texas Austin, Coll Educ, Dept Educ Psychol, Counseling Psychol, 1 Univ Stn D5800, Austin, TX 78712 USA. [Amen, Sally] Univ Texas Austin, Dept Stat & Data Sci, 2317 Speedway D9800, Austin, TX 78712 USA. RP De Luca, SM (reprint author), Univ Texas Austin, Sch Social Work, 1925 San Jacinto Blvd,Stop D3500, Austin, TX 78712 USA. EM sdeluca@austin.utexas.edu; John.blosnich@va.gov; elizwilson@gmail.com; sally.amen@austin.utexas.edu NR 27 TC 0 Z9 0 U1 3 U2 18 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0010-3853 EI 1573-2789 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD JAN PY 2016 VL 52 IS 2 BP 174 EP 179 DI 10.1007/s10597-015-9964-3 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DC7UX UT WOS:000369427100007 PM 26659853 ER PT J AU Jensen, DM Ohning, GV Kovacs, TOG Ghassemi, KA Jutabha, R Dulai, GS Machicado, GA AF Jensen, Dennis M. Ohning, Gordon V. Kovacs, Thomas O. G. Ghassemi, Kevin A. Jutabha, Rome Dulai, Gareth S. Machicado, Gustavo A. TI Doppler endoscopic probe as a guide to risk stratification and definitive hemostasis of peptic ulcer bleeding SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID RANDOMIZED-TRIAL; ADRENALINE INJECTION; VISIBLE VESSEL; HEATER PROBE; HEMORRHAGE; MANAGEMENT; THERAPY; COAGULATION; ULTRASOUND; CONSENSUS AB Background and Aims: For more than 4 decades endoscopists have relied on ulcer stigmata for risk stratification and as a guide to hemostasis. None used arterial blood flow underneath stigmata to predict outcomes. For patients with severe peptic ulcer bleeding (PUB), we used a Doppler endoscopic probe (DEP) for (1) detection of blood flow underlying stigmata of recent hemorrhage (SRH), (2) quantitating rates of residual arterial blood flow under SRH after visually directed standard endoscopic treatment, and (3) comparing risks of rebleeding and actual 30-day rebleed rates for spurting arterial bleeding (Forrest [F] IA) and oozing bleeding (F IB). Methods: Prospective cohort study of 163 consecutive patients with severe PUB and different SRH. Results: All blood flow detected by the DEP was arterial. Detection rates were 87.4% in major SRH-spurting arterial bleeding (F IA), non-bleeding visible vessel (F IIA), clot (F IIB)-and were significantly lower at 42.3% (P <.0001) for an intermediate group of oozing bleeding (F IB) or flat spot (F IIC). For spurting bleeding (F IA) versus oozing (F IB), baseline DEP arterial flow was 100% versus 46.7%, residual blood flow detected after endoscopic hemostasis was 35.7% versus 0%, and 30-day rebleed rates were 28.6% versus 0% (all P <.05). Conclusions: (1) For major SRH versus oozing or spot, the arterial blood flow detection rate by the DEP was significantly higher, indicating a higher rebleed risk. (2) Before and after endoscopic treatment, spurting (F IA) PUB had significantly higher rates of blood flow detection than oozing (F IB) PUB and a significantly higher 30-day rebleed rate. (3) The DEP is recommended as a new endoscopic guide with SRH to improve risk stratification and potentially definitive hemostasis for PUB. C1 [Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O. G.; Ghassemi, Kevin A.; Jutabha, Rome; Dulai, Gareth S.; Machicado, Gustavo A.] Univ Calif Los Angeles, Div Digest Dis, CURE Digest Dis Res Ctr, CURE Hemostasis Res Grp, Los Angeles, CA USA. [Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O. G.; Ghassemi, Kevin A.; Jutabha, Rome; Dulai, Gareth S.; Machicado, Gustavo A.] Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan Univ Calif Los Angeles, Dept Med,Med Ctr, Los Angeles, CA 90095 USA. [Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O. G.; Dulai, Gareth S.; Machicado, Gustavo A.] West Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. RP Jensen, DM (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, CURE DDRC, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU AstraZeneca; NIH CURE DDRC [41301]; VA Clinical Merit Review Grant; AstraZeneca USA; Vascular Technology Inc (VTI) FX D. Jensen is a consultant for Vascular Technology Incorporated and received an equipment grant for endoscopic Doppler control units to partially support this study. He was a consultant for AstraZeneca and received an investigator-initiated research grant from AstraZeneca, which partially supported a preliminary study. All other authors disclosed no financial relationships relevant to this publication. This study was partially funded by NIH CURE DDRC Grant 41301 (Human Studies Core), a VA Clinical Merit Review Grant (to Dr Jensen, PI), an Investigator Initiated Grant from AstraZeneca USA, and an equipment grant from Vascular Technology Inc (VTI). NR 37 TC 6 Z9 6 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2016 VL 83 IS 1 BP 129 EP 136 DI 10.1016/j.gie.2015.07.012 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DC5AA UT WOS:000369230900019 PM 26318834 ER PT J AU Sanduleanu, S Kaltenbach, T Barkun, A McCabe, RP Velayos, F Picco, MF Laine, L Soetikno, R McQuaid, KR AF Sanduleanu, Silvia Kaltenbach, Tonya Barkun, Alan McCabe, Robert P. Velayos, Fernando Picco, Michael F. Laine, Loren Soetikno, Roy McQuaid, Kenneth R. TI A roadmap to the implementation of chromoendoscopy in inflammatory bowel disease colonoscopy surveillance practice SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID INTERNATIONAL CONSENSUS STATEMENT; DEPRESSED COLORECTAL NEOPLASMS; STANDING ULCERATIVE-COLITIS; QUALITY INDICATORS; METHYLENE-BLUE; DNA-DAMAGE; CANCER; DYSPLASIA; RISK; ENDOSCOPY C1 [Sanduleanu, Silvia] Maastricht Univ, Med Ctr, Dept Med, Div Gastroenterol, NL-6200 MD Maastricht, Netherlands. [Sanduleanu, Silvia] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, NL-6200 MD Maastricht, Netherlands. [Kaltenbach, Tonya; Soetikno, Roy] Stanford Univ, Palo Alto, CA 94304 USA. [Kaltenbach, Tonya; Soetikno, Roy] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Barkun, Alan] McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal, PQ, Canada. [McCabe, Robert P.] Minnesota Gastroenterol, Minneapolis, MN USA. [Velayos, Fernando] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Picco, Michael F.] Mayo Clin, Dept Med, Div Gastroenterol, Jacksonville, FL 32224 USA. [Laine, Loren] Yale Univ, Sch Med, West Haven, CT 06516 USA. [Laine, Loren] VA Connecticut Healthcare Syst, West Haven, CT USA. [McQuaid, Kenneth R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [McQuaid, Kenneth R.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Sanduleanu, S (reprint author), Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Div Gastroenterol & Hepatol,Dept Internal Med, Postbox 5800, NL-6202 AZ Maastricht, Netherlands. NR 50 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2016 VL 83 IS 1 BP 213 EP 222 DI 10.1016/j.gie.2015.08.076 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DC5AA UT WOS:000369230900034 PM 26364967 ER PT J AU Li, G Chen, C Laing, SD Ballard, C Biju, KC Reddick, RL Clark, RA Li, S AF Li, G. Chen, C. Laing, S. D. Ballard, C. Biju, K. C. Reddick, R. L. Clark, R. A. Li, S. TI Hematopoietic knockdown of PPAR delta reduces atherosclerosis in LDLR-/- mice SO GENE THERAPY LA English DT Article ID ACTIVATED-RECEPTOR-DELTA; PREVENTS ENDOTHELIAL DYSFUNCTION; NF-KAPPA-B; METABOLIC SYNDROME; MOLECULAR-MECHANISMS; GENE-THERAPY; BETA/DELTA; EXPRESSION; DISEASE; INFLAMMATION AB PPAR(delta) (peroxisome proliferator-activated receptor delta) mediates inflammation in response to lipid accumulation. Systemic administration of a PPAR(delta) agonist can ameliorate atherosclerosis. Paradoxically, genetic deletion of PPAR(delta) in hematopoietic cells led to a reduction of atherosclerosis in murine models, suggesting that downregulation of PPAR(delta) expression in these cells may mitigate atherogenesis. To advance this finding forward to potential clinical translation through hematopoietic stem cell transplantation-based gene therapy, we employed a microRNA (miRNA) approach to knock down PPAR(delta) expression in bone marrow cells followed by transplantation of the cells into LDLR-/- mice. We found that knockdown of PPARd expression in the hematopoietic system caused a dramatic reduction in aortic atherosclerotic lesions. In macrophages, a key component in atherogenesis, knockdown of PPAR(delta) led to decreased expression of multiple pro-inflammatory factors, including monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-1 beta and IL-6. Expression of CCR2, a receptor for MCP-1, was also decreased. The downregulation of pro-inflammatory factors is consistent with significant reduction of macrophage presence in the lesions, which may also be attributable to elevation of ABCA1 (ATP-binding cassette, subfamily A, member 1) and depression of adipocyte differentiate-related protein. Furthermore, the abundance of both MCP-1 and matrix metalloproteinase-9 proteins was reduced in plaque areas. Our results demonstrate that miRNA-mediated PPAR delta knockdown in hematopoietic cells is able to ameliorate atherosclerosis. C1 [Li, G.; Chen, C.; Laing, S. D.; Ballard, C.; Biju, K. C.; Clark, R. A.; Li, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Li, G.; Chen, C.; Laing, S. D.; Ballard, C.; Biju, K. C.; Clark, R. A.; Li, S.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Reddick, R. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Li, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. RP Li, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.; Li, S (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.; Li, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM lis1@uthscsa.edu FU Research Division of the Department of Veterans Affairs; William and Ella Owens Medical Research Foundation; Clinical and Translational Science Award from the National Institutes of Health [TR001120]; US Veterans Health Administration FX We thank Xiaoling Xue and Qiong Zhang for excellent laboratory assistance. This study was supported by a Merit Review grant from the Research Division of the Department of Veterans Affairs and by a grant from William and Ella Owens Medical Research Foundation awarded to SL. RAC is supported by Clinical and Translational Science Award TR001120 from the National Institutes of Health. This study was supported by a grant from the US Veterans Health Administration. NR 52 TC 1 Z9 1 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0969-7128 EI 1476-5462 J9 GENE THER JI Gene Ther. PD JAN PY 2016 VL 23 IS 1 BP 78 EP 85 DI 10.1038/gt.2015.78 PG 8 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA DC9ND UT WOS:000369547400009 PM 26204499 ER PT J AU Bratcher, PE Rowe, SM Reeves, G Roberts, T Szul, T Harris, WT Tirouvanziam, R Gaggar, A AF Bratcher, Preston E. Rowe, Steven M. Reeves, Ginger Roberts, Tambra Szul, Tomasz Harris, William T. Tirouvanziam, Rabindra Gaggar, Amit TI Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor SO JOURNAL OF CYSTIC FIBROSIS LA English DT Article DE CFTR; G551D; Ivacaftor; VX-770; Leukocyte; Blood ID HUMAN NEUTROPHILS; CFTR POTENTIATOR; G551D MUTATION; EXPRESSION; RECEPTORS; DISEASE; CELLS AB Background: Ivacaftor improves clinical outcome by potentiation of mutant G551D CFTR. Due to the presence of CFTR in monocytes and polymorphonuclear neutrophils (PMNs), we hypothesized that ivacaftor may impact leukocyte activation. Methods: We examined blood leukocytes from G551D CF subjects prior to and at one and six months after receiving ivacaftor. Blood leukocytes from ivacaftor-naive G551D, F508del, and healthy controls were also treated with ivacaftor ex vivo to assess mutation-specific effects. Results: Compared to healthy controls, G551D CF subjects had significantly higher expression of active CD11b on PMNs and of CD63 on monocytes, which were normalized by in vivo ivacaftor treatment. Ex vivo exposure to ivacaftor of blood cells from G551D, but not F508del and healthy subjects, resulted in changes in CXCR2 and CD16 expression on PMNs. Conclusions: In vivo and ex vivo exposure of G551D CF leukocytes to ivacaftor resulted in an altered activation profile, suggesting mutation specific leukocyte modulation. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. C1 [Bratcher, Preston E.; Rowe, Steven M.; Szul, Tomasz; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, 424 THT,1900 Univ Blvd, Birmingham, AL 35294 USA. [Bratcher, Preston E.; Rowe, Steven M.; Szul, Tomasz; Gaggar, Amit] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, 424 THT,1900 Univ Blvd, Birmingham, AL 35294 USA. [Rowe, Steven M.; Reeves, Ginger; Roberts, Tambra; Harris, William T.; Gaggar, Amit] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, MCLM 790,1918 Univ Blvd, Birmingham, AL 35294 USA. [Rowe, Steven M.; Gaggar, Amit] Univ Alabama Birmingham, UAB Lung Hlth Ctr, 526 20th St South, Birmingham, AL 35294 USA. [Gaggar, Amit] US Dept Vet Affairs, Med Serv, Med Ctr, 700 19th St S, Birmingham, AL 35233 USA. [Rowe, Steven M.; Reeves, Ginger; Roberts, Tambra; Harris, William T.] Univ Alabama Birmingham, Dept Pediat Childrens Alabama, 1600 7th Ave South, Birmingham, AL 35233 USA. [Rowe, Steven M.] Dept Cell Dev & Integrat Biol, THT 926,1720 2nd Ave South, Birmingham, AL 35294 USA. [Bratcher, Preston E.; Szul, Tomasz; Harris, William T.; Tirouvanziam, Rabindra; Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, MCLM 760,1918 Univ Blvd, Birmingham, AL 35294 USA. [Tirouvanziam, Rabindra] Emory Univ, Dept Pediat, 2015 Uppergate Dr,Room 344, Atlanta, GA 30322 USA. [Tirouvanziam, Rabindra] Childrens Healthcare Atlanta, Ctr Cyst Fibrosis & Airway Dis Res, 2015 Uppergate Dr,Room 344, Atlanta, GA 30322 USA. RP Gaggar, A (reprint author), 1918 Univ Blvd,McCallum Room 760, Birmingham, AL 35294 USA. EM bratcher@uab.edu; smrowe@uab.edu; greeves@peds.uab.edu; troberts@peds.uab.edu; szultom@uab.edu; tharris@peds.uab.edu; tirouvanziam@emory.edu; agaggar1@uab.edu FU National Institutes of Health [HL102371, 5T32HL105346-02, P30 DK072482, UL1 TR000165]; Cystic Fibrosis Foundation [GAGGAR07, GOAL13K1, TIROUV13, Harris12Q0]; Ismail Moustafa Scholar Award; Emory Children's Center FX Funding: This work is supported by the National Institutes of Health (HL102371 to AG, 5T32HL105346-02 to PEB, P30 DK072482 to SMR, UL1 TR000165 to SMR), the Cystic Fibrosis Foundation (GAGGAR07 to AG, GOAL13K1 to SMR, TIROUV13 to RT, Harris12Q0 to WTH), the Ismail Moustafa Scholar Award (to AG) and by a faculty start-up from the Emory Children's Center (RT). NR 27 TC 6 Z9 6 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-1993 EI 1873-5010 J9 J CYST FIBROS JI J. Cyst. Fibros PD JAN PY 2016 VL 15 IS 1 BP 67 EP 73 DI 10.1016/j.jcf.2015.02.010 PG 7 WC Respiratory System SC Respiratory System GA DC8HT UT WOS:000369461200012 PM 25769931 ER PT J AU Baizano, J Fresenius, A Walker, P Berdella, M Portenoy, RK Bookbinder, M Glajchen, M Plachta, A Langfelder-Schwind, E Chen, J Dhingra, L AF Baizano, Julie Fresenius, Ashley Walker, Patricia Berdella, Maria Portenoy, Russell K. Bookbinder, Marilyn Glajchen, Myra Plachta, Amy Langfelder-Schwind, Elinor Chen, Jack Dhingra, Lara TI Web-based symptom screening in cystic fibrosis patients: A feasibility study SO JOURNAL OF CYSTIC FIBROSIS LA English DT Article DE Cystic fibrosis; Telehealth; Web-based monitoring; Symptom screening; Symptom burden; Advance care planning ID QUALITY-OF-LIFE; ADULT PATIENTS; DISTRESS; CANCER; SCALE AB Background: Cystic fibrosis (CF) causes high illness burden. Screening may identify patients who could potentially benefit from interventions for symptoms or other sources of distress. We evaluated the feasibility of a web-based system for routine monitoring. Methods: Adult CF patients enrolled in a study of palliative care service delivery completed web-based assessments every 30 days on global distress, physical and psychological symptom distress, and the perceived benefits of discussing advance care planning (ACP) with CF clinicians. Feasibility was assessed by the rate of survey completion, survey reminders, and missed surveys during a 9-month rolling enrollment period. Results: Of 74 participants (47.3% women, 94.4% white), 36.7% had comorbid diabetes, and 56.9% had an FEV1% predicted score of 40-69. In total, patients completed 456 (80.6%) of 566surveys every 30 days over the assessment period. Sixty-five (87.8%) completed 405 (79.7%) of 508 surveys online and 9 (12.2%) completed 51 (88.0%) of 58 surveys using a combination of online, telephone, and mail-based methods. Many surveys were completed without reminders (online: 261 [64.4%] of 405; combined methods: 29 [56.9%] of 51), with 166 (36.4%) surveys requiring 1 or more reminders. Further, 23.0% (17) of patients noted elevated global distress; 20.3% (15) endorsed physical symptom distress, 12.2% (9) had psychological distress, and 58.1% (43) reported that discussing ACP would be beneficial. Conclusions: Repeated web-based screening for symptom distress and ACP preferences is feasible in adult CF patients. Future studies should assess the system's generalizability and staff resources when implementing reminders and non-web methods of completion. (C) 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. C1 [Baizano, Julie] James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Fresenius, Ashley; Walker, Patricia; Berdella, Maria; Plachta, Amy; Langfelder-Schwind, Elinor] Mt Sinai Beth Israel, Dept Pulm Med, Cyst Fibrosis Ctr, First Ave,16th St, New York, NY 10003 USA. [Portenoy, Russell K.; Bookbinder, Marilyn; Glajchen, Myra; Chen, Jack; Dhingra, Lara] MJHS Inst Innovat Palliat Care, 39 Broadway,3rd Floor, New York, NY 10006 USA. RP Dhingra, L (reprint author), MJHS Inst Innovat Palliat Care, 39 Broadway,3rd Floor, New York, NY 10006 USA. EM LDhingra@mjhs.org FU Cystic Fibrosis Therapeutics, Inc. [PORTEN13A0] FX This research was supported by a grant from Cystic Fibrosis Therapeutics, Inc. (PORTEN13A0). None of the authors have any conflict of interest associated with this research. NR 19 TC 0 Z9 0 U1 4 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-1993 EI 1873-5010 J9 J CYST FIBROS JI J. Cyst. Fibros PD JAN PY 2016 VL 15 IS 1 BP 102 EP 108 DI 10.1016/j.jcf.2015.11.001 PG 7 WC Respiratory System SC Respiratory System GA DC8HT UT WOS:000369461200018 ER PT J AU Terrelonge, M Marder, KS Weintraub, D Alcalay, RN AF Terrelonge, Mark, Jr. Marder, Karen S. Weintraub, Daniel Alcalay, Roy N. TI CSF beta-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE CSF beta-amyloid 1-42; Cognitive impairment; Parkinson's disease; PPMI ID CEREBROSPINAL-FLUID; DEMENTIA; TAU; A-BETA(42); ASSOCIATION; PERFORMANCE; BIOMARKERS; GUIDELINES; AUTOPSY AB Low CSF beta-amyloid 1-42 has been associated with cognitive decline in advanced Parkinson's disease; data from a single cohort suggest beta-amyloid 1-42 may be an early marker of cognitive impairment. Newly diagnosed Parkinson's participants (mean duration, 6.9 months) in the Parkinson's Progression Markers Initiative (n = 341) were assessed at baseline (untreated state) and followed for 2 years. CSF beta-amyloid 1-42, alpha-synuclein, total tau, and tau phosphorylated at threonine 181 were collected at baseline. Participants were classified as having cognitive impairment (CI) if scores on two of six cognitive tests were 1.5 standard deviations below the standardized mean based on published norms in healthy controls. Multivariable regression analyses were used to determine the association between baseline CSF markers with cognitive impairment, defined by neuropsychological testing performance at 2-year follow-up. Fifty-five participants (16.1 %) had CI at baseline and were not included in further analyses. Thirty-seven of the 286 participants without CI at baseline (12.9 %) developed CI at 2 years. Participants with CI at 2 years had significantly lower mean baseline CSF beta-amyloid 1-42 levels than non-CI participants (343.8 vs. 380.4 pg/mL, p < 0.01); no significant difference was seen for alpha-synuclein, T-tau, or P-tau 181. In a regression model of 286 participants without baseline CI adjusted for age, gender, disease duration, education, motor severity, and depression status, lower baseline beta-amyloid 1-42 levels were associated with higher odds of CI at 2 years. (OR10pg/mL = 1.04, 95 % CI 1.01-1.08, p < 0.05). CSF beta-amyloid 1-42 level at disease onset is an independent predictor of cognitive impairment in early Parkinson's disease. C1 [Terrelonge, Mark, Jr.; Marder, Karen S.; Alcalay, Roy N.] Columbia Univ, Dept Neurol, 710 W 168th St, New York, NY 10032 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Alcalay, RN (reprint author), Columbia Univ, Dept Neurol, 710 W 168th St, New York, NY 10032 USA. EM RNA2104@COLUMBIA.EDU FU NIH [NS036630, 1UL1 RR024156-01, PO412196- G, PO412196-G]; Parkinson disease Foundation; MJ Fox Foundation; Michael J. Fox Foundation for Parkinson's Research; National Institutes of Health; Novartis Pharmaceuticals; Department of Veterans Affairs; Alzheimer's Disease Cooperative Study; University of Pennsylvania; Parkinson's Disease Foundation; National Institutes of Health [NS036630, K02NS080915, UL1 TR000040, UL1 RR024156]; Brookdale Foundation; [U01NS052592] FX Dr. Marder reports grants from NIH [#NS036630 (PI), 1UL1 RR024156-01(Director PCIR), PO412196- G (Co-I), and PO412196-G (Co-I)], grants from steering committee for U01NS052592, grants from Parkinson disease Foundation, and grants from MJ Fox Foundation and research funds from Teva Pharmaceuticals outside the submitted work. Dr. Weintraub received research funding from the Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health, Novartis Pharmaceuticals, Department of Veterans Affairs, and Alzheimer's Disease Cooperative Study; honoraria from Teva Pharmaceuticals, Lundbeck Inc., Pfizer, Avanir Pharmaceuticals, Merck & Co., UCB, Bristol-Myers Squibb Company, Novartis Pharmaceuticals, Eli Lilly and Company, Clintrex LLC, Theravance, Medivation, CHDI Foundation, and Alzheimer's Disease Cooperative Study; license fee payments from the University of Pennsylvania for the QUIP and QUIP-RS; and fees for testifying in court case related to impulse controls disorders in Parkinson's disease (March 2013). Dr. Alcalay is supported by the Parkinson's Disease Foundation, the National Institutes of Health (K02NS080915, NS036630, and UL1 TR000040, formerly the National Center for Research Resources, Grant Number UL1 RR024156), and the Brookdale Foundation. He consulted for Genzyme/Sanofi and Prophase. NR 24 TC 9 Z9 9 U1 1 U2 4 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 EI 1559-1166 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD JAN PY 2016 VL 58 IS 1 BP 88 EP 92 DI 10.1007/s12031-015-0647-x PG 5 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DC5RF UT WOS:000369277400010 PM 26330275 ER PT J AU Chahine, LM Weintraub, D Hawkins, KA Siderowf, A Eberly, S Oakes, D Seibyl, J Stern, MB Marek, K Jennings, D AF Chahine, Lama M. Weintraub, Daniel Hawkins, Keith A. Siderowf, Andrew Eberly, Shirley Oakes, David Seibyl, John Stern, Matthew B. Marek, Kenneth Jennings, Danna CA PARS Investigators TI Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's; cognition; prodromal; dopaminergic deficit; hyposmia ID SLEEP BEHAVIOR DISORDER; EXECUTIVE DYSFUNCTION; DOPAMINE TRANSPORTERS; PRODROMAL FEATURES; DISEASE; DEPRESSION; IMPAIRMENT; CARE AB ObjectivesThe Parkinson Associated Risk Syndrome Study identified a cohort of healthy adults with hyposmia and dopamine transporter binding reduction to characterize individuals at risk for Parkinson's disease (PD). We describe the cognitive profile of this cohort. MethodsIndividuals older than 50 y without PD were recruited. Two hundred twenty-five completed cognitive testing and were included in the final analysis. A neuropsychological test battery was administered and normative scores created for global cognition, memory, executive function/working memory, processing speed/attention, visuospatial abilities, and language domains. Other non-motor symptoms (constipation, depression, anxiety, and rapid eye movement sleep behavior disorder) were assessed through questionnaires. ResultsIndividuals with both hyposmia and reduced dopamine transporter binding (n=38) had lower mean scores for global cognition, executive function/working memory, and memory compared with all other participants (n=187). In separate multivariate logistic regression models, lower global cognition (odds ratio, 1.97, P=0.004), and specifically executive function/working memory (odds ratio, 1.84, P=0.004) scores were associated with membership in the hyposmia with dopamine transporter reduction group. Combining hyposmia with relative impairment on specific cognitive domains increased the odds of dopamine transporter binding reduction compared with hyposmia alone, with the greatest increase in odds for hyposmia plus executive function/working memory relative impairment (68% increase in odds from 4.14 to 6.96). ConclusionChanges in global cognitive abilities, and specifically executive function/working memory, are present in individuals at risk for PD. Combining non-motor features, including cognition, improves prediction of dopamine transporter binding reduction. (c) 2015 International Parkinson and Movement Disorder Society C1 [Chahine, Lama M.; Weintraub, Daniel; Stern, Matthew B.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Educ & Clin Ctr, PD Res, Philadelphia, PA USA. [Hawkins, Keith A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Siderowf, Andrew] Avid Radiopharmaceut, Philadelphia, PA USA. [Eberly, Shirley; Oakes, David] Univ Rochester, Sch Med, Dept Biostat, Rochester, NY USA. [Seibyl, John; Marek, Kenneth; Jennings, Danna] Inst Neurodegenerat Disorders, New Haven, CT USA. RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM Daniel.Weintraub@uphs.upenn.edu FU Department of Defense [W81XWH-06-067] FX Support for this study is provided by the Department of Defense award number W81XWH-06-067 NR 43 TC 12 Z9 12 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN PY 2016 VL 31 IS 1 BP 86 EP 94 DI 10.1002/mds.26373 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA DC7WL UT WOS:000369431300017 PM 26293177 ER PT J AU Mata, IF Leverenz, JB Weintraub, D Trojanowski, JQ Chen-Plotkin, A Van Deerlin, VM Ritz, B Rausch, R Factor, SA Wood-Siverio, C Quinn, JF Chung, KA Peterson-Hiller, AL Goldman, JG Stebbins, GT Bernard, B Espay, AJ Revilla, FJ Devoto, J Rosenthal, LS Dawson, TM Albert, MS Tsuang, D Huston, H Yearout, D Hu, SC Cholerton, BA Montine, TJ Edwards, KL Zabetian, CP AF Mata, Ignacio F. Leverenz, James B. Weintraub, Daniel Trojanowski, John Q. Chen-Plotkin, Alice Van Deerlin, Vivianna M. Ritz, Beate Rausch, Rebecca Factor, Stewart A. Wood-Siverio, Cathy Quinn, Joseph F. Chung, Kathryn A. Peterson-Hiller, Amie L. Goldman, Jennifer G. Stebbins, Glenn T. Bernard, Bryan Espay, Alberto J. Revilla, Fredy J. Devoto, Johnna Rosenthal, Liana S. Dawson, Ted M. Albert, Marilyn S. Tsuang, Debby Huston, Haley Yearout, Dora Hu, Shu-Ching Cholerton, Brenna A. Montine, Thomas J. Edwards, Karen L. Zabetian, Cyrus P. TI GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE cognition; GBA; neuropsychological tests; visuospatial; working memory ID APOLIPOPROTEIN-E GENOTYPE; GAUCHER-DISEASE; GLUCOCEREBROSIDASE MUTATIONS; DEMENTIA; RISK; PERFORMANCE; IMPAIRMENT; INCIDENT; ONSET; GENE AB BackgroundLoss-of-function mutations in the GBA gene are associated with more severe cognitive impairment in PD, but the nature of these deficits is not well understood and whether common GBA polymorphisms influence cognitive performance in PD is not yet known. MethodsWe screened the GBA coding region for mutations and the E326K polymorphism in 1,369 PD patients enrolled at eight sites from the PD Cognitive Genetics Consortium. Participants underwent assessments of learning and memory (Hopkins Verbal Learning Test-Revised), working memory/executive function (Letter-Number Sequencing Test and Trail Making Test A and B), language processing (semantic and phonemic verbal fluency), visuospatial abilities (Benton Judgment of Line Orientation), and global cognitive function (MoCA). We used linear regression to test for association between genotype and cognitive performance with adjustment for important covariates and accounted for multiple testing using Bonferroni's corrections. ResultsMutation carriers (n=60; 4.4%) and E326K carriers (n=65; 4.7%) had a higher prevalence of dementia (mutations, odds ratio=5.1; P=9.7x10(-6); E326K, odds ratio=6.4; P=5.7x10(-7)) and lower performance on Letter-Number Sequencing (mutations, corrected P[P-c]=9.0x10(-4); E326K, P-c=0.036), Trail Making B-A (mutations, P-c=0.018; E326K, P-c=0.018), and Benton Judgment of Line Orientation (mutations, P-c=0.0045; E326K, P-c=0.0013). ConclusionsBoth GBA mutations and E326K are associated with a distinct cognitive profile characterized by greater impairment in working memory/executive function and visuospatial abilities in PD patients. The discovery that E326K negatively impacts cognitive performance approximately doubles the proportion of PD patients we now recognize are at risk for more severe GBA-related cognitive deficits. (c) 2015 International Parkinson and Movement Disorder Society C1 [Mata, Ignacio F.; Tsuang, Debby; Huston, Haley; Yearout, Dora; Hu, Shu-Ching; Cholerton, Brenna A.; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Mata, Ignacio F.; Huston, Haley; Yearout, Dora; Hu, Shu-Ching; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Leverenz, James B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Neurol Inst, Cleveland, OH 44106 USA. [Weintraub, Daniel; Chen-Plotkin, Alice] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Trojanowski, John Q.; Van Deerlin, Vivianna M.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. [Ritz, Beate] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. [Ritz, Beate] Univ Calif Los Angeles, Sch Publ Hlth, Dept Environm Hlth Sci, Los Angeles, CA 90024 USA. [Ritz, Beate; Rausch, Rebecca] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Factor, Stewart A.; Wood-Siverio, Cathy] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson-Hiller, Amie L.] Portland VA Med Ctr, Portland, OR USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson-Hiller, Amie L.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Goldman, Jennifer G.; Stebbins, Glenn T.; Bernard, Bryan] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Espay, Alberto J.; Revilla, Fredy J.; Devoto, Johnna] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA. [Revilla, Fredy J.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA. [Rosenthal, Liana S.; Dawson, Ted M.; Albert, Marilyn S.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Neuroregenerat & Stem Cell Programs, Baltimore, MD USA. [Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD USA. [Dawson, Ted M.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA. [Tsuang, Debby; Cholerton, Brenna A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Edwards, Karen L.] Univ Calif Irvine, Sch Med, Dept Epidemiol, Irvine, CA 92717 USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU National Institutes of Health [K23 NS060949, P01 AG017586, P01 ES016732, P30 AG010124, P50 AG005136, P50 NS038367, P50 NS038377, P50 NS053488, P50 NS062684, R01 ES010544, R01 NS065070, U01 NS082133, U54 ES012078]; Department of Veterans Affairs [1I01BX000531]; Consolidated Anti-Aging Foundation; Dolsen Foundation; Jane and Lee Seidman Fund; Nancy and Buster Alvord Endowment; Parkinson's Disease Foundation; Sartain Lanier Family Foundation; Office of Research and Development Medical Research Service, Department of Veterans Affairs FX This work was supported by grants from the National Institutes of Health (K23 NS060949, P01 AG017586, P01 ES016732, P30 AG010124, P50 AG005136, P50 NS038367, P50 NS038377, P50 NS053488, P50 NS062684, R01 ES010544, R01 NS065070, U01 NS082133, and U54 ES012078), the Department of Veterans Affairs (1I01BX000531), the Consolidated Anti-Aging Foundation, the Dolsen Foundation, the Jane and Lee Seidman Fund, the Nancy and Buster Alvord Endowment, the Parkinson's Disease Foundation, and the Sartain Lanier Family Foundation. This material is based upon work supported, in part, by the Office of Research and Development Medical Research Service, Department of Veterans Affairs. NR 41 TC 17 Z9 17 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN PY 2016 VL 31 IS 1 BP 95 EP 102 DI 10.1002/mds.26359 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DC7WL UT WOS:000369431300018 PM 26296077 ER PT J AU Brennan, L Siderowf, A Rubright, JD Rick, J Dahodwala, N Duda, JE Hurtig, H Stern, M Xie, SX Rennert, L Karlawish, J Shea, JA Trojanowski, JQ Weintraub, D AF Brennan, Laura Siderowf, Andrew Rubright, Jonathan D. Rick, Jacqueline Dahodwala, Nabila Duda, John E. Hurtig, Howard Stern, Matthew Xie, Sharon X. Rennert, Lior Karlawish, Jason Shea, Judy A. Trojanowski, John Q. Weintraub, Daniel TI Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; instrumental activities of daily living; cognition; item response theory ID MILD COGNITIVE IMPAIRMENT; SOCIETY TASK-FORCE; INSTRUMENTAL ACTIVITIES; ALZHEIMERS-DISEASE; RATING-SCALE; DEMENTIA; RIVASTIGMINE; AGREEMENT; PATIENT AB ObjectiveThe aim of this work was to describe the development and psychometric analysis of the Penn Parkinson's Daily Activities Questionnaire. The questionnaire is an item response theory-based tool for rating cognitive instrumental activities of daily living in PD. MethodsCandidate items for the Penn Parkinson's Daily Activities Questionnaire were developed through literature review and focus groups of patients and knowledgeable informants. Item selection and calibration of item-response theory parameters were performed using responses from a cohort of PD patients and knowledgeable informants (n = 388). In independent cohorts of PD patients and knowledgeable informants, assessments of test-retest reliability (n = 50), and construct validity (n = 68) of the questionnaire were subsequently performed. Construct validity was assessed by correlating questionnaire scores with measures of motor function, cognition, an existing activities of daily living measure, and directly observed daily function. ResultsFifty items were retained in the final questionnaire item bank. Items were excluded owing to redundancy, difficult reading level, and when item-response theory parameters could not be calculated. Test-retest reliability was high (intraclass correlation coefficient = 0.97; P < 0.001). The questionnaire correlated strongly with cognition (r = 0.68; P < 0.001) and directly observed daily function (r = 0.87; P < 0.001), but not with motor impairment (r = 0.08; P = 0.53). The questionnaire score accurately discriminated between PD patients with and without dementia (receiver operating characteristic curve = 0.91; 95% confidence interval: 0.85-0.97). ConclusionsThe Penn Parkinson's Daily Activities Questionnaire shows strong evidence of reliability and validity. Item response theory-based psychometric analysis suggests that this questionnaire can discriminate across a range of daily functions. (c) 2015 International Parkinson and Movement Disorder Society C1 [Brennan, Laura; Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. [Brennan, Laura; Duda, John E.; Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Siderowf, Andrew] Avid Radiopharmaceut, Philadelphia, PA USA. [Rubright, Jonathan D.] Amer Inst Certified Publ Accountants, Ewing, NJ USA. [Rick, Jacqueline; Dahodwala, Nabila; Duda, John E.; Hurtig, Howard; Stern, Matthew; Trojanowski, John Q.; Weintraub, Daniel] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Xie, Sharon X.; Rennert, Lior] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Sch Med, PENN CMU Roybal Ctr Behav Econ & Hlth, LDI Ctr Hlth Incent,Dept Med Eth, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Sch Med, PENN CMU Roybal Ctr Behav Econ & Hlth, Dept Med,LDI Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Sch Med, Alzheimers Dis Ctr, Philadelphia, PA 19104 USA. [Shea, Judy A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Weintraub, D (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Morris K. Udall Parkinson's Disease Research Center of Excellence grant from the National Institute of Neurological Disorders and Stroke [NS-053488]; Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement [SAP4100027296, Act 2001-77] FX This study was funded by a Morris K. Udall Parkinson's Disease Research Center of Excellence grant from the National Institute of Neurological Disorders and Stroke (NS-053488) and by SAP4100027296, a health research grant awarded by the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 2001-77. NR 36 TC 2 Z9 2 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN PY 2016 VL 31 IS 1 BP 126 EP 134 DI 10.1002/mds.26339 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA DC7WL UT WOS:000369431300022 PM 26249849 ER PT J AU Hanlon, CA Owens, MM Joseph, JE Zhu, X George, MS Brady, KT Hartwell, KJ AF Hanlon, Colleen A. Owens, Max M. Joseph, Jane E. Zhu, Xun George, Mark S. Brady, Kathleen T. Hartwell, Karen J. TI Lower subcortical gray matter volume in both younger smokers and established smokers relative to non-smokers SO ADDICTION BIOLOGY LA English DT Article DE Gray matter; nicotine; smoking; voxel-based morphometry ID CIGARETTE-SMOKING; HUMAN-BRAIN; COGNITIVE PERFORMANCE; VISUAL-ATTENTION; RECEPTOR-BINDING; NICOTINE; TOBACCO; DEPENDENCE; AGE; MORPHOMETRY AB Although established adult smokers with long histories of nicotine dependence have lower neural tissue volume than non-smokers, it is not clear if lower regional brain volume is also observed in younger, less established smokers. The primary goal of this study was to investigate neural tissue volume in a large group of smokers and non-smokers, with a secondary goal of measuring the impact of age on these effects. We used voxel-based morphometry to compare regional gray matter volume in 118 individuals (59 smokers, 59 age- and gender-matched non-smokers). Younger smokers had significantly lower gray matter volume in the left thalamus and the left amygdala than their non-smoking peers (family-wise error-corrected clusters, P<0.05). There was no correlation between smoking use variables and tissue volume among younger smokers. Established smokers had significantly lower gray matter volume than age-matched non-smokers in the insula, parahippocampal gyrus and pallidum. Medial prefrontal cortex gray matter volume was negatively correlated with pack-years of smoking among the established smokers, but not the younger smokers. These data reveal that regional tissue volume differences are not limited exclusively to established smokers. Deficits in young adults indicate that cigarette smoking may either be deleterious to the thalamus and amygdala at an earlier age than previously reported, or that pre-existing differences in these areas may predispose individuals to the development of nicotine dependence. C1 [Hanlon, Colleen A.; Owens, Max M.; Hartwell, Karen J.] Med Univ S Carolina, Dept Psychiat, 67 President St, Charleston, SC 29425 USA. [Hanlon, Colleen A.; Joseph, Jane E.; Zhu, Xun] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Joseph, Jane E.] Univ Kentucky, Lexington, KY USA. [George, Mark S.; Brady, Kathleen T.] Med Univ S Carolina, Clin Neurosci Div, Charleston, SC 29425 USA. [George, Mark S.; Brady, Kathleen T.; Hartwell, Karen J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hanlon, CA (reprint author), Med Univ S Carolina, Dept Psychiat, 67 President St, Charleston, SC 29425 USA.; Hanlon, CA (reprint author), Med Univ S Carolina, Dept Neurosci, 67 President St, Charleston, SC 29425 USA. EM hanlon@musc.edu FU GRAND [GA30523K]; NICHD [K12HD055885, UL1 RR029882]; [K01DA027756]; [DA036085-03]; [5R21DA026085-02] FX Funding was provided by K01DA027756 (CAH), R33 (DA036085-03), GRAND (GA30523K), 5R21DA026085-02, NICHD K12HD055885 and UL1 RR029882 NR 47 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 EI 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD JAN PY 2016 VL 21 IS 1 BP 185 EP 195 DI 10.1111/adb.12171 PG 11 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA DC2ST UT WOS:000369067300016 PM 25125263 ER PT J AU Lee, AP Roth, MY Nya-Ngatchou, JJ Lin, K Walsh, TJ Page, ST Matsumoto, AM Bremner, WJ Amory, JK Anawalt, BD AF Lee, Ada P. Roth, Mara Y. Nya-Ngatchou, Jean-Jacques Lin, Kat Walsh, Thomas J. Page, Stephanie T. Matsumoto, Alvin M. Bremner, William J. Amory, John K. Anawalt, Bradley D. TI Testicular fine-needle aspiration for the assessment of intratesticular hormone concentrations SO ASIAN JOURNAL OF ANDROLOGY LA English DT Article DE male contraception; physiology; reproductive and urinary; testis ID TESTOSTERONE CONCENTRATIONS; NONOBSTRUCTIVE AZOOSPERMIA; GONADOTROPIN SUPPRESSION; SPERM ASPIRATION; HUMAN TESTIS; NORMAL MEN; BIOPSY AB Measurement of intratesticular sex steroid concentrations in men informs both the development of male hormonal contraceptives and the understanding of male infertility. Given the challenges of using invasive techniques to measure testicular hormone physiology, our group has used a minimally-invasive fine-needle aspiration technique to measure intratesticular hormones in normal healthy men. Herein, we present a post-hoc analysis of the safety and efficacy of testicular fine-needle aspiration (FNA) completed as part of six clinical trials. From 2001 through 2011, a total of 404 procedures were conducted among 163 research volunteers, 85.9% of which were successful in obtaining sufficient fluid for the measurement of intratesticular steroid concentrations. Pain was the most common side effect, with 36.8% of procedures associated with moderate procedural pain and 4.7% with severe procedural pain. Postprocedural pain was uncommon and abated within a few days. Mild local bruising occurred with 14.9% of procedures. Two serious adverse events (0.5%) required surgical intervention. The risk of an adverse event was not associated with age, body mass index, testicular size, or the volume of fluid aspirated. Testicular FNA to obtain fluid for measurement of intratesticular steroid concentrations frequently causes mild to moderate procedural pain, but serious adverse events occur rarely. Testicular FNA has been instrumental for defining human intratesticular hormone physiology and is a minimally-invasive, safe, effective method for obtaining fluid for research on testicular physiology and pathology. C1 [Lee, Ada P.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Roth, Mara Y.; Nya-Ngatchou, Jean-Jacques; Page, Stephanie T.; Matsumoto, Alvin M.; Bremner, William J.; Amory, John K.; Anawalt, Bradley D.] Univ Washington, Dept Med, Seattle, WA USA. [Roth, Mara Y.; Nya-Ngatchou, Jean-Jacques; Page, Stephanie T.; Matsumoto, Alvin M.; Bremner, William J.; Amory, John K.; Anawalt, Bradley D.] Univ Washington, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA. [Lin, Kat] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Walsh, Thomas J.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Dept Med, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Lin, Kat] Univ Washington, Seattle, WA 98195 USA. RP Anawalt, BD (reprint author), Univ Washington, Dept Med, Seattle, WA USA.; Anawalt, BD (reprint author), Univ Washington, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA. EM banawalt@medicine.washington.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development grants [U54 HD-42454]; National Institute of Diabetes and Digestive Kidney Diseases training grant [5T32 DK007247-35, K23 HD073164-02]; Veterans Administration Research and Development FX Funding provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development grants U54 HD-42454 (STP, WJB, JKA, BDA), the National Institute of Diabetes and Digestive Kidney Diseases training grant 5T32 DK007247-35 (JJNN) and K23 HD073164-02 (MYR), and by the Veterans Administration Research and Development (AMM, BDA). NR 17 TC 0 Z9 0 U1 1 U2 2 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1008-682X EI 1745-7262 J9 ASIAN J ANDROL JI Asian J. Androl. PD JAN PY 2016 VL 18 IS 1 BP 21 EP 24 DI 10.4103/1008-682X.156637 PG 4 WC Andrology; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA DA5MJ UT WOS:000367846900004 PM 26208394 ER PT J AU Zhang, C Meermeier, NP Terker, AS Blankenstein, KI Singer, JD Hadchouel, J Ellison, DH Yang, CL AF Zhang, Chong Meermeier, Nicholas P. Terker, Andrew S. Blankenstein, Katharina I. Singer, Jeffrey D. Hadchouel, Juliette Ellison, David H. Yang, Chao-Ling TI Degradation by Cullin 3 and effect on WNK kinases suggest a role of KLHL2 in the pathogenesis of Familial Hyperkalemic Hypertension SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Kelch-like protein 2; Cullin 3; WNK kinase; Degradation; Familial Hyperkalemic Hypertension ID PSEUDOHYPOALDOSTERONISM TYPE-II; DISEASE-CAUSING MUTATIONS; NA-CL COTRANSPORTER; UBIQUITINATION; SPAK; HOMEOSTASIS; INTERACTS; COMPLEX; NKCC2; CUL3 AB Mutations in WNK1 and WNK4, and in components of the Cullin-Ring Ligase system, kelch-like 3 (KLHL3) and Cullin 3 (CUL3), can cause the rare hereditary disease, Familial Hyperkalemic Hypertension (FHHt). The disease is characterized by overactivity of the renal sodium chloride cotransporter (NCC), which is phosphorylated and activated by the WNK-stimulated Ste20-type kinases, SPAT( and OSR1. WNK kinases themselves can be targeted for ubiquitination and degradataion by the CUL3-KLHL3 E3 ubiquitin ligase complex. It is unclear, however, why there are significant differences in phenotypic severity among FHHt patients with mutations in different genes. It was reported that kelch-like 2 (KLHL2), a homolog of KLHL3, can also target WNK kinases for ubiquitation and degradation, and may play a special role in the systemic vasculature. Our recent study revealed the disease mutant CUL3 exhibits enhanced degradation of its adaptor protein KLHL3, potentially resulting in accumulation of WNK kinases secondarily. To investigate if KLHL2 plays a role in FHHt, we studied the effect of wild type and FHHt mutant CUL3 on degradation of KLHL2 and WNK kinase proteins in HEK293 cells. Although CUL3 facilitates KLHL2 degradation, the disease mutant CUL3 is more active in this regard. KLHL2 facilitated the degradation of wild type but not disease mutant WNK4 protein. These results suggest that KLHL2 likely plays a role in the pathogenesis of FHHt, and aggravates the phenotype caused by mutations in CUL3 and WNK4. (C) 2015 Elsevier Inc. All rights reserved. C1 [Zhang, Chong] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Nephrol, Shanghai 200030, Peoples R China. [Meermeier, Nicholas P.; Terker, Andrew S.; Ellison, David H.; Yang, Chao-Ling] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA. [Blankenstein, Katharina I.] Charite, Inst Vegetat Anat, Campus Charite Mitte, D-13353 Berlin, Germany. [Hadchouel, Juliette] Portland State Univ, Dept Biol, Portland, OR 97207 USA. [Hadchouel, Juliette] Paris Cardiovasc Res Ctr, Paris, France. [Hadchouel, Juliette] Univ Paris 05, Sorbonne Paris Cite, Fac Med, Paris, France. [Ellison, David H.] Portland VA Med Ctr, Portland, OR USA. RP Zhang, C (reprint author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Nephrol, Shanghai 200030, Peoples R China.; Yang, CL (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA. EM zhangchongzc@gmail.com; yangch@ohsu.edu RI Hadchouel, Juliette/K-4593-2016 FU National Natural Science Foundation of China [81570634]; Shanghai Municipal Education Commission [15zz054]; NIH [R01 DK51496, 5T32DK067864-10] FX This work was supported by National Natural Science Foundation of China 81570634 and Shanghai Municipal Education Commission 15zz054 (to C. Zhang), and NIH grant R01 DK51496 (to C.-L. Yang and D.H. Ellison). A.S. Terker was supported by NIH 5T32DK067864-10. NR 25 TC 2 Z9 3 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD JAN 1 PY 2016 VL 469 IS 1 BP 44 EP 48 DI 10.1016/j.bbrc.2015.11.067 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA DB9WI UT WOS:000368868000007 PM 26607111 ER PT J AU Tuomela, JM Sandholm, JA Kaakinen, M Hayden, KL Haapasaari, KM Jukkola-Vuorinen, A Kauppila, JH Lehenkari, PP Harris, KW Graves, DE Selander, KS AF Tuomela, Johanna M. Sandholm, Jouko A. Kaakinen, Mika Hayden, Katherine L. Haapasaari, Kirsi-Maria Jukkola-Vuorinen, Arja Kauppila, Joonas H. Lehenkari, Petri P. Harris, Kevin W. Graves, David E. Selander, Katri S. TI Telomeric G-quadruplex-forming DNA fragments induce TLR9-mediated and LL-37-regulated invasion in breast cancer cells in vitro SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Toll-like receptor 9; Invasion; LL-37; Telomeric G-quadruplex DNA; 9-mer hairpin DNA ID TOLL-LIKE RECEPTOR-9; ANTIMICROBIAL PROTEIN HCAP18/LL-37; SUBCELLULAR-LOCALIZATION; HELICOBACTER-PYLORI; NUCLEASE RESISTANCE; CELLULAR INVASION; GENE-EXPRESSION; DENDRITIC CELLS; BACTERIAL-DNA; HUMAN GENOME AB Toll-like receptor 9 (TLR9) is a cellular DNA-receptor widely expressed in cancers. We previously showed that synthetic and self-derived DNA fragments induce TLR9-mediated breast cancer cell invasion in vitro. We investigated here the invasive effects of two nuclease-resistant DNA fragments, a 9-mer hairpin, and a G-quadruplex DNA based on the human telomere sequence, both having native phosphodiester backbone. Cellular uptake of DNAs was investigated with immunofluorescence, invasion was studied with Matrigel-assays, and mRNA and protein expression were studied with qPCR and Western blotting and protease activity with zymograms. TLR9 expression was suppressed through siRNA. Although both DNAs induced TLR9-mediated changes in pro-invasive mRNA expression, only the telomeric G-quadruplex DNA significantly increased cellular invasion. This was inhibited with GM6001 and aprotinin, suggesting MMP- and serine protease mediation. Furthermore, complexing with LL-37, a cathelicidin-peptide present in breast cancers, increased 9-mer hairpin and G-quadruplex DNA uptake into the cancer cells. However, DNA/LL-37 complexes decreased invasion, as compared with DNA-treatment alone. Invasion studies were conducted also with DNA fragments isolated from neoadjuvant chemotherapy-treated breast tumors. Also such DNA induced breast cancer cell invasion in vitro. As with the synthetic DNAs, this invasive effect was reduced by complexing the neoadjuvant tumor-derived DNAs with LL-37. We conclude that 9-mer hairpin and G-quadruplex DNA fragments are nuclease-resistant DNA structures that can act as invasion-inducing TLR9 ligands. Their cellular uptake and the invasive effects are regulated via LL-37. Although such structures may be present in chemotherapy-treated tumors, the clinical significance of this finding requires further studying. C1 [Tuomela, Johanna M.; Sandholm, Jouko A.; Harris, Kevin W.; Selander, Katri S.] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. [Tuomela, Johanna M.; Sandholm, Jouko A.; Harris, Kevin W.; Graves, David E.; Selander, Katri S.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Tuomela, Johanna M.] Univ Turku, Inst Biomed, Dept Cell Biol & Anat, Turku, Finland. [Sandholm, Jouko A.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland. [Sandholm, Jouko A.] Abo Akad Univ, Turku, Finland. [Kaakinen, Mika; Kauppila, Joonas H.; Lehenkari, Petri P.] Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland. [Kaakinen, Mika] Univ Oulu, Fac Biochem & Mol Med, Oulu Ctr Cell Matrix Res, Bioctr Oulu, Oulu, Finland. [Hayden, Katherine L.; Graves, David E.] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA. [Haapasaari, Kirsi-Maria; Kauppila, Joonas H.; Lehenkari, Petri P.] Univ Oulu, Dept Pathol, Oulu, Finland. [Jukkola-Vuorinen, Arja] Univ Hosp Oulu, Dept Oncol, Oulu, Finland. [Lehenkari, Petri P.] Oulu Univ Hosp, Dept Surg, Oulu, Finland. [Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Selander, Katri S.] Lapland Cent Hosp, Dept Pathol, Rovaniemi, Finland. [Selander, Katri S.] UAB, Dept Chem, CHEM 201 1720 2nd Ave South, Birmingham, AL 35294 USA. RP Selander, KS (reprint author), Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA.; Selander, KS (reprint author), Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.; Selander, KS (reprint author), Lapland Cent Hosp, Dept Pathol, Rovaniemi, Finland.; Selander, KS (reprint author), UAB, Dept Chem, CHEM 201 1720 2nd Ave South, Birmingham, AL 35294 USA. EM Katriselander@uabmc.edu RI Lehenkari, Petri/O-3009-2016 OI Lehenkari, Petri/0000-0002-0055-5183; Kauppila, Joonas/0000-0001-6740-3726; Tuomela, Johanna/0000-0003-4390-4563 FU Department of Defense [W81XWH-10-1-0308]; Finnish Cancer Organizations; Finnish Cultural Foundation; Maud Kuistila Memorial Foundation; Orion-Farmos Research Foundation; K. Albin Johansson Foundation; Cancer Foundation of South-Western Finland FX This work was funded by grants from the Department of Defense (W81XWH-10-1-0308, K.S.S., D.G.), Finnish Cancer Organizations (J.S.), Finnish Cultural Foundation (J.T.), Maud Kuistila Memorial Foundation (J.T.), Orion-Farmos Research Foundation (J.T.), K. Albin Johansson Foundation (J.T.), and Cancer Foundation of South-Western Finland (J.T). NR 51 TC 2 Z9 2 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD JAN PY 2016 VL 155 IS 2 BP 261 EP 271 DI 10.1007/s10549-016-3683-5 PG 11 WC Oncology SC Oncology GA DC1US UT WOS:000369003100006 PM 26780557 ER PT S AU Clancy, CJ Nguyen, MH AF Clancy, Cornelius J. Nguyen, M. Hong BE Calderone, R Cihlar, R TI Diagnostic Methods for Detection of Blood-Borne Candidiasis SO CANDIDA SPECIES: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Candidemia; Invasive candidiasis; Intra-abdominal candidiasis; beta-D-glucan; Fungitell; Polymerase chain reaction (PCR); T2Candida; Diagnosis; Bayesian ID PLACEBO-CONTROLLED TRIAL; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; D-GLUCAN ASSAY; INVASIVE CANDIDIASIS; SURGICAL-PATIENTS; FUNGAL-INFECTIONS; DOUBLE-BLIND; FLUCONAZOLE PROPHYLAXIS; HIGH-RISK AB beta-D-glucan (Fungitell) and polymerase chain reaction-based (T2Candida) assays of blood samples are FDA-approved adjuncts to cultures for diagnosing candidemia and other types of invasive candidiasis, but their clinical roles are unclear. In this chapter, we describe laboratory protocols for performing Fungitell and T2Candida assays. We then discuss step-by-step methods for interpreting test results at the bedside using a Bayesian framework, and for incorporating assays into rational patient management strategies. Prior to interpreting results, clinicians must recognize that test performance varies based on the type of invasive candidiasis being diagnosed. In general, the type of invasive candidiasis that is most likely in a given patient can be identifi ed, and the pretest likelihood of disease estimated. From there, positive and negative predictive values (PPV, NPV) for an assay can be calculated. At a population level, tests can be incorporated into screening strategies for antifungal treatment. NPV and PPV thresholds can be defined for discontinuing antifungal prophylaxis or initiating preemptive treatment, respectively. Using the thresholds, it is possible to assign windows of pretest likelihood for invasive candidiasis (and corresponding patient populations) in which tests are most likely to valuable. At the individual patient level, tests may be useful outside of the windows proposed for screening populations. The interpretive and clinical decision-making processes we discuss will be applicable to other diagnostic assays as they enter the clinic, and to existing assays as more data emerge from various populations. C1 [Clancy, Cornelius J.; Nguyen, M. Hong] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Clancy, Cornelius J.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. RP Clancy, CJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. NR 36 TC 1 Z9 1 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3052-4; 978-1-4939-3051-7 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1356 BP 215 EP 238 DI 10.1007/978-1-4939-3052-4_16 D2 10.1007/978-1-4939-3052-4 PG 24 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Microbiology; Mycology SC Biochemistry & Molecular Biology; Microbiology; Mycology GA BE2EJ UT WOS:000369087600017 PM 26519076 ER PT J AU Brennan, JM Sketch, MH Dai, D Trilesskaya, M Al-Hejily, W Rao, SV Brilakis, E Messenger, JC Shaw, RE Anstrom, KJ Peterson, ED Douglas, PS AF Brennan, J. Matthew Sketch, Michael H., Jr. Dai, David Trilesskaya, Marina Al-Hejily, Wesam Rao, Sunil V. Brilakis, Emmanouil Messenger, John C. Shaw, Richard E. Anstrom, Kevin J. Peterson, Eric D. Douglas, Pamela S. TI Safety and Clinical Effectiveness of Drug-Eluting Stents for Saphenous Vein Graft Intervention in Older Individuals: Results From the Medicare-Linked National Cardiovascular Data Registry (R) CathPCI Registry (R) (2005-2009) SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE saphenous vein grafts; drug-eluting stents; bare metal stents; outcomes ID BARE-METAL STENTS; FOLLOW-UP; TRIAL; LESIONS AB Objectives: To evaluate the safety of drug-eluting stents (DES) when treating patients with failing saphenous vein grafts (SVG). Background: DES reduce target vessel revascularization in patients with failing SVGs; however, compared with bare metal stents (BMS), DES have been variably associated with increased mortality. Methods: Clinical records from National Cardiovascular Data Registry (R) CathPCI Registry (R) (49,325 older individuals [>= 65 years] who underwent SVG stenting 2005-2009) were linked to Medicare claims to create a longitudinal record. Death, myocardial infarction (MI), and urgent revascularization with DES versus BMS were evaluated to 3 years using propensity matching (PM). Results were stratified by clinical presentation (acute coronary syndrome [ACS], non-ACS), previous lesion treatment (in-stent, de novo), and graft segment (aortic, body, distal anastomosis). Results: In this older cohort (median age, 75 years), acute presentations were prevalent (ACS, 69%; TIMI flow <3, 45%), and adverse clinical outcomes were common by 3 years (death, 24.5%; MI, 14.6%; urgent revascularization, 29.5%). Among DES patients (n = 31,403), 3-year mortality was lower (vs. BMS) (22.7% vs. 28.0%, P < 0.001; PM hazard ratio [HR] 0.87, 95% confidence interval 0.83-0.91), and no difference was observed in the adjusted risk for MI (PM HR 0.97, 0.91 to 1.03) or urgent revascularization (PM HR 1.04, 0.99-1.08). These findings were independent of clinical presentation, previous lesion treatment, and graft segment (P interaction, ns). Conclusions: In this large SVG PCI cohort, all-cause mortality was lower among those receiving DES, and no difference in MI or urgent revascularization was observed to 3 years. (C) 2015 Wiley Periodicals, Inc. C1 [Brennan, J. Matthew; Sketch, Michael H., Jr.; Dai, David; Al-Hejily, Wesam; Rao, Sunil V.; Anstrom, Kevin J.; Peterson, Eric D.; Douglas, Pamela S.] Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27710 USA. [Trilesskaya, Marina] Calif Pacific Med Ctr, Div Cardiol, Dept Internal Med, San Francisco, CA USA. [Brilakis, Emmanouil] Vet Affairs North Texas Healthcare Syst, Div Cardiol, Dept Internal Med, Dallas, TX USA. [Brilakis, Emmanouil] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Messenger, John C.] Denver Vet Affairs Med Ctr, Div Cardiol, Dept Med, Denver, CO USA. [Shaw, Richard E.] Sutter Pacif Heart Ctr, Div Cardiol, Dept Clin Informat, San Francisco, CA USA. RP Brennan, JM (reprint author), Duke Univ, Med Ctr, Div Cardiol, 2400 Pratt St,Rm 0311 Terrace Level, Durham, NC 27705 USA. EM j.matthew.brennan@dm.duke.edu FU Sanofi; Janssen; St Jude Medical; Terumo; Asahi; Abbott Vascular; Boston Scientific; Guerbet; AstraZeneca; Eli Lilly Company; Medtronic; American College of Cardiology; American Heart Association; Janssen Pharmaceuticals; Society of Thoracic Surgeons FX Dr. Brennan has no relevant disclosures to report. Dr. Sketch has no relevant disclosures to report. Dr. Dai has no relevant disclosures to report. Dr. Trilesskaya has no relevant disclosure to report. Dr. Al-Hejily has no relevant disclosure to report. Dr. Rao has non relevant disclosures to report. Dr. Brilakis reports honoraria/speaker fees from Sanofi (modest), Janssen (modest), St Jude Medical (modest), Terumo (modest), Asahi (significant), Abbott Vascular (modest), and Boston Scientific (significant); research grant from Guerbet (significant); spouse is an employee of Medtronic (significant). Dr. Messenger has no relevant disclosure to report. Dr. Shaw has no relevant disclosures to report. Dr. Anstrom reports research support from AstraZeneca (significant), Eli Lilly & Company (significant), and Medtronic (significant); has served as a consultant for Abbott Vascular (modest), AstraZeneca (modest), Bristol-Meyers Squibb (modest), Gilead (modest), Pfizer (modest), GSK (modest), Promedior (modest), and Ikaria (modest); has served on data monitoring committees for NIH (modest), University of North Carolina (modest), University of Miami (modest), Forest (modest), Pfizer (modest), GSK (modest), and Vertex (modest); and has an equity interest in Biscardia. Dr. Peterson reports research funding for the American College of Cardiology, American Heart Association, Eli Lilly & Company, Janssen Pharmaceuticals, and Society of Thoracic Surgeons (all significant); consulting (including CME) for Merck & Co. (modest), Boehringer Ingelheim, Genentech, Janssen Pharmaceuticals, and Sanofi-Aventis (all significant). Dr. Douglas has no relevant disclosures to report. NR 11 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD JAN 1 PY 2016 VL 87 IS 1 BP 43 EP 49 DI 10.1002/ccd.25979 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DB7ML UT WOS:000368699500015 PM 26153480 ER PT J AU Kita, AE Long, JL AF Kita, Ashley E. Long, Jennifer L. TI Hemangioma SO ENT-EAR NOSE & THROAT JOURNAL LA English DT Editorial Material C1 [Kita, Ashley E.; Long, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Long, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Kita, AE (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU VENDOME GROUP LLC PI NEW YORK PA 6 EAST 32 ST, 8 FLOOR, NEW YORK, NY 10016 USA SN 0145-5613 EI 1942-7522 J9 ENT-EAR NOSE THROAT JI ENT-Ear Nose Throat J. PD JAN PY 2016 VL 95 IS 1 BP 19 EP 20 PG 2 WC Otorhinolaryngology SC Otorhinolaryngology GA DB8HS UT WOS:000368758400004 PM 26829680 ER PT J AU Smucny, J Olincy, A Rojas, DC Tregellas, JR AF Smucny, Jason Olincy, Ann Rojas, Donald C. Tregellas, Jason R. TI Neuronal Effects of Nicotine During Auditory Selective Attention in Schizophrenia SO HUMAN BRAIN MAPPING LA English DT Article DE attention; fMRI; hippocampus; nicotine; schizophrenia; ventral parietal cortex ID BRAIN ACTIVATION PATTERNS; PURSUIT EYE-MOVEMENT; SUSTAINED-ATTENTION; ACETYLCHOLINE-RECEPTORS; HIPPOCAMPAL-FORMATION; HEMODYNAMIC-RESPONSE; ALPHA-BUNGAROTOXIN; ANTERIOR CINGULATE; HEALTHY-VOLUNTEERS; PREFRONTAL CORTEX AB Although nicotine has been shown to improve attention deficits in schizophrenia, the neurobiological mechanisms underlying this effect are poorly understood. We hypothesized that nicotine would modulate attention-associated neuronal response in schizophrenia patients in the ventral parietal cortex (VPC), hippocampus, and anterior cingulate based on previous findings in control subjects. To test this hypothesis, the present study examined response in these regions in a cohort of nonsmoking patients and healthy control subjects using an auditory selective attention task with environmental noise distractors during placebo and nicotine administration. In agreement with our hypothesis, significant diagnosis (Control vs. Patient) X drug (Placebo vs. Nicotine) interactions were observed in the VPC and hippocampus. The interaction was driven by task-associated hyperactivity in patients (relative to healthy controls) during placebo administration, and decreased hyperactivity in patients after nicotine administration (relative to placebo). No significant interaction was observed in the anterior cingulate. Task-associated hyperactivity of the VPC predicted poor task performance in patients during placebo. Poor task performance also predicted symptoms in patients as measured by the Brief Psychiatric Rating Scale. These results are the first to suggest that nicotine may modulate brain activity in a selective attention-dependent manner in schizophrenia. (C) 2015 Wiley Periodicals, Inc. C1 [Smucny, Jason; Tregellas, Jason R.] Univ Colorado, Neurosci Program, Anschutz Med Campus, Aurora, CO USA. [Smucny, Jason; Olincy, Ann; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA. [Olincy, Ann; Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Rojas, Donald C.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA. RP Smucny, J (reprint author), Univ Colorado, Neurosci Program, Anschutz Med Campus, Aurora, CO USA. EM jason.smucny@ucdenver.edu OI Smucny, Jason/0000-0001-5656-7987 FU VA Biomedical Laboratory and Clinical Science Research and Development Service [CX000459]; NIH [MH-089095, DK-103691, MH-102224, MH-102879]; Brain and Behavior Research Foundation FX Contract grant sponsor: VA Biomedical Laboratory and Clinical Science Research and Development Service; Contract grant number: CX000459; Contract grant sponsor: NIH; Contract grant numbers: MH-089095, DK-103691, MH-102224, MH-102879; Contract grant sponsor: the Brain and Behavior Research Foundation. NR 77 TC 3 Z9 3 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD JAN PY 2016 VL 37 IS 1 BP 410 EP 421 DI 10.1002/hbm.23040 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA DC3WU UT WOS:000369150500029 PM 26518728 ER PT J AU Hinchcliff, M Routson, R Segal, A Suri, P Czerniecki, J Aubin, P AF Hinchcliff, M. Routson, R. Segal, A. Suri, P. Czerniecki, J. Aubin, P. TI A BIOFEEDBACK SMART CANE TO REDUCE KNEE LOADING ASSOCIATED WITH OSTEOARTHRITIS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Hinchcliff, M.; Routson, R.; Segal, A.; Suri, P.; Czerniecki, J.; Aubin, P.] VA Puget Sound, Seattle, WA USA. [Hinchcliff, M.; Routson, R.; Suri, P.; Czerniecki, J.; Aubin, P.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 24 BP 144 EP 145 DI 10.1136/jim-d-15-00013.24 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600034 ER PT J AU Tsoi, S Vasti, E Moin, T AF Tsoi, S. Vasti, E. Moin, T. TI PRIMARY CARE PROVIDERS' PERCEPTIONS OF LIFESTYLE MODIFICATION AND MANAGEMENT FOR OBESITY AND PREDIABETES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Tsoi, S.; Moin, T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Vasti, E.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Vasti, E.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Moin, T.] HSR&D Ctr Study Healthcare Innovat Implementat &, Los Angeles, CA USA. [Moin, T.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 170 BP 209 EP 209 DI 10.1136/jim-d-15-00013.170 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600180 ER PT J AU Szkudlinska, MA Neuhouser, ML Utzschneider, KM AF Szkudlinska, M. A. Neuhouser, M. L. Utzschneider, K. M. TI RELATIONSHIP BETWEEN GLYCEMIC VARIABILITY AND B-CELL FUNCTION IN ADULTS AT HIGH RISK OF TYPE 2 DIABETES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Szkudlinska, M. A.] Univ Washington, Seattle, WA 98195 USA. [Neuhouser, M. L.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Utzschneider, K. M.] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 248 BP 241 EP 242 DI 10.1136/jim-d-15-00013.248 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600257 ER PT J AU Vasti, EC Tsoi, S Moin, T AF Vasti, E. C. Tsoi, S. Moin, T. TI PRIMARY CARE PROVIDERS' PERCEPTIONS OF DIABETES PREVENTION PROGRAMS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Vasti, E. C.; Tsoi, S.; Moin, T.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Tsoi, S.; Moin, T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Moin, T.] HSR&D Ctr Study Healthcare Innovat Implementat &, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 449 BP 329 EP 330 DI 10.1136/jim-d-15-00013.449 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600456 ER PT J AU Ryan, JS Wang, Q Wu, D Dong, Z Wu, P AF Ryan, J. S. Wang, Q. Wu, D. Dong, Z. Wu, P. TI CHARACTERIZATION OF A CUSTOM MONOCLONAL ANTIBODY AS A NOVEL TUMOR BIOMARKER IN HUMAN GASTROINTESTINAL CANCERS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-30, 2016 CL Carmel, CA SP Amer Federat Med Res C1 [Ryan, J. S.; Wu, D.; Dong, Z.; Wu, P.] Univ Washington, Sch Med, Seattle, WA USA. [Wang, Q.; Wu, D.; Dong, Z.; Wu, P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2016 VL 64 IS 1 MA 450 BP 330 EP 330 DI 10.1136/jim-d-15-00013.450 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DB7MM UT WOS:000368699600457 ER PT J AU Pan, P Huang, J Morioka, C Hathout, G El-Saden, SM AF Pan, P. Huang, J. Morioka, C. Hathout, G. El-Saden, S. M. TI Cost analysis of vestibular schwannoma screening with contrast-enhanced magnetic resonance imaging in patients with asymmetrical hearing loss SO JOURNAL OF LARYNGOLOGY AND OTOLOGY LA English DT Article DE Vestibular Schwannoma; Screening; Magnetic Resonance Imaging; Hearing Loss; Cost Analysis ID FAST SPIN-ECHO; ACOUSTIC NEUROMA; RADIOSURGERY; MANAGEMENT; SURGERY; MR; MICROSURGERY; PRESERVATION; EXPERIENCE AB Background: Vestibular schwannomas are a rare cause of asymmetrical hearing loss, and routine screening with magnetic resonance imaging can be costly. This paper reports results on vestibular schwannoma screening at our institution and compares the cost of screening to a utility of hearing benefit. Method: All screening examinations with magnetic resonance imaging performed for asymmetrical hearing loss between 2006 and 2011 were retrospectively reviewed. The cost per new vestibular schwannoma diagnosis was calculated. The cost per patient for those who benefitted from intervention was estimated based on rates of hearing preservation reported in the literature. Results: Forty-five (4.3 per cent) of 1050 screening examinations with magnetic resonance imaging performed for asymmetrical hearing loss were positive for vestibular schwannoma, and the cost per new diagnosis was $11 436. The estimated screening cost per patient for those who benefitted from surgery or radiation was $147 030, while US federal compensation for unilateral hearing loss was $44 888. Conclusion: Although we achieved a lower screening cost per new diagnosis than reported in the current literature, there remains disparity between the screening cost per benefitted patient and the benefit' of hearing. C1 [Pan, P.] Univ Calif Los Angeles, Med Ctr, Dept Radiol, 757 Westwood Blvd, Los Angeles, CA 90095 USA. [Huang, J.; Morioka, C.; Hathout, G.; El-Saden, S. M.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA. RP Pan, P (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Radiol, 757 Westwood Blvd, Los Angeles, CA 90095 USA. EM ppan@mednet.ucla.edu NR 30 TC 1 Z9 1 U1 4 U2 4 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0022-2151 EI 1748-5460 J9 J LARYNGOL OTOL JI J. Laryngol. Otol. PD JAN PY 2016 VL 130 IS 1 BP 21 EP 24 DI 10.1017/S0022215115002431 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA DB8RI UT WOS:000368783900005 PM 26365591 ER PT J AU Pattaro, C Teumer, A Gorski, M Chu, AY Li, M Mijatovic, V Garnaas, M Tin, A Sorice, R Li, Y Taliun, D Olden, M Foster, M Yang, Q Chen, MH Pers, TH Johnson, AD Ko, YA Fuchsberger, C Tayo, B Nalls, M Feitosa, MF Isaacs, A Dehghan, A d'Adamo, P Adeyemo, A Dieffenbach, AK Zonderman, AB Nolte, IM van der Most, PJ Wright, AF Shuldiner, AR Morrison, AC Hofman, A Smith, AV Dreisbach, AW Franke, A Uitterlinden, AG Metspalu, A Tonjes, A Lupo, A Robino, A Johansson, A Demirkan, A Kollerits, B Freedman, BI Ponte, B Oostra, BA Paulweber, B Kramer, BK Mitchell, BD Buckley, BM Peralta, CA Hayward, C Helmer, C Rotimi, CN Shaffer, CM Muller, C Sala, C van Duijn, CM Saint-Pierre, A Ackermann, D Shriner, D Ruggiero, D Toniolo, D Lu, YC Cusi, D Czamara, D Ellinghaus, D Siscovick, DS Ruderfer, D Gieger, C Grallert, H Rochtchina, E Atkinson, EJ Holliday, EG Boerwinkle, E Salvi, E Bottinger, EP Murgia, F Rivadeneira, F Ernst, F Kronenberg, F Hu, FB Navis, GJ Curhan, GC Ehret, GB Homuth, G Coassin, S Thun, GA Pistis, G Gambaro, G Malerba, G Montgomery, GW Eiriksdottir, G Jacobs, G Li, G Wichmann, HE Campbell, H Schmidt, H Wallaschofski, H Volzke, H Brenner, H Kroemer, HK Kramer, H Lin, HH Leach, IM Ford, I Guessous, I Rudan, I Prokopenko, I Borecki, I Heid, IM Kolcic, I Persico, I Jukema, JW Wilson, JF Felix, JF Divers, J Lambert, JC Stafford, JM Gaspoz, JM Smith, JA Faul, JD Wang, JJ Ding, JZ Hirschhorn, JN Attia, J Whitfield, JB Chalmers, J Viikari, J Coresh, J Denny, JC Karjalainen, J Fernandes, JK Endlich, K Butterbach, K Keene, KL Lohman, K Portas, L Launer, LJ Lyytikainen, LP Yengo, L Franke, L Ferrucci, L Rose, LM Kedenko, L Rao, M Struchalin, M Kleber, ME Cavalieri, M Haun, M Cornelis, MC Ciullo, M Pirastu, M de Andrade, M McEvoy, MA Woodward, M Adam, M Cocca, M Nauck, M Imboden, M Waldenberger, M Pruijm, M Metzger, M Stumvoll, M Evans, MK Sale, MM Kahonen, M Boban, M Bochud, M Rheinberger, M Verweij, N Bouatia-Naji, N Martin, NG Hastie, N Probst-Hensch, N Soranzo, N Devuyst, O Raitakari, O Gottesman, O Franco, OH Polasek, O Gasparini, P Munroe, PB Ridker, PM Mitchell, P Muntner, P Meisinger, C Smit, JH Kovacs, P Wild, PS Froguel, P Rettig, R Magi, R Biffar, R Schmidt, R Middelberg, RPS Carroll, RJ Penninx, BW Scott, RJ Katz, R Sedaghat, S Wild, SH Kardia, SLR Ulivi, S Hwang, SJ Enroth, S Kloiber, S Trompet, S Stengel, B Hancock, SJ Turner, ST Rosas, SE Stracke, S Harris, TB Zeller, T Zemunik, T Lehtimaki, T Illig, T Aspelund, T Nikopensius, T Esko, T Tanaka, T Gyllensten, U Volker, U Emilsson, V Vitart, V Aalto, V Gudnason, V Chouraki, V Chen, WM Igl, W Marz, W Koenig, W Lieb, W Loos, RJF Liu, YM Snieder, H Pramstaller, PP Parsa, A O'Connell, JR Susztak, K Hamet, P Tremblay, J de Boer, IH Boger, CA Goessling, W Chasman, DI Kottgen, A Kao, WHL Fox, CS AF Pattaro, Cristian Teumer, Alexander Gorski, Mathias Chu, Audrey Y. Li, Man Mijatovic, Vladan Garnaas, Maija Tin, Adrienne Sorice, Rossella Li, Yong Taliun, Daniel Olden, Matthias Foster, Meredith Yang, Qiong Chen, Ming-Huei Pers, Tune H. Johnson, Andrew D. Ko, Yi-An Fuchsberger, Christian Tayo, Bamidele Nalls, Michael Feitosa, Mary F. Isaacs, Aaron Dehghan, Abbas d'Adamo, Pio Adeyemo, Adebowale Dieffenbach, Aida Karina Zonderman, Alan B. Nolte, Ilja M. van der Most, Peter J. Wright, Alan F. Shuldiner, Alan R. Morrison, Alanna C. Hofman, Albert Smith, Albert V. Dreisbach, Albert W. Franke, Andre Uitterlinden, Andre G. Metspalu, Andres Tonjes, Anke Lupo, Antonio Robino, Antonietta Johansson, Asa Demirkan, Ayse Kollerits, Barbara Freedman, Barry I. Ponte, Belen Oostra, Ben A. Paulweber, Bernhard Kraemer, Bernhard K. Mitchell, Braxton D. Buckley, Brendan M. Peralta, Carmen A. Hayward, Caroline Helmer, Catherine Rotimi, Charles N. Shaffer, Christian M. Mueller, Christian Sala, Cinzia van Duijn, Cornelia M. Saint-Pierre, Aude Ackermann, Daniel Shriner, Daniel Ruggiero, Daniela Toniolo, Daniela Lu, Yingchang Cusi, Daniele Czamara, Darina Ellinghaus, David Siscovick, David S. Ruderfer, Douglas Gieger, Christian Grallert, Harald Rochtchina, Elena Atkinson, Elizabeth J. Holliday, Elizabeth G. Boerwinkle, Eric Salvi, Erika Bottinger, Erwin P. Murgia, Federico Rivadeneira, Fernando Ernst, Florian Kronenberg, Florian Hu, Frank B. Navis, Gerjan J. Curhan, Gary C. Ehret, George B. Homuth, Georg Coassin, Stefan Thun, Gian-Andri Pistis, Giorgio Gambaro, Giovanni Malerba, Giovanni Montgomery, Grant W. Eiriksdottir, Gudny Jacobs, Gunnar Li, Guo Wichmann, H-Erich Campbell, Harry Schmidt, Helena Wallaschofski, Henri Voelzke, Henry Brenner, Hermann Kroemer, Heyo K. Kramer, Holly Lin, Honghuang Leach, I. Mateo Ford, Ian Guessous, Idris Rudan, Igor Prokopenko, Inga Borecki, Ingrid Heid, Iris M. Kolcic, Ivana Persico, Ivana Jukema, J. Wouter Wilson, James F. Felix, Janine F. Divers, Jasmin Lambert, Jean-Charles Stafford, Jeanette M. Gaspoz, Jean-Michel Smith, Jennifer A. Faul, Jessica D. Wang, Jie Jin Ding, Jingzhong Hirschhorn, Joel N. Attia, John Whitfield, John B. Chalmers, John Viikari, Jorma Coresh, Josef Denny, Joshua C. Karjalainen, Juha Fernandes, Jyotika K. Endlich, Karlhans Butterbach, Katja Keene, Keith L. Lohman, Kurt Portas, Laura Launer, Lenore J. Lyytikaeinen, Leo-Pekka Yengo, Loic Franke, Lude Ferrucci, Luigi Rose, Lynda M. Kedenko, Lyudmyla Rao, Madhumathi Struchalin, Maksim Kleber, Marcus E. Cavalieri, Margherita Haun, Margot Cornelis, Marilyn C. Ciullo, Marina Pirastu, Mario de Andrade, Mariza McEvoy, Mark A. Woodward, Mark Adam, Martin Cocca, Massimiliano Nauck, Matthias Imboden, Medea Waldenberger, Melanie Pruijm, Menno Metzger, Marie Stumvoll, Michael Evans, Michele K. Sale, Michele M. Kaehoenen, Mika Boban, Mladen Bochud, Murielle Rheinberger, Myriam Verweij, Niek Bouatia-Naji, Nabila Martin, Nicholas G. Hastie, Nick Probst-Hensch, Nicole Soranzo, Nicole Devuyst, Olivier Raitakari, Olli Gottesman, Omri Franco, Oscar H. Polasek, Ozren Gasparini, Paolo Munroe, Patricia B. Ridker, Paul M. Mitchell, Paul Muntner, Paul Meisinger, Christa Smit, Johannes H. Kovacs, Peter Wild, Philipp S. Froguel, Philippe Rettig, Rainer Maegi, Reedik Biffar, Reiner Schmidt, Reinhold Middelberg, Rita P. S. Carroll, Robert J. Penninx, Brenda W. Scott, Rodney J. Katz, Ronit Sedaghat, Sanaz Wild, Sarah H. Kardia, Sharon L. R. Ulivi, Sheila Hwang, Shih-Jen Enroth, Stefan Kloiber, Stefan Trompet, Stella Stengel, Benedicte Hancock, Stephen J. Turner, Stephen T. Rosas, Sylvia E. Stracke, Sylvia Harris, Tamara B. Zeller, Tanja Zemunik, Tatijana Lehtimaeki, Terho Illig, Thomas Aspelund, Thor Nikopensius, Tiit Esko, Tonu Tanaka, Toshiko Gyllensten, Ulf Voelker, Uwe Emilsson, Valur Vitart, Veronique Aalto, Ville Gudnason, Vilmundur Chouraki, Vincent Chen, Wei-Min Igl, Wilmar Maerz, Winfried Koenig, Wolfgang Lieb, Wolfgang Loos, Ruth J. F. Liu, Yongmei Snieder, Harold Pramstaller, Peter P. Parsa, Afshin O'Connell, Jeffrey R. Susztak, Katalin Hamet, Pavel Tremblay, Johanne de Boer, Ian H. Boeger, Carsten A. Goessling, Wolfram Chasman, Daniel I. Koettgen, Anna Kao, W. H. Linda Fox, Caroline S. CA ICBP Consortium AGEN Consortium CARDIOGRAM CHARGe-Heart Failure Grp ECHOGen Consortium TI Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function SO NATURE COMMUNICATIONS LA English DT Article ID GENOME-WIDE ASSOCIATION; FALSE DISCOVERY RATES; STAGE RENAL-DISEASE; SERUM CREATININE; METAANALYSIS; VARIANTS; INDIVIDUALS; POPULATION; RISK; HYPERTENSION AB Reduced glomerular filtration rate defines chronic kidney disease and is associated with cardiovascular and all-cause mortality. We conducted a meta-analysis of genome-wide association studies for estimated glomerular filtration rate (eGFR), combining data across 133,413 individuals with replication in up to 42,166 individuals. We identify 24 new and confirm 29 previously identified loci. Of these 53 loci, 19 associate with eGFR among individuals with diabetes. Using bioinformatics, we show that identified genes at eGFR loci are enriched for expression in kidney tissues and in pathways relevant for kidney development and transmembrane transporter activity, kidney structure, and regulation of glucose metabolism. Chromatin state mapping and DNase I hypersensitivity analyses across adult tissues demonstrate preferential mapping of associated variants to regulatory regions in kidney but not extra-renal tissues. These findings suggest that genetic determinants of eGFR are mediated largely through direct effects within the kidney and highlight important cell types and biological pathways. C1 [Pattaro, Cristian; Taliun, Daniel; Fuchsberger, Christian; Saint-Pierre, Aude; Pramstaller, Peter P.] Med Univ Lubeck, European Acad Bozen Bolzano EURAC, Ctr Biomed, Via Galvani 31, I-39100 Bolzano, Italy. [Teumer, Alexander; Ernst, Florian; Homuth, Georg; Voelker, Uwe] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Genom, Friedrich Loeffler Str 15a, D-17487 Greifswald, Germany. [Teumer, Alexander; Voelzke, Henry] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Walther Rathenau Str 48, D-17487 Greifswald, Germany. [Gorski, Mathias; Olden, Matthias; Heid, Iris M.] Univ Regensburg, Inst Epidemiol & Prevent Med, Dept Genet Epidemiol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany. [Gorski, Mathias; Olden, Matthias; Rheinberger, Myriam; Boeger, Carsten A.] Univ Hosp Regensburg, Dept Nephrol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany. [Chu, Audrey Y.; Rose, Lynda M.; Chasman, Daniel I.] Brigham & Womens Hosp, Prevent Med, 900 Commonwealth Ave East, Boston, MA 02215 USA. [Li, Man; Tin, Adrienne; Coresh, Josef; Woodward, Mark; Koettgen, Anna; Kao, W. H. Linda] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA. [Mijatovic, Vladan; Malerba, Giovanni] Univ Verona, Dept Life & Reprod Sci, Str Grazie 8, I-37134 Verona, Italy. [Garnaas, Maija; Goessling, Wolfram] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet,Dept Med, New Res Bldg 77 Ave Louis Pasteur,Room 458, Boston, MA 02115 USA. [Sorice, Rossella; Ruggiero, Daniela; Ciullo, Marina] Inst Genet & Biophys Adriano Buzzati Traverso CNR, Via P Castellino 111, I-80131 Naples, Italy. [Li, Yong; Koettgen, Anna] Univ Hosp Freiburg, Dept Internal Med 4, Berliner Allee 29, D-79110 Freiburg, Germany. [Foster, Meredith; Rao, Madhumathi] Tufts Univ, Sch Med, Tufts Evidence Practice Ctr, Div Nephrol,Tufts Med Ctr, Boston, MA 02111 USA. [Yang, Qiong; Chen, Ming-Huei] Boston Univ, Sch Publ Hlth, Dept Biostat, 715 Albany St, Boston, MA 02118 USA. [Chen, Ming-Huei] Boston Univ, Sch Med, Dept Neurol, 72 East Concord ST B603, Boston, MA 02118 USA. [Pers, Tune H.; Hirschhorn, Joel N.; Esko, Tonu] Boston Childrens Hosp, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA. [Pers, Tune H.; Hirschhorn, Joel N.; Esko, Tonu] Boston Childrens Hosp, Ctr Basic & Translat Obes Res, 300 Longwood Ave, Boston, MA 02115 USA. [Pers, Tune H.; Hirschhorn, Joel N.] Broad Inst MIT & Harvard, Med & Populat Genet Program, Cambridge, MA USA. [Johnson, Andrew D.; Hwang, Shih-Jen; Fox, Caroline S.] NHLBIs Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. [Johnson, Andrew D.; Hwang, Shih-Jen; Fox, Caroline S.] Ctr Populat Studies, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. [Ko, Yi-An; Rosas, Sylvia E.; Susztak, Katalin] Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, 415 Curie Blvd,405B Clin Res Bldg, Philadelphia, PA 19104 USA. [Tayo, Bamidele; Kramer, Holly] Loyola Med Ctr, Dept Publ Hlth Sci, 2160 S First Ave, Maywood, IL 60153 USA. [Nalls, Michael] NIA, Neurogenet Lab, NIH, Bldg 35 Porter Bldg,1A1015, Bethesda, MD 20892 USA. [Feitosa, Mary F.; Borecki, Ingrid] Washington Univ, Sch Med, Div Stat Genom, 4444 Forest Pk Blvd,Box 8506, St Louis, MO 63108 USA. [Isaacs, Aaron; Demirkan, Ayse; van Duijn, Cornelia M.] Erasmus Univ, Med Ctr, Dept Epidemiol, Genet Epidemiol Unit, Dr Molewaterpl 50,POB 2040, NL-3000 CA Rotterdam, Netherlands. [Isaacs, Aaron] Ctr Med Syst Biol Leiden, Dr Molewaterpl 50,POB 2040, NL-3000 CA Rotterdam, Netherlands. [Dehghan, Abbas; Hofman, Albert; Felix, Janine F.; Franco, Oscar H.; Sedaghat, Sanaz] Erasmus Univ, Med Ctr, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands. [d'Adamo, Pio; Robino, Antonietta; Gasparini, Paolo] Inst Maternal & Child Hlth IRCCS Burlo Garofolo, Via Istria 65-1, I-34137 Trieste, Italy. [d'Adamo, Pio; Robino, Antonietta; Gasparini, Paolo] Univ Trieste, Via Istria 65-1, I-34137 Trieste, Italy. [Adeyemo, Adebowale; Rotimi, Charles N.; Shriner, Daniel] NHGRI, Ctr Res Genom & Global Hlth, Bldg 12A,Room 4047,12 South Dr,MSC 5635, Bethesda, MD 20892 USA. [Dieffenbach, Aida Karina; Brenner, Hermann; Butterbach, Katja] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Neuenheimer Feld 581, D-69120 Heidelberg, Germany. [Dieffenbach, Aida Karina; Brenner, Hermann] German Canc Consortium DKTK, Neuenheimer Feld 581, D-69120 Heidelberg, Germany. [Zonderman, Alan B.] NIA, Lab Personal & Cognit, NIH, Biomed Ctr, 251 Bayview Blvd,Suite 100, Baltimore, MD 21224 USA. [Nolte, Ilja M.; van der Most, Peter J.; Snieder, Harold] Univ Med Ctr Groningen, Dept Epidemiol, Unit Genet Epidemiol & Bioinformat, POB 30001, NL-9700 RB Groningen, Netherlands. [Wright, Alan F.; Hayward, Caroline; Hastie, Nick; Vitart, Veronique] Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland. [Shuldiner, Alan R.; Mitchell, Braxton D.; O'Connell, Jeffrey R.] Univ Maryland, Sch Med, Dept Med, 685 West Baltimore St, Baltimore, MD 21201 USA. [Shuldiner, Alan R.; Mitchell, Braxton D.] Vet Adm Med Ctr, Geriatr Res & Educ Clin Ctr, 10 North Greene St, Baltimore, MD 21201 USA. [Morrison, Alanna C.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, 1200 Pressler St Suite 453E, Houston, TX 77030 USA. [Smith, Albert V.; Eiriksdottir, Gudny; Aspelund, Thor; Emilsson, Valur; Gudnason, Vilmundur] Iceland Heart Assoc, Res Inst, Holtasmari 1, IS-201 Kopavogur, Iceland. [Smith, Albert V.; Aspelund, Thor; Gudnason, Vilmundur] Univ Iceland, Saemundargotu 2, IS-101 Reykjavik, Iceland. [Dreisbach, Albert W.] Univ Mississippi, Div Nephrol, 2500 North State St, Jackson, MS 39216 USA. [Franke, Andre; Ellinghaus, David] Univ Kiel, Inst Clin Mol Biol, Schittenhelmstr 12, D-24105 Kiel, Germany. [Uitterlinden, Andre G.; Rivadeneira, Fernando] Erasmus Univ, Med Ctr, Dept Internal Med, POB 1738, NL-3000 DR Rotterdam, Netherlands. [Metspalu, Andres; Maegi, Reedik; Nikopensius, Tiit; Esko, Tonu] Univ Tartu EGCUT, Estonian Genome Ctr, Riia 23B, EE-51010 Tartu, Estonia. [Metspalu, Andres; Nikopensius, Tiit; Esko, Tonu] Univ Tartu, Inst Mol & Cell Biol, Riia 23, EE-51010 Tartu, Estonia. [Metspalu, Andres; Nikopensius, Tiit; Esko, Tonu] Estonian Bioctr, Riia 23, EE-51010 Tartu, Estonia. [Tonjes, Anke; Stumvoll, Michael] Univ Leipzig, Dept Med, Liebigstr 18, D-04103 Leipzig, Germany. [Lupo, Antonio] Univ Verona, Dept Med, Div Nephrol, Piazzale Aristide Stefani 1, I-37126 Verona, Italy. [Johansson, Asa; Enroth, Stefan; Gyllensten, Ulf; Igl, Wilmar] Uppsala Univ, Biomed Ctr, Dept Immunol Genet & Pathol, SciLifeLab, SE-75108 Uppsala, Sweden. [Kollerits, Barbara; Kronenberg, Florian; Coassin, Stefan; Haun, Margot] Med Univ Innsbruck, Div Genet Epidemiol, Schoepfstr 41, A-6020 Innsbruck, Austria. [Freedman, Barry I.; Lohman, Kurt; Liu, Yongmei] Wake Forest Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Ponte, Belen; Ackermann, Daniel] Univ Hosp Geneva, Dept Specialties Internal Med, Div Nephrol, 4 Rue Gabrielle Perret Gentil, CH-1211 Geneva, Switzerland. [Oostra, Ben A.] Erasmus Univ, Med Ctr, Dept Clin Genet, Dr Molewaterpl 50,POB 2040, NL-3000 CA Rotterdam, Netherlands. [Paulweber, Bernhard; Kedenko, Lyudmyla] Paracelsus Med Univ, Salzburger Landeskliniken, Dept Internal Med 1, Mullner Hauptstr 48, A-5020 Salzburg, Austria. [Kraemer, Bernhard K.] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Med 5, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany. [Buckley, Brendan M.] Univ Coll Cork, Dept Pharmacol Therapeut, Clin Invest Bldg,Western Rd, Cork, Ireland. [Peralta, Carmen A.] Univ Calif San Francisco, Sch Med, Div Nephrol, 4150 Clement St, San Francisco, CA 94121 USA. [Peralta, Carmen A.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Helmer, Catherine] INSERM, Epidemiol Biostat U897, Ctr INSERM, ISPED, F-33000 Bordeaux, France. [Helmer, Catherine] Univ Bordeaux, ISPED, Ctr INSERM, Epidemiol Biostat U897, F-33000 Bordeaux, France. [Shaffer, Christian M.] Vanderbilt Univ, Sch Med, 2215-B Garland Ave 1224 MRB4 Light Hall, Nashville, TN 37232 USA. [Mueller, Christian; Zeller, Tanja] Univ Heart Ctr Hamburg, Clin Gen & Intervent Cardiol, Martinistr 52, D-20246 Hamburg, Germany. [Mueller, Christian; Zeller, Tanja] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Lubeck Kiel,Martinistr 52, D-20246 Hamburg, Germany. [Sala, Cinzia; Toniolo, Daniela; Pistis, Giorgio; Cocca, Massimiliano] Ist Sci San Raffaele, Div Genet & Cell Biol, Via Olgettina 58, I-20132 Milan, Italy. [Saint-Pierre, Aude] Etab Francais Sang, INSERM, U1078, 46 Rue Felix Le Dantec,CS 51819, 29218 Brest 2, France. [Toniolo, Daniela] Inst Mol Genet CNR, Via Abbiategrasso 207, I-27100 Pavia, Italy. [Lu, Yingchang; Bottinger, Erwin P.; Gottesman, Omri; Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA. [Cusi, Daniele; Salvi, Erika] Univ Milan, Dept Hlth Sci, Via Antonio Rudini 8, I-20142 Milan, Italy. [Czamara, Darina; Kloiber, Stefan] Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany. [Siscovick, David S.; Li, Guo] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA. [Siscovick, David S.; Li, Guo] Univ Washington, Dept Med, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA. [Ruderfer, Douglas] Icahn Sch Med Mt Sinai, Dept Psychiat, Div Psychiat Genom, New York, NY 10029 USA. [Gieger, Christian; Heid, Iris M.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany. [Grallert, Harald; Waldenberger, Melanie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany. [Grallert, Harald; Meisinger, Christa; Illig, Thomas] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, D-85764 Neuherberg, Germany. [Grallert, Harald] German Ctr Diabet Res DZD, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany. [Rochtchina, Elena] Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Westmead Hosp C24, Sydney, NSW 2145, Australia. [Atkinson, Elizabeth J.; Attia, John; de Andrade, Mariza] Mayo Clin, Div Biomed Stat & Informat, 200 First St SW, Rochester, MN 55905 USA. [Holliday, Elizabeth G.; Attia, John; Hancock, Stephen J.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Clin Epidemiol & Biostat, HMRI Bldg 1, New Lambton, NSW 2305, Australia. [Holliday, Elizabeth G.; Hancock, Stephen J.] Hunter Med Res Inst, Clin Res Design Informat Technol & Stat Support, 1 Kookaburra Circuit, New Lambton Hts, NSW 2305, Australia. [Murgia, Federico; Persico, Ivana; Portas, Laura; Pirastu, Mario] Inst Populat Genet CNR, Traversa La Crucca 3, I-07040 Sassari, Italy. [Hu, Frank B.; Cornelis, Marilyn C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave,Bldg 2, Boston, MA 02115 USA. [Navis, Gerjan J.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. [Curhan, Gary C.] Harvard Univ, Sch Med, Brigham & Womens Hosp, 181 Longwood Ave, Boston, MA 02115 USA. [Curhan, Gary C.] Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA. [Ehret, George B.] Univ Hosp Geneva, Dept Specialties Internal Med, Cardiol, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland. [Thun, Gian-Andri; Adam, Martin; Imboden, Medea; Probst-Hensch, Nicole] Swiss Trop & Publ Hlth Inst, POB 4002, Basel, Switzerland. [Thun, Gian-Andri; Adam, Martin; Imboden, Medea; Probst-Hensch, Nicole] Univ Basel, Peterspl 1, CH-4003 Basel, Switzerland. [Gambaro, Giovanni] Catholic Univ, Columbus Gemelli Univ Hosp, Dept Internal Med & Med Specialties, Div Nephrol, Via Moscati 31, I-00168 Rome, Italy. [Montgomery, Grant W.; Whitfield, John B.; Martin, Nicholas G.; Middelberg, Rita P. S.] QIMR, Genet Epidemiol, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia. [Jacobs, Gunnar; Lieb, Wolfgang] Univ Kiel, Inst Epidemiol, Niemannsweg 11, D-24105 Kiel, Germany. [Jacobs, Gunnar; Lieb, Wolfgang] Univ Kiel, Biobank Popgen, Niemannsweg 11, D-24105 Kiel, Germany. [Wichmann, H-Erich] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany. [Wichmann, H-Erich] Univ Munich, Inst Med Informat Biometry & Epidemiol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany. [Wichmann, H-Erich] Klinikum Grosshadern, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany. [Campbell, Harry; Rudan, Igor; Wilson, James F.; Wild, Sarah H.] Univ Edinburgh, Ctr Populat Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland. [Schmidt, Helena] Med Univ Graz, Dept Neurol, Inst Mol Biol & Biochem, Austrian Stroke Prevent Study, Harrachgasse 21, A-8010 Graz, Austria. [Wallaschofski, Henri; Nauck, Matthias] Univ Med Greifswald, Inst Clin Chem & Lab Med, Ferdinand Sauerbruch Str, D-17475 Greifswald, Germany. [Wallaschofski, Henri; Voelzke, Henry; Nauck, Matthias; Voelker, Uwe] German Ctr Cardiovasc Res DZHK, Partner Site Greifswald,Ferdinand Sauerbruch St, D-17475 Greifswald, Germany. [Kroemer, Heyo K.] Ernst Moritz Arndt Univ Greifswald, Inst Pharmacol, Friedrich Loeffler Str 23d, D-17487 Greifswald, Germany. [Lin, Honghuang] Boston Univ, Sch Med, 72 East Concord St,B-616, Boston, MA 02118 USA. [Leach, I. Mateo; Verweij, Niek] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, POB 30-001, NL-9700 RB Groningen, Netherlands. [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Robertson Ctr, R1122B Level 11,Boyd Orr Bldg, Glasgow G12 8QQ, Lanark, Scotland. [Guessous, Idris; Gaspoz, Jean-Michel] Univ Geneva, Dept Community Med Primary Care & Emergency Med, Div Primary Care Med, Geneva Univ Hosp,Fac Med, CH-1211 Geneva, Switzerland. [Guessous, Idris] Univ Lausanne Hosp, Univ Inst Social & Prevent Med, Community Prevent Unit, Route Corniche 10, CH-1010 Lausanne, Switzerland. [Guessous, Idris] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. [Prokopenko, Inga] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Genom Common Dis, London W12 0NN, England. [Kolcic, Ivana; Boban, Mladen; Polasek, Ozren; Zemunik, Tatijana] Univ Split, Sch Med, Croatian Ctr Global Hlth, Soltanska 2, Split 21000, Croatia. [Jukema, J. Wouter; Trompet, Stella] Leiden Univ, Med Ctr, Dept Cardiol, POB 9600, NL-2300 RC Leiden, Netherlands. [Jukema, J. Wouter] Interuniv Cardiol Inst Netherlands ICIN, Moreelsepk 1, NL-3511 EP Utrecht, Netherlands. [Jukema, J. Wouter] Einthoven Lab Expt Vasc Med, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands. [Jukema, J. Wouter] Durrer Ctr Cardiogenet Res, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. [Divers, Jasmin; Stafford, Jeanette M.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Div Publ Hlth Sci, 2326 Med Ctr Blvd, Winston Salem, NC 27157 USA. [Lambert, Jean-Charles; Stracke, Sylvia; Chouraki, Vincent] Inst Pasteur, INSERM, U744, 1 Rue Pr, F-59019 Lille, France. [Smith, Jennifer A.; Kardia, Sharon L. R.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA. [Faul, Jessica D.] Univ Michigan, Inst Social Res, Survey Res Ctr, 426 Thompson St,3456, Ann Arbor, MI 48104 USA. [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Westmead Hosp C24, Sydney, NSW 2145, Australia. [Ding, Jingzhong] Wake Forest Sch Med, Dept Internal Med Geriatr, Med Ctr Blvd, Winston Salem, NC 27157 USA. [Hirschhorn, Joel N.] Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur,NRB 0330, Boston, MA 02115 USA. [Chalmers, John; Woodward, Mark] Univ Sydney, George Inst Global Hlth, Level 10,King George V Bldg,83-117 Missenden Rd, Camperdown, NSW 2050, Australia. [Viikari, Jorma; Woodward, Mark] Univ Turku, Turku Univ Hosp, Dept Med, POB 52, Turku 20521, Finland. [Coresh, Josef; Kao, W. H. Linda] Welch Ctr Prevent Epidemiol & Clin Res, 2024 East Monument St,Suite 2-600, Baltimore, MD 21287 USA. [Denny, Joshua C.; Carroll, Robert J.] Vanderbilt Univ, Sch Med, Eskind Biomed Lib 448, 2209 Garland Ave, Nashville, TN 37212 USA. [Karjalainen, Juha; Franke, Lude] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, POB 72, NL-9700 AB Groningen, Netherlands. [Fernandes, Jyotika K.] Med Univ S Carolina, Div Endocrinol, 171 Ashley Ave, Charleston, SC 29425 USA. [Endlich, Karlhans] Ernst Moritz Arndt Univ Greifswald, Inst Anat & Cell Biol, Friedrich Loeffler Str 23c, D-17487 Greifswald, Germany. [Keene, Keith L.] E Carolina Univ, Dept Biol, Ctr Hlth Dispar, 1001 East 10th St,N209 Howell Sci Complex, Greenville, NC 27858 USA. [Launer, Lenore J.; Harris, Tamara B.] NIA, Intramural Res Program, Lab Epidemiol Demog & Biometry, Gateway Bldg,3C309,7201 Winsconsin Ave, Bethesda, MD 20892 USA. [Lyytikaeinen, Leo-Pekka; Lehtimaeki, Terho] Univ Tampere, Sch Med, Dept Clin Chem, Fimlab Labs, Tampere 33520, Finland. [Yengo, Loic; Froguel, Philippe] CNRS, UMR 8199, 1 Rue Prof Calmette, F-59000 Lille, France. [Yengo, Loic; Froguel, Philippe] Lille Pasteur Inst, 1 Rue Prof Calmette, F-59000 Lille, France. [Yengo, Loic; Froguel, Philippe] Univ Lille 2, 42 Rue Paul Duez, F-59000 Lille, France. [Ferrucci, Luigi; Tanaka, Toshiko] NIA, Clin Res Branch, 251 Bayview Blvd, Baltimore, MD 21250 USA. [Struchalin, Maksim] Erasmus Univ, Dept Epidemiol & Biostat, Med Ctr, Dr Molewaterpl, NL-3000 DR Rotterdam, Netherlands. [Struchalin, Maksim] Erasmus Univ, Med Ctr, Dept Forens Mol Biol, Dr Molewaterpl, Rotterdam, Netherlands. [Kleber, Marcus E.] Heidelberg Univ, Med Fac Mannheim, Med Clin 5, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany. [Cavalieri, Margherita; Schmidt, Reinhold] Med Univ Graz, Dept Neurol, Austrian Stroke Prevent Study, Div Special Neurol, Auenbruggerpl 22, A-8036 Graz, Austria. [McEvoy, Mark A.] Univ Newcastle, John Hunter Hosp, Hunter Med Res Inst, Ctr Clin Epidemiol & Biostat,HRMC, Locked Bag 1, Newcastle, NSW 2310, Australia. [Woodward, Mark] Univ Oxford, Nuffield Dept Populat Hlth, George Inst Global Hlth, Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England. [Pruijm, Menno] Univ Lausanne Hosp, Serv Nephrol, Rue Bugnon 17, CH-1005 Lausanne, Switzerland. [Metzger, Marie; Stengel, Benedicte] Univ Paris 11, INSERM, UMRS 1018, CESP Team 10, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France. [Evans, Michele K.] NIA, Hlth Dispar Res Sect, Clin Res Branch, NIH,Biomed Ctr, 251 Bayview Blvd,Suite 100, Baltimore, MD 21224 USA. [Sale, Michele M.; Chen, Wei-Min] Univ Virginia, Dept Med Cardiovasc Med, Ctr Publ Hlth Genom, POB 800717, Charlottesville, VA 22908 USA. [Kaehoenen, Mika] Univ Tampere, Sch Med, Tampere Univ Hosp, Dept Clin Physiol, Tampere 33521, Finland. [Bochud, Murielle] Univ Lausanne, CHU Vaudois, Univ Inst Social & Prevent Med, Route Corniche 2, CH-1066 Epalinges, Switzerland. [Bouatia-Naji, Nabila] Paris Cardiovasc Res Ctr PARCC, INSERM, UMR970, 56 Rue Leblanc, F-75015 Paris, France. [Bouatia-Naji, Nabila] Paris Descartes Univ, Fac Med, Sorbonne Paris Cite, 12 Rue Ecole Med, F-75006 Paris, France. [Martin, Nicholas G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA. [Soranzo, Nicole] Wellcome Trust Sanger Inst, Hinxton CB10 1HH, England. [Devuyst, Olivier] Univ Zurich, Inst Physiol, Mech Inherited Kidney Disorders Grp, Winterthurerstr 190, CH-8057 Zurich, Switzerland. [Raitakari, Olli; Aalto, Ville] Univ Turku, Turku Univ Hosp, Dept Clin Physiol, Res Ctr Appl & Prevent Cardiovasc Med, POB 52, Turku 20521, Finland. [Munroe, Patricia B.] Queen Mary Univ London, William Harvey Res Inst, Dept Clin Pharmacol, London EC1M 6BQ, England. [Munroe, Patricia B.] Queen Mary Univ London, NIHR Barts Cardiovasc Biomed Res Unit, London EC1M 6BQ, England. [Ridker, Paul M.; Chasman, Daniel I.] Harvard Univ, Sch Med, 900 Commonwealth Ave Eeast, Boston, MA 02115 USA. [Muntner, Paul] Univ Alabama Birmingham, Dept Med, 1530 3rd Ave, South Birmingham, AL 35294 USA. [Muntner, Paul] Univ Alabama Birmingham, Dept Epidemiol, 1530 3rd Ave, South Birmingham, AL 35294 USA. [Smit, Johannes H.; Penninx, Brenda W.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, AJ Ernststr 1187, NL-1081 HL Amsterdam, Netherlands. [Smit, Johannes H.; Penninx, Brenda W.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst, AJ Ernststr 1187, NL-1081 HL Amsterdam, Netherlands. [Kovacs, Peter] Univ Leipzig, IFB AdiposityDis, Liebigstr 21, D-04103 Leipzig, Germany. [Wild, Philipp S.] Med Univ Ctr Mainz, Langenbeckstr 1, D-55131 Mainz, Germany. [Rettig, Rainer] Ernst Moritz Arndt Univ Greifswald, Inst Physiol, D-17487 Greifswald, Germany. [Biffar, Reiner] Ernst Moritz Arndt Univ Greifswald, Clin Prosthodont Dent Gerostomatol & Mat Sci, Rotgerberstr 8, D-17475 Greifswald, Germany. [Scott, Rodney J.] Univ Newcastle, Sch Biomed Sci & Pharm, Hunter Med Res Inst, John Hunter Hosp,HRMC, Locked Bag 1, Newcastle, NSW 2310, Australia. [Katz, Ronit; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA. [Ulivi, Sheila] Inst Maternal & Child Health IRCCS Burlo Garofolo, Via Istria 65, I-34137 Trieste, Italy. [Turner, Stephen T.] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, 200 First St SW, Rochester, MN 55905 USA. [Stracke, Sylvia] Ernst Moritz Arndt Univ Greifswald, Clin Internal Med A, Friedrich Loeffler Str 23a, D-17475 Greifswald, Germany. [Emilsson, Valur] Univ Iceland, Fac Pharmaceut Sci, Saemundargata 2, IS-101 Reykjavik, Iceland. [Maerz, Winfried] Synlab Serv GmbH, Synlab Acad, Oberer Eselsberg 45, D-89081 Ulm, Germany. [Koenig, Wolfgang] Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, Albert Einstein Allee 23, D-89081 Ulm, Germany. [Loos, Ruth J. F.] Ichan Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA. [Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, Via Lorenz Bohler 5, I-39100 Bolzano, Italy. [Pramstaller, Peter P.] Med Univ Lubeck, Dept Neurol, Ratzeburger Allee 160, D-23538 Lubeck, Germany. [Parsa, Afshin] Univ Maryland, Sch Med, Div Nephrol, 685 W Baltimore St,MSTF 314, Baltimore, MD 21201 USA. [Hamet, Pavel; Tremblay, Johanne] Univ Montreal, CHUM Res Ctr, CRCHUM, Technopole Angus, 900 St Denis, Montreal, PQ H2X 0A9, Canada. [Fox, Caroline S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol, 221 Longwood Ave, Boston, MA 02115 USA. RP Pattaro, C (reprint author), Med Univ Lubeck, European Acad Bozen Bolzano EURAC, Ctr Biomed, Via Galvani 31, I-39100 Bolzano, Italy.; Kottgen, A (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.; Kottgen, A (reprint author), Univ Hosp Freiburg, Dept Internal Med 4, Berliner Allee 29, D-79110 Freiburg, Germany.; Fox, CS (reprint author), NHLBIs Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.; Fox, CS (reprint author), Ctr Populat Studies, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.; Fox, CS (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol, 221 Longwood Ave, Boston, MA 02115 USA. EM cristian.pattaro@eurac.edu; anna.koettgen@uniklinik-freiburg.de; foxca@nhlbi.nih.gov RI ; Prokopenko, Inga/H-3241-2014; Erdmann, Jeanette/P-7513-2014; Matullo, Giuseppe/K-6383-2016; Onland-Moret, N. Charlotte/G-9185-2011; Bochud, Murielle/A-3981-2010; van der Schouw, Yvonne/F-8327-2014; Ruderfer, Douglas/M-5795-2016; BOUATIA-NAJI, NABILA/D-5863-2013; d'Adamo, Adamo Pio/G-4064-2011; Schwarz, Peter/B-5127-2013; Johnson, Andrew/G-6520-2013; Franke, Lude/P-7036-2016; Karjalainen, Juha/P-8624-2016; Laan, Maris/A-4100-2011; Ellinghaus, David/G-4467-2012; Waldenberger, Melanie/B-5355-2014; Wang, Jie Jin/P-1499-2014; Singleton, Andrew/C-3010-2009; Kronenberg, Florian/B-1736-2008; Aulchenko, Yurii/M-8270-2013; Cossette, Suzanne/I-8008-2016; Lambert, jean-charles/A-9553-2014; Li, Yong/A-6283-2011; ruggiero, daniela/K-5638-2016; Lyytikainen, Leo-Pekka/C-8544-2016; Woodward, Mark/D-8492-2015; Mitchell, Paul/P-1498-2014; Grallert, Harald/B-3424-2013; Deloukas, Panos/B-2922-2013; Colaus, PsyColaus/K-6607-2013; Verweij, Niek/A-4499-2017; HELMER, Catherine/I-6581-2015; Brenner, Hermann/B-4627-2017; Franke, Andre/B-2151-2010; Lieb, Wolfgang/C-1990-2012; Yengo, Loic/D-2692-2017; Palmer, Lyle/K-3196-2014; Polasek, Ozren/B-6002-2011; Boban, Mladen/E-2777-2017; Kolcic, Ivana/E-2713-2017; Feitosa, Mary/K-8044-2012; Stengel, Benedicte/G-5730-2015 OI Wain, Louise/0000-0003-4951-1867; Peters, Annette/0000-0001-6645-0985; Johansson, Asa/0000-0002-2915-4498; Lawlor, Debbie A/0000-0002-6793-2262; Meitinger, Thomas/0000-0002-8838-8403; Magi, Reedik/0000-0002-2964-6011; Shuldiner, Alan/0000-0001-9921-4305; Smith, Albert Vernon/0000-0003-1942-5845; Ramachandran, Vasan/0000-0001-7357-5970; Goessling, Wolfram/0000-0001-9972-1569; Enroth, Stefan/0000-0002-5056-9137; Soranzo, Nicole/0000-0003-1095-3852; Chen, Wei-Min/0000-0002-2643-2333; Kumari, Meena/0000-0001-9716-1035; Meisinger, Christa/0000-0002-9026-6544; Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Prokopenko, Inga/0000-0003-1624-7457; Humphries, Stephen E/0000-0002-8221-6547; Verweij, Niek/0000-0002-4303-7685; Kloiber, Stefan/0000-0002-6838-4114; Cooper, Matthew/0000-0003-1139-3682; Org, Elin/0000-0003-1451-9375; Gieger, Christian/0000-0001-6986-9554; Beckmann, Jacques S /0000-0002-9741-1900; ELOSUA, ROBERTO/0000-0001-8235-0095; Cocca, Massimiliano/0000-0002-1127-7596; Erdmann, Jeanette/0000-0002-4486-6231; Bochud, Murielle/0000-0002-5727-0218; van der Schouw, Yvonne/0000-0002-4605-435X; Ruderfer, Douglas/0000-0002-2365-386X; d'Adamo, Adamo Pio/0000-0001-9367-4909; Schwarz, Peter/0000-0001-6317-7880; Franke, Lude/0000-0002-5159-8802; Laan, Maris/0000-0002-8519-243X; Waldenberger, Melanie/0000-0003-0583-5093; Wang, Jie Jin/0000-0001-9491-4898; Kronenberg, Florian/0000-0003-2229-1120; Aulchenko, Yurii/0000-0002-7899-1575; Lambert, jean-charles/0000-0003-0829-7817; Li, Yong/0000-0003-2651-8791; ruggiero, daniela/0000-0003-3898-7827; Lyytikainen, Leo-Pekka/0000-0002-7200-5455; Deloukas, Panos/0000-0001-9251-070X; HELMER, Catherine/0000-0002-5169-7421; Brenner, Hermann/0000-0002-6129-1572; Franke, Andre/0000-0003-1530-5811; Yengo, Loic/0000-0002-4272-9305; Palmer, Lyle/0000-0002-1628-3055; Polasek, Ozren/0000-0002-5765-1862; Boban, Mladen/0000-0003-1570-9621; Kolcic, Ivana/0000-0001-7918-6052; Feitosa, Mary/0000-0002-0933-2410; Salvi, Erika/0000-0002-2724-2291; Marmot, Michael/0000-0002-2431-6419; Prabhakaran, Dorairaj/0000-0002-3172-834X; Zonderman, Alan B/0000-0002-6523-4778; Mitchell, Braxton/0000-0003-4920-4744; Smith, Jennifer/0000-0002-3575-5468; Tai, E Shyong/0000-0003-2929-8966; Morris, Richard/0000-0001-7240-4563; Kleber, Marcus/0000-0003-0663-7275; Dehghan, Abbas/0000-0001-6403-016X FU NIH [R01DK090311, R24OD017870] FX Study-specific acknowledgements and funding sources for participating studies are reported in Supplementary Note. Zebrafish work was supported by NIH R01DK090311 and R24OD017870 to W.G. NR 48 TC 23 Z9 23 U1 14 U2 30 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JAN PY 2016 VL 7 AR 10023 DI 10.1038/ncomms10023 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC2FO UT WOS:000369032800001 PM 26831199 ER PT J AU Shi, YJ Zhang, LL Pu, HJ Mao, LL Hu, XM Jiang, XY Xu, N Stetler, RA Zhang, F Liu, XR Leak, RK Keep, RF Ji, XM Chen, J AF Shi, Yejie Zhang, Lili Pu, Hongjian Mao, Leilei Hu, Xiaoming Jiang, Xiaoyan Xu, Na Stetler, R. Anne Zhang, Feng Liu, Xiangrong Leak, Rehana K. Keep, Richard F. Ji, Xunming Chen, Jun TI Rapid endothelial cytoskeletal reorganization enables early blood-brain barrier disruption and long-term ischaemic reperfusion brain injury SO NATURE COMMUNICATIONS LA English DT Article ID FOCAL CEREBRAL-ISCHEMIA; TIGHT JUNCTION PROTEINS; APPARENT DIFFUSION-COEFFICIENT; ACTIN STRESS FIBERS; MATRIX METALLOPROTEINASES; HSP27 PROTECTS; NEURONAL DEATH; STROKE; PERMEABILITY; BREAKDOWN AB The mechanism and long-term consequences of early blood-brain barrier (BBB) disruption after cerebral ischaemic/reperfusion (I/R) injury are poorly understood. Here we discover that I/R induces subtle BBB leakage within 30-60 min, likely independent of gelatinase B/MMP-9 activities. The early BBB disruption is caused by the activation of ROCK/MLC signalling, persistent actin polymerization and the disassembly of junctional proteins within microvascular endothelial cells (ECs). Furthermore, the EC alterations facilitate subsequent infiltration of peripheral immune cells, including MMP-9-producing neutrophils/macrophages, resulting in late-onset, irreversible BBB damage. Inactivation of actin depolymerizing factor (ADF) causes sustained actin polymerization in ECs, whereas EC-targeted overexpression of constitutively active mutant ADF reduces actin polymerization and junctional protein disassembly, attenuates both early-and late-onset BBB impairment, and improves long-term histological and neurological outcomes. Thus, we identify a previously unexplored role for early BBB disruption in stroke outcomes, whereby BBB rupture may be a cause rather than a consequence of parenchymal cell injury. C1 [Shi, Yejie; Zhang, Lili; Pu, Hongjian; Mao, Leilei; Hu, Xiaoming; Jiang, Xiaoyan; Stetler, R. Anne; Zhang, Feng; Liu, Xiangrong; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Shi, Yejie; Liu, Xiangrong; Ji, Xunming] Capital Med Univ, Xuanwu Hosp, China Amer Inst Neurosci, Beijing 100053, Peoples R China. [Zhang, Lili; Pu, Hongjian; Mao, Leilei; Hu, Xiaoming; Jiang, Xiaoyan; Xu, Na; Stetler, R. Anne; Zhang, Feng; Chen, Jun] Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Zhang, Lili; Pu, Hongjian; Mao, Leilei; Hu, Xiaoming; Jiang, Xiaoyan; Xu, Na; Stetler, R. Anne; Chen, Jun] Fudan Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200032, Peoples R China. [Zhang, Lili; Hu, Xiaoming; Stetler, R. Anne; Zhang, Feng; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Keep, Richard F.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.; Ji, XM (reprint author), Capital Med Univ, Xuanwu Hosp, China Amer Inst Neurosci, Beijing 100053, Peoples R China.; Chen, J (reprint author), Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.; Chen, J (reprint author), Fudan Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200032, Peoples R China.; Chen, J (reprint author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. EM jixm@ccmu.edu.cn; chenj2@upmc.edu OI Shi, Yejie/0000-0001-7502-9201 FU US National Institutes of Health [NS089534, NS045048, NS056118, NS092810]; US Department of Veterans Affairs Research Career Scientist Award; VA Merit Review Award [BX002495]; American Heart Association [15POST22260011]; Chinese Natural Science Foundation Outstanding Young Investigator Award [81325007]; Chang Jiang Scholars Program from the Chinese Ministry of Education [T2014251] FX This project was supported by the US National Institutes of Health grants NS089534, NS045048 and NS056118 (to J.C.), the US Department of Veterans Affairs Research Career Scientist Award and VA Merit Review Award BX002495 (to J.C.). Y.S. was supported by the American Heart Association grant 15POST22260011. X.Ji was supported by the Chinese Natural Science Foundation Outstanding Young Investigator Award (#81325007) and the Chang Jiang Scholars Program (#T2014251) from the Chinese Ministry of Education. F.Z. was supported by the US National Institutes of Health grant NS092810. We are indebted to Pat Strickler for excellent administrative support. NR 67 TC 13 Z9 13 U1 4 U2 20 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JAN PY 2016 VL 7 AR 10523 DI 10.1038/ncomms10523 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC2CJ UT WOS:000369024500002 PM 26813496 ER PT J AU Birtolo, C Go, VLW Ptasznik, A Eibl, G Pandol, SJ AF Birtolo, Chiara Go, Vay Liang W. Ptasznik, Andrzej Eibl, Guido Pandol, Stephen J. TI Phosphatidylinositol 3-Kinase A Link Between Inflammation and Pancreatic Cancer SO PANCREAS LA English DT Review DE PI3K; pancreatic cancer; chronic pancreatitis; inflammation ID ALCOHOLIC CHRONIC-PANCREATITIS; KEY PATHOLOGICAL RESPONSES; STELLATE CELLS; DUCTAL ADENOCARCINOMA; TUMOR PROGRESSION; ACINAR-CELLS; PHOSPHOINOSITIDE 3-KINASE; MACROPHAGE POLARIZATION; BREAST-CANCER; SIGNAL-TRANSDUCTION AB Even though a strong association between inflammation and cancer has been widely accepted, the underlying precise molecular mechanisms are still largely unknown. A complex signaling network between tumor and stromal cells is responsible for the infiltration of inflammatory cells into the cancer microenvironment. Tumor stromal cells such as pancreatic stellate cells (PSCs) and immune cells create a microenvironment that protects cancer cells through a complex interaction, ultimately facilitating their local proliferation and their migration to different sites. Furthermore, PSCs have multiple functions related to local immunity, angiogenesis, inflammation, and fibrosis. Recently, many studies have shown that members of the phosphoinositol-3-phosphate kinase (PI3K) family are activated in tumor cells, PSCs, and tumor-infiltrating inflammatory cells to promote cancer growth. Proinflammatory cytokines and chemokines secreted by immune cells and fibroblasts within the tumor environment can activate the PI3K pathway both in cancer and inflammatory cells. In this review, we focus on the central role of the PI3K pathway in regulating the cross talk between immune/stromal cells and cancer cells. Understanding the role of the PI3K pathway in the development of chronic pancreatitis and cancer is crucial for the discovery of novel and efficacious treatment options. C1 [Birtolo, Chiara; Ptasznik, Andrzej; Pandol, Stephen J.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Birtolo, Chiara] Univ Bologna, S Orsola M Malpighi Hosp, Dept Internal Med, Bologna, Italy. [Go, Vay Liang W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Eibl, Guido] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Pandol, Stephen J.] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA. RP Pandol, SJ (reprint author), Cedars Sinai Med Ctr, Basic & Translat Pancreas Res, Gastroenterol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA. EM stephen.pandol@cshs.org FU Department of Veterans Affairs; [P50 AA11999]; [P01 CA163200]; [P01 DK098108]; [P01AT3960] FX The study was partly supported by P50 AA11999, P01 CA163200, P01 DK098108, and P01AT3960 grants, as well as the Department of Veterans Affairs. NR 148 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD JAN PY 2016 VL 45 IS 1 BP 21 EP 31 DI 10.1097/MPA.0000000000000531 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB6AZ UT WOS:000368596800004 PM 26658038 ER PT J AU Vital, P Castro, P Ittmann, M AF Vital, Paz Castro, Patricia Ittmann, Michael TI Oxidative Stress Promotes Benign Prostatic Hyperplasia SO PROSTATE LA English DT Article DE oxidative stress; benign prostatic hyperplasia; Nox4; oxidative DNA damage; transgenic ID EPITHELIAL GROWTH-FACTOR; URINARY-TRACT SYMPTOMS; CANCER PROGRESSION; PARACRINE INDUCER; NAD(P)H OXIDASE; GENE-EXPRESSION; RAT PROSTATE; CELLS; BPH; FIBROSIS AB BACKGROUND. Benign prostatic hyperplasia (BPH) is characterized by increased tissue mass in the transition zone of the prostate, which leads to obstruction of urine outflow and significant morbidity in the majority of older men. Plasma markers of oxidative stress are increased in men with BPH but it is unclear whether oxidative stress and/or oxidative DNA damage are causal in the pathogenesis of BPH. METHODS. Levels of 8-OH deoxyguanosine (8-OH dG), a marker of oxidative stress, were measured in prostate tissues from normal transition zone and BPH by ELISA. 8-OH dG was also detected in tissues by immunohistochemistry and staining quantitated by image analysis. Nox4 promotes the formation of reactive oxygen species. We therefore created and characterized transgenic mice with prostate specific expression of Nox4 under the control of the prostate specific ARR2PB promoter. RESULTS. Human BPH tissues contained significantly higher levels of 8-OH dG than control transition zone tissues and the levels of 8-OH dG were correlated with prostate weight. Cells with 8-OH dG staining were predominantly in the epithelium and were present in a patchy distribution. The total fraction of epithelial staining with 8-OH dG was significantly increased in BPH tissues by image analysis. The ARR2PB-Nox4 mice had increased oxidative DNA damage in the prostate, increased prostate weight, increased epithelial proliferation, and histological changes including epithelial proliferation, stromal thickening, and fibrosis when compared to wild type controls. CONCLUSIONS. Oxidative stress and oxidative DNA damage are important in the pathogenesis of BPH. Prostate 76: 58-67, 2016. (C) 2015 Wiley Periodicals, Inc. C1 [Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, One Baylor Plaza Houston, Houston, TX 77030 USA. Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, One Baylor Plaza Houston, Houston, TX 77030 USA. EM mittmann@bcm.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK083244, P20 DK097775 T32-DK007763]; National Institute on Aging [T32-AG000183]; National Cancer Institute P30 Cancer Center [P30 CA125123] FX Grant sponsor: National Institute of Diabetes and Digestive and Kidney Diseases; Grant numbers: R01 DK083244; P20 DK097775 T32-DK007763; Grant sponsor: National Institute on Aging; Grant number: T32-AG000183; Grant sponsor: National Cancer Institute P30 Cancer Center; Grant number: P30 CA125123. NR 33 TC 9 Z9 9 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 EI 1097-0045 J9 PROSTATE JI Prostate PD JAN 1 PY 2016 VL 76 IS 1 BP 58 EP 67 DI 10.1002/pros.23100 PG 10 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA DB9AZ UT WOS:000368809600007 PM 26417670 ER PT J AU Butler, CR O'Hare, AM AF Butler, Catherine R. O'Hare, Ann M. TI Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE Lipids; Cholesterol; Statin; Ezetimibe; Clinical trials; SHARP; Older adults; Kidney disease; Guidelines ID PRIMARY CARDIOVASCULAR PREVENTION; DENSITY-LIPOPROTEIN CHOLESTEROL; UNITED-STATES; PRACTICE GUIDELINE; COST-EFFECTIVENESS; RENAL PROTECTION; STATINS; CKD; HEART; DEATH AB The Study of Heart and Renal Protection (SHARP) found that treatment with ezetemibe and low-dose simvastatin reduced the incidence of major atherosclerotic events in patients with kidney disease. Due to the paucity of evidence-based interventions that lower cardiovascular morbidity in this high-risk population, the SHARP trial will likely have a large impact on clinical practice. However, applying the results of clinical trials conducted in select populations to the care of individual patients in real world settings can be fraught with difficulty. This is especially true when caring for older adults with complex comorbidity and limited life expectancy. These patients are often excluded from clinical trials, frequently have competing health priorities, and may be less likely to benefit and more likely to be harmed by medications. We discuss key considerations in applying the results of the SHARP trial to the care of older adults with CKD in real-world clinical settings using guiding principles set forth by the American Geriatrics Society's Expert Panel on the Care of Older Adults with Multimorbidity. Using this schema, we emphasize the importance of evaluating trial results in the unique context of each patient's goals, values, priorities, and circumstances. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. C1 Dept Med, Seattle, WA USA. Univ Washington, Harborview Med Ctr, Div Hospitalist Med, 325 9Th Ave, Seattle, WA 98104 USA. VA Puget Sound Healthcare Syst, Hosp & Specialty Med Serv, Nephrol Sect, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. RP O'Hare, AM (reprint author), VA Puget Sound Healthcare Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM ann.ohare@va.gov FU NIH; CDC; VA FX A.M.O'H. receives research funding from NIH, CDC, and VA. She has received honoraria from UpToDate and the American Society of Nephrology, The Japanese Society of Dialysis, and Transplantation and Henry Ford Hospital System. NR 52 TC 1 Z9 1 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 EI 1548-5609 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD JAN PY 2016 VL 23 IS 1 BP 29 EP 35 DI 10.1053/j.ackd.2015.11.004 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DB6UW UT WOS:000368652200006 PM 26709060 ER PT J AU Lan, CW Fiellin, DA Barry, DT Bryant, KJ Gordon, AJ Edelman, EJ Gaither, JR Maisto, SA Marshall, BDL AF Lan, Chiao-Wen Fiellin, David A. Barry, Declan T. Bryant, Kendall J. Gordon, Adam J. Edelman, E. Jennifer Gaither, Julie R. Maisto, Stephen A. Marshall, Brandon D. L. TI The Epidemiology of Substance Use Disorders in US Veterans: A Systematic Review and Analysis of Assessment Methods SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; VA HEALTH-CARE; RANDOMIZED CLINICAL-TRIAL; MAJOR DEPRESSIVE DISORDER; AMERICAN-INDIAN VETERANS; HAZARDOUS ALCOHOL-USE; SPINAL-CORD-INJURY; PSYCHIATRIC-DISORDERS; BIPOLAR DISORDER; DRUG-USE AB Background: Substance use disorders (SUDs), which encompass alcohol and drug use disorders (AUDs, DUDs), constitute a major public health challenge among US veterans. SUDs are among the most common and costly of all health conditions among veterans. Objectives: This study sought to examine the epidemiology of SUDs among US veterans, compare the prevalence of SUDs in studies using diagnostic and administrative criteria assessment methods, and summarize trends in the prevalence of SUDs reported in studies sampling US veterans over time. Methods: Comprehensive electronic database searches were conducted. A total of 3,490 studies were identified. We analyzed studies sampling US veterans and reporting prevalence, distribution, and examining AUDs and DUDs. Results: Of the studies identified, 72 met inclusion criteria. The studies were published between 1995 and 2013. Studies using diagnostic criteria reported higher prevalence of AUDs (32% vs. 10%) and DUDs (20% vs. 5%) than administrative criteria, respectively. Regardless of assessment method, both the lifetime and past year prevalence of AUDs in studies sampling US veterans has declined gradually over time. Conclusion: The prevalence of SUDs reported in studies sampling US veterans are affected by assessment method. Given the significant public health problems of SUDs among US veterans, improved guidelines for clinical screening using validated diagnostic criteria to assess AUDs and DUDs in US veteran populations are needed. Scientific Significance: These findings may inform VA and other healthcare systems in prevention, diagnosis, and intervention for SUDs among US veterans. C1 [Lan, Chiao-Wen] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA USA. [Fiellin, David A.; Edelman, E. Jennifer] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Barry, Declan T.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Barry, Declan T.] APT Fdn Inc, Pain Treatment Serv, New Haven, CT USA. [Bryant, Kendall J.] NIAAA, NIH, Bethesda, MD USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Hlth Res Educ & Clin Ctr, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Gaither, Julie R.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Maisto, Stephen A.] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Marshall, Brandon D. L.] Brown Univ, Dept Epidemiol, Sch Publ Hlth, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA. RP Marshall, BDL (reprint author), Brown Univ, Dept Epidemiol, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA. EM brandon_marshall@brown.edu OI Fiellin, David/0000-0002-4006-010X FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [U24-AA022000]; Yale Drug Abuse, Addiction and HIV Research Scholars (DAHRS) Program [K12-DA-33312-03]; Brown University; [K05-AA16928] FX This work was supported in part by grant U24-AA022000 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr. Edelman is funded by the Yale Drug Abuse, Addiction and HIV Research Scholars (DAHRS) Program (K12-DA-33312-03). Dr. Maisto is supported by grant K05-AA16928 (NIAAA). Dr. Marshall is supported by a Richard B. Salomon Faculty Research Award from Brown University. NR 113 TC 1 Z9 1 U1 4 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2016 VL 25 IS 1 BP 7 EP 24 DI 10.1111/ajad.12319 PG 18 WC Substance Abuse SC Substance Abuse GA DB4TS UT WOS:000368506900001 PM 26693830 ER PT J AU McRae-Clark, AL Baker, NL Gray, KM Killeen, T Hartwell, KJ Simonian, SJ AF McRae-Clark, Aimee L. Baker, Nathaniel L. Gray, Kevin M. Killeen, Therese Hartwell, Karen J. Simonian, Susan J. TI Vilazodone for Cannabis Dependence: A Randomized, Controlled Pilot Trial SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; 5-HT1A RECEPTORS; FLUOXETINE; SMOKERS AB Background and Objectives: The purpose of this study was to evaluate the efficacy of vilazodone, a selective serotonin receptor inhibitor and partial 5-HT1A agonist, for treatment of cannabis dependence. Methods: Seventy-six cannabis-dependent adults were randomized to receive either up to 40 mg/day of vilazodone (n = 41) or placebo (n = 35) for 8 weeks combined with a brief motivational enhancement therapy intervention and contingency management to encourage study retention. Cannabis use outcomes were assessed via weekly urine cannabinoid tests; secondary outcomes included cannabis use self-report and cannabis craving. Results: Participants in both groups reported reduced self-reported cannabis use over the course of the study; however, vilazodone provided no advantage over placebo in reducing cannabis use. Men had significantly lower creatinine-adjusted cannabinoid levels and a trend for increased negative urine cannabinoid tests than women. Discussion and Conclusions: Vilazodone was not more efficacious than placebo in reducing cannabis use. Important gender differences were noted, with women having worse cannabis use outcomes than men. Scientific Significance: Further medication development efforts for cannabis use disorders are needed, and gender should be considered as an important variable in future trials. C1 [McRae-Clark, Aimee L.; Gray, Kevin M.; Killeen, Therese; Hartwell, Karen J.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Baker, Nathaniel L.] Med Univ S Carolina, Dept Publ Hlth Sci, 125 Doughty St,Suite 190, Charleston, SC 29403 USA. [Hartwell, Karen J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Simonian, Susan J.] Coll Charleston, Dept Psychol, Charleston, SC 29401 USA. RP McRae-Clark, AL (reprint author), Med Univ S Carolina, 125 Doughty St,Suite 190, Charleston, SC 29403 USA. EM mcraeal@musc.edu FU NIH [R21DA34089] FX Support for this project was provided by NIH grant R21DA34089 (McRae-Clark). NR 27 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2016 VL 25 IS 1 BP 69 EP 75 DI 10.1111/ajad.12324 PG 7 WC Substance Abuse SC Substance Abuse GA DB4TS UT WOS:000368506900010 PM 26685701 ER PT S AU Whitaker, RM Corum, D Beeson, CC Schnellmann, RG AF Whitaker, Ryan M. Corum, Daniel Beeson, Craig C. Schnellmann, Rick G. BE Insel, PA TI Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases SO ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56 SE Annual Review of Pharmacology and Toxicology LA English DT Review; Book Chapter DE mitochondrial homeostasis; tissue bioenergetics; drug screening; high-throughput respirometry ID ISCHEMIA-REPERFUSION INJURY; ACUTE KIDNEY INJURY; THROUGHPUT RESPIROMETRIC ASSAY; ACTIVATED RECEPTOR-GAMMA; PROTEIN-QUALITY CONTROL; HIGH-FAT DIET; OXIDATIVE STRESS; MYOCARDIAL-INFARCTION; TRANSCRIPTION FACTOR; PARKINSONS-DISEASE AB Mitochondrial dysfunction is a key pathophysiological component of many acute and chronic diseases. Maintenance of mitochondrial homeostasis through the balance of mitochondrial turnover, fission and fusion, and generation of new mitochondria via mitochondrial biogenesis is critical for tissue health. Pharmacological activation of mitochondrial biogenesis can enhance oxidative metabolism and tissue bioenergetics, and improve organ function in conditions characterized by mitochondrial dysfunction. However, owing to the complexity of mitochondrial assembly and maintenance, identification of specific activators of mitochondrial biogenesis has been difficult. This review provides an overview of the role of mitochondrial dysfunction in acute and chronic diseases, details the current state of therapeutics for the stimulation of mitochondrial biogenesis and their effects on disease outcomes, describes new screening methodologies to identify novel stimulators and noncanonical pathways of mitochondrial biogenesis, and discusses potential hurdles of mitochondrial biogenesis as a therapeutic strategy. C1 [Whitaker, Ryan M.; Corum, Daniel; Beeson, Craig C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Whitaker, RM; Corum, D; Beeson, CC; Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.; Schnellmann, RG (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. EM rmw3@musc.edu; corumd@musc.edu; beesonc@musc.edu; schnell@musc.edu FU NIDDK NIH HHS [F30 DK096964]; NIGMS NIH HHS [R01 GM084147] NR 142 TC 9 Z9 10 U1 7 U2 22 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0362-1642 BN 978-0-8243-0456-0 J9 ANNU REV PHARMACOL JI Annu. Rev. Pharmacol. Toxicol. PY 2016 VL 56 BP 229 EP 249 DI 10.1146/annurev-pharmtox-010715-103155 PG 21 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA BE1PJ UT WOS:000368345700013 PM 26566156 ER PT S AU Sharma, S Powers, A Bradley, B Ressler, KJ AF Sharma, Sumeet Powers, Abigail Bradley, Bekh Ressler, Kerry J. BE Fiske, ST TI Gene x Environment Determinants of Stress- and Anxiety-Related Disorders SO ANNUAL REVIEW OF PSYCHOLOGY, VOL 67 SE Annual Review of Psychology LA English DT Review; Book Chapter DE anxiety; depression; posttraumatic stress disorder; stress; trauma; epigenetics; gene-by-environment interaction; genome-wide association study ID GENOME-WIDE ASSOCIATION; SEROTONIN TRANSPORTER GENE; LINKED POLYMORPHIC REGION; MAJOR DEPRESSIVE DISORDER; COPY-NUMBER VARIATION; EARLY-LIFE STRESS; POSTTRAUMATIC-STRESS; CHILDHOOD-TRAUMA; PSYCHIATRIC-DISORDERS; 5-HTTLPR GENOTYPE AB The burgeoning field of gene-by-environment (G x E) interactions has revealed fascinating biological insights, particularly in the realm of stress-, anxiety-, and depression-related disorders. In this review we present an integrated view of the study of GxE interactions in stress and anxiety disorders, including the evolution of genetic association studies from genetic epidemiology to contemporary large-scale genome-wide association studies and GxE studies. We convey the importance of consortia efforts and collaboration to gain the large sample sizes needed to move the field forward. Finally, we discuss several robust and well-reproduced GxE interactions and demonstrate how epidemiological identification of GxE interactions has naturally led to a plethora of basic research elucidating the mechanisms of high-impact genetic variants. C1 [Sharma, Sumeet; Powers, Abigail; Bradley, Bekh; Ressler, Kerry J.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. [Sharma, Sumeet; Ressler, Kerry J.] Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA. [Bradley, Bekh] US Dept Vet Affairs, Atlanta VA Med Ctr, Decatur, GA 30033 USA. RP Ressler, KJ (reprint author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.; Ressler, KJ (reprint author), Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA. EM kressler@mclean.harvard.edu FU Howard Hughes Medical Institute; NCRR NIH HHS [M01RR00039]; NICHD NIH HHS [HD071982]; NIMH NIH HHS [MH071537, MH096764, MH102890] NR 80 TC 5 Z9 5 U1 14 U2 40 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0066-4308 BN 978-0-8243-0267-2 J9 ANNU REV PSYCHOL JI Annu. Rev. Psychol PY 2016 VL 67 BP 239 EP 261 DI 10.1146/annurev-psych-122414-033408 PG 23 WC Psychology; Psychology, Multidisciplinary SC Psychology GA BE1PH UT WOS:000368344500011 PM 26442668 ER PT J AU Bensinger, WI Becker, PS Gooley, TA Chauncey, TR Maloney, DG Gopal, AK Green, DJ Press, OW Lill, M Ifthikharuddin, JJ Vescio, R Holmberg, LA Phillips, GL AF Bensinger, W. I. Becker, P. S. Gooley, T. A. Chauncey, T. R. Maloney, D. G. Gopal, A. K. Green, D. J. Press, O. W. Lill, M. Ifthikharuddin, J. J. Vescio, R. Holmberg, L. A. Phillips, G. L. TI A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT SO BONE MARROW TRANSPLANTATION LA English DT Article ID STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; ORAL MUCOSITIS; MARROW-TRANSPLANTATION; STANDARD CHEMOTHERAPY; CONDITIONING REGIMENS; INDUCTION TREATMENT; TRIAL; BORTEZOMIB; AMIFOSTINE AB We aimed to examine whether doses of melphalan higher than 200 mg/m(2) improve response rates when used as conditioning before autologous transplant (ASCT) in multiple myeloma (MM) patients. Patients with MM, n=131, were randomized to 200 mg/m(2) (mel200) vs 280 mg/m(2) (mel280) using amifostine pretreatment. The primary end point was the proportion of patients achieving near complete response (>= nCR). No treatment-related deaths occurred in this study. Responses following ASCT were for mel200 vs mel280, respectively, >= nCR 22 vs 39%, P=0.03, >= PR 57 vs 74%, P=0.04. The hazard of mortality was not statistically significantly different between groups (mel200 vs mel280; hazard ratio (HR) = 1.15 (95% confidence interval (CI), 0.62-2.13, P=0.66)) nor was the rate of progression/mortality (HR = 0.81 (0.52-1.27, P=0.36)). The estimated PFS at 1 and 3 years were 83 and 46%, respectively, for mel200 and 78 and 54%, respectively, for mel280. Amifostine and mel280 were well tolerated, with no grade 4 regimen-related toxicities and only one grade 3 mucositis (none with mel200) and three grade 3 gastrointestinal (GI) toxicities (two in mel200). Hospitalization rates were more frequent in the mel280 group (59 vs 43%, P=0.08). Mel280 resulted in a higher major response rate (CR+nCR) and should be evaluated in larger studies. C1 [Bensinger, W. I.; Gooley, T. A.; Maloney, D. G.; Gopal, A. K.; Green, D. J.; Press, O. W.; Holmberg, L. A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Bensinger, W. I.; Becker, P. S.; Gooley, T. A.; Chauncey, T. R.; Maloney, D. G.; Gopal, A. K.; Green, D. J.; Press, O. W.; Holmberg, L. A.] Univ Washington, Seattle, WA 98195 USA. [Chauncey, T. R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lill, M.; Vescio, R.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Ifthikharuddin, J. J.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Phillips, G. L.] Wake Forest Baptist Med Ctr, Winston Salem, NC USA. [Bensinger, W. I.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D5-390, Seattle, WA 98109 USA. RP Bensinger, WI (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D5-390, Seattle, WA 98109 USA. EM wbensing@fhcrc.org FU NIH/NCI [R21 CA155911-01, P01 CA18029-28]; VA Puget Sound Health Care System, Seattle, WA FX This study was supported in part by research funds supplied by Astra-Zeneca, R21 CA155911-01, and by P01 CA18029-28 both from NIH/NCI. Previously published at the 2012 ASH Annual Meeting, Atlanta, GA December 2012. This study was supported in part by resources of the VA Puget Sound Health Care System, Seattle, WA. NR 24 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD JAN PY 2016 VL 51 IS 1 BP 67 EP 71 DI 10.1038/bmt.2015.211 PG 5 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA DB4FV UT WOS:000368469800010 PM 26367217 ER PT J AU Rose, AJ Allen, AL Minichello, T AF Rose, Adam J. Allen, Arthur L. Minichello, Tracy TI A Call to Reduce the Use of Bridging Anticoagulation SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE anticoagulants; evidence-based medicine; heparin; low-molecular weight; humans; perioperative care; practice guideline; warfarin ID VENOUS THROMBOEMBOLISM; WARFARIN INTERRUPTION; ATRIAL-FIBRILLATION; BLOOD-COAGULATION; WITHDRAWAL; REGISTRY; ABRUPT AB Because of the recent publication of several important studies, there has been a major change in how we think about perioperative management of anticoagulation. Because of these changes, existing consensus guidelines are suddenly out of date and can no longer be used as is, particularly the 2012 American College of Chest Physicians Antithrombotic Guidelines, version 9. We estimate that well over 90% of patients receiving warfarin therapy should not receive bridging anticoagulation during periprocedural interruptions of therapy, except under unusual circumstances and with appropriate justification. Accumulating evidence also suggests that bridging is not indicated among patients receiving direct-acting oral anticoagulant therapy. The large number of patients potentially affected represents an important safety concern and requires an immediate change in practice. C1 [Rose, Adam J.] Bedford VA Med Ctr, Ctr Healthcare Org & Implementat Res, 200 Springs Rd,Bldg 70, Bedford, MA USA. [Rose, Adam J.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02215 USA. [Allen, Arthur L.] VA Salt Lake City Healthcare Syst, Dept Pharm, Salt Lake City, UT USA. [Minichello, Tracy] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Minichello, Tracy] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA. RP Rose, AJ (reprint author), Bedford VA Med Ctr, Ctr Healthcare Org & Implementat Res, 200 Springs Rd,Bldg 70, Bedford, MA USA. EM adamrose@bu.edu NR 13 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JAN PY 2016 VL 9 IS 1 BP 64 EP 67 DI 10.1161/CIRCOUTCOMES.115.002430 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DB6FZ UT WOS:000368611000010 PM 26715651 ER PT J AU Garimella, PS Katz, R Patel, KV Kritchevsky, SB Parikh, CR Ix, JH Fried, LF Newman, AB Shlipak, MG Harris, TB Sarnak, MJ AF Garimella, Pranav S. Katz, Ronit Patel, Kushang V. Kritchevsky, Stephen B. Parikh, Chirag R. Ix, Joachim H. Fried, Linda F. Newman, Anne B. Shlipak, Michael G. Harris, Tamara B. Sarnak, Mark J. CA Hlth ABC Study TI Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality The Health Aging and Body Composition Study SO CIRCULATION-HEART FAILURE LA English DT Article DE cardiovascular outcomes; chronic kidney disease; death; erythropoietin; heart failure ID CONGESTIVE-HEART-FAILURE; EPOETIN-ALPHA; ENDOGENOUS ERYTHROPOIETIN; DARBEPOETIN-ALPHA; OLDER-ADULTS; CYSTATIN-C; INFLAMMATORY MARKERS; DISEASE; ANEMIA; RISK AB Background Studies suggest that in patients with heart failure (HF), high serum erythropoietin is associated with risk of recurrent HF and mortality. Trials of erythropoietin-stimulating agents in persons with kidney disease have also suggested an increased incidence of adverse clinical events. No large studies of which we are aware have evaluated the association of endogenous erythropoietin levels with clinical outcomes in the community-living older adults. Methods and Results Erythropoietin concentration was measured in 2488 participants aged 70-79 years in the Health, Aging and Body Composition Study. Associations of erythropoietin with incident HF, coronary heart disease, stroke, mortality, and 30% decline in estimated glomerular filtration rate were examined using Cox proportional hazards and logistic regression over 10.7 years of follow-up. Mean (SD) age was 75 (3) years and median (quartile 1, quartile 3) erythropoietin was 12.3 (9.0, 17.2) mIU/mL. There were 503 incident HF events, and each doubling of serum erythropoietin was associated with a 25% increased risk of incident HF 1.25 (95% confidence interval 1.13, 1.48) after adjusting for demographics, prevalent cardiovascular disease, cardiovascular disease risk factors, kidney function, and serum hemoglobin. There was no interaction of serum erythropoietin with chronic kidney disease or anemia (P>0.50). There were 330 incident coronary heart disease events, 161 strokes, 1112 deaths, and 698 outcomes of 30% decline in estimated glomerular filtration rate. Serum erythropoietin was not significantly associated with these outcomes. Conclusions Higher levels of endogenous erythropoietin are associated with incident HF in older adults. Studies need to elucidate the mechanisms through which endogenous erythropoietin levels associate with specific outcomes. C1 [Garimella, Pranav S.; Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA 02111 USA. [Katz, Ronit] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Kritchevsky, Stephen B.] Wake Forest Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Parikh, Chirag R.] Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06510 USA. [Ix, Joachim H.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Prevent Med, San Diego, CA 92103 USA. [Fried, Linda F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15260 USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. [Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. RP Sarnak, MJ (reprint author), Tufts Med Ctr, Div Nephrol, 800 Washington St,Box 391, Boston, MA 02111 USA. EM msarnak@tuftsmedicalcenter.org OI Newman, Anne B./0000-0002-0106-1150 FU Intramural Research Program of the National Institutes of Health (NIH); National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050, 5R01AG027002]; NINR [R01-NR012459]; American Heart Association [14EIA18560026]; National Center on Minority Health and Health Disparities, NIH [MD-07-080] FX This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH) and the National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, and NINR grant R01-NR012459. Drs Shlipak, Sarnak, Ix, and Katz were supported by NIA grant 5R01AG027002, Dr Ix by an American Heart Association Award #14EIA18560026, and Dr Patel was supported by National Center on Minority Health and Health Disparities, NIH grant MD-07-080. The study sponsors had no role in study design; collection, analysis, and interpretation of the data; writing the report; and the decision to submit the report for publication. NR 44 TC 3 Z9 3 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JAN PY 2016 VL 9 IS 1 AR e002124 DI 10.1161/CIRCHEARTFAILURE.115.002124 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DB6HN UT WOS:000368615500001 PM 26721912 ER PT J AU McCollister, K Yang, X Mckay, JR AF McCollister, Kathryn Yang, Xuan McKay, James R. TI Cost-effectiveness analysis of a continuing care intervention for cocaine-dependent adults SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Continuing care; Cost-effectiveness analysis; Substance use disorders; Economic evaluation ID SUBSTANCE USE DISORDERS; ALCOHOL DEPENDENCE; RANDOMIZED-TRIAL; 24-MONTH OUTCOMES; MANAGEMENT; FRAMEWORK; BENEFITS; ABUSERS; DISEASE AB Introduction: The study conducts a cost-effectiveness analysis (CEA) of a continuing care Telephone Monitoring and Counseling (TMC) intervention for adults diagnosed with cocaine dependence. Participants were randomly assigned to a control condition of intensive outpatient treatment only (treatment-as usual, or TAU; N = 108), or to one of two treatment conditions featuring TMC (N=106) and TMC plus incentives (TMC-plus; N = 107). Follow-up assessments were conducted over a 2-year period. Methods: Intervention and client costs were collected with the program and client versions of the Drug Abuse Treatment Cost Analysis Program (DATCAP). Effectiveness was measured as the number of days abstinent during follow-up. Secondary analyses consider alternative measures of effectiveness and the reduced societal costs of physical and mental health problems and criminal justice involvement. Results: From the societal perspective, TMC dominates both TAU and TMC-plus as a cost-effective and cost saving intervention. Results varied by substance-using status, however, with the subgroup of participants in TMC-plus that were using drugs at intake and early in treatment having the greatest number of days of abstinence and generating similar savings during follow-up than the TMC subgroup using drugs at intake. Conclusions: Telephone monitoring and counseling appears to be a cost-effective and potentially cost saving strategy for reducing substance use among chronic substance users. Providing client incentives added to total intervention costs but did not improve overall effectiveness. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [McCollister, Kathryn; Yang, Xuan] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Clin Res Bldg,Off 1026,1120 NW 14th St, Miami, FL 33136 USA. [McKay, James R.] Univ Penn, Philadelphia, PA 19104 USA. [McKay, James R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP McCollister, K (reprint author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Clin Res Bldg,Off 1026,1120 NW 14th St, Miami, FL 33136 USA. EM kmccolli@miami.edu FU National Institute on Drug Abuse (NIDA) [R01 DA020623, R01 DA031785] FX Financial assistance for this study was provided by the National Institute on Drug Abuse (NIDA; grant numbers R01 DA020623 & R01 DA031785). The funding sources had no involvement in the study design, in the collection, analysis and interpretation of the data, in the writing of the report, or in the decision to submit the article for publication. NR 28 TC 2 Z9 2 U1 1 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 1 PY 2016 VL 158 BP 38 EP 44 DI 10.1016/j.drugalcdep.2015.10.032 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DB5PN UT WOS:000368566200005 PM 26621551 ER PT J AU Chavez, LJ Liu, CF Tefft, N Hebert, PL Clark, BJ Rubinsky, AD Lapham, GT Bradley, KA AF Chavez, Laura J. Liu, Chuan-Fen Tefft, Nathan Hebert, Paul L. Clark, Brendan J. Rubinsky, Anna D. Lapham, Gwen T. Bradley, Katharine A. TI Unhealthy alcohol use in older adults: Association with readmissions and emergency department use in the 30 days after hospital discharge SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol screening; Quality; Unhealthy alcohol use; Emergency department; Readmissions; Post-discharge care ID CARE TRANSITIONS INTERVENTION; VETERANS-AFFAIRS; SCREENING SCORES; USE DISORDERS; AUDIT-C; MEDICARE BENEFICIARIES; HEALTH-CARE; RISK; METAANALYSIS; CONSUMPTION AB Background: Unhealthy alcohol use could impair recovery of older patients after medical or surgical hospitalizations. However, no prior research has evaluated whether older patients who screen positive for unhealthy alcohol use are at increased risk of readmissions or emergency department (ED) visits within 30 days after discharge. This study examined the association between AUDIT-C alcohol screening results and 30-day readmissions or ED visits. Methods: Veterans Affairs (VA) patients age 65 years or older, were eligible if they were hospitalized for a medical or surgical condition (2/1/2009-10/1/2011) and had an AUDIT-C score documented in their VA electronic medical record in the year before they were hospitalized. VA and Medicare data identified VA or non-VA index hospitalizations, readmissions, and ED visits. Primary analyses adjusted for demographics, comorbid conditions, and past-year health care utilization. Results: Among 579,330 hospitalized patients, 13.7% were readmitted and 12.0% visited an ED within 30 days of discharge. In primary analyses, high-risk drinking (n = 7,167) and nondrinking (n = 357,086) were associated with increased probability of readmission (13.8%, 95% CI 13.0-14.6%; and 14.2%, 95% CI 14.1-14.3%, respectively), relative to low-risk drinking (12.9%; 95% CI 12.7-13.0%). Only nondrinkers had increased risk for ED visits. Conclusions: Alcohol screening results indicating high-risk drinking that were available in medical records were modestly associated with risk for 30-day readmissions and were not associated with risk for ED visits. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Chavez, Laura J.; Liu, Chuan-Fen; Hebert, Paul L.; Rubinsky, Anna D.; Lapham, Gwen T.; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Ctr Innovat Vet Ctr & Value Driven Care, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA. [Rubinsky, Anna D.; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, 1660 S Columbian Way, Seattle, WA 98108 USA. [Chavez, Laura J.; Liu, Chuan-Fen; Hebert, Paul L.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, 1959 NE Pacific St, Seattle, WA 98195 USA. [Tefft, Nathan] Bates Coll, 2 Andrews Rd, Lewiston, ME 04240 USA. [Clark, Brendan J.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, 12700 E 19th Ave, Aurora, CO 80045 USA. [Lapham, Gwen T.; Bradley, Katharine A.] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. RP Chavez, LJ (reprint author), Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA. EM ljchavez@uw.edu; chuan-fen.liu@va.gov; ntefft@bates.edu; paul.hebert2@va.gov; brendan.clark@ucdenver.edu; anna.rubinsky@va.gov; lapham.g@ghc.org; bradley.k@ghc.org FU Agency for Healthcare Research and Quality (AHRQ) [NIH 1R36HS022800-01]; Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound; NIAAA R21 [5R21AA020894-02]; NIH [K23 AA 021814] FX Ms. Chavez's work on this study was supported by an Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH 1R36HS022800-01). Dr. Bradley's and Ms. Rubinsky's time on this study was supported by the Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound. Dr. Bradley's NIAAA R21 (5R21AA020894-02) supported the collection of the data used in this study. Dr. Clark is supported by NIH grant K23 AA 021814. NR 55 TC 2 Z9 2 U1 2 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 1 PY 2016 VL 158 BP 94 EP 101 DI 10.1016/j.drugalcdep.2015.11.008 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DB5PN UT WOS:000368566200012 PM 26644137 ER PT S AU Thomas, T Seay, K Zheng, JH Zhang, C Ochsenbauer, C Kappes, JC Goldstein, H AF Thomas, Tynisha Seay, Kieran Zheng, Jian Hua Zhang, Cong Ochsenbauer, Christina Kappes, John C. Goldstein, Harris BE Prasad, VR Kalpana, GV TI High-Throughput Humanized Mouse Models for Evaluation of HIV-1 Therapeutics and Pathogenesis SO HIV PROTOCOLS, 3RD EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE HIV-1; Mouse model; Antiretroviral treatment ID IMMUNODEFICIENCY-VIRUS TYPE-1; RAG2(-/-)GAMMA(-/-)(C) MICE; CYCLIN T1; INFECTION; REPLICATION; CELLS; TAT AB Mice cannot be used as a model to evaluate HIV-1 therapeutics because they do not become infected by HIV-1 due to structural differences between several human and mouse proteins required for HIV-1 replication. This has limited their use for in vivo assessment of anti-HIV-1 therapeutics and the mechanism by which cofactors, such as illicit drug use accelerate HIV-1 replication and disease course in substance abusers. Here, we describe the development and application of two in vivo humanized mouse models that are highly sensitive and useful models for the in vivo evaluation of candidate anti-HIV therapeutics. The first model, hu-spl-PBMC-NSG mice, uses NOD-SCID IL2r gamma(-/-) (NSG) mice intrasplenically injected with human peripheral blood mononuclear cells (PBMC) which develop productive splenic HIV-1 infection after intrasplenic inoculation with a replication-competent HIV-1 expressing Renilla reniformis luciferase (HIVLucR) and enables investigators to use bioluminescence to visualize and quantitate the temporal effects of therapeutics on HIV-1 infection. The second model, hCD4/R5/cT1 mice, consists of transgenic mice carrying human CD4, CCR5 and cyclin T1 genes, which enables murine CD4-expressing cells to support HIV-1 entry, Tat-mediated LTR transcription and consequently develop productive infection. The hCD4/R5/cT1 mice develop disseminated infection of tissues including the spleen, small intestine, lymph nodes and lungs after intravenous injection with HIV-1-LucR. Because these mice can be infected with HIV-LucR expressing transmitted/founder and clade A/E and C Envs, these mouse models can also be used to evaluate the in vivo efficacy of broadly neutralizing antibodies and antibodies induced by candidate HIV-1 vaccines. Furthermore, because hCD4/R5/cT1 mice can be infected by vaginal inoculation with replication-competent HIV-1 expressing NanoLuc (HIV-nLucR)-, this mouse model can be used to evaluate the mechanisms by which substance abuse and other factors enhance mucosal transmission of HIV-1. C1 [Thomas, Tynisha; Seay, Kieran; Zheng, Jian Hua; Zhang, Cong; Goldstein, Harris] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. [Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. [Goldstein, Harris] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA. RP Thomas, T (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. OI Ochsenbauer, Christina/0000-0003-1166-5879 FU NIAID NIH HHS [P30 AI027767]; NIDA NIH HHS [R01 DA033788, R01 DA036171] NR 25 TC 1 Z9 1 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3046-3; 978-1-4939-3045-6 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1354 BP 221 EP 235 DI 10.1007/978-1-4939-3046-3_15 D2 10.1007/978-1-4939-3046-3 PG 15 WC Immunology; Virology SC Immunology; Virology GA BE1XH UT WOS:000368688500016 PM 26714715 ER PT J AU Dusser, D Wise, RA Dahl, R Anzueto, A Carter, K Fowler, A Calverley, PM AF Dusser, Daniel Wise, Robert A. Dahl, Ronald Anzueto, Antonio Carter, Kerstine Fowler, Andy Calverley, Peter M. TI Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR (R) trial SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE TIOSPIR (R); GOLD; cardiovascular comorbidity; mortality; respiratory death; cardiovascular death ID OBSTRUCTIVE PULMONARY-DISEASE; ECLIPSE COHORT; CLASSIFICATION; EXACERBATION; DYSPNEA; DEATH AB Background: The aim of this study was to evaluate whether Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification could predict mortality risk factors and whether baseline treatment intensity would relate to mortality within each group, using data from TIOSPIR (R), the largest randomized clinical trial in COPD performed to date. Methods: A total of 17,135 patients from TIOSPIR (R) were pooled and grouped by GOLD grading (A-D) according to baseline Medical Research Council breathlessness score, exacerbation history, and spirometry. All-cause mortality and adjudicated cardiovascular (CV) and respiratory mortality were assessed. Results: Of the 16,326 patients classified, 1,248 died on treatment. Group B patients received proportionally more CV treatment at baseline. CV mortality risk, but not all-cause mortality risk, was significantly higher in Group B than Group C patients (CV mortality - hazard ratio [HR] = 1.74, P = 0.004; all-cause mortality - HR = 1.18, P = 0.11). Group D patients had a higher incidence of all-cause mortality than Group B patients (10.9% vs 6.6%). Similar trends were observed regardless of respiratory or CV medication at baseline. In contrast, respiratory deaths increased consistently from Groups A-D (0.3%, 0.8%, 1.6%, and 4.2% of patients, respectively). Conclusion: The data obtained from the TIOSPIR (R) trial, supporting earlier studies, suggest that proportionally more CV medication and CV deaths occur in GOLD Group B COPD patients, although deaths attributed to respiratory causes are more prevalent in Groups C and D. C1 [Dusser, Daniel] Univ Paris 05, AP HP, Hop Cochin, Sorbonne Paris Cite,Serv Pneumol, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France. [Wise, Robert A.] Johns Hopkins Univ, Sch Med, Asthma & Allergy Ctr, Baltimore, MD USA. [Dahl, Ronald] Odense Univ Hosp, Allergy Ctr, DK-5000 Odense C, Denmark. [Anzueto, Antonio] Univ Texas San Antonio, Pulm Crit Care, San Antonio, TX USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Carter, Kerstine] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA. [Fowler, Andy] Boehringer Ingelheim Pharma Ltd, Bracknell, Berks, England. [Calverley, Peter M.] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England. RP Dusser, D (reprint author), Univ Paris 05, AP HP, Hop Cochin, Sorbonne Paris Cite,Serv Pneumol, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France. EM daniel.dusser@aphp.fr FU Boehringer Ingelheim; Pfizer; Novartis; Chiesi; Nycomed; Dey Pharma; GlaxoSmithKline; Pearl Therapeutics; Forest Laboratories; Bristol-Myers Squibb; Janssen; Mylan; Sunovion; Pulmonx; Spiration; Roche; Grifols; AstraZeneca; Takeda FX Daniel Dusser reports receiving consulting fees, lecture fees, and payment for the development of educational activities from Boehringer Ingelheim, Pfizer, Novartis, Chiesi, Nycomed, and Dey Pharma. Robert Wise reports receiving consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Mylan, Novartis, Pfizer, Sunovion, Pulmonx, Spiration, Roche, Grifols, and AstraZeneca, and grant support from Boehringer Ingelheim, GlaxoSmithKline, Pearl Therapeutics, and Forest Laboratories. Ronald Dahl reports receiving consulting fees, lecture fees, and grant support from Boehringer Ingelheim and Novartis. Antonio Anzueto reports receiving consulting fees, lecture fees, and travel support from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, and Novartis, and grant support from GlaxoSmithKline. Kerstine Carter and Andy Fowler report being employees of Boehringer Ingelheim. Peter Calverley reports receiving consulting fees, lecture fees, and travel support from Novartis, GlaxoSmithKline, Boehringer Ingelheim, and Takeda. The authors report no other conflicts of interest in this work. NR 15 TC 0 Z9 0 U1 0 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2016 VL 11 BP 133 EP 145 DI 10.2147/COPD.S97924 PG 13 WC Respiratory System SC Respiratory System GA DB3KP UT WOS:000368410400002 PM 26855568 ER PT J AU Luk, FS Kim, RY Li, K Ching, D Wong, DK Joshi, SK Imhof, I Honbo, N Hoover, H Zhu, BQ Lovett, DH Karliner, JS Raffai, RL AF Luk, Fu Sang Kim, Roy Y. Li, Kang Ching, Daniel Wong, David K. Joshi, Sunil K. Imhof, Isabella Honbo, Norman Hoover, Holly Zhu, Bo-Qing Lovett, David H. Karliner, Joel S. Raffai, Robert L. TI Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE FTY720; S1P; ApoE; coronary atherosclerosis; heart failure; cardioprotection; immunosuppression ID MATRIX METALLOPROTEINASE-2 EXPRESSION; ISCHEMIA-REPERFUSION INJURY; NFAT NUCLEAR FACTOR; SPHINGOSINE-1-PHOSPHATE ANALOG; SPHINGOSINE 1-PHOSPHATE; GENE REPAIR; IN-VIVO; HEART; CELL; PROMOTES AB Aims:We recently reported that immunosuppression with FTY720 improves cardiac function and extends longevity in Hypomorphic ApoE mice deficient in scavenger receptor Type-BI expression, also known as the HypoE/SR-BI-/- mouse model of diet-induced coronary atherosclerosis and myocardial infarction (MI). In this study, we tested the impact of FTY720 on cardiac dysfunction in HypoE/SR-BI-/- mice that survive MI and subsequently develop chronic heart failure.Methods/Results:HypoE/SR-BI-/- mice were bred to Mx1-Cre transgenic mice, and offspring were fed a high-fat diet (HFD) for 3.5 weeks to provoke hyperlipidemia, coronary atherosclerosis, and recurrent MIs. In contrast to our previous study, hyperlipidemia was rapidly reversed by inducible Cre-mediated gene repair of the HypoE allele and switching mice to a normal chow diet. Mice that survived the period of HFD were subsequently given oral FTY720 in drinking water or not, and left ventricular (LV) function was monitored using serial echocardiography for up to 15 weeks. In untreated mice, LV performance progressively deteriorated. Although FTY720 treatment did not initially prevent a decline of heart function among mice 6 weeks after Cre-mediated gene repair, it almost completely restored normal LV function in these mice by 15 weeks. Reversal of heart failure did not result from reduced atherosclerosis as the burden of aortic and coronary atherosclerosis actually increased to similar levels in both groups of mice. Rather, FTY720 caused systemic immunosuppression as assessed by reduced numbers of circulating T and B lymphocytes. In contrast, FTY720 did not enhance the loss of T cells or macrophages that accumulated in the heart during the HFD feeding period, but it did enhance the loss of B cells soon after plasma lipid lowering. Moreover, FTY720 potently reduced the expression of matrix metalloproteinase-2 and genes involved in innate immunity-associated inflammation in the heart.Conclusions:Our data demonstrate that immunosuppression with FTY720 prevents postinfarction myocardial remodeling and chronic heart failure. C1 [Luk, Fu Sang; Kim, Roy Y.; Li, Kang; Ching, Daniel; Wong, David K.; Raffai, Robert L.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, San Francisco, CA 94121 USA. [Joshi, Sunil K.; Imhof, Isabella; Honbo, Norman; Hoover, Holly; Zhu, Bo-Qing; Lovett, David H.; Karliner, Joel S.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. RP Raffai, RL (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, 4150 Clement St, San Francisco, CA 94121 USA. EM robert.raffai@ucsf.edu FU National Institutes of Health [HL089871, HL090606]; Department of Veterans Affairs [5I01BX000532] FX This work was supported by Grants from the National Institutes of Health HL089871 (RLR) and HL090606 (JSK) which were administered by the Northern California Institute for Research and Education, and a Merit Review grant from the Department of Veterans Affairs 5I01BX000532 to RLR, and with resources of the Veterans Affairs Medical Center, San Francisco, California. NR 42 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0160-2446 EI 1533-4023 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD JAN PY 2016 VL 67 IS 1 BP 47 EP 56 DI 10.1097/FJC.0000000000000312 PG 10 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA DB4SW UT WOS:000368504500006 PM 26322923 ER PT J AU Huang, T Wang, ZH Wei, LN Kindy, M Zheng, YF Xi, TF Gao, BZ AF Huang, Ting Wang, Zhonghai Wei, Lina Kindy, Mark Zheng, Yufeng Xi, Tingfei Gao, Bruce Z. TI Microelectrode Array-evaluation of Neurotoxic Effects of Magnesium as an Implantable Biomaterial SO JOURNAL OF MATERIALS SCIENCE & TECHNOLOGY LA English DT Article DE Magnesium; Microelectrode array; Neuroelectrophysiology; Neuron viability; Neuronal network ID NEURONAL APOPTOSIS; IN-VITRO; ALLOYS; CORROSION; CULTURE; ASSAYS; CELLS; TERM; PH AB Magnesium (Mg)-based biomaterials have shown great potential in clinical applications. However, the cytotoxic effects of excessive Mg2+ and the corrosion products from Mg-based biomaterials, particularly their effects on neurons, have been little studied. Although viability tests are most commonly used, a functional evaluation is critically needed. Here, both methyl thiazolyl tetrazolium (MTT) and lactate dehydrogenase (LDH) assays were used to test the effect of Mg2+ and Mg-extract solution on neuronal viability. Microelectrode arrays (MEAs), which provide long-term, real-time recording of extracellular electro-physiological signals of in vitro neuronal networks, were used to test for toxic effects. The minimum effective concentrations (ECmin) of Mg2+ from the MTT and LDH assays were 3 mmol/L and 100 mmol/L, respectively, while the ECmin obtained from the MEA assay was 0.1 mmol/L. MEA data revealed significant loss of neuronal network activity when the culture was exposed to 25% Mg-extract solution, a concentration that did not affect neuronal viability. For evaluating the biocompatibility of Mg-based biomaterials with neurons, MEA electrophysiological testing is a more precise method than basic cell-viability testing. Copyright (C) 2015, The editorial office of Journal of Materials Science & Technology. Published by Elsevier Limited. All rights reserved. C1 [Huang, Ting; Wei, Lina; Zheng, Yufeng; Xi, Tingfei] Peking Univ, Acad Adv Interdisciplinary Studies, Ctr Biomed Mat & Tissue Engn, Beijing 100871, Peoples R China. [Wang, Zhonghai; Kindy, Mark; Gao, Bruce Z.] Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA. [Kindy, Mark] Med Univ S Carolina, Dept Neurosci & Regenerat Med, Charleston, SC 29466 USA. [Kindy, Mark] Med Univ S Carolina, Dept Cell Biol, Charleston, SC 29466 USA. [Kindy, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA. [Zheng, Yufeng] Peking Univ, Coll Engn, Dept Mat Sci & Engn, Beijing 100871, Peoples R China. [Xi, Tingfei] Peking Univ, Shenzhen Inst, Shenzhen Key Lab Human Tissue Regenerat & Repair, Shenzhen 518057, Peoples R China. RP Xi, TF (reprint author), Peking Univ, Acad Adv Interdisciplinary Studies, Ctr Biomed Mat & Tissue Engn, Beijing 100871, Peoples R China.; Gao, BZ (reprint author), Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA. EM xitingfei@pku.edu.cn; zgao@clemson.edu RI Zheng, Yufeng/A-4146-2010 OI Zheng, Yufeng/0000-0002-7402-9979 FU National Basic Research Program of China (973 Program) [2012CB619102]; National Natural Science Foundation of China [31070847, 31370956]; National Science and Technology Support Program [2012BAI18B01]; Strategic New Industry Development Special Foundation of Shenzhen, China [JCYJ20130402172114948]; Guangdong Provincial Department of Science and Technology, China [2011B050400011]; NIH NIGMS COBRE [NIH P20GM103444] FX This work was supported by the National Basic Research Program of China (973 Program, No. 2012CB619102); the National Natural Science Foundation of China (Nos. 31070847 and 31370956); the National Science and Technology Support Program (No. 2012BAI18B01); the Strategic New Industry Development Special Foundation of Shenzhen, China (No. JCYJ20130402172114948); the Guangdong Provincial Department of Science and Technology, China (No. 2011B050400011); and NIH NIGMS COBRE (No. NIH P20GM103444). NR 18 TC 1 Z9 1 U1 4 U2 9 PU JOURNAL MATER SCI TECHNOL PI SHENYANG PA 72 WENHUA RD, SHENYANG 110015, PEOPLES R CHINA SN 1005-0302 J9 J MATER SCI TECHNOL JI J. Mater. Sci. Technol. PD JAN PY 2016 VL 32 IS 1 BP 89 EP 96 DI 10.1016/j.jmst.2015.08.009 PG 8 WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering SC Materials Science; Metallurgy & Metallurgical Engineering GA DB5NI UT WOS:000368560500013 PM 27110081 ER PT J AU Kaatz, A Dattalo, M Regner, C Filut, A Carnes, M AF Kaatz, Anna Dattalo, Melissa Regner, Caitlin Filut, Amarette Carnes, Molly TI Patterns of Feedback on the Bridge to Independence: A Qualitative Thematic Analysis of NIH Mentored Career Development Award Application Critiques SO JOURNAL OF WOMENS HEALTH LA English DT Article ID GENDER-DIFFERENCES; MEDICAL-FACULTY; SEX-DIFFERENCES; WOMENS HEALTH; DEVELOPMENT AWARDEES; ONE INSTITUTION; JOB APPLICANTS; FEMALE; DISCRIMINATION; RECOMMENDATION AB Background: NIH Mentored Career Development (K) Awards bridge investigators from mentored to independent research. A smaller proportion of women than men succeed in this transition. The aim of this qualitative study was to analyze reviewers' narrative critiques of K award applications and explore thematic content of feedback provided to male and female applicants. Method: We collected 88 critiques, 34 from 9 unfunded and 54 from 18 funded applications, from 70% (n=26) of investigators at the University of Wisconsin-Madison with K awards funded between 2005 and 2009 on the first submission or after revision. We qualitatively analyzed text in the 5 critique sections: candidate, career development plan, research plan, mentors, and environment and institutional commitment. We explored thematic content within these sections for male and female applicants and for applicants who had received a subsequent independent research award by 2014. Results: Themes revealed consistent areas of criticism for unfunded applications and praise for funded applications. Subtle variations in thematic content appeared for male and female applicants: For male applicants criticism was often followed by advice but for female applicants it was followed by questions about ability; praise recurrently characterized male but not female applicants' research as highly significant with optimism for future independence. Female K awardees that obtained subsequent independent awards stood out as having track records described as outstanding. Conclusion: This exploratory study suggests that K award reviewer feedback, particularly for female applicants, should be investigated as a potential contributor to research persistence and success in crossing the bridge to independence. C1 [Kaatz, Anna; Filut, Amarette] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Regner, Caitlin] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53715 USA. [Dattalo, Melissa] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Coll Engn, Dept Ind & Syst Engn, Madison, WI 53715 USA. RP Kaatz, A (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM akaatz@wisc.edu FU NIH [R25GM083252, R01GM111002]; Department of Medicine; Shapiro Research Scholars Program in the School of Medicine and Public Health at the University of Wisconsin-Madison; Shaprio Summer Research Program at the UW-Madison School; Medicine and Public Health FX The authors wish to thank Kristin Cox and Katherine Muratore at University of Wisconsin's Center for Women's Health Research who aided in formatting and de-identifying critiques. Dr. Carnes' and Dr. Kaatz's work on increasing scientific workforce diversity is funded by NIH grants R01GM111002 and R25GM083252, the Department of Medicine, and the Shapiro Research Scholars Program in the School of Medicine and Public Health at the University of Wisconsin-Madison. Ms. Regner received funding to participate in this research from the Shaprio Summer Research Program at the UW-Madison School or Medicine and Public Health. The funders played no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. This study was approved by the University of Wisconsin-Madison institutional review board. NR 57 TC 0 Z9 0 U1 3 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD JAN 1 PY 2016 VL 25 IS 1 BP 78 EP 90 DI 10.1089/jwh.2015.5254 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA DB4YX UT WOS:000368520700013 PM 26418619 ER PT J AU Banks, WA Abrass, CK Hansen, KM AF Banks, William A. Abrass, Christine K. Hansen, Kim M. TI Differentiating the Influences of Aging and Adiposity on Brain Weights, Levels of Serum and Brain Cytokines, Gastrointestinal Hormones, and Amyloid Precursor Protein SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Aging; Cytokines; Obesity; Leptin; Amyloid precursor protein ID COLONY-STIMULATING FACTOR; ALZHEIMERS-DISEASE; CALORIC RESTRICTION; COGNITIVE IMPAIRMENT; OBESITY; INFLAMMATION; LEPTIN; INSULIN; DIET; INJECTIONS AB Aging and obesity exert important effects on disease. Differentiating these effects is difficult, however, because weight gain often accompanies aging. Here, we used a nested design of aged, calorically restricted, and refed rats to measure changes in brain and blood levels of cytokines and gastrointestinal hormones, brain amyloid precursor protein levels, and brain and body weights. By comparing groups and using path analysis, we found divergent influences of chronological aging versus body weight, our main findings being (i) changes in whole brain weight and serum macrophage colony-stimulating factor levels correlated better with body weight than with chronological aging, (ii) a decrease in brain cytokines and brain plasminogen activator inhibitor levels correlated better with chronological aging than with body weight, (iii) serum erythropoietin levels were influenced by both body weight and aging, (iv) serum plasminogen activator inhibitor, serum cytokines, and brain tumor necrosis factor were not influenced by aging or body weight, and (v) brain amyloid precursor protein more closely related to body weight and serum levels of gastrointestinal hormones than to brain weight, chronological aging, or cytokines. These findings show that although aging and body weight interact, their influences are distinct not only among various cytokines and hormones but also between the central nervous system and the peripheral tissue compartments. C1 [Banks, William A.; Hansen, Kim M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Abrass, Christine K.] Dept Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Care Med, Seattle, WA USA. RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Rm 810A,Bldg 1,1660 S Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU Veterans Affairs Merit Reviews; AG [RO-1029839] FX The authors were supported by Veterans Affairs Merit Reviews (W.A.B.; C.K.A.) and AG RO-1029839 (W.A.B.). NR 34 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2016 VL 71 IS 1 BP 21 EP 29 DI 10.1093/gerona/glu100 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DB2UZ UT WOS:000368366900003 PM 25128822 ER PT J AU Reyes, RC Cittolin-Santos, GF Kim, JE Won, SJ Brennan-Minnella, AM Katz, M Glass, GA Swanson, RA AF Reyes, Reno C. Cittolin-Santos, Giordano Fabricio Kim, Ji-Eun Won, Seok Joon Brennan-Minnella, Angela M. Katz, Maya Glass, Graham A. Swanson, Raymond A. TI Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid SO NEUROTHERAPEUTICS LA English DT Article DE Cysteine; Parkinson's disease; oxidative stress; human; cerebrospinal fluid; target engagement ID PARKINSONS-DISEASE; OXIDATIVE STRESS; NITRIC-OXIDE; ACETYLCYSTEINE; METABOLISM; DEPLETION; BRAIN; SUPEROXIDE; NEURODEGENERATION; DEFICIENCY AB N-acetyl cysteine (NAC) supports the synthesis of glutathione (GSH), an essential substrate for fast, enzymatically catalyzed oxidant scavenging and protein repair processes. NAC is entering clinical trials for adrenoleukodystrophy, Parkinson's disease, schizophrenia, and other disorders in which oxidative stress may contribute to disease progression. However, these trials are hampered by uncertainty about the dose of NAC required to achieve biological effects in human brain. Here we describe an approach to this issue in which mice are used to establish the levels of NAC in cerebrospinal fluid (CSF) required to affect brain neurons. NAC dosing in humans can then be calibrated to achieve these NAC levels in human CSF. The mice were treated with NAC over a range of doses, followed by assessments of neuronal GSH levels and neuronal antioxidant capacity in ex vivo brain slices. Neuronal GSH levels and antioxidant capacity were augmented at NAC doses that produced peak CSF NAC concentrations of >= 50 nM. Oral NAC administration to humans produced CSF concentrations of up to 10 mu M, thus demonstrating that oral NAC administration can surpass the levels required for biological activity in brain. Variations of this approach may similarly facilitate and rationalize drug dosing for other agents targeting central nervous system disorders. C1 [Reyes, Reno C.; Cittolin-Santos, Giordano Fabricio; Kim, Ji-Eun; Won, Seok Joon; Brennan-Minnella, Angela M.; Katz, Maya; Glass, Graham A.; Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, 4150 Clement St, San Francisco, CA 94121 USA. [Reyes, Reno C.; Cittolin-Santos, Giordano Fabricio; Kim, Ji-Eun; Won, Seok Joon; Brennan-Minnella, Angela M.; Katz, Maya; Glass, Graham A.; Swanson, Raymond A.] Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. [Cittolin-Santos, Giordano Fabricio] Univ Fed Rio Grande do Sul, Programa Pos Grad Ciencias Biol Bioquim, Porto Alegre, RS, Brazil. [Cittolin-Santos, Giordano Fabricio] CNPq, Sci Borders, Brasilia, DF, Brazil. RP Swanson, RA (reprint author), San Francisco VA Med Ctr, Neurol Serv, 4150 Clement St, San Francisco, CA 94121 USA.; Swanson, RA (reprint author), Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. EM raymond.swanson@ucsf.edu FU Michael J. Fox Foundation; San Luis Obispo County Community Foundation; Singing Field Foundation; Department of Veterans Affairs FX We thank Drs. Caroline Tanner (University of California San Francisco) and Dean Jones (Emory University) for many helpful discussions. This study was supported by the Michael J. Fox Foundation, the San Luis Obispo County Community Foundation, the Singing Field Foundation, and the Department of Veterans Affairs. NR 39 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1933-7213 EI 1878-7479 J9 NEUROTHERAPEUTICS JI Neurotherapeutics PD JAN PY 2016 VL 13 IS 1 BP 217 EP 225 DI 10.1007/s13311-015-0404-4 PG 9 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DB5SU UT WOS:000368574700019 PM 26572666 ER PT J AU Reyes, RC Cittolin-Santos, GF Kim, JE Won, SJ Brennan-Minnella, AM Katz, M Glass, GA Swanson, RA AF Reyes, Reno C. Cittolin-Santos, Giordano Fabricio Kim, Ji-Eun Won, Seok Joon Brennan-Minnella, Angela M. Katz, Maya Glass, Graham A. Swanson, Raymond A. TI Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid (vol 13, pg 217, 2016) SO NEUROTHERAPEUTICS LA English DT Correction C1 [Reyes, Reno C.; Cittolin-Santos, Giordano Fabricio; Kim, Ji-Eun; Won, Seok Joon; Brennan-Minnella, Angela M.; Katz, Maya; Glass, Graham A.; Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, 4150 Clement St, San Francisco, CA 94121 USA. [Reyes, Reno C.; Cittolin-Santos, Giordano Fabricio; Kim, Ji-Eun; Won, Seok Joon; Brennan-Minnella, Angela M.; Katz, Maya; Glass, Graham A.; Swanson, Raymond A.] Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. [Cittolin-Santos, Giordano Fabricio] Univ Fed Rio Grande do Sul, Programa Pos Grad Ciencias Biol Bioquim, Porto Alegre, RS, Brazil. [Cittolin-Santos, Giordano Fabricio] CNPq, Sci Without Borders, Brasilia, DF, Brazil. RP Swanson, RA (reprint author), San Francisco VA Med Ctr, Neurol Serv, 4150 Clement St, San Francisco, CA 94121 USA.; Swanson, RA (reprint author), Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. EM raymond.swanson@ucsf.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1933-7213 EI 1878-7479 J9 NEUROTHERAPEUTICS JI Neurotherapeutics PD JAN PY 2016 VL 13 IS 1 BP 239 EP 239 DI 10.1007/s13311-015-0413-3 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DB5SU UT WOS:000368574700023 PM 26659493 ER PT J AU Keller, AC Knaub, LA McClatchey, PM Connon, CA Bouchard, R Miller, MW Geary, KE Walker, LA Klemm, DJ Reusch, JEB AF Keller, Amy C. Knaub, Leslie A. McClatchey, P. Mason Connon, Chelsea A. Bouchard, Ron Miller, Matthew W. Geary, Kate E. Walker, Lori A. Klemm, Dwight J. Reusch, Jane E. B. TI Differential Mitochondrial Adaptation in Primary Vascular Smooth Muscle Cells from a Diabetic Rat Model SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY LA English DT Article ID NITRIC-OXIDE SYNTHASE; OXYGEN SPECIES PRODUCTION; REACTIVE OXYGEN; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; INSULIN-RESISTANCE; SKELETAL-MUSCLE; BIOGENESIS; DYNAMICS; HEART AB Diabetes affects more than 330 million people worldwide and causes elevated cardiovascular disease risk. Mitochondria are critical for vascular function, generate cellular reactive oxygen species (ROS), and are perturbed by diabetes, representing a novel target for therapeutics. We hypothesized that adaptive mitochondrial plasticity in response to nutrient stress would be impaired in diabetes cellular physiology via a nitric oxide synthase- (NOS-) mediated decrease in mitochondrial function. Primary smooth muscle cells (SMCs) from aorta of the nonobese, insulin resistant rat diabetes model Goto-Kakizaki (GK) and the Wistar control rat were exposed to high glucose (25 mM). At baseline, significantly greater nitric oxide evolution, ROS production, and respiratory control ratio (RCR) were observed in GK SMCs. Upon exposure to high glucose, expression of phosphorylated eNOS, uncoupled respiration, and expression of mitochondrial complexes I, II, III, and V were significantly decreased in GK SMCs (p < 0.05). Mitochondrial superoxide increased with high glucose in Wistar SMCs (p < 0.05) with no change in the GK beyond elevated baseline concentrations. Baseline comparisons show persistent metabolic perturbations in a diabetes phenotype. Overall, nutrient stress in GK SMCs caused a persistent decline in eNOS and mitochondrial function and disrupted mitochondrial plasticity, illustrating eNOS and mitochondria as potential therapeutic targets. C1 [Keller, Amy C.; Knaub, Leslie A.; McClatchey, P. Mason; Connon, Chelsea A.; Miller, Matthew W.; Geary, Kate E.; Reusch, Jane E. B.] Univ Colorado, Div Endocrinol, Anschutz Med Campus, Aurora, CO 80045 USA. [Keller, Amy C.; Knaub, Leslie A.; McClatchey, P. Mason; Connon, Chelsea A.; Bouchard, Ron; Miller, Matthew W.; Geary, Kate E.; Reusch, Jane E. B.] Denver VA Med Ctr, Dept Med, Denver, CO 80220 USA. [McClatchey, P. Mason] Univ Colorado, Dept Bioengn, Aurora, CO 80045 USA. [Walker, Lori A.] Univ Colorado, Dept Cardiol, Aurora, CO 80045 USA. [Klemm, Dwight J.] Univ Colorado, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. [Reusch, Jane E. B.] Univ Colorado, Sch Med, Ctr Womens Hlth Res, Aurora, CO 80045 USA. RP Reusch, JEB (reprint author), Univ Colorado, Div Endocrinol, Anschutz Med Campus, Aurora, CO 80045 USA.; Reusch, JEB (reprint author), Denver VA Med Ctr, Dept Med, Denver, CO 80220 USA.; Reusch, JEB (reprint author), Univ Colorado, Sch Med, Ctr Womens Hlth Res, Aurora, CO 80045 USA. EM jane.reusch@ucdenver.edu FU VA Merit, Denver Research Institute [NIH-5T32HL007171, NIH-5P01HL014985, CCTSI-UL1RR025780]; Center for Women's Health Research; Department of Bioengineering; National Cancer Institute Cancer Center Support Grant [P30CA046934] FX The authors wish to acknowledge Dr. Pete Watson, University of Colorado Anschutz Medical Campus, for his intellectual contributions to this work, Dr. Rebecca Scalzo, University of Colorado Anschutz Medical Campus, for critical input on the paper, and Ms. Molly McCullough for her initial mitochondrial imaging analyses. Sources of funding for this study were provided by VA Merit, Denver Research Institute, NIH-5T32HL007171 (Amy C. Keller), NIH-5P01HL014985 (Amy C. Keller), CCTSI-UL1RR025780 (Jane E. B. Reusch), the Center for Women's Health Research (Jane E. B. Reusch), and the Department of Bioengineering (P. Mason McClatchey). Flow Cytometry is supported through a National Cancer Institute Cancer Center Support Grant (P30CA046934). NR 58 TC 1 Z9 1 U1 1 U2 2 PU HINDAWI LTD PI LONDON PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND SN 1942-0900 EI 1942-0994 J9 OXID MED CELL LONGEV JI Oxidative Med. Cell. Longev. PY 2016 AR 8524267 DI 10.1155/2016/8524267 PG 15 WC Cell Biology SC Cell Biology GA DB9SN UT WOS:000368857300001 ER PT J AU Dale, CL Brown, EG Fisher, M Herman, AB Dowling, AF Hinkley, LB Subramaniam, K Nagarajan, SS Vinogradov, S AF Dale, Corby L. Brown, Ethan G. Fisher, Melissa Herman, Alexander B. Dowling, Anne F. Hinkley, Leighton B. Subramaniam, Karuna Nagarajan, Srikantan S. Vinogradov, Sophia TI Auditory Cortical Plasticity Drives Training-Induced Cognitive Changes in Schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Article ID REMEDIATION THERAPY; MAGNETIC-FIELDS; HUMAN-BRAIN; MEMORY; LOCALIZATION; PERFORMANCE; COMPONENT; DYNAMICS; DEFICITS; SPEECH AB Schizophrenia is characterized by dysfunction in basic auditory processing, as well as higher-order operations of verbal learning and executive functions. We investigated whether targeted cognitive training of auditory processing improves neural responses to speech stimuli, and how these changes relate to higher-order cognitive functions. Patients with schizophrenia performed an auditory syllable identification task during magnetoencephalography before and after 50 hours of either targeted cognitive training or a computer games control. Healthy comparison subjects were assessed at baseline and after a 10 week no-contact interval. Prior to training, patients N = 34) showed reduced M100 response in primary auditory cortex relative to healthy participants N = 13). At reassessment, only the targeted cognitive training patient group N = 18) exhibited increased M100 responses. Additionally, this group showed increased induced high gamma band activity within left dorsolateral prefrontal cortex immediately after stimulus presentation, and later in bilateral temporal cortices. Training-related changes in neural activity correlated with changes in executive function scores but not verbal learning and memory. These data suggest that computerized cognitive training that targets auditory and verbal learning operations enhances both sensory responses in auditory cortex as well as engagement of prefrontal regions, as indexed during an auditory processing task with low demands on working memory. This neural circuit enhancement is in turn associated with better executive function but not verbal memory. C1 [Dale, Corby L.; Herman, Alexander B.; Dowling, Anne F.; Hinkley, Leighton B.; Nagarajan, Srikantan S.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Dale, Corby L.; Fisher, Melissa; Subramaniam, Karuna; Vinogradov, Sophia] San Francisco VA Med Ctr, NCIRE, San Francisco, CA USA. [Brown, Ethan G.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Fisher, Melissa; Subramaniam, Karuna; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Herman, Alexander B.; Nagarajan, Srikantan S.] Univ Calif Berkeley, UC San Francisco Grad Program Bioengn, San Francisco, CA USA. RP Dale, CL (reprint author), Biomagnet Imaging Lab, Box 0628,513 Parnassus Ave,S362, San Francisco, CA 94143 USA. EM corby.dale@ucsf.edu FU National Institutes of Health [R01DC004855, R01DC010145, R21NS076171, R01MH068725]; Howard Hughes Medical Institute Research Fellowship program; San Francisco Department of Veterans' Affairs Medical Center FX National Institutes of Health (R01DC004855, R01DC010145, R21NS076171, R01MH068725); Howard Hughes Medical Institute Research Fellowship program (to E.G.B.); San Francisco Department of Veterans' Affairs Medical Center. The cognitive training software used in this study was supplied to the senior author free of charge by Posit Science Corporation. NR 41 TC 6 Z9 6 U1 4 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JAN PY 2016 VL 42 IS 1 BP 220 EP 228 DI 10.1093/schbul/sbv087 PG 9 WC Psychiatry SC Psychiatry GA DB6ML UT WOS:000368629000025 PM 26152668 ER PT J AU Raugi, GJ Nelson, W Miethke, M Boyd, M Markham, C Dougall, B Bratten, D Comer, T AF Raugi, Gregory J. Nelson, William Miethke, Marion Boyd, Marvin Markham, Craig Dougall, Brittany Bratten, Dustin Comer, Tara TI Teledermatology Implementation in a VHA Secondary Treatment Facility Improves Access to Face-to-Face Care SO TELEMEDICINE AND E-HEALTH LA English DT Article DE dermatology; teledermatology; telehealth; telemedicine ID FORWARD TELEDERMATOLOGY; DERMATOLOGY AB Background:Teledermatology is a mainstream modality for delivering care in the Veterans Health Administration, especially in rural areas where access to traditional dermatology care is constrained. Previous investigations of the effect of teledermatology on improving patient access have focused largely on the metrics of visits avoided. However, the effect of teledermatology on improving patient access to face-to-face dermatology has not been well documented. The purpose of this study was to assess the impact of the implementation of store-and-forward teledermatology on access to face-to-face dermatology at the Mann-Grandstaff Spokane Veterans Administration (VA) Medical Center in Spokane, WA.Materials and Methods:Completed requests for dermatology and teledermatology consultation originating from the Spokane main facility from January 1, 2012 through June 30, 2013 were obtained from the Corporate Data Warehouse by SQL query. The numbers of consult requests and wait times for care for overall dermatology, face-to-face dermatology, and teledermatology were compared across the baseline, transition, and intervention periods.Results:Within 6 months of implementation, the total number of requests for dermatology services increased by 40%. Access to face-to-face dermatology care improved, with a decrease in the duration of the interval between consultation request and consultation completion from a mean of 64.2 days to 20.3 days; overall access to dermatology (teledermatology and face-to-face dermatology) care improved with a decrease in the duration of the same from a mean of 61.2 days to 10.3 days.Conclusions:Implementation of a teledermatology program at the Mann-Grandstaff Spokane VA Medical Center improved access to face-to-face dermatology care. C1 [Raugi, Gregory J.; Markham, Craig; Dougall, Brittany; Bratten, Dustin; Comer, Tara] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Raugi, Gregory J.] Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98115 USA. [Nelson, William; Miethke, Marion; Boyd, Marvin] Spokane VA Med Ctr, Spokane, WA 99205 USA. RP Raugi, GJ (reprint author), Fed Off Bldg 909 1st Ave,Suite 630, Seattle, WA 98104 USA. EM gregory.raugi@va.gov NR 11 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 EI 1556-3669 J9 TELEMED E-HEALTH JI Telemed. e-Health PD JAN 1 PY 2016 VL 22 IS 1 BP 12 EP 17 DI 10.1089/tmj.2015.0036 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DB3YE UT WOS:000368448900003 PM 26393782 ER PT J AU Kwon, I Bharmal, N Choi, S Araiza, D Moore, MR Trejo, L Sarkisian, CA AF Kwon, Ivy Bharmal, Nazleen Choi, Sarah Araiza, Daniel Moore, Mignon R. Trejo, Laura Sarkisian, Catherine A. TI Older Ethnic Minority Women's Perceptions of Stroke Prevention and Walking SO WOMENS HEALTH ISSUES LA English DT Article ID AMERICAN-HEART-ASSOCIATION; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; GENDER-DIFFERENCES; SEX-DIFFERENCES; RISK-FACTORS; HEALTH; EPIDEMIOLOGY; BARRIERS; BELIEFS AB Objective: To inform the development of a tailored behavioral stroke risk reduction intervention for ethnic minority seniors, we sought to explore gender differences in perceptions of stroke prevention and physical activity (walking). Methods: In collaboration with community-based organizations, we conducted 12 mixed-gender focus groups of African American, Latino, Chinese, and Korean seniors aged 60 years and older with a history of hypertension (89 women and 42 men). Transcripts were coded and recurring topics compared by gender. Results: Women expressed beliefs that differed from men in 4 topic areas: 1) stroke-related interest, 2) barriers to walking, 3) facilitators to walking, and 4) health behavior change attitudes. Compared with men, women were more interested in their role in response to a stroke and post-stroke care. Women described walking as an acceptable form of exercise, but cited neighborhood safety and pain as walking barriers. Fear of nursing home placement and weight loss were identified as walking facilitators. Women were more prone than men to express active/control attitudes toward health behavior change. Conclusions: Older ethnic minority women, a high-risk population for stroke, may be more receptive to behavioral interventions that address the gender-specific themes identified by this study. Published by Elsevier Inc. C1 [Kwon, Ivy; Araiza, Daniel; Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Bharmal, Nazleen] RAND Corp, Hlth Unit, Arlington, VA USA. [Choi, Sarah] Univ Calif Irvine, Coll Hlth Sci, Dept Nursing Sci, Irvine, CA USA. [Moore, Mignon R.] Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90095 USA. [Trejo, Laura] City Los Angeles Dept Aging, Los Angeles, CA USA. [Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. RP Sarkisian, CA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, 10945 Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM csarkisian@mednet.ucla.edu OI Kwon, Ivy/0000-0003-4160-6546 FU National Institute of Neurological Disorders and Stroke [1U54NS081764]; National Institutes of Health Office of Research on Women's Health [1U54NS081764-03S1]; National Institute on Aging [1K24AG047899-01]; National Institute on Aging UCLA Older Americans Independence Center [P30AG028747]; National Institute on Aging Resource Centers for Minority Aging Research IV/Center for Health Improvement of Minority Elderly III [2P30AG021684] FX This work was supported by the National Institute of Neurological Disorders and Stroke [1U54NS081764]; National Institutes of Health Office of Research on Women's Health [1U54NS081764-03S1]; and the National Institute on Aging [1K24AG047899-01]. Additional sources of support for this project include the National Institute on Aging UCLA Older Americans Independence Center [P30AG028747] and National Institute on Aging Resource Centers for Minority Aging Research IV/Center for Health Improvement of Minority Elderly III [2P30AG021684]. No competing financial interests exist. NR 41 TC 0 Z9 0 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JAN-FEB PY 2016 VL 26 IS 1 BP 80 EP 86 DI 10.1016/j.whi.2015.08.003 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DB1IS UT WOS:000368262500017 PM 26411494 ER PT J AU Blosnich, JR Nasuti, LJ Mays, VM Cochran, SD AF Blosnich, John R. Nasuti, Laura J. Mays, Vickie M. Cochran, Susan D. TI Suicidality and Sexual Orientation: Characteristics of Symptom Severity, Disclosure, and Timing Across the Life Course SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY LA English DT Article DE mental disorders; gay; lesbian; bisexual; sexual minority; suicide ID NATIONAL COMORBIDITY SURVEY; WORLD-HEALTH-ORGANIZATION; MENTAL-HEALTH; RISK-FACTORS; PSYCHOLOGICAL DISTRESS; REPRESENTATIVE SAMPLE; BISEXUAL POPULATIONS; GENERAL-POPULATION; UNITED-STATES; SUBSTANCE USE AB This investigation explored suicide-related characteristics and help-seeking behavior by sexual orientation. Population-based data are from the California Quality of Life Surveys, which included 1,478 sexual minority (lesbian, gay, bisexual, and homosexually experienced individuals) and 3,465 heterosexual individuals. Bisexual women had a nearly six-fold increased risk of lifetime suicide attempts than heterosexual women (RR = 5.88, 95%CI: 3.89-8.90), and homosexually experienced men had almost 7 times higher risk of lifetime suicide attempts than heterosexual men (RR = 6.93, 95%CI: 3.65-13.15). Sexual minority men and women were more likely than heterosexual men and women to have disclosed suicide attempts to a medical professional (RR = 1.48 and RR = 1.44, respectively). Among persons who ever attempted suicide, sexual minority women had a younger age of index attempt than heterosexual women (15.9 vs. 19.6 years of age, respectively). Healthcare professionals should be aware of suicidal risk heterogeneity among sexual minority individuals, including vulnerable points of risk and evidenced-based treatments. C1 [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Blosnich, John R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15260 USA. [Nasuti, Laura J.; Cochran, Susan D.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. [Mays, Vickie M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. [Mays, Vickie M.; Cochran, Susan D.] Univ Calif Los Angeles, Ctr Bridging Res Innovat Training & Educ Minor Hl, Los Angeles, CA 90024 USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C 151-CU,Bldg 30, Pittsburgh, PA 15240 USA. EM john.blosnich@va.gov FU NIDA NIH HHS [R01 DA015539, R01 DA020826]; NIMHD NIH HHS [P60 MD000508]; VA [VA999999] NR 62 TC 0 Z9 0 U1 1 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0002-9432 EI 1939-0025 J9 AM J ORTHOPSYCHIAT JI Am. J. Orthopsychiatr. PD JAN PY 2016 VL 86 IS 1 BP 69 EP 78 DI 10.1037/ort0000112 PG 10 WC Psychiatry; Social Work SC Psychiatry; Social Work GA DA9HQ UT WOS:000368120000007 PM 26752446 ER PT J AU Lawson, EH Louie, R Zingmond, DS Sacks, GD Brook, RH Hall, BL Ko, CY AF Lawson, Elise H. Louie, Rachel Zingmond, David S. Sacks, Greg D. Brook, Robert H. Hall, Bruce Lee Ko, Clifford Y. TI Using Both Clinical Registry and Administrative Claims Data to Measure Risk-adjusted Surgical Outcomes SO ANNALS OF SURGERY LA English DT Article DE ACS-NSQIP; administrative claims; clinical registry; quality measure; surgery ID QUALITY IMPROVEMENT PROGRAM; POSTOPERATIVE ADVERSE EVENTS; AMERICAN-COLLEGE; VALIDITY; CARE AB Objective:To examine the validity of hybrid quality measures that use both clinical registry and administrative claims data, capitalizing on the strengths of each data source.Background:Previous studies demonstrate substantial disagreement between clinical registry and administrative claims data on the occurrence of postoperative complications. Clinical data have greater validity than claims data for quality measurement but can be burdensome for hospitals to collect.Methods:American College of Surgeons National Surgical Quality Improvement Program records were linked to Medicare inpatient claims (2005-2008). National Quality Forum-endorsed risk-adjusted measures of 30-day postoperative complications or death assessed hospital quality for patients undergoing colectomy, lower extremity bypass, or all surgical procedures. Measures use hierarchical multivariable logistic regression to identify statistical outliers. Measures were applied using clinical data, claims data, or a hybrid of both data sources. Kappa statistics assessed agreement on determinations of hospital quality.Results:A total of 111,984 patients participated from 206 hospitals. Agreement on hospital quality between clinical and claims data was poor. Hybrid models using claims data to risk-adjust complications identified by clinical data had moderate agreement with all clinical data models, whereas hybrid models using clinical data to risk-adjust complications identified by claims data had routinely poor agreement with all clinical data models.Conclusions:Assessments of hospital quality differ substantially when using clinical registry versus administrative claims data. A hybrid approach using claims data for risk adjustment and clinical data for complications may be a valid alternative with lower data collection burden. For quality measures focused on postoperative complications to be meaningful, such policies should require, at a minimum, collection of clinical outcomes data. C1 [Lawson, Elise H.; Sacks, Greg D.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Lawson, Elise H.; Hall, Bruce Lee; Ko, Clifford Y.] Amer Coll Surgeons, Div Res & Optimal Patient Care, Chicago, IL USA. [Lawson, Elise H.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Louie, Rachel; Zingmond, David S.; Brook, Robert H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brook, Robert H.] RAND Corp, Santa Monica, CA USA. [Brook, Robert H.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Hall, Bruce Lee] BJC Healthcare, St Louis, MO USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU VA Health Services Research and Development program [RWJ 65-020]; American College of Surgeons (ACS) through the Robert Wood Johnson Foundation Clinical Scholars Program; Centers for Medicare & Medicaid Services FX E.H.L.'s time was supported by the VA Health Services Research and Development program (RWJ 65-020) and the American College of Surgeons (ACS) through the Robert Wood Johnson Foundation Clinical Scholars Program. R.L., D.S.Z., and B.L.H. are consultants for the ACS, and C.Y.K. is staff at the ACS. Supported by a contract from the Centers for Medicare & Medicaid Services. The remaining authors declare no conflicts of interest. NR 17 TC 4 Z9 4 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD JAN PY 2016 VL 263 IS 1 BP 50 EP 57 DI 10.1097/SLA.0000000000001031 PG 8 WC Surgery SC Surgery GA DA7SN UT WOS:000368004500011 PM 25405553 ER PT J AU Dedert, EA Resick, PA McFall, ME Dennis, PA Olsen, M Beckham, JC AF Dedert, Eric A. Resick, Patricia A. McFall, Miles E. Dennis, Paul A. Olsen, Maren Beckham, Jean C. TI Pilot Cases of Combined Cognitive Processing Therapy and Smoking Cessation for Smokers With Posttraumatic Stress Disorder SO BEHAVIOR THERAPY LA English DT Article DE tobacco use cessation; posttraumatic stress disorder; cognitive therapy; comorbidity; psychotherapy ID CIGARETTE-SMOKING; CONTROLLED-TRIAL; BECK DEPRESSION; CLINICAL-TRIAL; VETERANS; PTSD; INVENTORY; SURVIVORS; SYMPTOMS; OUTCOMES AB Posttraumatic stress disorder (PTSD) and smoking are often comorbid, and both problems are in need of improved access to evidence-based treatment. The combined approach could address two high-priority problems and increase patient access to both treatments, but research is needed to determine whether this is feasible and has promise for addressing both PTSD and smoking. We collected data from 15 test cases that received a treatment combining two evidence-based treatments: cognitive processing therapy cognitive version (CPT-C) for PTSD and integrated care for smoking cessation (ICSC). We explored two combined treatment protocols including a brief (six-session) CPT-C with five follow-up in-person sessions focused on smoking cessation (n = 9) and a full 12-session CPT-C protocol with ICSC (n = 6). The combined interventions were feasible and acceptable to patients with PTSD making a quit attempt. Initial positive benefits of the combined treatments were observed. The six-session dose of CPT-C and smoking cessation resulted in 6-month bioverified smoking abstinence in two of nine participants, with clinically meaningful PTSD symptom reduction in three of nine participants. In the second cohort (full CPT-C and smoking treatment), both smoking and PTSD symptoms were improved, with three of six participants abstinent from smoking and four of six participants reporting clinically meaningful reduction in PTSD symptoms. Results suggested that individuals with PTSD who smoke are willing to engage in concurrent treatment of these problems and that combined treatment is feasible. C1 [Dedert, Eric A.; Dennis, Paul A.; Beckham, Jean C.] Durham Vet Affairs Med Ctr, 508 Fulton St,Bldg 16,2nd Floor, Durham, NC 27705 USA. [Dedert, Eric A.; Beckham, Jean C.] Vet Affairs Midatlantic Reg Mental Illness Res Ed, Durham, NC USA. [Dedert, Eric A.; Resick, Patricia A.; Dennis, Paul A.; Beckham, Jean C.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [McFall, Miles E.] VA Puget Sound Hlth Care Syst, Seattle Div, New York, NY USA. [McFall, Miles E.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Olsen, Maren] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Olsen, Maren] Duke Univ, Sch Med, Durham, NC 27706 USA. RP Dedert, EA (reprint author), Durham Vet Affairs Med Ctr, 508 Fulton St,Bldg 16,2nd Floor, Durham, NC 27705 USA. EM eric.dedert@duke.edu FU CSRAMP;D Research AMP; Development Service of the VA Office of Research and Development [1IK2CX000718] FX The authors thank all of the veterans who volunteered to participate in this study. The views expressed in this paper are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government. The project described was supported by Award Number 1IK2CX000718 to Dr. Dedert from the CSR&D Research & Development Service of the VA Office of Research and Development. NR 39 TC 0 Z9 0 U1 4 U2 7 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD JAN PY 2016 VL 47 IS 1 BP 54 EP 65 PG 12 WC Psychology, Clinical SC Psychology GA DB2CF UT WOS:000368315200005 PM 26763497 ER PT J AU Eidelman, P Talbot, L Ivers, H Belanger, L Morin, CM Harvey, AG AF Eidelman, Polina Talbot, Lisa Ivers, Hans Belanger, Lynda Morin, Charles M. Harvey, Allison G. TI Change in Dysfunctional Beliefs About Sleep in Behavior Therapy, Cognitive Therapy, and Cognitive-Behavioral Therapy for Insomnia SO BEHAVIOR THERAPY LA English DT Article DE insomnia; beliefs; sleep; cognitive-behavioral therapy; behavioral experiments ID RANDOMIZED CONTROLLED-TRIAL; SOCIAL-ADJUSTMENT SCALE; PERSISTENT INSOMNIA; COMPONENT ANALYSIS; ANXIETY DISORDER; SEVERITY INDEX; OLDER-ADULTS; ATTITUDES; EFFICACY; WORK AB As part of a larger randomized controlled trial, 188 participants were randomized to behavior therapy (BT), cognitive therapy (CT), or cognitive-behavioral therapy (CBT) for insomnia. The aims of this study were threefold: (a) to determine whether change in dysfunctional beliefs about sleep was related to change in sleep, insomnia symptoms, and impairment following treatment; (b) to determine whether BT, CT, and CBT differ in their effects on dysfunctional beliefs; and (c) to determine whether the treatments differ in their effects on particular kinds of dysfunctional beliefs. Beliefs, sleep, insomnia symptoms, and sleep-related psychosocial impairment were assessed at pretreatment, posttreatment, and 6- and 12-month follow-up. Greater change in dysfunctional beliefs occurring over the course of BT, CT, or CBT was associated with greater improvement in insomnia symptoms and impairment at posttreatment and both follow-ups. All groups experienced a significant decrease in dysfunctional beliefs during treatment, which were sustained through 6- and 12-month follow-up. Compared with the BT group, a greater proportion of participants in the CT and/or CBT groups endorsed dysfunctional beliefs below a level considered clinically significant at posttreatment and 12-month follow-up. The results demonstrate the importance of targeting dysfunctional beliefs in insomnia treatment, suggest that beliefs may be significantly modified with BT alone, and indicate that cognitive interventions may be particularly powerful in enhancing belief change. C1 [Eidelman, Polina] Cognit Behav Therapy & Sci Ctr, Oakland, CA USA. [Talbot, Lisa] San Francisco VA Med Ctr, San Francisco, CA USA. [Ivers, Hans; Belanger, Lynda; Morin, Charles M.] Univ Laval, Quebec City, PQ G1K 7P4, Canada. [Harvey, Allison G.] Univ Calif Berkeley, Berkeley, CA 94720 USA. RP Harvey, AG (reprint author), Univ Calif Berkeley, Dept Psychol, 2205 Tolman Hall 1650, Berkeley, CA 94720 USA. EM aharvey@berkeley.edu FU National Institute of Mental Health [RO1MH079188] FX This project was supported by National Institute of Mental Health Grant RO1MH079188 (C.M.M., A.G.H.); clinical trial NCT 00869934. NR 51 TC 1 Z9 1 U1 4 U2 18 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD JAN PY 2016 VL 47 IS 1 BP 102 EP 115 PG 14 WC Psychology, Clinical SC Psychology GA DB2CF UT WOS:000368315200009 PM 26763501 ER PT J AU Chhatbar, PY Ramakrishnan, V Kautz, S George, MS Adams, RJ Feng, WW AF Chhatbar, Pratik Y. Ramakrishnan, Viswanathan Kautz, Steven George, Mark S. Adams, Robert J. Feng, Wuwei TI Transcranial Direct Current Stimulation Post-Stroke Upper Extremity Motor Recovery Studies Exhibit a Dose-Response Relationship SO BRAIN STIMULATION LA English DT Article DE Stroke; Transcranial direct current stimulation; tDCS; Motor recovery; Dose-response relationship; Meta-analysis; Meta-regression; Hedge's g ID INTERHEMISPHERIC INHIBITION; SUBACUTE STROKE; TDCS; METAANALYSIS; THERAPY; CORTEX; BRAIN; EXCITABILITY; MODULATION; PHASE AB Background and purpose: Transcranial direct current stimulation (tDCS) has shown mixed results in poststroke motor recovery, possibly because of tDCS dose differences. The purpose of this meta-analysis was to explore whether the outcome has a dose-response relationship with various dose-related parameters. Methods: The literature was searched for double-blind, randomized, sham-controlled clinical trials investigating the role of tDCS (= 5 sessions) in post-stroke motor recovery as measured by the Fugl-Meyer Upper Extremity (FM-UE) scale. Improvements in FM-UE scores were compared between active and sham groups by calculating standardized mean differences (Hedge's g) to derive a summary effect size. Inversevariance- weighted linear meta-regression across individual studies was performed between various tDCS parameters and Hedge's g to test for dose-response relationships. Results: Eight studies with total of 213 stroke subjects were included. Summary Hedge's g was statistically significant in favor of the active group (Hedge's g = 0.61, p = 0.02) suggesting moderate effect. Specifically, studies that used bihemispheric tDCS montage (Hedge's g = 1.30, p = 0.08) or that recruited chronic stroke patients (Hedge's g = 1.23, p = 0.02) showed large improvements in the active group. A positive dose-response relationship was found with current density (p = 0.017) and charge density (p = 0.004), but not with current amplitude. Moreover, a negative dose-response relationship was found with electrode size (p < 0.001, smaller electrodes were more effective). Conclusions: Our meta-analysis and meta-regression results suggest superior motor recovery in the active group when compared to the sham group and dose-response relationships relating to electrode size, charge density and current density. These results need to be confirmed in future dedicated studies. (C) 2015 Elsevier Inc. All rights reserved. C1 [Chhatbar, Pratik Y.; Adams, Robert J.; Feng, Wuwei] Med Univ S Carolina, Coll Med, Dept Neurol, Charleston, SC 29425 USA. [Ramakrishnan, Viswanathan] Med Univ S Carolina, Coll Med, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Kautz, Steven; Feng, Wuwei] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [George, Mark S.] Med Univ S Carolina, Coll Med, Brain Stimulat Lab, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Feng, WW (reprint author), Med Univ S Carolina, Coll Med, Dept Neurol, Charleston, SC 29425 USA. EM feng@musc.edu FU National Institute of General Medical Sciences of the National Institutes of Health [P20GM109040]; American Heart Association [14SDG1829003]; Rehabilitation Research and Development Service of the VA FX All of authors are supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM109040. Dr. Feng is also supported by American Heart Association (14SDG1829003). Dr. Kautz is also funded by the Rehabilitation Research and Development Service of the VA. NR 46 TC 12 Z9 12 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD JAN-FEB PY 2016 VL 9 IS 1 BP 16 EP 26 DI 10.1016/j.brs.2015.09.002 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DA8XF UT WOS:000368089500003 PM 26433609 ER PT J AU Schlosser, RJ Carroll, WW Soler, ZM Pasquini, WN Mulligan, JK AF Schlosser, Rodney J. Carroll, William W. Soler, Zachary M. Pasquini, Whitney N. Mulligan, Jennifer K. TI Reduced sinonasal levels of 1-hydroxylase are associated with worse quality of life in chronic rhinosinusitis with nasal polyps SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE vitamin D; sinusitis; 1-alpha-hydroxylase; nasal polyp; allergic fungal rhinosinusitis ID VITAMIN-D DEFICIENCY; ALLERGIC FUNGAL RHINOSINUSITIS; RANDOMIZED CLINICAL-TRIAL; 25-HYDROXYVITAMIN D; D SUPPLEMENTATION; D-METABOLISM; EXTRARENAL EXPRESSION; DENDRITIC CELLS; SINUS MUCOSA; ASTHMA AB BackgroundPatients with chronic rhinosinusitis with nasal polyps (CRSwNP) have deficiencies in circulating and sinonasal levels of the inactive form of vitamin D3, 25-hydroxycholecalciferol (25VD3). Moreover, CRSwNP patients have reduced epithelial cell-specific expression of 1-hydroxylase; the enzyme responsible for the conversion of 25VD3 to its metabolically active form, 1,25-dihydroxyvitamin D3 (1,25VD3). The objective of this work was to determine the impact of sinonasal 1-hydroxylase levels combined from all cellular sources on subjective disease severity and to identify variables influencing its expression. MethodsBlood and sinus tissue explants were collected at the time of surgery from control, chronic rhinosinusitis without nasal polyps (CRSsNP), CRSwNP, and allergic fungal rhinosinusitis (AFRS) patients. 1-Hydroxylase was measured by immunostaining with flow cytometric analysis. Subjective disease severity was measured by the 22-item Sino-Nasal Outcomes Test (SNOT-22). 1,25VD3 and 25VD3 were measured by enzyme-linked immunosorbent assay (ELISA). ResultsPatients with CRSwNP or AFRS have reduced 1-hydroxylase and 1,25VD3 compared to controls or CRSsNP. Circulating 1,25VD3 levels were the same among all groups. No differences in sinonasal 1-hydroxylase or 1,25VD3 were found between CRSwNP and AFRS. Gender, age, race, atopy, and systemic 25VD3 had no impact on sinonasal 1-hydroxylase levels in any group. However, CRSwNP patients with asthma had higher 1-hydroxylase than those without asthma. Total 1-hydroxylase levels inversely correlated with SNOT-22 in CRSwNP, but not CRSsNP. ConclusionPatients with CRSwNP and AFRS both have reduced sinonasal 1-hydroxylase and 1,25VD3 compared to controls or CRSsNP. Reductions in intracellular 1-hydroxylase combined from all sinonasal cell types were associated with more severe subjective disease severity in CRSwNP. C1 [Schlosser, Rodney J.; Carroll, William W.; Soler, Zachary M.; Pasquini, Whitney N.; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Mulligan, JK (reprint author), 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM konopa@musc.edu FU Flight Attendant Medical Research Institute [113039, 092401]; Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award [CSRD 1I01CX000377-01A2] FX Funding sources for the study: Flight Attendant Medical Research Institute (113039 to R.J.S., 092401 to J.K.M.); Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award (CSRD 1I01CX000377-01A2 to R.J.S.). NR 51 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD JAN PY 2016 VL 6 IS 1 BP 58 EP 65 DI 10.1002/alr.21576 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA DA7TU UT WOS:000368007900009 PM 26575398 ER PT J AU Lee, LY Harberg, C Matkowskyj, KA Cook, S Roenneburg, D Werner, S Johnson, J Foley, DP AF Lee, Lung-Yi Harberg, Calvin Matkowskyj, Kristina A. Cook, Shelly Roenneburg, Drew Werner, Sabine Johnson, Jeffrey Foley, David P. TI Overactivation of the Nuclear Factor (Erythroid-Derived 2)-Like 2-Antioxidant Response Element Pathway in Hepatocytes Decreases Hepatic Ischemia/Reperfusion Injury in Mice SO LIVER TRANSPLANTATION LA English DT Article ID ISCHEMIA-REPERFUSION INJURY; LIVER ISCHEMIA; REACTIVE OXYGEN; RISK-FACTORS; APOPTOSIS; NRF2; ACTIVATION; PROTECTS; NECROSIS; RATS AB Hepatic ischemia/reperfusion injury (IRI) is a critical component of hepatic surgery. Oxidative stress has long been implicated as a key player in IRI. In this study, we examine the cell-specific role of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-antioxidant response element pathway in warm hepatic IRI. Nrf2 knockout (KO) and wild-type (WT) animals and novel transgenic mice expressing a constitutively active nuclear factor (erythroid-derived 2)-like 2 (caNrf2) mutant in hepatocytes (AlbCre+/caNrf2+) and their littermate controls underwent partial hepatic ischemia or sham surgery. The animals were killed 6 hours after reperfusion, and their serum and tissue were collected for analysis. As compared to WT animals after ischemia/reperfusion (IR), Nrf2 KO mice had increased hepatocellular injury with increased serum alanine aminotransferase and aspartate aminotransferase, Suzuki score, apoptosis, an increased inflammatory infiltrate, and enhanced inflammatory cytokine expression. On the other hand, AlbCre+/caNrf2+ that underwent IR had significantly reduced serum transaminases, less necrosis on histology, and a less pronounced inflammatory infiltrate and inflammatory cytokine expression as compared to the littermate controls. However, there were no differences in apoptosis. Taken together, Nrf2 plays a critical role in our murine model of warm hepatic IRI, with Nrf2 deficiency exacerbating hepatic IRI and hepatocyte-specific Nrf2 overactivation providing protection against warm hepatic IRI. (C) 2015 AASLD. C1 [Lee, Lung-Yi; Harberg, Calvin; Roenneburg, Drew; Foley, David P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Matkowskyj, Kristina A.; Cook, Shelly] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA. [Johnson, Jeffrey] Univ Wisconsin, Div Pharmaceut Sci, Madison, WI 53792 USA. [Johnson, Jeffrey] Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53792 USA. [Johnson, Jeffrey] Univ Wisconsin, Ctr Neurosci, Madison, WI 53792 USA. [Johnson, Jeffrey] Univ Wisconsin, Waisman Ctr, Madison, WI 53792 USA. [Matkowskyj, Kristina A.] US Dept Vet Affairs, William S Middleton Mem Hosp, Pathol Serv, Madison, WI USA. [Foley, David P.] US Dept Vet Affairs, William S Middleton Mem Hosp, Surg Serv, Madison, WI USA. [Werner, Sabine] Swiss Fed Inst Technol, Inst Mol Hlth Sci, Dept Biol, Zurich, Switzerland. RP Foley, DP (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, 600 Highland Ave,Clin Sci Ctr H4-766, Madison, WI 53792 USA. EM foley@surgery.wisc.edu FU Clinical and Translational Science Award program through the National Institutes of Health Center for Advancing Translational Sciences [UL1TR000427]; American Society of Transplant Surgeons-Pfizer Mid-Level Faculty Award; National Institutes of Health [T32 CA0900217]; Swiss National Science Foundation [310030_132884] FX The project was supported by the Clinical and Translational Science Award program through the National Institutes of Health Center for Advancing Translational Sciences (UL1TR000427) for David P. Foley. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The project was also supported by the American Society of Transplant Surgeons-Pfizer Mid-Level Faculty Award for David P. Foley, National Institutes of Health (T32 CA0900217) for Lung-Yi Lee, and the Swiss National Science Foundation (310030_132884) for Sabine Werner. NR 33 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD JAN PY 2016 VL 22 IS 1 BP 91 EP 102 DI 10.1002/lt.24303 PG 12 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA DA9PA UT WOS:000368140500011 PM 26285140 ER PT J AU Williams, GR Bethard, JR Berkaw, MN Nagel, AK Luttrell, LM Ball, LE AF Williams, Grace R. Bethard, Jennifer R. Berkaw, Mary N. Nagel, Alexis K. Luttrell, Louis M. Ball, Lauren E. TI Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics SO METHODS LA English DT Article DE G protein-coupled receptor; Mass spectrometry; Parathyroid hormone receptor; Phosphoproteomics; Osteoblast ID REVERSED-PHASE CHROMATOGRAPHY; IN-VIVO; QUANTITATIVE PROTEOMICS; MASS-SPECTROMETRY; POSTTRANSLATIONAL MODIFICATIONS; PHOSPHORYLATION NETWORKS; FRACTION CONCATENATION; FUNCTIONAL SELECTIVITY; SITE LOCALIZATION; MC3T3-E1 CELLS AB The type 1 parathyroid hormone receptor (PTH1R) is a key regulator of calcium homeostasis and bone turnover. Here, we employed SILAC-based quantitative mass spectrometry and bioinformatic pathways analysis to examine global changes in protein phosphorylation following short-term stimulation of endogenously expressed PTH1R in osteoblastic cells in vitro. Following 5 min exposure to the conventional agonist, PTH(1-34), we detected significant changes in the phosphorylation of 224 distinct proteins. Kinase substrate motif enrichment demonstrated that consensus motifs for PKA and CAMK2 were the most heavily upregulated within the phosphoproteome, while consensus motifs for mitogen-activated protein kinases were strongly downregulated. Signaling pathways analysis identified ERK1/2 and ART as important nodal kinases in the downstream network and revealed strong regulation of small GTPases involved in cytoskeletal rearrangement, cell motility, and focal adhesion complex signaling. Our data illustrate the utility of quantitative mass spectrometry in measuring dynamic changes in protein phosphorylation following GPCR activation. (C) 2015 Elsevier Inc. All rights reserved. C1 [Williams, Grace R.; Bethard, Jennifer R.; Berkaw, Mary N.; Nagel, Alexis K.; Ball, Lauren E.] Med Univ S Carolina, Dept Mol & Cellular Pharmacol, Charleston, SC 29425 USA. [Nagel, Alexis K.; Ball, Lauren E.] Med Univ S Carolina, Dept Oral Hlth Sci, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Ball, LE (reprint author), Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave,BSB 358,MSC 509, Charleston, SC 29425 USA. EM ballle@musc.edu OI Ball, Lauren/0000-0001-6780-1679 FU University Research Resource Facility [P20 GM103542]; [R01 DE020925]; [S10 D010731]; [R01 DK055524]; [R01 GM095497] FX The authors thank Susana Comte-Walters, Michael Schilling and Benjamin Neely for assistance. Mass spectrometry was performed in the MUSC Mass Spectrometry Facility, a University Research Resource Facility funded through the Office of the Provost and the SC COBRE in Oxidants, Redox Balance and Signaling (P20 GM103542). This work was supported by grants R01 DE020925 (LEB), S10 D010731 (LEB), R01 DK055524 (LML) and R01 GM095497 (LML). NR 94 TC 1 Z9 1 U1 4 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-2023 EI 1095-9130 J9 METHODS JI Methods PD JAN 1 PY 2016 VL 92 BP 36 EP 50 DI 10.1016/j.ymeth.2015.06.022 PG 15 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DB0QL UT WOS:000368212500005 PM 26160508 ER PT J AU Bilousova, T Miller, CA Poon, WW Vinters, HV Corrada, M Kawas, C Hayden, EY Tepow, DB Glabe, C Albay, R Cole, GM Teng, E Gylys, KH AF Bilousova, Tina Miller, Carol. A. Poon, Wayne W. Vinters, Harry V. Corrada, Maria Kawas, Claudia Hayden, Eric Y. Tepow, David B. Glabe, Charles Albay, Ricardo, III Cole, Gregory M. Teng, Edmond Gylys, Karen H. TI Synaptic Amyloid-beta Oligomers Precede p-Tau and Differentiate High Pathology Control Cases SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID ENDOSOMAL-LYSOSOMAL SYSTEM; ALZHEIMERS-DISEASE CORTEX; INTRANEURONAL A-BETA; TRANSGENIC RAT MODEL; IN-VIVO; MOUSE MODEL; NEUROFIBRILLARY TANGLES; COGNITIVE IMPAIRMENT; SOLUBLE OLIGOMERS; SENILE PLAQUES AB Amyloid-beta (A beta) and hyperphosphorylated tau (p-tau) aggregates form the two discrete pathologies of Alzheimer disease (AD), and oligomeric assemblies of each protein are localized to synapses. To determine the sequence by which pathology appears in synapses, A beta and p-tau were quantified across AD disease stages in parietal cortex. Nondemented cases with high Levels of AD-related pathology were included to determine factors that confer protection from clinical symptoms. Flow cytometric analysis of synaptosome preparations was used to quantify A beta and p-tau in Large populations of individual synaptic terminals. Soluble A beta oligomers were assayed by a single antibody sandwich enzyme-Linked immunosorbent assay. Total in situ A beta was elevated in patients with early- and late-stage AD dementia, but not in high pathology nondemented controls compared with age-matched normal controls. However, soluble A beta oligomers were highest in early AD synapses, and this assay distinguished early AD cases from high pathology controls. Overall, synapse-associated p-tau did not increase until Late-stage disease in human and transgenic rat cortex, and p-tau was elevated in individual A beta-positive synaptosomes in early AD. These results suggest that soluble oligomers in surviving neocortical synaptic terminals are associated with dementia onset and suggest an amyloid cascade hypothesis in which oligomeric All drives phosphorylated tau accumulation and synaptic spread. These results indicate that antiamyloid therapies will be less effective once p-tau pathology is developed. C1 [Bilousova, Tina; Gylys, Karen H.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Bilousova, Tina; Hayden, Eric Y.; Tepow, David B.; Cole, Gregory M.; Teng, Edmond; Gylys, Karen H.] Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Res, Los Angeles, CA USA. [Vinters, Harry V.; Hayden, Eric Y.; Tepow, David B.; Cole, Gregory M.; Teng, Edmond] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. [Vinters, Harry V.] Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA. [Cole, Gregory M.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Miller, Carol. A.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. [Miller, Carol. A.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. [Miller, Carol. A.] Univ So Calif, Keck Sch Med, Program Neurosci, Los Angeles, CA 90033 USA. [Poon, Wayne W.; Corrada, Maria; Kawas, Claudia] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA USA. [Corrada, Maria; Kawas, Claudia] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA. [Kawas, Claudia] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92717 USA. [Glabe, Charles; Albay, Ricardo, III] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA. [Cole, Gregory M.; Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Gylys, KH (reprint author), Box 956919,Factor Bldg, Los Angeles, CA 90095 USA. EM kgylys@sonnet.ucla.edu FU NIH [AG27465, NS038328, AG041295, CA16042, AI 28697]; National Institute on Aging (NIA) [AG18879, AG34628]; NIA [R01AG21055]; American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers; University of California Los Angeles Clinical and Translational Science Institute (UCLA CTSI) grant [UL1TR000124]; UCLA Older Americans Independence Center grant [P30 AG028748]; Daljit S. and Elaine Sarkaria Chair in Diagnostic Medicine; AD Research Center Neuropathology Cores NIA grants [P50 AG05142, P50 AG16970, P50 AG16573] FX Supported by NIH grants AG27465 (K.H.G.), NS038328 (D.B.T.), and AG041295 (D.B.T.); National Institute on Aging (NIA) grants AG18879 (C.A.M.) and AG34628 (jointly sponsored by the NIA, American Federation for Aging Research, the John A. Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation, and an anonymous donor; to E.T.); the Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers (D.B.T.); University of California Los Angeles Clinical and Translational Science Institute (UCLA CTSI) grant UL1TR000124 (U.Y.H.); UCLA Older Americans Independence Center grant P30 AG028748 (E.Y.H.); and the Daljit S. and Elaine Sarkaria Chair in Diagnostic Medicine (H.V.V.). Tissue was obtained from the AD Research Center Neuropathology Cores NIA grants P50 AG05142 (USC), P50 AG16970 (UCLA), and P50 AG16573 (UC Irvine). Flow cytometry was performed in the UCLA Jonsson Comprehensive Cancer Center (JCCC) and Center for AIDS Research Flow Cytometry Core Facility, supported by NIH grants CA16042 and AI 28697 and by the JCCC, the UCLA AIDS Institute, the David Geffen School of Medicine, and the Chancellor's Office at UCLA. Diagnosis, characterization, and follow-up of >90 study subjects was supported by NIA grant R01AG21055. NR 88 TC 10 Z9 10 U1 5 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD JAN PY 2016 VL 186 IS 1 BP 185 EP 198 DI 10.1016/j.ajpath.2015.09.018 PG 14 WC Pathology SC Pathology GA DA3NV UT WOS:000367705300018 PM 26718979 ER PT J AU Brady, KT McCauley, JL Back, SE AF Brady, Kathleen T. McCauley, Jenna L. Back, Sudie E. TI Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; BUPRENORPHINE-NALOXONE TREATMENT; DRUG-ABUSE; MAINTENANCE TREATMENT; ADDICTION TREATMENT; SCREENING-TEST; USE DISORDERS; CHRONIC PAIN; RISK TOOL; OVERDOSE AB Objective: Prescription opioid abuse and dependence have escalated rapidly in the United States over the past 20 years, leading to high rates of overdose deaths and a dramatic increase in the number of people seeking treatment for opioid dependence. The authors review the scope of the abuse and overdose epidemic, prescription practices, and the assessment, treatment, and prevention of prescription opioid misuse and dependence. Method: The authors provide an overview of the literature from 2006 to the present, with the twin goals of highlighting advances in prevention and treatment and identifying remaining gaps in the science. Results: A number of policy and educational initiatives at the state and federal government level have been undertaken in the past 5 years to help providers and consumers, respectively, prescribe and use opioids more responsibly. Initial reports suggest that diversion and abuse levels have begun to plateau, likely as a result of these initiatives. While there is a large body of research suggesting that opioid substitution coupled with psychosocial interventions is the best treatment option for heroin dependence, there is limited research focusing specifically on the treatment of prescription opioid dependence. In particular, the treatment of chronic pain in individuals with prescription opioid use disorders is underexplored. Conclusions: While policy and educational initiatives appear to be effective in decreasing prescription opioid abuse and misuse, research focusing on the development and evaluation of treatments specific to prescription opioid dependence and its common comorbidities (e.g., chronic pain, depression) is critically needed. C1 [Brady, Kathleen T.] Med Univ S Carolina, Addict Sci Div, Inst Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Brady, KT (reprint author), Med Univ S Carolina, Addict Sci Div, Inst Psychiat & Behav Sci, Charleston, SC 29425 USA. EM bradyk@musc.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [2 P50 DA016511]; NIDA [5 U10 DA013727, 1 K23 DA036566] FX Supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 2 P50 DA016511 and NIDA grants 5 U10 DA013727 and 1 K23 DA036566. NR 59 TC 14 Z9 14 U1 14 U2 52 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD JAN PY 2016 VL 173 IS 1 BP 18 EP 26 DI 10.1176/appi.ajp.2015.15020262 PG 9 WC Psychiatry SC Psychiatry GA DA2QK UT WOS:000367640700008 PM 26337039 ER PT J AU England, BR Sayles, H Michaud, K Caplan, L Davis, LA Cannon, GW Sauer, BC Solow, EB Reimold, AM Kerr, GS Schwab, P Baker, JF Mikuls, TR AF England, Bryant R. Sayles, Harlan Michaud, Kaleb Caplan, Liron Davis, Lisa A. Cannon, Grant W. Sauer, Brian C. Solow, Elizabeth B. Reimold, Andreas M. Kerr, Gail S. Schwab, Pascale Baker, Josh F. Mikuls, Ted R. TI Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID DISEASE-ACTIVITY; INFLAMMATORY POLYARTHRITIS; CARDIOVASCULAR-DISEASE; LUNG-DISEASE; POPULATION; ASSOCIATION; CANCER; COHORT; INDEX; METHOTREXATE AB Objective. There has been limited investigation into cause-specific mortality and the associated risk factors in men with rheumatoid arthritis (RA). We investigated all-cause and cause-specific mortality in men with RA, examining determinants of survival. Methods. Men from a longitudinal RA registry were followed from enrollment until death or through 2013. Vital status and cause of death were determined using the National Death Index. Crude mortality rates and standardized mortality ratios (SMRs) were calculated for all-cause, cardiovascular disease (CVD), cancer, and respiratory mortality. Associations with all-cause and cause-specific mortality were examined using multivariable Cox proportional hazards and competing-risks regression. Results. There were 1,652 men with RA and 332 deaths. The leading causes of death were CVD (31.6%; SMR 1.77 [95% confidence interval (95% CI) 1.46-2.14]), cancer (22.9%; SMR 1.50 [95% CI 1.20-1.89]), and respiratory disease (15.1%; SMR 2.90 [95% CI 2.20-3.83]). Factors associated with all-cause mortality included older age, white race, smoking, low body weight, comorbidity, disease activity, and prednisone use. Rheumatoid factor concentration and nodules were associated with CVD mortality. There were no associations of methotrexate or biologic agent use with all-cause or cause-specific mortality. Conclusion. Men in this RA cohort experienced increased all-cause and cause-specific mortality, with a 3-fold risk of respiratory-related deaths compared to age-matched men in the general population. Further studies are needed in order to examine whether interventions targeting potentially modifiable correlates of mortality might lead to improved long-term survival in men with RA. C1 [England, Bryant R.; Sayles, Harlan; Mikuls, Ted R.] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [England, Bryant R.; Sayles, Harlan; Mikuls, Ted R.] Univ Nebraska, Med Ctr, Omaha, NE USA. [Michaud, Kaleb] Univ Nebraska, Med Ctr, Vet Affairs Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Caplan, Liron; Davis, Lisa A.] Denver VAMC, Denver, CO USA. [Caplan, Liron; Davis, Lisa A.] Univ Colorado, Denver, CO 80202 USA. [Davis, Lisa A.] Denver Hlth Med Ctr, Denver, CO USA. [Cannon, Grant W.; Sauer, Brian C.] Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Cannon, Grant W.; Sauer, Brian C.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Solow, Elizabeth B.; Reimold, Andreas M.] Dallas Vet Affairs, Dallas, TX USA. [Solow, Elizabeth B.; Reimold, Andreas M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Kerr, Gail S.] Vet Affairs Med Ctr & Georgetown, Washington, DC USA. [Kerr, Gail S.] Howard Univ, Washington, DC 20059 USA. [Schwab, Pascale] Portland Vet Affairs Hlth Care Syst, Portland, OR USA. [Schwab, Pascale] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Baker, Josh F.] Philadelphia VAMC, Philadelphia, PA USA. [Baker, Josh F.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Mikuls, TR (reprint author), 986270 Nebraska Med Ctr, Omaha, NE 68198 USA. EM tmikuls@unmc.edu OI England, Bryant R./0000-0002-9649-3588 FU Rheumatology Research Foundation Resident Research Preceptorship; Rheumatology Research Foundation Investigator Award; Rheumatology Research Foundation Scientific Development Award; Veterans Affairs Merit Award FX Dr. England's work was supported by a Rheumatology Research Foundation Resident Research Preceptorship. Dr. Michaud's work was supported by a Rheumatology Research Foundation Investigator Award. Dr. Davis' work was supported by a Rheumatology Research Foundation Scientific Development Award. Dr. Mikuls' work was supported by a Veterans Affairs Merit Award. NR 39 TC 8 Z9 8 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JAN PY 2016 VL 68 IS 1 BP 36 EP 45 DI 10.1002/acr.2264 PG 10 WC Rheumatology SC Rheumatology GA DA3FQ UT WOS:000367682800003 PM 26097231 ER PT J AU Cheng, A Owens, D AF Cheng, Andrew Owens, David TI Marfan syndrome, inherited aortopathies and exercise: What is the right answer? SO BRITISH JOURNAL OF SPORTS MEDICINE LA English DT Article ID ARTERIAL BLOOD-PRESSURE; SUDDEN CARDIAC DEATH; AORTIC DISSECTION; CARDIOVASCULAR-DISEASE; HEMODYNAMIC-RESPONSE; SPORTS PARTICIPATION; RESISTANCE EXERCISE; PHYSICAL-ACTIVITY; RECOMMENDATIONS; MANAGEMENT AB Exercise recommendations for those who have Marfan syndrome or other genetic predisposition for thoracic aortic disease remain controversial and at times ambiguous. There are no outcomes studies to help guide recommendations. In this review, we examine the guidelines regarding exercise and inherited aortic conditions, the theoretical reasoning and circumstantial evidence that support the guidelines, as well as the knowledge gaps that continue to exist. C1 [Cheng, Andrew] VA Puget Sound, Dept Cardiol, Seattle, WA 98108 USA. [Cheng, Andrew; Owens, David] Univ Washington, Dept Cardiol, Seattle, WA 98195 USA. RP Cheng, A (reprint author), VA Puget Sound, Dept Cardiol, 1660 South Columbian Way, Seattle, WA 98108 USA. EM ACheng@cardiology.washington.edu OI Owens, David/0000-0002-7293-9688 NR 38 TC 0 Z9 0 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-3674 EI 1473-0480 J9 BRIT J SPORT MED JI Br. J. Sports Med. PD JAN PY 2016 VL 50 IS 2 BP 100 EP + DI 10.1136/bjsports-2014-306440rep PG 6 WC Sport Sciences SC Sport Sciences GA DA2FB UT WOS:000367609600009 PM 26729892 ER PT J AU Liang, KV Sileanu, FE Clermont, G Murugan, R Pike, F Palevsky, PM Kellum, JA AF Liang, Kelly V. Sileanu, Florentina E. Clermont, Gilles Murugan, Raghavan Pike, Francis Palevsky, Paul M. Kellum, John A. TI Modality of RRT and Recovery of Kidney Function after AKI in Patients Surviving to Hospital Discharge SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID RENAL REPLACEMENT THERAPY; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMODIAFILTRATION; INTENSIVE-CARE-UNIT; RANDOMIZED CLINICAL-TRIAL; INTERMITTENT HEMODIALYSIS; RETROSPECTIVE COHORT; MULTIPLE-ORGAN; FAILURE; INJURY AB Background and objectives Observational evidence has suggested that RRT modality may affect recovery after AKI. It is unclear whether initial choice of intermittent hemodialysis or continuous RRT affects renal recovery, survival, or development of ESRD in critically ill patients when modality choice is made primarily on hemodynamics. Design, setting, participants, & measurements We performed a retrospective cohort study examining adults (>= 18 years old) admitted to intensive care units from 2000 to 2008 who received RRT for AKI and survived to hospital discharge or 90 days. We analyzed renal recovery (alive and not requiring RRT) and reasons for non-recovery (death or ESRD) at 90 and 365 days. Conditional multivariable logistic regression was used to assess differences in renal recovery at 90 and 365 days between continuous RRT and intermittent hemodialysis. Models were stratified by propensity for continuous RRT and adjusted for age and reference creatinine. Results Of 4738 patients with Kidney Disease Improving Global Outcomes stage 3 AKI, 1338 (28.2%) received RRT, and 638 (47.7%) survived to hospital discharge (353 intermittent hemodialysis and 285 continuous RRT). Recovery from AKI was lower for intermittent hemodialysis versus continuous RRT at 90 days (66.6% intermittent hemodialysis versus 75.4% continuous RRT; P=0.02) but similar at 365 days (54.1% intermittent hemodialysis versus 59.6% continuous RRT; P=0.17). In multivariable analysis, there was no difference in odds of recovery at 90 or 365 days for patients initially treated with continuous RRT versus intermittent hemodialysis (90 days: odds ratio, 1.19; 95% confidence interval, 0.91 to 1.55; P=0.20; 365 days: odds ratio, 0.93; 95% confidence interval, 0.72 to 1.2; P=0.55). Conclusions We found no significant difference in hazards for nonrecovery or reasons for nonrecovery (mortality or ESRD) with intermittent hemodialysis versus continuous RRT. These results suggest that, when initial RRT modality is chosen primarily on hemodynamics, renal recovery and clinical outcomes in survivors are similar between intermittent hemodialysis and continuous RRT. C1 [Liang, Kelly V.; Palevsky, Paul M.; Kellum, John A.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Sileanu, Florentina E.; Murugan, Raghavan; Pike, Francis; Palevsky, Paul M.; Kellum, John A.] Univ Pittsburgh, Sch Med, Ctr Crit Care Nephol, Dept Crit Care Med, Pittsburgh, PA USA. [Sileanu, Florentina E.; Murugan, Raghavan; Pike, Francis; Palevsky, Paul M.; Kellum, John A.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Sileanu, Florentina E.; Clermont, Gilles; Murugan, Raghavan; Pike, Francis; Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness Ctr, Pittsburgh, PA USA. [Sileanu, Florentina E.; Pike, Francis] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Kellum, JA (reprint author), Ctr Crit Care Nephrol, Dept Crit Care Med, 604 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM kellumja@ccm.upmc.edu FU Gambro/Baxter, Waukegan, IL FX This work was supported by Gambro/Baxter, Waukegan, IL. NR 50 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2016 VL 11 IS 1 BP 30 EP 38 DI 10.2215/CJN.01290215 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA DA4JM UT WOS:000367766200008 PM 26681135 ER PT J AU Hoffman, W Lakkis, FG Chalasani, G AF Hoffman, William Lakkis, Fadi G. Chalasani, Geetha TI B Cells, Antibodies, and More SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; RENAL-ALLOGRAFT REJECTION; GERMINAL CENTER B; IDIOPATHIC MEMBRANOUS NEPHROPATHY; MIXED CRYOGLOBULINEMIA VASCULITIS; DEPLETING INDUCTION THERAPY; RANDOMIZED CONTROLLED-TRIAL; INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH RECOMBINATION; ANCA-ASSOCIATED VASCULITIS AB B cells play a central role in the immunopathogenesis of glomerulonephritides and transplant rejection. B cells secrete antibodies that contribute to tissue injury via multiple mechanisms. In addition, B cells contribute to disease pathogenesis in autoimmunity and alloimmunity by presenting antigens as well as providing costimulation and cytokines to T cells. B cells also play an immunomodulatory role in regulating the immune response by secreting cytokines that inhibit disease onset and/or progression. B cell-targeted approaches for treating immune diseases of the kidney and other organs have gained significant momentum. However, much remains to be understood about B-cell biology in order to determine the timing, duration, and context of optimal therapeutic response to B cell-targeted approaches. In this review, we discuss the multifaceted roles of B cells as enhancers and regulators of immunity with relevance to kidney disease and transplantation. C1 [Hoffman, William; Lakkis, Fadi G.; Chalasani, Geetha] Univ Pittsburgh, Sch Med, Dept Med Renal Electrolyte, Pittsburgh, PA 15261 USA. [Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA. [Lakkis, Fadi G.; Chalasani, Geetha] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15261 USA. [Lakkis, Fadi G.; Chalasani, Geetha] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15261 USA. [Chalasani, Geetha] Vet Affairs Pittsburgh Hlth Care Syst, Renal Sect, Pittsburgh, PA 15261 USA. RP Chalasani, G (reprint author), Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Hlth Care Syst, Thomas E Starzl Transplantat Inst, 200 Lothrop St,W1554 Biomed Sci Tower, Pittsburgh, PA 15261 USA. EM gec12@pitt.edu FU National Institutes of Health [R01 AI079177] FX This work was supported by funds from National Institutes of Health grant R01 AI079177 (G.C.). NR 192 TC 7 Z9 7 U1 0 U2 8 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2016 VL 11 IS 1 BP 137 EP 154 DI 10.2215/CJN.09430915 PG 18 WC Urology & Nephrology SC Urology & Nephrology GA DA4JM UT WOS:000367766200020 PM 26700440 ER PT J AU Tsai, J Sippel, LM Mota, N Southwick, SM Pietrzak, RH AF Tsai, Jack Sippel, Lauren M. Mota, Natalie Southwick, Steven M. Pietrzak, Robert H. TI LONGITUDINAL COURSE OF POSTTRAUMATIC GROWTH AMONG US MILITARY VETERANS: RESULTS FROM THE NATIONAL HEALTH AND RESILIENCE IN VETERANS STUDY SO DEPRESSION AND ANXIETY LA English DT Article DE posttraumatic stress disorder; resilience; stress; spirituality; quality of life ID BREAST-CANCER; HAPPINESS; SYMPTOMS; ALTRUISM; STRESS; TRAUMA; WAR; BIBLIOTHERAPY; SATISFACTION; METAANALYSIS AB BackgroundPosttraumatic growth (PTG) is increasingly recognized as an important psychosocial phenomenon, but few studies have evaluated the longitudinal course of PTG. This study identified courses of PTG over a 2-year period in a contemporary, nationally representative sample of U.S. military veterans, and examined sociodemographic, military, trauma, medical, and psychosocial predictors of PTG course. Methods Data were based on a Web-based survey of a nationally representative sample of 1,838 U.S. veterans who reported at least one potentially traumatic event and provided data at two time points (October-December 2011 and September-October 2013). Results Five different courses of PTG were identifiedConsistently Low (33.6%), Moderately Declining (19.4%), Increasing PTG (16.8%), Dramatically Declining (15.7%), and Consistently High (14.5%). More than half (59.4%) of veterans who reported at least moderate PTG maintained that level of PTG 2 years later. Posttraumatic stress disorder symptoms, medical conditions, purpose in life, altruism, gratitude, religiosity, and an active reading lifestyle predicted maintenance or increase in PTG. Conclusions PTG has a heterogeneous course and is not only common, but can persist over time especially in the presence of posttraumatic stress and certain psychosocial factors. Clinicians and researchers should consider the personal growth that can result from trauma and help trauma survivors find ways to maintain this growth over time. C1 [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT 06516 USA. [Tsai, Jack; Sippel, Lauren M.; Mota, Natalie; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Sippel, Lauren M.; Mota, Natalie; Southwick, Steven M.; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT 06516 USA. RP Tsai, J (reprint author), US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, 950 Campbell Ave,151D, West Haven, CT 06516 USA. EM Jack.Tsai@yale.edu FU United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder; United States Department of Veterans Affairs, Office of Research and Development FX This work was supported in part by the United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, the United States Department of Veterans Affairs, Office of Research and Development, and a private donation. The views presented here are those of the authors alone and do not represent the position of any federal agency or of the United States Government. None of the authors report any conflicts of interest with this work. NR 47 TC 3 Z9 3 U1 7 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD JAN PY 2016 VL 33 IS 1 BP 9 EP 18 DI 10.1002/da.22371 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DA3TX UT WOS:000367722900001 PM 25914061 ER PT J AU Kaz, AM Dominitz, JA AF Kaz, Andrew M. Dominitz, Jason A. TI Can individuals with colonic polyposis be managed safely with colonoscopic surveillance? SO ENDOSCOPY LA English DT Article ID FAMILIAL ADENOMATOUS POLYPOSIS; APC C1 [Kaz, Andrew M.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA 98108 USA. [Kaz, Andrew M.; Dominitz, Jason A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Kaz, Andrew M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. RP Kaz, AM (reprint author), VA Puget Sound Hlth Care Syst, Gastroenterol Sect, 1660 S Columbian Way,S-111-Gastro, Seattle, WA 98108 USA. EM Andrew.Kaz@va.gov FU VA Puget Sound Health Care System FX This material is the result of work supported in part by resources from the VA Puget Sound Health Care System. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 12 TC 0 Z9 0 U1 0 U2 1 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PD JAN PY 2016 VL 48 IS 1 BP 7 EP 8 DI 10.1055/s-0034-1393637 PG 2 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA CZ9YU UT WOS:000367454600003 PM 26710280 ER PT J AU Saigusa, T Dang, YJ Mullick, AE Yeh, ST Zile, MR Baicu, CF Bell, PD AF Saigusa, Takamitsu Dang, Yujing Mullick, Adam E. Yeh, Steve T. Zile, Michael R. Baicu, Catalin F. Bell, P. Darwin TI Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model SO FASEB JOURNAL LA English DT Article DE renin angiotensin system; antisense oligonucleotide; polycystic kidney disease; hypertension ID BLOOD-PRESSURE; ANTISENSE OLIGODEOXYNUCLEOTIDES; IN-VIVO; DISEASE; RENIN; SYSTEM; INHIBITOR; CELL; HYPERTENSION; RATS AB Activation of the intrarenal renin angiotensin system(RAS) is believed to play an important role in the development of hypertension and cystogenesis in autosomal dominant polycystic kidney disease (ADPKD). Results of clinical studies testing RAS inhibitors in slowing the progression of cystic disease in ADPKD are inconclusive, and we hypothesized that current RAS inhibitors do not adequately suppress intrarenal RAS. For this study, we compared a novel Gen 2 antisense oligonucleotide (ASO) that inhibits angiotensinogen (Agt) synthesis to lisinopril in adult conditional Pkd1 systemic-knockout mice, a model of ADPKD. Six weeks after Pkd1 global gene knockout, the mice were treated with Agt-ASO (66 mg/kg/wk), lisinopril (100 mg/kg/d), PBS (control), or scrambled ASO (66 mg/kg/wk) for 10 wk, followed by tissue collection. Agt ASO resulted in significant reduction in plasma, liver, and kidney Agt, and increased kidney renin compared with control treatments. Kidneys from Agt-ASO-treated mice were not as enlarged and showed reduced cystic volume compared with lisinopril or control treatments. Blood pressure was better controlled with lisinopril than with Agt-ASO. Agt-ASO suppressed cell proliferation in both cystic and noncystic cells compared with lisinopril and control treatments. However, Agt-ASO did not reduce cell proliferation in liver, which indicates that Agt-ASO targets cell signaling pathways that specifically suppresses cystogenesis in the kidney. These data suggest that Agt-ASO effectively attenuates intrarenal RAS and therefore can be a novel and effective agent for treating ADPKD. C1 [Saigusa, Takamitsu; Dang, Yujing; Bell, P. Darwin] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. [Zile, Michael R.; Baicu, Catalin F.] Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA. [Saigusa, Takamitsu; Dang, Yujing; Zile, Michael R.; Baicu, Catalin F.; Bell, P. Darwin] Ralph Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Mullick, Adam E.; Yeh, Steve T.] ISIS Pharmaceut, Carlsbad, CA 92008 USA. RP Saigusa, T (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,CSB 829, Charleston, SC 29425 USA. EM saigusa@musc.edu; bellpd@musc.edu OI Mullick, Adam/0000-0003-4600-961X FU U.S. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [K08DK106465, P30 DK074038]; U.S. Department of Veterans Affairs Merit Award; Dialysis Clinic, Inc. (Nashville, TN, USA) FX This work was supported by U.S. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Grants K08DK106465 (to T.S.) and P30 DK074038 (to P.D.B.); U.S. Department of Veterans Affairs Merit Award (to P.D.B.); and a Dialysis Clinic, Inc. (Nashville, TN, USA) grant (to T.S. and P.D.B.). The authors declare no conflicts of interest. NR 42 TC 4 Z9 4 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD JAN PY 2016 VL 30 IS 1 BP 370 EP 379 DI 10.1096/fj.15-279299 PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA DA2JL UT WOS:000367621000035 PM 26391272 ER PT J AU Good, CB Gellad, WF AF Good, Chester B. Gellad, Walid F. TI Off-label Drug Use and Adverse Drug Events Turning up the Heat on Off-label Prescribing SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Good, Chester B.] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. [Good, Chester B.; Gellad, Walid F.] Univ Pittsburgh, Dept Med, Div Gen Med, Pittsburgh, PA USA. [Good, Chester B.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Good, Chester B.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. RP Good, CB (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Room 2A135,Univ Dr C, Pittsburgh, PA 15240 USA. EM chester.good@va.gov NR 9 TC 2 Z9 2 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2016 VL 176 IS 1 BP 63 EP 64 DI 10.1001/jamainternmed.2015.6068 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DA1II UT WOS:000367549100016 PM 26524668 ER PT J AU Ishida, JH Johansen, KL AF Ishida, Julie H. Johansen, Kirsten L. TI Exclusion of Patients With Kidney Disease From Cardiovascular Trials SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Ishida, Julie H.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94121 USA. [Ishida, Julie H.; Johansen, Kirsten L.] San Francisco VA Med Ctr, Dept Med, Div Nephrol, San Francisco, CA USA. RP Johansen, KL (reprint author), Univ Calif San Francisco, Dept Med, Div Nephrol, 4150 Clement St,Box 111J, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU NIDDK NIH HHS [K23DK103963, K24DK085153, K23 DK103963, K24 DK085153] NR 6 TC 2 Z9 2 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2016 VL 176 IS 1 BP 124 EP 125 DI 10.1001/jamainternmed.2015.6403 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DA1II UT WOS:000367549100034 PM 26618994 ER PT J AU Hoang, TD Reis, J Zhu, N Jacobs, DR Launer, LJ Whitmer, RA Sidney, S Yaffe, K AF Hoang, Tina D. Reis, Jared Zhu, Na Jacobs, David R., Jr. Launer, Lenore J. Whitmer, Rachel A. Sidney, Stephen Yaffe, Kristine TI Effect of Early Adult Patterns of Physical Activity and Television Viewing on Midlife Cognitive Function SO JAMA PSYCHIATRY LA English DT Article ID YOUNG-ADULTS; SEDENTARY BEHAVIOR; ALZHEIMERS-DISEASE; OLDER-ADULTS; EXECUTIVE FUNCTION; RISK DEVELOPMENT; TEMPORAL TRENDS; LIFE-COURSE; MIDDLE-AGE; TIME USE AB IMPORTANCE Sedentary behaviors and physical inactivity are not only increasing worldwide but also are critical risk factors for adverse health outcomes. Yet, few studies have examined the effects of sedentary behavior on cognition or the long-term role of either behavior in early to middle adulthood. OBJECTIVE To investigate the association between 25-year patterns of television viewing and physical activity and midlife cognition. DESIGN, SETTING, AND PARTICIPANTS Prospective study of 3247 adults (black and white races; aged 18-30 years) enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) Study (March 25, 1985, to August 31, 2011). Data analysis was performed June 1, 2014, through April 15, 2015. MAIN OUTCOMES AND MEASURES We assessed television viewing and physical activity at repeated visits (>= 3 assessments) over 25 years using a validated questionnaire. A 25-year pattern of high television viewing was defined as watching TV above the upper baseline quartile (>3 hours/d) for more than two-thirds of the visits, and a 25-year pattern of low physical activity was defined as activity levels below the lower, sex-specific baseline quartile for more than two-thirds of the of the visits. We evaluated cognitive function at year 25 using the Digit Symbol Substitution Test (DSST), Stroop test, and Rey Auditory Verbal Learning Test. RESULTS At baseline, the mean (SD) age of the 3247 study participants was 25.1 (3.6) years, 1836 (56.5%) were female, 1771 (54.5%) were white, and 3015 (92.9%) had completed at least high school. Compared with participants with low television viewing, those with high television viewing during 25 years (353 of 3247 [10.9%]) were more likely to have poor cognitive performance (<1 SD below the race-specific mean) on the DSST and Stroop test, with findings reported as adjusted odds ratio (95% CI): DSST, 1.64 (1.21-2.23) and Stroop test, 1.56 (1.13-2.14), but not the Rey Auditory Verbal Learning Test, adjusted for age, race, sex, educational level, smoking, alcohol use, body mass index, and hypertension. Low physical activity during 25 years in 528 of 3247 participants (16.3%) was significantly associated with poor performance on the DSST, 1.47 (1.14-1.90). Compared with participants with low television viewing and high physical activity, the odds of poor performance were almost 2 times higher for adults with both high television viewing and low physical activity in 107 of 3247 (3.3%) (DSST, 1.95 [1.19-3.22], and Stroop test, 2.20 [1.36-3.56]). CONCLUSIONS AND RELEVANCE High television viewing and low physical activity in early adulthood were associated with worse midlife executive function and processing speed. This is one of the first studies to demonstrate that these risk behaviors may be critical targets for prevention of cognitive aging even before middle age. C1 [Hoang, Tina D.] Northern Calif Inst Res & Educ, San Francisco, CA 94121 USA. [Reis, Jared] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. [Zhu, Na; Jacobs, David R., Jr.] Univ Minnesota, Div Epidemiol, Sch Publ Hlth, Minneapolis, MN 55455 USA. [Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Whitmer, Rachel A.; Sidney, Stephen] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Hoang, TD (reprint author), Northern Calif Inst Res & Educ, Vet Affairs Med Ctr, 4150 Clement St,116-H, San Francisco, CA 94121 USA. EM tina.hoang@va.gov RI Dey, Kamalesh/E-6568-2017 FU National Heart, Lung, and Blood Institute (NHLBI); University of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern University [HHSN268201300027C]; University of Minnesota [HHSN268201300028C]; Kaiser Foundation Research Institute [HHSN268201300029C]; Johns Hopkins University School of Medicine [HHSN268200900041C]; Intramural Research Program of the National Institute on Aging (NIA); NIA [AG0005, K24 AG031155]; NHLBI [AG0005, HL122658] FX The Coronary Artery Risk Development in Young Adults (CARDIA) Study is conducted and supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201300025C and HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and the Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-agency agreement between the NIA and NHLBI (AG0005). The CARDIA Cognitive Function Ancillary Study is supported by grant HL122658 from the NHLBI. Dr Yaffe is also supported by grant K24 AG031155 from the NIA. NR 66 TC 2 Z9 2 U1 7 U2 15 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JAN PY 2016 VL 73 IS 1 BP 73 EP 79 DI 10.1001/jamapsychiatry.2015.2468 PG 7 WC Psychiatry SC Psychiatry GA DA5CP UT WOS:000367820000012 PM 26629780 ER PT J AU Schafer, AL AF Schafer, Anne L. TI Decline in Bone Mass During Weight Loss: A Cause for Concern? SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; OBESE OLDER-ADULTS; OVERWEIGHT POSTMENOPAUSAL WOMEN; LONG-DURATION SPACEFLIGHT; LIFE-STYLE INTERVENTION; MIDDLE-AGED NORWEGIANS; GASTRIC BYPASS-SURGERY; MINERAL DENSITY; HIP FRACTURE; CALORIC RESTRICTION C1 [Schafer, Anne L.] San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA 94158 USA. [Schafer, Anne L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Schafer, Anne L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Schafer, AL (reprint author), San Francisco VA Med Ctr, Endocrine Res Unit, 1700 Owens St,Room 367, San Francisco, CA 94158 USA. EM anne.schafer@ucsf.edu FU CSRD VA [IK2 CX000549] NR 56 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JAN PY 2016 VL 31 IS 1 BP 36 EP 39 DI 10.1002/jbmr.2754 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DA3JP UT WOS:000367693300003 PM 26595270 ER PT J AU Zou, CB Synan, MJ Li, J Xiong, S Manni, ML Liu, Y Chen, BB Zhao, YT Shiva, S Tyurina, YY Jiang, JF Lee, JS Das, S Ray, A Ray, P Kagan, VE Mallampalli, RK AF Zou, Chunbin Synan, Matthew J. Li, Jin Xiong, Sheng Manni, Michelle L. Liu, Yuan Chen, Bill B. Zhao, Yutong Shiva, Sruti Tyurina, Yulia Y. Jiang, Jianfei Lee, Janet S. Das, Sudipta Ray, Anuradha Ray, Prabir Kagan, Valerian E. Mallampalli, Rama K. TI LPS impairs oxygen utilization in epithelia by triggering degradation of the mitochondrial enzyme Alcat1 SO JOURNAL OF CELL SCIENCE LA English DT Article DE Degradation; Mitochondria; Ubiquitin ID PLURIPOTENT STEM-CELL; BARTH-SYNDROME; HISTONE DEACETYLASE; LYSOCARDIOLIPIN ACYLTRANSFERASE; CARDIOLIPIN DEFICIENCY; SUBSTRATE RECOGNITION; UBIQUITIN LIGASE; LIVER-MITOCHONDRIA; OXIDATIVE STRESS; LUNG INJURY AB Cardiolipin (also known as PDL6) is an indispensable lipid required for mitochondrial respiration that is generated through de novo synthesis and remodeling. Here, the cardiolipin remodeling enzyme, acyl-CoA:lysocardiolipin-acyltransferase-1 (Alcat1; SwissProt ID, Q6UWP7) is destabilized in epithelia by lipopolysaccharide (LPS) impairing mitochondrial function. Exposure to LPS selectively decreased levels of carbon 20 (C-20)-containing cardiolipin molecular species, whereas the content of C-18 or C-16 species was not significantly altered, consistent with decreased levels of Alcat1. Alcat1 is a labile protein that is lysosomally degraded by the ubiquitin E3 ligase Skp-Cullin-F-box containing the Fbxo28 subunit (SCF-Fbxo28) that targets Alcat1 for monoubiquitylation at residue K183. Interestingly, K183 is also an acetylation-acceptor site, and acetylation conferred stability to the enzyme. Histone deacetylase 2 (HDAC2) interacted with Alcat1, and expression of a plasmid encoding HDAC2 or treatment of cells with LPS deacetylated and destabilized Alcat1, whereas treatment of cells with a pan-HDAC inhibitor increased Alcat1 levels. Alcat1 degradation was partially abrogated in LPS-treated cells that had been silenced for HDAC2 or treated with MLN4924, an inhibitor of Cullin-RING E3 ubiquitin ligases. Thus, LPS increases HDAC2-mediated Alcat1 deacetylation and facilitates SCF-Fbxo28-mediated disposal of Alcat1, thus impairing mitochondrial integrity. C1 [Zou, Chunbin; Synan, Matthew J.; Li, Jin; Manni, Michelle L.; Liu, Yuan; Chen, Bill B.; Zhao, Yutong; Lee, Janet S.; Das, Sudipta; Ray, Anuradha; Ray, Prabir; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Xiong, Sheng] Jinan Univ, Inst Biomed, Coll Life Sci & Technol, Guangzhou 510630, Guangdong, Peoples R China. [Xiong, Sheng] Jinan Univ, Natl Engn Res Ctr Genet Med, Coll Life Sci & Technol, Guangzhou 510630, Guangdong, Peoples R China. [Shiva, Sruti; Kagan, Valerian E.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA. [Tyurina, Yulia Y.; Jiang, Jianfei; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol & Bioengn, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, 930 Scaife Hall, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; Merit Review Award from the US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01HL114453, ES020693, U19AIO68021, CA 165065, OH008282]; Human Frontier Science Program [HFSPRGP0013/2014, HL116472, HL01916, HL112791, HL125435, 12SDG12040330]; MOST of China [2012ZX09103-301-033, 2012ZX09202-301-001] FX This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs; National Institutes of Health [R01 grant numbers HL096376, HL097376, HL098174, HL081784, 1UH2HL123502 and P01HL114453 to R.K.M.; and ES020693, U19AIO68021, CA 165065, OH008282 (to V.E.K.)]; and Human Frontier Science Program [grant numbers HFSPRGP0013/2014 (to V.E.K.); HL116472 (to B.B.C.); HL01916 and HL112791 (to Y.Z.); and HL125435 and 12SDG12040330 (to C.Z.)]. S.X. was supported from the MOST of China [grant number 2012ZX09103-301-033 and 2012ZX09202-301-001]. The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government. Deposited in PMC for release after 12 months. NR 93 TC 3 Z9 3 U1 1 U2 11 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 EI 1477-9137 J9 J CELL SCI JI J. Cell Sci. PD JAN 1 PY 2016 VL 129 IS 1 BP 51 EP 64 DI 10.1242/jcs.176701 PG 14 WC Cell Biology SC Cell Biology GA DA1LI UT WOS:000367556900006 PM 26604221 ER PT J AU Haas, JS Sprague, BL Klabunde, CN Tosteson, ANA Chen, JS Bitton, A Beaber, EF Onega, T Kim, JJ MacLean, CD Harris, K Yamartino, P Howe, K Pearson, L Feldman, S Brawarsky, P Schapira, MM AF Haas, Jennifer S. Sprague, Brian L. Klabunde, Carrie N. Tosteson, Anna N. A. Chen, Jane S. Bitton, Asaf Beaber, Elisabeth F. Onega, Tracy Kim, Jane J. MacLean, Charles D. Harris, Kimberly Yamartino, Phillip Howe, Kathleen Pearson, Loretta Feldman, Sarah Brawarsky, Phyllis Schapira, Marilyn M. CA PROSPR Population-Based Res Optimi TI Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening Guidelines SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE breast cancer screening; cervical cancer screening; provider practice patterns; primary care; clinical practice guidelines ID PRIMARY-CARE-PHYSICIANS; SERVICES TASK-FORCE; UNITED-STATES; MAMMOGRAPHY; RECOMMENDATIONS; CONSISTENT; ADHERENCE; SOCIETY; MODEL AB Changes to national guidelines for breast and cervical cancer screening have created confusion and controversy for women and their primary care providers. To characterize women's primary health care provider attitudes towards screening and changes in practice in response to recent revisions in guidelines for breast and cervical cancer screening. In 2014, we distributed a confidential web and mail survey to 668 women's health care providers affiliated with the four clinical care networks participating in the three PROSPR (Population-based Research Optimizing Screening through Personalized Regimens) consortium breast cancer research centers (385 respondents; response rate 57.6 %). We assessed self-reported attitudes toward breast and cervical cancer screening, as well as practice changes in response to the most recent revisions of the U.S. Preventive Services Task Force (USPSTF) recommendations. The majority of providers believed that mammography screening was effective for reducing cancer mortality among women ages 40-74 years, and that Papanicolaou (Pap) testing was very effective for women ages 21-64 years. While the USPSTF breast and cervical cancer screening recommendations were widely perceived by the respondents as influential, 75.7 and 41.2 % of providers (for mammography and cervical cancer screening, respectively) reported screening practices in excess of those recommended by USPSTF. Provider-reported barriers to concordance with guideline recommendations included: patient concerns (74 and 36 % for breast and cervical, respectively), provider disagreement with the recommendations (50 and 14 %), health system measurement of a provider's screening practices that use conflicting measurement criteria (40 and 21 %), concern about malpractice risk (33 and 11 %), and lack of time to discuss the benefits and harms with their patients (17 and 8 %). Primary care providers do not consistently follow recent USPSTF breast and cervical cancer screening recommendations, despite noting that these guidelines are influential. C1 [Haas, Jennifer S.; Chen, Jane S.; Bitton, Asaf; Harris, Kimberly; Feldman, Sarah; Brawarsky, Phyllis] Brigham & Womens Hosp, Boston, MA 02120 USA. [Haas, Jennifer S.; Bitton, Asaf; Feldman, Sarah] Harvard Univ, Sch Med, Boston, MA USA. [Sprague, Brian L.; MacLean, Charles D.; Howe, Kathleen] Univ Vermont, Burlington, VT USA. [Tosteson, Anna N. A.; Onega, Tracy; Pearson, Loretta] Geisel Sch Med Dartmouth, Lebanon, NH USA. [Tosteson, Anna N. A.; Onega, Tracy; Pearson, Loretta] Norris Cotton Canc Ctr, Lebanon, NH USA. [Klabunde, Carrie N.] NIH, Off Dis Prevent, Off Director, Bethesda, MD 20892 USA. [Beaber, Elisabeth F.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Kim, Jane J.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Yamartino, Phillip; Schapira, Marilyn M.] Univ Penn, Philadelphia, PA 19104 USA. [Yamartino, Phillip; Schapira, Marilyn M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Haas, Jennifer S.] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA. RP Haas, JS (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA. EM jhaas@partners.org FU National Cancer Institute-funded consortium, Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) [U54 CA163307, U54 CA 163313, U54 CA163303, U01CA163304, U54CA164336] FX We appreciate the input of Alan Waxman, MD, on the development of the survey. This study was conducted as part of the National Cancer Institute-funded consortium, Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) (grant numbers U54 CA163307, U54 CA 163313, U54 CA163303, U01CA163304, U54CA164336). A list of PROSPR investigators and contributing research staff is provided at: http://healthcaredelivery.cancer.gov/prospr/ NR 27 TC 8 Z9 8 U1 4 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2016 VL 31 IS 1 BP 52 EP 59 DI 10.1007/s11606-015-3449-5 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DA1FB UT WOS:000367540600013 PM 26129780 ER PT J AU Berchuck, JE Patel, S AF Berchuck, Jacob E. Patel, Shalini TI An Often-Overlooked Etiology of Pleuritic Chest Pain SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE Clinical image; Diagnosis; Cardiovascular disease; Pulmonary disease C1 [Berchuck, Jacob E.; Patel, Shalini] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Patel, Shalini] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Berchuck, JE (reprint author), Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Room M-987, San Francisco, CA 94143 USA. EM jacob.berchuck@ucsf.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2016 VL 31 IS 1 BP 138 EP 138 DI 10.1007/s11606-015-3316-4 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DA1FB UT WOS:000367540600034 PM 25869019 ER PT J AU Lapps, J Flansbaum, B Leykum, L Boswell, J Haines, L AF Lapps, Joshua Flansbaum, Bradley Leykum, Luci Boswell, Josh Haines, Luigi TI Updating threshold-based identification of hospitalists in 2012 Medicare pay data SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID CARE AB In the absence of a unique identifier, it is difficult to assess the number of practicing hospitalists. We use a variety of thresholds of billing activity to identify hospitalists in a dataset of publicly released 2012 Medicare physician pay data. Our study updates previous estimates of the number of hospitalists practicing nationwide in 2012 and suggests the field continues to grow. This research also highlights a need for a more precise system of identifying hospitalists. Journal of Hospital Medicine 2016;11:45-47. (c) 2015 Society of Hospital Medicine C1 [Lapps, Joshua; Boswell, Josh] Soc Hosp Med, Govt Relat Dept, Philadelphia, PA 19130 USA. [Flansbaum, Bradley] Lenox Hill Hosp, North Shore Long Isl Jewish Hlth Syst, New York, NY 10021 USA. [Leykum, Luci] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Leykum, Luci] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Haines, Luigi] Soc Hosp Med, Dept Informat Technol, Philadelphia, PA 19130 USA. [Haines, Luigi] Adv Solut Int Inc, Austin, TX USA. RP Lapps, J (reprint author), Soc Hosp Med, 1500 Spring Garden St,Suite 501, Philadelphia, PA 19130 USA. EM jlapps@hospitalmedicine.org FU Department of Veterans Affairs, Veterans Health Administration; South Texas Veterans Health Care System FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration. Investigator salary support is provided through the South Texas Veterans Health Care System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors report no conflicts of interest. NR 9 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2016 VL 11 IS 1 BP 45 EP 47 DI 10.1002/jhm.2480 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DA3VR UT WOS:000367728300006 PM 26381496 ER PT J AU Rao, K Safdar, N AF Rao, Krishna Safdar, Nasia TI Fecal microbiota transplantation for the treatment of Clostridium difficile infection SO JOURNAL OF HOSPITAL MEDICINE LA English DT Review ID ULCERATIVE-COLITIS; INTESTINAL MICROBIOTA; BACTERIOTHERAPY; HEALTH; METAANALYSIS; DISEASE; COLONIZATION; EPIDEMIOLOGY; VANCOMYCIN; RESISTANCE AB Clostridium difficile, a major cause of healthcare-associated diarrhea due to perturbation of the normal gastrointestinal microbiome, is responsible for significant morbidity, mortality, and healthcare expenditures. The incidence and severity of C difficile infection (CDI) is increasing, and recurrent disease is common. Recurrent infection can be difficult to manage with conventional antibiotic therapy. Fecal microbiota transplantation (FMT), which involves instillation of stool from a healthy donor into the gastrointestinal tract of the patient, restores the gut microbiome to a healthy state. FMT has emerged as a promising new treatment for CDI. There are limited data on FMT for treatment of primary CDI, but FMT appears safe and effective for recurrent CDI. The safety and efficacy of FMT in patients with severe primary or severe recurrent CDI has not been established. Patients with inflammatory bowel disease (IBD) who undergo FMT for CDI may be at increased risk of IBD flare, and caution should be exercised with use of FMT in that population. The long-term safety of FMT is unknown; thus, rigorously conducted prospective studies are needed. Journal of Hospital Medicine 2016;11:56-61. (c) 2015 Society of Hospital Medicine C1 [Rao, Krishna] Univ Michigan, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA. [Rao, Krishna] Vet Affairs Ann Arbor Healthcare Syst, Div Infect Dis, Ann Arbor, MI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Infect Dis Sect, Dept Med, Madison, WI 53705 USA. RP Safdar, N (reprint author), Univ Wisconsin, Infect Dis Sect, Dept Med, Sch Med & Publ Hlth,MFCB, 1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu FU Claude D. Pepper Older Americans Independence Center [AG-024824]; Michigan Institute for Clinical and Health Research [2UL1TR000433]; VA MERIT award FX K.R. is supported by grants from the Claude D. Pepper Older Americans Independence Center (grant number AG-024824) and the Michigan Institute for Clinical and Health Research (grant number 2UL1TR000433). N.S. is supported by a VA MERIT award. The contents of this article do not necessarily represent the views of the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors report no conflicts of interest. NR 65 TC 9 Z9 9 U1 3 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2016 VL 11 IS 1 BP 56 EP 61 DI 10.1002/jhm.2449 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DA3VR UT WOS:000367728300009 PM 26344412 ER PT J AU Silvestri, MT Bongiovanni, TR Glover, JG Gross, CP AF Silvestri, Mark T. Bongiovanni, Tasce R. Glover, Janis G. Gross, Cary P. TI Impact of price display on provider ordering: A systematic review SO JOURNAL OF HOSPITAL MEDICINE LA English DT Review ID EMERGENCY-DEPARTMENT; HEALTH-CARE; LABORATORY TESTS; COST; INFORMATION; PHYSICIANS; BEHAVIOR; TRANSPARENCY; SERVICES; CHARGES AB BACKGROUNDDisplaying order prices to physicians is 1 potential strategy to reduce unnecessary health expenditures, but its impact on patterns of care is unclear. OBJECTIVETo review characteristics of previous price display interventions, impact on order costs and volume, effects on patient safety, acceptability to physicians, and the quality of this evidence. DESIGNSystematic review of studies that showed numeric prices of laboratory tests, imaging studies, or medications to providers in real time during the ordering process and evaluated the impact on provider ordering. Two investigators independently extracted data for each study and evaluated study quality using a modified Downs and Black checklist. RESULTSOf 1494 studies reviewed, 19 met inclusion criteria, including 5 randomized trials, 13 pre-post intervention studies, and 1 time series analysis. Studies were published between 1983 and 2014. Of 15 studies reporting the quantitative impact of price display on aggregate order costs or volume, 10 demonstrated a statistically significant decrease in the intervention group. Price display was found to decrease aggregate order costs (9 of 13 studies) more frequently than order volume (3 of 8 studies). Patient safety was evaluated in 5 studies and was unaffected by price display. Provider acceptability tended to be positive, although evidence was limited. Study quality was mixed, with checklist scores ranging from 5/21 to 20/21. CONCLUSIONSProvider price display likely reduces order costs to a modest degree. Patient safety appeared unchanged, though evidence was limited. More high-quality evidence is needed to confirm these findings within a modern context. Journal of Hospital Medicine 2016;11:65-76. (c) 2015 Society of Hospital Medicine C1 [Silvestri, Mark T.; Bongiovanni, Tasce R.; Gross, Cary P.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA. [Bongiovanni, Tasce R.] US Dept Vet Affairs, Connecticut Healthcare Syst, West Haven, CT USA. [Glover, Janis G.] Yale Univ, Harvey Cushing John Hay Whitney Med Lib, New Haven, CT USA. [Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Silvestri, MT (reprint author), Robert Wood Johnson Fdn, Clin Scholars Program, POB 208088,333 Cedar St,SHM IE-61, New Haven, CT 06520 USA. EM mark.silvestri@yale.edu FU Johnson Johnson; Medtronic Inc.; 21st Century Oncology; Fair Health Inc.; ASTRO FX Dr. Silvestri, Dr. Bongiovanni, and Ms. Glover have nothing to disclose. Dr. Gross reports grants from Johnson & Johnson, Medtronic Inc., and 21st Century Oncology during the conduct of this study. In addition, he received payment from Fair Health Inc. and ASTRO outside the submitted work. NR 32 TC 2 Z9 2 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2016 VL 11 IS 1 BP 65 EP 76 DI 10.1002/jhm.2500 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA DA3VR UT WOS:000367728300011 PM 26498736 ER PT J AU McCaslin, SE Maguen, S Metzler, T Bosch, J Neylan, TC Marmar, CR AF McCaslin, Shannon E. Maguen, Shira Metzler, Thomas Bosch, Jeane Neylan, Thomas C. Marmar, Charles R. TI Assessing posttraumatic stress related impairment and well-being: The Posttraumatic Stress Related Functioning Inventory (PRFI) SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE PTSD; Functioning; Veterans; Assessment; Outcomes ID MALE VIETNAM VETERANS; ABUSE SCREENING-TEST; QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; INTERPERSONAL VIOLENCE; DISORDER SYMPTOMS; HEALTH; WAR; TRAUMA; IRAQ AB Posttraumatic stress symptoms are associated with poorer social and occupational functioning and quality of life. However, general assessments of functioning do not determine the extent to which these difficulties are directly related to PTSD symptoms. This study examines the psychometric properties of a self-report measure, the 27-item Posttraumatic Stress Related Functioning Inventory (PRFI), which was developed to provide a self-report tool for clinicians and researchers to better understand the perceived impact of PTSD symptoms on functioning. The psychometric properties of the PRFI were examined utilizing data collected within a larger study examining quality of life and functioning in 251 veterans who had served in OEF/OIF/OND and endorsed the presence of subsyndromal or greater levels of PTSD symptoms at screening. One-year test-retest reliability of the measure was examined in a subset of the baseline sample who received a second administration of the PRFI (n = 109). Higher levels of PTSD symptoms were associated with poorer functioning in all domains. The PRFI demonstrated convergent validity with a measure of PTSD symptoms and was less correlated with measures of alcohol and drug use, good internal consistency and test-retest reliability from baseline to one-year follow-up. The PRFI provides self-report information regarding several domains of functioning. This initial examination of psychometric properties of the scale indicated that it may be useful for efficiently eliciting information about the ways in which PTSD symptoms in veterans impact everyday functioning. Published by Elsevier Ltd. C1 [McCaslin, Shannon E.] Natl Ctr PTSD, Disseminat & Training Div, Menlo Pk, CA USA. [McCaslin, Shannon E.; Maguen, Shira; Metzler, Thomas; Neylan, Thomas C.] San Francisco Vet Adm Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [McCaslin, Shannon E.; Maguen, Shira; Metzler, Thomas; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Bosch, Jeane] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA. [Marmar, Charles R.] NYU, Steven & Alexandra Cohen Vet Ctr, New York, NY USA. [Marmar, Charles R.] NYU, Dept Psychiat, Langone Med Ctr, New York, NY 10016 USA. RP McCaslin, SE (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Shannon.McCaslin@va.gov FU United States (U.S.) Department of Veterans Affairs, Clinical Sciences Research and Development Service [CDA-2-032-06F]; United States (U.S.) Department of Veterans Affairs, Health Services Research and Development Service [RCD 06-042] FX This work was supported by Career Development Award (CDA-2-032-06F: McCaslin) from the United States (U.S.) Department of Veterans Affairs, Clinical Sciences Research and Development Service and Career Development Award (RCD 06-042: Maguen) from the United States (U.S.) Department of Veterans Affairs, Health Services Research and Development Service.The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 35 TC 0 Z9 0 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JAN PY 2016 VL 72 BP 104 EP 111 DI 10.1016/j.jpsychires.2015.10.016 PG 8 WC Psychiatry SC Psychiatry GA DA0KB UT WOS:000367484900016 PM 26615453 ER PT J AU Winkler, EA Yue, JK McAllister, TW Temkin, NR Oh, SS Burchard, EG Hu, DL Ferguson, AR Lingsma, HF Burke, JF Sorani, MD Rosand, J Yuh, EL Barber, J Tarapore, PE Gardner, RC Sharma, S Satris, GG Eng, C Puccio, AM Wang, KKW Mukherjee, P Valadka, AB Okonkwo, DO Diaz-Arrastia, R Manley, GT AF Winkler, Ethan A. Yue, John K. McAllister, Thomas W. Temkin, Nancy R. Oh, Sam S. Burchard, Esteban G. Hu, Donglei Ferguson, Adam R. Lingsma, Hester F. Burke, John F. Sorani, Marco D. Rosand, Jonathan Yuh, Esther L. Barber, Jason Tarapore, Phiroz E. Gardner, Raquel C. Sharma, Sourabh Satris, Gabriela G. Eng, Celeste Puccio, Ava M. Wang, Kevin K. W. Mukherjee, Pratik Valadka, Alex B. Okonkwo, David O. Diaz-Arrastia, Ramon Manley, Geoffrey T. CA TRACK-TBI Investigators TI COMT Val (158) Met polymorphism is associated with nonverbal cognition following mild traumatic brain injury SO NEUROGENETICS LA English DT Article DE Traumatic brain injury; Genetic factors; Cognitive function; Outcome measures; Human studies ID COMMON DATA ELEMENTS; CATECHOL-O-METHYLTRANSFERASE; VERBAL-LEARNING TEST; WORKING-MEMORY; GENE POLYMORPHISMS; PREFRONTAL CORTEX; PERFORMANCE; GENOTYPE; RECOMMENDATIONS; RESILIENCE AB Mild traumatic brain injury (mTBI) results in variable clinical outcomes, which may be influenced by genetic variation. A single-nucleotide polymorphism in catechol-o-methyltransferase (COMT), an enzyme which degrades catecholamine neurotransmitters, may influence cognitive deficits following moderate and/or severe head trauma. However, this has been disputed, and its role in mTBI has not been studied. Here, we utilize the Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) study to investigate whether the COMT Val (158) Met polymorphism influences outcome on a cognitive battery 6 months following mTBI-Wechsler Adult Intelligence Test Processing Speed Index Composite Score (WAIS-PSI), Trail Making Test (TMT) Trail B minus Trail A time, and California Verbal Learning Test, Second Edition Trial 1-5 Standard Score (CVLT-II). All patients had an emergency department Glasgow Coma Scale (GCS) of 13-15, no acute intracranial pathology on head CT, and no polytrauma as defined by an Abbreviated Injury Scale (AIS) score of a parts per thousand yen3 in any extracranial region. Results in 100 subjects aged 40.9 (SD 15.2) years (COMT Met (158) /Met (158) 29 %, Met (158) /Val (158) 47 %, Val (158) /Val (158) 24 %) show that the COMT Met (158) allele (mean 101.6 +/- SE 2.1) associates with higher nonverbal processing speed on the WAIS-PSI when compared to Val (158) /Val (158) homozygotes (93.8 +/- SE 3.0) after controlling for demographics and injury severity (mean increase 7.9 points, 95 % CI [1.4 to 14.3], p = 0.017). The COMT Val (158) Met polymorphism did not associate with mental flexibility on the TMT or with verbal learning on the CVLT-II. Hence, COMT Val (158) Met may preferentially modulate nonverbal cognition following uncomplicated mTBI. Registry: ClinicalTrials.gov Identifier NCT01565551. C1 Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA. [Winkler, Ethan A.; Yue, John K.; Ferguson, Adam R.; Burke, John F.; Sorani, Marco D.; Yuh, Esther L.; Tarapore, Phiroz E.; Sharma, Sourabh; Satris, Gabriela G.; Mukherjee, Pratik; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA. [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA. [Temkin, Nancy R.; Barber, Jason] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA. [Temkin, Nancy R.; Barber, Jason; Eng, Celeste] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Oh, Sam S.; Burchard, Esteban G.; Hu, Donglei; Eng, Celeste] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94110 USA. [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. [Rosand, Jonathan; Gardner, Raquel C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA. [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94110 USA. [Gardner, Raquel C.] San Francisco Vet Adm Med Ctr, Dept Neurol, San Francisco, CA USA. [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA. [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA. [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA. [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA. [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA. [Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA. RP Manley, GT (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA. EM manleyg@neurosurg.ucsf.edu RI Yue, John/P-1348-2015 OI Yue, John/0000-0001-9694-7722 FU NIH [RC2 NS069409, RC2 NS069409-02S1, U01 NS086090-01]; DOD [USAMRAAW81XWH-13-1-0441, W81XWH-14-2-0176] FX This work was supported by the following grants: NIH RC2 NS069409, NIH RC2 NS069409-02S1, NIH U01 NS086090-01, DOD USAMRAAW81XWH-13-1-0441, DOD W81XWH-14-2-0176 NR 68 TC 2 Z9 3 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1364-6745 EI 1364-6753 J9 NEUROGENETICS JI Neurogenetics PD JAN PY 2016 VL 17 IS 1 BP 31 EP 41 DI 10.1007/s10048-015-0467-8 PG 11 WC Genetics & Heredity; Clinical Neurology SC Genetics & Heredity; Neurosciences & Neurology GA DA3KJ UT WOS:000367695300005 PM 26576546 ER PT J AU Greenwood, TA Lazzeroni, LC Calkins, ME Freedman, R Green, MF Gur, RE Gur, RC Light, GA Nuechterlein, KH Olincy, A Radant, AD Seidman, LJ Siever, LJ Silverman, JM Stone, WS Sugar, CA Swerdlow, NR Tsuang, DW Tsuang, MT Turetsky, BI Braff, DL AF Greenwood, Tiffany A. Lazzeroni, Laura C. Calkins, Monica E. Freedman, Robert Green, Michael F. Gur, Raquel E. Gur, Ruben C. Light, Gregory A. Nuechterlein, Keith H. Olincy, Ann Radant, Allen D. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Stone, William S. Sugar, Catherine A. Swerdlow, Neal R. Tsuang, Debby W. Tsuang, Ming T. Turetsky, Bruce I. Braff, David L. TI Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Endophenotype; Genetics; Schizophrenia; Association; Linkage; Heritability ID GENOME-WIDE ASSOCIATION; DE-NOVO MUTATIONS; TRAIT LINKAGE ANALYSIS; BIPOLAR-DISORDER; DOPAMINE TRANSPORTER; SUSTAINED ATTENTION; CANDIDATE GENES; SCHIZOAFFECTIVE DISORDER; INTELLECTUAL DISABILITY; 1ST-DEGREE RELATIVES AB The Consortium on the Genetics of Schizophrenia Family Study (COGS-1) has previously reported our efforts to characterize the genetic architecture of 12 primary endophenotypes for schizophrenia. We now report the characterization of 13 additional measures derived from the same endophenotype test paradigms in the COGS-1 families. Nine of the measures were found to discriminate between schizophrenia patients and controls, were significantly heritable (31 to 62%), and were sufficiently independent of previously assessed endophenotypes, demonstrating utility as additional endophenotypes. Genotyping via a custom array of 1536 SNPs from 94 candidate genes identified associations for CTNNA2, ERBB4, GRID1, GRID2, GRIK3, GRIK4, GRIN2B, NOS1AP, NRG1, and RELN across multiple endophenotypes. An experiment-wide p value of 0.003 suggested that the associations across all SNPs and endophenotypes collectively exceeded chance. Linkage analyses performed using a genome-wide SNP array further identified significant or suggestive linkage for six of the candidate endophenotypes, with several genes of interest located beneath the linkage peaks (e.g., CSMD1, DISC1, DLGAP2, GRIK2, GRIN3A, and SLC6A3). While the partial convergence of the association and linkage likely reflects differences in density of gene coverage provided by the distinct genotyping platforms, it is also likely an indication of the differential contribution of rare and common variants for some genes and methodological differences in detection ability. Still, many of the genes implicated by COGS through endophenotypes have been identified by independent studies of common, rare, and de novo variation in schizophrenia, all converging on a functional genetic network related to glutamatergic neurotransmission that warrants further investigation. (C) 2015 Elsevier B. V. All rights reserved. C1 [Greenwood, Tiffany A.; Light, Gregory A.; Swerdlow, Neal R.; Tsuang, Ming T.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Calkins, Monica E.; Gur, Raquel E.; Gur, Ruben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Light, Gregory A.; Braff, David L.] VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, San Diego, CA 92161 USA. [Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Radant, Allen D.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Seidman, Larry J.; Stone, William S.] Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.; Silverman, Jeremy M.] James J Peters VA Med Ctr, New York, NY USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Tsuang, Ming T.] Univ Calif San Diego, Inst Genom Med, Ctr Behav Genom, La Jolla, CA 92093 USA. [Tsuang, Ming T.] Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. RP Greenwood, TA (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,MC 0689, La Jolla, CA 92093 USA. EM tgreenwood@ucsd.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Greenwood, Tiffany/0000-0002-6080-6503 FU National Institute of Mental Health [R01-MH065571, R01-MH065588, R01-MH065562, R01-MH065707, R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, K01-MH087889]; National Institutes of Health [HHSN268200782096C] FX The authors wish to thank all of the participants and support staff that made this study possible. This study was supported by grants R01-MH065571, R01-MH065588, R01-MH065562, R01-MH065707, R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, and K01-MH087889 (TAG) from the National Institute of Mental Health. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, Contract Number HHSN268200782096C. COGS website: http://www.npistat.com/cogs/. NR 100 TC 6 Z9 6 U1 2 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 2016 VL 170 IS 1 BP 30 EP 40 DI 10.1016/j.schres.2015.11.008 PG 11 WC Psychiatry SC Psychiatry GA DA1DC UT WOS:000367535500003 PM 26597662 ER PT J AU Lizano, PL Keshavan, MS Tandon, N Mathew, IT Mothi, SS Montrose, DM Yao, JK AF Lizano, Paulo L. Keshavan, Matcheri S. Tandon, Neeraj Mathew, Ian T. Mothi, Suraj Sarvode Montrose, Debra M. Yao, Jeffrey K. TI Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients: A preliminary study SO SCHIZOPHRENIA RESEARCH LA English DT Article DE High risk; First episode psychosis; Soluble fms-like tyrosine kinase; Angiogenesis; Inflammation/immune ID ENDOTHELIAL GROWTH-FACTOR; 1ST EPISODE PSYCHOSIS; CYTOKINE ALTERATIONS; INTERFERON-GAMMA; SCHIZOPHRENIA; VEGF; SYMPTOMS; RECEPTOR; FLT-1; SFLT1 AB Schizophrenia (SZ) is a heterogeneous disorder that presents in adolescence, persists into adulthood, and has many clinical features. Recent evidence suggests that abnormalities in inflammatory, neurotrophic, and angiogenic processes may play a role in the etiology of SZ. The identification of molecular biomarkers early in the course of disease is crucial to transforming diagnostic and therapeutic avenues. We investigated 14 molecular analytes focusing on inflammatory, neurotrophic and angiogenic pathways from the plasma of antipsychotic-naive familial high risk for SZ (FHR; n = 35) and first-episode psychosis (FEP; n = 45) subjects, in comparison to healthy controls (HC, n = 39). We identified distinct alterations in molecular signatures in young relatives at FHR for SZ prior to psychosis onset and FEP subjects. Firstly, the expression of soluble fms-like tyrosine kinase (sFlt-1), an anti-angiogenic factor that binds vascular endothelial growth factor (VEGF), was significantly increased in the FHR group compared to HC, but not in FEP. Secondly, interferon gamma (IFN gamma) was significantly reduced in the FEP group compared to HC. Thirdly, network analysis revealed a positive correlation between sFlt-1 and VEGF, suggesting an activation of the angiogenic cascade in the FHR group, which persists in FEP. Our results indicate an angiogenesis and immunological dysfunction early in the course of disease, shifting the balance towards anti-angiogenesis and inflammation. Published by Elsevier B.V. C1 [Lizano, Paulo L.; Keshavan, Matcheri S.; Tandon, Neeraj; Mathew, Ian T.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Lizano, Paulo L.; Keshavan, Matcheri S.; Mothi, Suraj Sarvode] Massachusetts Mental Hlth Ctr, Div Publ Psychiat, Boston, MA 02115 USA. [Keshavan, Matcheri S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Keshavan, Matcheri S.; Montrose, Debra M.; Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Tandon, Neeraj] Baylor Coll Med, Houston, TX 77030 USA. [Yao, Jeffrey K.] Med Res Serv, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. RP Yao, JK (reprint author), VA Pittsburg Healthcare Syst, B-1-2E-140,Univ Dr C, Pittsburgh, PA 15240 USA. EM jkyao@pitt.edu FU Department of Veterans Affairs; VA Pittsburgh Healthcare System; National Institute of Health [MH58141, MH64023, KO2 MH 01180, MH45156, c UL1 RR024153]; National Institute of Health, NIH/NCRR/GCRC [M01 RR00056]; Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]; Harvard University and its affiliated academic healthcare centers FX This work was supported in part by Department of Veterans Affairs [Merit Reviews (JKY) and Senior Research Career Scientist Award (JKY)] and the VA Pittsburgh Healthcare System, National Institute of Health [MH58141 (JKY), MH64023 (MSK), KO2 MH 01180 (MSK), MH45156 (MSK), c UL1 RR024153, and NIH/NCRR/GCRC Grant M01 RR00056]. Biostatistician consultation was supported by Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. NR 74 TC 0 Z9 0 U1 3 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 2016 VL 170 IS 1 BP 115 EP 122 DI 10.1016/j.schres.2015.12.001 PG 8 WC Psychiatry SC Psychiatry GA DA1DC UT WOS:000367535500014 PM 26692348 ER PT J AU Szymusiak, R AF Szymusiak, Ronald TI Chapter 5 Journal SLEEP SO SLEEP LA English DT Editorial Material C1 [Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Szymusiak, Ronald] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Szymusiak, R (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD JAN 1 PY 2016 VL 39 IS 1 BP 5 EP 5 DI 10.5665/sleep.5298 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DA0VM UT WOS:000367515700001 PM 26940459 ER PT J AU Janney, CA Kilbourne, AM Germain, A Lai, ZS Hoerster, KD Goodrich, DE Klingaman, EA Verchinina, L Richardson, CR AF Janney, Carol A. Kilbourne, Amy M. Germain, Anne Lai, Zongshan Hoerster, Katherine D. Goodrich, David E. Klingaman, Elizabeth A. Verchinina, Lilia Richardson, Caroline R. TI The Influence of Sleep Disordered Breathing on Weight Loss in a National Weight Management Program SO SLEEP LA English DT Article DE MOVE; obesity; population health; sleep apnea; veterans; weight loss ID LIFE-STYLE INTERVENTION; MENTAL-HEALTH; APNEA; OBESITY; RISK; REDUCTION; DISEASE; IMPACT; ADULTS; TRIAL AB Study Objective: To investigate the influence of sleep disordered breathing (SDB) on weight loss in overweight/obese veterans enrolled in MOVE!, a nationally implemented behavioral weight management program delivered by the National Veterans Health Administration health system. Methods: This observational study evaluated weight loss by SDB status in overweight/obese veterans enrolled in MOVE! from May 2008-February 2012 who had at least two MOVE! visits, baseline weight, and at least one follow-up weight (n = 84,770). SDB was defined by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Primary outcome was weight change (lb) from MOVE! enrollment to 6- and 12-mo assessments. Weight change over time was modeled with repeated-measures analyses. Results: SDB was diagnosed in one-third of the cohort (n = 28,269). At baseline, veterans with SDB weighed 29 [48] lb more than those without SDB (P < 0.001). On average, veterans attended eight MOVE! visits. Weight loss patterns over time were statistically different between veterans with and without SDB (P < 0.001); veterans with SDB lost less weight (-2.5 [0.1] lb) compared to those without SDB (-3.3 [0.1] lb; P = 0.001) at 6 months. At 12 mo, veterans with SDB continued to lose weight whereas veterans without SDB started to re-gain weight. Conclusions: Veterans with sleep disordered breathing (SDB) had significantly less weight loss over time than veterans without SDB. SDB should be considered in the development and implementation of weight loss programs due to its high prevalence and negative effect on health. C1 [Janney, Carol A.; Kilbourne, Amy M.; Lai, Zongshan; Goodrich, David E.; Verchinina, Lilia; Richardson, Caroline R.] VA Ann Arbor Healthcare Syst, CCMR, Ann Arbor, MI 48109 USA. [Kilbourne, Amy M.] VA Qual Enhancement Res Initiat QUERI, Hlth Serv Res & Dev, Washington, DC USA. [Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Seattle Div Mental Hlth Serv, Seattle, WA USA. [Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Klingaman, Elizabeth A.] VA Maryland Healthcare Syst, Baltimore, MD USA. [Klingaman, Elizabeth A.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Richardson, Caroline R.] Univ Michigan, Sch Med, Dept Family Med, Ann Arbor, MI USA. RP Kilbourne, AM (reprint author), VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, 2800 Plymouth Rd,NCRC Bldg 16, Ann Arbor, MI 48109 USA. EM amy.kilbourne@va.gov OI Goodrich, David/0000-0003-3232-2189 FU QUERI programs for Diabetes and Mental Health research as a locally initiated project [QLP 55-017]; VA Center for Clinical Management Research, Health Services Research and Development; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment FX This was not an industry supported study. This report was conducted as a joint quality improvement evaluation involving VA Health Services Research and Development Quality Enhancement Research Initiative (QUERI) programs, VHA National Center for Health Promotion & Disease Prevention (NCP), and VA Serious Mental Illness Resource and Evaluation Center (SMITREC). It is part of a larger quality improvement evaluation of MOVE! conducted by the SMITREC at the request of NCP. Funding was obtained by Dr. Janney and Dr. Goodrich from the QUERI programs for Diabetes and Mental Health research as a locally initiated project (QLP 55-017). Dr. Janney was supported by the VA Center for Clinical Management Research, Health Services Research and Development as a postdoctoral fellow at the VA Ann Arbor Healthcare System. Dr. Klingaman was supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment. The funding bodies had no role in the manuscript other than financial support. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Kilbourne is a co-author of the workbook "Overcoming Bipolar Disorder: A Comprehensive Workbook for Managing Your Symptoms & Achieving Your Life Goals" (New Harbinger Publications, Inc., 2008) and receives publication royalties. The other authors have no conflicts of interest to disclose. MOVE! was developed internally by VA behavioral change experts to meet the needs of Veterans and is not a commercial product. NR 35 TC 2 Z9 2 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD JAN 1 PY 2016 VL 39 IS 1 BP 59 EP 65 DI 10.5665/sleep.5318 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DA0VM UT WOS:000367515700011 PM 26350475 ER PT J AU Reynolds, K Pietrzak, RH Mackenzie, CS Chou, KL Sareen, J AF Reynolds, Kristin Pietrzak, Robert H. Mackenzie, Corey S. Chou, Kee Lee Sareen, Jitender TI Post-Traumatic Stress Disorder Across the Adult Lifespan: Findings From a Nationally Representative Survey SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Epidemiology; PTSD; Characteristics; Lifespan; Older adults ID PSYCHIATRIC DIAGNOSTIC MODULES; COMORBIDITY-SURVEY-REPLICATION; GENERAL-POPULATION SAMPLE; ALCOHOL-USE-DISORDER; IV AUDADIS-IV; OLDER-ADULTS; GERMAN COMMUNITY; MENTAL-DISORDERS; TRAUMA EXPOSURE; AGE-DIFFERENCES AB Objective: There is a dearth of community-based epidemiologic literature that examines post-traumatic stress disorder (PTSD) across the adult lifespan. In the current study the authors address this gap by examining the ways in which PTSD differs among young (ages 20-34), middle-aged (ages 35-64), and older (age 65+) adults with respect to past-year prevalence, nature of "worst" stressful experience ever experienced before the onset of PTSD, all traumatic experiences, symptom expression, psychiatric comorbidities, and mental health-related quality of life. Methods: We analyzed Wave 2 data from the National Epidemiologic Survey on Alcohol and Related Conditions, including adults with past-year diagnoses of PTSD (N = 1,715). Results: The prevalence of past-year PTSD was significantly higher for young (4.3% [SE: 0.3]) and middle-aged (5.2% [SE: 0.2]) adults compared with older adults (2.6% [SE: 0.2]). Respondents in the three age groups differed with regard to their "worst" stressful experience ever experienced before the onset of PTSD and to all traumatic experiences. Older adults experienced significantly fewer traumatic experiences (mean: 5.2; SE: 0.2) compared with young (mean: 5.7; SE: 0.2) and middle-aged adults (mean: 6.4; SE: 0.1). Young and middle-aged adults had significantly greater symptom counts and greater odds of comorbid psychiatric disorders when compared with older adults. PTSD had similar effects on mental health-related quality of life across the adult lifespan. Conclusion: Results highlight key differences in the characteristics of PTSD across the adult lifespan. The overall pattern of findings indicates that increasing age is associated with less severe PTSD profiles, including lower prevalence, fewer traumatic experiences, lower symptom counts, and lower odds of psychiatric comorbidity. C1 [Reynolds, Kristin; Mackenzie, Corey S.] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada. [Sareen, Jitender] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, US Dept Vet Affairs,Ctr Posttraumat Stress Disord, New Haven, CT 06520 USA. [Chou, Kee Lee] Univ Hong Kong, Dept Asian & Policy Studies, Pokfulam, Hong Kong, Peoples R China. RP Pietrzak, RH (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. EM robert.pietrzak@yale.edu FU Canadian Institutes of Health Research Doctoral Research Award; Manitoba Graduate Scholarship; U.S. Department of Veterans Affairs National Center; Research Grant Council from Strategic Public Policy Research [HKIEd 7001-SPPR-11]; Humanities and Social Sciences Prestigious Fellowship Scheme [38600214]; Manitoba Health Research Council Chair Award FX Reynolds is supported by a Canadian Institutes of Health Research Doctoral Research Award and a Manitoba Graduate Scholarship, R. H. Pietrzak is supported by the U.S. Department of Veterans Affairs National Center for PTSD and a private donation, K.-L. Chou is supported by the Research Grant Council from Strategic Public Policy Research (HKIEd 7001-SPPR-11) and Humanities and Social Sciences Prestigious Fellowship Scheme (38600214), and J. Sareen is supported by a Manitoba Health Research Council Chair Award. The aforementioned funding sources did not have a role in the writing of the manuscript or the decision to submit it for publication. The NESARC was conducted and funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), with supplemental support from the National Institute on Drug Abuse. The authors thank the NIAAA and the U.S. Census Bureau field representatives who administrated the NESARC interviews and made data available to researchers. NR 42 TC 2 Z9 2 U1 4 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JAN PY 2016 VL 24 IS 1 BP 81 EP 93 DI 10.1016/j.jagp.2015.11.001 PG 13 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CZ8FA UT WOS:000367334400011 PM 26706912 ER PT J AU Basu, A Jenkins, AJ Zhang, Y Stoner, JA Klein, RL Lopes-Virella, MF Garvey, WT Lyons, TJ AF Basu, Arpita Jenkins, Alicia J. Zhang, Ying Stoner, Julie A. Klein, Richard L. Lopes-Virella, Maria F. Garvey, W. Timothy Lyons, Timothy J. CA DCCT EDIC Res Grp TI Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes SO ATHEROSCLEROSIS LA English DT Article DE Type 1 diabetes; LDL particles; Non-HDL cholesterol; Nuclear magnetic resonance-determined; lipoprotein subclass profiles ID LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; DCCT/EDIC COHORT; PARTICLE-SIZE; COMPLICATIONS TRIAL/EPIDEMIOLOGY; SUBCLINICAL ATHEROSCLEROSIS; PITTSBURGH EPIDEMIOLOGY; INSULIN-RESISTANCE; RISK-FACTOR; CHOLESTEROL AB Background: Dyslipidemia has been linked to vascular complications of Type 1 diabetes (T1DM). We investigated the prospective associations of nuclear magnetic resonance-determined lipoprotein subclass profiles (NMR-LSP) and conventional lipid profiles with carotid intima-media thickness (IMT) in T1DM. Methods: NMR-LSP and conventional lipids were measured in a subset of Diabetes Control and Complications Trial (DCCT) participants (n = 455) at study entry ('baseline', 1983-89), and were related to carotid IMT determined by ultrasonography during the observational follow-up of the DCCT, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, at EDIC Year 12 (2004-2006). Associations were defined using multiple linear regression stratified by gender, and following adjustment for HbA1c, diabetes duration, body mass index, albuminuria, DCCT randomization group, smoking status, statin use, and ultrasound devices. Results: In men, significant positive associations were observed between some baseline NMR-subclasses of LDL (total IDL/LDL and large LDL) and common and/or internal carotid IMT, and between conventional total- and LDL-cholesterol and non-HDL-cholesterol and common carotid IMT, at EDIC Year 12; these persisted in adjusted analyses (p < 0.05). Large LDL particles and conventional triglycerides were positively associated with common carotid IMT changes over 12 years (p < 0.05). Inverse associations of mean HDL diameter and large HDL concentrations, and positive associations of small LDL with common and/or internal carotid IMT (all p < 0.05) were found, but did not persist in adjusted analyses. No significant associations were observed in women. Conclusion: NMR-LSP-derived LDL particles, in addition to conventional lipid profiles, may help in identifying men with T1DM at highest risk for vascular disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Basu, Arpita] Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA. [Jenkins, Alicia J.; Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK USA. [Jenkins, Alicia J.] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia. [Zhang, Ying; Stoner, Julie A.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA. [Klein, Richard L.; Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol, Charleston, SC 29425 USA. [Klein, Richard L.; Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Lyons, Timothy J.] Queens Univ Belfast, Ctr Med Expt, Belfast BT12 6BA, Antrim, North Ireland. RP Lyons, TJ (reprint author), Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, ICS Block A,Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland. EM t.lyons@qub.ac.uk FU National Institutes of Health [R01DK080043]; American Diabetes Association [7-12-CT-46]; Division of Diabetes Endocrinology and Metabolic Diseases of National Institute of Diabetes and Digestive and Kidney Disease; National Eye Institute; National Institute of Neurologic Disorders and Stroke; Genetic Clinical Research Centers Program; Clinical Translational Science Center Program, Bethesda, Maryland, USA FX This project was funded by grants from the National Institutes of Health (R01DK080043) and the American Diabetes Association (7-12-CT-46).; DCCT/EDIC has been supported by U01 Cooperative Agreement grants (1982-93, 2011-2016), and contracts (1982-2011) with the Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease, and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the Genetic Clinical Research Centers Program (1993-2007), and Clinical Translational Science Center Program (2006-present), Bethesda, Maryland, USA. A complete list of participants in the DCCT/EDIC research group can be found in New England Journal of Medicine, 2011; 365: 2366-2376. NR 48 TC 0 Z9 0 U1 3 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD JAN PY 2016 VL 244 BP 93 EP 100 DI 10.1016/j.atherosclerosis.2015.10.106 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CZ8UR UT WOS:000367375100052 PM 26600440 ER PT J AU Fontaine, DA Davis, DB AF Fontaine, Danielle A. Davis, Dawn Belt TI Attention to Background Strain Is Essential for Metabolic Research: C57BL/6 and the International Knockout Mouse Consortium SO DIABETES LA English DT Article ID NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; DIET-INDUCED OBESITY; HIGH-FAT DIET; GENETIC-ANALYSIS; MICE; SUBSTRAINS; EXPRESSION; MUTATION; ISLETS; RELEASE AB The International Knockout Mouse Consortium (IKMC) introduces its targeted constructs into C57BL/6N embryonic stem cells. However, breeding with a Cre-recombinase and/or Flp-recombinase mouse is required for the generation of a null allele with the IKMC cassette. Many recombinase strains are in the C57BL/6J background, resulting in knockout animals on a mixed strain background. This can lead to variability in metabolic data and the use of improper control groups. While C57BL/6N and C57BL/6J are derived from the same parental C57BL/6 strain, there are key genotypic and phenotypic differences between these substrains. Many researchers may not even be aware of these differences, as the shorthand C57BL/6 is often used to describe both substrains. We found that 58% of articles involving genetically modified mouse models did not completely address background strain. This review will describe these two substrains and highlight the importance of separate consideration in mouse model development. Our aim is to increase awareness of this issue in the diabetes research community and to provide practical strategies to enable researchers to avoid mixed strain animals when using IKMC knockout mice. C1 [Fontaine, Danielle A.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53706 USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Davis, DB (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53706 USA. EM dbd@medicine.wisc.edu FU University of Wisconsin-Madison (UW-Madison) Institute on Aging (from the National Institute on Aging) [T32 AG000213]; UW-Madison Science and Medicine Graduate Research Scholars program; U.S. Department of Veterans Affairs [1I01BX001880]; UW-Madison Department of Medicine FX D.A.F. is supported by a training grant from the University of Wisconsin-Madison (UW-Madison) Institute on Aging (from the National Institute on Aging [T32 AG000213]) and has been supported by the UW-Madison Science and Medicine Graduate Research Scholars program. D.B.D. is supported by the U.S. Department of Veterans Affairs (1I01BX001880) and the UW-Madison Department of Medicine. NR 62 TC 13 Z9 13 U1 1 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD JAN PY 2016 VL 65 IS 1 BP 25 EP 33 DI 10.2337/db15-0982 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CZ9NS UT WOS:000367424900006 PM 26696638 ER PT J AU Fortney, JC Curran, GM Hunt, JB Cheney, AM Lu, LY Valenstein, M Eisenberg, D AF Fortney, John C. Curran, Geoffrey M. Hunt, Justin B. Cheney, Ann M. Lu, Liya Valenstein, Marcia Eisenberg, Daniel TI Prevalence of probable mental disorders and help-seeking behaviors among veteran and non-veteran community college students SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Psychiatric epidemiology; Community colleges; Veterans; Service utilization ID PSYCHIATRIC-DISORDERS; SOCIAL-CONSEQUENCES; HEALTH; INTERVENTIONS; POPULATION; DEPRESSION; ALCOHOL; SERVICE; PEERS; PTSD AB Objective: Millions of disadvantaged youth and returning veterans are enrolled in community colleges. Our objective was to determine the prevalence of mental disorders and help-seeking behaviors among community college students. Methods: Veterans (n=211) and non-veterans (n=554) were recruited from 11 community colleges and administered screeners for depression (PHQ-9), generalized anxiety (GAD-7), posttraumatic stress disorder (PC-PTSD), non-lethal self-injury, suicide ideation and suicide intent. The survey also asked about the perceived need for, barriers to and utilization of services. Regression analysis was used to compare prevalence between non-veterans and veterans adjusting for non-modifiable factors (age, gender and race/ethnicity). Results: A large proportion of student veterans and non-veterans screened positive and unadjusted bivariate comparisons indicated that student veterans had a significantly higher prevalence of positive depression screens (33.1% versus 19.5%, P<.01), positive PTSD screens (25.7% versus 12.6%, P<.01) and suicide ideation (19.2% versus 10.6%, P=.01). Adjusting for age, gender and race/ethnicity, veterans were significantly more likely than non-veterans to screen positive for depression (OR=2.10, P=.01) and suicide ideation (OR=2.31, P=.03). Student veterans had significantly higher odds of perceiving a need for treatment than non-veterans (OR=1.93, P=.02) but were more likely to perceive stigma (beta=0.28, P=.02). Despite greater need among veterans, there were no significant differences between veterans and non-veterans in use of psychotropic medications, although veterans were more likely to receive psychotherapy (OR=2.35, P=.046). Conclusions: Findings highlight the substantial gap between the prevalence of probable mental health disorders and treatment seeking among community college students. Interventions are needed to link community college students to services, especially for student veterans. (C) 2016 Published by Elsevier Inc. C1 [Fortney, John C.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA. [Fortney, John C.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Curran, Geoffrey M.] Univ Arkansas Med Sci, Dept Pharm Practice, Coll Pharm, Little Rock, AR 72205 USA. [Curran, Geoffrey M.] Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, Hlth Serv Res & Dev, North Little Rock, AR 72114 USA. [Curran, Geoffrey M.; Hunt, Justin B.; Lu, Liya] Univ Arkansas Med Sci, Dept Psychiat, Coll Med, Little Rock, AR 72205 USA. [Hunt, Justin B.] Vet Hlth Care Syst Ozarks, Fayetteville, AR 72703 USA. [Cheney, Ann M.] Univ Calif Riverside, Dept Psychiat, Riverside, CA 92521 USA. [Valenstein, Marcia] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Valenstein, Marcia] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Hlth Serv Res & Dev, Ann Arbor, MI 48105 USA. [Eisenberg, Daniel] Univ Michigan, Sch Publ Hlth, Hlth Management & Policy, Ann Arbor, MI 48109 USA. RP Fortney, JC (reprint author), Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA. EM fortneyj@uw.edu FU National Institute of Mental Health [MH092641]; Department of Defense [DM090465] FX This work was supported by grant number MH092641 from the National Institute of Mental Health and by grant number DM090465 from the Department of Defense. NR 31 TC 3 Z9 3 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 EI 1873-7714 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD JAN-FEB PY 2016 VL 38 IS 1 BP 99 EP 104 DI 10.1016/j.genhosppsych.2015.09.007 PG 6 WC Psychiatry SC Psychiatry GA CZ8OC UT WOS:000367358000019 PM 26598288 ER PT J AU Lu, MW Plagge, JM Marsiglio, MC Dobscha, SK AF Lu, Mary W. Plagge, Jane M. Marsiglio, Mary C. Dobscha, Steven K. TI Clinician Documentation on Receipt of Trauma-Focused Evidence-Based Psychotherapies in a VA PTSD Clinic SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-PROCESSING THERAPY; MENTAL-HEALTH-SERVICES; BEHAVIORAL THERAPY; EXPOSURE THERAPY; ASSAULT VICTIMS; VETERANS; IRAQ; AFGHANISTAN; CARE AB The U.S. Department of Veterans Affairs (VA) is implementing two trauma-focused, evidence-based psychotherapies (TF-EBPs) for posttraumatic stress disorder (PTSD): cognitive processing therapy and prolonged exposure therapy (PE). Veterans with PTSD often do not receive these treatments, and little is known about the reasons veterans may not receive TF-EBPs. The aim of this qualitative study was to summarize clinician-reported reasons in medical records for nonreceipt of TF-EBPs. All veterans (N = 63) identified through PTSD screening who were newly engaged in mental health care and received individual evaluations in a PTSD specialty clinic in fiscal year 2008 were included in the sample. Content analysis of electronic medical records revealed multiple potential reasons for nonreceipt of TF-EBPs including referral to other PTSD treatments, other clinical priorities, poor engagement in care, practical barriers, negative beliefs, and receipt of care in other settings. Eight veterans (13 %) initiated TF-EBPs. Further interventions to promote engagement in PTSD treatment are warranted. C1 [Lu, Mary W.; Plagge, Jane M.; Marsiglio, Mary C.; Dobscha, Steven K.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97239 USA. RP Lu, MW (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, POB 1034,Mail Code P3MHDC,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Mary.Lu@va.gov; Jane.Plagge@va.gov; Mary.Marsiglio@va.gov; Steven.Dobscha@va.gov FU VA Health Services Research and Development Service (HSRD) [REA 06-174]; Pacific Northwest Mental Illness Research and Education and Clinical Center (MIRECC) FX This work was supported by VA Health Services Research and Development Service (HSR&D) grants REA 06-174 and the Pacific Northwest Mental Illness Research and Education and Clinical Center (MIRECC). The authors acknowledge the PTSD Clinical Team at the Portland VA Medical Center, Jonathan Duckart, Anais Tuepker, Joseph Warren, Molly DeLorit, Brittany Tremblay, Sondra Long, William Minium, and Linda Ganzini. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the U.S. Department of Veterans Affairs or the U.S. government. NR 42 TC 6 Z9 6 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1094-3412 EI 1556-3308 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD JAN PY 2016 VL 43 IS 1 BP 71 EP 87 DI 10.1007/s11414-013-9372-9 PG 17 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CZ8GE UT WOS:000367337400006 PM 24158464 ER PT J AU Chiu, C Feuz, MA McMahan, RD Miao, YH Sudore, RL AF Chiu, Catherine Feuz, Mariko A. McMahan, Ryan D. Miao, Yinghui Sudore, Rebecca L. TI "Doctor, Make My Decisions": Decision Control Preferences, Advance Care Planning, and Satisfaction With Communication Among Diverse Older Adults SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Decision control preferences; advance care planning; aging; health disparities; communication ID PERCEIVED INVOLVEMENT; MEDICAL CONSULTATIONS; PATIENT PARTICIPATION; HOSPITALIZED-PATIENTS; MAKING PREFERENCES; CANCER; PHYSICIANS; LIFE; ILLNESS; END AB Context. Culturally diverse older adults may prefer varying control over medical decisions. Decision control preferences (DCPs) may profoundly affect advance care planning (ACP) and communication. Objectives. To determine the DCPs of diverse, older adults and whether DCPs are associated with participant characteristics, ACP, and communication satisfaction. Methods. A total of 146 participants were recruited from clinics and senior centers in San Francisco. We assessed DCPs using the control preferences scale: doctor makes all decisions (low), shares with doctor (medium), makes own decisions (high). We assessed associations between DCPs and demographics; prior advance directives; ability to make in-the-moment goals of care decisions; self-efficacy, readiness, and prior asked questions; and satisfaction with patient-doctor communication (on a five-point Likert scale), using Chi-square and Kruskal-Wallis analysis of variance. Results. Mean age was 71 +/- 10 years, 53% were non-white, 47% completed an advance directive, and 70% made goals of care decisions. Of the sample, 18% had low DCPs, 33% medium, and 49% high. Older age was the only characteristic associated with DCPs (low: 75 +/- 11 years, medium: 69 +/- 10 years, high: 70 +/- 9 years, P = 0.003). DCPs were not associated with ACP, in-the-moment decisions, or communication satisfaction. Readiness was the only question-asking behavior associated (low: 3.8 +/- 1.2, medium: 4.1 +/- 1.2, high: 4.3 +/- 1.2, P = 0.05). Conclusion. Nearly one-fifth of diverse, older adults want doctors to make their medical decisions. Older age and lower readiness to ask questions were the only demographic variables significantly associated with low DCPs. Yet, older adults with low DCPs still engaged in ACP, asked questions, and reported communication satisfaction. Clinicians can encourage ACP and questions for all patients, but should assess DCPs to provide the desired amount of decision support. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Chiu, Catherine; Feuz, Mariko A.; McMahan, Ryan D.; Miao, Yinghui; Sudore, Rebecca L.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Feuz, Mariko A.; McMahan, Ryan D.; Miao, Yinghui; Sudore, Rebecca L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Chiu, C (reprint author), 500 Parnassus Ave, San Francisco, CA 94122 USA. EM catherine.chiu@ucsf.edu FU Medical Student Training in Aging Research (MSTAR) Program; National Institute on Aging [T35AG026736]; John A. Hartford Foundation; MetLife Foundation; Lillian R. Gleitsman Foundation FX The research was supported by the Medical Student Training in Aging Research (MSTAR) Program. The MSTAR program is funded by the National Institute on Aging (T35AG026736), the John A. Hartford Foundation, the MetLife Foundation, and the Lillian R. Gleitsman Foundation. The investigators retained full independence in the conduct of this research. The authors declare no conflicts of interest. NR 43 TC 2 Z9 2 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2016 VL 51 IS 1 BP 33 EP 40 DI 10.1016/j.jpainsymman.2015.07.018 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA CZ8WE UT WOS:000367379000007 PM 26342727 ER PT J AU Hartwell, KJ Hanlon, CA Li, XB Borckardt, JJ Canterberry, M Prisciandaro, JJ Moran-Santa Maria, MM LeMatty, T George, MS Brady, KT AF Hartwell, Karen J. Hanlon, Colleen A. Li, Xingbao Borckardt, Jeffrey J. Canterberry, Melanie Prisciandaro, James J. Moran-Santa Maria, Megan M. LeMatty, Todd George, Mark S. Brady, Kathleen T. TI Individualized real-time fMRI neurofeedback to attenuate craving in nicotine-dependent smokers SO JOURNAL OF PSYCHIATRY & NEUROSCIENCE LA English DT Article ID ANTERIOR CINGULATE CORTEX; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MEDIAL PREFRONTAL CORTEX; SMOKING CUES; SELF-REGULATION; ADOLESCENT SMOKERS; DECISION-MAKING; UNITED-STATES; DSM-IV; BRAIN AB Background Cue-induced craving plays an important role in relapse, and the neural correlates of cue-induced craving have been elucidated using fMRI. This study examined the utility of real-time fMRI (rtfMRI) neurofeedback to strengthen self-regulation of craving-related neural activation and cue-reactivity in cigarette smokers. Methods Nicotine-dependent smokers were randomized to rtfMRI neurofeedback or to a no-feedback control group. Participants completed 3 neuroimaging visits. Within each visit, an initial run during which smoking-related cues were used to provoke craving, an individualized craving-related region of interest (ROI) in the prefrontal cortex or anterior cingulate cortex was identified. In the rtfMRI group, activity from the ROI was fed back via a visual display during 3 subsequent runs while participants were instructed to reduce craving during cue exposure. The control group had an identical experience with no feedback provided. Results Forty-four nicotine-dependent smokers were recruited to participate in our study; data from the 33 participants who completed a 1-week follow-up visit were included in the analysis. Subjective craving ratings and cue-induced brain activation were lower in the rtfMRI group than in the control group. Limitations As participants were not seeking treatment, clinical outcomes are lacking. Conclusion Nicotine-dependent smokers receiving rtfMRI feedback from an individualized ROI attenuated smoking cue-elicited neural activation and craving, relative to a control group. Further studies are needed in treatment-seeking smokers to determine if this intervention can translate into a clinically meaningful treatment modality. C1 [Hartwell, Karen J.; Hanlon, Colleen A.; Li, Xingbao; Borckardt, Jeffrey J.; Canterberry, Melanie; Prisciandaro, James J.; Moran-Santa Maria, Megan M.; LeMatty, Todd; George, Mark S.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Hartwell, Karen J.; George, Mark S.; Brady, Kathleen T.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hartwell, KJ (reprint author), 125 Doughty St,Suite 190, Charleston, SC 29403 USA. EM hartwelk@musc.edu FU National Institute of Drug Abuse [5R21DA026085, 5R33DA026085] FX The study was supported by grant 5R21DA026085 and 5R33DA026085 from the National Institute of Drug Abuse (co-primary investigators: K. Brady and M. George). The National Institute of Drug Abuse had no role in the study design nor conduct of the study, including data collection, data analysis, interpretation of the results, manuscript preparation, review, and approval or the decision to submit the manuscript for publication. The authors thank Danielle Paquette for her assistance with the laboratory cue-reactivity sessions outside of the scanner and everyone who shared their expertise and assisted in the development of the real-time fMRI neurofeedback paradigm. NR 56 TC 3 Z9 3 U1 2 U2 11 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 1180-4882 EI 1488-2434 J9 J PSYCHIATR NEUROSCI JI J. Psychiatry Neurosci. PD JAN PY 2016 VL 41 IS 1 BP 48 EP 55 DI 10.1503/jpn.140200 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CZ9SV UT WOS:000367438200006 PM 26505139 ER PT J AU Harvey, PD Aslan, M Du, MT Zhao, HY Siever, LJ Pulver, A Gaziano, JM Concato, J AF Harvey, Philip D. Aslan, Mihaela Du, Mengtian Zhao, Hongyu Siever, Larry J. Pulver, Ann Gaziano, J. Michael Concato, John TI Factor Structure of Cognition and Functional Capacity in Two Studies of Schizophrenia and Bipolar Disorder: Implications for Genomic Studies SO NEUROPSYCHOLOGY LA English DT Article DE bipolar disorder; schizophrenia; cognition; functional capacity; factor analysis ID ASHKENAZI JEWISH FAMILIES; GENOMEWIDE LINKAGE SCAN; SUSCEPTIBILITY LOCI; CANDIDATE GENES; MENTAL-ILLNESS; I DISORDER; GENETICS; ENDOPHENOTYPES; IMPAIRMENT; CONSORTIUM AB Objective: Impairments in cognition and everyday functioning are common in schizophrenia and bipolar disorder (BPD). In this article, we present factor analyses of cognitive and functional capacity (FC) measures based on 2 studies of schizophrenia (SCZ) and bipolar I disorder (BPI) using similar methods. The overall goal of these analyses was to determine whether performance-based assessments should be examined individually, or aggregated on the basis of the correlational structure of the tests, as well as to evaluate the similarity of factor structures of SCZ and BPI. Method: Veterans Affairs Cooperative Studies Program Study #572 (Harvey et al., 2014) evaluated cognitive and FC measures among 5,414 BPI and 3,942 SCZ patients. A 2nd study evaluated similar neuropsychological (NP) and FC measures among 368 BPI and 436 SCZ patients. Principal components analysis, as well as exploratory and CFAs, were used to examine the data. Results: Analyses in both datasets suggested that NP and FC measures were explained by a single underlying factor in BPI and SCZ patients, both when analyzed separately or as in a combined sample. The factor structure in both studies was similar, with or without inclusion of FC measures; homogeneous loadings were observed for that single factor across cognitive and FC domains across the samples. Conclusion: The empirically derived factor model suggests that NP performance and FC are best explained as a single latent trait applicable to people with SCZ and BPD. This single measure may enhance the robustness of the analyses relating genomic data to performance-based phenotypes. C1 [Harvey, Philip D.] Bruce W Carter Miami Vet Affairs Med Ctr, Dept Res Serv, Miami, FL USA. [Harvey, Philip D.] Univ Miami, Dept Psychiat & Behav Sci, Miller Sch Med, Miami, FL 33136 USA. [Aslan, Mihaela; Zhao, Hongyu; Concato, John] Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA. [Aslan, Mihaela; Concato, John] Yale Univ, Dept Med, Sch Med, New Haven, CT 06520 USA. [Du, Mengtian] Yale Univ, Dept Stat, Grad Sch Arts & Sci, New Haven, CT 06520 USA. [Zhao, Hongyu] Yale Univ, Dept Biostat, Sch Publ Hlth, New Haven, CT 06520 USA. [Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Dept Psychiat Serv, Bronx, NY USA. [Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Pulver, Ann] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. [Pulver, Ann] Johns Hopkins Univ, Dept Psychiat, Sch Med, Baltimore, MD 21218 USA. [Gaziano, J. Michael] Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Jamaica Plain, MA USA. [Gaziano, J. Michael] Harvard Univ, Dept Cardiol, Sch Med, Cambridge, MA 02138 USA. RP Harvey, PD (reprint author), Univ Miami, Dept Psychiat & Behav Sci, Miller Sch Med, 1120 Northwest 14th St,Suite 1450, Miami, FL 33136 USA. EM philip.harvey2@va.gov FU U.S. Department of Veterans Affairs Cooperative Studies Program; NIMH [R01MH079784] FX This research was supported by the U.S. Department of Veterans Affairs Cooperative Studies Program. Dr. Harvey has served as a consultant to Boeheringer Ingelheim, Forum Pharmaceuticals, Genentech, Otsuka America, Roche, Sanofi, Sunovion Pharma, and Takeda Pharma, on Phase-2 or -3 drug development; this consulting work is not related to the content of the paper. This research was also supported in part by NIMH grant R01MH079784 to Dr. Pulver. NR 39 TC 0 Z9 0 U1 6 U2 10 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 EI 1931-1559 J9 NEUROPSYCHOLOGY JI Neuropsychology PD JAN PY 2016 VL 30 IS 1 BP 28 EP 39 DI 10.1037/neu0000245 PG 12 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA CZ8CC UT WOS:000367326600004 PM 26710094 ER PT J AU Cheng, A Owens, D AF Cheng, Andrew Owens, David TI Republished: Marfan syndrome, inherited aortopathies and exercise: What is the right answer? SO POSTGRADUATE MEDICAL JOURNAL LA English DT Review ID ARTERIAL BLOOD-PRESSURE; SUDDEN CARDIAC DEATH; AORTIC DISSECTION; CARDIOVASCULAR-DISEASE; HEMODYNAMIC-RESPONSE; SPORTS PARTICIPATION; RESISTANCE EXERCISE; PHYSICAL-ACTIVITY; ASSOCIATION; RECOMMENDATIONS AB Exercise recommendations for those who have Marfan syndrome or other genetic predisposition for thoracic aortic disease remain controversial and at times ambiguous. There are no outcomes studies to help guide recommendations. In this review, we examine the guidelines regarding exercise and inherited aortic conditions, the theoretical reasoning and circumstantial evidence that support the guidelines, as well as the knowledge gaps that continue to exist. C1 [Cheng, Andrew] VA Puget Sound, Dept Cardiol, Seattle, WA 98108 USA. [Cheng, Andrew; Owens, David] Univ Washington, Dept Cardiol, Seattle, WA 98195 USA. RP Cheng, A (reprint author), VA Puget Sound, Dept Cardiol, 1660 S Columbian Way, Seattle, WA 98108 USA. EM ACheng@cardiology.washington.edu NR 39 TC 0 Z9 0 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0032-5473 EI 1469-0756 J9 POSTGRAD MED J JI Postgrad. Med. J. PD JAN PY 2016 VL 92 IS 1083 BP 51 EP 56 DI 10.1136/postgradmedj-2014-306440rep PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DA0HR UT WOS:000367478700009 PM 26676914 ER PT J AU Lehrner, A Flory, JD Sierer, LM Makotkine, I Marmar, CR Yehuda, R AF Lehrner, Amy Flory, Janine D. Sierer, Linda M. Makotkine, Iouri Marmar, Charles R. Yehuda, Rachel TI Sexual dysfunction and neuroendocrine correlates of posttraumatic stress disorder in combat veterans: Preliminary findings SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Sexual dysfunction; Posttraumatic stress disorder; Neurobiology; Neuroendocrinology ID WAR VETERANS; PTSD; MEN; SYMPTOMS; TRIAL AB Sexual dysfunction is not a symptom of PTSD but is a common clinical complaint in trauma survivors with this disorder. In that there are biological parallels in the neuroendocrine processes underlying both PTSD and sexual behavior, we conducted an exploratory investigation of the relationship of PTSD and related neuroendocrine indicators with sexual dysfunction in armed service veterans. Major Depressive Disorder, highly comorbid with PTSD and sexual dysfunction, was also assessed. In veterans with PTSD, sexual problems were associated with plasma DHEA and cortisol, urinary catecholamines, and glucocorticoid sensitivity, even when controlling for the effects of comorbid depression. In a subsample analysis, testosterone levels did not distinguish PTSD or sexual dysfunction, suggesting that sexual problems reported by veterans in this sample were not the result of organic disorder. PTSD did predict higher dihydrotestosterone (DHT) levels, which were associated with sexual problems. More detailed assessment of sexual dysfunction in biologically informed studies of PTSD is warranted to clarify the relationships of PTSD symptomatology and related neurobiology with sexual dysfunction. Published by Elsevier Ltd. C1 [Lehrner, Amy; Flory, Janine D.; Sierer, Linda M.; Makotkine, Iouri; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY 10468 USA. [Lehrner, Amy; Flory, Janine D.; Sierer, Linda M.; Makotkine, Iouri; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Marmar, Charles R.] NYU, Langone Sch Med, New York, NY USA. RP Lehrner, A (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM amy.lehrner@va.gov FU Lightfighter Trust [LFT2009-02-1]; US Department of Defense [DOD W81XWH-06-0032, DOD W81XWH-10-2-0072, DOD W81XWH-09-2-0044] FX Parent studies for the data included in this report were funded by the Lightfighter Trust (LFT2009-02-1) and the US Department of Defense (DOD W81XWH-06-0032, DOD W81XWH-10-2-0072, DOD W81XWH-09-2-0044). NR 24 TC 0 Z9 0 U1 6 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD JAN PY 2016 VL 63 BP 271 EP 275 DI 10.1016/j.psyneuen.2015.10.015 PG 5 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA CZ9MT UT WOS:000367422400033 PM 26529050 ER PT J AU Barry, CL Kennedy-Hendricks, A Gollust, SE Niederdeppe, J Bachhuber, MA Webster, DW McGinty, EE AF Barry, Colleen L. Kennedy-Hendricks, Alene Gollust, Sarah E. Niederdeppe, Jeff Bachhuber, Marcus A. Webster, Daniel W. McGinty, Emma E. TI Understanding Americans' views on opioid pain reliever abuse SO ADDICTION LA English DT Article DE Addiction; opioid analgesics; policy; public opinion; substance abuse; surveys ID POLICY; OPINION; SUPPORT AB AimsOpioid pain reliever abuse rates have increased sharply in the United States. This study examines Americans' personal experience with opioid pain reliever use and abuse, and views about the seriousness of the problem, factors causing it, responsibility for addressing it and support for policies to resolve it. DesignPublic opinion survey. Setting and ParticipantsA nationally representative US adult sample (n=1111). MeasuresExperiences with opioid pain relievers and views about the seriousness, causes of and responsibility for addressing the problem, and support for policies to reduce opioid pain reliever abuse. Findings28.2 per cent of Americans reported using opioid pain relievers in the last 12 months, 69.5% have used them in their life-time and 17.3% reported using these medications when not prescribed to them. Fifty-eight per cent ranked the problem as serious, on a par with other major health concerns. Individual-orientated factors, including a lack of understanding about how easy it is to become addicted (80.0%) and improper storage (65.1%) and disposal (64.1%), ranked highest as causes, and those abusing opioid pain relievers (83.8%) and their physicians (78.0%) were viewed as most responsible for solving the problem. Of the policies recommended to curb the epidemic, 14 of 16 were supported by a majority of Americans. ConclusionsAmericans view the problem of opioid pain reliever abuse as serious, and support nearly all the policies recommended by medical, law enforcement, disease control and public health experts to curb the epidemic. C1 [Barry, Colleen L.; Kennedy-Hendricks, Alene; Webster, Daniel W.; McGinty, Emma E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA. [Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA. [Barry, Colleen L.; Bachhuber, Marcus A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Gollust, Sarah E.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA. [Niederdeppe, Jeff] Cornell Univ, Dept Commun, Ithaca, NY USA. [Bachhuber, Marcus A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Bachhuber, Marcus A.] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. [Webster, Daniel W.; McGinty, Emma E.] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Ctr Injury Res & Policy, Baltimore, MD 21205 USA. RP Barry, CL (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 403, Baltimore, MD 21205 USA. EM cbarry@jhu.edu OI Bachhuber, Marcus/0000-0002-5610-8382 FU AIG, Inc. FX Funding for this study was obtained through an unrestricted research grant from AIG, Inc. The funder had no role in the study design, analysis, interpretation or drafting of this manuscript. The authors have no conflicts of interests to declare. NR 28 TC 4 Z9 4 U1 3 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 85 EP 93 DI 10.1111/add.13077 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500017 PM 26212522 ER PT J AU Baker, TB Collins, LM Mermelstein, R Piper, ME Schlam, TR Cook, JW Bolt, DM Smith, SS Jorenby, DE Fraser, D Loh, WY Theobald, WE Fiore, MC AF Baker, Timothy B. Collins, Linda M. Mermelstein, Robin Piper, Megan E. Schlam, Tanya R. Cook, Jessica W. Bolt, Daniel M. Smith, Stevens S. Jorenby, Douglas E. Fraser, David Loh, Wei-Yin Theobald, Wendy E. Fiore, Michael C. TI Enhancing the effectiveness of smoking treatment research: conceptual bases and progress SO ADDICTION LA English DT Article DE Chronic care smoking treatment; cigarettes; comparative effectiveness; factorial experiment; methodology; Multiphase Optimization Strategy (MOST); phase-based model; primary care; quitting smoking; smoking cessation; tobacco dependence ID NICOTINE REPLACEMENT THERAPY; HEALTH BEHAVIOR-CHANGE; RANDOMIZED CONTROLLED-TRIAL; CHRONIC DISEASE MANAGEMENT; ELECTRONIC MEDICAL-RECORD; BUPROPION SR; STOP SMOKING; INTERVENTION COMPONENTS; CESSATION INTERVENTION; FACTORIAL-EXPERIMENTS AB Background and aimsA chronic care strategy could potentially enhance the reach and effectiveness of smoking treatment by providing effective interventions for all smokers, including those who are initially unwilling to quit. This paper describes the conceptual bases of a National Cancer Institute-funded research program designed to develop an optimized, comprehensive, chronic care smoking treatment. MethodsThis research is grounded in three methodological approaches: (1) the Phase-Based Model, which guides the selection of intervention components to be experimentally evaluated for the different phases of smoking treatment (motivation, preparation, cessation, and maintenance); (2) the Multiphase Optimization Strategy (MOST), which guides the screening of intervention components via efficient experimental designs and, ultimately, the assembly of promising components into an optimized treatment package; and (3) pragmatic research methods, such as electronic health record recruitment, that facilitate the efficient translation of research findings into clinical practice. Using this foundation and working in primary care clinics, we conducted three factorial experiments (reported in three accompanying papers) to screen 15 motivation, preparation, cessation and maintenance phase intervention components for possible inclusion in a chronic care smoking treatment program. ResultsThis research identified intervention components with relatively strong evidence of effectiveness at particular phases of smoking treatment and it demonstrated the efficiency of the MOST approach in terms both of the number of intervention components tested and of the richness of the information yielded. ConclusionsA new, synthesized research approach efficiently evaluates multiple intervention components to identify promising components for every phase of smoking treatment. Many intervention components interact with one another, supporting the use of factorial experiments in smoking treatment development. C1 [Baker, Timothy B.; Piper, Megan E.; Schlam, Tanya R.; Cook, Jessica W.; Smith, Stevens S.; Jorenby, Douglas E.; Fraser, David; Theobald, Wendy E.; Fiore, Michael C.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. [Baker, Timothy B.; Piper, Megan E.; Schlam, Tanya R.; Cook, Jessica W.; Smith, Stevens S.; Jorenby, Douglas E.; Fraser, David; Theobald, Wendy E.; Fiore, Michael C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53711 USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Collins, Linda M.] Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53711 USA. [Loh, Wei-Yin] Univ Wisconsin, Dept Stat, Madison, WI 53711 USA. RP Fiore, MC (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM mcf@ctri.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; NSF [DMS-1305725]; NIH [P50DA10075, R01DK097364] FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. This work was carried out in part while T.R.S. was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. W.-Y.L. is also supported by NSF grant DMS-1305725. L.M.C. is also supported by NIH grants P50DA10075 and R01DK097364. NR 88 TC 5 Z9 5 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 107 EP 116 DI 10.1111/add.13154 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500019 PM 26581974 ER PT J AU Cook, JW Collins, LM Fiore, MC Smith, SS Fraser, D Bolt, DM Baker, TB Piper, ME Schlam, TR Jorenby, D Loh, WY Mermelstein, R AF Cook, Jessica W. Collins, Linda M. Fiore, Michael C. Smith, Stevens S. Fraser, David Bolt, Daniel M. Baker, Timothy B. Piper, Megan E. Schlam, Tanya R. Jorenby, Douglas Loh, Wei-Yin Mermelstein, Robin TI Comparative effectiveness of motivation phase intervention components for use with smokers unwilling to quit: a factorial screening experiment SO ADDICTION LA English DT Article DE Chronic care smoking treatment; comparative effectiveness; factorial experiment; motivational interviewing; Multi-phase Optimization Strategy (MOST); nicotine replacement therapy; Phase-Based Model; primary care; smoking cessation; smoking reduction ID NICOTINE REPLACEMENT THERAPY; INCREASE FUTURE CESSATION; CURRENT CIGARETTE-SMOKING; RANDOMIZED-TRIAL; UNITED-STATES; ADULT SMOKERS; BEHAVIORAL INTERVENTIONS; TOBACCO DEPENDENCE; DISEASE MANAGEMENT; GENERAL-POPULATION AB AimsTo screen promising intervention components designed to reduce smoking and promote abstinence in smokers initially unwilling to quit. DesignA balanced, four-factor, randomized factorial experiment. SettingEleven primary care clinics in southern Wisconsin, USA. ParticipantsA total of 517 adult smokers (63.4% women, 91.1% white) recruited during primary care visits who were willing to reduce their smoking but not quit. InterventionsFour factors contrasted intervention components designed to reduce smoking and promote abstinence: (1) nicotine patch versus none; (2) nicotine gum versus none; (3) motivational interviewing (MI) versus none; and (4) behavioral reduction counseling (BR) versus none. Participants could request cessation treatment at any point during the study. MeasurementsThe primary outcome was percentage change in cigarettes smoked per day at 26weeks post-study enrollment; the secondary outcomes were percentage change at 12 weeks and point-prevalence abstinence at 12 and 26 weeks post-study enrollment. FindingsThere were few main effects, but a significant four-way interaction at 26weeks post-study enrollment (P=0.01, =0.12) revealed relatively large smoking reductions by two component combinations: nicotine gum combined with BR and BR combined with MI. Further, BR improved 12-week abstinence rates (P=0.04), and nicotine gum, when used without MI, increased 26-week abstinence after a subsequent aided quit attempt (P=0.01). ConclusionsMotivation-phase nicotine gum and behavioral reduction counseling are promising intervention components for smokers who are initially unwilling to quit. C1 [Cook, Jessica W.; Fiore, Michael C.; Smith, Stevens S.; Fraser, David; Baker, Timothy B.; Piper, Megan E.; Schlam, Tanya R.; Jorenby, Douglas] Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, Madison, WI 53711 USA. [Cook, Jessica W.; Fiore, Michael C.; Smith, Stevens S.; Fraser, David; Baker, Timothy B.; Piper, Megan E.; Schlam, Tanya R.; Jorenby, Douglas] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53711 USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53711 USA. [Loh, Wei-Yin] Univ Wisconsin, Dept Stat, Madison, WI 53711 USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Collins, Linda M.] Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. RP Cook, JW (reprint author), Univ Wisconsin, Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. EM jwcook@ctri.medicine.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; NSF [DMS-1305725]; NIH [P50DA10075, R01DK097364]; Merit Review Award from the US Department of Veterans Affairs [101CX00056]; Eli Lilly and Company FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. This work was carried out in part while T.R.S. was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. W.-Y.L. is also supported by NSF grant DMS-1305725. L. M.C. is also supported by NIH grants P50DA10075 and R01DK097364. J.W.C. is supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs. The authors have received no direct or indirect funding from, nor do they have a connection with, the tobacco, alcohol, pharmaceutical or gaming industries or anybody funded substantially by one of these organizations. W.-Y.L. is supported partially by a grant from Eli Lilly and Company for research that is unrelated to smoking or tobacco dependence treatment. NR 70 TC 4 Z9 4 U1 5 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 117 EP 128 DI 10.1111/add.13161 PG 12 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500020 PM 26582140 ER PT J AU Piper, ME Fiore, MC Smith, SS Fraser, D Bolt, DM Collins, LM Mermelstein, R Schlam, TR Cook, JW Jorenby, DE Loh, WY Baker, TB AF Piper, Megan E. Fiore, Michael C. Smith, Stevens S. Fraser, David Bolt, Daniel M. Collins, Linda M. Mermelstein, Robin Schlam, Tanya R. Cook, Jessica W. Jorenby, Douglas E. Loh, Wei-Yin Baker, Timothy B. TI Identifying effective intervention components for smoking cessation: a factorial screening experiment SO ADDICTION LA English DT Article DE Chronic care smoking treatment; comparative effectiveness; factorial experiment; Multiphase Optimization Strategy (MOST); nicotine replacement therapy; Phase-Based Model of smoking treatment; primary care; smoking cessation; tobacco dependence ID NICOTINE REPLACEMENT THERAPY; RANDOMIZED-TRIAL; PRECESSATION TREATMENT; WITHDRAWAL SYMPTOMS; SELF-DETERMINATION; TOBACCO CESSATION; FUTURE CESSATION; CIGARETTE USE; ABSTINENCE; PATCH AB Aim To identify promising intervention components intended to help smokers to attain and maintain abstinence in their quit smoking attempts. DesignA fully crossed, six-factor randomized fractional factorial experiment. SettingEleven primary care clinics in southern Wisconsin, USA. ParticipantsA total of 637 adult smokers (55% women, 88% white) motivated to quit smoking who visited primary care clinics. InterventionsSix intervention components designed to prepare smokers to quit, and achieve and maintain abstinence (i.e. for the preparation, cessation and maintenance phases of smoking treatment): (1) preparation nicotine patch versus none; (2) preparation nicotine gum versus none; (3) preparation counseling versus none; (4) intensive cessation in-person counseling versus minimal; (5) intensive cessation telephone counseling versus minimal; and (6) 16 versus 8weeks of combination nicotine replacement therapy (nicotine patch + nicotine gum). MeasurementsSeven-day self-reported point-prevalence abstinence at 16weeks. FindingsPreparation counseling significantly improved week 16 abstinence rates (P = .04), while both forms of preparation nicotine replacement therapy interacted synergistically with intensive cessation in-person counseling (P<0.05). Conversely, intensive cessation phone counseling and intensive cessation in-person counseling interacted antagonistically (P<0.05)these components produced higher abstinence rates by themselves than in combination. ConclusionsPreparation counseling and the combination of intensive cessation in-person counseling with preparation nicotine gum or patch are promising intervention components for smoking and should be evaluated as an integrated treatment package. C1 [Piper, Megan E.; Fiore, Michael C.; Smith, Stevens S.; Fraser, David; Schlam, Tanya R.; Cook, Jessica W.; Jorenby, Douglas E.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. [Piper, Megan E.; Fiore, Michael C.; Smith, Stevens S.; Schlam, Tanya R.; Cook, Jessica W.; Jorenby, Douglas E.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53711 USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53711 USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Loh, Wei-Yin] Univ Wisconsin, Dept Stat, Madison, WI 53711 USA. RP Piper, ME (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM mep@ctri.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; NIH [P50DA10075, R01DK097364]; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; Merit Review Award from the US Department of Veterans Affairs [101CX00056]; NSF [DMS-1305725]; Eli Lilly and Company FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. L.M. C. is also supported by NIH grants P50DA10075 and R01DK097364. This work was carried out in part while T.R.S. was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. J.W.C. is also supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs. W.-Y.L. is also supported by NSF grant DMS-1305725. The authors have received no direct or indirect funding from, nor do they have a connection with, the tobacco, alcohol, pharmaceutical or gaming industries or anybody substantially funded by one of these organizations. W.-Y.L. is partially supported by a grant from Eli Lilly and Company for research that is unrelated to smoking or tobacco dependence treatment. NR 71 TC 10 Z9 11 U1 8 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 129 EP 141 DI 10.1111/add.13162 PG 13 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500021 PM 26582269 ER PT J AU Schlam, TR Fiore, MC Smith, SS Fraser, D Bolt, DM Collins, LM Mermelstein, R Piper, ME Cook, JW Jorenby, DE Loh, WY Baker, TB AF Schlam, Tanya R. Fiore, Michael C. Smith, Stevens S. Fraser, David Bolt, Daniel M. Collins, Linda M. Mermelstein, Robin Piper, Megan E. Cook, Jessica W. Jorenby, Douglas E. Loh, Wei-Yin Baker, Timothy B. TI Comparative effectiveness of intervention components for producing long-term abstinence from smoking: a factorial screening experiment SO ADDICTION LA English DT Article DE Chronic care smoking treatment; comparative effectiveness; electronic medication monitoring; factorial experiment; medication adherence; Multiphase Optimization Strategy (MOST); nicotine replacement therapy; Phase-Based Model of smoking treatment; primary care; relapse prevention; smoking cessation; tobacco dependence ID NICOTINE REPLACEMENT THERAPY; RANDOMIZED CLINICAL-TRIAL; RELAPSE PREVENTION; QUITTING SMOKING; MEDICATION ADHERENCE; MEMS FEEDBACK; ADULT SMOKERS; CESSATION; PATCH; CIGARETTE AB AimsTo identify promising intervention components that help smokers attain and maintain abstinence during a quit attempt. DesignA 2x2x2x2x2 randomized factorial experiment. SettingEleven primary care clinics in Wisconsin, USA. ParticipantsA total of 544 smokers (59% women, 86% white) recruited during primary care visits and motivated to quit. InterventionsFive intervention components designed to help smokers attain and maintain abstinence: (1) extended medication (26 versus 8 weeks of nicotine patch+nicotine gum); (2) maintenance (phone) counseling versus none; (3) medication adherence counseling versus none; (4) automated (medication) adherence calls versus none; and (5) electronic medication monitoring with feedback and counseling versus electronic medication monitoring alone. MeasurementsThe primary outcome was 7-day self-reported point-prevalence abstinence 1 year after the target quit day. FindingsOnly extended medication produced a main effect. Twenty-six versus 8 weeks of medication improved point-prevalence abstinence rates (43 versus 34% at 6 months; 34 versus 27% at 1 year; P =0.01 for both). There were four interaction effects at 1 year, showing that an intervention component's effectiveness depended upon the components with which it was combined. ConclusionsTwenty-six weeks of nicotine patch+nicotine gum (versus 8 weeks) and maintenance counseling provided by phone are promising intervention components for the cessation and maintenance phases of smoking treatment. C1 [Schlam, Tanya R.; Fiore, Michael C.; Smith, Stevens S.; Fraser, David; Piper, Megan E.; Cook, Jessica W.; Jorenby, Douglas E.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. [Schlam, Tanya R.; Fiore, Michael C.; Smith, Stevens S.; Piper, Megan E.; Cook, Jessica W.; Jorenby, Douglas E.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53711 USA. [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53711 USA. [Collins, Linda M.] Penn State Univ, Methodol Ctr, State Coll, PA USA. [Collins, Linda M.] Penn State Univ, Dept Human Dev & Family Studies, State Coll, PA USA. [Mermelstein, Robin] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53711 USA. [Loh, Wei-Yin] Univ Wisconsin, Dept Stat, Madison, WI 53711 USA. RP Schlam, TR (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM trschlam@ctri.wisc.edu FU National Cancer Institute [9P50CA143188, 1K05CA139871]; Wisconsin Partnership Program; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; National Science Foundation [DMS-1305725]; NIH [P50DA10075, R01DK097364]; Merit Review Award from the US Department of Veterans Affairs [101CX00056]; Eli Lilly and Company FX This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. This work was carried out in part while T.R.S. was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. W.-Y.L. is also supported by National Science Foundation grant DMS-1305725. L.M.C. is also supported by NIH grants P50DA10075 and R01DK097364. J.W.C. is supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs.; The authors have received no direct or indirect funding from, nor do they have a connection with, the tobacco, alcohol, pharmaceutical or gaming industries or anybody funded substantially by one of these organizations. W.-Y.L. is supported partially by a grant from Eli Lilly and Company for research that is unrelated to smoking or tobacco dependence treatment. NR 63 TC 6 Z9 6 U1 6 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2016 VL 111 IS 1 BP 142 EP 155 DI 10.1111/add.13153 PG 14 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CZ4JY UT WOS:000367070500022 PM 26581819 ER PT J AU Greenan, CW Christensen, C Wojciechowski, B Taam, R Newman, RB AF Greenan, Candice W. Christensen, Colleen Wojciechowski, Barbara Taam, Rosalea Newman, Roger B. TI Gestational weight gain in twin pregnancies: does achievement of body mass index-specific weight gain recommendations reduce preterm birth and neonatal morbidity? SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Meeting Abstract CT 36th Annual Pregnancy Meeting of the Society-for-Maternal-Fetal-Medicine CY FEB 01-06, 2016 CL Atlanta, GA SP Soc Maternal Fetal Med C1 [Greenan, Candice W.; Christensen, Colleen; Taam, Rosalea; Newman, Roger B.] Med Univ S Carolina, Charleston, SC 29425 USA. [Wojciechowski, Barbara] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JAN PY 2016 VL 214 IS 1 SU S MA 422 BP S233 EP S233 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CZ4SK UT WOS:000367092800416 ER PT J AU Greenan, CW Christensen, C Wojciechowski, B Taam, R Newman, R AF Greenan, Candice W. Christensen, Colleen Wojciechowski, Barbara Taam, Rosalea Newman, Roger TI Validation of body mass index (BMI)-specific weight gain recommendations for twin gestations in all maternal BMI categories SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Meeting Abstract CT 36th Annual Pregnancy Meeting of the Society-for-Maternal-Fetal-Medicine CY FEB 01-06, 2016 CL Atlanta, GA SP Soc Maternal Fetal Med C1 [Greenan, Candice W.; Christensen, Colleen; Taam, Rosalea; Newman, Roger] Med Univ S Carolina, Charleston, SC 29425 USA. [Wojciechowski, Barbara] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JAN PY 2016 VL 214 IS 1 SU S MA 282 BP S163 EP S163 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CZ4SK UT WOS:000367092800278 ER PT J AU Khan, M Dhammu, TS Matsuda, F Annamalai, B Dhindsa, TS Singh, I Singh, AK AF Khan, Mushfiquddin Dhammu, Tajinder S. Matsuda, Fumiyo Annamalai, Balasubramaniam Dhindsa, Tejbir Singh Singh, Inderjit Singh, Avtar K. TI Targeting the nNOS/peroxynitrite/calpain system to confer neuroprotection and aid functional recovery in a mouse model of TBI SO BRAIN RESEARCH LA English DT Article DE TBI; GSNO; Calpain; Peroxynitrite; nNOS; Neurodegeneration ID TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; S-NITROSOGLUTATHIONE; EXPERIMENTAL STROKE; RAT MODEL; CYTOSKELETAL DEGRADATION; PEROXYNITRITE FORMATION AB Traumatic brain injury (TB!) derails nitric oxide (NO)-based anti-inflammatory and anti-excitotoxicity mechanisms. NO is consumed by superoxide to form peroxynitrite, leading to decreased NO bioavailability for S-nitrosoglutathione (GSNO) synthesis and regulation of neuroprotective pathways. Neuronal peroxynitrite is implicated in neuronal loss and functional deficits following TBI. Using a contusion mouse model of TBI, we investigated mechanisms for the opposed roles of GSNO versus peroxynitrite for neuroprotection and functional recovery. TBI was induced by controlled cortical impact (CCI) in adult male mice. GSNO treatment at 2 h after CCI decreased the expression levels of phospho neuronal nitric oxide synthase (pnNOS), alpha II spectrin degraded products, and 3-NT, while also decreasing the activities of nNOS and calpains. Treatment of TBI with FeTPPS, a peroxynitrite scavenger, had effects similar to GSNO treatment. GSNO treatment of TBI also reduced neuronal degeneration and improved neurobehavioral function in a two-week TB! study. In a cell free system, SIN-1 (a peroxynitrite donor and 3-nitrotyrosinating agent) increased whereas GSNO (an S-nitrosylating agent) decreased calpain activity, and these activities were reversed by, respectively, FeTPPS and mercuric chloride, a cysteine-NO bond cleaving agent. These data indicate that peroxynitrite-mediated activation and GSNO-mediated inhibition of the deleterious nNOS/calpain system play critical roles in the pathobiology of neuronal protection and functional recovery in TBI disease. Given GSNO's safety record in other diseases, its neuroprotective efficacy and promotion of functional recovery in this TBI study make low-dose GSNO a potential candidate for preclinical evaluation. (C) 2015 Elsevier B.V. All rights reserved. C1 [Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Annamalai, Balasubramaniam; Dhindsa, Tejbir Singh; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan. [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM khanm@musc.edu; dhammu@musc.edu; fumiyo@health.nop.kagoshima-u.ac.jp; annamal@musc.edu; dhindsat@musc.edu; singhi@musc.edu; singha@musc.edu FU NIH [NS-72511]; VA Merit Award [BX001062, BX002829]; NIH from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR018823, C06 RR015455] FX This work was supported by grants from NIH (NS-72511) and VA Merit Award (BX001062 and BX002829). This work was also supported by the NIH, Grants C06 RR018823 and No. C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan and Ms. Terry Hope for their technical help and secretarial assistance. We are grateful to Ms. Danielle Lowe (MD/PhD student at the MUSC) for statistical analysis. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing of the manuscript. NR 63 TC 2 Z9 2 U1 2 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD JAN 1 PY 2016 VL 1630 BP 159 EP 170 DI 10.1016/j.brainres.2015.11.015 PG 12 WC Neurosciences SC Neurosciences & Neurology GA CZ4YU UT WOS:000367109900016 PM 26596859 ER PT J AU Ijadi-Maghsoodi, R Cook, M Barnert, ES Gaboian, S Bath, E AF Ijadi-Maghsoodi, Roya Cook, Mekeila Barnert, Elizabeth S. Gaboian, Shushanik Bath, Eraka TI Understanding and Responding to the Needs of Commercially Sexually Exploited Youth Recommendations for the Mental Health Provider SO CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Commercially sexually exploited children; Commercial sexual exploitation of children; Sex trafficking; Human trafficking; Exploitation ID RANDOMIZED CONTROLLED-TRIAL; SEX TRAFFICKING; UNITED-STATES; TRAUMA; ABUSE; WOMEN; PROSTITUTION; SERVICES; CHILDREN; THERAPY AB Mental health providers are frequently at the forefront of addressing the multifaceted needs of commercially sexually exploited youth. This article provides an overview of the definition of commercial sexual exploitation of children and relevant legislation including the shift toward decriminalization of commercially sexually exploited youth. To provide clinicians with tools needed to deliver competent care to this population, a review of risk factors for commercial sexual exploitation of children and the role of the clinician in identification, assessment, and treatment of commercially sexually exploited youth are discussed. C1 [Ijadi-Maghsoodi, Roya] Off Healthcare Transformat & Innovat, VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA 90073 USA. [Ijadi-Maghsoodi, Roya] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Cook, Mekeila] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Integrated Subst Abuse Programs, Los Angeles, CA 90025 USA. [Barnert, Elizabeth S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Gaboian, Shushanik] Univ Calif Los Angeles, Dept Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Bath, Eraka] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Child Forens Serv, Los Angeles, CA 90095 USA. RP Ijadi-Maghsoodi, R (reprint author), Off Healthcare Transformat & Innovat, VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, 11301 Wilshire Blvd,Bldg 500,Room 1601, Los Angeles, CA 90073 USA. EM rijadimaghsoodi@mednet.ucla.edu FU VA Office of Academic Affiliations through VA Advanced Fellowship in Women's Health; NIMH [2P20 MD000182]; Los Angeles County Department of Probation FX Dr R. Ijadi-Maghsoodi is supported by the VA Office of Academic Affiliations through the VA Advanced Fellowship in Women's Health. Dr E. Bath receives funding from the NIMH (2P20 MD000182) and the Los Angeles County Department of Probation. Dr R. Ijadi-Maghsoodi, Dr E.S. Barnert, Dr M. Cook, and Ms S. Gaboian have nothing to disclose. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs or the United States Government. NR 37 TC 1 Z9 1 U1 8 U2 26 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1056-4993 EI 1558-0490 J9 CHILD ADOL PSYCH CL JI Child Adolesc. Psychiatr. N. Am. PD JAN PY 2016 VL 25 IS 1 BP 107 EP + DI 10.1016/j.chc.2015.08.007 PG 17 WC Psychiatry SC Psychiatry GA CZ1RE UT WOS:000366882200011 PM 26593123 ER PT J AU Pierre, JF Busch, RA Kudsk, KA AF Pierre, Joseph F. Busch, Rebecca A. Kudsk, Kenneth A. TI The Gastrointestinal Immune System: Implications for the Surgical Patient SO CURRENT PROBLEMS IN SURGERY LA English DT Review C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Pierre, Joseph F.] Univ Chicago, Dept Med, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA. [Busch, Rebecca A.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Div Gen Surg, Madison, WI USA. RP Pierre, JF (reprint author), Univ Chicago, Dept Med, Sect Gastroenterol Hepatol & Nutr, 5841 S Maryland Ave, Chicago, IL 60637 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-3840 EI 1535-6337 J9 CURR PROB SURG JI Curr. Probl. Surg. PD JAN PY 2016 VL 53 IS 1 BP 6 EP 10 DI 10.1067/j.cpsurg.2015.10.006 PG 5 WC Surgery SC Surgery GA CZ6KT UT WOS:000367210900002 PM 26699623 ER PT J AU Camus, M Jensen, DM Ohning, GV Kovacs, TO Jutabha, R Ghassemi, KA Machicado, GA Dulai, GS Jensen, ME Gornbein, JA AF Camus, Marine Jensen, Dennis M. Ohning, Gordon V. Kovacs, Thomas O. Jutabha, Rome Ghassemi, Kevin A. Machicado, Gustavo A. Dulai, Gareth S. Jensen, Mary E. Gornbein, Jeffrey A. TI Comparison of Three Risk Scores to Predict Outcomes of Severe Lower Gastrointestinal Bleeding SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE prognosis score; gastrointestinal bleeding; Charlson index; ASA score; CURE Hemostasis prognosis score ID RANDOMIZED CONTROLLED-TRIAL; LENGTH-OF-STAY; OUTPATIENT CARE; HEMORRHAGE; MORTALITY; MANAGEMENT; VALIDATION; ENDOSCOPY; MORBIDITY; COST AB Background and Aims: Improved medical decisions by using a score at the initial patient triage level may lead to improvements in patient management, outcomes, and resource utilization. There is no validated score for management of lower gastrointestinal bleeding (LGIB) unlike for upper gastrointestinal bleeding. The aim of our study was to compare the accuracies of 3 different prognostic scores [Center for Ulcer Research and Education Hemostasis prognosis score, Charlson index, and American Society of Anesthesiologists (ASA) score] for the prediction of 30-day rebleeding, surgery, and death in severe LGIB. Methods: Data on consecutive patients hospitalized with severe gastrointestinal bleeding from January 2006 to October 2011 in our 2 tertiary academic referral centers were prospectively collected. Sensitivities, specificities, accuracies, and area under the receiver operator characteristic curve were computed for 3 scores for predictions of rebleeding, surgery, and mortality at 30 days. Results: Two hundred thirty-five consecutive patients with LGIB were included between 2006 and 2011. Twenty-three percent of patients rebled, 6% had surgery, and 7.7% of patients died. The accuracies of each score never reached 70% for predicting rebleeding or surgery in either. The ASA score had a highest accuracy for predicting mortality within 30 days (83.5%), whereas the Center for Ulcer Research and Education Hemostasis prognosis score and the Charlson index both had accuracies <75% for the prediction of death within 30 days. Conclusions: ASA score could be useful to predict death within 30 days. However, a new score is still warranted to predict all 30 days outcomes (rebleeding, surgery, and death) in LGIB. C1 [Camus, Marine; Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O.; Jutabha, Rome; Ghassemi, Kevin A.; Machicado, Gustavo A.; Dulai, Gareth S.; Jensen, Mary E.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, CURE Hemostasis Res Grp, Los Angeles, CA 90095 USA. [Camus, Marine; Jensen, Dennis M.; Kovacs, Thomas O.; Jutabha, Rome; Ghassemi, Kevin A.; Machicado, Gustavo A.; Dulai, Gareth S.; Jensen, Mary E.] Univ Calif Los Angeles, UCLA Ronald Reagan Med Ctr, Div Digest Dis, Los Angeles, CA 90095 USA. [Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O.; Machicado, Gustavo A.; Dulai, Gareth S.] Univ Calif Los Angeles, Div Gastroenterol, VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90095 USA. [Gornbein, Jeffrey A.] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA. [Camus, Marine] Univ Paris 07, Lariboisiere Hosp, AP HP, Dept Gastroenterol, Paris, France. RP Jensen, DM (reprint author), VA Greater Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM djensen@mednet.ucla.edu FU CURE Center Grant Human Studies CORE [NIH41301]; VA Clinical Merit Review Grant; Philippe Foundation FX Partially supported by NIH41301 CURE Center Grant Human Studies CORE and a VA Clinical Merit Review Grant (D.M.J.). M.C. received a grant from the Philippe Foundation for supporting her research exchange program between France and the United States. NR 28 TC 3 Z9 3 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0192-0790 EI 1539-2031 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD JAN PY 2016 VL 50 IS 1 BP 52 EP 58 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CZ2ND UT WOS:000366941000010 PM 25599218 ER PT J AU Gardner, RC Hess, CP Brus-Ramer, M Possin, KL Cohn-Sheehy, BI Kramer, JH Berger, MS Yaffe, K Miller, B Rabinovici, GD AF Gardner, Raquel C. Hess, Christopher P. Brus-Ramer, Marcel Possin, Katherine L. Cohn-Sheehy, Brendan I. Kramer, Joel H. Berger, Mitchel S. Yaffe, Kristine Miller, Bruce Rabinovici, Gil D. TI Cavum Septum Pellucidum in Retired American Pro-Football Players SO JOURNAL OF NEUROTRAUMA LA English DT Article DE concussion; magnetic resonance imaging; septum pellucidum; traumatic brain injury ID TRAUMATIC BRAIN-INJURY; ENCEPHALOPATHY; DEMENTIA; DISEASE; BOXERS; MRI AB Previous studies report that cavum septum pellucidum (CSP) is frequent among athletes with a history of repeated traumatic brain injury (TBI), such as boxers. Few studies of CSP in athletes, however, have assessed detailed features of the septum pellucidum in a case-control fashion. This is important because prevalence of CSP in the general population varies widely (2% to 85%) between studies. Further, rates of CSP among American pro-football players have not been described previously. We sought to characterize MRI features of the septum pellucidum in a series of retired pro-football players with a history of repeated concussive/subconcussive head traumas compared with controls. We retrospectively assessed retired American pro-football players presenting to our memory clinic with cognitive/behavioral symptoms in whom structural MRI was available with slice thickness 2mm (n=17). Each player was matched to a memory clinic control patient with no history of TBI. Scans were interpreted by raters blinded to clinical information and TBI/football history, who measured CSP grade (0-absent, 1-equivocal, 2-mild, 3-moderate, 4-severe) and length according to a standard protocol. Sixteen of 17 (94%) players had a CSP graded 2 compared with 3 of 17 (18%) controls. CSP was significantly higher grade (p<0.001) and longer in players than controls (mean length +/- standard deviation: 10.6mm +/- 5.4 vs. 1.1mm +/- 1.3, p<0.001). Among patients presenting to a memory clinic, long high-grade CSP was more frequent in retired pro-football players compared with patients without a history of TBI. C1 [Gardner, Raquel C.; Possin, Katherine L.; Cohn-Sheehy, Brendan I.; Kramer, Joel H.; Miller, Bruce; Rabinovici, Gil D.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94121 USA. [Gardner, Raquel C.; Yaffe, Kristine] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Hess, Christopher P.; Brus-Ramer, Marcel] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA. [Berger, Mitchel S.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. RP Gardner, RC (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St,Neurol Box 127, San Francisco, CA 94121 USA. EM raquel.gardner@ucsf.edu FU Department of Veterans Affairs Advanced Fellowship in Mental Illness Research/Treatment; UCSF Pepper Center Research Career Development Core; NIA [K24-AG031155, R01-AG045611, K23-AG037566]; Alzheimer's Association; Avid Radiopharmaceuticals; John Douglas French Alzheimer's Foundation; Hellman Family Foundation; Tau Consortium; UCSF ADRC [P50 AG023501]; State Center grants FX We thank our patients and their families for contributing to research on TBI. We acknowledge administrative and technical support from Trishna Subas and Shirley Reeder. Funding: Department of Veterans Affairs Advanced Fellowship in Mental Illness Research/Treatment (RCG); UCSF Pepper Center Research Career Development Core (RCG); NIA K24-AG031155 (KY), NIA R01-AG045611 (GDR), Alzheimer's Association (GDR), Avid Radiopharmaceuticals (GDR), John Douglas French Alzheimer's Foundation (GDR), Hellman Family Foundation (GDR), Tau Consortium (GDR), UCSF ADRC (P50 AG023501) (GDR, BM), and State Center grants (BM), NIA K23-AG037566 (KP). NR 15 TC 2 Z9 2 U1 3 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JAN 1 PY 2016 VL 33 IS 1 BP 157 EP 161 DI 10.1089/neu.2014.3805 PG 5 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CZ4EW UT WOS:000367057200018 PM 25970145 ER PT J AU Dumanovsky, T Augustin, R Rogers, M Lettang, K Meier, DE Morrison, RS AF Dumanovsky, Tamara Augustin, Rachel Rogers, Maggie Lettang, Katrina Meier, Diane E. Morrison, R. Sean TI The Growth of Palliative Care in US Hospitals: A Status Report SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID UNITED-STATES; ACCESS AB Background: Palliative care is expanding rapidly in the United States. Objective: To examine variation in access to hospital palliative care. Methods: Data were obtained from the American Hospital Association (AHA) Annual Surveys for Fiscal Years 2012 and 2013, the National Palliative Care Registry, the Dartmouth Atlas of Healthcare, the American Census Bureau's American Community Survey (ACS), web searches, and telephone interviews of hospital administrators and program directors. Multivariable logistic regression was used to examine predictors of hospital palliative care programs. Results: Sixty-seven percent of hospitals with 50 or more total facility beds reported a palliative care program. Institutional characteristics were strongly associated with the presence of a hospital palliative care program. Ninety percent of hospitals with 300 beds or more were found to have palliative care programs as compared to 56% of hospitals with fewer than 300 beds. Tax status was also a significant predictor. Not-for-profit hospitals and public hospitals were, respectively, 4.8 times and 7.1 times more likely to have a palliative care program as compared to for-profit hospitals. Palliative care penetration was highest in the New England (88% of hospitals), Pacific (77% of hospitals), and mid-Atlantic (77% of hospitals) states and lowest in the west south central (43% of hospitals) and east south central (42% of hospitals) states. Conclusions: This study demonstrates continued steady growth in the number of hospital palliative care programs in the United States, with almost universal access to services in large U.S. hospitals and academic medical centers. Nevertheless access to palliative care remains uneven and depends on accidents of geography and hospital ownership. C1 [Dumanovsky, Tamara; Augustin, Rachel; Rogers, Maggie; Lettang, Katrina; Meier, Diane E.] Icahn Sch Med Mt Sinai, Ctr Adv Palliat Care, New York, NY 10029 USA. [Meier, Diane E.; Morrison, R. Sean] Icahn Sch Med Mt Sinai, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Morrison, R. Sean] Icahn Sch Med Mt Sinai, Natl Palliat Care Res Ctr, New York, NY 10029 USA. [Morrison, R. Sean] James J Peters VA Med Ctr, Bronx, NY USA. RP Morrison, RS (reprint author), Icahn Sch Med Mt Sinai, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Palliat Med, Box 1070, New York, NY 10029 USA. EM sean.morrison@mssm.edu FU National Institute on Aging [R24AG044300, P30AG028741]; Cambia Health Foundation; Clinical Research Professor Award from the American Cancer Society FX This work was supported by grants from the National Institute on Aging (R24AG044300, P30AG028741) and the Cambia Health Foundation. Dr. Morrison is the recipient of a Clinical Research Professor Award from the American Cancer Society. NR 10 TC 22 Z9 22 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD JAN 1 PY 2016 VL 19 IS 1 BP 8 EP 15 DI 10.1089/jpm.2015.0351 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CZ4FB UT WOS:000367057700005 PM 26417923 ER PT J AU Collins, GT Gerak, LR Javors, MA France, CP AF Collins, Gregory T. Gerak, Lisa R. Javors, Martin A. France, Charles P. TI Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID 5-HT2C RECEPTOR AGONISTS; MEDICATION DEVELOPMENT; INDUCED REINSTATEMENT; ADDICTIVE DISORDERS; SQUIRREL-MONKEYS; SEEKING BEHAVIOR; ABUSE; DEPENDENCE; RATS; MODULATION AB Cocaine abuse and obesity are serious public health problems, and studies suggest that both dopamine and serotonin systems are involved in regulating the consumption of drugs and food. Lorcaserin has serotonin (5-HT)(2C) receptor agonist actions, is approved by the U.S. Food and Drug Administration for treating obesity, and might be effective for treating cocaine abuse. These studies characterized the pharmacokinetic and behavioral profiles of lorcaserin (intragastric administration) and determined the effectiveness of lorcaserin to alter discriminative stimulus and reinforcing effects of cocaine (intravenous administration) in rhesus monkeys. Administered acutely, lorcaserin dose-dependently increased the occurrence of yawning while decreasing spontaneous activity and operant responding for food. These effects appeared within 30-60 minutes of administration and began to dissipate by 240 minutes, a time course closely matching plasma concentrations of lorcaserin. In monkeys discriminating cocaine from saline, lorcaserin alone did not occasion cocaine-appropriate responding but shifted the cocaine dose-response curve to the right and down in two of three monkeys. When administered acutely, lorcaserin dose-dependently decreased the rate at which monkeys responded for infusions of cocaine. When administered chronically, 3.2 mg/kg lorcaserin reduced the rate of cocaine-maintained responding by 50% for the duration of a 14-day treatment period. Together, these results show that lorcaserin attenuates the discriminative stimulus effects of cocaine after acute administration and the reinforcing effects of cocaine after acute and repeated administration, consistent with the view that it might have utility in treating cocaine abuse. C1 [Collins, Gregory T.; Gerak, Lisa R.; Javors, Martin A.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Javors, Martin A.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Collins, Gregory T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP France, CP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM france@uthscsa.edu RI Collins, Gregory/K-3125-2012 FU National Institutes of Health National Institute on Drug Abuse [U01DA034992, K05DA017918] FX This research was supported by the National Institutes of Health National Institute on Drug Abuse [Grants U01DA034992 and K05DA017918]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Institute on Drug Abuse. NR 47 TC 4 Z9 4 U1 1 U2 6 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD JAN PY 2016 VL 356 IS 1 BP 85 EP 95 DI 10.1124/jpet.115.228833 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CZ2NN UT WOS:000366942000010 PM 26534942 ER PT J AU Williams, EC Achtmeyer, CE Young, JP Rittmueller, SE Ludman, EJ Lapham, GT Lee, AK Chavez, LJ Berger, D Bradley, KA AF Williams, Emily C. Achtmeyer, Carol E. Young, Jessica P. Rittmueller, Stacey E. Ludman, Evette J. Lapham, Gwen T. Lee, Amy K. Chavez, Laura J. Berger, Douglas Bradley, Katharine A. TI Local Implementation of Alcohol Screening and Brief Intervention at Five Veterans Health Administration Primary Care Clinics: Perspectives of Clinical and Administrative Staff SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Qualitative; Alcohol; Screening; Brief intervention; Implementation ID RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS; GENERAL-PRACTITIONERS; MENTAL-ILLNESS; USE DISORDERS; STRATEGIES; CONSUMPTION; PERFORMANCE; STIGMA; TRANSFORMATION AB Background and Objective: Population-based alcohol screening, followed by brief intervention for patients who screen positive for unhealthy alcohol use, is widely recommended for primary care settings and considered a top prevention priority, but is challenging to implement. However, new policy initiatives in the U.S., including the Affordable Care Act, may help launch widespread implementation. While the nationwide Veterans Health Administration (VA) has achieved high rates of documented alcohol screening and brief intervention, research has identified quality problems with both. We conducted a qualitative key informant study to describe local implementation of alcohol screening and brief intervention from the perspectives of frontline adopters in VA primary care in order to understand the process of implementation and factors underlying quality problems. Methods: A purposive snowball sampling method was used to identify and recruit key informants from 5 VA primary care clinics in the northwestern U.S. Key informants completed 20-30 minute semi-structured interviews, which were recorded, transcribed, and qualitatively analyzed using template analysis. Results: Key informants (N = 32) included: clinical staff (n = 14), providers (n = 14), and administrative informants (n = 4) with varying participation in implementation of and responsibility for alcohol screening and brief intervention at the medical center. Ten inter-related themes (5 a priori and 5 emergent) were identified and grouped into 3 applicable domains of Greenhalgh's conceptual framework for dissemination of innovations, including values of adopters (theme 1), processes of implementation (themes 2 and 3), and post-implementation consequences in care processes (themes 4-10). While key informants believed alcohol use was relevant to health and important to address, the process of implementation (in which no training was provided and electronic clinical reminders "just showed up") did not address critical training and infrastructure needs. Key informants lacked understanding of the goals of screening and brief intervention, believed referral to specialty addictions treatment (as opposed to offering brief intervention) was the only option for following up on a positive screen, reported concern regarding limited availability of treatment resources, and lacked optimism regarding patients' interest in seeking help. Conclusions: Findings suggest that the local process of implementing alcohol screening and brief intervention may have inadequately addressed important adopter needs and thus may have ultimately undermined, instead of capitalized on, staff and providers' belief in the importance of addressing alcohol use as part of primary care. Additional implementation strategies, such as training or academic detailing, may address some unmet needs and help improve the quality of both screening and brief intervention. However, these strategies may be resource-intensive and insufficient for comprehensively addressing implementation barriers. Published by Elsevier Inc. C1 [Williams, Emily C.; Achtmeyer, Carol E.; Young, Jessica P.; Lapham, Gwen T.; Lee, Amy K.; Chavez, Laura J.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr Value Driven Care, HSR&D, Seattle, WA 98108 USA. [Achtmeyer, Carol E.; Berger, Douglas] Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Div, Primary & Specialty Med Care Serv, Seattle, WA 98108 USA. [Achtmeyer, Carol E.; Lapham, Gwen T.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Div, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Berger, Douglas; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Williams, Emily C.; Chavez, Laura J.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Ludman, Evette J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Williams, Emily C.; Ludman, Evette J.; Lapham, Gwen T.; Lee, Amy K.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Rittmueller, Stacey E.] Pacific Northwest Univ Sci, Coll Osteopath Med, Yakima, WA 98901 USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,HSRD S-152, Seattle, WA 98108 USA. EM Emily.Williams3@va.gov; Carol.Achtmeyer@va.gov; Jessica.Young@va.gov; stacey.ritt@gmail.com; ludman.e@ghc.org; lapham.g@ghc.org; Amy.Lee6@va.gov; Laura.Chavez2@va.gov; Douglas.Berger@va.gov; bradley.k@ghc.org FU VA Health Services Research Development; VA Quality Enhancement Research Initiative [RRP 11-268]; Career Development Award from VA Health Services Research Development [CDA 12-276]; Implementation Research Institute (IRI) at George Warren Brown School of Social Work at Washington University in St. Louis; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service; Quality Enhancement Research Initiative (QUERI); Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound; Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant [NIH 1R36HS022800-01] FX This study was funded by VA Health Services Research & Development and VA Quality Enhancement Research Initiative (RRP 11-268; Williams PI). Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276) and is an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University in St. Louis. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). Dr. Bradley's time on this study was supported by the Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound. Ms. Chavez is supported by an Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH 1R36HS022800-01). NR 80 TC 3 Z9 3 U1 3 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JAN PY 2016 VL 60 SI SI BP 27 EP 35 DI 10.1016/j.jsat.2015.07.011 PG 9 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CZ1RH UT WOS:000366882500005 PM 26297322 ER PT J AU Backhus, LM Farjah, F Liang, CKJ He, H Varghese, TK Au, DH Flum, DR Zeliadt, SB AF Backhus, Leah M. Farjah, Farhood Liang, Chao-Kang Jason He, Hao Varghese, Thomas K., Jr. Au, David H. Flum, David R. Zeliadt, Steven B. TI Imaging surveillance and survival for surgically resected non-small-cell lung cancer SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Imaging surveillance; Lung cancer survival; Cancer follow-up; Guidelines ID REGULAR FOLLOW-UP; COMPUTED-TOMOGRAPHY; SURGERY; RECURRENCE; MANAGEMENT; RELEVANCE; CHEST; CT AB Introduction: The importance of imaging surveillance after treatment for lung cancer is not well characterized. We examined the association between initial guideline recommended imaging surveillance and survival among early-stage resected nonesmall-cell lung cancer (NSCLC) patients. Methods: A retrospective study was conducted using Surveillance, Epidemiology, and End ResultseMedicare data (1995-2010). Surgically resected patients, with stage I and II NSCLC, were categorized by imaging received during the initial surveillance period (4-8 mo) after surgery. Primary outcome was overall survival. Secondary treatment interventions were examined as intermediary outcomes. Results: Most (88%) patients had at least one outpatient clinic visit, and 24% received an initial computerized tomography (CT) during the first surveillance period. Five-year survival by initial surveillance imaging was 61% for CT, 58% for chest radiography, and 60% for no imaging. After adjustment, initial CT was not associated with improved overall survival (hazard ratio [HR], 1.04; 95% confidence interval [CI] 0.96 1.14). On subgroup analysis, restricted to patients with demonstrated initial postoperative follow-up, CT was associated with a lower overall risk of death for stage I patients (HR, 0.85; 95% CI, 0.74-0.98), but not for stage II (HR, 1.01; 95% CI, 0.71-1.42). There was no significant difference in rates of secondary interventions predicted by type of initial imaging surveillance. Conclusions: Initial surveillance CT is not associated with improved overall or lung cancer -specific survival among early-stage NSCLC patients undergoing surgical resection. Stage I patients with early follow-up may represent a subpopulation that benefits from initial surveillance although this may be influenced by healthy patient selection bias. Published by Elsevier Inc. C1 [Backhus, Leah M.] VA Palo Alto Hlth Care Syst, Surg Serv, Palo Alto, CA USA. [Backhus, Leah M.] Stanford Univ, Dept Cardiothorac Surg, Stanford, CA 94305 USA. [Farjah, Farhood; He, Hao; Varghese, Thomas K., Jr.; Flum, David R.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Liang, Chao-Kang Jason; Zeliadt, Steven B.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Au, David H.; Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. [Au, David H.] Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA USA. RP Backhus, LM (reprint author), Stanford Univ, Dept Cardiothorac Surg, 300 Pasteur Dr,Falk Res Bldg, Stanford, CA 94305 USA. EM lbackhus@stanford.edu FU NIH/NCATS [2 KL2 TR000421-06 KL2] FX Funded by NIH/NCATS National Center for Research Resources 2 KL2 TR000421-06 KL2 Scholar ITHS Multidisciplinary Clinical Research Training Program. Views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 33 TC 2 Z9 2 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD JAN PY 2016 VL 200 IS 1 BP 171 EP 176 DI 10.1016/j.jss.2015.06.048 PG 6 WC Surgery SC Surgery GA CZ1BM UT WOS:000366840700025 PM 26231974 ER PT J AU Brothers, TE Zhang, JW Mauldin, PD Tonnessen, BH Robison, JG Vallabhaneni, R Hallett, JW AF Brothers, Thomas E. Zhang, Jingwen Mauldin, Patrick D. Tonnessen, Britt H. Robison, Jacob G. Vallabhaneni, Raghuveer Hallett, John W., Jr. TI Predicting outcomes for infrapopliteal limb-threatening ischemia using the Society for Vascular Surgery Vascular Quality Initiative SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID ARTERIAL OCCLUSIVE DISEASE; LEG BASIL TRIAL; INFRAINGUINAL BYPASS; RISK STRATIFICATION; OF-LIFE; SURGICAL OUTCOMES; SCORING METHOD; REVASCULARIZATION; MORTALITY; MODEL AB Objective: The outcomes of open surgical or endovascular intervention for limb-threatening ischemia (LTI) involving the infrapopliteal vessels are dependent on complex anatomic, demographic, and disease factors. To assist in decision-making, we used the Vascular Quality Initiative (VQI) to derive a model using only preoperatively available factors to predict important outcomes for open or endovascular revascularization. Methods: National VQI data for the infrainguinal bypass and peripheral vascular intervention (PVI) modules were reviewed in a blinded fashion for patients who underwent intervention for LTI of the infrapopliteal vessels. Primary outcomes consisted of major adverse limb event (MALE) and amputation-free survival (AFS). Generalized linear modeling was used for the multivariate analyses, with entry of variables dependent on results of univariate analysis. Results: From January 2003 through August 2014 a total of 19,053 infrainguinal open bypass and 48,739 PVI procedures were identified, among which 5264 and 5252, respectively, represented infrapopliteal (tibial-peroneal-pedal) revascularization for LTI. From these, 3036 infrapopliteal open bypass patients and 1319 infrapopliteal PVI patients had sufficient follow-up data for study inclusion. For open surgery, the reduced generalized linear model revealed that American Society of Anesthesiologists class 4 or 5, previous major amputation, living at home, and female sex had the greatest adverse effect on MALE, and dialysis dependence, low body mass index, and lack of great saphenous vein as a conduit had the greatest negative effect on AFS. For PVI, lesion length from 10 to 15 cm, treatment of three or more arteries, and classification other than A on the Trans-Atlantic Inter-Society Consensus demonstrated the largest adverse effects on MALE, and dialysis dependence, low body mass index, and congestive heart failure most negatively affected AFS. Conclusions: This study on a cross-section of patients selected for intervention in academic and community hospitals offers a "real world" glimpse of factors predictive of outcome. The VQI can be used to derive models that predict the outcomes of open surgical bypass or PVI for LTI involving the infrapopliteal vessels. C1 [Brothers, Thomas E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Surg Serv, Charleston, SC USA. [Brothers, Thomas E.; Robison, Jacob G.] Med Univ S Carolina, Div Vasc & Endovasc Surg, Charleston, SC 29425 USA. [Zhang, Jingwen; Mauldin, Patrick D.] Med Univ S Carolina, Dept Internal Med, Charleston, SC 29425 USA. [Tonnessen, Britt H.; Hallett, John W., Jr.] Roper St Francis Heart & Vasc Ctr, Div Vasc Surg, Charleston, SC USA. [Vallabhaneni, Raghuveer] Univ N Carolina, Div Vasc Surg, Chapel Hill, NC USA. RP Brothers, TE (reprint author), 114 Doughty St,Ste BM654,MSC 295, Charleston, SC 29425 USA. EM brothete@musc.edu NR 31 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2016 VL 63 IS 1 BP 114 EP U183 DI 10.1016/j.jvs.2015.08.063 PG 16 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CZ2ON UT WOS:000366944600019 PM 26432282 ER PT J AU Davidson, BP Belcik, JT Mott, BH Landry, G Lindner, JR AF Davidson, Brian P. Belcik, J. Todd Mott, Brian H. Landry, Gregory Lindner, Jonathan R. TI Quantification of residual limb skeletal muscle perfusion with contrast-enhanced ultrasound during application of a focal junctional tourniquet SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID BLOOD-FLOW; CAPILLARY RECRUITMENT; DIABETES-MELLITUS; ISCHEMIA; EXERCISE; REST AB Objective: Focal junctional tourniquets (JTs) have been developed to control hemorrhage from proximal limb injuries. These devices may permit greater collateral perfusion than circumferential tourniquets. We hypothesized that JTs eliminate large-vessel pulse pressure yet allow a small amount of residual limb perfusion that could be useful for maintaining tissue viability. Methods: Ten healthy control subjects were studied. Transthoracic echocardiography, Doppler ultrasound of the femoral artery (FA) and posterior tibial artery, and contrast-enhanced ultrasound (CEU) perfusion imaging of the anterior thigh extensor and calf plantar flexor muscles were performed at baseline and during application of a JT over the common FA. Intramuscular arterial pulsatility index was also measured from CEU intensity variation during the cardiac cycle. Results: FA flow was eliminated by JTs in all subjects; posterior tibial flow was eliminated in all but one. Perfusion measured in the thigh and calf muscles was similar at baseline (0.33 +/- 0.29 vs 0.29 +/- 0.22 mL/min/g). Application of the JT resulted in a reduction of perfusion (P < .05) that was similar for the thigh and calf (0.08 +/- 0.07 and 0.10 +/- 0.03 mL/min/g). On CEU, microvascular flux rate was reduced by z55%, and functional microvascular blood volume was reduced by approximate to 35%. Arterial pulsatility index was reduced by approximate to 90% in the calf. JT inflation did not alter left ventricle dimensions, fractional shortening, cardiac output, or arterial elastance as a measure of total systolic load. Conclusions: Application of a JT eliminates conduit arterial pulse and markedly reduces intramuscular pulse pressure, but thigh and calf skeletal muscle perfusion is maintained at 25% to 35% of basal levels. These data suggest that JTs that are used to control limb hemorrhage allow residual tissue perfusion even when pulse pressure is absent. C1 [Davidson, Brian P.; Belcik, J. Todd; Mott, Brian H.; Landry, Gregory; Lindner, Jonathan R.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA. [Davidson, Brian P.] Portland VA Med Ctr, Portland, OR USA. RP Lindner, JR (reprint author), Oregon Hlth & Sci Univ, Div Cardiovasc, UHN 62,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM lindnerj@ohsu.edu FU NHLBI NIH HHS [R01 HL111969, R01 HL078610, R01 HL130046] NR 26 TC 0 Z9 0 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2016 VL 63 IS 1 BP 148 EP 153 DI 10.1016/j.jvs.2014.06.107 PG 6 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CZ2ON UT WOS:000366944600023 PM 25065582 ER PT J AU Korenstein, D Duan, K Diaz, MJ Ahn, R Keyhani, S AF Korenstein, Deborah Duan, Kevin Diaz, Manuel J. Ahn, Rosa Keyhani, Salomeh TI Do Health Care Delivery System Reforms Improve Value? The Jury Is Still Out SO MEDICAL CARE LA English DT Article DE care delivery system; quality of care; cost containment ID CENTERED MEDICAL HOME; PAY-FOR-PERFORMANCE; QUALITY-OF-CARE; INNOVATION PROFILE; ALTERNATIVE QUALITY; COST; OUTCOMES; PROGRAM; IMPACT; PILOT AB Background:Widespread restructuring of health delivery systems is underway in the United States to reduce costs and improve the quality of health care.Objective:To describe studies evaluating the impact of system-level interventions (incentives and delivery structures) on the value of US health care, defined as the balance between quality and cost.Research Design:We identified articles in PubMed (2003 to July 2014) using keywords identified through an iterative process, with reference and author tracking. We searched tables of contents of relevant journals from August 2014 through 11 August 2015 to update our sample.Subjects:We included prospective or retrospective studies of system-level changes, with a control, reporting both quality and either cost or utilization of resources.Measures:Data about study design, study quality, and outcomes was extracted by one reviewer and checked by a second.Results:Thirty reports of 28 interventions were included. Interventions included patient-centered medical home implementations (n=12), pay-for-performance programs (n=10), and mixed interventions (n=6); no other intervention types were identified. Most reports (n=19) described both cost and utilization outcomes. Quality, cost, and utilization outcomes varied widely; many improvements were small and process outcomes predominated. Improved value (improved quality with stable or lower cost/utilization or stable quality with lower cost/utilization) was seen in 23 reports; 1 showed decreased value, and 6 showed unchanged, unclear, or mixed results.Study limitations included variability among specific endpoints reported, inconsistent methodologies, and lack of full adjustment in some observational trials. Lack of standardized MeSH terms was also a challenge in the search.Conclusions:On balance, the literature suggests that health system reforms can improve value. However, this finding is tempered by the varying outcomes evaluated across studies with little documented improvement in outcome quality measures. Standardized measures of value would facilitate assessment of the impact of interventions across studies and better estimates of the broad impact of system change. C1 [Korenstein, Deborah] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10017 USA. [Duan, Kevin; Diaz, Manuel J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Ahn, Rosa; Keyhani, Salomeh] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Keyhani, Salomeh] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Korenstein, D (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, 485 Lexington Ave, New York, NY 10017 USA. EM korenstd@mskcc.org OI Korenstein, Deborah/0000-0003-1859-0574 FU NCI NIH HHS [P30 CA008748] NR 45 TC 2 Z9 2 U1 6 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD JAN PY 2016 VL 54 IS 1 BP 55 EP 66 DI 10.1097/MLR.0000000000000445 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CZ2MT UT WOS:000366940000010 PM 26492216 ER PT J AU Charalambous, CC Bowden, MG Adkins, DL AF Charalambous, Charalambos C. Bowden, Mark G. Adkins, DeAnna L. TI Motor Cortex and Motor Cortical Interhemispheric Communication in Walking After Stroke: The Roles of Transcranial Magnetic Stimulation and Animal Models in Our Current and Future Understanding SO NEUROREHABILITATION AND NEURAL REPAIR LA English DT Article DE walking; interhemispheric motor cortical communication; stroke; rehabilitation; rodent models; translational science ID ADULT SQUIRREL-MONKEYS; SENSORIMOTOR CORTEX; CORTICOMOTOR EXCITABILITY; TRANSCALLOSAL INHIBITION; POSTSTROKE HEMIPARESIS; BRAIN-STIMULATION; CORPUS-CALLOSUM; GAIT IMPAIRMENT; RATS; FORELIMB AB Despite the plethora of human neurophysiological research, the bilateral involvement of the leg motor cortical areas and their interhemispheric interaction during both normal and impaired human walking is poorly understood. Using transcranial magnetic stimulation (TMS), we have expanded our understanding of the role upper-extremity motor cortical areas play in normal movements and how stroke alters this role, and probed the efficacy of interventions to improve post-stroke arm function. However, similar investigations of the legs have lagged behind, in part, due to the anatomical difficulty in using TMS to stimulate the leg motor cortical areas. Additionally, leg movements are predominately bilaterally controlled and require interlimb coordination that may involve both hemispheres. The sensitive, but invasive, tools used in animal models of locomotion hold great potential for increasing our understanding of the bihemispheric motor cortical control of walking. In this review, we discuss 3 themes associated with the bihemispheric motor cortical control of walking after stroke: (a) what is known about the role of the bihemispheric motor cortical control in healthy and poststroke leg movements, (b) how the neural remodeling of the contralesional hemisphere can affect walking recovery after a stroke, and (c) what is the effect of behavioral rehabilitation training of walking on the neural remodeling of the motor cortical areas bilaterally. For each theme, we discuss how rodent models can enhance the present knowledge on human walking by testing hypotheses that cannot be investigated in humans, and how these findings can then be back-translated into the neurorehabilitation of poststroke walking. C1 [Charalambous, Charalambos C.; Bowden, Mark G.; Adkins, DeAnna L.] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Bowden, Mark G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Adkins, DeAnna L.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Adkins, DL (reprint author), Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave,CRI404D,MSC 510, Charleston, SC 29425 USA. EM adkinsdl@musc.edu FU NINDS [NS065866]; Career Development Award [2 RRD N0787-W]; Office or Research and Development, Rehabilitation R&D Service, Department of Veterans Affairs; Ralph H. Johnson VA Medical Center, Charleston, SC; NIH [P20 GM109040-01] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This material is the result of work supported in part by NINDS NS065866 (DLA), Career Development Award-2 RR&D N0787-W (MGB) and the Office or Research and Development, Rehabilitation R&D Service, Department of Veterans Affairs, and the Ralph H. Johnson VA Medical Center, Charleston, SC, and NIH P20 GM109040-01 (MGB and DLA). NR 75 TC 2 Z9 2 U1 2 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1545-9683 EI 1552-6844 J9 NEUROREHAB NEURAL RE JI Neurorehabil. Neural Repair PD JAN PY 2016 VL 30 IS 1 BP 94 EP 102 DI 10.1177/1545968315581418 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CZ5VH UT WOS:000367169900009 PM 25878201 ER PT J AU Mathews, CA Perez, VB Roach, BJ Fekri, S Vigil, O Kupferman, E Mathalon, DH AF Mathews, C. A. Perez, V. B. Roach, B. J. Fekri, S. Vigil, O. Kupferman, E. Mathalon, D. H. TI Error-related brain activity dissociates hoarding disorder from obsessive-compulsive disorder SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Electroencephalography/event-related potentials (EEG/ERP); error monitoring; error-related negativity (ERN); hoarding; neurophysiological; obsessive-compulsive disorder (OCD) ID ANTERIOR CINGULATE CORTEX; COGNITIVE CONTROL; CLINICAL-FEATURES; DECISION-MAKING; TASK-DIFFICULTY; FRONTAL-CORTEX; NEGATIVITY; CONFLICT; SYMPTOMS; AGE AB Background. Obsessive-compulsive disorder (OCD) is associated with an abnormally large error-related negativity (ERN), an electrophysiological measure of error monitoring in response to performance errors, but it is unclear if hoarding disorder (HD) also shows this abnormality. This study aimed to determine whether the neurophysiological mechanisms underlying error monitoring are similarly compromised in HD and OCD. Method. We used a visual flanker task to assess ERN in response to performance errors in 14 individuals with HD, 27 with OCD, 10 with HD+OCD, and 45 healthy controls (HC). Age-corrected performance and ERN amplitudes were examined using analyses of variance and planned pairwise group comparisons. Results. A main effect of hoarding on ERN (p = 0.031) was observed, indicating ERN amplitudes were attenuated in HD relative to non-HD subjects. A group x age interaction effect on ERN was also evident. In HD-positive subjects, ERN amplitude deficits were significantly greater in younger individuals (r = -0.479, p = 0.018), whereas there were no significant ERN changes with increasing age in OCD and HC participants. Conclusions. The reduced ERN in HD relative to OCD and HC provides evidence that HD is neurobiologically distinct from OCD, and suggests that deficient error monitoring may be a core pathophysiological feature of HD. This effect was particularly prominent in younger HD participants, further suggesting that deficient error monitoring manifests most strongly early in the illness course and/or in individuals with a relatively early illness onset. C1 [Mathews, C. A.; Roach, B. J.; Fekri, S.; Vigil, O.; Kupferman, E.; Mathalon, D. H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Mathews, C. A.] Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA. [Perez, V. B.] Alliant Int Univ, CSPP, San Diego, CA USA. [Perez, V. B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Perez, V. B.] Vet Affairs San Diego Healthcare Syst, VISN 22, La Jolla, CA USA. [Roach, B. J.; Mathalon, D. H.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Mathews, CA (reprint author), Univ Florida, Dept Psychiat, 100 S Newell Dr L4-100, Gainesville, FL 32610 USA. EM carolmathews@ufl.edu FU National Institutes of Mental Health [CAM: R21MH087748]; Althea Foundation FX This study was supported by the National Institutes of Mental Health (CAM: R21MH087748) and by the Althea Foundation. NR 80 TC 3 Z9 3 U1 4 U2 13 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD JAN PY 2016 VL 46 IS 2 BP 367 EP 379 DI 10.1017/S0033291715001889 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA CZ5VV UT WOS:000367171300012 PM 26415671 ER PT J AU Albert, TJ Swenson, ER AF Albert, Tyler J. Swenson, Erik R. TI Circumstances When Arterial Blood Gas Analysis Can Lead Us Astray SO RESPIRATORY CARE LA English DT Editorial Material ID SAMPLE; HEPARIN; ERRORS C1 [Albert, Tyler J.] Vet Affairs Puget Sound Hlth Care Syst, Hosp & Specialty Med, Seattle, WA 98108 USA. [Albert, Tyler J.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Pulm & Crit Care Med, Seattle, WA 98108 USA. RP Albert, TJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111-PULM, Seattle, WA 98108 USA. EM Tyler.Albert@va.gov NR 12 TC 0 Z9 0 U1 2 U2 5 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD JAN PY 2016 VL 61 IS 1 BP 119 EP 121 DI 10.4187/respcare.04556 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CZ4GU UT WOS:000367062300019 PM 26682966 ER PT J AU Webb, TN Carrisoza-Gaytan, R Montalbetti, N Rued, A Roy, A Socovich, AM Subramanya, AR Satlin, LM Kleyman, TR Carattino, MD AF Webb, Tennille N. Carrisoza-Gaytan, Rolando Montalbetti, Nicolas Rued, Anna Roy, Ankita Socovich, Alexandra M. Subramanya, Arohan R. Satlin, Lisa M. Kleyman, Thomas R. Carattino, Marcelo D. TI Cell-specific regulation of L-WNK1 by dietary K+ SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE high-conductance calcium-activated potassium channels; potassium adaptation; kidney-specific with-no-lysine kinase 1; pseudohypoaldosteronism; with-no-lysine kinase 1; long with-no-lysine kinase 1 ID CORTICAL COLLECTING DUCT; FAMILIAL HYPERKALEMIC HYPERTENSION; CONDUCTANCE POTASSIUM CHANNELS; BINDING INTERCALATED CELLS; DISTAL TUBULAR POTASSIUM; KINASE-DEFECTIVE ISOFORM; APICAL MEMBRANE; MAXI-K; BLOOD-PRESSURE; CONNECTING TUBULE AB Flow-induced K+ secretion in the aldosterone-sensitive distal nephron is mediated by high-conductance Ca2+ -activated K+ (BK) channels. Familial hyperkalemic hypertension (pseudohypoaldosteronism type II) is an inherited form of hypertension with decreased K+ secretion and increased Na+ reabsorption. This disorder is linked to mutations in genes encoding with-no-lysine kinase 1 (WNK1), WNK4, and Kelch-like 3/Cullin 3, two components of an E3 ubiquitin ligase complex that degrades WNKs. We examined whether the full-length (or "long") form of WNK1 (L-WNK1) affected the expression of BK alpha-subunits in HEK cells. Overexpression of L-WNK1 promoted a significant increase in BK alpha-subunit whole cell abundance and functional channel expression. BK alpha-subunit abundance also increased with coexpression of a kinase dead L-WNK1 mutant (K233M) and with kidney-specific WNK1 (KS-WNK1), suggesting that the catalytic activity of L-WNK1 was not required to increase BK expression. We examined whether dietary K+ intake affected L-WNK1 expression in the aldosterone-sensitive distal nephron. We found a paucity of L-WNK1 labeling in cortical collecting ducts (CCDs) from rabbits on a low-K+ diet but observed robust staining for L-WNK1 primarily in intercalated cells when rabbits were fed a high-K+ diet. Our results and previous findings suggest that L-WNK1 exerts different effects on renal K+ secretory channels, inhibiting renal outer medullary K+ channels and activating BK channels. A high-K+ diet induced an increase in L-WNK1 expression selectively in intercalated cells and may contribute to enhanced BK channel expression and K+ secretion in CCDs. C1 [Webb, Tennille N.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15261 USA. [Montalbetti, Nicolas; Rued, Anna; Roy, Ankita; Socovich, Alexandra M.; Subramanya, Arohan R.; Kleyman, Thomas R.; Carattino, Marcelo D.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. [Subramanya, Arohan R.; Kleyman, Thomas R.; Carattino, Marcelo D.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15261 USA. [Kleyman, Thomas R.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA. [Carrisoza-Gaytan, Rolando; Satlin, Lisa M.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Kleyman, TR (reprint author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM kleyman@pitt.edu OI Montalbetti, Nicolas/0000-0003-2897-9540 FU National Institute of Diabetes and Digestive and Kidney Diseases Grants [R01-DK-038470, R01-DK-084184, R01-DK-098145, R37-DK-051391, T32-DK091202, P30-DK-079307]; CONACYT [232526] FX This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants, including R01-DK-038470 (L. M. Satlin and T. R. Kleyman), R01-DK-084184 (M. D. Carattino), R01-DK-098145 (A. R. Subramanya), R37-DK-051391 (T. R. Kleyman and L. M. Satlin), T32-DK091202, and P30-DK-079307 (Pittsburgh Center for Kidney Research). R. Carrisoza-Gaytan was supported, in part, by a CONACYT postdoctoral scholarship (232526). NR 108 TC 2 Z9 2 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JAN 1 PY 2016 VL 310 IS 1 BP F15 EP F26 DI 10.1152/ajprenal.00226.2015 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA CY7MT UT WOS:000366593500004 PM 26662201 ER PT J AU Tsai, MH Boggs, SD AF Tsai, Mitchell H. Boggs, Steven D. TI Disruption Interrupted SO ANESTHESIA AND ANALGESIA LA English DT Letter C1 [Tsai, Mitchell H.] Univ Vermont, Coll Med, Dept Anesthesiol, Burlington, VT 05405 USA. [Boggs, Steven D.] James J Peters VA Med Ctr, Dept Anesthesiol, Bronx, NY USA. [Boggs, Steven D.] Icahn Sch Med Mt Sinai, Dept Anesthesiol, New York, NY USA. RP Tsai, MH (reprint author), Univ Vermont, Coll Med, Dept Anesthesiol, Burlington, VT 05405 USA. EM Mitchell.Tsai@uvmhealth.org NR 3 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD JAN PY 2016 VL 122 IS 1 BP 294 EP 295 DI 10.1213/ANE.0000000000000961 PG 2 WC Anesthesiology SC Anesthesiology GA CY9EK UT WOS:000366710000017 PM 26678481 ER PT J AU Clayburgh, DR Byrd, JK Bonfili, J Duvvuri, U AF Clayburgh, Daniel R. Byrd, J. Kenneth Bonfili, Jennifer Duvvuri, Umamaheswar TI Intraoperative Ultrasonography During Transoral Robotic Surgery SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE transoral robotic surgery; oropharynx; ultrasound ID ULTRASOUND; TORS AB Objective: This study describes the potential application of intraoperative ultrasound imaging during transoral robotic surgery (TORS). Methods: Ultrasound imaging was performed during transoral robotic resection of oropharyngeal tumors in 10 patients at a tertiary academic center. Ultrasound imaging was utilized to identify large-caliber vessels adjacent to the surgical site. Measurements were also taken on the ultrasound of tumor thickness to determine the deep margin. Following resection, the tumor was sectioned, and a gross measurement of the tumor thickness was obtained. Results: Intraoperative ultrasound use led to the identification of larger-caliber blood vessels within the operative field prior to encountering them visually. Ultrasound could also aid in defining deep tumor margins; the tumor thickness measured via ultrasound was found to be accurate within 1 to 2 mm of the grossly measured tumor thickness. This allowed for focused, careful dissection to protect and avoid blood vessels during dissection as well as improved tumor resection. Conclusions: The use of intraoperative ultrasound provides additional information to the head and neck surgeon during TORS. This may be used to identify blood vessels and assess tumor margins, thereby improving the safety and efficacy of TORS. C1 [Clayburgh, Daniel R.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Clayburgh, Daniel R.] Portland VA Med Ctr, Portland, OR USA. [Byrd, J. Kenneth] Georgia Regents Univ, Dept Otolaryngol Head & Neck Surg, Augusta, GA USA. [Duvvuri, Umamaheswar] Univ Pittsburgh, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst Penn, Pittsburgh, PA USA. [Bonfili, Jennifer] Univ Pittsburgh, Med Ctr, Div Perioperat Nursing, Pittsburgh, PA 15213 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Inst Eye & Ear, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu FU Career Development Award from the Department of Veterans Affairs BLRD; PNC Foundation FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded in part by a Career Development Award from the Department of Veterans Affairs BLR&D, and the PNC Foundation (U.D.). NR 8 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-4894 EI 1943-572X J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD JAN PY 2016 VL 125 IS 1 BP 37 EP 42 DI 10.1177/0003489415596754 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA CY7PY UT WOS:000366602000006 PM 26215725 ER PT J AU Zhao, J Giles, BM Taylor, RL Yette, GA Lough, KM Ng, HL Abraham, LJ Wu, H Kelly, JA Glenn, SB Adler, AJ Williams, AH Comeau, ME Ziegler, JT Marion, M Alarcon-Riquelme, ME Alarcon, GS Anaya, JM Bae, SC Kim, D Lee, HS Criswell, LA Freedman, BI Gilkeson, GS Guthridge, JM Jacob, CO James, JA Kamen, DL Merrill, JT Sivils, KM Niewold, TB Petri, MA Ramsey-Goldman, R Reveille, JD Scofield, RH Stevens, AM Vila, LM Vyse, TJ Kaufman, KM Harley, JB Langefeld, CD Gaffney, PM Brown, EE Edberg, JC Kimberly, RP Ulgiati, D Tsao, BP Boackle, SA AF Zhao, Jian Giles, Brendan M. Taylor, Rhonda L. Yette, Gabriel A. Lough, Kara M. Ng, Han Leng Abraham, Lawrence J. Wu, Hui Kelly, Jennifer A. Glenn, Stuart B. Adler, Adam J. Williams, Adrienne H. Comeau, Mary E. Ziegler, Julie T. Marion, Miranda Alarcon-Riquelme, Marta E. Alarcon, Graciela S. Anaya, Juan-Manuel Bae, Sang-Cheol Kim, Dam Lee, Hye-Soon Criswell, Lindsey A. Freedman, Barry I. Gilkeson, Gary S. Guthridge, Joel M. Jacob, Chaim O. James, Judith A. Kamen, Diane L. Merrill, Joan T. Sivils, Kathy Moser Niewold, Timothy B. Petri, Michelle A. Ramsey-Goldman, Rosalind Reveille, John D. Scofield, R. Hal Stevens, Anne M. Vila, Luis M. Vyse, Timothy J. Kaufman, Kenneth M. Harley, John B. Langefeld, Carl D. Gaffney, Patrick M. Brown, Elizabeth E. Edberg, Jeffrey C. Kimberly, Robert P. Ulgiati, Daniela Tsao, Betty P. Boackle, Susan A. CA BIOLUPUS GENLES Networks TI Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-CELL ACTIVATION; MURINE CD21 GENE; CR-2; EXPRESSION; LYMPHOCYTES; ADMIXTURE; PROMOTER; DATABASE; AUTOANTIBODIES AB Objectives Systemic lupus erythematosus (SLE; OMIM 152700) is characterised by the production of antibodies to nuclear antigens. We previously identified variants in complement receptor 2 (CR2/CD21) that were associated with decreased risk of SLE. This study aimed to identify the causal variant for this association. Methods Genotyped and imputed genetic variants spanning CR2 were assessed for association with SLE in 15 750 case-control subjects from four ancestral groups. Allele-specific functional effects of associated variants were determined using quantitative real-time PCR, quantitative flow cytometry, electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP)-PCR. Results The strongest association signal was detected at rs1876453 in intron 1 of CR2 (p(meta)=4.2x10(-4), OR 0.85), specifically when subjects were stratified based on the presence of dsDNA autoantibodies (case-control p(meta)=7.6x10(-7), OR 0.71; case-only p(meta)=1.9x10(-4), OR 0.75). Although allele-specific effects on B cell CR2 mRNA or protein levels were not identified, levels of complement receptor 1 (CR1/CD35) mRNA and protein were significantly higher on B cells of subjects harbouring the minor allele (p=0.0248 and p=0.0006, respectively). The minor allele altered the formation of several DNA protein complexes by EMSA, including one containing CCCTC-binding factor (CTCF), an effect that was confirmed by ChIP-PCR. Conclusions These data suggest that rs1876453 in CR2 has long-range effects on gene regulation that decrease susceptibility to lupus. Since the minor allele at rs1876453 is preferentially associated with reduced risk of the highly specific dsDNA autoantibodies that are present in preclinical, active and severe lupus, understanding its mechanisms will have important therapeutic implications. C1 [Zhao, Jian; Wu, Hui; Tsao, Betty P.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA. [Giles, Brendan M.; Yette, Gabriel A.; Lough, Kara M.; Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO 80045 USA. [Taylor, Rhonda L.; Ng, Han Leng; Abraham, Lawrence J.; Ulgiati, Daniela] Univ Western Australia, Ctr Genet Origins Hlth & Dis, Sch Pathol & Lab Med, Crawley, WA, Australia. [Kelly, Jennifer A.; Glenn, Stuart B.; Adler, Adam J.; Alarcon-Riquelme, Marta E.; Guthridge, Joel M.; James, Judith A.; Sivils, Kathy Moser; Scofield, R. Hal; Gaffney, Patrick M.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Williams, Adrienne H.; Comeau, Mary E.; Ziegler, Julie T.; Marion, Miranda; Langefeld, Carl D.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Williams, Adrienne H.; Comeau, Mary E.; Ziegler, Julie T.; Marion, Miranda; Langefeld, Carl D.] Wake Forest Sch Med, Ctr Publ Hlth Genom, Winston Salem, NC USA. [Alarcon-Riquelme, Marta E.; Brown, Elizabeth E.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Granada, Pfizer, Junta de Andalucia Ctr Genom & Oncol Res, Granada, Spain. [Alarcon, Graciela S.; Brown, Elizabeth E.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res CREA, Bogota, Colombia. [Bae, Sang-Cheol; Kim, Dam; Lee, Hye-Soon] Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul 133791, South Korea. [Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Ephraim P Engleman Rheumatol Res, San Francisco, CA 94143 USA. [Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Gilkeson, Gary S.; Kamen, Diane L.] Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA. [Jacob, Chaim O.] Univ So Calif, Dept Med, Los Angeles, CA USA. [James, Judith A.; Sivils, Kathy Moser] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA. [James, Judith A.; Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Dept Clin Pharmacol, Oklahoma City, OK 73104 USA. [Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA. [Niewold, Timothy B.] Mayo Clin, Dept Immunol, Rochester, MN USA. [Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Div Rheumatol, Feinberg Sch Med, Chicago, IL 60611 USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Dept Rheumatol & Clin Immunogenet, Houston, TX 77030 USA. [Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA. [Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA. [Vila, Luis M.] Univ Puerto Rico, Dept Med, Div Rheumatol, San Juan, PR 00936 USA. [Vyse, Timothy J.] Kings Coll London, Div Genet & Mol Med & Immunol, London WC2R 2LS, England. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Brown, Elizabeth E.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Boackle, Susan A.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Boackle, SA (reprint author), Univ Colorado, Sch Med, 1775 Aurora Court,Room 3102 B,Mail Stop B115, Aurora, CO 80045 USA. EM susan.boackle@ucdenver.edu RI Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249; Kimberly, Robert/0000-0002-5330-3086; Niewold, Timothy/0000-0003-3532-6660 FU NIH/NCI Cancer Core Support Grant [P30 CA046934]; National Institutes of Health (NIH) [P30 DK57516]; US National Institutes of Health [R01AI070983, K24AI078004, T32AR07534, K24AR002138, LRPAI071651, K08AI083790, N01AR062277, P01AI083194, P01AR049084, P20RR020143, P30AR048311, P30AR053483, P30AR055385, P30GM103510, P60AR030692, P60AR062755, P60AR053308, R01AI063274, R01AR033062, R01AR042460, R01AR043274, R01AR43727, R01AR043814, R01AR051545, R01AR057172, R01CA141700, R21AI070304, R37AI024717, RC1AR058621, U01AI101934, U19AI082714, U54RR023417, UL1RR024999, UL1RR025014, UL1RR025741, UL1RR025777, UL1RR029882, UL1TR000004]; Alliance for Lupus Research; Lupus Research Institute; US Department of Veterans Affairs; US Department of Defense [PR094002]; Arthritis National Research Foundation; Arthritis Foundation; Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [A121983]; European Science Foundation RNP (BIOLUPUS Research Network); Wellcome Trust; Arthritis Research UK; Kirkland Scholar Award; Wake Forest School of Medicine Center for Public Health Genomics FX The quality of the RNA samples prepared from healthy human subjects was evaluated in the University of Colorado Cancer Center Microarray Core, which is supported by the NIH/NCI Cancer Core Support Grant (P30 CA046934). Flow cytometry was carried out in the Barbara Davis Center Flow Cytometry Core Facility, which was supported by National Institutes of Health (NIH) grant P30 DK57516. This work was also supported by the US National Institutes of Health [R01AI070983 (S.A.B, B.P.T., D.U.), K24AI078004 (S.A.B.), T32AR07534 (B.M.G.), K24AR002138 (R.R.G.), LRPAI071651 (T.B.N.), K08AI083790 (T.B.N.), N01AR062277 (J.B.H.), P01AI083194 (J.B.H.), P01AR049084 (R.P.K., J.B.H., J.C.E., E.E.B., G.S.A., J.D.R., R.R.G., and M.A.P.), P20RR020143 (J.B.H.), P30AR048311 (E.E.B.), P30AR053483 (J.A.J and J.M.G.), P30AR055385 (E.E.B.), P30GM103510 (J.A.J.), P60AR030692 (R.R.G.), P60AR062755 (D.L.K.), P60AR053308 (L.A.C.), R01AI063274 (P.M.G.), R01AR033062 (R.P.K.), R01AR042460 (J.B.H.), R01AR043274 (K.M.S.), R01AR43727 (M.A.P.), R01AR043814 (B.P.T.), R01AR051545 (A.M.S.), R01AR057172 (C.O.J.), R01CA141700 (M.E.A.R.), R21AI070304 (S.A.B.), R37AI024717 (J.B.H.), RC1AR058621 (M.E.A.R.), U01AI101934 (J.A.J. and J.M.G.), U19AI082714 (J.A.J. and J.M.G.), U54RR023417 (J.D.R.), UL1RR024999 (T.B.N.), UL1RR025014 (A.M.S.), UL1RR025741 (R.R.G.), UL1RR025777 (R.P.K. and J.C.E.), UL1RR029882 (D.L.K.), and UL1TR000004 (L.A.C.)], the Alliance for Lupus Research (S.A.B., B.P.T., D.U., K.M.S., T.B.N., L.A.C. and C.O.J.), the Lupus Research Institute (B.P.T., T.B.N.), the US Department of Veterans Affairs (Merit Awards; J.B.H., G.S.G.), the US Department of Defense (PR094002, J.B.H.), the Arthritis National Research Foundation (Eng Tan Scholar Award; J.Z. and T.B.N.), the Arthritis Foundation (A.M.S., and P.M.G.), the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A121983; S.C.B.), the European Science Foundation RNP (BIOLUPUS Research Network), the Wellcome Trust (T.J.V.), Arthritis Research UK (T.J.V.), a Kirkland Scholar Award (L.A.C.), and the Wake Forest School of Medicine Center for Public Health Genomics (C.D.L.). The funders had no role in study design, data collection, analysis and interpretation, writing of the report or decision to submit the paper for publication. NR 40 TC 1 Z9 1 U1 0 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JAN PY 2016 VL 75 IS 1 BP 242 EP 252 DI 10.1136/annrheumdis-2014-205584 PG 11 WC Rheumatology SC Rheumatology GA CY4TW UT WOS:000366402400033 PM 25180293 ER PT J AU Berry, K Lerrigo, R Liou, IW Ioannou, GN AF Berry, Kristin Lerrigo, Robert Liou, Iris W. Ioannou, George N. TI Association Between Transjugular Intrahepatic Portosystemic Shunt and Survival in Patients With Cirrhosis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE MELD Score; Hepatorenal Syndrome; Hepatic Hydrothorax; Hepatocellular Carcinoma; Transjugular Intrahepatic Portosystemic Shunt; TIPS; Cirrhosis; Mortality; Liver Transplantation ID PARACENTESIS PLUS ALBUMIN; REFRACTORY ASCITES; HEPATORENAL-SYNDROME; HEPATIC HYDROTHORAX; RANDOMIZED-TRIAL; RENAL-FUNCTION; TIPS; PREVENTION; METAANALYSIS AB BACKGROUND & AIMS: A transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment of refractory ascites and variceal bleeding. However, it is unclear whether a TIPS affects long-term survival. We investigated whether a TIPS is associated with survival in patients with cirrhosis awaiting liver transplantation. METHODS: By using the United Network for Organ Sharing registries from 2002 to 2013, we followed up a cohort of transplant-naive adults with cirrhosis (N = 97,063) from the time of transplant listing until the time of death or transplantation. We used Cox proportional hazards and competing-risks analyses to compare these primary outcomes between patients with a TIPS (n = 7475; 7.7%) and without a TIPS (n = 89,588; 92.3%) at the time of listing, adjusting for baseline characteristics. RESULTS: During an average follow-up period of 1.61 years, 23,305 (24%) patients died before undergoing transplantation, 47,563 (49%) underwent transplantation, and the remaining 26,195 (27%) still were alive without having received a liver transplant. Compared with patients without a TIPS, patients with a TIPS had a lower risk of death (adjusted subhazard ratio, 0.95; 95% confidence interval, 0.9-0.99), transplantation (adjusted subhazard ratio, 0.92, 95% confidence interval, 0.88-0.95), or the combined outcome of death or transplantation (adjusted hazard ratio, 0.85; 95% confidence interval, 0.83-0.88). CONCLUSIONS: Among patients with cirrhosis awaiting liver transplantation, patients with a TIPS had a lower mortality rate than patients without a TIPS. C1 [Berry, Kristin; Ioannou, George N.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98195 USA. [Lerrigo, Robert] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Internal Med, Seattle, WA 98195 USA. [Liou, Iris W.; Ioannou, George N.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Research Enhancement Award Program, Office of Research and Development, Veterans Affairs; Health Resources and Services Administration [231-00-0115] FX Supported by the Research Enhancement Award Program, Office of Research and Development, Veterans Affairs, and supported in part by Health Resources and Services Administration contract 231-00-0115. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services. NR 26 TC 2 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD JAN PY 2016 VL 14 IS 1 BP 118 EP 123 DI 10.1016/j.cgh.2015.06.042 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CY8HQ UT WOS:000366649800025 PM 26192147 ER PT J AU Kurichi, JE Streim, JE Bogner, HR Xie, DW Kwong, PL Hennessy, S AF Kurichi, Jibby E. Streim, Joel E. Bogner, Hillary R. Xie, Dawei Kwong, Pui L. Hennessy, Sean TI Comparison of predictive value of activity limitation staging systems based on dichotomous versus trichotomous responses in the Medicare Current Beneficiary Survey SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Staging; Disability; Medicare Current Beneficiary Survey; Activities of daily living ID CARE AB Background: Traditional ways of measuring disability include summary indices, binary expressions, or counts of limitations. However, counts of activity of daily living (ADL) or instrumental activity of daily living (IADL) limitations do not specify which activities are limited. Activity limitation staging systems within the ADL and IADL domains depict both the severity and types of limitations experienced and specify clinically meaningful patterns of increasing difficulty with self-care. Objective: To compare the predictive value and utility of ADL and IADL stages based on dichotomous versus trichotomous responses to ADL and IADL questions based on "difficulty'' and "receive help'' responses. Methods: Data were analyzed from the 2005, 2006, and 2007 Medicare Current Beneficiary Survey (MCBS) entry panels on 11,706 beneficiaries. This was a prospective cohort study that examined time to inpatient admission, all-cause mortality, skilled nursing facility (SNF) admission, and long-term care (LTC) facility admission based on dichotomous versus trichotomous stages. Results: For both ADLs and IADLs, Akaike information criteria for most outcomes were lower (indicating better-performing models) for the trichotomous staging systems than the dichotomous staging systems. The hazard ratios (HRs) and 95% confidence intervals (CIs) of the dichotomous ADL staging system increased as disability increased, whereas the HRs of the other staging systems fluctuated. Conclusions: Both staging systems have strong associations with each outcome. The dichotomous staging system is more clinically relevant while the trichotomous staging system may provide utility for clinicians, health care organizations, and policy makers seeking to predict death or admission to a hospital, SNF, or LTC facility. (C) 2016 Elsevier Inc. All rights reserved. C1 [Kurichi, Jibby E.; Bogner, Hillary R.; Xie, Dawei; Kwong, Pui L.; Hennessy, Sean] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Streim, Joel E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA. [Streim, Joel E.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Philadelphia, PA USA. [Hennessy, Sean] Univ Penn, Ctr Pharmacoepidemiol Res & Training, Philadelphia, PA 19104 USA. RP Kurichi, JE (reprint author), 907 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jkurichi@mailmed.upenn.edu FU National Institutes of Health [AG040105, HD074756]; NIMH [MH082799, MH047447] FX The research for this manuscript was supported by grants from the National Institutes of Health (AG040105 and HD074756) for Drs. Hennessy, Streim, and Xie, Ms. Kwong, and Ms. Kurichi. Dr. Bogner was supported by NIMH grants MH082799 and MH047447. There are no personal conflicts of interest of any of the authors, and no authors reported disclosures beyond the funding source. The opinions and conclusions of the authors are not necessarily those of the sponsoring agencies. NR 19 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 EI 1876-7583 J9 DISABIL HEALTH J JI Disabil. Health J. PD JAN PY 2016 VL 9 IS 1 BP 64 EP 73 DI 10.1016/j.dhjo.2015.08.006 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA CY7AQ UT WOS:000366560600010 PM 26590119 ER PT J AU Turner, AP Roubinov, DS Atkins, DC Haselkorn, JK AF Turner, Aaron P. Roubinov, Danielle S. Atkins, David C. Haselkorn, Jodie K. TI Predicting medication adherence in multiple sclerosis using telephone-based home monitoring SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Medication adherence; Multiple sclerosis; Chronic illness self-management; Telehealth ID DISEASE-MODIFYING THERAPIES; INJECTION ANXIETY; SELF-EFFICACY; CARE-SYSTEM; IMPAIRMENT; PREVALENCE; VETERANS; UTILITY; EXPECTATIONS; DISABILITY AB Background: Poor medication adherence exerts a substantial negative impact on the health and well-being of individuals with multiple sclerosis (MS). Improving adherence rates requires a proactive approach of frequent and ongoing monitoring; however, this can be difficult to achieve within traditional, reactive health care systems that generally emphasize acute care services. Telephone-based home monitoring may circumvent these barriers and facilitate optimal care coordination and management for individuals with MS and other chronic illnesses. Objective: The current study evaluated the utility of a one-item, telephone-administered measure of adherence expectations as a prospective predictor of medication adherence across a six month period among individuals with MS. Methods: As part of a longitudinal study, Veterans with MS (N = 89) who were receiving medical services through the Veterans Health Administration completed monthly telephone-based interviews for six months. Results: Using mixed model regression analyses, adherence expectations predicted adherence after adjusting for demographic, illness-related, and psychosocial factors (B = -5.54, p < .01). Conclusions: Brief, telephone-based assessments of adherence expectations may represent an easy and efficient method for monitoring medication use among individuals with MS. The results offer an efficient method to detect and provide support for individuals who may benefit from interventions to promote medication adherence. (C) 2016 Elsevier Inc. All rights reserved. C1 [Turner, Aaron P.; Roubinov, Danielle S.; Haselkorn, Jodie K.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Turner, Aaron P.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Atkins, David C.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Roubinov, Danielle S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Turner, AP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117 RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM aaron.turner@va.gov OI Atkins, David/0000-0002-5781-9880 FU Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award [B3319VA]; VA MS Center of Excellence West FX This research was supported by Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award (B3319VA) to Aaron P. Turner. Additional support was provided by the VA MS Center of Excellence West. NR 41 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 EI 1876-7583 J9 DISABIL HEALTH J JI Disabil. Health J. PD JAN PY 2016 VL 9 IS 1 BP 83 EP 89 DI 10.1016/j.dhjo.2015.08.008 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA CY7AQ UT WOS:000366560600012 PM 26454560 ER PT J AU Ladebue, AC Helfrich, CD Gerdes, ZT Fihn, SD Nelson, KM Sayre, GG AF Ladebue, Amy C. Helfrich, Christian D. Gerdes, Zachary T. Fihn, Stephan D. Nelson, Karin M. Sayre, George G. TI The experience of Patient Aligned Care Team (PACT) members SO HEALTH CARE MANAGEMENT REVIEW LA English DT Article DE evaluation; patient-centered care; patient-centered medical home (PCMH); team-based care; teamlet ID CENTERED MEDICAL HOME; SAFETY OUTCOMES; HEALTH-CARE; BURNOUT; IMPLEMENTATION; VETERANS; SURGEONS; QUALITY; ERRORS; LIFE AB Background: In April 2010, the Veterans Health Administration (VHA) launched the Patient Aligned Care Team (PACT) initiative to implement a patient-centered medical home (PCMH) model. Few evaluations have addressed the effects of PCMH on health care professionals' experiences. Purposes: The aim of this study was to contribute to evaluation of the PACT initiative and the broader literature on PCMH by assessing respondents' experiences of implementing a PCMH model and becoming a teamlet. Methodology/Approach: A retrospective qualitative analysis of open-text responses in a survey fielded to all VHA Primary Care personnel (VHA Primary Care physicians, nurse practitioners, physician assistants, nurse care managers, clinical associates, and administrative clerks) in May and June 2012 (approximately 2 years into the 5-year planned implementation of PACT) using deductive and inductive content analysis. The main measures were two open-response fields: Is there anything else you would like us to relay to the VA leadership in Central Office? and Do you have any other comments or feedback on PACT? The data consisted of free text responses of 3,868 survey participants who provided text for one or both of the open-response fields. Findings: Although respondents viewed PACT positively as a model and reported it improved relationships with patients and increased patient satisfaction, they described multiple barriers to achieving functioning teamlets and unintended consequences, including reduced time with patients, increased participant burnout, and decreased team efficacy because of low-performing team members. A central theme related to staffing being insufficient for the new model. Practice Implications: Insufficient staffing of PCMH teams is a critical barrier to realizing the benefits of the new model. Frontline staff have concrete recommendations for other problems, such as using back-up teams to cover during absences, but that will require providing more opportunities for feedback from staff to be heard. C1 [Ladebue, Amy C.] Seattle Univ, Coll Arts & Sci, Hlth Serv Res & Dev Ctr Innovat Veteran Centered, Seattle, WA 98122 USA. [Helfrich, Christian D.; Nelson, Karin M.; Sayre, George G.] Univ Washington, Hlth Serv Res & Dev Ctr Innovat Veteran Centered, Seattle, WA USA. [Helfrich, Christian D.; Fihn, Stephan D.; Sayre, George G.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Gerdes, Zachary T.] Univ Akron, Hlth Serv Res andDevelopmentCenter Innovat Vetera, Akron, OH 44325 USA. [Gerdes, Zachary T.] Univ Akron, Dept Psychol, Akron, OH 44325 USA. [Fihn, Stephan D.] US Dept Vet Affairs, Off Analyt & Business Intelligence, Seattle, WA USA. [Fihn, Stephan D.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. RP Ladebue, AC (reprint author), Seattle Univ, Coll Arts & Sci, Hlth Serv Res & Dev Ctr Innovat Veteran Centered, Seattle, WA 98122 USA. RI Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768 FU VA Office of Patient Care Services FX This work was undertaken as part of the VA's PACT Demonstration Laboratory initiative, supporting and evaluating VA's transition to a PCMH model. Funding for the PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.. NR 36 TC 0 Z9 0 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0361-6274 EI 1550-5030 J9 HEALTH CARE MANAGE R JI Health Care Manage. Rev. PD JAN-MAR PY 2016 VL 41 IS 1 BP 2 EP 10 DI 10.1097/HMR.0000000000000048 PG 9 WC Health Policy & Services SC Health Care Sciences & Services GA CY9GV UT WOS:000366716300002 PM 25539056 ER PT J AU Ferguson, S Trupin, L Yazdany, J Yelin, E Barton, J Katz, P AF Ferguson, S. Trupin, L. Yazdany, J. Yelin, E. Barton, J. Katz, P. TI Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication SO LUPUS LA English DT Article DE Contraception; family planning; teratogen; systemic lupus erythematosus ID UNITED-STATES; UNINTENDED PREGNANCY; RHEUMATOID-ARTHRITIS; ERYTHEMATOSUS; WOMEN; VALIDATION; HEALTH; CARE; OUTCOMES; IMPACT AB Objective Family planning discussions are an important aspect of medical care for women with systemic lupus erythematosus (SLE) as active disease is a risk factor for poor pregnancy outcomes, and the medications used for treatment can be harmful to the fetus when used during conception and pregnancy. Our objective was to examine the impact of patient perception of quality and type of communication on receiving contraception counseling. Methods Data were derived from patients enrolled in the University of California, San Francisco Lupus Outcomes Study. Individuals participate in a yearly structured telephone interview that includes assessment of contraception counseling when starting new medications, and measures of communication and decision making. Logistic regression was performed to identify predictors of not receiving contraception counseling. Results Of the 68 women included in this analysis, one-third did not receive contraception counseling when starting new medications. Older age, white race, depressive symptoms, and higher SLE disease activity were independently associated with not receiving contraception counseling. Participants who did not receive contraception counseling rated their physicians lower in shared decision-making (SDM) communication. Conclusions This study demonstrates a gap in family planning counseling among women with SLE starting new medications. Future studies to address these potential areas of intervention, including education about the need for contraception through menopause, and mechanisms to engage in SDM surrounding contraception are needed to improve quality of care for women with lupus. C1 [Ferguson, S.; Trupin, L.; Yazdany, J.; Yelin, E.; Katz, P.] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA. [Barton, J.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR USA. RP Ferguson, S (reprint author), Univ Calif San Francisco, Div Rheumatol, Room 270,3333 Calif St,Box 0920, San Francisco, CA 94143 USA. EM sancia.ferguson@ucsf.edu FU National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60-AR-053308]; NIH/National Center for Research Resources through a University of California, San Francisco (UCSF), Clinical and Translational Science Institute grant [Ul1-RR-024131] FX This work was supported by the National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant (P60-AR-053308), and the NIH/National Center for Research Resources through a University of California, San Francisco (UCSF), Clinical and Translational Science Institute grant (Ul1-RR-024131). NR 29 TC 0 Z9 0 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 EI 1477-0962 J9 LUPUS JI Lupus PD JAN PY 2016 VL 25 IS 1 BP 12 EP 17 DI 10.1177/0961203315596079 PG 6 WC Rheumatology SC Rheumatology GA CY7PV UT WOS:000366601700002 PM 26190169 ER PT J AU Aranovich, GJ McClure, SM Fryer, S Mathalon, DH AF Aranovich, Gabriel J. McClure, Samuel M. Fryer, Susanna Mathalon, Daniel H. TI The effect of cognitive challenge on delay discounting SO NEUROIMAGE LA English DT Article ID IMPULSIVE DECISION-MAKING; WORKING-MEMORY; PREFRONTAL CORTEX; SELF-CONTROL; INTERTEMPORAL CHOICE; NEURAL SYSTEMS; FMRI; REWARDS; MODEL; ADDICTION AB Recent findings suggest that the dorsolateral prefrontal cortex (DLPFC), a region consistently associated with impulse control, is vulnerable to transient suppression of its activity and attendant functions by excessive stress and/or cognitive demand. Using functional magnetic resonance imaging, we show that a capacity-exceeding cognitive challenge induced decreased DLPFC activity and correlated increases in the preference for immediately available rewards. Consistent with growing evidence of a link between working memory capacity and delay discounting, the effect was inversely proportional to baseline performance on a working memory task. Subjects who performed well on the working memory task had unchanged, or even decreased, delay discounting rates, suggesting that working memory ability may protect cognitive control from cognitive challenge. (C) 2015 Elsevier Inc. All rights reserved. C1 [Aranovich, Gabriel J.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [McClure, Samuel M.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA. [Fryer, Susanna; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Fryer, Susanna; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Aranovich, GJ (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. EM gabe.aranovich@ucsf.edu FU NIMH [R25MH060482, R01 MH076989]; NSF [1358507]; VA CSRD [IK2 CX001028] FX This work was supported by grants NIMH R25MH060482 (to G.J. Aranovich), NSF 1358507 (to S.M. McClure), VA CSR&D: and IK2 CX001028 (S. Fryer), and NIMH R01 MH076989 (to D.H. Mathalon). NR 44 TC 0 Z9 0 U1 2 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 BP 733 EP 739 DI 10.1016/j.neuroimage.2015.09.027 PN A PG 7 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY8GL UT WOS:000366646700068 PM 26394377 ER PT J AU Bowers, ME Yehuda, R AF Bowers, Mallory E. Yehuda, Rachel TI Intergenerational Transmission of Stress in Humans SO NEUROPSYCHOPHARMACOLOGY LA English DT Review ID ANTENATAL MATERNAL ANXIETY; GLUCOCORTICOID-RECEPTOR GENE; INFANT BIRTH-WEIGHT; HOLOCAUST SURVIVORS; PRENATAL STRESS; CORTISOL-LEVELS; NURTURING RELATIONSHIPS; CHERNOBYL EXPOSURE; TRAUMA EXPOSURE; PRETERM BIRTH AB The hypothesis that offspring are affected by parental trauma or stress exposure, first noted anecdotally, is now supported empirically by data from Holocaust survivor offspring cohorts and other populations. These findings have been extended to less extreme forms of stress, where differential physical, behavioral, and cognitive outcomes are observed in affected offspring. Parental stress-mediated effects in offspring could be explained by genetics or social learning theory. Alternatively, biological variations stemming from stress exposure in parents could more directly have an impact on offspring, a concept we refer to here as 'intergenerational transmission', via changes to gametes and the gestational uterine environment. We further extend this definition to include the transmission of stress to offspring via early postnatal care, as animal studies demonstrate the importance of early maternal care of pups in affecting offsprings' long-term behavioral changes. Here, we review clinical observations in offspring, noting that offspring of stress- or trauma-exposed parents may be at greater risk for physical, behavioral, and cognitive problems, as well as psychopathology. Furthermore, we review findings concerning offspring biological correlates of parental stress, in particular, offspring neuroendocrine, epigenetic, and neuroanatomical changes, in an attempt to determine the extent of parental stress effects. Although understanding the etiology of effects in offspring is currently impeded by methodological constraints, and limitations in our knowledge, we summarize current information and conclude by presenting hypotheses that have been prompted by recent studies in the field. C1 [Bowers, Mallory E.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Bronx, NY 10468 USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA. RP Yehuda, R (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, JJP VAMC, 526 OOMH PTSD 116-A,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov NR 104 TC 15 Z9 15 U1 9 U2 38 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 232 EP 244 DI 10.1038/npp.2015.247 PG 13 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400015 PM 26279078 ER PT J AU Vinogradov, S Herman, A AF Vinogradov, Sophia Herman, Alexander TI Psychiatric Illnesses as Oscillatory Connectomopathies SO NEUROPSYCHOPHARMACOLOGY LA English DT Editorial Material ID NETWORK OSCILLATIONS C1 [Vinogradov, Sophia; Herman, Alexander] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Vinogradov, Sophia] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. RP Vinogradov, S (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM sophia.vinogradov@ucsf.edu FU NIMH NIH HHS [R01 MH068725, MH68725] NR 6 TC 2 Z9 2 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2016 VL 41 IS 1 BP 387 EP 388 DI 10.1038/npp.2015.308 PG 3 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CY7OP UT WOS:000366598400039 PM 26657965 ER PT J AU Reddy, BG Dai, Q McNicholas, CM Fuller, CM Kappes, JC DeLucas, LJ AF Reddy, Bharat G. Dai, Qun McNicholas, Carmel M. Fuller, Catherine M. Kappes, John C. DeLucas, Lawrence J. TI Expression and purification of the alpha subunit of the epithelial sodium channel, ENaC SO PROTEIN EXPRESSION AND PURIFICATION LA English DT Article DE Epithelial sodium channel; ENaC; GFP; GFP Affinity Column; Membrane Protein Purification; Membrane Protein Expression ID CELL-SURFACE EXPRESSION; NA+ CHANNEL; MEMBRANE-PROTEINS; ION-CHANNEL; RETROVIRAL VECTORS; LENTIVIRAL VECTOR; GAMMA-SUBUNIT; AMILORIDE; STOICHIOMETRY; FLUORESCENCE AB The epithelial sodium channel (ENaC) plays a critical role in maintaining Na+ homeostasis in various tissues throughout the body. An understanding of the structure of the ENaC subunits has been developed from homology modeling based on the related acid sensing ion channel 1 (ASIC1) protein structure, as well as electrophysiological approaches. However, ENaC has several notable functional differences compared to ASIC1, thereby providing justification for determination of its three-dimensional structure. Unfortunately, this goal remains elusive due to several experimental challenges. Of the subunits that comprise a physiological hetero-trimeric alpha beta gamma ENaC, the alpha-subunit is unique in that it is capable of forming a homo-trimeric structure that conducts Na+ ions. Despite functional and structural interest in alpha ENaC, a key factor complicating structural studies has been its interaction with multiple other proteins, disrupting its homogeneity. In order to address this issue, a novel protocol was used to reduce the number of proteins that associate and co-purify with alpha ENaC. In this study, we describe a novel expression system coupled with a two-step affinity purification approach using NiNTA, followed by a GFP antibody column as a rapid procedure to improve the purity and yield of rat aENaC. (C) 2015 Elsevier Inc. All rights reserved. C1 [Dai, Qun; Kappes, John C.] Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35294 USA. [Dai, Qun; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [McNicholas, Carmel M.; Fuller, Catherine M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [DeLucas, Lawrence J.] Univ Alabama Birmingham, Dept Optometry, Birmingham, AL 35294 USA. [Reddy, Bharat G.; Fuller, Catherine M.; Kappes, John C.; DeLucas, Lawrence J.] Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL 35233 USA. RP DeLucas, LJ (reprint author), Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA. EM duke2@uab.edu FU NIH [NIGMS R01GM095639, NIDDK R01DK037206, P30 AR048311]; Virology, Genetic Sequencing and Flow Cytometry Cores of the UAB Center for AIDS Research [P30 AI27767]; UAB CF Research & Translational Core Center [P30 DK072482] FX This research was supported by the following NIH Grants NIGMS R01GM095639 and NIDDK R01DK037206, and the Virology, Genetic Sequencing and Flow Cytometry Cores of the UAB Center for AIDS Research (P30 AI27767), and the UAB CF Research & Translational Core Center (P30 DK072482). They antibodies were made by RDCC Analytical Imaging and Immunoreagent Core with supported from NIH P30 AR048311. We would also Casey Weaver for the use of his hybridoma and Suman Bharara and Kevin Macon for their help in culturing the hybridoma to produce the GFP antibody. Finally we would like to thank the late Dale Benos, without whom, none of this would have been done. NR 62 TC 0 Z9 0 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-5928 EI 1096-0279 J9 PROTEIN EXPRES PURIF JI Protein Expr. Purif. PD JAN PY 2016 VL 117 BP 67 EP 75 DI 10.1016/j.pep.2015.09.014 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA CZ0JU UT WOS:000366791900009 PM 26394093 ER PT J AU Bhatt, SP Wells, JM Kinney, GL Washko, GR Budoff, M Kim, YI Bailey, WC Nath, H Hokanson, JE Silverman, EK Crapo, J Dransfield, MT AF Bhatt, Surya P. Wells, James M. Kinney, Gregory L. Washko, George R., Jr. Budoff, Matthew Kim, Young-il Bailey, William C. Nath, Hrudaya Hokanson, John E. Silverman, Edwin K. Crapo, James Dransfield, Mark T. CA COPDGene Investigators TI beta-Blockers are associated with a reduction in COPD exacerbations SO THORAX LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; RISK; ASTHMA; HYPERTENSION; THERAPY; CLASSIFICATION; METAANALYSIS AB Background While some retrospective studies have suggested that beta-blocker use in patients with COPD is associated with a reduction in the frequency of acute exacerbations and lower mortality, there is concern that their use in patients with severe COPD on home oxygen may be harmful. Methods Subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2-4 COPD participating in a prospective follow-up of the COPDGene cohort, a multicentre observational cohort of current and former smokers were recruited. Total and severe exacerbation rates were compared between groups categorised by beta-blocker use on longitudinal follow-up using negative binomial regression analyses, after adjustment for demographics, airflow obstruction, % emphysema on CT, respiratory medications, presence of coronary artery disease, congestive heart failure and coronary artery calcification, and after adjustment for propensity to prescribe beta-blockers. Results 3464 subjects were included. During a median of 2.1 years of follow-up, beta-blocker use was associated with a significantly lower rate of total (incidence risk ratio (IRR) 0.73, 95% CI 0.60 to 0.90; p=0.003) and severe exacerbations (IRR 0.67, 95% CI 0.48 to 0.93; p=0.016). In those with GOLD stage 3 and 4 and on home oxygen, use of beta-blockers was again associated with a reduction in the rate of total (IRR 0.33, 95% CI 0.19 to 0.58; p<0.001) and severe exacerbations (IRR 0.35, 95% CI 0.16 to 0.76; p=0.008). Exacerbation reduction was greatest in GOLD stage B. There was no difference in all-cause mortality with beta-blocker use. Conclusions beta-Blockers are associated with a significant reduction in COPD exacerbations regardless of severity of airflow obstruction. The findings of this study should be tested in a randomised, placebo-controlled trial. C1 [Bhatt, Surya P.; Wells, James M.; Bailey, William C.; Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Kinney, Gregory L.; Hokanson, John E.] Univ Colorado, Dept Epidemiol, Aurora, CO USA. [Washko, George R., Jr.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Kim, Young-il] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL 35294 USA. [Nath, Hrudaya] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35294 USA. [Silverman, Edwin K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA. [Crapo, James] Natl Jewish Hlth, Div Pulm & Crit Care, Denver, CO USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Bhatt, SP (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, THT 422,1720,2nd Ave South, Birmingham, AL 35294 USA. EM spbhatt@uab.edu FU NIH [R01 HL089897, R01 HL089856, R01 HL122438]; TRDRP Award [20XT-0014] FX COPDGene is supported by NIH grant numbers R01 HL089897, R01 HL089856 and R01 HL122438. The coronary calcification data is supported by TRDRP Award No. 20XT-0014. NR 43 TC 16 Z9 18 U1 4 U2 9 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 EI 1468-3296 J9 THORAX JI Thorax PD JAN PY 2016 VL 71 IS 1 BP 8 EP 14 DI 10.1136/thoraxjnl-2015-207251 PG 7 WC Respiratory System SC Respiratory System GA CY8TV UT WOS:000366682100004 PM 26283710 ER PT J AU Estock, JL Curinga, HK Li, A Grieve, LB Brackney, CR AF Estock, Jamie L. Curinga, Holly K. Li, Airan Grieve, Lorin B. Brackney, Christopher R. TI Comparison of chest compression interruption times across 2 automated devices: a randomized, crossover simulation study SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; OVER MANNEQUIN; TRIAL; SYSTEM; HELICOPTER; QUALITY; CPR AB Objective: The goal of this study was to compare chest compression interruption times required to apply, adjust, and remove 2 different automated chest compression (ACC) devices using the same evaluation protocol. Methods: Twenty-nine registered nurses and respiratory therapists used 2 ACC devices in separate resuscitation scenarios involving a patient manikin simulating a 45-year-old man in cardiac arrest in his intensive care unit room. Device presentation was randomized, with half of the participants using LUCAS 2 in the first scenario and the other half using AutoPulse in the first scenario. Results: The mean chest compression interruption time to apply the ACC device to the patient was significantly shorter for AutoPulse (mean [M] = 31.6 +/- 8.44) than for LUCAS 2 (M = 39.1 +/- 11.20; t(28) = 3.65, P = .001). The mean chest compression interruption time to remove the ACC device from the patient and resume manual compressions was also significantly shorter for AutoPulse (M = 6.5 +/- 3.65) than for LUCAS 2 (M = 10.1 +/- 3.97; t(26) = 3.36, P = .002). There was no difference in the mean chest compression interruption time to adjust the position of the ACC device on the patient between AutoPulse (M = 14.3 +/- 5.24) and LUCAS 2 (M = 12.5 +/- 3.89; t(23)= -1.45, P = .162). Conclusions: The results of this study trended in favor of AutoPulse. However, the interruption in chest compression to apply either device to the patient was notably longer than the maximum interruption time recommended by the American Heart Association. Published by Elsevier Inc. C1 [Estock, Jamie L.; Li, Airan] VA Pittsburgh Healthcare Syst, Ctr Med Prod End User Testing, Pittsburgh, PA USA. [Curinga, Holly K.; Brackney, Christopher R.] VA Pittsburgh Healthcare Syst, Crit Care Serv, Pittsburgh, PA USA. [Grieve, Lorin B.] VA Pittsburgh Healthcare Syst, Dept Educ, Pittsburgh, PA USA. RP Estock, JL (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C Res Bldg 30,G-39, Pittsburgh, PA 15240 USA. EM jamie.estock@va.gov OI Estock, Jamie/0000-0001-8279-2811 FU Medical Education and Patient Safety grant through the Veterans Research Foundation at VA Pittsburgh Healthcare System, Pittsburgh, PA FX The execution of this work was supported by a Medical Education and Patient Safety grant through the Veterans Research Foundation at VA Pittsburgh Healthcare System, Pittsburgh, PA. The sponsor of this research had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit this article for publication. NR 28 TC 0 Z9 0 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD JAN PY 2016 VL 34 IS 1 BP 57 EP 62 DI 10.1016/j.ajem.2015.09.011 PG 6 WC Emergency Medicine SC Emergency Medicine GA CY1IH UT WOS:000366159400012 PM 26472511 ER PT J AU Mancini, M Chiari, L Holmstrom, L Salarian, A Horak, FB AF Mancini, Martina Chiari, Lorenzo Holmstrom, Lars Salarian, Arash Horak, Fay B. TI Validity and reliability of an IMU-based method to detect APAs prior to gait initiation SO GAIT & POSTURE LA English DT Article DE Gait initiation; Inertial sensors; Force plates; Parkinson's disease ID ANTICIPATORY POSTURAL ADJUSTMENTS; PARKINSONS-DISEASE; STEP INITIATION; WEARABLE SENSORS; MOVEMENT; BALANCE; PERTURBATIONS; COORDINATION; STIMULATION; WALKING AB Anticipatory postural adjustments (APAs) prior to gait initiation have been largely studied in traditional, laboratory settings using force plates under the feet to characterize the displacement of the center of pressure. However clinical trials and clinical practice would benefit from a portable, inexpensive method for characterizing APAs. Therefore, the main objectives of this study were (1) to develop a novel, automatic IMU-based method to detect and characterize APAs during gait initiation and (2) to measure its test-retest reliability. Experiment I was carried out in the laboratory to determine the validity of the IMU-based method in 10 subjects with PD (OFF medication) and 12 control subjects. Experiment II was carried out in the clinic, to determine test-retest reliability of the IMU-based method in a different set of 17 early-to-moderate, treated subjects with PD (tested ON medication) and 17 age-matched control subjects. Results showed that gait initiation characteristics (both APAs and 1st step) detected with our novel method were significantly correlated to the characteristics calculated with a force plate and motion analysis system. The size of APAs measured with either inertial sensors or force plate was significantly smaller in subjects with PD than in control subjects (p < 0.05). Test-retest reliability for the gait initiation characteristics measured with inertial sensors was moderate-to-excellent (0.56 < ICC < 0.82) for both groups. Our findings support the feasibility of automatically characterizing postural preparation and gait initiation with body-worn inertial sensors that would be practical for unsupervised clinical and home settings. (C) 2015 Elsevier B.V. All rights reserved. C1 [Mancini, Martina; Salarian, Arash; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, Portland, OR 97201 USA. [Chiari, Lorenzo] Univ Bologna, Dept Elect Elect & Informat Engn Guglielmo Marcon, Bologna, Italy. [Holmstrom, Lars; Horak, Fay B.] APDM Inc, Portland, OR USA. [Horak, Fay B.] Portland VA Med Ctr, Dept Res, Portland, OR USA. RP Mancini, M (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, 3181 Sam Jackson Pk Rd, Portland, OR 97201 USA. EM mancinim@ohsu.edu; lorenzo.chiari@unibo.it; lars@apdm.com; arash.salarian@gmail.com; horakf@ohsu.edu RI Salarian, Arash/E-8311-2016 OI Salarian, Arash/0000-0001-7332-0062; Chiari, Lorenzo/0000-0002-2318-4370 FU NIH [RC1 NS068678, R42 HD071760-03] FX We thank Kelsey Priest for scheduling and helping with data collection. This publication was made possible with support from NIH RC1 NS068678 and R42 HD071760-03. NR 30 TC 4 Z9 4 U1 3 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 EI 1879-2219 J9 GAIT POSTURE JI Gait Posture PD JAN PY 2016 VL 43 BP 125 EP 131 DI 10.1016/j.gaitpost.2015.08.015 PG 7 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA CY1HW UT WOS:000366158300021 PM 26433913 ER PT J AU Poelke, G Ventura, MI Byers, AL Yaffe, K Sudore, R Barnes, DE AF Poelke, Gina Ventura, Maria I. Byers, Amy L. Yaffe, Kristine Sudore, Rebecca Barnes, Deborah E. TI Leisure activities and depressive symptoms in older adults with cognitive complaints SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE leisure activities; depressive symptoms; mild cognitive impairment; aging ID PHYSICAL-ACTIVITY; CARDIOVASCULAR HEALTH; CONTROLLED-TRIAL; IMPAIRMENT; EXERCISE; INTERVENTIONS; PREVALENCE; COMMUNITY; DEMENTIA; DECLINE AB Background: Depressive symptoms are common in older adults and associated with increased risk of cognitive impairment. Leisure activities are often promoted for individuals with mood symptoms but few studies compare the effects of different types of leisure activities on reducing depressive symptoms. Methods: Data were analyzed from participants enrolled from 2008-2009 in the Mental Activity and eXercise (MAX) Trial, which examined the effects of physical plus mental activity over 12 weeks in inactive older adults with cognitive complaints. There were no significant differences between intervention groups on the primary outcome of cognitive function or the secondary outcome of depressive symptoms; therefore, all participants were combined for the current analyses in which we examined changes in leisure activity engagement (Community Healthy Activities Model Program for Seniors (CHAMPS)), and changes in depressive symptoms (Geriatric Depression Scale (GDS)) as a function of changes in leisure activity engagement from baseline to post-intervention. Results: Participants' mean age was 73.0 years, 61.6% were female, and 63.6% were non-Hispanic white. There was a significant change in total hours per week engaged in leisure activities from baseline (36.7 hours, SD = 12.7) to post-intervention (40.4 hours, SD = 15.7; paired t-test p = 0.02), and mean change in depressive symptoms was significantly inversely correlated with change in leisure activity hours such that increases in total leisure activity were associated with decreases in depressive symptoms (r = -0.21, p = 0.04). Conclusions: Increasing the total amount of leisure activity levels may help lower depressive symptoms in inactive older adults with cognitive complaints. C1 [Poelke, Gina; Ventura, Maria I.; Byers, Amy L.; Yaffe, Kristine; Sudore, Rebecca; Barnes, Deborah E.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94102 USA. RP Poelke, G (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 870 Market St,Suite 1123, San Francisco, CA 94102 USA. EM gpoelke@gmail.com FU Career Development Award from the National Institute on Aging [K01-AG024069]; Alzheimer's Association [IIRG-06-27306]; University of California School of Medicine; Institutes of Health/National Center for Research Resources/University of California; San Francisco - Clinical and Translational Science Institute [KL2 RR024130]; NIH [5-T32-AG000212] FX This study was supported in part by a Career Development Award from the National Institute on Aging (grant K01-AG024069), the Alzheimer's Association (grant IIRG-06-27306), the University of California School of Medicine, the Institutes of Health/National Center for Research Resources/University of California, San Francisco - Clinical and Translational Science Institute (grant KL2 RR024130) and NIH grant 5-T32-AG000212. NR 28 TC 0 Z9 0 U1 2 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD JAN PY 2016 VL 28 IS 1 BP 63 EP 69 DI 10.1017/S1041610215001246 PG 7 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA CY1WM UT WOS:000366198900009 PM 26299193 ER PT J AU Keator, DB van Erp, TGM Turner, JA Glover, GH Mueller, BA Liu, TT Voyvodic, JT Rasmussen, J Calhoun, VD Lee, HJ Toga, AW McEwen, S Ford, JM Mathalon, DH Diaz, M O'Leary, DS Bockholt, HJ Gadde, S Preda, A Wible, CG Stern, HS Belger, A McCarthy, G Ozyurt, B Potkin, SG AF Keator, David B. van Erp, Theo G. M. Turner, Jessica A. Glover, Gary H. Mueller, Bryon A. Liu, Thomas T. Voyvodic, James T. Rasmussen, Jerod Calhoun, Vince D. Lee, Hyo Jong Toga, Arthur W. McEwen, Sarah Ford, Judith M. Mathalon, Daniel H. Diaz, Michele O'Leary, Daniel S. Bockholt, H. Jeremy Gadde, Syam Preda, Adrian Wible, Cynthia G. Stern, Hal S. Belger, Aysenil McCarthy, Gregory Ozyurt, Burak Potkin, Steven G. CA FBIRN TI The Function Biomedical Informatics Research Network Data Repository SO NEUROIMAGE LA English DT Article ID MULTICENTER FMRI; CORTICAL THICKNESS; RATING-SCALE; SCHIZOPHRENIA; VARIABILITY; ACTIVATION; IDENTIFICATION; ABNORMALITIES; RELIABILITY; INSTRUMENT AB The Function Biomedical Informatics Research Network (FBIRN) developed methods and tools for conducting multi-scanner functional magnetic resonance imaging (fMRI) studies. Method and tool development were based on two major goals: 1) to assess the major sources of variation in fMRI studies conducted across scanners, including instrumentation, acquisition protocols, challenge tasks, and analysis methods, and 2) to provide a distributed network infrastructure and an associated federated database to host and query large, multi-site, fMRI and clinical data sets. In the process of achieving these goals the FBIRN test bed generated several multi-scanner brain imaging data sets to be shared with the wider scientific community via the BIRN Data Repository (BDR). The FBIRN Phase 1 data set consists of a traveling subject study of 5 healthy subjects, each scanned on 10 different 1.5 to 4 T scanners. The FBIRN Phase 2 and Phase 3 data sets consist of subjects with schizophrenia or schizoaffective disorder along with healthy comparison subjects scanned at multiple sites. In this paper, we provide concise descriptions of FBIRN's multi-scanner brain imaging data sets and details about the BIRN Data Repository instance of the Human Imaging Database (HID) used to publicly share the data. (C) 2015 Elsevier Inc. All rights reserved. C1 [Keator, David B.; van Erp, Theo G. M.; Rasmussen, Jerod; Preda, Adrian; Potkin, Steven G.] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92697 USA. [Turner, Jessica A.; Calhoun, Vince D.] Mind Res Networlc, Albuquerque, NM USA. [Turner, Jessica A.] Georgia State Univ, Dept Psychiat, Atlanta, GA 30303 USA. [Turner, Jessica A.] Georgia State Univ, Inst Neurosci, Atlanta, GA 30303 USA. [Glover, Gary H.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA. [Mueller, Bryon A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Liu, Thomas T.] Univ Calif San Diego, Ctr Funct MRI, San Diego, CA 92103 USA. [Voyvodic, James T.; Gadde, Syam] Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC USA. [Calhoun, Vince D.; Bockholt, H. Jeremy] Univ New Mexico, Dept ECE, Albuquerque, NM 87131 USA. [Calhoun, Vince D.] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA. [Lee, Hyo Jong] Chonbuk Natl Univ, Dept Comp Sci & Engn, Jeonju, South Korea. [Toga, Arthur W.] Univ So Calif, Lab Neuro Imaging, Los Angeles, CA USA. [Toga, Arthur W.] Univ So Calif, Inst Neuroimaging & Informat, Los Angeles, CA USA. [Toga, Arthur W.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [McEwen, Sarah] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Brain Imaging & EEG Lab, San Francisco, CA 94143 USA. [Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Diaz, Michele] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA. [O'Leary, Daniel S.; Bockholt, H. Jeremy] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA. [Wible, Cynthia G.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Wible, Cynthia G.] Brockton VAMC, Boston, MA USA. [Stern, Hal S.] Univ Calif Irvine, Dept Stat, Irvine, CA 92697 USA. [Belger, Aysenil] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Belger, Aysenil] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA. [McCarthy, Gregory] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. [Ozyurt, Burak] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Keator, DB (reprint author), Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine Hall,Room 163, Irvine, CA 92697 USA. EM dbkeator@uci.edu RI Preda, Adrian /K-8889-2013 OI Preda, Adrian /0000-0003-3373-2438 FU National Center for Research Resources at the National Institutes of Health (Function Biomedical Informatics Research Network) [NIH 1 U24 RR021992]; National Center for Research Resources at the National Institutes of Health (Biomedical Informatics Research Network Coordinating Center) [NIH 1 U24 RR025736-01] FX We are thankful to Mrs. Liv McMillan for overall study coordination, to Ms. Shichun Ling for editorial assistance, and to the research subjects for their participation. This work was supported by the National Center for Research Resources at the National Institutes of Health (grant numbers: NIH 1 U24 RR021992) (Function Biomedical Informatics Research Network) and NIH 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; www.birncommunity.org). The funding sources had no role in the study design, data collection, or publication of the data. NR 54 TC 3 Z9 3 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 SI SI BP 1074 EP 1079 DI 10.1016/j.neuroimage.2015.09.003 PN B PG 6 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY1FB UT WOS:000366151000003 PM 26364863 ER PT J AU Labus, JS Naliboff, B Kilpatrick, L Liu, C Ashe-McNalley, C dos Santos, IR Alaverdyan, M Woodworth, D Gupta, A Ellingson, BM Tillisch, K Mayer, EA AF Labus, Jennifer S. Naliboff, Bruce Kilpatrick, Lisa Liu, Cathy Ashe-McNalley, Cody dos Santos, Ivani R. Alaverdyan, Mher Woodworth, Davis Gupta, Arpana Ellingson, Benjamin M. Tillisch, Kirsten Mayer, Emeran A. TI Pain and Interoception Imaging Network (PAIN): A multimodal, multisite, brain-imaging repository for chronic somatic and visceral pain disorders SO NEUROIMAGE LA English DT Article DE Chronic pain; Neuroimaging data repository; Archived repository; Standardized repository; Large biological datasets; Multiple sites ID MAPP RESEARCH NETWORK; CHRONIC PELVIC PAIN; MRI AB The Pain and Interoception Imaging Network (PAIN) repository (painrepository.org) is a newly created NIH (NIDA/NCCAM) funded neuroimaging data repository that aims to accelerate scientific discovery regarding brain mechanisms in pain and to provide more rapid benefits to pain patients through the harmonization of efforts and data sharing. The PAIN Repository consists of two components, an Archived Repository and a Standardized Repository. Similar to other 'open' imaging repositories, neuroimaging researchers can deposit any dataset of chronic pain patients and healthy controls into the Archived Repository. Scans in the Archived Repository can be very diverse in terms of scanning procedures and clinical metadata, complicating the merging of datasets for analyses. The Standardized Repository overcomes these limitations through the use of standardized scanning protocols along with a standardized set of clinical metadata, allowing an unprecedented ability to perform pooled analyses. The Archived Repository currently includes 741 scans and is rapidly growing. The Standardized Repository currently includes 433 scans. Pain conditions currently represented in the PAIN repository include: irritable bowel syndrome, vulvodynia, migraine, chronic back pain, and inflammatory bowel disease. Both the PAIN Archived and Standardized Repositories promise to be important resources in the field of chronic pain research. The enhanced ability of the Standardized Repository to combine imaging, clinical and other biological datasets from multiple sites in particular make it a unique resource for significant scientific discoveries. (C) 2015 Elsevier Inc. All rights reserved. C1 [Labus, Jennifer S.; Naliboff, Bruce; Kilpatrick, Lisa; Liu, Cathy; Ashe-McNalley, Cody; dos Santos, Ivani R.; Alaverdyan, Mher; Woodworth, Davis; Gupta, Arpana; Ellingson, Benjamin M.; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Oppenheimer Family Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Kilpatrick, Lisa; Liu, Cathy; Ashe-McNalley, Cody; dos Santos, Ivani R.; Gupta, Arpana; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA. [Labus, Jennifer S.; Naliboff, Bruce; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. [Tillisch, Kirsten] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Labus, Jennifer S.; Naliboff, Bruce; Kilpatrick, Lisa; Liu, Cathy; Ashe-McNalley, Cody; dos Santos, Ivani R.; Gupta, Arpana; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, PAIN, Los Angeles, CA 90095 USA. [Woodworth, Davis; Ellingson, Benjamin M.] Univ Calif Los Angeles, David Geffen Sch Med, Radiol, Los Angeles, CA 90095 USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, David Sch Med, Div Digest Dis, Oppenheimer Family Ctr Neurobiol Stress, CHS 42-210 MC737818,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM emayer@ucla.edu FU National Institutes of Health: NCCAM/NIDA [R01 AT007137, P30 DK041301, R01 DK048351, R01 HD076756] FX This research was supported in part by grants from the National Institutes of Health: NCCAM/NIDA: R01 AT007137 (KT, BN), P30 DK041301, R01 DK048351 (EAM), and R01 HD076756 (JSL). NR 13 TC 4 Z9 4 U1 1 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2016 VL 124 SI SI BP 1232 EP 1237 DI 10.1016/j.neuroimage.2015.04.018 PN B PG 6 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CY1FB UT WOS:000366151000029 PM 25902408 ER PT J AU Bird, ER Gilmore, AK George, WH Lewis, MA AF Bird, Elizabeth R. Gilmore, Amanda K. George, William H. Lewis, Melissa A. TI The role of social drinking factors in the relationship between incapacitated sexual assault and drinking before sexual activity SO ADDICTIVE BEHAVIORS LA English DT Article DE Incapacitated sexual assault; Drinking motives; Drinking norms; Alcohol use; Sexual activity ID COLLEGE-STUDENTS; ALCOHOL-USE; SUBSTANCE USE; RISK-FACTORS; RECIPROCAL RELATIONSHIPS; CASUAL SEX; WOMEN; VICTIMIZATION; RAPE; CONSUMPTION AB White House Council on Women and Girls (2014) highlighted sexual assault prevention as a high priority issue in need of immediate attention. A risk factor associated with sexual assault victimization and revictimization is drinking before sexual activity. The current study examined the relationship between incapacitated sexual assault (ISA) and drinking before sexual activity. Given the typical social context of both drinking before sexual activity and sexual assault in college settings, social-related drinking factors including drinking to conform motives, social drinking motives, and perceived drinking norms were examined. Six hundred and three undergraduate college women completed a survey online assessing history of ISA, social factors associated with drinking, and frequency of drinking before sexual activity. Path analysis indicated that both ISA before college and since entering college were associated with higher perceived drinking norms, more social drinking motive endorsement, and more drinking to conform. However, only higher perceived drinking norms and more social drinking motive endorsement were associated with both more severe ISA histories and more frequent drinking before sexual activity. Thus, a more severe ISA history was indeed associated with more frequent drinking before sexual activity and social factors related to drinking played a significant role in this relationship. Social factors can be easily targeted through brief interventions and these findings can inform future programming to promote more careful use of alcohol in social and sexual situations. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Bird, Elizabeth R.; Gilmore, Amanda K.; George, William H.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Gilmore, Amanda K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lewis, Melissa A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Bird, ER (reprint author), Univ Washington, Dept Psychol, Box 351525, Seattle, WA 98195 USA. EM ebird@uw.edu FU National Institute for Alcohol Abuse and Alcoholism (NIAAA) [F31AA020134]; Alcohol and Drug Abuse Institute at the University of Washington [ADAI-0311-2]; University of Washington; NIAAA [R01AA016281, R01AA021379] FX Data collection and manuscript preparation were supported by grants from the National Institute for Alcohol Abuse and Alcoholism (NIAAA) awarded to A. K. Gilmore (F31AA020134) as well as a grant from the Alcohol and Drug Abuse Institute at the University of Washington (ADAI-0311-2), as well as the Bolles Fellowship and Hunt Fellowship from the University of Washington awarded to A. K. Gilmore. Manuscript preparation was also supported by grants from NIAAA awarded to W. H. George (R01AA016281) and to M. A. Lewis (R01AA021379). NR 59 TC 1 Z9 2 U1 7 U2 17 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD JAN PY 2016 VL 52 BP 28 EP 33 DI 10.1016/j.addbeh.2015.08.001 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CX0HI UT WOS:000365377100005 PM 26348279 ER PT J AU Grossbard, JR Leo, NRM Geisner, IM Atkins, D Ray, AE Kilmer, JR Mallett, K Larimer, ME Turrisi, R AF Grossbard, Joel R. Leo, Nadine R. Mastro Geisner, Irene Markman Atkins, David Ray, Anne E. Kilmer, Jason R. Mallett, Kimberly Larimer, Mary E. Turrisi, Rob TI Drinking norms, readiness to change, and gender as moderators of a combined alcohol intervention for first-year college students SO ADDICTIVE BEHAVIORS LA English DT Article DE Alcohol intervention; College students; Moderators; Readiness to change; Norms ID BRIEF MOTIVATIONAL INTERVENTIONS; PERSONALIZED NORMATIVE FEEDBACK; HEAVY-DRINKING; RANDOMIZED FACTORIAL; EMERGENCY-DEPARTMENT; CHANGE QUESTIONNAIRE; CONTROLLED-TRIAL; NATIONAL-SURVEY; NONMEDICAL USE; FOLLOW-UP AB Introduction: Alcohol interventions targeting college students and their parents have been shown to be efficacious. Little research has examined moderators of intervention efficacy to help tailor interventions for subgroups of students. Method: This study is a secondary data analysis of readiness to change, drinking norms, and gender as moderators of an efficacious peer- and parent-based intervention (Turrisi et al., 2009). Students (n = 680) were randomized to the combined peer and parent intervention (n = 342) or assessment-only control (n = 338). Results: The combined intervention reduced peak blood alcohol content (BAC) compared to control. Gender and norms did not moderate the relationship between the intervention and drinking. Significant interactions were found between gender, precontemplation, and intervention. Students in the combined condition with higher precontemplation had lower weekly drinking compared to those with lower precontemplation. This pattern was also found among men for peak BAC and alcohol-related consequences but not among women, indicating a three-way interaction. Conclusion: Interventions may need to consider readiness to change and gender to optimize effectiveness. Published by Elsevier Ltd. C1 [Grossbard, Joel R.] Vet Affairs Univ Washington, Dept Hlth Serv, Seattle, WA 98108 USA. [Leo, Nadine R. Mastro] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Geisner, Irene Markman; Atkins, David; Kilmer, Jason R.; Larimer, Mary E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA. [Ray, Anne E.] Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ 08854 USA. [Mallett, Kimberly; Turrisi, Rob] Penn State Univ, Biobehav Hlth & Prevent Ctr, University Pk, PA 16802 USA. RP Grossbard, JR (reprint author), VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM joel.Grossbard@va.gov OI Atkins, David/0000-0002-5781-9880 FU National Institute on Alcohol Abuse and Alcoholism [R01 AA 12529] FX This research was supported in part by a grant from the National Institute on Alcohol Abuse and Alcoholism R01 AA 12529 awarded to Rob Turrisi. NR 74 TC 2 Z9 2 U1 6 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD JAN PY 2016 VL 52 BP 75 EP 82 DI 10.1016/j.addbeh.2015.07.028 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CX0HI UT WOS:000365377100012 PM 26363307 ER PT J AU Leslie, RD Palmer, J Schloot, NC Lernmark, A AF Leslie, R. David Palmer, Jerry Schloot, Nanette C. Lernmark, Ake TI Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment SO DIABETOLOGIA LA English DT Review DE Autoantibodies; Genetic variants; LADA; MODY; Personalised medicine; Review; Tcells; Treatment; Type 1 diabetes; Type 2 diabetes ID BETA-CELL FUNCTION; INSULIN SENSITIVITY; GAD ANTIBODIES; RISK-FACTORS; LADA CHINA; C-PEPTIDE; TYPE-2; ONSET; ADULTS; AUTOIMMUNITY AB Diabetes is not a single homogeneous disease but composed of many diseases with hyperglycaemia as a common feature. Four factors have, historically, been used to identify this diversity: the age at onset; the severity of the disease, i.e. degree of loss of beta cell function; the degree of insulin resistance and the presence of diabetes-associated autoantibodies. Our broad understanding of the distinction between the two major types, type 1 diabetes mellitus and type 2 diabetes mellitus, are based on these factors, but it has become apparent that they do not precisely capture the different disease forms. Indeed, both major types of diabetes have common features, encapsulated by adult-onset autoimmune diabetes and maturity-onset diabetes of the young. As a result, there has been a repositioning of our understanding of diabetes. In this review, drawing on recent literature, we discuss the evidence that autoimmune type 1 diabetes has a broad clinical phenotype with diverse therapeutic options, while the term non-autoimmune type 2 diabetes obscures the optimal management strategy because it encompasses substantial heterogeneity. Underlying these developments is a general progression towards precision medicine with the need for precise patient characterisation, currently based on clinical phenotypes but in future augmented by laboratory-based tests. C1 [Leslie, R. David] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England. [Palmer, Jerry] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Schloot, Nanette C.] Univ Dusseldorf, German Diabet Ctr, Inst Clin Diabetol, Dusseldorf, Germany. [Schloot, Nanette C.] Lilly Deutschland GmbH, Bad Homburg, Germany. [Lernmark, Ake] Lund Univ, CRC, Dept Clin Sci, Malmo, Sweden. RP Leslie, RD (reprint author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England. EM r.d.g.leslie@qmul.ac.uk NR 45 TC 11 Z9 11 U1 2 U2 23 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD JAN PY 2016 VL 59 IS 1 BP 13 EP 20 DI 10.1007/s00125-015-3789-z PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CX6IN UT WOS:000365804500004 PM 26498592 ER PT B AU Cavazos, JE AF Cavazos, Jose E. BE Husain, AM TI First-Generation Antiepileptic Drugs SO PRACTICAL EPILEPSY LA English DT Article; Book Chapter ID PARTIAL-ONSET SEIZURES; TONIC CLONIC SEIZURES; STATUS EPILEPTICUS; CARBAMAZEPINE; MONOTHERAPY; OUTCOMES; EPILEPSY; THERAPY C1 [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Cavazos, Jose E.] South Texas Vet Hlth Care Syst, San Antonio VA Epilepsy Ctr Excellence, San Antonio, TX USA. RP Cavazos, JE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. NR 9 TC 0 Z9 0 U1 0 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-62070-029-7 PY 2016 BP 263 EP 276 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA BD9PI UT WOS:000365049500026 ER PT J AU Ashrafioun, L Pigeon, WR Conner, KR Leong, SH Oslin, DW AF Ashrafioun, Lisham Pigeon, Wilfred R. Conner, Kenneth R. Leong, Shirley H. Oslin, David W. TI Prevalence and correlates of suicidal ideation and suicide attempts among veterans in primary care referred for a mental health evaluation SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicidal ideation; Suicide attempt; Primary care; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; COMPLETED SUICIDE; RECEIVING CARE; RISK-FACTORS; COMORBIDITY; DEPRESSION; SYSTEM; PTSD; METAANALYSIS; ASSOCIATION AB Background: The Veterans Health Administration has made concerted efforts to increase mental health services offered in primary care. However, few studies have evaluated correlates of suicidal ideation and suicide attempt in veterans in primary care-mental health integration (PCMHI). The purpose of the present study is to examine associations between suicidal ideation and suicide attempts as dependent variables and demographic and clinical factors as the independent variables. Methods: Veterans (n=3004) referred from primary care to PCMHI were contacted for further assessment, which included past-year severity of suicidal thoughts (none, low, high) and attempts using the Paykel Suicide Scale, mental health disorders, and illicit drug use. Multinomial logistic regression models were used to identify correlates of suicidal ideation and suicide attempts. Results: Thoughts of taking one's life was endorsed by 24% of participants and suicide attempts were reported in 2%. In adjusted models, depression, psychosis, mania, PTSD and generalized anxiety disorder were associated with high severity suicidal ideation, but not suicide attempt. Illicit drug use was not associated with suicidal ideation, but was the only variable associated with suicide attempt. Limitations: The study was cross-sectional, focused on one clinical setting, and the suicide attempt analyses had limited power. Conclusions: PCMHI is a critical setting to assess suicidal ideation and suicide attempt and researchers and clinicians should be aware that the differential correlates of these suicide-related factors. Future research is needed to identify prospective risk factors and assess the utility of follow-up care in preventing suicide. Published by Elsevier B.V. C1 [Ashrafioun, Lisham; Pigeon, Wilfred R.; Conner, Kenneth R.] Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. [Ashrafioun, Lisham; Pigeon, Wilfred R.; Conner, Kenneth R.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14627 USA. [Leong, Shirley H.; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Leong, Shirley H.; Oslin, David W.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. RP Ashrafioun, L (reprint author), Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM Lisham.Ashrafioun@va.gov NR 50 TC 2 Z9 2 U1 6 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 1 PY 2016 VL 189 BP 344 EP 350 DI 10.1016/j.jad.2015.09.014 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CV3PD UT WOS:000364170200051 PM 26474375 ER PT J AU Foster, GR Afdhal, N Roberts, SK Brau, N Gane, EJ Pianko, S Lawitz, E Thompson, A Shiffman, ML Cooper, C Towner, WJ Conway, B Ruane, P Bourliere, M Asselah, T Berg, T Zeuzem, S Rosenberg, W Agarwal, K Stedman, CAM Mo, H Dvory-Sobol, H Han, L Wang, J McNally, J Osinusi, A Brainard, DM McHutchison, JG Mazzotta, F Tran, TT Gordon, SC Patel, K Reau, N Mangia, A Sulkowski, M AF Foster, G. R. Afdhal, N. Roberts, S. K. Braeu, N. Gane, E. J. Pianko, S. Lawitz, E. Thompson, A. Shiffman, M. L. Cooper, C. Towner, W. J. Conway, B. Ruane, P. Bourliere, M. Asselah, T. Berg, T. Zeuzem, S. Rosenberg, W. Agarwal, K. Stedman, C. A. M. Mo, H. Dvory-Sobol, H. Han, L. Wang, J. McNally, J. Osinusi, A. Brainard, D. M. McHutchison, J. G. Mazzotta, F. Tran, T. T. Gordon, S. C. Patel, K. Reau, N. Mangia, A. Sulkowski, M. CA ASTRAL-2 & ASTRAL-3 Investigators TI Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID C VIRUS-INFECTION; RANDOMIZED-TRIAL AB BACKGROUND In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3. METHODS We conducted two randomized, phase 3, open-label studies involving patients who had received previous treatment for HCV genotype 2 or 3 and those who had not received such treatment, including patients with compensated cirrhosis. In one trial, patients with HCV genotype 2 were randomly assigned in a 1: 1 ratio to receive sofosbuvir-velpatasvir,in a once-daily, fixed-dose combination tablet (134 patients), or sofosbuvir plus weight-based ribavirin (132 patients) for 12 weeks. In a second trial, patients with HCV genotype 3 were randomly assigned in a 1: 1 ratio to receive sofosbuvir-velpatasvir for 12 weeks (277 patients) or sofosbuvir-ribavirin for 24 weeks (275 patients). The primary end point for the two trials was a sustained virologic response at 12 weeks after the end of therapy. RESULTS Among patients with HCV genotype 2, the rate of sustained virologic response in the sofosbuvir-velpatasvir group was 99% (95% confidence interval [CI], 96 to 100), which was superior to the rate of 94% (95% CI, 88 to 97) in the sofosbuvir-ribavirin group (P = 0.02). Among patients with HCV genotype 3, the rate of sustained virologic response in the sofosbuvir-velpatasvir group was 95% (95% CI, 92 to 98), which was superior to the rate of 80% (95% CI, 75 to 85) in the sofosbuvir-ribavirin group (P<0.001). The most common adverse events in the two studies were fatigue, headache, nausea, and insomnia. CONCLUSIONS Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment with sofosbuvir-ribavirin. C1 [Foster, G. R.] Queen Mary Univ London, London E1 4AT, England. [Rosenberg, W.] UCL, London WC1E 6BT, England. [Rosenberg, W.] Kings Coll Hosp London, London SE5 8RX, England. [Agarwal, K.] Inst Liver Studies, London, England. [Afdhal, N.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Roberts, S. K.] Alfred Hlth, Melbourne, Vic, Australia. [Roberts, S. K.] Monash Univ, Melbourne, Vic 3004, Australia. [Thompson, A.] St Vincents Hosp, Melbourne, Vic, Australia. [Pianko, S.] Monash Hlth, Clayton, Vic, Australia. [Pianko, S.] Monash Univ, Clayton, Vic, Australia. [Braeu, N.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Braeu, N.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Gane, E. J.] Auckland Clin Studies, Auckland, New Zealand. [Stedman, C. A. M.] Christchurch Clin Studies Trust & Univ Otago, Christchurch, New Zealand. [Lawitz, E.] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA. [Shiffman, M. L.] Liver Inst Virginia, Richmond, VA USA. [Cooper, C.] Univ Ottawa, Ottawa, ON, Canada. [Conway, B.] Vancouver Infect Dis Ctr, Vancouver, BC, Canada. [Towner, W. J.] Kaiser Permanente, Los Angeles, CA USA. [Ruane, P.] Ruane Med, Los Angeles, CA USA. [Tran, T. T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Berg, T.; Mo, H.; Dvory-Sobol, H.; Han, L.; Wang, J.; McNally, J.; Osinusi, A.; Brainard, D. M.; McHutchison, J. G.] Gilead Sci Inc, Foster City, CA 94404 USA. [Bourliere, M.] Hop St Joseph, Marseille, France. [Asselah, T.] Univ Paris Diderot, INSERM, UMR 1149, Hop Beaujon,Serv Hepatol, Clichy, France. [Berg, T.] Univ Hosp Leipzig, Leipzig, Germany. [Zeuzem, S.] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany. [Mazzotta, F.] Santa Maria Annunziata Hosp, Florence, Italy. [Mangia, A.] Casa Sollievo Sofferenza Hosp, San Giovanni Rotondo, Italy. [Gordon, S. C.] Henry Ford Hlth Syst, Detroit, MI USA. [Patel, K.] Duke Univ, Sch Med, Durham, NC USA. [Reau, N.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Sulkowski, M.] Johns Hopkins Univ, Baltimore, MD USA. RP Foster, GR (reprint author), Queen Mary Univ London, Liver Unit, 4 Newark St, London E1 4AT, England. EM g.r.foster@qmul.ac.uk RI Loustaud-Ratti, Veronique/A-5262-2017; Leggett, Barbara/D-3579-2011 OI Rosenberg, William/0000-0002-2732-2304 FU Gilead Sciences FX Funded by Gilead Sciences; ASTRAL-2 ClinicalTrials.gov number, NCT02220998; and ASTRAL-3, NCT02201953. NR 17 TC 121 Z9 123 U1 7 U2 25 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 31 PY 2015 VL 373 IS 27 BP 2608 EP 2617 DI 10.1056/NEJMoa1512612 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CZ8UH UT WOS:000367374100006 PM 26575258 ER PT J AU Alawieh, A Elvington, A Zhu, H Yu, J Kindy, MS Atkinson, C Tomlinson, S AF Alawieh, Ali Elvington, Andrew Zhu, Hong Yu, Jin Kindy, Mark S. Atkinson, Carl Tomlinson, Stephen TI Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Ischemic stroke; Complement inhibition; Neuroinflammation; Neuroprotection ID MANNOSE-BINDING LECTIN; NEURAL PROGENITOR CELLS; FOCAL CEREBRAL-ISCHEMIA; SUBVENTRICULAR ZONE; BRAIN-INJURY; IN-VITRO; STROKE; NEUROGENESIS; RECEPTOR; SYSTEM AB Background: Complement promotes neuroinflammation and injury in models of stroke. However, complement is also being increasingly implicated in repair and regeneration after central nervous system (CNS) injury, and some complement deficiencies have been shown to provide acute, but not subacute, protection after murine stroke. Here, we investigate the dual role of complement in injury and repair after cerebral ischemia and reperfusion. Methods: We used complement-deficient mice and different complement inhibitors in a model of transient middle cerebral artery occlusion to investigate complement-dependent cellular and molecular changes that occur through the subacute phase after stroke. Results: C3 deficiency and site-targeted complement inhibition with either CR2-Crry (inhibits all pathways) or CR2-fH (inhibits alternative pathway) significantly reduced infarct size, reduced apoptotic cell death, and improved neurological deficit score in the acute phase after stroke. However, only in CR2-fH-treated mice was there sustained protection with no evolution of injury in the subacute phase. Whereas both inhibitors significantly reduced microglia/macrophage activation and astrogliosis in the subacute phase, only CR2-fH improved neurological deficit and locomotor function, maintained neurogenesis markers, enhanced neuronal migration, and increased VEGF expression. These findings in CR2-fH-treated mice correlated with improved performance in spatial learning and passive avoidance tasks. The complement anaphylatoxins have been implicated in repair and regenerative mechanisms after CNS injury, and in this context CR2-fH significantly reduced, but did not eliminate the generation of C5a within the brain, unlike CR2-Crry that completely blocked C5a generation. Gene expression profiling revealed that CR2-fH treatment downregulated genes associated with apoptosis, TGF beta signaling, and neutrophil activation, and decreased neutrophil infiltration was confirmed by immunohistochemistry. CR2-fH upregulated genes for neural growth factor and mediators of neurogenesis and neuronal migration. Live animal imaging demonstrated that following intravenous injection, CR2-fH targeted specifically to the post-ischemic brain, with a tissue half-life of 48.5 h. Finally, unlike C3 deficiency, targeted complement inhibition did not increase susceptibility to lethal post-stroke infection, an important consideration for stroke patients. Conclusions: Ischemic brain tissue-targeted and selective inhibition of alternative complement pathway provide self-limiting inhibition of complement activation and reduces acute injury while maintaining complement-dependent recovery mechanisms into the subacute phase after stroke. C1 [Alawieh, Ali; Elvington, Andrew; Atkinson, Carl; Tomlinson, Stephen] Med Univ S Carolina, Childrens Res Inst, Department Microbiol & Immunol, Charleston, SC 29425 USA. [Zhu, Hong; Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Inst Neurosci, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark S.; Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Childrens Res Inst, Department Microbiol & Immunol, 173 Ashley Ave BSB 201, Charleston, SC 29425 USA. EM tomlinss@musc.edu OI Alawieh, Ali/0000-0003-2601-8850 FU NIH [1P20GM109040]; Department of Veterans Affairs (Merit Award) [1I01RX001141, 1BX001218]; American Heart Association [15PRE25250009] FX This work was supported by grants from the NIH (1P20GM109040), the Department of Veterans Affairs (Merit Award 1I01RX001141 and 1BX001218), and an American Heart Association Pre-doctoral Fellowship to AA (15PRE25250009). NR 40 TC 2 Z9 2 U1 1 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD DEC 30 PY 2015 VL 12 AR 247 DI 10.1186/s12974-015-0464-8 PG 15 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DA0UG UT WOS:000367512400005 PM 26714866 ER PT J AU Chen, YX Zhu, WB Zhang, WR Libal, N Murphy, SJ Offner, H Alkayed, NJ AF Chen, Yingxin Zhu, Wenbin Zhang, Wenri Libal, Nicole Murphy, Stephanie J. Offner, Halina Alkayed, Nabil J. TI A novel mouse model of thromboembolic stroke SO JOURNAL OF NEUROSCIENCE METHODS LA English DT Article DE Cerebral ischemia; Stroke, Thromboembolic; Mouse; tPA; Optical microangiography ID CEREBRAL-ARTERY OCCLUSION; SPONTANEOUSLY HYPERTENSIVE-RATS; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; INTRALUMINAL SUTURE; EMBOLIC STROKE; BRAIN ISCHEMIA; INFARCT SIZE; REPERFUSION; MICE AB Background: We previously demonstrated that tissue plasminogen activator (tPA) reduces infarct size after mechanical middle cerebral artery occlusion (MCAO) in wild-type (WT) mice and transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). Clinically, tPA limits ischemic damage by dissolving the clot blocking blood flow through a cerebral artery. To mimic the clinical situation, we developed a new mouse model of thromboembolic stroke, and tested the efficacy of tPA in WT and DR2-Tg mice. New Method Autologous blood is withdrawn into a PE-8 catheter filled with 2 IU alpha-thrombin. After exposing the catheter briefly to air, the catheter is reintroduced into the external (ECA) and advanced into the internal carotid artery (ICA) to allow for intravascular injection of thrombin at the MCA bifurcation. To validate the model, we tested the effect of tPA on laser-Doppler perfusion (LDP) over the MCA territory and infarct size in WT and DR2-Tg mice. Results: The procedure results in a consistent drop in LDP, and leads to a highly reproducible ischemic lesion. When administered at 15 min after thrombosis, tPA restored LDP and resulted in a significant reduction in infarct size at 24 h after thrombosis in both WT and DR2-Tg. Comparison with Existing Methods: Our model significantly reduces surgery time, requires a single anesthesia exposure, and produces a consistent and predictable infarction, with low variability and mortality. Conclusion: We validated the efficacy of tPA in restoring blood flow and reducing infarct in a new model of endovascular thromboembolic stroke in the mouse. (C) 2015 Elsevier B.V. All rights reserved. C1 [Chen, Yingxin; Zhu, Wenbin; Zhang, Wenri; Libal, Nicole; Murphy, Stephanie J.; Offner, Halina; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Offner, Halina; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA. [Offner, Halina] Portland VA Med Ctr, Neuroimmunol Res, Portland, OR USA. RP Alkayed, NJ (reprint author), Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Dept Anesthesiol & Perioperat Med, UHN 2,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM alkayedn@ohsu.edu FU NIH [R42NS065515, R01NS070837] FX This project was supported by NIH grants R42NS065515 (Offner & Alkayed) and R01NS070837 (Alkayed). NR 40 TC 3 Z9 3 U1 9 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0270 EI 1872-678X J9 J NEUROSCI METH JI J. Neurosci. Methods PD DEC 30 PY 2015 VL 256 BP 203 EP 211 DI 10.1016/j.jneumeth.2015.09.013 PG 9 WC Biochemical Research Methods; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA CY7VW UT WOS:000366618400021 PM 26386284 ER PT J AU Cortese, BM Uhde, TW Brady, KT McClernon, FJ Yang, QX Collins, HR LeMatty, T Hartwell, KJ AF Cortese, Bernadette M. Uhde, Thomas W. Brady, Kathleen T. McClernon, F. Joseph Yang, Qing X. Collins, Heather R. LeMatty, Todd Hartwell, Karen J. TI The fMRI BOLD response to unisensory and multisensory smoking cues in nicotine-dependent adults SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Odors; Smoking; Tobacco dependence; Craving; Cue-reactivity; Neuroimaging ID ALCOHOL CUES; OLFACTORY FUNCTION; CIGARETTE-SMOKING; PREFRONTAL CORTEX; RISK DRINKERS; DRUG CUES; IN-VIVO; REACTIVITY; RELAPSE; SMOKERS AB Given that the vast majority of functional magnetic resonance imaging (fMRI) studies of drug cue reactivity use unisensory visual cues, but that multisensory cues may elicit greater craving-related brain responses, the current study sought to compare the fMRI BOLD response to unisensory visual and multisensory, visual plus odor, smoking cues in 17 nicotine-dependent adult cigarette smokers. Brain activation to smoking-related, compared to neutral, pictures was assessed under cigarette smoke and odorless odor conditions. While smoking pictures elicited a pattern of activation consistent with the addiction literature, the multisensory (odor+picture) smoking cues elicited significantly greater and more widespread activation in mainly frontal and temporal regions. BOLD signal elicited by the multisensory, but not unisensory cues, was significantly related to participants' level of control over craving as well. Results demonstrated that the co-presentation of cigarette smoke odor with smoking-related visual cues, compared to the visual cues alone, elicited greater levels of craving-related brain activation in key regions implicated in reward. These preliminary findings support future research aimed at a better understanding of multisensory integration of drug cues and craving. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Cortese, Bernadette M.; Uhde, Thomas W.; Brady, Kathleen T.; LeMatty, Todd; Hartwell, Karen J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Brady, Kathleen T.; Hartwell, Karen J.] Ralph H Johnson VAMC, Charleston, SC USA. [McClernon, F. Joseph] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Yang, Qing X.] Penn State Coll Med, Dept Radiol & Neurosurg, Ctr NMR Res, Hershey, PA USA. [Collins, Heather R.] Med Univ S Carolina, Dept Radiol & Radiol Sci, Ctr Biomed Imaging, Charleston, SC 29425 USA. RP Cortese, BM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, MSC 861, Charleston, SC 29425 USA. EM corteseb@musc.edu FU NIMH [K01MH090548]; NCATS [UL1 TR000062] FX Funding for this study was provided by NIMH Grant K01MH090548 (BMC), and by NCATS Grant UL1 TR000062 (pilot project to KJH and BMC). Study sponsors had no role in the study design, collection, analysis, interpretation of data, writing of the report, or the decision to submit the article for publication. NR 51 TC 1 Z9 1 U1 5 U2 17 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 EI 1872-7506 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD DEC 30 PY 2015 VL 234 IS 3 BP 321 EP 327 DI 10.1016/j.pscychresns.2015.10.008 PG 7 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CX9FU UT WOS:000366011200006 PM 26475784 ER PT J AU Jiang, RZ Lu, YT Ho, H Li, B Chen, JF Lin, M Li, FQ Wu, K Wu, HJ Lichterman, J Wan, HL Lu, CL OuYang, W Ni, M Wang, LL Li, GB Lee, T Zhang, XQ Yang, JT Rettig, M Chung, LWK Yang, HM Li, KC Hou, Y Tseng, HR Hou, S Xu, X Wang, J Posadas, EM AF Jiang, Runze Lu, Yi-Tsung Ho, Hao Li, Bo Chen, Jie-Fu Lin, Millicent Li, Fuqiang Wu, Kui Wu, Hanjie Lichterman, Jake Wan, Haolei Lu, Chia-Lun OuYang, William Ni, Ming Wang, Linlin Li, Guibo Lee, Tom Zhang, Xiuqing Yang, Jonathan Rettig, Matthew Chung, Leland W. K. Yang, Huanming Li, Ker-Chau Hou, Yong Tseng, Hsian-Rong Hou, Shuang Xu, Xun Wang, Jun Posadas, Edwin M. TI A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer SO ONCOTARGET LA English DT Article DE circulating tumor cell; prostate cancer; whole genome sequencing; liquid biopsy; cancer heterogeneity ID METASTATIC BREAST-CANCER; COPY-NUMBER; LUNG-CANCER; SINGLE-NUCLEOTIDE; PERIPHERAL-BLOOD; PD-1 BLOCKADE; MUTATIONS; EVOLUTION; DNA; REARRANGEMENTS AB Previous studies have demonstrated focal but limited molecular similarities between circulating tumor cells (CTCs) and biopsies using isolated genetic assays. We hypothesized that molecular similarity between CTCs and tissue exists at the single cell level when characterized by whole genome sequencing (WGS). By combining the NanoVelcro CTC Chip with laser capture microdissection (LCM), we developed a platform for single-CTC WGS. We performed this procedure on CTCs and tissue samples from a patient with advanced prostate cancer who had serial biopsies over the course of his clinical history. We achieved 30X depth and >= 95% coverage. Twenty-nine percent of the somatic single nucleotide variations (SSNVs) identified were founder mutations that were also identified in CTCs. In addition, 86% of the clonal mutations identified in CTCs could be traced back to either the primary or metastatic tumors. In this patient, we identified structural variations (SVs) including an intrachromosomal rearrangement in chr3 and an interchromosomal rearrangement between chr13 and chr15. These rearrangements were shared between tumor tissues and CTCs. At the same time, highly heterogeneous short structural variants were discovered in PTEN, RB1, and BRCA2 in all tumor and CTC samples. Using high-quality WGS on single-CTCs, we identified the shared genomic alterations between CTCs and tumor tissues. This approach yielded insight into the heterogeneity of the mutational landscape of SSNVs and SVs. It may be possible to use this approach to study heterogeneity and characterize the biological evolution of a cancer during the course of its natural history. C1 [Jiang, Runze; Li, Bo; Li, Fuqiang; Wu, Kui; Wu, Hanjie; Ni, Ming; Wang, Linlin; Li, Guibo; Yang, Huanming; Hou, Yong; Xu, Xun; Wang, Jun] Beijing Genome Inst Shenzhen, Shenzhen 51803, Peoples R China. [Lu, Yi-Tsung; Chen, Jie-Fu; Lichterman, Jake; Lu, Chia-Lun; Chung, Leland W. K.; Posadas, Edwin M.] Cedars Sinai Med Ctr, Urol Oncol Res Program, Los Angeles, CA 90048 USA. [Ho, Hao; Li, Ker-Chau] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90095 USA. [Ho, Hao; Li, Ker-Chau] Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan. [Chen, Jie-Fu; Lin, Millicent; OuYang, William; Yang, Jonathan; Tseng, Hsian-Rong; Hou, Shuang] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Wan, Haolei] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Lee, Tom; Tseng, Hsian-Rong] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA. [Zhang, Xiuqing] BGI Shenzhen, Guangdong Enterprise Key Lab Human Dis Genom, Shenzhen 51803, Peoples R China. [Rettig, Matthew] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Rettig, Matthew] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. [Rettig, Matthew] VA Greater Los Angeles Healthcare Syst, Div Hematol Oncol, Dept Med, Los Angeles, CA 90073 USA. [Yang, Huanming; Wang, Jun] King Abdulaziz Univ, Princess Al Jawhara Ctr Excellence Res Hereditary, Jeddah 21589, Saudi Arabia. [Yang, Huanming] Zhejiang Univ, James D Watson Inst Genome Sci, Hangzhou 310058, Zhejiang, Peoples R China. [Wang, Jun] Univ Copenhagen, Dept Biol, DK-1599 Copenhagen, Denmark. [Wang, Jun] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, DK-1599 Copenhagen, Denmark. RP Posadas, EM (reprint author), Cedars Sinai Med Ctr, Urol Oncol Res Program, Los Angeles, CA 90048 USA. EM HRTseng@mednet.ucla.edu; wangj@genomics.cn; Edwin.Posadas@csmc.edu FU National High Technology Research and Development Program of China-863 Program [2012AA02A201]; National Basic Research Program of China (973 program) [2011CB809202, 2011CB809203]; Key Laboratory Project - Shenzhen City [CXB201108250096A]; Major Industrial Technology Research Program of Shenzhen [BGI20100001]; Science, Technology and Innovation Committee of Shenzhen Municipality [JSGG20140702161347218]; China National GeneBank-Shenzhen; Prostate Cancer Foundation (PCF); UCLA Prostate Cancer SPORE Program; NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program [R21 CA151159, R33 CA157396]; DoD Idea Award [W81XWH-11-1-0422]; Steven Spielberg Discovery Fund in Prostate Cancer Research; PCF Young Investigator Award; St. Anthony Fund for Prostate Cancer Research; CD McKinnon Fund; Berns Family Fund for Prostate Cancer Research; Innovative Research Team Project of Guangdong; Guangdong Enterprise Key Laboratory of Human Disease Genomics [2011A060906007]; National Natural Science Fund [81272899, 81172510]; Discipline Booster Plan of Xi Jing Hospital [XJZT12Z07]; Danish Natural Science Research Council; Danish National Research Foundation; National Natural Science Foundation of China; Shenzhen Municipal Government; Local Government of the Yantian District of Shenzhen FX The work at BGI was supported by the National High Technology Research and Development Program of China-863 Program (No. 2012AA02A201), a National Basic Research Program of China (973 program No. 2011CB809202 and 2011CB809203), the Key Laboratory Project Supported by Shenzhen City (No. CXB201108250096A), Major Industrial Technology Research Program of Shenzhen (No. BGI20100001), the Science, Technology and Innovation Committee of Shenzhen Municipality (JSGG20140702161347218), and China National GeneBank-Shenzhen. The research endeavors at UCLA were supported by a Creativity Award from the Prostate Cancer Foundation (PCF), the UCLA Prostate Cancer SPORE Program, and research grants (R21 CA151159 and R33 CA157396) from the NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program. The research endeavors at Cedars-Sinai Medical Center were supported by a DoD Idea Award (W81XWH-11-1-0422), the Steven Spielberg Discovery Fund in Prostate Cancer Research, a PCF Young Investigator Award, the St. Anthony Fund for Prostate Cancer Research, the CD McKinnon Fund, and the Berns Family Fund for Prostate Cancer Research. This project was also supported by grants from the Innovative Research Team Project of Guangdong, the Guangdong Enterprise Key Laboratory of Human Disease Genomics (No. 2011A060906007), the National Natural Science Fund (81272899 and 81172510) and Discipline Booster Plan of Xi Jing Hospital (XJZT12Z07). We also acknowledge an Ole Romer grant from the Danish Natural Science Research Council, the Danish National Research Foundation, the National Natural Science Foundation of China, and funds from the Shenzhen Municipal Government and the Local Government of the Yantian District of Shenzhen. NR 53 TC 15 Z9 15 U1 5 U2 14 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD DEC 29 PY 2015 VL 6 IS 42 BP 44781 EP 44793 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DD4QX UT WOS:000369908800053 PM 26575023 ER PT J AU Londino, JD Gulick, D Isenberg, JS Mallampalli, RK AF Londino, James D. Gulick, Dexter Isenberg, Jeffrey S. Mallampalli, Rama K. TI Cleavage of Signal Regulatory Protein alpha (SIRP alpha) Enhances Inflammatory Signaling SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYLOID PRECURSOR PROTEIN; C-TERMINAL FRAGMENT; NF-KAPPA-B; CELL-MIGRATION; SECRETASE; ACTIVATION; CD47; SHPS-1; ADAM10; GROWTH AB Signal regulatory protein alpha (SIRP alpha) is a membrane glycoprotein immunoreceptor abundant in cells of monocyte lineage. SIRP alpha ligation by a broadly expressed transmembrane protein, CD47, results in phosphorylation of the cytoplasmic immunoreceptor tyrosine-based inhibitory motifs, resulting in the inhibition of NF-kappa B signaling in macrophages. Here we observed that proteolysis of SIRP alpha during inflammation is regulated by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10), resulting in the generation of a membrane-associated cleavage fragment in both THP-1 monocytes and human lung epithelia. We mapped a charge-dependent putative cleavage site near the membrane-proximal domain necessary for ADAM10-mediated cleavage. In addition, a secondary proteolytic cleavage within the membrane-associated SIRP alpha fragment by gamma-secretase was identified. Ectopic expression of a SIRP alpha mutant plasmid encoding a proteolytically resistant form in HeLa cells inhibited activation of the NF-kappa B pathway and suppressed STAT1 phosphorylation in response to TNF alpha to a greater extent than expression of wild-type SIRP alpha. Conversely, overexpression of plasmids encoding the proteolytically cleaved SIRP alpha fragments in cells resulted in enhanced STAT-1 and NF-kappa B pathway activation. Thus, the data suggest that combinatorial actions of ADAM10 and gamma-secretase on SIRP alpha cleavage promote inflammatory signaling. C1 [Londino, James D.; Gulick, Dexter; Isenberg, Jeffrey S.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol & Bioengn, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15213 USA. [Isenberg, Jeffrey S.] Univ Pittsburgh, Sch Med, Div Pulm,Allergy & Crit Care Med, Vasc Med Inst,Starzl Transplantat Inst,Dept Pharm, Pittsburgh, PA 15213 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Pulm Allergy & Crit Care Med, Dept Med, NW628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu RI Regan, Clinton/E-6250-2012 FU United States Department of Veterans Affairs Merit Review Award; National Institutes of Health [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, HL114453, T32 5T32HL007563-28] FX This work was partially supported by a United States Department of Veterans Affairs Merit Review Award and partially by National Institutes of Health R01 Grants HL096376, HL097376, HL098174, HL081784, and 1UH2HL123502 and P01 Grant HL114453 (to R. K. M.) and Grant T32 5T32HL007563-28 (to J. D. L.). The authors declare no conflict of interests. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 42 TC 4 Z9 4 U1 1 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 25 PY 2015 VL 290 IS 52 BP 31113 EP 31125 DI 10.1074/jbc.M115.682914 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CZ6GK UT WOS:000367199000039 PM 26534964 ER PT J AU Singh, H Graber, ML AF Singh, Hardeep Graber, Mark L. TI Improving Diagnosis in Health Care - The Next Imperative for Patient Safety SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID ERRORS C1 [Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Graber, Mark L.] RTI Int, Raleigh, NC USA. [Graber, Mark L.] Soc Improve Diag Med, New York, NY USA. [Graber, Mark L.] SUNY Stony Brook, Stony Brook, NY 11794 USA. RP Singh, H (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Houston, TX 77030 USA. NR 5 TC 20 Z9 20 U1 1 U2 8 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 24 PY 2015 VL 373 IS 26 BP 2493 EP 2495 DI 10.1056/NEJMp1512241 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CZ7SG UT WOS:000367299700004 PM 26559457 ER PT J AU Sharma, A Hoover, DR Shi, QH Gustafson, D Plankey, MW Hershow, RC Tien, PC Golub, ET Anastos, K AF Sharma, Anjali Hoover, Donald R. Shi, Qiuhu Gustafson, Deborah Plankey, Michael W. Hershow, Ronald C. Tien, Phyllis C. Golub, Elizabeth T. Anastos, Kathryn TI Relationship between Body Mass Index and Mortality in HIV-Infected HAART Users in the Women's Interagency HIV Study SO PLOS ONE LA English DT Article ID STARTING ANTIRETROVIRAL THERAPY; ALL-CAUSE MORTALITY; IMMUNE CELL COUNTS; UNITED-STATES; DISEASE PROGRESSION; NUTRITIONAL-STATUS; PROSPECTIVE COHORT; BLACK ADULTS; OBESITY; IMPACT AB Background Early HIV studies suggested protective associations of overweight against mortality, yet data are lacking for the era of potent highly active antiretroviral therapy (HAART). We evaluated associations of pre-HAART initiation body mass index (BMI) with mortality among HAART-using women. Methods Prospective study of time to death after HAART initiation among continuous HAART users in the Women's Interagency HIV Study. Unadjusted Kaplan-Meier and adjusted proportional hazards survival models assessed time to AIDS and non-AIDS death by last measured pre-HAART BMI. Results Of 1428 continuous HAART users 39 (2.7%) were underweight, 521 (36.5%) normal weight, 441 (30.9%) overweight, and 427 (29.9%) obese at time of HAART initiation. A total of 322 deaths occurred during median follow-up of 10.4 years (IQR 5.9-14.6). Censoring at non-AIDS death, the highest rate of AIDS death was observed among underweight women (p = 0.0003 for all 4 categories). In multivariate models, women underweight prior to HAART died from AIDS more than twice as rapidly vs. normal weight women (aHR 2.04, 95% CI 1.03, 4.04); but being overweight or obese (vs. normal weight) was not independently associated with AIDS death. Cumulative incidence of non-AIDS death was similar across all pre-HAART BMI categories. Conclusions Among continuous HAART-using women, being overweight prior to initiation was not associated with lower risk of AIDS or non-AIDS death. Being underweight prior to HAART was associated with over double the rate of AIDS death in adjusted analyses. Although overweight and obesity may be associated with many adverse health conditions, neither was predictive of mortality among the HAART-using women. C1 [Sharma, Anjali; Anastos, Kathryn] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Shi, Qiuhu] New York Med Coll, Dept Epidemiol & Community Hlth, Valhalla, NY 10595 USA. [Gustafson, Deborah] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA. [Plankey, Michael W.] Georgetown Univ, Med Ctr, Dept Med, Div Infect Dis, Washington, DC 20007 USA. [Hershow, Ronald C.] Univ Illinois, Dept Epidemiol, Chicago, IL USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Sharma, A (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. EM anjali.sharma@einstein.yu.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI Grant) [UL1 RR024131]; National Institutes of Health [K23AR06199301] FX The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. This research was also supported by National Institutes of Health K23AR06199301 (AS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 1 Z9 1 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 23 PY 2015 VL 10 IS 12 AR e0143740 DI 10.1371/journal.pone.0143740 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CZ4SI UT WOS:000367092600009 PM 26699870 ER PT J AU Olson, KA Beatty, AL Heidecker, B Regan, MC Brody, EN Foreman, T Kato, S Mehler, RE Singer, BS Hveem, K Dalen, H Sterling, DG Lawn, RM Schiller, NB Williams, SA Whooley, MA Ganz, P AF Olson, Kristoff A. Beatty, Alexis L. Heidecker, Bettina Regan, Mathilda C. Brody, Edward N. Foreman, Trudi Kato, Shintaro Mehler, Robert E. Singer, Britta S. Hveem, Kristian Dalen, Havard Sterling, David G. Lawn, Richard M. Schiller, Nelson B. Williams, Stephen A. Whooley, Mary A. Ganz, Peter TI Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts SO EUROPEAN HEART JOURNAL LA English DT Article DE Growth differentiation factor 11 and 8; Ageing; Cardiovascular outcomes; Epidemiology; Hypertrophy ID LEFT-VENTRICULAR MASS; SKELETAL-MUSCLE; DISEASE; FRAMINGHAM; FAILURE; AGE; DYSFUNCTION; SOCIETY; INDEX; RISK AB Aims Growth differentiation factor 11 and/or its homologue growth differentiation factor 8 (GDF11/8) reverses age-related cardiac hypertrophy and vascular ageing in mice. We investigated whether GDF11/8 associates with cardiovascular outcomes, left ventricular hypertrophy (LVH), or age in humans. Methods and results We measured plasma GDF11/8 levels in 928 participants with stable ischaemic heart disease in the Heart and Soul study. We adjudicated heart failure hospitalization, stroke, myocardial infarction, death, and their composite endpoint. Left ventricular hypertrophy was evaluated by echocardiography. We used multivariable Cox proportional hazards models to compare rates of cardiovascular events and death across GDF11/8 quartiles and logistic regression models to evaluate the association between GDF11/8 and LVH. Four hundred and fifty participants (48.5%) experienced a cardiovascular event or death during 8.9 years of follow-up. The adjusted risk of the composite endpoint was lower in the highest compared with the lowest GDF11/8 quartile [hazard ratio (HR), 0.45; 95% confidence interval (CI), 0.33-0.60; P < 0.001]. We replicated this relationship of GDF11/8 to adverse events in 971 participants in the HUNT3 cohort (adjusted HR, 0.34; 95% CI, 0.23-0.51; P < 0.001). Left ventricular hypertrophy was present in 368 participants (39.7%) at baseline. Participants in the highest quartile of GDF11/8 were less likely to have LVH than those in the lowest quartile (adjusted OR, 0.55; 95% CI, 0.35-0.86; P = 0.009). GDF11/8 levels were lower in older individuals (P < 0.001). Conclusion In patients with stable ischaemic heart disease, higher GDF11/8 levels are associated with lower risk of cardiovascular events and death. Our findings suggest that GDF11/8 has similar cardioprotective properties in humans to those demonstrated in mice. C1 [Olson, Kristoff A.; Beatty, Alexis L.; Heidecker, Bettina; Schiller, Nelson B.; Whooley, Mary A.; Ganz, Peter] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Beatty, Alexis L.] Vet Affairs Puget Sound Hlth Care Syst, Cardiol Sect, Seattle, WA USA. [Beatty, Alexis L.] Univ Washington, Dept Med, Seattle, WA USA. [Regan, Mathilda C.] Vet Hlth Res Inst, San Francisco, CA USA. [Brody, Edward N.; Foreman, Trudi; Mehler, Robert E.; Singer, Britta S.; Sterling, David G.; Lawn, Richard M.; Williams, Stephen A.] SomaLogic Inc, Boulder, CO USA. [Kato, Shintaro] NEC Corp Amer, Irving, TX 75063 USA. [Hveem, Kristian] Lifandis AS, Levanger, Norway. [Hveem, Kristian] NTNU, Dept Publ Hlth, HUNT Res Ctr, Trondheim, Norway. [Dalen, Havard] Nord Trondelag Hlth Trust, Levanger Hosp, Dept Med, Levanger, Norway. [Dalen, Havard] Norwegian Univ Sci & Technol, MI Lab, Trondheim, Norway. [Dalen, Havard] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Trondheim, Norway. [Whooley, Mary A.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Ganz, Peter] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA. RP Ganz, P (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM peter.ganz@ucsf.edu FU Department of Veterans Affairs (Epidemiology Merit Review Program); National Heart, Lung and Blood Institute [R01 HL079235]; Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program); Ischemia Research and Education Foundation; National Center for Advancing Translational Sciences [KL2TR000143]; SomaLogic FX This study was supported by grants from the Department of Veterans Affairs (Epidemiology Merit Review Program); the National Heart, Lung and Blood Institute (grant number: R01 HL079235); the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); the American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program); and the Ischemia Research and Education Foundation. None of these funding sources had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The contents of this research are solely the responsibility of the investigators and do not necessarily represent the official views of the NIH. A.L.B. is supported by the National Center for Advancing Translational Sciences (grant number: KL2TR000143). This study was also supported in part by a research grant to M.A.W. from SomaLogic. NR 18 TC 18 Z9 21 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD DEC 21 PY 2015 VL 36 IS 48 BP 3426 EP 3434 DI 10.1093/eurheartj/ehv385 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DE1GD UT WOS:000370373900010 PM 26294790 ER PT J AU Shukla, SK Cook, D Meyer, J Vernon, SD Le, T Clevidence, D Robertson, CE Schrodi, SJ Yale, S Frank, DN AF Shukla, Sanjay K. Cook, Dane Meyer, Jacob Vernon, Suzanne D. Le, Thao Clevidence, Derek Robertson, Charles E. Schrodi, Steven J. Yale, Steven Frank, Daniel N. TI Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) SO PLOS ONE LA English DT Article ID NITROSATIVE STRESS PATHWAYS; GRAM-NEGATIVE ENTEROBACTERIA; SYNDROME CFS; INFLAMMATORY PATHWAYS; LEAKY GUT; TRANSLOCATION; LPS; NORMALIZATION; RESPONSES; SYMPTOMS AB Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disease characterized by intense and debilitating fatigue not due to physical activity that has persisted for at least 6 months, post-exertional malaise, unrefreshing sleep, and accompanied by a number of secondary symptoms, including sore throat, memory and concentration impairment, headache, and muscle/joint pain. In patients with post-exertional malaise, significant worsening of symptoms occurs following physical exertion and exercise challenge serves as a useful method for identifying biomarkers for exertion intolerance. Evidence suggests that intestinal dysbiosis and systemic responses to gut microorganisms may play a role in the symptomology of ME/CFS. As such, we hypothesized that post-exertion worsening of ME/CFS symptoms could be due to increased bacterial translocation from the intestine into the systemic circulation. To test this hypothesis, we collected symptom reports and blood and stool samples from ten clinically characterized ME/CFS patients and ten matched healthy controls before and 15 minutes, 48 hours, and 72 hours after a maximal exercise challenge. Microbiomes of blood and stool samples were examined. Stool sample microbiomes differed between ME/CFS patients and healthy controls in the abundance of several major bacterial phyla. Following maximal exercise challenge, there was an increase in relative abundance of 6 of the 9 major bacterial phyla/genera in ME/CFS patients from baseline to 72 hours post-exercise compared to only 2 of the 9 phyla/genera in controls (p = 0.005). There was also a significant difference in clearance of specific bacterial phyla from blood following exercise with high levels of bacterial sequences maintained at 72 hours post-exercise in ME/CFS patients versus clearance in the controls. These results provide evidence for a systemic effect of an altered gut microbiome in ME/CFS patients compared to controls. Upon exercise challenge, there were significant changes in the abundance of major bacterial phyla in the gut in ME/CFS patients not observed in healthy controls. In addition, compared to controls clearance of bacteria from the blood was delayed in ME/CFS patients following exercise. These findings suggest a role for an altered gut microbiome and increased bacterial translocation following exercise in ME/CFS patients that may account for the profound post-exertional malaise experienced by ME/CFS patients. C1 [Shukla, Sanjay K.; Le, Thao; Schrodi, Steven J.] Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. [Cook, Dane; Meyer, Jacob] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Cook, Dane; Clevidence, Derek] Univ Wisconsin, Madison, WI USA. [Vernon, Suzanne D.] Bateman Horne Ctr Excellence, Salt Lake City, UT USA. [Robertson, Charles E.; Frank, Daniel N.] Univ Colorado Denver, Aurora, CO USA. [Yale, Steven] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. RP Shukla, SK (reprint author), Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. EM shukla.sanjay@mcrf.mfldclin.edu OI Schrodi, Steven/0000-0003-2304-8528 FU CFIDS Association of America; Marshfield Clinic Research Foundation FX This study was funded from a grant from The CFIDS Association of America to SKS and donors to the Marshfield Clinic Research Foundation. The funding agency has no role in the study design or in the preparation of the manuscript. NR 57 TC 7 Z9 7 U1 6 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 18 PY 2015 VL 10 IS 12 AR e0145453 DI 10.1371/journal.pone.0145453 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9KM UT WOS:000366725800078 PM 26683192 ER PT J AU Meier, DT Tu, LH Zraika, S Hogan, MF Templin, AT Hull, RL Raleigh, DP Kahn, SE AF Meier, Daniel T. Tu, Ling-Hsien Zraika, Sakeneh Hogan, Meghan F. Templin, Andrew T. Hull, Rebecca L. Raleigh, Daniel P. Kahn, Steven E. TI Matrix Metalloproteinase-9 Protects Islets from Amyloid-induced Toxicity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID BETA-CELL APOPTOSIS; FIBRIL FORMATION; PANCREATIC-ISLETS; TRANSGENIC MOUSE; HUMAN AMYLIN; POLYPEPTIDE; DEPOSITION; INHIBITORS; CYTOTOXICITY; MECHANISM AB Deposition of human islet amyloid polypeptide (hIAPP, also known as amylin) as islet amyloid is a characteristic feature of the pancreas in type 2 diabetes, contributing to increased beta-cell apoptosis and reduced beta-cell mass. Matrix metalloproteinase-9 (MMP-9) is active in islets and cleaves hIAPP. We investigated whether hIAPP fragments arising from MMP-9 cleavage retain the potential to aggregate and cause toxicity, and whether over-expressing MMP-9 in amyloid-prone islets reduces amyloid burden and the resulting beta-cell toxicity. Synthetic hIAPP was incubated with MMP-9 and the major hIAPP fragments observed by MS comprised residues 1-15, 1-25, 16-37, 16-25, and 26-37. The fragments 1-15, 1-25, and 26-37 did not form amyloid fibrils in vitro and they were not cytotoxic when incubated with b cells. Mixtures of these fragments with full-length hIAPP did not modulate the kinetics of fibril formation by full-length hIAPP. In contrast, the 16-37 fragment formed fibrils more rapidly than full-length hIAPP but was less cytotoxic. Co-incubation of MMP-9 and fragment 16-37 ablated amyloidogenicity, suggesting that MMP-9 cleaves hIAPP 16-37 into non-amyloidogenic fragments. Consistent with MMP-9 cleavage resulting in largely non-amyloidogenic degradation products, adenoviral overexpression of MMP-9 in amyloid-prone islets reduced amyloid deposition and beta-cell apoptosis. These findings suggest that increasing islet MMP-9 activity might be a strategy to limit beta-cell loss in type 2 diabetes. C1 [Meier, Daniel T.; Zraika, Sakeneh; Hogan, Meghan F.; Templin, Andrew T.; Hull, Rebecca L.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Meier, Daniel T.; Zraika, Sakeneh; Hogan, Meghan F.; Templin, Andrew T.; Hull, Rebecca L.; Kahn, Steven E.] Univ Washington, Seattle, WA 98108 USA. [Tu, Ling-Hsien] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan. [Tu, Ling-Hsien; Raleigh, Daniel P.] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA. [Raleigh, Daniel P.] UCL, Dept Struct & Mol Biol, London WC1E 6BT, England. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@uw.edu RI Regan, Clinton/E-6250-2012 OI Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087; raleigh, daniel/0000-0003-3248-7493 FU Dept. of Veterans Affairs [BX001060]; NIH [DK-007247, DK-017047, DK-020595, DK-080945, DK-088082, DK-098506, GM-078114, HL-007028]; Swiss National Foundation Fellowship; Dick and Julia McAbee Endowed Fellowship in Diabetes from the University of Washington; American Diabetes Association FX This work was supported by the Dept. of Veterans Affairs Grant BX001060, NIH Grants DK-007247, DK-017047, DK-020595, DK-080945, DK-088082, DK-098506, GM-078114, and HL-007028. The authors declare that they have no conflict of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Supported by a Swiss National Foundation Fellowship and the Dick and Julia McAbee Endowed Fellowship in Diabetes from the University of Washington.; Supported by an American Diabetes Association Mentor-based Fellowship. NR 49 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 18 PY 2015 VL 290 IS 51 BP 30475 EP 30485 DI 10.1074/jbc.M115.676692 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CY9PG UT WOS:000366738200024 PM 26483547 ER PT J AU Ruegsegger, GN Company, JM Toedebusch, RG Roberts, CK Roberts, MD Booth, FW AF Ruegsegger, Gregory N. Company, Joseph M. Toedebusch, Ryan G. Roberts, Christian K. Roberts, Michael D. Booth, Frank W. TI Rapid Alterations in Perirenal Adipose Tissue Transcriptomic Networks with Cessation of Voluntary Running SO PLOS ONE LA English DT Article ID GENE-EXPRESSION; ADIPOCYTE HYPERPLASIA; INSULIN-RESISTANCE; CHILDHOOD OBESITY; WEIGHT-REDUCTION; EPIDIDYMAL FAT; CELL-CYCLE; INFLAMMATION; PROTEIN; RATS AB In maturing rats, the growth of abdominal fat is attenuated by voluntary wheel running. After the cessation of running by wheel locking, a rapid increase in adipose tissue growth to a size that is similar to rats that have never run (i.e. catch-up growth) has been previously reported by our lab. In contrast, diet-induced increases in adiposity have a slower onset with relatively delayed transcriptomic responses. The purpose of the present study was to identify molecular pathways associated with the rapid increase in adipose tissue after ending 6 wks of voluntary running at the time of puberty. Age-matched, male Wistar rats were given access to running wheels from 4 to 10 weeks of age. From the 10th to 11th week of age, one group of rats had continued wheel access, while the other group had one week of wheel locking. Perirenal adipose tissue was extracted, RNA sequencing was performed, and bioinformatics analyses were executed using Ingenuity Pathway Analysis (IPA). IPA was chosen to assist in the understanding of complex ` omics data by integrating data into networks and pathways. Wheel locked rats gained significantly more fat mass and significantly increased body fat percentage between weeks 10-11 despite having decreased food intake, as compared to rats with continued wheel access. IPA identified 646 known transcripts differentially expressed (p < 0.05) between continued wheel access and wheel locking. In wheel locked rats, IPA revealed enrichment of transcripts for the following functions: extracellular matrix, macrophage infiltration, immunity, and pro-inflammatory. These findings suggest that increases in visceral adipose tissue that accompanies the cessation of pubertal physical activity are associated with the alteration of multiple pathways, some of which may potentiate the development of pubertal obesity and obesity-associated systemic low-grade inflammation that occurs later in life. C1 [Ruegsegger, Gregory N.; Company, Joseph M.; Toedebusch, Ryan G.; Roberts, Michael D.; Booth, Frank W.] Univ Missouri, Coll Vet Med, Dept Biomed Sci, Columbia, MO 65211 USA. [Roberts, Christian K.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Booth, Frank W.] Univ Missouri, Dept Med Pharmacol & Physiol, Columbia, MO USA. [Booth, Frank W.] Univ Missouri, Dept Nutr & Exercise Physiol, Columbia, MO USA. [Booth, Frank W.] Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO USA. RP Booth, FW (reprint author), Univ Missouri, Coll Vet Med, Dept Biomed Sci, Columbia, MO 65211 USA. EM boothf@missouri.edu NR 47 TC 3 Z9 3 U1 2 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 17 PY 2015 VL 10 IS 12 AR e0145229 DI 10.1371/journal.pone.0145229 PG 22 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9JO UT WOS:000366723400060 PM 26678390 ER PT J AU Shen, RZ Achenbach, J Shen, Y Palaia, J Rahkola, JT Nick, HJ Smythies, LE McConnell, M Fowler, MG Smith, PD Janoff, EN AF Shen, Ruizhong Achenbach, Jenna Shen, Yue Palaia, Jana Rahkola, Jeremy T. Nick, Heidi J. Smythies, Lesley E. McConnell, Michelle Fowler, Mary G. Smith, Phillip D. Janoff, Edward N. TI Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women SO PLOS ONE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-ASSOCIATED HIV-1; TYPE-1 TRANSCYTOSIS; EPITHELIAL-CELLS; DENDRITIC CELLS; SECRETORY IGA; POSITIVE MOTHERS; FED INFANTS; R5 HIV-1; INFECTION AB Breast milk is a vehicle of infection and source of protection in post-natal mother-to-child HIV-1 transmission (MTCT). Understanding the mechanism by which breast milk limits vertical transmission will provide critical insight into the design of preventive and therapeutic approaches to interrupt HIV-1 mucosal transmission. However, characterization of the inhibitory activity of breast milk in human intestinal mucosa, the portal of entry in postnatal MTCT, has been constrained by the limited availability of primary mucosal target cells and tissues to recapitulate mucosal transmission ex vivo. Here, we characterized the impact of skimmed breast milk, breast milk antibodies (Igs) and non-Ig components from HIV-1-infected Ugandan women on the major events of HIV-1 mucosal transmission using primary human intestinal cells and tissues. HIV-1-specific IgG antibodies and non-Ig components in breast milk inhibited the uptake of Ugandan HIV-1 isolates by primary human intestinal epithelial cells, viral replication in and transport of HIV-1-bearing dendritic cells through the human intestinal mucosa. Breast milk HIV-1-specific IgG and IgA, as well as innate factors, blocked the uptake and transport of HIV-1 through intestinal mucosa. Thus, breast milk components have distinct and complementary effects in reducing HIV-1 uptake, transport through and replication in the intestinal mucosa and, therefore, likely contribute to preventing postnatal HIV-1 transmission. Our data suggests that a successful preventive or therapeutic approach would require multiple immune factors acting at multiple steps in the HIV-1 mucosal transmission process. C1 [Shen, Ruizhong; Nick, Heidi J.; Smythies, Lesley E.; Smith, Phillip D.] Univ Alabama Birmingham, Dept Med, Div Gastroenterol, Birmingham, AL 35294 USA. [Achenbach, Jenna; Palaia, Jana; Rahkola, Jeremy T.; Janoff, Edward N.] Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA. [Shen, Yue] Auburn Univ, Dept Biol Sci, Auburn, AL 36849 USA. [Rahkola, Jeremy T.; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. [McConnell, Michelle] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fowler, Mary G.] Makerere Univ Johns Hopkins Univ Res Collaborat, Kampala, Uganda. [Smith, Phillip D.] Vet Affairs Med Ctr, Birmingham, AL USA. RP Janoff, EN (reprint author), Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA. EM rshen@uab.edu; Edward.Janoff@ucdenver.edu FU National Institutes of Health [AI093151, AI106395, AI083127, DK064400, AI41361, HD059527, AI083615]; UAB Center for AIDS Research (CFAR); Comprehensive Cancer Center Pilot Grant Program; amfAR; Foundation for AIDS Research [108015-49-RGRL]; Elisabeth Glaser Pediatric AIDS Foundations [MV-00-9-900-01432-0-00]; Research Service of the Veterans Administration FX National Institutes of Health grants AI093151 and AI106395 (RS), AI083127 and DK064400 (PDS), AI41361, HD059527 and AI083615 (ENJ); UAB Center for AIDS Research (CFAR) and Comprehensive Cancer Center Pilot Grant Program (RS); amfAR, the Foundation for AIDS Research 108015-49-RGRL (PDS); the Elisabeth Glaser Pediatric AIDS Foundations MV-00-9-900-01432-0-00 (ENJ); and the Research Service of the Veterans Administration (PDS and ENJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 0 Z9 0 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 17 PY 2015 VL 10 IS 12 AR e0145150 DI 10.1371/journal.pone.0145150 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9JO UT WOS:000366723400051 PM 26680219 ER PT J AU Singh, JA Qu, HY Yazdany, J Chatham, W Shewchuk, R AF Singh, Jasvinder A. Qu, Haiyan Yazdany, Jinoos Chatham, Winn Shewchuk, Richard TI Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making SO ARTHRITIS RESEARCH & THERAPY LA English DT Article DE Lupus; Systemic lupus erythematosus; Hispanic; African-American; Minorities; Race; Facilitators; Challenges; Immunosuppressive medication; Adherence ID QUALITY-OF-LIFE; TREATMENT ADHERENCE; RHEUMATIC-DISEASE; HEALTH-CARE; ERYTHEMATOSUS; COHORT; WOMEN AB Background: Medication decision-making poses a challenge for a significant proportion of patients. This is an even more challenging for patients who have complex, rare, immune conditions that affect them at a young age and are associated with the use of life-long treatment, perceived by some as having significant risk of side effects and toxicity. Introduction: The aim of our study was to examine the perspectives of women with lupus nephritis on facilitators to medication decision-making. Methods: We used the nominal group technique (NGT), a structured formative process to elicit patient perspectives. An NGT expert moderated eight patient group meetings. Participants (n = 52) responded to the question "What sorts of things make it easier for people to decide to take the medicines that doctors prescribe for treating their lupus kidney disease?" Patients nominated, discussed, and prioritized facilitators to medication decisional processes. Results: Fifty-two women with lupus nephritis participated in eight NGT meetings (27 African-American, 13 Hispanic, and 12 Caucasian). Average age was 40.6 years (standard deviation (SD) = 13.3), and disease duration was 11.8 years (SD = 8.3); 36.5 % obtained at least a college education, and 55.8 % had difficulty in reading health materials. Patients generated 280 decision-making facilitators (range of 26 to 42 per panel). Of these, 102 (36 %) facilitators were perceived by patients as having relatively more influence in decision-making processes than others. Prioritized facilitators included effective patient-physician communication regarding benefits/harms, patient desire to live a normal life and improve quality of life, concern for their dependents, experiencing benefits and few/infrequent/no harms with lupus medications, and their affordability. Relative to African-Americans, Caucasian and Hispanic patients endorsed a smaller percentage of facilitators as influential. Level of agreement with which patients within panels independently agreed in their selections of the three most influential facilitators ranged from 33 % to 60 %. Conclusions: We identified facilitators to lupus medication decision-making. This information will be used to populate a decision aid for lupus nephritis. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Chatham, Winn] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Coll Med, Rochester, MN 55905 USA. [Qu, Haiyan; Shewchuk, Richard] Univ Alabama Birmingham, Sch Hlth Profess, Dept Hlth Serv Adm, Birmingham, AL 35233 USA. [Yazdany, Jinoos] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, 510,20th St South,FOT 805B, Birmingham, AL 35233 USA. EM jassingh@uab.edu FU Patient-Centered Outcomes Research Institute [CE-1304-6631]; NIH [K23 AR060259]; Rosalind Russell Medical Research Center for Arthritis FX This material is the result of work supported by research contract CE-1304-6631 from the Patient-Centered Outcomes Research Institute. JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, AL, USA. JY is also supported by NIH K23 AR060259 and the Rosalind Russell Medical Research Center for Arthritis. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 23 TC 1 Z9 1 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD DEC 17 PY 2015 VL 17 AR 367 DI 10.1186/s13075-015-0883-z PG 11 WC Rheumatology SC Rheumatology GA CY8UD UT WOS:000366682900001 PM 26680561 ER PT J AU Wang, K Smith, ZM Buxton, RB Swenson, ER Dubowitz, DJ AF Wang, Kang Smith, Zachary M. Buxton, Richard B. Swenson, Erik R. Dubowitz, David J. TI Acetazolamide during acute hypoxia improves tissue oxygenation in the human brain SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE cerebral oxygen metabolism; cerebral oxygenation; cerebral blood flow; acetazolamide; hypoxia; magnetic resonance imaging ID ACUTE MOUNTAIN-SICKNESS; CEREBRAL-BLOOD-FLOW; CARBON-DIOXIDE; HIGH-ALTITUDE; TRUST MRI; EXERCISE; METABOLISM; PREVENTION; PERFUSION; METAANALYSIS AB Low doses of the carbonic anhydrase inhibitor acetazolamide provides accelerated acclimatization to high-altitude hypoxia and prevention of cerebral and other symptoms of acute mountain sickness. We previously observed increases in cerebral O-2 metabolism (CMRO2) during hypoxia. In this study, we investigate whether low-dose oral acetazolamide (250 mg) reduces this elevated CMRO2 and in turn might improve cerebral tissue oxygenation (Pti(O2)) during acute hypoxia. Six normal human subjects were exposed to 6 h of normobaric hypoxia with and without acetazolamide prophylaxis. We determined CMRO2 and cerebral Pti(O2) from MRI measurements of cerebral blood flow (CBF) and cerebral venous O-2 saturation. During normoxia, low-dose acetazolamide resulted in no significant change in CBF, CMRO2, or Pti(O2). During hypoxia, we observed increases in CBF [48.5 (SD 12.4) (normoxia) to 65.5 (20.4) ml.100 ml(-1).min(-1) (hypoxia), P < 0.05] and CMRO2 [1.54 (0.19) to 1.79 (0.25) mu mol.ml(-1).min(-1), P < 0.05] and a dramatic decline in Pti(O2) [25.0 to 11.4 (2.7) mmHg, P < 0.05]. Acetazolamide prophylaxis mitigated these rises in CBF [53.7 (20.7) ml.100 ml(-1).min(-1) (hypoxia + acetazolamide)] and CMRO2 [1.41 (0.09) mu mol.ml(-1).min(-1) (hypoxia + acetazolamide)] associated with acute hypoxia but also reduced O-2 delivery [6.92 (1.45) (hypoxia) to 5.60 (1.14) mmol/min (hypoxia + acetazolamide), P < 0.05]. The net effect was improved cerebral tissue Pti(O2) during acute hypoxia [11.4 (2.7) (hypoxia) to 16.5 (3.0) mmHg (hypoxia + acetazolamide), P < 0.05]. In addition to its renal effect, low-dose acetazolamide is effective at the capillary endothelium, and we hypothesize that local interruption in cerebral CO2 excretion accounts for the improvements in CMRO2 and ultimately in cerebral tissue oxygenation during hypoxia. This study suggests a potentially pivotal role of cerebral CO2 and pH in modulating CMRO2 and Pti(O2) during acute hypoxia. C1 [Wang, Kang; Smith, Zachary M.; Buxton, Richard B.; Dubowitz, David J.] Univ Calif San Diego, Dept Radiol, Ctr Funct MRI, San Diego, CA 92103 USA. [Wang, Kang] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Swenson, Erik R.] Univ Washington, Dept Med, Seattle, WA USA. [Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Dubowitz, DJ (reprint author), UCSD Ctr Funct MRI, 9500 Gilman Dr,MC 0677, La Jolla, CA 92093 USA. EM dubowitz@ucsd.edu FU National Institute of Neurological Disorders and Stroke [R01-NS-053934, R21-NS-075812, R01-NS-036722] FX This work was supported by National Institute of Neurological Disorders and Stroke Grants R01-NS-053934, R21-NS-075812, and R01-NS-036722. NR 49 TC 5 Z9 5 U1 2 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD DEC 15 PY 2015 VL 119 IS 12 BP 1494 EP 1500 DI 10.1152/japplphysiol.00117.2015 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA DA2BP UT WOS:000367600600016 PM 26472861 ER PT J AU An, NF Xiong, Y LaRue, AC Kraft, AS Cen, B AF An, Ningfei Xiong, Ying LaRue, Amanda C. Kraft, Andrew S. Cen, Bo TI Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors SO CANCER RESEARCH LA English DT Article ID ACQUIRED-RESISTANCE; PROSTATE-CANCER; GENE AMPLIFICATION; RECEPTOR; CELLS; TRANSLATION; PROTEIN; GROWTH; CRIZOTINIB; INITIATION AB Mesenchymal-epithelial transition (MET) blockade offers a new targeted therapy particularly in those cancers with MET amplification. However, the efficacy and the duration of the response to MET inhibitors are limited by the emergence of drug resistance. Here, we report that resistance to small-molecule inhibitors of MET can arise from increased expression of the prosurvival Pim protein kinases. This resistance mechanism was documented in non-small cell lung cancer and gastric cancer cells with MET amplification. Inhibition of Pim kinases enhanced cell death triggered by short-term treatment with MET inhibitors. Pim kinases control the translation of anti-apoptotic protein Bcl-2 at an internal ribosome entry site and this mechanism was identified as the basis for Pim-mediated resistance to MET inhibitors. Protein synthesis was increased in drug-resistant cells, secondary to a Pim-mediated increase in cap-independent translation. In cells rendered drug resistant by chronic treatment with MET inhibitors, genetic or pharmacologic inhibition of Pim kinases was sufficient to restore sensitivity in vitro and in vivo. Taken together, our results rationalize Pim inhibition as a strategy to augment responses and blunt acquired resistance to MET inhibitors in cancer. (C)2015 AACR. C1 [An, Ningfei; Cen, Bo] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [An, Ningfei; Xiong, Ying; LaRue, Amanda C.; Cen, Bo] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Xiong, Ying; LaRue, Amanda C.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [LaRue, Amanda C.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Kraft, Andrew S.] Univ Arizona, Ctr Canc, Tucson, AZ USA. RP Cen, B (reprint author), Med Univ S Carolina, Dept Med, 86 Jonathan Lucas St, Charleston, SC 29425 USA. EM akraft@uacc.arizona.edu; cen@musc.edu FU NIH [1K01DK085196, 1R01CA173200]; DOD [W81XWH-12-10560] FX This work was supported by NIH grants 1K01DK085196 (B. Cen), 1R01CA173200 (A.S. Kraft), and DOD grant W81XWH-12-10560 (A.S. Kraft). NR 40 TC 2 Z9 2 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD DEC 15 PY 2015 VL 75 IS 24 BP 5318 EP 5328 DI 10.1158/0008-5472.CAN-15-0544 PG 11 WC Oncology SC Oncology GA DA1JL UT WOS:000367552000017 PM 26670562 ER PT J AU Connor, K Cheng, E Siebens, HC Lee, ML Mittman, BS Ganz, DA Vickrey, B AF Connor, Karen Cheng, Eric Siebens, Hilary C. Lee, Martin L. Mittman, Brian S. Ganz, David A. Vickrey, Barbara TI Study protocol of "CHAPS": a randomized controlled trial protocol of Care Coordination for Health Promotion and Activities in Parkinson's Disease to improve the quality of care for individuals with Parkinson's disease SO BMC NEUROLOGY LA English DT Article DE Care coordination; Parkinson's disease; Behavioral intervention; Clinical trial; Quality of health care; Nursing care management ID DOMAIN MANAGEMENT MODEL; INCREASE FUNCTIONAL INDEPENDENCE; CHRONIC ILLNESS; INPATIENT REHABILITATION; DEMENTIA CAREGIVERS; COLLABORATIVE CARE; DISCHARGE RATE; INTERVENTION; VALIDATION; VALIDITY AB Background: Parkinson's disease, the second most common neurodegenerative disease, is diagnostically defined by motor impairments, but also includes often under-recognized impairments in cognition, mood, sleep, and the autonomic nervous system. These problems can severely affect individuals' quality of life. In our prior research, we have developed indicators to measure the quality of care delivered to patients with Parkinson's disease, and we identified gaps in delivering evidence-based treatments for this population. Effective strategies to close these gaps are needed to improve patient quality of life. Methods/design: Building on prior research we developed a multi-faceted proactive implementation program called Care Coordination for Health Promotion and Activities in Parkinson's Disease (CHAPS). To be eligible, patients had to have at least two visits with a primary diagnosis of idiopathic Parkinson's disease (ICD-9 code: 332.0) at one of five Veterans Affairs Medical Centers in the southwestern United States from 2010 to 2014. The program consists of telephone assessments, evidence-based protocols, and tools to enhance patient self-management, care planning, and coordination of care across providers, including an electronic database to support and track coordination of care. Our mixed-methods study employs a randomized, controlled trial design to test whether the CHAPS intervention improves performance in 38 quality measures among an analytic sample of 346 patients. The 38 qualitymeasures are categorized into overarching areas of communication, education, and continuity; regulatory reporting; diagnosis; periodic assessment; medication use; management of motor and non-motor symptoms; use of non-pharmacological approaches and therapies; palliative care; and health maintenance. Secondary outcomes are patient health-related quality of life, self-efficacy, and perceptions of care quality. We are also evaluating the extent of the CHAPS Program implementation and measuring program costs and impacts on health services utilization, in order to perform a analysis of the CHAPS program from the perspective of the Veterans Health Administration (VA). Outcomes are assessed by interviewer-administered surveys collected at baseline and at 6, 12, and 18 months, and by medical record chart abstractions. Analyses will be intention-to-treat. Discussion: The CHAPS Program is poised for dissemination within the VA National Parkinson's Disease Research, Education, and Clinical Center Consortium if demonstrated efficacious. C1 [Connor, Karen; Cheng, Eric; Vickrey, Barbara] VA Greater Los Angeles Healthcare Syst, PADRECC Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Connor, Karen; Cheng, Eric; Vickrey, Barbara] Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Siebens, Hilary C.] Siebens Patient Care Commun, Seal Beach, CA 90740 USA. [Lee, Martin L.] VA Greater Los Angeles Healthcare Syst, Sepulveda VA Ambulatory Care Ctr, North Hills, CA 91343 USA. [Lee, Martin L.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Mittman, Brian S.] Vet Affairs Greater Los Angeles Healthcare Syst 1, CIPRS, Sepulveda, CA 91343 USA. [Ganz, David A.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA 90073 USA. RP Connor, K (reprint author), VA Greater Los Angeles Healthcare Syst, PADRECC Parkinsons Dis Res Educ & Clin Ctr, 11301 Wilshire Blvd,B500,ML 127, Los Angeles, CA 90073 USA. EM Karen.Connor@va.gov FU Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service [NRI 11-126] FX The research reported here was supported by the Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service (NRI 11-126). Dr. Karen Connor is a Health Scientist at the Parkinson's Disease Research, Education, and Clinical Center (PADRECC), VA Greater Los Angeles Healthcare System. The authors wish to thank the CHAPS Advisory Board: Dr. Robert Ruff, Dr. Jeff Bronstein, Dr. Sharon Valente, Dr. Fran Weaver, Dr. Peter Schmidt, Michele Popadynec RN MPS, John Ball, Edna Ball and the CHAPS Steering Committee: Dr. Dorothee Cole, Dr. Evelyn Tecoma, Dr. Denson Fujikawa, Dr. Emad Farag, Virginia Janovsky, Dr. Steven Schreiber, Dr. Selina Parveen, Dr. Donna McNeese-Smith, Dr. Donna Benton, Ms. Jo Rosen. We wish to thank Virginia Janovsky MN, MS, RN and Erik Ernst DNP who provided nursing practice expertise in the CHAPS Program design. We wish to thank Michael McGowan and Lisa Edwards for their contributions to the ongoing research study. We wish to acknowledge Megan Connor's programming expertise in the CHAPS care management tool development. NR 59 TC 0 Z9 0 U1 10 U2 23 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD DEC 15 PY 2015 VL 15 AR 258 DI 10.1186/s12883-015-0506-y PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA CZ1WE UT WOS:000366895800002 PM 26670300 ER PT J AU Scott, JL Cunningham, MA Naga, OS Wirth, JR Eudaly, JG Gilkeson, GS AF Scott, Jennifer L. Cunningham, Melissa A. Naga, Osama S. Wirth, Jena R. Eudaly, Jackie G. Gilkeson, Gary S. TI Estrogen Receptor alpha Deficiency Modulates TLR Ligand-Mediated PDC-TREM Expression in Plasmacytoid Dendritic Cells in Lupus-Prone Mice SO JOURNAL OF IMMUNOLOGY LA English DT Article ID I INTERFERON; MURINE LUPUS; DIFFERENTIATION; ERYTHEMATOSUS; TRANSCRIPTION; PROMOTES; DISEASE; MOUSE; LY49Q; AUTOIMMUNITY AB Female lupus-prone NZM2410 estrogen receptor alpha (ER alpha)-deficient mice are protected from renal disease and have prolonged survival compared with wild-type littermates; however, the mechanism of protection is unknown. Plasmacytoid dendritic cells (pDCs) and type I IFN drive lupus pathogenesis. Estrogen acting via ER alpha enhances both pDC development and IFN production. The objectives for this study were to determine if ER alpha modulates pDC function and IFN activity in predisease NZM2410 mice as a possible protective mechanism of ER alpha deficiency in lupus-prone mice. We measured the effect of ER alpha deficiency on spleen pDC frequency, number, maturation, and activation state. ER alpha deficiency reduced type I IFN activity and the frequency of MHC class II+ pDCs in the spleen without altering overall pDC frequency, number, or maturation state. Additionally, ER alpha-deficient NZM2410 mice had a significantly decreased frequency of pDCs expressing PDC-TREM, a modulator of TLR-mediated IFN production. After in vitro TLR9 stimulation, ER alpha deficiency significantly reduced the expression of PDC-TREM on pDCs from both NZM2410 and C57BL/6 mice. Thus, we have identified a significant effect of ER alpha deficiency on pDCs in predisease NZM2410 mice, which may represent a mechanism by which ER alpha deficiency protects NZM2410 mice from lupuslike disease. C1 [Scott, Jennifer L.] Med Univ S Carolina, Coll Grad Studies, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Scott, Jennifer L.; Cunningham, Melissa A.; Naga, Osama S.; Wirth, Jena R.; Eudaly, Jackie G.; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. RP Gilkeson, GS (reprint author), Med Univ S Carolina, Dept Med, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA. EM gilkeson@musc.edu FU Veterans Affairs Merit Review Grant [BX000470]; National Institutes of Health Grant [UT1 TR000062]; American Association of Immunology Careers in Immunology Fellowship; Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center; Medical University of South Carolina [P30 CA138313]; National Institutes of Health-National Institute of General Medical Sciences Grant [P30 GM103342] FX This work was supported by Veterans Affairs Merit Review Grant BX000470, the National Institutes of Health Grant UT1 TR000062, and an American Association of Immunology Careers in Immunology Fellowship. This work was supported in part by the Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, and Medical University of South Carolina (Grant P30 CA138313). This study used the services of the Medical University of South Carolina Flow Cytometry Facility, which is supported by National Institutes of Health-National Institute of General Medical Sciences Grant P30 GM103342 to the South Carolina Center of Biomedical Research Excellence for Developmentally Based Cardiovascular Diseases. NR 36 TC 3 Z9 3 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD DEC 15 PY 2015 VL 195 IS 12 BP 5561 EP 5571 DI 10.4049/jimmunol.1500315 PG 11 WC Immunology SC Immunology GA CY9OB UT WOS:000366735100006 PM 26553076 ER PT J AU Heatwole, C Johnson, N Bode, R Dekdebrun, J Dilek, N Hilbert, JE Luebbe, E Martens, W McDermott, MP Quinn, C Rothrock, N Thornton, C Vickrey, BG Victorson, D Moxley, RT AF Heatwole, Chad Johnson, Nicholas Bode, Rita Dekdebrun, Jeanne Dilek, Nuran Hilbert, James E. Luebbe, Elizabeth Martens, William McDermott, Michael P. Quinn, Christine Rothrock, Nan Thornton, Charles Vickrey, Barbara G. Victorson, David Moxley, Richard T., III TI Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2) SO NEUROLOGY LA English DT Article ID FACIOSCAPULOHUMERAL DYSTROPHY; CHRONIC PAIN; CEREBRAL INVOLVEMENT; DAYTIME SLEEPINESS; WORKSHOP REPORT; DYSFUNCTION; INTENSITY AB Objective:To determine the frequency and relative importance of the most life-affecting symptoms in myotonic dystrophy type 2 (DM2) and to identify the factors that have the strongest association with these symptoms.Methods:We conducted a cross-sectional study of adult patients with DM2 from a National Registry of DM2 Patients to assess the prevalence and relative importance of 310 symptoms and 21 symptomatic themes. Participant responses were compared by age categories, sex, educational attainment, employment status, and duration of symptoms.Results:The symptomatic themes with the highest prevalence in DM2 were the inability to do activities (94.4%), limitations with mobility or walking (89.2%), hip, thigh, or knee weakness (89.2%), fatigue (89.2%), and myotonia (82.6%). Participants identified the inability to do activities and fatigue as the symptomatic themes that have the greatest overall effect on their lives. Unemployment, a longer duration of symptoms, and less education were associated with a higher average prevalence of all symptomatic themes (p < 0.01). Unemployment, a longer duration of symptoms, sex, and increased age were associated with a higher average effect of all symptomatic themes among patients with DM2 (p < 0.01).Conclusions:The lives of patients with DM2 are affected by a variety of symptoms. These symptoms have different levels of significance and prevalence in this population and vary across DM2 subgroups in different demographic categories. C1 [Heatwole, Chad; Dekdebrun, Jeanne; Dilek, Nuran; Hilbert, James E.; Luebbe, Elizabeth; Martens, William; McDermott, Michael P.; Thornton, Charles; Moxley, Richard T., III] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. [McDermott, Michael P.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA. [Quinn, Christine] Univ Rochester, Med Ctr, James P Wilmot Canc Inst, Rochester, NY 14642 USA. [Johnson, Nicholas] Univ Utah, Salt Lake City, UT USA. [Bode, Rita; Rothrock, Nan; Victorson, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Vickrey, Barbara G.] Univ Calif Los Angeles, Med Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Vickrey, Barbara G.] Greater Los Angeles VA HealthCare Syst, Los Angeles, CA USA. RP Heatwole, C (reprint author), Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. EM Chad_Heatwole@urmc.rochester.edu FU Goldberg Nathan Foundation for Myotonic Dystrophy Type-2 Research; National Institute of Arthritis and Musculoskeletal and Skin Disorders [1K23AR055947]; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center [U54NS48843-01]; Muscular Dystrophy Association; New York State Empire Clinical Research Investigator Program; Saunders Family Fund; University of Rochester Clinical Translational Science Institute FX Support for PRISM-2 was provided by the Goldberg Nathan Foundation for Myotonic Dystrophy Type-2 Research, the National Institute of Arthritis and Musculoskeletal and Skin Disorders (1K23AR055947), the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (U54NS48843-01), the Muscular Dystrophy Association, the New York State Empire Clinical Research Investigator Program, the Saunders Family Fund, and the University of Rochester Clinical Translational Science Institute. NR 28 TC 1 Z9 1 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC 15 PY 2015 VL 85 IS 24 BP 2136 EP 2146 DI 10.1212/WNL.0000000000002225 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA CY5QI UT WOS:000366461900008 PM 26581301 ER PT J AU Forsyth, JK Bachman, P Mathalon, DH Roach, BJ Asarnow, RF AF Forsyth, Jennifer K. Bachman, Peter Mathalon, Daniel H. Roach, Brian J. Asarnow, Robert F. TI Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE D-cycloserine; NMDA receptor; neuroplasticity; long-term potentiation; learning ID LONG-TERM POTENTIATION; COGNITIVE-BEHAVIORAL THERAPY; NONEMOTIONAL MEMORY TASKS; D-CYCLOSERINE; SYNAPTIC PLASTICITY; BASAL GANGLIA; PSYCHIATRIC-DISORDERS; EVOKED-POTENTIALS; VISUAL-CORTEX; SCHIZOPHRENIA AB Experience-dependent plasticity is a fundamental property of the brain. It is critical for everyday function, is impaired in a range of neurological and psychiatric disorders, and frequently depends on long-term potentiation (LTP). Preclinical studies suggest that augmenting N-methyl-D-aspartate receptor (NMDAR) signaling may promote experience-dependent plasticity; however, a lack of noninvasive methods has limited our ability to test this idea in humans until recently. We examined the effects of enhancing NMDAR signaling using D-cycloserine (DCS) on a recently developed LTP EEG paradigm that uses high-frequency visual stimulation (HFvS) to induce neural potentiation in visual cortex neurons, as well as on three cognitive tasks: a weather prediction task (WPT), an information integration task (IIT), and a n-back task. The WPT and IIT are learning tasks that require practice with feedback to reach optimal performance. The n-back assesses working memory. Healthy adults were randomized to receive DCS (100 mg; n = 32) or placebo (n = 33); groups were similar in IQ and demographic characteristics. Participants who received DCS showed enhanced potentiation of neural responses following repetitive HFvS, as well as enhanced performance on the WPT and IIT. Groups did not differ on the n-back. Augmenting NMDAR signaling using DCS therefore enhanced activity-dependent plasticity in human adults, as demonstrated by lasting enhancement of neural potentiation following repetitive HFvS and accelerated acquisition of two learning tasks. Results highlight the utility of considering cellular mechanisms underlying distinct cognitive functions when investigating potential cognitive enhancers. C1 [Forsyth, Jennifer K.; Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Bachman, Peter] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Daniel H.; Roach, Brian J.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Asarnow, RF (reprint author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. EM rasarnow@mednet.ucla.edu FU Della Martin Foundation; National Science Foundation FX We thank Dr. Gregory Ashby and Dr. Vivian Valentin for consultation on implementation and modeling of the IIT and Dr. Barbara Knowlton for consultation on implementation of the WPT. We also thank Elissa Ye, Cheryl Li, Heather Hansen, Devin Deer, and Chantelle Kinzel for assistance with data collection, data processing, and/or programming. This work was supported by the Della Martin Foundation and a National Science Foundation Graduate Research Fellowship (to J.K.F.). NR 56 TC 5 Z9 5 U1 0 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 15 PY 2015 VL 112 IS 50 BP 15331 EP 15336 DI 10.1073/pnas.1509262112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY4UN UT WOS:000366404200046 PM 26621715 ER PT J AU Collins, GT France, CP AF Collins, Gregory T. France, Charles P. TI Determinants of conditioned reinforcing effectiveness: Dopamine D-2-like receptor agonist-stimulated responding for cocaine-associated stimuli SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Article DE Conditioned reinforcement; Dopamine D2-like receptors; Pramipexole; Cocaine self-administration ID DRUG-SEEKING BEHAVIOR; PROGRESSIVE-RATIO SCHEDULES; CUE-INDUCED REINSTATEMENT; EXTENDED ACCESS; IMPULSE CONTROL; D-3 RECEPTORS; ADDICTION; REWARD; PRAMIPEXOLE; ANTAGONISTS AB Environmental stimuli associated with drug use can take on conditioned properties capable of promoting drug-seeking behaviors during abstinence. This study investigated the relative importance of the amount of reinforced responding, number of cocaine-stimulus pairings, total cocaine intake, and reinforcing effectiveness of the self-administered dose of cocaine to the conditioned reinforcing effectiveness of cocaine-associated stimuli (CS). Male rats were trained to self-administer cocaine (0.1 [small] or 1.0 mg/kg/ inf [large]) under a fixed ratio schedule of reinforcement. A progressive ratio (PR) schedule was used to quantify the reinforcing effectiveness of each dose of cocaine, as well as the conditioned reinforcing effectiveness of the CS following treatment with saline or the dopamine D2-like receptor agonist pramipexole (0.1-3.2 mg/kg). The large dose of cocaine maintained larger final ratios and greater levels of cocaine intake, whereas the small dose resulted in more cocaine-CS pairings. The total amount of responding was comparable between groups. During PR tests of conditioned reinforcement, pramipexole increased responding for CS presentations in both groups; however, the final ratio completed was significantly greater in large-as compared to small-dose group. In addition to highlighting a central role for dopamine D2-like receptors in modulating the effectiveness of cocaine-paired stimuli to reinforce behavior, these results suggest that conditioned reinforcing effectiveness is primarily determined by the reinforcing effectiveness of the self-administered dose of cocaine and/or total cocaine intake, and not the total amount of responding or number cocaine-stimulus pairings. These findings have implications for understanding how different patterns of drug-taking might impact vulnerability to relapse. Published by Elsevier B.V. C1 [Collins, Gregory T.; France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Collins, Gregory T.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [France, Charles P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. RP Collins, GT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM collinsg@uthscsa.edu RI Collins, Gregory/K-3125-2012 FU National Institute on Drug Abuse Senior Scientist Award [K05 DA017918] FX CPF is supported by a National Institute on Drug Abuse Senior Scientist Award (K05 DA017918) NR 39 TC 3 Z9 3 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 EI 1879-0712 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD DEC 15 PY 2015 VL 769 BP 242 EP 249 DI 10.1016/j.ejphar.2015.11.024 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CY1AG UT WOS:000366137800030 PM 26593427 ER PT J AU Dewey, D McDonald, MK Brown, WJ Boyd, SJ Bunnell, BE Schuldberg, D AF Dewey, Daniel McDonald, Molly K. Brown, Wilson J. Boyd, Steven J. Bunnell, Brian E. Schuldberg, David TI The impact of ecological momentary assessment on posttraumatic stress symptom trajectory SO PSYCHIATRY RESEARCH LA English DT Article DE Posttraumatic stress disorder; Ecological momentary assessment; Self-monitoring; Traumatic stress ID RANDOMIZED CONTROLLED-TRIAL; PSYCHOMETRIC PROPERTIES; TRAUMA EXPOSURE; DISORDER; DISTRESS AB Ecological momentary assessment includes continuous, real-time gathering of self-report data in a participant's natural environment. The current study evaluated the possible impact of this assessment strategy on severity of posttraumatic stress (PTS) in a sample of participants who reported experiencing a past traumatic event. Participants with clinically elevated PTS symptoms reported symptom severity at three time-points: during an initial screening, following an unmonitored period, and following two weeks of monitoring. During the monitoring period, participants carried an Android device which prompted them to report PTS symptoms and negative emotions six times daily. PTS severity scores were then compared across these three time-points. Results indicated that participating in the ecological momentary assessment protocol was associated with a significant reduction in PTS severity, whereas significant changes were not noted over the unmonitored control condition. The authors conclude that ecological momentary assessment may have therapeutic value even when not combined with formal intervention, and it may be a useful tool for improving the efficiency of a stepped-care approach to treating PTS symptoms. Published by Elsevier Ireland Ltd. C1 [Dewey, Daniel; Brown, Wilson J.; Boyd, Steven J.; Bunnell, Brian E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Dewey, Daniel; McDonald, Molly K.; Schuldberg, David] Univ Montana, Dept Psychol, Missoula, MT 59812 USA. RP Dewey, D (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116,109 Bee St, Charleston, SC 29401 USA. EM daniel.dewey@va.gov NR 19 TC 0 Z9 0 U1 3 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 15 PY 2015 VL 230 IS 2 BP 300 EP 303 DI 10.1016/j.psychres.2015.09.009 PG 4 WC Psychiatry SC Psychiatry GA CY0DV UT WOS:000366077400026 PM 26381184 ER PT J AU Ballard, ME Dean, AC Mandelkern, MA London, ED AF Ballard, Michael E. Dean, Andy C. Mandelkern, Mark A. London, Edythe D. TI Striatal Dopamine D-2/D-3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users SO PLOS ONE LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; REFERENCE TISSUE MODEL; PREFRONTAL CORTEX; COGNITIVE PERFORMANCE; DISTRIBUTION VOLUME; COCAINE ADDICTION; D-2 RECEPTORS; BRAIN IMAGES; DEFICITS; ABUSERS AB Background Dopamine D-2/D-3 receptor availability in the striatum has been linked with executive function in healthy individuals, and is below control levels among drug addicts, possibly contributing to diminished executive function in the latter group. This study tested for an association of striatal D-2/D-3 receptor availability with a measure of executive function among research participants who met DSM-IV criteria for methamphetamine dependence. Methods Methamphetamine users and non-user controls (n = 18 per group) completed the Wisconsin Card Sorting Test and positron emission tomography with [F-18]fallypride. Results The methamphetamine users displayed significantly lower striatal D-2/D-3 receptor availability on average than controls after controlling for age and education (p = 0.008), but they did not register greater proportions of either perseverative or non-perseverative errors when controlling for education (both ps >= 0.622). The proportion of non-perseverative, but not perseverative, errors was negatively correlated with striatal D2/D3 receptor availability among controls (r = -0.588, p = 0.010), but not methamphetamine users (r = 0.281, p = 0.258), and the group-wise interaction was significant (p = 0.030). Conclusions These results suggest that cognitive flexibility, as measured by perseverative errors on the Wisconsin Card Sorting Test, is not determined by signaling through striatal D-2/D-3 receptors in healthy controls, and that in stimulant abusers, who have lower D-2/D-3 receptor availability, compensation can effectively maintain other executive functions, which are associated with D-2/D-3 receptor signaling in controls. C1 [Ballard, Michael E.; Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Ballard, Michael E.; Mandelkern, Mark A.; London, Edythe D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. RP London, ED (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. EM elondon@mednet.ucla.edu RI Ballard, Michael/F-9146-2013 OI Ballard, Michael/0000-0002-2651-6588 FU National Institutes of Health [R01 DA020726, P20 DA022539, K23 DA027734, M0I RR00865]; Marjorie M. Greene Trust; Thomas P. and Katherine K. Pike Chair in Addiction Studies; [T32 DA024635] FX The research was supported by National Institutes of Health grants R01 DA020726 (EDL), P20 DA022539 (EDL), K23 DA027734 (ACD), M0I RR00865 (UCLA GCRC), by endowments from the Thomas P. and Katherine K. Pike Chair in Addiction Studies (EDL), and the Marjorie M. Greene Trust. MEB was supported by T32 DA024635. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 70 TC 0 Z9 0 U1 5 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 14 PY 2015 VL 10 IS 12 AR e0143510 DI 10.1371/journal.pone.0143510 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CY9GR UT WOS:000366715900012 PM 26657223 ER PT J AU Sudore, R Le, GM McMahon, R Feuz, M Katen, M Barnes, DE AF Sudore, Rebecca Le, Gem M. McMahon, Ryan Feuz, Mariko Katen, Mary Barnes, Deborah E. TI The advance care planning PREPARE study among older Veterans with serious and chronic illness: study protocol for a randomized controlled trial SO TRIALS LA English DT Article DE advance care planning; aging; medical decision-making; randomized trial; chronic disease management; geriatrics; veterans; health behavior; advance directive; vulnerable populations ID MENTAL STATUS QUESTIONNAIRE; LIMITED HEALTH LITERACY; QUALITY-OF-LIFE; DECISION-MAKING; ADMINISTRATIVE DATA; ADVANCED CANCER; BEHAVIOR-CHANGE; MEDICAL-CARE; ADULTS; VALIDATION AB Background: Advance care planning (ACP) is a process whereby patients prepare for medical decision-making. The traditional objective of ACP has focused on the completion of advance directives. We have developed a new paradigm of ACP focused on preparing patients and their loved ones for communication and informed medical decision-making. To operationalize this new paradigm of ACP, we created an interactive, patient-centered website called PREPARE (www.prepareforyourcare.org) designed for diverse older adults. Methods/Design: This randomized controlled trial with blinded outcome assessment is designed to determine the efficacy of PREPARE to engage older Veterans in the ACP process. Veterans who are >= 60 years of age, have >= two medical conditions, and have seen a primary care physician >= two times in the last year are being randomized to one of two study arms. The PREPARE study arm reviews the PREPARE website and an easy-to-read advance directive. The control arm only reviews the advance directive. The primary outcome is documentation of an advance directive and ACP discussions. Other clinically important outcomes using validated surveys include ACP behavior change process measures (knowledge, contemplation, self-efficacy, and readiness) and a full range of ACP action measures (identifying a surrogate, identifying values and goals, choosing leeway or flexibility for the surrogate, communicating with clinicians and surrogates, and documenting one's wishes). We will also assess satisfaction with decision-making and Veteran activation within primary care visits by direct audio recording. To examine the outcomes at 1 week, 3 months, and 6 months between the two study arms, we will use mixed effects linear, Poisson, or negative binomial regression and mixed effects logistic regression. Discussion: This study will determine whether PREPARE increases advance directive completion rates and engagement with the ACP process. If PREPARE is efficacious, it could prove to be an easy and effective intervention to help older adults engage in the ACP process within or outside of the medical environment. PREPARE may also help older adults communicate their medical wishes and goals to their loved ones and clinicians, improve medical decision-making, and ensure their wishes are honored over the life course. C1 [Sudore, Rebecca; Le, Gem M.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Sudore, Rebecca; McMahon, Ryan; Feuz, Mariko; Katen, Mary] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. [Le, Gem M.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, Ctr Vulnerable Populat, San Francisco, CA 94110 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Sudore, R (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 3333 Calif St,Suite 380, San Francisco, CA 94143 USA. EM rebecca.sudore@ucsf.edu FU Veterans Affairs Health Services Research Development [11-110-2] FX The Veterans Affairs Health Services Research & Development is the primary funder of this study (#11-110-2). The funder has no role in the study design, the interpretation of data, or the publication of results. NR 60 TC 1 Z9 1 U1 5 U2 18 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD DEC 12 PY 2015 VL 16 AR 570 DI 10.1186/s13063-015-1055-9 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CY2RB UT WOS:000366254700001 PM 26654250 ER PT J AU Lyons, BE Austin, D Seelye, A Petersen, J Yeargers, J Riley, T Sharma, N Mattek, N Dodge, H Wild, K Kaye, JA AF Lyons, Bayard E. Austin, Daniel Seelye, Adriana Petersen, Johanna Yeargers, Jonathan Riley, Thomas Sharma, Nicole Mattek, Nora Dodge, Hiroko Wild, Katherine Kaye, Jeffrey A. TI Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy (vol 7, 102, 2015) SO FRONTIERS IN AGING NEUROSCIENCE LA English DT Correction DE Alzheimer's disease (AD); dementia; mild cognitive impairment (MCI); home monitoring; OHSU; ORCATECH; Layton Aging and Alzheimer's Disease Center C1 [Lyons, Bayard E.; Austin, Daniel; Seelye, Adriana; Petersen, Johanna; Yeargers, Jonathan; Riley, Thomas; Sharma, Nicole; Mattek, Nora; Dodge, Hiroko; Wild, Katherine; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. [Lyons, Bayard E.; Seelye, Adriana; Mattek, Nora; Dodge, Hiroko; Wild, Katherine; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Austin, Daniel; Petersen, Johanna; Yeargers, Jonathan; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA. [Kaye, Jeffrey A.] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. RP Lyons, BE (reprint author), Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. EM lyonsb@ohsu.edu FU NIA NIH HHS [R01 AG024059, R01 AG042191, P30 AG024978, R01 AG033581, P30 AG008017, K01 AG023014] NR 1 TC 0 Z9 0 U1 0 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1663-4365 J9 FRONT AGING NEUROSCI JI Front. Aging Neurosci. PD DEC 11 PY 2015 VL 7 AR 232 DI 10.3389/fnagi.2015.00232 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA CY7ND UT WOS:000366594500001 PM 26696884 ER PT J AU Revuelta, GJ Embry, A Elm, JJ Gregory, C Delambo, A Kautz, S Hinson, VK AF Revuelta, Gonzalo J. Embry, Aaron Elm, Jordan J. Gregory, Chris Delambo, Amy Kautz, Steve Hinson, Vanessa K. TI Pilot study of atomoxetine in patients with Parkinson's disease and dopa-unresponsive Freezing of Gait SO TRANSLATIONAL NEURODEGENERATION LA English DT Article DE Parkinson's disease; Freezing of gait; Noradrenaline; Atomoxetine; Dopa-response ID ATTENTION AB Background: Freezing of gait (FoG) is a common and debilitating condition in Parkinson's disease (PD) associated with executive dysfunction. A subtype of FoG does not respond to dopaminergic therapy and may be related to noradrenergic deficiency. This pilot study explores the effects of atomoxetine on gait in PD patients with dopaunresponsive FoG using a novel paradigm for objective gait assessment. Findings: Ten patients with PD and dopa-unresponsive FoG were enrolled in this eight-week open label pilot study. Assessments included an exploratory gait analysis protocol that quantified spatiotemporal parameters during straight-away walking and turning, while performing a dual task. Clinical, and subjective assessments of gait, quality of life, and safety were also administered. The primary outcome was a validated subjective assessment for FoG (FOG-Q). Atomoxetine was well tolerated, however, no significant change was observed in the primary outcome. The gait analysis protocol correlated well with clinical scales, but not with subjective assessments. DBS patients were more likely to increase gait velocity (p = 0.033), and improved in other clinical assessments. Conclusions: Objective gait analysis protocols assessing gait while dual tasking are feasible and useful for this patient population, and may be superior correlates of FoG severity than subjective measures. These findings can inform future trials in this population. C1 [Revuelta, Gonzalo J.; Delambo, Amy; Hinson, Vanessa K.] Med Univ S Carolina, Coll Med, Dept Neurol, Movement Disorders Div, Charleston, SC 29425 USA. [Embry, Aaron; Gregory, Chris; Kautz, Steve] Med Univ S Carolina, Coll Hlth Profess, Ctr Rehabil Res Neurol Condit, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Elm, Jordan J.] Med Univ S Carolina, Dept Publ Hlth Sci, Coll Med, Charleston, SC 29425 USA. [Gregory, Chris; Kautz, Steve] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Revuelta, GJ (reprint author), Med Univ S Carolina, Coll Med, Dept Neurol, Movement Disorders Div, 208B Rutledge Ave,MSC 108, Charleston, SC 29425 USA. EM revuelta@musc.edu FU NCATS NIH HHS [UL1 TR000062]; NINDS NIH HHS [K23 NS091391] NR 12 TC 1 Z9 1 U1 3 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2047-9158 J9 TRANSL NEURODEGENER JI Transl. Neurodegener. PD DEC 10 PY 2015 VL 4 AR UNSP 24 DI 10.1186/s40035-015-0047-8 PG 4 WC Neurosciences SC Neurosciences & Neurology GA CY3OK UT WOS:000366318900001 PM 26693006 ER PT J AU Delgado, C Grimes, BA Glidden, DV Shlipak, M Sarnak, MJ Johansen, KL AF Delgado, Cynthia Grimes, Barbara A. Glidden, David V. Shlipak, Michael Sarnak, Mark J. Johansen, Kirsten L. TI Association of Frailty based on self-reported physical function with directly measured kidney function and mortality SO BMC NEPHROLOGY LA English DT Article DE Self-report frailty; Kidney function and mortality ID BODY-COMPOSITION; RENAL-DISEASE; OLDER-ADULTS; HEMODIALYSIS; HEALTH; PERFORMANCE; PROGRESSION; PREVALENT; PROTEIN AB Background: Use of serum creatinine to estimate GFR may lead to underestimation of the association between self-reported frailty and kidney function. Our objectives were to evaluate the association of measured GFR (mGFR) with self-reported frailty among patients with CKD and to determine whether self-reported frailty was associated with death after adjusting for mGFR. Methods: Participants in the Modification of Diet in Renal Disease study (1989-1993) had GFR measured using iothalamate clearance (mGFR), and GFR was estimated based on the CKD-EPI creatinine (eGFRcr) and cystatin C (eGFRcys) equations. We defined self-reported frailty as three or more of: exhaustion, poor physical function, low physical activity, and low body weight. Death was ascertained through 2007 using the National Death Index and the United States Renal Data System. Results: Eight hundred twelve MDRD participants (97 %) had complete data on self-reported frailty (16 % prevalence, N = 130) and mGFR (mean (SD) 33.1 +/- 11.7 ml/min/1.73 m(2)). Higher GFR was associated with lower odds of self-reported frailty based on mGFR, (OR 0.71, 95 % CI 0.60-0.86 per 10 ml/min/1.73 m(2)), eGFRcr (OR 0.80, 95 % CI 0.67-0.94 per 10 ml/min/1.73 m2), and eGFRcys (OR 0.75, 95 % CI 0.62-0.90 per 10 ml/min/1.73 m(2)). Median follow-up was 17 (IQR 11-18) years, with 371 deaths. Self-reported frailty was associated with a higher risk of death (HR 1.71, 95 % CI 1.26-2.30), which was attenuated to a similar degree when mGFR (HR 1.48, 95 % CI 1.08-2.00), eGFRcr (HR 1.57, 95 % CI 1.15-2.10), or eGFRcys (HR 1.51, 95 % CI 1.10-2.10) was included as an indicator of kidney function. Conclusions: We found an inverse association between kidney function and self-reported frailty that was similar for mGFR, eGFR and eGFRcys. In this relatively healthy cohort of clinical trial participants with CKD, using serum creatinine to estimate GFR did not substantially alter the association of GFR with self-reported frailty or of self-reported frailty with death. C1 [Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Grimes, Barbara A.; Glidden, David V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. RP Delgado, C (reprint author), San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. EM Cynthia.Delgado@ucsf.edu FU United States Department of Veteran Affairs, Clinical Science Research and Development Program [1IK2CX000527-01A2]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [1K24DK085153]; National Institute of Aging (NIA) [R01AG027002] FX Cynthia Delgado MD's work was supported by Career Development Award # 1IK2CX000527-01A2 from the United States Department of Veteran Affairs, Clinical Science Research and Development Program; Dr. Johansen is supported by 1K24DK085153 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).; Drs. Shlipak and Sarnak are supported by R01AG027002 from the National Institute of Aging (NIA). NR 21 TC 1 Z9 1 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD DEC 9 PY 2015 VL 16 AR 203 DI 10.1186/s12882-015-0202-6 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA CY1NE UT WOS:000366173000001 PM 26645070 ER PT J AU Chen, DH Meneret, A Friedman, JR Korvatska, O Gad, A Bonkowski, ES Stessman, HA Doummar, D Mignot, C Anheim, M Bernes, S Davis, MY Damon-Perriere, N Degos, B Grabli, D Gras, D Hisama, FM Mackenzie, KM Swanson, PD Tranchant, C Vidailhet, M Winesett, S Trouillard, O Amendola, LM Dorschner, MO Weiss, M Eichler, EE Torkamani, A Roze, E Bird, TD Raskind, WH AF Chen, Dong-Hui Meneret, Aurelie Friedman, Jennifer R. Korvatska, Olena Gad, Alona Bonkowski, Emily S. Stessman, Holly A. Doummar, Diane Mignot, Cyril Anheim, Mathieu Bernes, Saunder Davis, Marie Y. Damon-Perriere, Nathalie Degos, Bertrand Grabli, David Gras, Domitille Hisama, Fuki M. Mackenzie, Katherine M. Swanson, Phillip D. Tranchant, Christine Vidailhet, Marie Winesett, Steven Trouillard, Oriane Amendola, Laura M. Dorschner, Michael O. Weiss, Michael Eichler, Evan E. Torkamani, Ali Roze, Emmanuel Bird, Thomas D. Raskind, Wendy H. TI ADCY5-related dyskinesia Broader spectrum and genotype-phenotype correlations SO NEUROLOGY LA English DT Article ID BENIGN HEREDITARY CHOREA; TYPE-5 ADENYLYL-CYCLASE; FACIAL MYOKYMIA FDFM; FAMILIAL DYSKINESIA; ADCY5 MUTATIONS; FOLLOW-UP; DYSTONIA; DYSFUNCTION; MICE AB Objective: To investigate the clinical spectrum and distinguishing features of adenylate cyclase 5 (ADCY5)-related dyskinesia and genotype-phenotype relationship. Methods: We analyzed ADCY5 in patients with choreiform or dystonic movements by exome or targeted sequencing. Suspected mosaicism was confirmed by allele-specific amplification. We evaluated clinical features in our 50 new and previously reported cases. Results: We identified 3 new families and 12 new sporadic cases with ADCY5 mutations. These mutations cause a mixed hyperkinetic disorder that includes dystonia, chorea, and myoclonus, often with facial involvement. The movements are sometimes painful and show episodic worsening on a fluctuating background. Many patients have axial hypotonia. In 2 unrelated families, a p.A726T mutation in the first cytoplasmic domain (C1) causes a relatively mild disorder of prominent facial and hand dystonia and chorea. Mutations p.R418W or p.R418Q in C1, de novo in 13 individuals and inherited in 1, produce a moderate to severe disorder with axial hypotonia, limb hypertonia, paroxysmal nocturnal or diurnal dyskinesia, chorea, myoclonus, and intermittent facial dyskinesia. Somatic mosaicism is usually associated with a less severe phenotype. In one family, a p.M1029K mutation in the C2 domain causes severe dystonia, hypotonia, and chorea. The progenitor, whose childhood-onset episodic movement disorder almost disappeared in adulthood, was mosaic for the mutation. Conclusions: ADCY5-related dyskinesia is a childhood-onset disorder with a wide range of hyperkinetic abnormal movements. Genotype-specific correlations and mosaicism play important roles in the phenotypic variability. Recurrent mutations suggest particular functional importance of residues 418 and 726 in disease pathogenesis. C1 [Chen, Dong-Hui; Bonkowski, Emily S.; Davis, Marie Y.; Swanson, Phillip D.; Weiss, Michael; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Korvatska, Olena; Raskind, Wendy H.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Stessman, Holly A.; Eichler, Evan E.] Univ Washington, Dept Genom Sci, Seattle, WA 98195 USA. [Hisama, Fuki M.; Amendola, Laura M.; Raskind, Wendy H.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Dorschner, Michael O.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Eichler, Evan E.] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] INSERM, U 1127, Paris, France. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] CNRS, UMR 7225, Paris, France. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] Univ Paris 06, Sorbonne Univ, UMR S 1127, Paris, France. [Meneret, Aurelie; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] ICM, Inst Cerveau & Moe Epiniere, Paris, France. [Meneret, Aurelie; Degos, Bertrand; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France. [Meneret, Aurelie; Degos, Bertrand; Grabli, David; Vidailhet, Marie; Trouillard, Oriane; Roze, Emmanuel] Hop La Pitie Salpetriere, AP HP, Dept Genet, Paris, France. [Friedman, Jennifer R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Friedman, Jennifer R.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA. [Friedman, Jennifer R.] Rady Childrens Hosp, San Diego, CA USA. [Gad, Alona] Tel Aviv Med Sch, Tel Aviv Brill Community Mental Hlth Ctr, Tel Aviv, Israel. [Doummar, Diane] Hop Trousseau, AP HP, Serv Neuropediat, F-75571 Paris, France. [Doummar, Diane] Ctr Reference Mouvements Anormaux Enfant Adulte, Paris, France. [Mignot, Cyril] Ctr Deficiences Intellectuelles Causes Rares, Paris, France. [Anheim, Mathieu; Tranchant, Christine] Hospices Civils Strasbourg, Dept Neurol, Illkirch Graffenstaden, France. [Anheim, Mathieu; Tranchant, Christine] Univ Strasbourg, FMTS, Illkirch Graffenstaden, France. [Anheim, Mathieu; Tranchant, Christine] Univ Strasbourg, CNRS UMR7104, INSERM U964, IGBMC, Illkirch Graffenstaden, France. [Bernes, Saunder] Phoenix Childrens Hosp, Phoenix, AZ USA. [Damon-Perriere, Nathalie] CHU Bordeaux, Explorat Fonct Syst Nerveux, Paris, France. [Gras, Domitille] Hop Robert Debre, AP HP, Serv Neuropediat, F-75019 Paris, France. [Mackenzie, Katherine M.] Stanford Univ, Lucile Packard Childrens Hosp, Dept Child Neurol, Palo Alto, CA 94304 USA. [Winesett, Steven] Johns Hopkins All Childrens Hosp, St Petersburg, FL USA. [Torkamani, Ali] Scripps Hlth, Scripps Translat Sci Inst, San Diego, CA USA. [Torkamani, Ali] Scripps Res Inst, San Diego, CA USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Raskind, Wendy H.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. RP Raskind, WH (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM tomnroz@uw.edu; wendyrun@uw.edu FU NIH [R01 NS069719, R01 MH101221, U01 HG006476]; NIH (Clinical and Translational Science Award (CTSA) [UL1 TR001114-03]; Journees de Neurologie en Langue Francaise; INSERM (COSSEC); AP-HP (DRC-PHRC); Fondation pour la Recherche sur le Cerveau (FRC); DHOS-INSERM; ANR (French National Institutes); AMADYS; Alliance France Dystonie; Department of Veterans Affairs FX Supported in part by funds from the NIH (R01 NS069719) to W. H. R., R01 MH101221 to E. E. E., U01 HG006476 to A. T., Clinical and Translational Science Award (CTSA; UL1 TR001114-03) to A. T., Journees de Neurologie en Langue Francaise to A. M., INSERM (COSSEC) to E. R., AP-HP (DRC-PHRC) to E. R., Fondation pour la Recherche sur le Cerveau (FRC) to E. R., DHOS-INSERM to M. V., ANR (French National Institutes) to M. V., AMADYS to M. V., Alliance France Dystonie to A. M., and the Department of Veterans Affairs (T.D.B., W.H.R.). NR 30 TC 14 Z9 14 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC 8 PY 2015 VL 85 IS 23 BP 2026 EP 2035 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DF8WV UT WOS:000371642200010 PM 26537056 ER PT J AU Teerlink, JR Felker, GM McMurray, JJV Solomon, SD Monsalvo, ML Legg, J Malik, FI Honarpour, N AF Teerlink, John R. Felker, G. Michael McMurray, John J. V. Solomon, Scott D. Monsalvo, Maria Laura Legg, Jason Malik, Fady I. Honarpour, Narimon CA COSMIC-HF Investigators TI Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Final Results from a Double-blind, Randomized, Placebo-controlled, Multicenter Study SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium CY NOV 15-19, 2015 CL Chicago, IL SP Amer Heart Assoc C1 [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Felker, G. Michael] Duke Univ, Sch Med, Durham, NC USA. [McMurray, John J. V.] Univ Glasgow, Glasgow, Lanark, Scotland. [Solomon, Scott D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Solomon, Scott D.] Harvard Univ, Sch Med, Boston, MA USA. [Monsalvo, Maria Laura; Legg, Jason; Honarpour, Narimon] Amgen Inc, Thousand Oaks, CA 91320 USA. [Malik, Fady I.] Cytokinetics Inc, San Francisco, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 8 PY 2015 VL 132 IS 23 MA 24294 BP 2269 EP 2269 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CX7DH UT WOS:000365861100017 ER PT J AU Dhaliwal, G AF Dhaliwal, Gurpreet TI The Greatest Generation SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID PHYSICIANS C1 [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Dhaliwal, G (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM gurpreet.dhaliwal@ucsf.edu NR 7 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 8 PY 2015 VL 314 IS 22 BP 2353 EP 2354 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CX8XT UT WOS:000365989100006 PM 26647253 ER PT J AU Singh, SP Schwartz, MP Tokuda, EY Luo, Y Rogers, RE Fujita, M Ahn, NG Anseth, KS AF Singh, S. P. Schwartz, M. P. Tokuda, E. Y. Luo, Y. Rogers, R. E. Fujita, M. Ahn, N. G. Anseth, K. S. TI A synthetic modular approach for modeling the role of the 3D microenvironment in tumor progression SO SCIENTIFIC REPORTS LA English DT Article ID CELL-MIGRATION; 3-DIMENSIONAL CULTURE; MALIGNANT PHENOTYPE; MATRIX STIFFNESS; DRUG-RESISTANCE; GENE-EXPRESSION; ELASTIC-MODULI; CANCER; HYDROGELS; INVASION AB Here, we demonstrate the flexibility of peptide-functionalized poly(ethylene glycol) (PEG) hydrogels for modeling tumor progression. The PEG hydrogels were formed using thiol-ene chemistry to incorporate a matrix metalloproteinase-degradable peptide crosslinker (KKCGGPQG down arrow IWGQGCKK) permissive to proteolytic remodeling and the adhesive CRGDS peptide ligand. Tumor cell function was investigated by culturing WM239A melanoma cells on PEG hydrogel surfaces or encapsulating cells within the hydrogels, and either as monocultures or indirect (non-contact) cocultures with primary human dermal fibroblasts (hDFs). WM239A cluster size and proliferation rate depended on the shear elastic modulus for cells cultured on PEG hydrogels, while growth was inhibited by coculture with hDFs regardless of hydrogel stiffness. Cluster size was also suppressed by hDFs for WM239A cells encapsulated in PEG hydrogels, which is consistent with cells seeded on top of hydrogels. Notably, encapsulated WM239A clusters and single cells adopted invasive phenotypes in the hDF coculture model, which included single cell and collective migration modes that resembled invasion from human melanoma patient-derived xenograft tumors encapsulated in equivalent PEG hydrogels. Our combined results demonstrate that peptide-functionalized PEG hydrogels provide a useful platform for investigating aspects of tumor progression in 2D and 3D microenvironments, including single cell migration, cluster growth and invasion. C1 [Singh, S. P.; Tokuda, E. Y.; Anseth, K. S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA. [Singh, S. P.; Tokuda, E. Y.; Anseth, K. S.] Univ Colorado, BioFrontiers Inst, Boulder, CO 80309 USA. [Schwartz, M. P.] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA. [Luo, Y.; Fujita, M.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA. [Rogers, R. E.] Texas A&M Hlth Sci Ctr, Coll Med, Bryan, TX USA. [Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Ahn, N. G.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA. [Anseth, K. S.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA. RP Anseth, KS (reprint author), Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA. EM kristi.anseth@colorado.edu RI Schwartz, Michael/B-3417-2008; Schwartz, Mike/O-7963-2016 OI Schwartz, Michael/0000-0003-3785-6606; Schwartz, Mike/0000-0003-3785-6606 FU Howard Hughes Medical Institute; National Institutes of Health [RO1 CA132633-02, T32 GM-065103] FX The authors acknowledge the Howard Hughes Medical Institute and the National Institutes of Health (RO1 CA132633-02) for funding this work. SPS acknowledges the biophysics training program (NIH grant T32 GM-065103) for fellowship support. MPS acknowledges a donation in the memory of Gerald E. Whitbeck (generously provided by his family and Follett Corp). NR 66 TC 3 Z9 3 U1 5 U2 31 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD DEC 7 PY 2015 VL 5 AR 17814 DI 10.1038/srep17814 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CX7CB UT WOS:000365857300001 PM 26638791 ER PT J AU Forouzanfar, MH Alexander, L Anderson, HR Bachman, VF Biryukov, S Brauer, M Burnett, R Casey, D Coates, MM Cohen, A Delwiche, K Estep, K Frostad, JJ Astha, KC Kyu, HH Moradi-Lakeh, M Ng, M Slepak, EL Thomas, BA Wagner, J Aasvang, GM Abbafati, C Ozgoren, AA Abd-Allah, F Abera, SF Aboyans, V Abraham, B Abraham, JP Abubakar, I Abu-Rmeileh, NME Aburto, TC Achoki, T Adelekan, A Adofo, K Adou, AK Adsuar, JC Afshin, A Agardh, EE Al Khabouri, MJ Al Lami, FH Alam, SS Alasfoor, D Albittar, MI Alegretti, MA Aleman, AV Alemu, ZA Alfonso-Cristancho, R Alhabib, S Ali, R Ali, MK Alla, F Allebeck, P Allen, PJ Alsharif, U Alvarez, E Alvis-Guzman, N Amankwaa, AA Amare, AT Ameh, EA Ameli, O Amini, H Ammar, W Anderson, BO Antonio, CAT Anwari, P Cunningham, SA Arnlov, J Arsenijevic, VSA Artaman, A Asghar, RJ Assadi, R Atkins, LS Atkinson, C Avila, MA Awuah, B Badawi, A Bahit, MC Bakfalouni, T Balakrishnan, K Balalla, S Balu, RK Banerjee, A Barber, RM Barker-Collo, SL Barquera, S Barregard, L Barrero, LH Barrientos-Gutierrez, T Basto-Abreu, AC Basu, A Basu, S Basulaiman, MO Ruvalcaba, CB Beardsley, J Bedi, N Bekele, T Bell, ML Benjet, C Bennett, DA Benzian, H Bernabe, E Beyene, TJ Bhala, N Bhalla, A Bhutta, ZQA Bikbov, B Bin Abdulhak, AA Blore, JD Blyth, FM Bohensky, MA Basara, BB Borges, G Bornstein, NM Bose, D Boufous, S Bourne, RR Brainin, M Brazinova, A Breitborde, NJ Brenner, H Briggs, ADM Broday, DM Brooks, PM Bruce, NG Brugha, TS Brunekreef, B Buchbinder, R Bui, LN Bukhman, G Bulloch, AG Burch, M Burney, PGJ Campos-Nonato, IR Campuzano, JC Cantoral, AJ Caravanos, J Cardenas, R Cardis, E Carpenter, DO Caso, V Castaneda-Orjuela, CA Castro, RE Catala-Lopez, F Cavalleri, F Ccedil;avlin, A Chadha, VK Chang, JC Charlson, FJ Chen, HL Chen, WQ Chen, ZM Chiang, PP Chimed-Ochir, O Chowdhury, R Christophi, CA Chuang, TW Chugh, SS Cirillo, M Classen, TKD Colistro, V Colomar, M Colquhoun, SM Contreras, AG Cooper, C Cooperrider, K Cooper, LT Coresh, J Courville, KJ Criqui, MH Cuevas-Nasu, L Damsere-Derry, J Danawi, H Dandona, L Dandona, R Dargan, PI Davis, A Davitoiu, DV Dayama, A de Castro, EF De la Cruz-Gongora, V De Leo, D de Lima, G Degenhardt, L del Pozo-Cruz, B Dellavalle, RP Deribe, K Derrett, S Jarlais, DCD Dessalegn, M deVeber, GA Devries, KM Dharmaratne, SD Dherani, MK Dicker, D Ding, EL Dokova, K Dorsey, ER Driscoll, TR Duan, L Durrani, AM Ebel, BE Ellenbogen, RG Elshrek, YM Endres, M Ermakov, SP Erskine, HE Eshrati, B Esteghamati, A Fahimi, S Faraon, EJA Farzadfar, F Fay, DFJ Feigin, VL Feigl, AB Fereshtehnejad, SM Ferrari, AJ Ferri, CP Flaxman, AD Fleming, TD Foigt, N Foreman, KJ Paleo, UF Franklin, RC Gabbe, B Gaffikin, L Gakidou, E Gamkrelidze, A Gankpe, FG Gansevoort, RT Garcia-Guerra, FA Gasana, E Geleijnse, JM Gessner, BD Gething, P Gibney, KB Gillum, RF Ginawi, IAM Giroud, M Giussani, G Goenka, S Goginashvili, K Dantes, HG Gona, P de Cosio, TG Gonzalez-Castell, D Gotay, CC Goto, A Gouda, HN Guerrant, RL Gugnani, HC Guillemin, F Gunnell, D Gupta, R Gupta, R Gutierrez, RA Hafezi-Nejad, N Hagan, H Hagstromer, M Halasa, YA Hamadeh, RR Hammami, M Hankey, GJ Hao, YT Harb, HL Haregu, TN Haro, JM Havmoeller, R Hay, SI Hedayati, MT Heredia-Pi, IB Hernandez, L Heuton, KR Heydarpour, P Hijar, M Hoek, HW Man, HJH Hornberger, JC Hosgood, HD Hoy, DG Hsairi, M Hu, GQ Hu, H Huang, C Huang, JJ Hubbell, BJ Huiart, L Husseini, A Iannarone, ML Iburg, KM Idrisov, BT Ikeda, N Innos, K Inoue, M Islami, F Ismayilova, S Jacobsen, KH Jansen, HA Jarvis, DL Jassal, SK Jauregui, A Jayaraman, S Jeemon, P Jensen, PN Jha, V Jiang, F Jiang, GH Jiang, Y Jonas, JB Juel, K Kan, HD Roseline, SSK Karam, NE Karch, A Karema, CK Karthikeyan, G Kaul, A Kawakami, N Kazi, DS Kemp, AH Kengne, AP Keren, A Khader, YS Khalifa, SEAH Khan, EA Khang, YH Khatibzadeh, S Khonelidze, I Kieling, C Kim, D Kim, S Kim, Y Kimokoti, RW Kinfu, Y Kinge, JM Kissela, BM Kivipelto, M Knibbs, LD Knudsen, AK Kokubo, Y Kose, MR Kosen, S Kraemer, A Kravchenko, M Krishnaswami, S Kromhout, H Ku, T Defo, BK Bicer, BK Kuipers, EJ Kulkarni, C Kulkarni, VS Kumar, GA Kwan, GF Lai, T Balaji, AL Lalloo, R Lallukka, T Lam, H Lan, Q Lansingh, VC Larson, HJ Larsson, A Laryea, DO Lavados, PM Lawrynowicz, AE Leasher, JL Lee, JT Leigh, J Leung, R Levi, M Li, Y Li, Y Liang, J Liang, XF Lim, SS Lindsay, MP Lipshultz, SE Liu, SW Liu, Y Lloyd, BK Logroscino, G London, SJ Lopez, N Lortet-Tieulent, J Lotufo, PA Lozano, R Lunevicius, R Ma, JX Ma, S Machado, VMP MacIntyre, MF Magis-Rodriguez, C Mahdi, AA Majdan, M Malekzadeh, R Mangalam, S Mapoma, CC Marape, M Marcenes, W Margolis, DJ Margono, C Marks, GB Martin, RV Marzan, MB Mashal, MT Masiye, F Mason-Jones, AJ Matsushita, K Matzopoulos, R Mayosi, BM Mazorodze, TT Mckay, AC Mckee, M McLain, A Meaney, PA Medina, C Mehndiratta, MM Mejia-Rodriguez, F Mekonnen, W Melaku, YA Meltzer, M Memish, ZA Mendoza, W Mensah, GA Meretoja, A Mhimbira, FA Micha, R Miller, TR Mills, EJ Misganaw, A Mishra, S Ibrahim, NM Mohammad, KA Mokdad, AH Mola, GL Monasta, L Hernandez, JCM Montico, M Moore, AR Morawska, L Mori, R Moschandreas, J Moturi, WN Arian, DM Mueller, UO Mukaigawara, M Mullany, EC Murthy, KS Naghavi, M Nahas, Z Naheed, A Naidoo, KS Naldi, L Nand, D Nangia, V Narayan, KMV Nash, D Neal, B Nejjari, C Neupane, SP Newton, CR Ngalesoni, FN Ngirabega, JD Nguyen, G Nguyen, NT Nieuwenhuijsen, MJ Nisar, MI Nogueira, JR Nolla, JM Nolte, S Norheim, OF Norman, RE Norrving, B Nyakarahuka, L Oh, IH Ohkubo, T Olusanya, BO Omer, SB Opio, JN Orozco, R Pagcatipunan, RS Pain, AW Pandian, JD Panelo, CIA Papachristou, C Park, EK Parry, CD Caicedo, AJP Patten, SB Paul, VK Pavlin, BI Pearce, N Pedraza, LS Pedroza, A Stokic, LP Pekericli, A Pereira, DM Perez-Padilla, R Perez-Ruiz, F Perico, N Perry, SAL Pervaiz, A Pesudovs, K Peterson, CB Petzold, M Phillips, MR Phua, HP Plass, D Poenaru, D Polanczyk, GV Polinder, S Pond, CD Pope, CA Pope, D Popova, S Pourmalek, F Powles, J Prabhakaran, D Prasad, NM Qato, DM Quezada, AD Quistberg, DAA Racape L Rafay, A Rahimi, K Rahimi-Movaghar, V Rahman, SU Raju, M Rakovac, I Rana, SM Rao, M Razavi, H Reddy, KS Refaat, AH Rehm, J Remuzzi, G Ribeiro, AL Riccio, PM Richardson, L Riederer, A Robinson, M Roca, A Rodriguez, A Rojas-Rueda, D Romieu, I Ronfani, L Room, R Roy, N Ruhago, GM Rushton, L Sabin, N Sacco, RL Saha, S Sahathevan, R Sahraian, MA Salomon, JA Salvo, D Sampson, UK Sanabria, JR Sanchez, LM Sanchez-Pimienta, TG Sanchez-Riera, L Sandar, L Santos, IS Sapkota, A Satpathy, M Saunders, JE Sawhney, M Saylan, MI Scarborough, P Schmidt, JC Schneider, IJC Schottker, B Schwebel, DC Scott, JG Seedat, S Sepanlou, SG Serdar, B Servan-Mori, EE Shaddick, G Shahraz, S Levy, TS Shangguan, S She, J Sheikhbahaei, S Shibuya, K Shin, HH Shinohara, Y Shiri, R Shishani, K Shiue, I Sigfusdottir, ID Silberberg, DH Simard, EP Sindi, S Singh, A Singh, GM Singh, JA Skirbekk, V Sliwa, K Soljak, M Soneji, S Soreide, K Soshnikov, S Sposato, LA Sreeramareddy, CT Stapelberg, NJC Stathopoulou, V Steckling, N Stein, DJ Stein, MB Stephens, N Stockl, H Straif, K Stroumpoulis, K Sturua, L Sunguya, BF Swaminathan, S Swaroop, M Sykes, BL Tabb, KM Takahashi, K Talongwa, RT Tandon, N Tanne, D Tanner, M Tavakkoli, M Ao, BJT Teixeira, CM Rojo, MMT Terkawi, AS Texcalac-Sangrador, JL Thackway, SV Thomson, B Thorne-Lyman, AL Thrift, AG Thurston, GD Tillmann, T Tobollik, M Tonelli, M Topouzis, F Towbin, JRA Toyoshima, H Traebert, JE Tran, BX Trasande, L Trillini, M Trujillo, U Dimbuene, ZT Tsilimbaris, M Tuzcu, EM Uchendu, US Ukwaja, KN Uzun, SB van de Vijver, S Van Dingenen, R Van Gool, CH Van Os, J Varakin, YY Vasankari, TJ Vasconcelos, AMN Vavilala, MS Veerman, LJ Velasquez-Melendez, G Venketasubramanian, N Vijayakumar, L Villalpando, S Violante, FS Vlassov, VV Vollset, SE Wagner, GR Waller, SG Wallin, MT Wan, X Wang, HD Wang, JL Wang, LH Wang, WZ Wang, YP Warouw, TS Watts, CH Weichenthal, S Weiderpass, E Weintraub, RG Werdecker, A Wessells, KR Westerman, R Whiteford, HA Wilkinson, JD Williams, HC Williams, TN Woldeyohannes, SM Wolfe, CDA Wong, JQ Woolf, AD Wright, JL Wurtz, B Xu, G Yan, LJL Yang, GH Yano, Y Ye, PP Yenesew, M Yentur, GK Yip, P Yonemoto, N Yoon, SJ Younis, MZ Younoussi, Z Yu, CH Zaki, ME Zhao, Y Zheng, YF Zhou, MG Zhu, J Zhu, SK Zou, XN Zunt, JR Lopez, AD Vos, T Murray, CJ AF Forouzanfar, Mohammad H. Alexander, Lily Anderson, H. Ross Bachman, Victoria F. Biryukov, Stan Brauer, Michael Burnett, Richard Casey, Daniel Coates, Matthew M. Cohen, Aaron Delwiche, Kristen Estep, Kara Frostad, Joseph J. Astha, K. C. Kyu, Hmwe H. Moradi-Lakeh, Maziar Ng, Marie Slepak, Erica Leigh Thomas, Bernadette A. Wagner, Joseph Aasvang, Gunn Marit Abbafati, Cristiana Ozgoren, Ayse Abbasoglu Abd-Allah, Foad Abera, Semaw F. Aboyans, Victor Abraham, Biju Abraham, Jerry Puthenpurakal Abubakar, Ibrahim Abu-Rmeileh, Niveen M. E. Aburto, Tania C. Achoki, Tom Adelekan, Ademola Adofo, Koranteng Adou, Arsene K. Adsuar, Jose C. Afshin, Ashkan Agardh, Emilie E. Al Khabouri, Mazin J. Al Lami, Faris H. Alam, Sayed Saidul Alasfoor, Deena Albittar, Mohammed I. Alegretti, Miguel A. Aleman, Alicia V. Alemu, Zewdie A. Alfonso-Cristancho, Rafael Alhabib, Samia Ali, Raghib Ali, Mohammed K. Alla, Francois Allebeck, Peter Allen, Peter J. Alsharif, Ubai Alvarez, Elena Alvis-Guzman, Nelson Amankwaa, Adansi A. Amare, Azmeraw T. Ameh, Emmanuel A. Ameli, Omid Amini, Heresh Ammar, Walid Anderson, Benjamin O. Antonio, Carl Abelardo T. Anwari, Palwasha Cunningham, Solveig Argeseanu Arnlov, Johan Arsenijevic, Valentina S. Arsic Artaman, Al Asghar, Rana J. Assadi, Reza Atkins, Lydia S. Atkinson, Charles Avila, Marco A. Awuah, Baffour Badawi, Alaa Bahit, Maria C. Bakfalouni, Talal Balakrishnan, Kalpana Balalla, Shivanthi Balu, Ravi Kumar Banerjee, Amitava Barber, Ryan M. Barker-Collo, Suzanne L. Barquera, Simon Barregard, Lars Barrero, Lope H. Barrientos-Gutierrez, Tonatiuh Basto-Abreu, Ana C. Basu, Arindam Basu, Sanjay Basulaiman, Mohammed O. Ruvalcaba, Carolina Batis Beardsley, Justin Bedi, Neeraj Bekele, Tolesa Bell, Michelle L. Benjet, Corina Bennett, Derrick A. Benzian, Habib Bernabe, Eduardo Beyene, Tariku J. Bhala, Neeraj Bhalla, Ashish Bhutta, Zulfi Qar A. Bikbov, Boris Bin Abdulhak, Aref A. Blore, Jed D. Blyth, Fiona M. Bohensky, Megan A. Basara, Berrak Bora Borges, Guilherme Bornstein, Natan M. Bose, Dipan Boufous, Soufiane Bourne, Rupert R. Brainin, Michael Brazinova, Alexandra Breitborde, Nicholas J. Brenner, Hermann Briggs, Adam D. M. Broday, David M. Brooks, Peter M. Bruce, Nigel G. Brugha, Traolach S. Brunekreef, Bert Buchbinder, Rachelle Bui, Linh N. Bukhman, Gene Bulloch, Andrew G. Burch, Michael Burney, Peter G. J. Campos-Nonato, Ismael R. Campuzano, Julio C. Cantoral, Alejandra J. Caravanos, Jack Cardenas, Rosario Cardis, Elisabeth Carpenter, David O. Caso, Valeria Castaneda-Orjuela, Carlos A. Castro, Ruben E. Catala-Lopez, Ferran Cavalleri, Fiorella Cavlin, Alanur Chadha, Vineet K. Chang, Jung-chen Charlson, Fiona J. Chen, Honglei Chen, Wanqing Chen, Zhengming Chiang, Peggy P. Chimed-Ochir, Odgerel Chowdhury, Rajiv Christophi, Costas A. Chuang, Ting-Wu Chugh, Sumeet S. Cirillo, Massimo Classen, Thomas K. D. Colistro, Valentina Colomar, Mercedes Colquhoun, Samantha M. Contreras, Alejandra G. Cooper, Cyrus Cooperrider, Kimberly Cooper, Leslie T. Coresh, Josef Courville, Karen J. Criqui, Michael H. Cuevas-Nasu, Lucia Damsere-Derry, James Danawi, Hadi Dandona, Lalit Dandona, Rakhi Dargan, Paul I. Davis, Adrian Davitoiu, Dragos V. Dayama, Anand de Castro, E. Filipa De la Cruz-Gongora, Vanessa De Leo, Diego de Lima, Graca Degenhardt, Louisa del Pozo-Cruz, Borja Dellavalle, Robert P. Deribe, Kebede Derrett, Sarah Jarlais, Don C. Des Dessalegn, Muluken deVeber, Gabrielle A. Devries, Karen M. Dharmaratne, Samath D. Dherani, Mukesh K. Dicker, Daniel Ding, Eric L. Dokova, Klara Dorsey, E. Ray Driscoll, Tim R. Duan, Leilei Durrani, Adnan M. Ebel, Beth E. Ellenbogen, Richard G. Elshrek, Yousef M. Endres, Matthias Ermakov, Sergey P. Erskine, Holly E. Eshrati, Babak Esteghamati, Alireza Fahimi, Saman Faraon, Emerito Jose A. Farzadfar, Farshad Fay, Derek F. J. Feigin, Valery L. Feigl, Andrea B. Fereshtehnejad, Seyed-Mohammad Ferrari, Alize J. Ferri, Cleusa P. Flaxman, Abraham D. Fleming, Thomas D. Foigt, Nataliya Foreman, Kyle J. Paleo, Urbano Fra Franklin, Richard C. Gabbe, Belinda Gaffikin, Lynne Gakidou, Emmanuela Gamkrelidze, Amiran Gankpe, Fortune G. Gansevoort, Ron T. Garcia-Guerra, Francisco A. Gasana, Evariste Geleijnse, Johanna M. Gessner, Bradford D. Gething, Pete Gibney, Katherine B. Gillum, Richard F. Ginawi, Ibrahim A. M. Giroud, Maurice Giussani, Giorgia Goenka, Shifalika Goginashvili, Ketevan Dantes, Hector Gomez Gona, Philimon de Cosio, Teresita Gonzalez Gonzalez-Castell, Dinorah Gotay, Carolyn C. Goto, Atsushi Gouda, Hebe N. Guerrant, Richard L. Gugnani, Harish C. Guillemin, Francis Gunnell, David Gupta, Rahul Gupta, Rajeev Gutierrez, Reyna A. Hafezi-Nejad, Nima Hagan, Holly Hagstromer, Maria Halasa, Yara A. Hamadeh, Randah R. Hammami, Mouhanad Hankey, Graeme J. Hao, Yuantao Harb, Hilda L. Haregu, Tilahun Nigatu Haro, Josep Maria Havmoeller, Rasmus Hay, Simon I. Hedayati, Mohammad T. Heredia-Pi, Ileana B. Hernandez, Lucia Heuton, Kyle R. Heydarpour, Pouria Hijar, Martha Hoek, Hans W. Man, Howard J. Hoff Hornberger, John C. Hosgood, H. Dean Hoy, Damian G. Hsairi, Mohamed Hu, Guoqing Hu, Howard Huang, Cheng Huang, John J. Hubbell, Bryan J. Huiart, Laetitia Husseini, Abdullatif Iannarone, Marissa L. Iburg, Kim M. Idrisov, Bulat T. Ikeda, Nayu Innos, Kaire Inoue, Manami Islami, Farhad Ismayilova, Samaya Jacobsen, Kathryn H. Jansen, Henrica A. Jarvis, Deborah L. Jassal, Simerjot K. Jauregui, Alejandra Jayaraman, Sudha Jeemon, Panniyammakal Jensen, Paul N. Jha, Vivekanand Jiang, Fan Jiang, Guohong Jiang, Ying Jonas, Jost B. Juel, Knud Kan, Haidong Roseline, Sidibe S. Kany Karam, Nadim E. Karch, Andre Karema, Corine K. Karthikeyan, Ganesan Kaul, Anil Kawakami, Norito Kazi, Dhruv S. Kemp, Andrew H. Kengne, Andre P. Keren, Andre Khader, Yousef S. Khalifa, Shams Eldin Ali Hassan Khan, Ejaz A. Khang, Young-Ho Khatibzadeh, Shahab Khonelidze, Irma Kieling, Christian Kim, Daniel Kim, Sungroul Kim, Yunjin Kimokoti, Ruth W. Kinfu, Yohannes Kinge, Jonas M. Kissela, Brett M. Kivipelto, Miia Knibbs, Luke D. Knudsen, Ann Kristin Kokubo, Yoshihiro Kose, M. Rifat Kosen, Soewarta Kraemer, Alexander Kravchenko, Michael Krishnaswami, Sanjay Kromhout, Hans Ku, Tiffany Defo, Barthelemy Kuate Bicer, Burcu Kucuk Kuipers, Ernst J. Kulkarni, Chanda Kulkarni, Veena S. Kumar, G. Anil Kwan, Gene F. Lai, Taavi Balaji, Arjun Lakshmana Lalloo, Ratilal Lallukka, Tea Lam, Hilton Lan, Qing Lansingh, Van C. Larson, Heidi J. Larsson, Anders Laryea, Dennis O. Lavados, Pablo M. Lawrynowicz, Alicia E. Leasher, Janet L. Lee, Jong-Tae Leigh, James Leung, Ricky Levi, Miriam Li, Yichong Li, Yongmei Liang, Juan Liang, Xiaofeng Lim, Stephen S. Lindsay, M. Patrice Lipshultz, Steven E. Liu, Shiwei Liu, Yang Lloyd, Belinda K. Logroscino, Giancarlo London, Stephanie J. Lopez, Nancy Lortet-Tieulent, Joannie Lotufo, Paulo A. Lozano, Rafael Lunevicius, Raimundas Ma, Jixiang Ma, Stefan Machado, Vasco M. P. MacIntyre, Michael F. Magis-Rodriguez, Carlos Mahdi, Abbas A. Majdan, Marek Malekzadeh, Reza Mangalam, Srikanth Mapoma, Christopher C. Marape, Marape Marcenes, Wagner Margolis, David J. Margono, Christopher Marks, Guy B. Martin, Randall V. Marzan, Melvin B. Mashal, Mohammad T. Masiye, Felix Mason-Jones, Amanda J. Matsushita, Kunihiro Matzopoulos, Richard Mayosi, Bongani M. Mazorodze, Tasara T. Mckay, Abigail C. Mckee, Martin McLain, Abigail Meaney, Peter A. Medina, Catalina Mehndiratta, Man Mohan Mejia-Rodriguez, Fabiola Mekonnen, Wubegzier Melaku, Yohannes A. Meltzer, Michele Memish, Ziad A. Mendoza, Walter Mensah, George A. Meretoja, Atte Mhimbira, Francis Apolinary Micha, Renata Miller, Ted R. Mills, Edward J. Misganaw, Awoke Mishra, Santosh Ibrahim, Norlinah Mohamed Mohammad, Karzan A. Mokdad, Ali H. Mola, Glen L. Monasta, Lorenzo Hernandez, Julio C. Montaez Montico, Marcella Moore, Ami R. Morawska, Lidia Mori, Rintaro Moschandreas, Joanna Moturi, Wilkister N. Arian, Dariush Mozaff Mueller, Ulrich O. Mukaigawara, Mitsuru Mullany, Erin C. Murthy, Kinnari S. Naghavi, Mohsen Nahas, Ziad Naheed, Aliya Naidoo, Kovin S. Naldi, Luigi Nand, Devina Nangia, Vinay Narayan, K. M. Venkat Nash, Denis Neal, Bruce Nejjari, Chakib Neupane, Sudan P. Newton, Charles R. Ngalesoni, Frida N. Ngirabega, Jean de Dieu Nguyen, Grant Nguyen, Nhung T. Nieuwenhuijsen, Mark J. Nisar, Muhammad I. Nogueira, Jose R. Nolla, Joan M. Nolte, Sandra Norheim, Ole F. Norman, Rosana E. Norrving, Bo Nyakarahuka, Luke Oh, In-Hwan Ohkubo, Takayoshi Olusanya, Bolajoko O. Omer, Saad B. Opio, John Nelson Orozco, Ricardo Pagcatipunan, Rodolfo S., Jr. Pain, Amanda W. Pandian, Jeyaraj D. Panelo, Carlo Irwin A. Papachristou, Christina Park, Eun-Kee Parry, Charles D. Caicedo, Angel J. Paternina Patten, Scott B. Paul, Vinod K. Pavlin, Boris I. Pearce, Neil Pedraza, Lilia S. Pedroza, Andrea Stokic, Ljiljana Pejin Pekericli, Ayfer Pereira, David M. Perez-Padilla, Rogelio Perez-Ruiz, Fernando Perico, Norberto Perry, Samuel A. L. Pervaiz, Aslam Pesudovs, Konrad Peterson, Carrie B. Petzold, Max Phillips, Michael R. Phua, Hwee Pin Plass, Dietrich Poenaru, Dan Polanczyk, Guilherme V. Polinder, Suzanne Pond, Constance D. Pope, C. Arden Pope, Daniel Popova, Svetlana Pourmalek, Farshad Powles, John Prabhakaran, Dorairaj Prasad, Noela M. Qato, Dima M. Quezada, Amado D. Quistberg, D. Alex A. Racape, Lionel Rafay, Anwar Rahimi, Kazem Rahimi-Movaghar, Vafa Rahman, Sajjad Ur Raju, Murugesan Rakovac, Ivo Rana, Saleem M. Rao, Mayuree Razavi, Homie Reddy, K. Srinath Refaat, Amany H. Rehm, Juergen Remuzzi, Giuseppe Ribeiro, Antonio L. Riccio, Patricia M. Richardson, Lee Riederer, Anne Robinson, Margaret Roca, Anna Rodriguez, Alina Rojas-Rueda, David Romieu, Isabelle Ronfani, Luca Room, Robin Roy, Nobhojit Ruhago, George M. Rushton, Lesley Sabin, Nsanzimana Sacco, Ralph L. Saha, Sukanta Sahathevan, Ramesh Sahraian, Mohammad Ali Salomon, Joshua A. Salvo, Deborah Sampson, Uchechukwu K. Sanabria, Juan R. Sanchez, Luz Maria Sanchez-Pimienta, Tania G. Sanchez-Riera, Lidia Sandar, Logan Santos, Itamar S. Sapkota, Amir Satpathy, Maheswar Saunders, James E. Sawhney, Monika Saylan, Mete I. Scarborough, Peter Schmidt, Juergen C. Schneider, Ione J. C. Schoettker, Ben Schwebel, David C. Scott, James G. Seedat, Soraya Sepanlou, Sadaf G. Serdar, Berrin Servan-Mori, Edson E. Shaddick, Gavin Shahraz, Saeid Levy, Teresa Shamah Shangguan, Siyi She, Jun Sheikhbahaei, Sara Shibuya, Kenji Shin, Hwashin H. Shinohara, Yukito Shiri, Rahman Shishani, Kawkab Shiue, Ivy Sigfusdottir, Inga D. Silberberg, Donald H. Simard, Edgar P. Sindi, Shireen Singh, Abhishek Singh, Gitanjali M. Singh, Jasvinder A. Skirbekk, Vegard Sliwa, Karen Soljak, Michael Soneji, Samir Soreide, Kjetil Soshnikov, Sergey Sposato, Luciano A. Sreeramareddy, Chandrashekhar T. Stapelberg, Nicolas J. C. Stathopoulou, Vasiliki Steckling, Nadine Stein, Dan J. Stein, Murray B. Stephens, Natalie Stoeckl, Heidi Straif, Kurt Stroumpoulis, Konstantinos Sturua, Lela Sunguya, Bruno F. Swaminathan, Soumya Swaroop, Mamta Sykes, Bryan L. Tabb, Karen M. Takahashi, Ken Talongwa, Roberto T. Tandon, Nikhil Tanne, David Tanner, Marcel Tavakkoli, Mohammad Ao, Braden J. Te Teixeira, Carolina M. Rojo, Martha M. Tellez Terkawi, Abdullah S. Texcalac-Sangrador, Jose Luis Thackway, Sarah V. Thomson, Blake Thorne-Lyman, Andrew L. Thrift, Amanda G. Thurston, George D. Tillmann, Taavi Tobollik, Myriam Tonelli, Marcello Topouzis, Fotis Towbin, Jeff Rey A. Toyoshima, Hideaki Traebert, Jeff Erson Tran, Bach X. Trasande, Leonardo Trillini, Matias Trujillo, Ulises Dimbuene, Zacharie Tsala Tsilimbaris, Miltiadis Tuzcu, Emin Murat Uchendu, Uche S. Ukwaja, Kingsley N. Uzun, Selen B. van de Vijver, Steven Van Dingenen, Rita Van Gool, Coen H. Van Os, Jim Varakin, Yuri Y. Vasankari, Tommi J. Vasconcelos, Ana Maria N. Vavilala, Monica S. Veerman, Lennert J. Velasquez-Melendez, Gustavo Venketasubramanian, N. Vijayakumar, Lakshmi Villalpando, Salvador Violante, Francesco S. Vlassov, Vasiliy Victorovich Vollset, Stein Emil Wagner, Gregory R. Waller, Stephen G. Wallin, Mitchell T. Wan, Xia Wang, Haidong Wang, JianLi Wang, Linhong Wang, Wenzhi Wang, Yanping Warouw, Tati S. Watts, Charlotte H. Weichenthal, Scott Weiderpass, Elisabete Weintraub, Robert G. Werdecker, Andrea Wessells, K. Ryan Westerman, Ronny Whiteford, Harvey A. Wilkinson, James D. Williams, Hywel C. Williams, Thomas N. Woldeyohannes, Solomon M. Wolfe, Charles D. A. Wong, John Q. Woolf, Anthony D. Wright, Jonathan L. Wurtz, Brittany Xu, Gelin Yan, Lijing L. Yang, Gonghuan Yano, Yuichiro Ye, Pengpeng Yenesew, Muluken Yentuer, Goekalp K. Yip, Paul Yonemoto, Naohiro Yoon, Seok-Jun Younis, Mustafa Z. Younoussi, Zourkaleini Yu, Chuanhua Zaki, Maysaa E. Zhao, Yong Zheng, Yingfeng Zhou, Maigeng Zhu, Jun Zhu, Shankuan Zou, Xiaonong Zunt, Joseph R. Lopez, Alan D. Vos, Theo Murray, Christopher J. CA GBD 2013 Risk Factors TI Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 SO LANCET LA English DT Article ID BODY-MASS INDEX; CORONARY-HEART-DISEASE; CAUSE-SPECIFIC MORTALITY; FINE PARTICULATE MATTER; OUTDOOR AIR-POLLUTION; MALE BRITISH DOCTORS; ALL-CAUSE MORTALITY; LONG-TERM EXPOSURE; BLOOD-PRESSURE; TOBACCO SMOKING AB Background The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution. Methods Attributable deaths, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 2010 methods. Risk-outcome pairs meeting explicit evidence criteria were assessed for 188 countries for the period 1990-2013 by age and sex using three inputs: risk exposure, relative risks, and the theoretical minimum risk exposure level (TMREL). Risks are organised into a hierarchy with blocks of behavioural, environmental and occupational, and metabolic risks at the first level of the hierarchy. The next level in the hierarchy includes nine clusters of related risks and two individual risks, with more detail provided at levels 3 and 4 of the hierarchy. Compared with GBD 2010, six new risk factors have been added: handwashing practices, occupational exposure to trichloroethylene, childhood wasting, childhood stunting, unsafe sex, and low glomerular filtration rate. For most risks, data for exposure were synthesised with a Bayesian meta-regression method, DisMod-MR 2.0, or spatial-temporal Gaussian process regression. Relative risks were based on meta-regressions of published cohort and intervention studies. Attributable burden for clusters of risks and all risks combined took into account evidence on the mediation of some risks such as high body-mass index (BMI) through other risks such as high systolic blood pressure and high cholesterol. Findings All risks combined account for 57.2% (95% uncertainty interval [UI] 55.8-58.5) of deaths and 41.6% (40.1-43.0) of DALYs. Risks quantified account for 87.9% (86.5-89.3) of cardiovascular disease DALYs, ranging to a low of 0% for neonatal disorders and neglected tropical diseases and malaria. In terms of global DALYs in 2013, six risks or clusters of risks each caused more than 5% of DALYs: dietary risks accounting for 11.3 million deaths and 241.4 million DALYs, high systolic blood pressure for 10.4 million deaths and 208.1 million DALYs, child and maternal malnutrition for 1.7 million deaths and 176.9 million DALYs, tobacco smoke for 6.1 million deaths and 143.5 million DALYs, air pollution for 5.5 million deaths and 141.5 million DALYs, and high BMI for 4.4 million deaths and 134.0 million DALYs. Risk factor patterns vary across regions and countries and with time. In sub-Saharan Africa, the leading risk factors are child and maternal malnutrition, unsafe sex, and unsafe water, sanitation, and handwashing. In women, in nearly all countries in the Americas, north Africa, and the Middle East, and in many other high-income countries, high BMI is the leading risk factor, with high systolic blood pressure as the leading risk in most of Central and Eastern Europe and south and east Asia. For men, high systolic blood pressure or tobacco use are the leading risks in nearly all high-income countries, in north Africa and the Middle East, Europe, and Asia. For men and women, unsafe sex is the leading risk in a corridor from Kenya to South Africa. Interpretation Behavioural, environmental and occupational, and metabolic risks can explain half of global mortality and more than one-third of global DALYs providing many opportunities for prevention. Of the larger risks, the attributable burden of high BMI has increased in the past 23 years. In view of the prominence of behavioural risk factors, behavioural and social science research on interventions for these risks should be strengthened. Many prevention and primary care policy options are available now to act on key risks. C1 [Forouzanfar, Mohammad H.; Alexander, Lily; Bachman, Victoria F.; Biryukov, Stan; Brauer, Michael; Casey, Daniel; Coates, Matthew M.; Cohen, Aaron; Delwiche, Kristen; Estep, Kara; Frostad, Joseph J.; Kyu, Hmwe H.; Moradi-Lakeh, Maziar; Ng, Marie; Slepak, Erica Leigh; Thomas, Bernadette A.; Wagner, Joseph; Achoki, Tom; Atkinson, Charles; Barber, Ryan M.; Cooperrider, Kimberly; Dandona, Lalit; Dicker, Daniel; Flaxman, Abraham D.; Fleming, Thomas D.; Foreman, Kyle J.; Gakidou, Emmanuela; Hay, Simon I.; Heuton, Kyle R.; Iannarone, Marissa L.; Ku, Tiffany; Larson, Heidi J.; Lim, Stephen S.; Lozano, Rafael; MacIntyre, Michael F.; Margono, Christopher; McLain, Abigail; Mokdad, Ali H.; Mullany, Erin C.; Naghavi, Mohsen; Nguyen, Grant; Pain, Amanda W.; Richardson, Lee; Robinson, Margaret; Sandar, Logan; Stephens, Natalie; Thomson, Blake; Wan, Xia; Wurtz, Brittany; Lopez, Alan D.; Vos, Theo; Murray, Christopher J.] Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Ebel, Beth E.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA. [Ellenbogen, Richard G.] Univ Washington, Harborview UW Med, Seattle, WA 98195 USA. [Wright, Jonathan L.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Alfonso-Cristancho, Rafael; Anderson, Benjamin O.; Jensen, Paul N.; Quistberg, D. Alex A.; Riederer, Anne; Vavilala, Monica S.; Zunt, Joseph R.] Univ Washington, Seattle, WA 98195 USA. [Anderson, H. Ross] Univ London, St Georges, London, England. [Pourmalek, Farshad] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada. [Brauer, Michael; Gotay, Carolyn C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Burnett, Richard; Shin, Hwashin H.; Weichenthal, Scott] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Cohen, Aaron] Hlth Effects Inst, Boston, MA USA. [Moradi-Lakeh, Maziar] Iran Univ Med Sci, Dept Community Med, Tehran, Iran. [Knudsen, Ann Kristin] Norwegian Inst Publ Hlth, Dept Hlth Registries, Oslo, Norway. [Aasvang, Gunn Marit; Kinge, Jonas M.; Skirbekk, Vegard; Vollset, Stein Emil] Norwegian Inst Publ Hlth, Oslo, Norway. [Abbafati, Cristiana] Univ Roma La Sapienza, I-00185 Rome, Italy. [Ozgoren, Ayse Abbasoglu; Cavlin, Alanur] Hacettepe Univ, Inst Populat Studies, Ankara, Turkey. [Bicer, Burcu Kucuk] Hacettepe Univ, Inst Publ Hlth, Ankara, Turkey. [Abd-Allah, Foad] Cairo Univ, Fac Med, Cairo, Egypt. [Abera, Semaw F.] Mekelle Univ, Sch Publ Hlth, Coll Hlth Sci, Mekelle, Ethiopia. [Melaku, Yohannes A.] Mekelle Univ, Mekelle, Ethiopia. [Abera, Semaw F.] Kilte Awlaelo Hlth & Demog Surveillance Site, Mekelle, Ethiopia. [Aboyans, Victor] Dupuytren Univ Hosp, Limoges, France. [Abraham, Biju] Govt Coll Munnar, Munnar, India. [Abraham, Jerry Puthenpurakal] Univ So Calif, Calif Hosp, Family Med Residency Program, Los Angeles, CA USA. [Abraham, Jerry Puthenpurakal] Harvard Univ, Inst Global Hlth, Boston, MA 02115 USA. [Thorne-Lyman, Andrew L.] Harvard Univ, Dept Nutr, Boston, MA 02115 USA. [Ding, Eric L.; Fahimi, Saman; Khatibzadeh, Shahab; Wagner, Gregory R.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Bukhman, Gene] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA. [Campos-Nonato, Ismael R.; Feigl, Andrea B.; Salomon, Joshua A.] Harvard Univ, Boston, MA 02115 USA. [Benzian, Habib] UCL, Dept Epidemiol & Publ Hlth, London, England. [Abubakar, Ibrahim] UCL, London, England. [Abu-Rmeileh, Niveen M. E.] Birzeit Univ, Inst Community & Publ Hlth, Ramallah, Pakistan. [Aburto, Tania C.; Avila, Marco A.; Barquera, Simon; Barrientos-Gutierrez, Tonatiuh; Campos-Nonato, Ismael R.; Campuzano, Julio C.; Cantoral, Alejandra J.; Contreras, Alejandra G.; Cuevas-Nasu, Lucia; De la Cruz-Gongora, Vanessa; Garcia-Guerra, Francisco A.; Dantes, Hector Gomez; de Cosio, Teresita Gonzalez; Gonzalez-Castell, Dinorah; Heredia-Pi, Ileana B.; Hernandez, Lucia; Jauregui, Alejandra; Lozano, Rafael; Medina, Catalina; Mejia-Rodriguez, Fabiola; Hernandez, Julio C. Montaez; Pedraza, Lilia S.; Pedroza, Andrea; Quezada, Amado D.; Salvo, Deborah; Sanchez, Luz Maria; Sanchez-Pimienta, Tania G.; Servan-Mori, Edson E.; Levy, Teresa Shamah; Rojo, Martha M. Tellez; Villalpando, Salvador] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. [Adelekan, Ademola] Publ Hlth Promot Alliance, Osogbo, Nigeria. [Adofo, Koranteng] Kwame Nkrumah Univ Sci, Kumasi, Ghana. [Adou, Arsene K.] Assoc Ivoirienne Bien Etre Familial, Abidjan, Cote Ivoire. [Adsuar, Jose C.; Paleo, Urbano Fra] Univ Extremadura, Caceres, Spain. [Afshin, Ashkan; Micha, Renata; Arian, Dariush Mozaff] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA USA. [Shahraz, Saeid; Shangguan, Siyi] Tufts Univ, Tufts Med Ctr, Boston, MA USA. [Agardh, Emilie E.] Inst Publ Hlth Sci, Stockholm, Sweden. [Al Khabouri, Mazin J.] Minist Hlth, Muscat, Oman. [Al Lami, Faris H.] Baghdad Coll Med, Baghdad, Iraq. [Alam, Sayed Saidul; Naheed, Aliya] icddr b, Dhaka, Bangladesh. [Alasfoor, Deena] Minist Hlth, Al Khuwair, Oman. [Albittar, Mohammed I.] Independent, Damascus, Syria. [Alegretti, Miguel A.] Univ Republica, Dept Prevent & Social Med, Montevideo, Uruguay. [Cavalleri, Fiorella] Univ Republica, Fac Med, Montevideo, Uruguay. [Alemu, Zewdie A.] Debre Markos Univ, Addis Ababa, Ethiopia. [Alhabib, Samia] King Abdullah Bin Abdulaziz Univ Hosp, Riyadh, Saudi Arabia. [Chen, Zhengming] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England. [Gething, Pete] Univ Oxford, Dept Zool, Oxford, England. [Ali, Raghib; Bennett, Derrick A.; Briggs, Adam D. M.; Hay, Simon I.; Rahimi, Kazem; Scarborough, Peter] Univ Oxford, Oxford, England. [Singh, Gitanjali M.] Tufts Univ, Boston, MA USA. [Aleman, Alicia V.; Colistro, Valentina] Univ Republica, Montevideo, Uruguay. [Simard, Edgar P.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA USA. [Ali, Mohammed K.; Cunningham, Solveig Argeseanu; Liu, Yang; Narayan, K. M. Venkat; Omer, Saad B.] Emory Univ, Atlanta, GA USA. [Alla, Francois; Guillemin, Francis] Univ Lorraine, Nancy, France. [Allebeck, Peter; Roy, Nobhojit] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Kivipelto, Miia] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden. [Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Fereshtehnejad, Seyed-Mohammad] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden. [Havmoeller, Rasmus; Sindi, Shireen] Karolinska Inst, Stockholm, Sweden. [Allen, Peter J.] Minist Hlth, Belmopan, Belize. [Alsharif, Ubai; Endres, Matthias; Nolte, Sandra; Papachristou, Christina] Charite, Berlin, Germany. [Alvarez, Elena] Govt, Madrid, Spain. [Alvis-Guzman, Nelson; Caicedo, Angel J. Paternina] Univ Cartagena, Cartagena De Indias, Colombia. [Amankwaa, Adansi A.] Albany State Univ, Albany, GA 31705 USA. [Amare, Azmeraw T.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Hoek, Hans W.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands. [Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Amare, Azmeraw T.] Bahir Dar Univ, Coll Med & Hlth Sci, Bahir Dar, Ethiopia. [Yenesew, Muluken] Bahir Dar Univ, Bahir Dar, Ethiopia. [Ameh, Emmanuel A.] Ahmadu Bello Univ, Zaria, Nigeria. [Ameli, Omid] Boston Univ, Boston, MA USA. [Amini, Heresh] Kurdistan Univ Med Sci, Kurdistan Environm Hlth Res Ctr, Sanandaj, Iran. [Amini, Heresh] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland. [Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Amini, Heresh] Univ Basel, Basel, Switzerland. [Ammar, Walid; Harb, Hilda L.] Minist Publ Hlth, Beirut, Lebanon. [Faraon, Emerito Jose A.] Univ Philippines Manila, Coll Publ Hlth, Manila, Philippines. [Antonio, Carl Abelardo T.] Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, Philippines. [Panelo, Carlo Irwin A.] Univ Philippines Manila, Manila, Philippines. [Arnlov, Johan] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Larsson, Anders] Uppsala Univ, Uppsala, Sweden. [Arnlov, Johan] Dalarna Univ, Falun, Sweden. [Arsenijevic, Valentina S. Arsic] Univ Belgrade, Inst Microbiol & Immunol, Sch Med, Belgrade, Serbia. [Arsenijevic, Valentina S. Arsic] Univ Childrens Hosp Belgrade, Belgrade, Serbia. [Asghar, Rana J.] South Asian Publ Hlth Forum, Islamabad, Pakistan. [Assadi, Reza] Mashhad Univ Med Sci, Mashhad, Iran. [Atkins, Lydia S.] Minist Hlth, Wellness Human Serv & Gender Relat, St Lucia, Qld, Australia. [Awuah, Baffour; Laryea, Dennis O.] Komfo Anokye Teaching Hosp, Kumasi, Ghana. [Badawi, Alaa] Publ Hlth Agcy Canada, Toronto, ON, Canada. [Bahit, Maria C.] INECO Neurociencias, Rosario, Argentina. [Bakfalouni, Talal] Minist Hlth, Damascus, Syria. [Balakrishnan, Kalpana] Sri Ramachandra Univ, Madras, Tamil Nadu, India. [Balalla, Shivanthi; Feigin, Valery L.] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand. [Ao, Braden J. Te] Auckland Univ Technol, Auckland, New Zealand. [Balu, Ravi Kumar; Dandona, Lalit; Dandona, Rakhi; Goenka, Shifalika; Kumar, G. Anil; Murthy, Kinnari S.; Reddy, K. Srinath] Publ Hlth Fdn India, Delhi, India. [Banerjee, Amitava] Univ Birmingham, Birmingham, W Midlands, England. [Barker-Collo, Suzanne L.] Univ Auckland, Sch Psychol, Auckland, New Zealand. [del Pozo-Cruz, Borja] Univ Auckland, Auckland, New Zealand. [Barregard, Lars] Univ Gothenburg, Dept Occupat & Environm Hlth, Gothenburg, Sweden. [Barrero, Lope H.] Pontificia Univ Javeriana, Dept Ind Engn, Bogota, Colombia. [Basto-Abreu, Ana C.; Ruvalcaba, Carolina Batis; de Castro, E. Filipa; Lopez, Nancy; Texcalac-Sangrador, Jose Luis] Natl Inst Publ Hlth, Mexico City, DF, Mexico. [Basu, Arindam] Univ Canterbury, Sch Hlth Sci, Christchurch, New Zealand. [Gaffikin, Lynne] Stanford Univ, Sch Med, Stanford, CA USA. [Basu, Sanjay] Stanford Univ, Stanford, CA 94305 USA. [Basulaiman, Mohammed O.; Memish, Ziad A.] Minist Hlth, Riyadh, Saudi Arabia. [Beardsley, Justin] Univ Oxford, Ho Hi Minh City, Vietnam. [Bedi, Neeraj] Coll Publ Hlth & Trop Med, Jazan, Saudi Arabia. [Bekele, Tolesa] Madawalabu Univ, Bale Robe, Ethiopia. [Bell, Michelle L.] Yale Univ, New Haven, CT USA. [Benjet, Corina; Borges, Guilherme; Gutierrez, Reyna A.; Orozco, Ricardo] Natl Inst Psychiat Ramon Fuente Muniz, Mexico City, DF, Mexico. [Benzian, Habib] NYU, Coll Dent, Dept Epidemiol & Hlth Promot, New York, NY 10003 USA. [Trasande, Leonardo] NYU, Sch Med, New York, NY USA. [Hagan, Holly] NYU, New York, NY 10003 USA. [Bernabe, Eduardo; Wolfe, Charles D. A.] Kings Coll London, London, England. [Beyene, Tariku J.] Addis Ababa Univ, Debre Zeyit, Ethiopia. [Bhala, Neeraj] Queen Elizabeth Hosp, Birmingham, W Midlands, England. [Bhala, Neeraj] Univ Otago, Capital & Coast District Hlth Board, Wellington, New Zealand. [Derrett, Sarah] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Wellington, New Zealand. [Bhalla, Ashish; Jha, Vivekanand] Postgrad Inst Med Educ & Res, Chandigarh, India. [Bhutta, Zulfi Qar A.] Aga Khan Univ, Med Ctr, Karachi, Pakistan. [Nisar, Muhammad I.] Aga Khan Univ, Karachi, Pakistan. [Bikbov, Boris] AI Evdokimov Moscow State Univ Med & Dent, Moscow, Russia. [Bikbov, Boris] Acad VI Shumakov Fed Res Ctr Transplantol & Artif, Moscow, Russia. [Bin Abdulhak, Aref A.] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. [Vijayakumar, Lakshmi] Univ Melbourne, Ctr Youth Mental Hlth, Melbourne, Vic, Australia. [Chiang, Peggy P.] Univ Melbourne, Gen Practice & Primary Hlth Care Acad Ctr, Melbourne, Vic, Australia. [Blore, Jed D.; Brooks, Peter M.; Colquhoun, Samantha M.; Balaji, Arjun Lakshmana; Weintraub, Robert G.; Lopez, Alan D.] Univ Melbourne, Melbourne, Vic, Australia. [Blyth, Fiona M.] Univ Sydney, Concord, NSW, Australia. [Meretoja, Atte] Univ Melbourne, Dept Florey, Parkville, Vic, Australia. [Meretoja, Atte] Univ Melbourne, Dept Med, Parkville, Vic, Australia. [Bohensky, Megan A.] Univ Melbourne, Parkville, Vic, Australia. [Basara, Berrak Bora; Yentuer, Goekalp K.] Minist Hlth, Gen Directorate Hlth Res, Ankara, Turkey. [Kose, M. Rifat; Pekericli, Ayfer; Uzun, Selen B.] Minist Hlth, Ankara, Turkey. [Bornstein, Natan M.] Tel Aviv Saurasky Med Ctr, Tel Aviv, Israel. [Bose, Dipan] World Bank, Washington, DC USA. [Boufous, Soufiane] Univ New S Wales, Transport & Rd Safety, Sydney, NSW, Australia. [Degenhardt, Louisa] Univ New S Wales, Sydney, NSW, Australia. [Bourne, Rupert R.] Anglia Ruskin Univ, Cambridge, England. [Brainin, Michael] Danube Univ Krems, Krems, Austria. [Brazinova, Alexandra; Majdan, Marek] Trnava Univ, Fac Hlth Sci & Social Work, Trnava, Slovakia. [Breitborde, Nicholas J.] Ohio State Univ, Columbus, OH USA. [Breitborde, Nicholas J.] Univ Arizona, Tucson, AZ USA. [Schoettker, Ben] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Brenner, Hermann] German Canc Res Ctr, Heidelberg, Germany. [Broday, David M.] Technion, Haifa, Israel. [Lunevicius, Raimundas] Univ Liverpool, Sch Med, Liverpool, Merseyside, England. [Bruce, Nigel G.; Dherani, Mukesh K.; Pope, Daniel] Univ Liverpool, Liverpool, Merseyside, England. [Brugha, Traolach S.] Univ Leicester, Leicester, Leics, England. [Brunekreef, Bert; Kromhout, Hans] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands. [Buchbinder, Rachelle] Cabrini Inst, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia. [Buchbinder, Rachelle] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia. [Gabbe, Belinda; Gibney, Katherine B.; Thrift, Amanda G.] Monash Univ, Melbourne, Vic, Australia. [Bui, Linh N.; Nguyen, Nhung T.] Hanoi Sch Publ Hlth, Hanoi, Vietnam. [Bulloch, Andrew G.; Patten, Scott B.; Tonelli, Marcello; Wang, JianLi] Univ Calgary, Calgary, AB, Canada. [Burch, Michael] Great Ormond St Hosp Sick Children, London, England. [Burney, Peter G. J.; Foreman, Kyle J.; Jarvis, Deborah L.; Rodriguez, Alina; Rushton, Lesley; Soljak, Michael; Williams, Thomas N.] Univ London Imperial Coll Sci Technol & Med, London, England. [Caravanos, Jack; Nash, Denis] CUNY, Sch Publ Hlth, New York, NY USA. [Cardenas, Rosario] Univ Autonoma Metropolitana, Mexico City, DF, Mexico. [Cardis, Elisabeth; Nieuwenhuijsen, Mark J.; Rojas-Rueda, David] Ctr Res Environm Epidemiol, Barcelona, Spain. [Carpenter, David O.; Leung, Ricky] SUNY Albany, Rensselaer, NY USA. [Caso, Valeria] Univ Perugia, Stroke Unit, Perugia, Italy. [Castaneda-Orjuela, Carlos A.] Colombian Natl Hlth Observ, Inst Nacl Salud, Bogota, Colombia. [Castaneda-Orjuela, Carlos A.] Univ Nacl Colombia, Dept Publ Hlth, Epidemiol & Publ Hlth Evaluat Grp, Bogota, Colombia. [Castro, Ruben E.] Univ Diego Portales, Santiago, Chile. [Catala-Lopez, Ferran] Spanish Med & Healthcare Prod Agcy, Minist Hlth, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain. [Catala-Lopez, Ferran] Univ Valencia, Dept Med, CIBERSAM, Valencia, Spain. [Chadha, Vineet K.] Natl TB Inst, Bangalore, Karnataka, India. [Chang, Jung-chen] Natl Taiwan Univ, Taipei, Taiwan. [Scott, James G.] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia. [Hoy, Damian G.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia. [Knibbs, Luke D.] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia. [Charlson, Fiona J.; Erskine, Holly E.; Ferrari, Alize J.; Gouda, Hebe N.; Veerman, Lennert J.; Whiteford, Harvey A.] Univ Queensland, Brisbane, Qld, Australia. [Chen, Wanqing; Zou, Xiaonong] Chinese Acad Med Sci, Canc Inst, Beijing, Peoples R China. [Wan, Xia] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing, Peoples R China. [Chen, Honglei; London, Stephanie J.] NIEHS, Div Intramural Res, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC USA. [Jiang, Ying] Univ Occupat & Environm Hlth, Dept Hlth Dev, Kitakyushu, Fukuoka 807, Japan. [Takahashi, Ken] Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Kitakyushu, Fukuoka 807, Japan. [Chimed-Ochir, Odgerel] Univ Occupat & Environm Hlth, Dept Environm Epidemiol, Kitakyushu, Fukuoka 807, Japan. [Chowdhury, Rajiv; Powles, John] Univ Cambridge, Cambridge, England. [Christophi, Costas A.] Cyprus Univ Technol, Limassol, Cyprus. [Chuang, Ting-Wu] Taipei Med Univ, Taipei, Taiwan. [Chugh, Sumeet S.] Cedars Sinai Med Ctr, Los Angeles, CA USA. [Cirillo, Massimo] Univ Salerno, Baronissi, Italy. [Classen, Thomas K. D.] Univ Bielefeld, Dept Environm & Hlth, Bielefeld, Germany. [Kraemer, Alexander; Tobollik, Myriam] Univ Bielefeld, Sch Publ Hlth, Bielefeld, Germany. [Colomar, Mercedes] UNICEM, Montevideo, Uruguay. [Colquhoun, Samantha M.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Cooper, Cyrus] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England. [Cooper, Leslie T.] Mayo Clin, Rochester, MN USA. [Coresh, Josef; Matsushita, Kunihiro] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. [Tran, Bach X.] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Courville, Karen J.] Hosp Dr Gustavo N Collado, Chitre, Panama. [Criqui, Michael H.; Stein, Murray B.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Damsere-Derry, James] Bldg & Rd Res Inst, Kumasi, Ghana. [Danawi, Hadi; Refaat, Amany H.] Walden Univ, Minneapolis, MN USA. [Dargan, Paul I.] Guys & St Thomas NHS Fdn Trust, London, England. [Davis, Adrian; Fay, Derek F. J.; Schmidt, Juergen C.] Publ Hlth England, London, England. [Davitoiu, Dragos V.] Univ Med & Pharm Bucharest, Bucharest, Romania. [Dayama, Anand] Jacobi Med Ctr, Dept Surg, Atlanta, GA USA. [De Leo, Diego] Griffith Univ, Brisbane, Qld, Australia. [de Lima, Graca] Local Hlth Unit Matosinhos, Matosinhos, Portugal. [de Lima, Graca; Machado, Vasco M. P.] Northern Reg Hlth Adm, Dept Publ Hlth, Oporto, Portugal. [Nogueira, Jose R.; Teixeira, Carolina M.] Northern Reg Hlth Adm, Oporto, Portugal. [Dellavalle, Robert P.] Eastern Colorado Healthcare Syst, US Dept Vet Affairs, Denver, CO USA. [Deribe, Kebede] Brighton & Sussex Med Sch, Brighton, E Sussex, England. [Deribe, Kebede] Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, Ethiopia. [Mekonnen, Wubegzier] Univ Addis Ababa, Addis Ababa, Ethiopia. [Derrett, Sarah] Massey Univ, Coll Hlth, Sch Publ Hlth, Palmerston North, New Zealand. [Jarlais, Don C. Des] Mt Sinai Beth Israel, New York, NY USA. [Jarlais, Don C. Des] Icahn Sch Med Mt Sinai, New York, NY USA. [Dessalegn, Muluken] Africa Med & Res Fdn Ethiopia, Addis Ababa, Ethiopia. [deVeber, Gabrielle A.] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada. [Lindsay, M. Patrice] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Hu, Howard] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Devries, Karen M.; Larson, Heidi J.; Mckee, Martin; Pearce, Neil; Stoeckl, Heidi; Tillmann, Taavi; Watts, Charlotte H.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England. [Dharmaratne, Samath D.] Univ Peradeniya, Peradeniya, Sri Lanka. [Dokova, Klara] Med Univ Varna, Fac Publ Hlth, Dept Social Med, Varna, Bulgaria. [Dorsey, E. Ray] Univ Rochester, Med Ctr, Rochester, NY USA. [Driscoll, Tim R.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia. [Marks, Guy B.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia. [Leigh, James] Univ Sydney, Sydney, NSW 2006, Australia. [Duan, Leilei; Li, Yichong; Liu, Shiwei; Ma, Jixiang; Wang, Linhong; Ye, Pengpeng; Zhou, Maigeng] Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China. [Durrani, Adnan M.] Natl Inst Hlth, Montgomery Village, MD USA. [Elshrek, Yousef M.] Univ Tripoli, Fac Agr, Dept Food Sci, Tripoli, Libya. [Ermakov, Sergey P.] Russian Acad Sci, Inst Social & Econ Studies Populat, Moscow, Russia. [Ermakov, Sergey P.; Soshnikov, Sergey] Minist Hlth Russian Federat, Fed Res Inst Hlth Org & Informat, Moscow, Russia. [Liang, Xiaofeng] China CDC, Beijing, Peoples R China. [Eshrati, Babak] Arak Univ Med Sci & Hlth Affairs, Arak, Iran. [Farzadfar, Farshad] Univ Tehran Med Sci, NonCommunicable Dis Res Ctr, Tehran, Iran. [Heydarpour, Pouria; Sahraian, Mohammad Ali] Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Neurosci Inst, Tehran, Iran. [Sepanlou, Sadaf G.] Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran. [Rahimi-Movaghar, Vafa] Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, Iran. [Ferri, Cleusa P.] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Foigt, Nataliya] Acad Med Sci, Inst Gerontol, Kiev, Ukraine. [Franklin, Richard C.] James Cook Univ, Townsville, Qld, Australia. [Gamkrelidze, Amiran; Khonelidze, Irma; Sturua, Lela] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia. [Gankpe, Fortune G.] Leras Afrique, Cotonou, Benin. [Gankpe, Fortune G.] CHU Hassan II, Fes, Morocco. [Gasana, Evariste] Rwanda Biomed Ctr, TB & Other Respir Dis Div, Kigali, Rwanda. [Sabin, Nsanzimana] Rwanda Biomed Ctr, Kigali, Rwanda. [Geleijnse, Johanna M.] Wageningen Univ, Div Human Nutr, Wageningen, Netherlands. [Gessner, Bradford D.] Agence Med Prevent, Paris, France. [Gibney, Katherine B.] Melbourne Hlth, Parkville, Vic, Australia. [Gillum, Richard F.] Howard Univ, Washington, DC USA. [Ginawi, Ibrahim A. M.] Univ Hail, Coll Med, Hailsham, E Sussex, England. [Giroud, Maurice] Univ Hosp Dijon, Dijon, France. [Giussani, Giorgia] IRCCS Mario Negri Inst Pharmacol Res, Milan, Italy. [Goginashvili, Ketevan] Minist Labour Hlth & Social Affairs, Tbilisi, Rep of Georgia. [Esteghamati, Alireza; Hafezi-Nejad, Nima; Sheikhbahaei, Sara] Univ Tehran Med Sci, Endocrinol & Metab Res Inst, Tehran, Iran. [Gona, Philimon] Univ Massachusetts Boston, Boston, MA USA. [Goto, Atsushi] Tokyo Womens Med Univ, Dept Publ Hlth, Tokyo, Japan. [Guerrant, Richard L.] Univ Virginia, Sch Med, Charlottesville, VA USA. [Terkawi, Abdullah S.] Univ Virginia, Dept Anesthesiol, Charlottesville, VA USA. [Gugnani, Harish C.] St James Sch Med, Kralendijk, Netherlands. [Gunnell, David] Univ Bristol, Bristol, Avon, England. [Gupta, Rahul] West Virginia Bur Publ Hlth, Charleston, WV USA. [Gupta, Rajeev] Fortis Escorts Hosp, Jaipur, Rajasthan, India. [Hagstromer, Maria] Karolinska Inst, Huddinge, Sweden. [Halasa, Yara A.; Idrisov, Bulat T.] Brandeis Univ, Waltham, MA USA. [Hamadeh, Randah R.] Arabian Gulf Univ, Manama, Bahrain. [Hammami, Mouhanad] Wayne Cty Dept Hlth & Human Serv, Detroit, MI USA. [Hankey, Graeme J.] Univ Western Australia, Perth, WA, Australia. [Hao, Yuantao] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China. [Zheng, Yingfeng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China. [Haregu, Tilahun Nigatu; van de Vijver, Steven] African Populat & Hlth Res Ctr, Nairobi, Kenya. [Haro, Josep Maria] CIBERSAM, Parc Sanitari St Joan de Deu, Sant Boi De Llobregat, Spain. [Haro, Josep Maria] Univ Barcelona, Barcelona, Spain. [Hedayati, Mohammad T.] Mazandaran Univ Med Sci, Sari, Mazandaran, Iran. [Hijar, Martha] Fdn Entornos AC, Cuernavaca, Morelos, Mexico. [Hoek, Hans W.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Man, Howard J. Hoff] Natl Inst Deafness & Other Commun Disorders, Epidemiol & Stat Program, NIH, Bethesda, MD USA. [Mensah, George A.] NIH, Ctr Translat Res & Implementat Sci, Bethesda, MD USA. [Sampson, Uchechukwu K.] NIH, NHLBI, Bethesda, MD USA. [Hornberger, John C.] Cedar Associates, Menlo Pk, CA USA. [Hosgood, H. Dean] Albert Einstein Coll Med, Bronx, NY USA. [Hsairi, Mohamed] Natl Inst Publ Hlth, Tunis, Tunisia. [Hoy, Damian G.] Secretariat Pacific Community, Publ Hlth Div, Noumea, New Caledonia. [Hu, Guoqing] Cent S Univ, Changsha, Peoples R China. [Huang, Cheng] George Washington Univ, Washington, DC USA. [Hubbell, Bryan J.] US EPA, Res Triangle Pk, NC USA. [Huiart, Laetitia; Racape, Lionel] CHU La Reunion, Saint Denis, France. [Husseini, Abdullatif] Qatar Univ, Doha, Qatar. [Iburg, Kim M.] Aarhus Univ, Aarhus, Denmark. [Ikeda, Nayu] Natl Inst Hlth Nutr, Tokyo, Japan. [Innos, Kaire] Natl Inst Hlth Dev, Tallinn, Estonia. [Inoue, Manami] Univ Tokyo, Grad Sch Med, Tokyo, Japan. [Kawakami, Norito] Univ Tokyo, Sch Publ Hlth, Tokyo, Japan. [Shibuya, Kenji] Univ Tokyo, Tokyo, Japan. [Islami, Farhad] Amer Canc Soc, New York, NY USA. [Jacobsen, Kathryn H.] George Mason Univ, Fairfax, VA USA. [Jansen, Henrica A.] UNFPA Asia & Pacific Reg Off, Bangkok, Thailand. [Jassal, Simerjot K.] Univ Calif San Diego, San Diego, CA USA. [Jayaraman, Sudha] Virginia Commonwealth Univ, Richmond, VA USA. [Jeemon, Panniyammakal; Prabhakaran, Dorairaj] Ctr Chron Dis Control, New Delhi, India. [Jiang, Fan] Shanghai Childrens Med Ctr, Tianjin, Peoples R China. [Jiang, Guohong] Tianjin Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Phillips, Michael R.] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China. [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany. [Juel, Knud] Natl Inst Publ Hlth, Copenhagen, Denmark. [She, Jun] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China. [Kan, Haidong] Fudan Univ, Shanghai, Peoples R China. [Roseline, Sidibe S. Kany] MARIKANI, Bamako, Mali. [Karam, Nadim E.] Univ Balamand, Beirut, Lebanon. [Karch, Andre] Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, Germany. [Karch, Andre] German Ctr Infect Res, Hannover Braunschweig Site, Braunschweig, Germany. [Karema, Corine K.] Minist Hlth, Malaria & Other Parasit Dis Div, Kigali City, Rwanda. [Karthikeyan, Ganesan; Paul, Vinod K.; Satpathy, Maheswar; Tandon, Nikhil] All India Inst Med Sci, New Delhi, India. [Kaul, Anil] Oklahoma State Univ, Tulsa, OK USA. [Kazi, Dhruv S.] Univ Calif San Francisco, San Francisco, CA USA. [Kemp, Andrew H.; Lotufo, Paulo A.; Polanczyk, Guilherme V.; Santos, Itamar S.] Univ Sao Paulo, Sao Paulo, Brazil. [Kemp, Andrew H.] Univ Sydney, Camperdown, NSW, Australia. [Kengne, Andre P.; Matzopoulos, Richard; Parry, Charles D.] South African Med Res Council, Cape Town, South Africa. [Sliwa, Karen] Univ Cape Town, Fac Hlth Sci, Hatter Inst Cardiovasc Res Africa, Cape Town, South Africa. [Matzopoulos, Richard] Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South Africa. [Kengne, Andre P.; Mayosi, Bongani M.; Stein, Dan J.] Univ Cape Town, Cape Town, South Africa. [Keren, Andre] Hadassah Kerem Univ Hosp, Cardiol, Jerusalem, Israel. [Khader, Yousef S.] Jordan Univ Sci & Technol, Irbid, Jordan. [Khalifa, Shams Eldin Ali Hassan] Supreme Council Hlth, Doha, Qatar. [Khan, Ejaz A.] Hlth Serv Acad, Islamabad, Pakistan. [Khan, Ejaz A.] Expanded Programme Immunizat, Islamabad, Pakistan. [Khang, Young-Ho] Seoul Natl Univ, Coll Med, Seoul, South Korea. [Kieling, Christian] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil. [Kim, Daniel] Northeastern Univ, Boston, MA USA. [Kim, Sungroul] Soonchunhyang Univ, Seoul, South Korea. [Kim, Yunjin] Southern Univ Coll, Johor Baharu, Malaysia. [Kimokoti, Ruth W.] Simmons Coll, Boston, MA USA. [Kinfu, Yohannes] Univ Canberra, Canberra, ACT, Australia. [Kissela, Brett M.] Univ Cincinnati, Cincinnati, OH USA. [Kokubo, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Suita, Osaka, Japan. [Kosen, Soewarta] Minist Hlth Indonesia, NIHRD, Ctr Community Empowerment Hlth Policy & Human, Jakarta, Indonesia. [Warouw, Tati S.] Minist Hlth Indonesia, NIHRD, Jakarta, Indonesia. [Kravchenko, Michael] Res Ctr Neurol, Moscow, Russia. [Krishnaswami, Sanjay] Oregon Hlth & Sci Univ, Portland, OR USA. [Defo, Barthelemy Kuate] Univ Montreal, Montreal, PQ, Canada. [Kuipers, Ernst J.] Univ Med Ctr, Erasmus MC, Rotterdam, Netherlands. [Kulkarni, Chanda] Rajrajeswari Med Coll & Hosp, Bangalore, Karnataka, India. [Kulkarni, Veena S.] Arkansas State Univ, State Univ, AR USA. [Kwan, Gene F.] Boston Med Ctr, Boston, MA USA. [Lai, Taavi] Fourth View Consulting, Tallinn, Estonia. [Lalloo, Ratilal] Griffith Univ, Sch Dent & Oral Hlth, Gold Coast, Qld, Australia. [Lalloo, Ratilal] Univ Adelaide, Sch Dent, Australian Res Ctr Populat Oral Hlth, Adelaide, SA, Australia. [Lallukka, Tea] Finnish Inst Occupat Hlth, Disabil Prevent Res Ctr, Helsinki, Finland. [Shiri, Rahman] Finnish Inst Occupat Hlth, Helsinki, Finland. [Lallukka, Tea] Univ Helsinki, Fac Med, Helsinki, Finland. [Lam, Hilton] NIH, Inst Hlth Policy & Dev Studies, Manila, Philippines. [Lan, Qing] NCI, Rockville, MD USA. [Lansingh, Van C.] Help Me See Inc, New York, NY USA. [Lansingh, Van C.] Inst Mexicano Oftalmol, Queretaro, Mexico. [Lavados, Pablo M.] Univ Desarrollo, Serv Neurol, Clin Alemana, Santiago, Chile. [Lawrynowicz, Alicia E.] Inst Nacl Epidemiol Dr Juan H Jara, Mar Del Plata, Buenos Aires, Argentina. [Leasher, Janet L.] Nova SE Univ, Coll Optometry, Ft Lauderdale, FL USA. [Lee, Jong-Tae; Yoon, Seok-Jun] Korea Univ, Seoul, South Korea. [Levi, Miriam] Tuscany Reg Ctr Occupat Injuries & Dis, Florence, Italy. [Li, Yichong] Anolinx LLC, Salt Lake City, UT USA. [Liang, Juan; Wang, Yanping; Zhu, Jun] Sichuan Univ, West China Univ Hosp 2, Natl Off Maternal & Child Hlth Surveillance, Chengdu, Peoples R China. [Lindsay, M. Patrice] Heart & Stroke Fdn Canada, Ottawa, ON, Canada. [Lipshultz, Steven E.] Wayne State Univ, Detroit, MI USA. [Lloyd, Belinda K.] Monash Univ, Eastern Hlth Clin Sch, Fitzroy, Vic, Australia. [Lloyd, Belinda K.; Room, Robin] Eastern Hlth, Turning Point Alcohol & Drug Ctr, Fitzroy, Vic, Australia. [Logroscino, Giancarlo] Univ Bari, Bari, Italy. [Lortet-Tieulent, Joannie] Amer Canc Soc, Atlanta, GA USA. [Lunevicius, Raimundas] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England. [Ma, Stefan; Phua, Hwee Pin] Minist Hlth Singapore, Singapore, Singapore. [Ma, Stefan] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore. [Magis-Rodriguez, Carlos] Secretaria Salud Mexico, Ctr Nacl Prevenc & Control VIH SIDA, Mexico City, DF, Mexico. [Mahdi, Abbas A.] King Georges Med Univ, Lucknow, Uttar Pradesh, India. [Malekzadeh, Reza] Shariati Hosp, Digest Dis Reseach Inst, Tehran, Iran. [Malekzadeh, Reza] Shiraz Univ Med Sci, Shiraz, Iran. [Mangalam, Srikanth] Tech Stand & Safety Author, Toronto, ON, Canada. [Masiye, Felix] Univ Zambia, Lusaka, Zambia. [Marape, Marape] Botswana Baylor Childrens Clin Ctr Excellence, Gaborone, Botswana. [Marcenes, Wagner] Queen Mary Univ London, London, England. [Meaney, Peter A.] Univ Penn, Pereleman Sch Med, Philadelphia, PA USA. [Martin, Randall V.] Dalhousie Univ, Halifax, NS, Canada. [Marzan, Melvin B.] Univ East Ramon Magsaysay Memorial, Med Ctr, Quezon City, Philippines. [Mashal, Mohammad T.] Minist Publ Hlth, Kabul, Afghanistan. [Mason-Jones, Amanda J.] Univ York, York, N Yorkshire, England. [Mazorodze, Tasara T.] Automot Ind Dev Ctr Eastern Cape, Port Elizabeth, South Africa. [Mckay, Abigail C.] EmergentCorp, Belize City, Belize. [Meaney, Peter A.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Mehndiratta, Man Mohan] Janakpuri Superspecialty Hosp, New Delhi, India. [Meltzer, Michele] Thomas Jefferson Univ, Philadelphia, PA USA. [Mendoza, Walter] United Nations Populat Fund, Lima, Peru. [Meretoja, Atte] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland. [Mhimbira, Francis Apolinary] Ifakara Hlth Inst, Bagamoyo, Tanzania. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Miller, Ted R.] Curtin Univ, Ctr Populat Hlth, Perth, WA, Australia. [Mills, Edward J.] Univ Ottawa, Ottawa, ON, Canada. [Margolis, David J.; Silberberg, Donald H.] Univ Penn, Philadelphia, PA USA. [Mishra, Santosh] SNDT Womens Univ, Populat Educ Resource Ctr, Dept Continuing & Adult Educ & Extens, Bombay, Maharashtra, India. [Ibrahim, Norlinah Mohamed] Univ Kebangsaan Malaysia, Med Ctr, Dept Med, Bandar Tun Razak, Malaysia. [Mohammad, Karzan A.] Univ Salahaddin, Erbil, Iraq. [Mola, Glen L.] Univ Papua New Guinea, Boroko, Papua N Guinea. [Monasta, Lorenzo; Montico, Marcella; Ronfani, Luca] Inst Maternal & Child Hlth, IRCCS Burlo Garofolo, Trieste, Italy. [Moore, Ami R.] Univ N Texas, Denton, TX USA. [Morawska, Lidia] Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, Australia. [Norman, Rosana E.] Queensland Univ Technol, Inst Hlth Biomed Innovat, Brisbane, Qld, Australia. [Mori, Rintaro] Natl Ctr Child Hlth & Dev, Setagaya Ku, Tokyo, Japan. [Tsilimbaris, Miltiadis] Univ Crete, Dept Med, Iraklion, Greece. [Moschandreas, Joanna] Univ Crete, Iraklion, Greece. [Moturi, Wilkister N.] Egerton Univ, Egerton, Kenya. [Werdecker, Andrea] Competence Ctr Mortal Follow Up German Natl Cohor, Heidelberg, Germany. [Mueller, Ulrich O.; Westerman, Ronny] Fed Inst Populat Res, Wiesbaden, Germany. [Mukaigawara, Mitsuru] Okinawa Chubu Hosp, Okinawa, Japan. [Nahas, Ziad] Amer Univ Beirut, Med Ctr, Beirut, Lebanon. [Naidoo, Kovin S.] Univ KwaZulu Natal, Durban, South Africa. [Naldi, Luigi] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy. [Nand, Devina] Minist Hlth Fiji, Suva, Fiji. [Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India. [Neal, Bruce] George Inst Global Hlth, Sydney, NSW, Australia. [Nejjari, Chakib] Fac Med, Fes, Morocco. [Neupane, Sudan P.] Univ Oslo, Oslo, Norway. [Ngalesoni, Frida N.] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania. [Ngirabega, Jean de Dieu] East African Community Hlth Res Commiss, Kigali, Rwanda. [Nolla, Joan M.] Hosp Univ Bellvitge, Lhospitalet De Llobregat, Spain. [Nolte, Sandra] Deakin Univ, Melbourne, Vic, Australia. [Vollset, Stein Emil] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway. [Norheim, Ole F.] Univ Bergen, Bergen, Norway. [Norrving, Bo] Lund Univ, Dept Clin Sci, Lund, Sweden. [Nyakarahuka, Luke] Makerere Univ, Kampala, Uganda. [Oh, In-Hwan] Kyung Hee Univ, Seoul, South Korea. [Ohkubo, Takayoshi] Teikyo Univ, Sch Med, Tokyo, Japan. [Olusanya, Bolajoko O.] Ctr Hlth Start Initiat, Ikoyi, Nigeria. [Opio, John Nelson] Lira Municipal Council, Lira Dist Local Govt, Lira, Uganda. [Pagcatipunan, Rodolfo S., Jr.] United Lab Inc, Mandaluyong City, Philippines. [Pandian, Jeyaraj D.] Christian Med Coll Ludhiana, Ludhiana, Punjab, India. [Park, Eun-Kee] Kosin Univ, Coll Med, Busan, South Korea. [Stein, Dan J.] South African Med Res Council, Unit Anxiety & Stress Disorders, Cape Town, South Africa. [Parry, Charles D.] South African Med Res Council, Cape Town, South Africa. [Parry, Charles D.; Seedat, Soraya] Univ Stellenbosch, Cape Town, South Africa. [Stokic, Ljiljana Pejin] Econ Inst, Belgrade, Serbia. [Pereira, David M.] Univ Porto, REQUIMTE, Fac Farm, Dept Quim,Lab Farmacognosia, Oporto, Portugal. [Perez-Padilla, Rogelio] Natl Inst Resp Dis, Mexico City, DF, Mexico. [Perez-Ruiz, Fernando] Hosp Univ Cruces, OSI EE Cruces, Baracaldo, Spain. [Perez-Ruiz, Fernando] Biocruces Hlth Res Inst, Baracaldo, Spain. [Perico, Norberto; Remuzzi, Giuseppe; Trillini, Matias] IRCCS Mario Negri Inst Pharmacol Res, Bergamo, Italy. [Perry, Samuel A. L.] Washington State Dept Hlth, Kent, WA USA. [Pervaiz, Aslam] Postgrad Med Inst, Lahore, Pakistan. [Pesudovs, Konrad] Flinders Univ S Australia, Adelaide, SA, Australia. [Peterson, Carrie B.] Aalborg Univ, Aalborg Esst, Denmark. [Petzold, Max] Hlth Metr Unit, Gothenburg, Sweden. [Petzold, Max] Univ Witwatersrand, Johannesburg, South Africa. [Phillips, Michael R.] Emory Univ, Atlanta, GA USA. [Plass, Dietrich] Fed Environm Agcy, Sect Exposure Assessment & Environm Hlth Indicato, Berlin, Germany. [Poenaru, Dan] McGill Univ, Montreal Childrens Hosp, Montreal, PQ, Canada. [Poenaru, Dan] MyungSung Med Coll, Addis Ababa, Ethiopia. [Pond, Constance D.] Univ Newcastle, Callaghan, NSW 2308, Australia. [Pope, C. Arden] Brigham Young Univ, Provo, UT USA. [Popova, Svetlana; Rehm, Juergen] Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Prasad, Noela M.] Fred Hollows Fdn, Sydney, NSW, Australia. [Qato, Dima M.] Univ Illinois, Coll Pharm, Chicago, IL USA. [Rafay, Anwar; Rana, Saleem M.] Contech Int Hlth Consultants, Lahore, Pakistan. [Rafay, Anwar; Rana, Saleem M.] Contech Sch Publ Hlth, Lahore, Pakistan. [Rahman, Sajjad Ur] Hamad Med Corp, Doha, Qatar. [Raju, Murugesan] Univ Missouri, Columbia, MO USA. [Rakovac, Ivo] WHO Reg Off Europe, Copenhagen, Denmark. [Rao, Mayuree] Brown Univ, Warren Alpert Med Sch, Providence, RI USA. [Razavi, Homie] Ctr Dis Anal, Louisville, CO USA. [Refaat, Amany H.] Suez Canal Univ, Ismailia, Egypt. [Ribeiro, Antonio L.] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil. [Velasquez-Melendez, Gustavo] Univ Fed Minas Gerais, Escola Enfermagem, Belo Horizonte, MG, Brazil. [Riccio, Patricia M.; Sposato, Luciano A.] Univ Western Ontario, Dept Clin Neurol Sci, London Hlth Sci Ctr, London, ON, Canada. [Riederer, Anne] George Washington Univ, Washington, DC USA. [Roca, Anna] MRC Unit, Fajara, Gambia. [Rodriguez, Alina] Mid Sweden Univ, Stersund, Sweden. [Romieu, Isabelle; Straif, Kurt] WHO, IARC, Lyon, France. [Roy, Nobhojit] HBNI Univ, BARC Hosp, Bombay, Maharashtra, India. [Ruhago, George M.; Sunguya, Bruno F.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Miami, FL USA. [Saha, Sukanta] Pk Ctr Mental Hlth, Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia. [Sahathevan, Ramesh] Univ Kebangsaan Malaysia, Med Ctr, Kuala Lumpur, Malaysia. [Sahathevan, Ramesh] Calvary Healthcare Bruce, Canberra, ACT, Australia. [Sanabria, Juan R.] Case Western Reserve Univ, Cleveland, OH USA. [Sanabria, Juan R.] RFU Chicago Med Sch, Canc Treatment Ctr Amer, N Chicago, IL USA. [Sanchez-Riera, Lidia] Univ Zurich, Ctr Ageing & Mobil, Zurich, Switzerland. [Sanchez-Riera, Lidia] City Hosp Waid, Zurich, Switzerland. [Sapkota, Amir] Univ Maryland, Sch Publ Hlth, College Pk, MD USA. [Saunders, James E.] Dartmouth Coll, Dartmouth Hitchcock Med Ctr, Lebanon, NH USA. [Soneji, Samir] Dartmouth Coll, Lebanon, NH USA. [Sawhney, Monika] Marshall Univ, Huntington, WV USA. [Saylan, Mete I.] Novartis Turkey, Istanbul, Turkey. [Schneider, Ione J. C.] Univ Fed Santa Catarina, Florianopolis, SC, Brazil. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Serdar, Berrin] Univ Colorado, Aurora, CO USA. [Shaddick, Gavin] Univ Bath, Bath BA2 7AY, Avon, England. [Shangguan, Siyi] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Shinohara, Yukito] Tachikawa Hosp, Tokyo, Japan. [Shiri, Rahman] Univ Tampere, Sch Hlth Sci, Tampere, Finland. [Shishani, Kawkab] Washington State Univ, Spokane, WA USA. [Shiue, Ivy] Northumbria Univ, Hlth & Life Sci, Newcastle Upon Tyne, Tyne & Wear, England. [Shiue, Ivy] Univ Edinburgh, Alzheimer Scotland Dementia Res Ctr, Edinburgh, Midlothian, Scotland. [Sigfusdottir, Inga D.] Reykjavik Univ, Reykjavik, Iceland. [Singh, Abhishek] Int Inst Populat Sci, Bombay, Maharashtra, India. [Soreide, Kjetil] Stavanger Univ Hosp, Stavanger, Norway. [Sreeramareddy, Chandrashekhar T.] Univ Tunku Abdul Rahman, Fac Med & Hlth Sci, Kajang, Cheras, Malaysia. [Stapelberg, Nicolas J. C.] Griffith Univ, Southport, Qld, Australia. [Stathopoulou, Vasiliki] Attikon Univ Hosp, Athens, Greece. [Steckling, Nadine] Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, Munich, Germany. [Stroumpoulis, Konstantinos] Alexandra Gen Hosp Athens, Athens, Greece. [Stroumpoulis, Konstantinos] Ctr Hosp Publ Cotentin, Cherbourg, France. [Swaminathan, Soumya] Natl Inst Res TB, Madras, Tamil Nadu, India. [Swaroop, Mamta; Yano, Yuichiro] Northwestern Univ, Chicago, IL USA. [Sykes, Bryan L.] Univ Calif Irvine, Irvine, CA USA. [Tabb, Karen M.] Univ Illinois, Champaign, IL USA. [Talongwa, Roberto T.] Minist Hlth, MINSANTE, Yaounde, Cameroon. [Tanne, David] Chaim Sheba Med Ctr, Tel Hashomer, Israel. [Tanne, David] Tel Aviv Univ, Tel Hashomer, Israel. [Tavakkoli, Mohammad] Westchester Med Ctr, Valhalla, NY USA. [Terkawi, Abdullah S.] Outcomes Res Consortium, Cleveland, OH USA. [Terkawi, Abdullah S.] King Fahad Med City, Dept Anesthesiol, Riyadh, Saudi Arabia. [Thackway, Sarah V.] New South Wales Hlth, Sydney, NSW, Australia. [Thurston, George D.] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY USA. [Topouzis, Fotis] Aristotle Univ Thessaloniki, Thessaloniki, Greece. [Towbin, Jeff Rey A.] Bonheur Childrens Hosp, Memphis, TN USA. [Towbin, Jeff Rey A.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN USA. [Toyoshima, Hideaki] Anjo Kosei Hosp, Hlth Care Ctr, Anjo City, Japan. [Traebert, Jeff Erson] Univ Southern Santa Catarina, Palhoca, Brazil. [Tran, Bach X.] Hanoi Med Univ, Hanoi, Vietnam. [Trujillo, Ulises] Serv Canario Salud, Tenerife, Spain. [Dimbuene, Zacharie Tsala] Univ Kinshasa, Fac Econ & Management, Dept Populat Sci & Dev, Kinshasa, Zaire. [Tuzcu, Emin Murat] Cleveland Clin, Cleveland, OH USA. [Uchendu, Uche S.] Dept Vet Affairs, Washington, DC USA. [Ukwaja, Kingsley N.] Fed Teaching Hosp, Dept Internal Med, Abakaliki, Nigeria. [Van Dingenen, Rita] European Commiss, Joint Res Ctr, Ispra, Italy. [Van Gool, Coen H.] Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands. [Van Os, Jim] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Vasankari, Tommi J.] UKK Inst Hlth Promot Res, Tampere, Finland. [Vasconcelos, Ana Maria N.] Univ Brasilia, Brasilia, DF, Brazil. [Vijayakumar, Lakshmi] VHS SNEHA, Madras, Tamil Nadu, India. [Violante, Francesco S.] Univ Bologna, Bologna, Italy. [Vlassov, Vasiliy Victorovich] Higher Sch Econ, Moscow, Russia. [Wagner, Gregory R.] Natl Inst Occupat Safety & Hlth, Washington, DC USA. [Waller, Stephen G.] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA. [Wallin, Mitchell T.] Georgetown Univ, Dept Neurol, Arlington, VA USA. [Wallin, Mitchell T.] VA Med Ctr, Washington, DC USA. [Wang, Wenzhi] Beijing Neurosurg Inst, Beijing, Peoples R China. [Weintraub, Robert G.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Wessells, K. Ryan] Univ Calif Davis, Davis, CA USA. [Westerman, Ronny] German Natl Cohort Consortium, Heidelberg, Germany. [Wilkinson, James D.] Wayne State Univ, Detroit, MI USA. [Williams, Hywel C.] Univ Nottingham, Nottingham, England. [Woldeyohannes, Solomon M.] Univ Gondar, Inst Publ Hlth, Gondar, Ethiopia. [Wong, John Q.] Manila Univ, Ateneo Sch Med & Publ Hlth, Pasig, Philippines. [Woolf, Anthony D.] Royal Cornwall Hosp, Truro, Cornwall, England. [Xu, Gelin] Nanjing Univ, Sch Med, Jinling Hosp, Nanjing, Peoples R China. [Yan, Lijing L.] Duke Kunshan Univ, Kunshan, Peoples R China. [Yang, Gonghuan] Peking Union Med Coll, Beijing, Peoples R China. [Yano, Yuichiro] Jichi Med Sch, Tochigi, Japan. [Yip, Paul] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Yonemoto, Naohiro] Natl Ctr Neurol & Psychiat, Kodaira, Tokyo, Japan. [Younis, Mustafa Z.] Jackson State Univ, Jackson, MS USA. [Younoussi, Zourkaleini] Univ Niamey, Niamey, Niger. [Yu, Chuanhua] Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China. [Yu, Chuanhua] Wuhan Univ, Global Hlth Inst, Wuhan, Peoples R China. [Zaki, Maysaa E.] Mansoura Fac Med, Mansoura, Egypt. [Zhao, Yong] Chongqing Med Univ, Chongqing, Peoples R China. [Zhu, Shankuan] Zhejiang Univ, Sch Publ Hlth, Hangzhou, Peoples R China. RP Murray, CJ (reprint author), Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA. EM cjlm@uw.edu RI ; Alsharif, Ubai/C-6527-2017; Amini, Heresh/B-3076-2010; Lotufo, Paulo/A-9843-2008; Karch, Andre/D-6973-2017; Hedayati, Mohammad T./E-2304-2017; Scott, James/D-5900-2012; Franklin, Richard/H-1731-2012; Giussani, Giorgia/E-8057-2017; Ermakov, Sergey/G-1709-2016; Pereira, David/M-9286-2013; NORMAN, ROSANA/F-2774-2010; Kravchenko, Michael/B-2596-2012; Nolte, Sandra/B-7498-2008; Stein, Dan/A-1752-2008; Tonelli, Marcello/B-3028-2009; Lalloo, Ratilal/O-5624-2014; Tillmann, Taavi/R-6026-2016; Salomon, Joshua/D-3898-2009; Beyene, Tariku Jibat/A-6875-2017; Varakin, Yuriy/C-8634-2012; Brenner, Hermann/B-4627-2017; Majdan, Marek/K-5017-2012; Cardis, Elisabeth/C-3904-2017; Nieuwenhuijsen, Mark/C-3914-2017; Ferri, Cleusa/B-2922-2010; Devries, Karen/K-1083-2016; Jacobsen, Kathryn/B-5857-2008; LOGROSCINO, GIANCARLO/K-5148-2016; wang, YA XING/K-9671-2016; Ribeiro, Antonio/C-2707-2009; Hay, Simon/F-8967-2015; Naldi, Luigi/K-6343-2016; Thrift, Amanda/I-6251-2012; Weiderpass, Elisabete/M-4029-2016; Dokova, Klara/N-2448-2016; Montico, Marcella/B-5290-2013; Parry, Charles/A-2906-2009; Haro, Josep Maria/D-1423-2011; Degenhardt, Louisa/D-4515-2012; Martin, Randall/C-1205-2014; Hankey, Graeme /H-4968-2014; Kaul, Anil/B-2075-2016; Rakovac, Ivo/A-7678-2013; Fra.Paleo, Urbano/B-8088-2016; Monasta, Lorenzo/B-1388-2012; Sepanlou, Sadaf/H-9343-2016; Banerjee, Amitava/D-4381-2014; Charlson, Fiona/F-5290-2011; Patten, Scott/B-4434-2011 OI Norheim, Ole F./0000-0002-5748-5956; Hoek, Hans/0000-0001-6353-5465; Castaneda-Orjuela, Carlos/0000-0002-8735-6223; Aburto, Tania/0000-0002-6932-9344; Bernabe, Eduardo/0000-0002-1858-3713; Derrett, Sarah/0000-0003-2867-0498; London, Stephanie/0000-0003-4911-5290; Santos, Itamar/0000-0003-3212-8466; Erskine, Holly/0000-0003-3119-9211; Aboyans, Victor/0000-0002-0322-9818; Gouda, Hebe/0000-0002-5709-4509; Chen, Honglei/0000-0003-3446-7779; Perez-Ruiz, Fernando/0000-0002-5268-1894; Kissela, Brett/0000-0002-9773-4013; Catala-Lopez, Ferran/0000-0002-3833-9312; Broday, David/0000-0002-6525-3979; Alsharif, Ubai/0000-0002-4024-3950; Amini, Heresh/0000-0002-4825-1322; Lotufo, Paulo/0000-0002-4856-8450; Karch, Andre/0000-0003-3014-8543; Hedayati, Mohammad T./0000-0001-6415-4648; Scott, James/0000-0002-0744-0688; Franklin, Richard/0000-0003-1864-4552; Ermakov, Sergey/0000-0003-1072-1162; Pereira, David/0000-0003-0384-7592; NORMAN, ROSANA/0000-0002-9742-1957; Leung, Ricky/0000-0002-2852-6771; Kieling, Christian/0000-0001-7691-4149; Sindi, Shireen/0000-0002-3786-0552; Gething, Peter/0000-0001-6759-5449; Husseini, Abdullatif/0000-0001-8767-5956; Benjet, Corina/0000-0002-4569-6094; Gabbe, Belinda/0000-0001-7096-7688; Prabhakaran, Dorairaj/0000-0002-3172-834X; Neupane, Sudan Prasad/0000-0002-7389-4178; Khang, Young-Ho/0000-0002-9585-8266; Kemp, Andrew/0000-0003-1146-3791; Xu, Gelin/0000-0002-6194-0341; Goto, Atsushi/0000-0003-0669-654X; Soshnikov, Sergey/0000-0002-6983-7066; assadi, reza/0000-0002-5016-2994; Vlassov, Vasiliy/0000-0001-5203-549X; Soreide, Kjetil/0000-0001-7594-4354; Villalpando, Salvador/0000-0001-6429-3816; Borges, Guilherme/0000-0002-3269-0507; Miller, Ted/0000-0002-0958-2639; Giussani, Giorgia/0000-0003-2460-3095; Balakrishnan, Kalpana/0000-0002-5905-1801; Newton, Charles/0000-0002-6999-5507; Mhimbira, Francis/0000-0001-8989-6832; Heredia-Pi, Ileana Beatriz/0000-0002-9998-9239; Sreeramareddy, Chandrashekhar/0000-0002-5693-7631; Kravchenko, Michael/0000-0001-5187-5518; Nolte, Sandra/0000-0001-6185-9423; Stein, Dan/0000-0001-7218-7810; Lalloo, Ratilal/0000-0001-5822-1269; Tillmann, Taavi/0000-0002-8428-3719; Salomon, Joshua/0000-0003-3929-5515; Beyene, Tariku Jibat/0000-0002-7474-1966; Brenner, Hermann/0000-0002-6129-1572; Majdan, Marek/0000-0001-8037-742X; Nieuwenhuijsen, Mark/0000-0001-9461-7981; Ferri, Cleusa/0000-0002-1815-7685; Devries, Karen/0000-0001-8935-2181; Jacobsen, Kathryn/0000-0002-4198-6246; LOGROSCINO, GIANCARLO/0000-0003-0423-3242; wang, YA XING/0000-0003-2749-7793; Ribeiro, Antonio/0000-0002-2740-0042; Hay, Simon/0000-0002-0611-7272; Naldi, Luigi/0000-0002-3160-2835; Thrift, Amanda/0000-0001-8533-4170; Weiderpass, Elisabete/0000-0003-2237-0128; Montico, Marcella/0000-0003-0377-8232; Parry, Charles/0000-0001-9787-2785; Haro, Josep Maria/0000-0002-3984-277X; Degenhardt, Louisa/0000-0002-8513-2218; Martin, Randall/0000-0003-2632-8402; Hankey, Graeme /0000-0002-6044-7328; Rakovac, Ivo/0000-0003-3462-2636; Fra.Paleo, Urbano/0000-0001-6192-7684; Monasta, Lorenzo/0000-0001-7774-548X; Sepanlou, Sadaf/0000-0002-3669-5129; Banerjee, Amitava/0000-0001-8741-3411; Charlson, Fiona/0000-0003-2876-5040; Patten, Scott/0000-0001-9871-4041; Olusanya, Bolajoko/0000-0002-3826-0583; Goenka, Shifalika/0000-0001-6993-2883; Quezada, Amado David/0000-0003-3258-8198; Heydarpour, Pouria/0000-0001-5644-7555; Moradi-Lakeh, Maziar/0000-0001-7381-5305; Stockl, Heidi/0000-0002-0907-8483; Vlassov, Valentin/0000-0003-2845-2992; Davis, Adrian/0000-0001-7134-7528; Paternina-Caicedo, Angel/0000-0002-6332-5174; Leasher, Janet/0000-0002-8779-5162; Hu, Howard/0000-0002-3676-2707 FU Bill AMP; Melinda Gates Foundation FX Funding Bill & Melinda Gates Foundation. NR 86 TC 266 Z9 283 U1 170 U2 369 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD DEC 5 PY 2015 VL 386 IS 10010 BP 2287 EP 2323 DI 10.1016/S0140-6736(15)00128-2 PG 37 WC Medicine, General & Internal SC General & Internal Medicine GA CX8ZB UT WOS:000365993200031 ER PT J AU Carey, A Cleary, MM Edwards, DK Eide, CA Traer, E McWeeney, SK Tyner, JW Bagby, GC Druker, BJ Agarwal, A AF Carey, Alyssa Cleary, Megan M. Edwards, David K. Eide, Christopher A. Traer, Elie McWeeney, Shannon K. Tyner, Jeffrey W. Bagby, Grover C. Druker, Brian J. Agarwal, Anupriya TI The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Carey, Alyssa; Cleary, Megan M.; Eide, Christopher A.; Traer, Elie; Bagby, Grover C.; Druker, Brian J.; Agarwal, Anupriya] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA. [Edwards, David K.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Eide, Christopher A.; Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA. [McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Bioinformat & Computat Biol, Portland, OR 97201 USA. [Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019002303 ER PT J AU Chin, D Kutny, MA Grim, J Gerbing, RB Miller, K Farrar, JE Auvil, JMG Smith, MA Gerhard, DS Davidsen, TM Gesuwan, P Hermida, LC Marra, MA Mungall, AJ Moore, R Long, W Ma, Y Zong, S Kolb, EA Gamis, AS Alonzo, TA Meshinchi, S AF Chin, Diana Kutny, Matthew A. Grim, Jonathan Gerbing, Robert B. Miller, Kristen Farrar, Jason E. Auvil, Jaime M. Guidry Smith, Malcolm A. Gerhard, Daniela S. Davidsen, Tanja M. Gesuwan, Patee Hermida, Leandro C. Marra, Marco A. Mungall, Andrew J. Moore, Richard Long, William Ma, Yussanne Zong, Stuart Kolb, E. Anders Gamis, Alan S. Alonzo, Todd A. Meshinchi, Soheil TI Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Chin, Diana; Miller, Kristen; Meshinchi, Soheil] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Kutny, Matthew A.] Univ Alabama Birmingham, Dept Pediat, Div Hematol Oncol, Birmingham, AL USA. [Grim, Jonathan] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Gerbing, Robert B.] Childrens Oncol Grp, Monrovia, CA USA. [Farrar, Jason E.] Univ Arkansas Med Sci, Dept Pediat, Hematol Oncol Sect, Little Rock, AR 72205 USA. [Auvil, Jaime M. Guidry; Gerhard, Daniela S.; Davidsen, Tanja M.; Gesuwan, Patee; Hermida, Leandro C.] NCI, Off Canc Genom, Bethesda, MD 20892 USA. [Smith, Malcolm A.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Marra, Marco A.; Moore, Richard] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada. [Mungall, Andrew J.; Long, William; Ma, Yussanne; Zong, Stuart] British Columbia Canc Agcy, Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada. [Kolb, E. Anders] Alfred I duPont Hosp Children, Nemours Ctr Canc & Blood Disorders, Wilmington, DE USA. [Gamis, Alan S.] Childrens Mercy Hosp & Clin, Div Hematol Oncol Bone Marrow Transplantat, Kansas City, MO USA. [Alonzo, Todd A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019000234 ER PT J AU Newell, LF Holtan, SG Rosenzweig, J Yates, J Garbati, M Rathbun, RK Keeble, W Tyner, JW Burd, I Bagby, GC AF Newell, Laura F. Holtan, Shernan G. Rosenzweig, Jason Yates, Jane Garbati, Michael Rathbun, R. K. Keeble, Winifred Tyner, Jeffrey W. Burd, Irina Bagby, Grover C. TI Placental Growth Factor Enhances Toll-like Receptor-Induced Inflammatory Cytokine Gene Expression Transcriptionally in Human Mononuclear Phagocytes SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Newell, Laura F.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Holtan, Shernan G.] Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA. [Rosenzweig, Jason; Burd, Irina] Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD USA. [Yates, Jane; Garbati, Michael; Rathbun, R. K.; Keeble, Winifred] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Yates, Jane] Portland VA Med Ctr, Portland, OR USA. [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA. [Bagby, Grover C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003130 ER PT J AU Shatzel, J Azar, S Gay, ND Luo, J Deloughery, TG Recht, M Taylor, JA AF Shatzel, Joseph Azar, Sharl Gay, Nathanael David Luo, Jai Deloughery, Thomas G. Recht, Michael Taylor, Jason A. TI The Clinical Associations and Outcomes of Patients Admitted with Acquired Hemophilia; A Review of the 2012 National Inpatient Sample SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Shatzel, Joseph] Oregon Hlth & Sci Univ, Dept Hematol Oncol, Portland, OR 97201 USA. [Azar, Sharl; Recht, Michael; Taylor, Jason A.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Azar, Sharl] Portland VA Med Ctr, Portland, OR USA. [Gay, Nathanael David; Deloughery, Thomas G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Luo, Jai] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XN UT WOS:000368019003215 ER PT J AU Callander, NS Freytes, CO Luo, SH Carson, KR AF Callander, Natalie Scott Freytes, Cesar O. Luo, Suhong Carson, Kenneth R. TI Previous Agent Orange Exposure Is Correlated with Worse Outcome in Patients with Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Callander, Natalie Scott] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Callander, Natalie Scott] Williams S Middleton Mem Vet Hosp, Madison, WI USA. [Freytes, Cesar O.] Audie L Murphy Mem Vet Adm Med Ctr, Med, San Antonio, TX 78284 USA. [Luo, Suhong; Carson, Kenneth R.] St Louis Vet Adm Med Ctr, Res Serv, St Louis, MO USA. [Carson, Kenneth R.] Washington Univ, Sch Med, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 2 WC Hematology SC Hematology GA DA7YP UT WOS:000368021801136 ER PT J AU Qiu, HY Sandmaier, BM Storer, BE Chauncey, T Petersen, F Pulsipher, MA Bruno, B Flowers, M Mielcarek, M Storb, R Maloney, DG AF Qiu, Huiying Sandmaier, Brenda M. Storer, Barry E. Chauncey, Thomas Petersen, Finn Pulsipher, Michael A. Bruno, Benedetto Flowers, Mary Mielcarek, Marco Storb, Rainer Maloney, David G. TI A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience SO BLOOD LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2015 CL Orlando, FL SP Amer Soc Hematol C1 [Qiu, Huiying; Sandmaier, Brenda M.; Flowers, Mary; Mielcarek, Marco; Storb, Rainer] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Sandmaier, Brenda M.; Storer, Barry E.; Chauncey, Thomas; Flowers, Mary; Mielcarek, Marco; Storb, Rainer] Univ Washington, Seattle, WA 98195 USA. [Storer, Barry E.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Petersen, Finn] LDS Hosp, Salt Lake City, UT USA. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Pulsipher, Michael A.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Maloney, David G.] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD DEC 3 PY 2015 VL 126 IS 23 PG 3 WC Hematology SC Hematology GA DA7XY UT WOS:000368020100114 ER PT J AU Kwoh, CK Vina, ER Cloonan, YK Hannon, MJ Boudreau, RM Ibrahim, SA AF Kwoh, C. Kent Vina, Ernest R. Cloonan, Yona K. Hannon, Michael J. Boudreau, Robert M. Ibrahim, Said A. TI Determinants of patient preferences for total knee replacement: African-Americans and whites SO ARTHRITIS RESEARCH & THERAPY LA English DT Article DE Osteoarthritis; Knee replacement surgery; Race; Health disparity; Treatment preference ID TOTAL JOINT ARTHROPLASTY; RACIAL-DIFFERENCES; ETHNIC-DIFFERENCES; SOCIAL SUPPORT; UNITED-STATES; OSTEOARTHRITIS; HIP; ARTHRITIS; WILLINGNESS; SURGERY AB Introduction: Patient preferences contribute to marked racial disparities in the utilization of total knee replacement (TKR). The objectives of this study were to identify the determinants of knee osteoarthritis (OA) patients' preferences regarding TKR by race and to identify the variables that may mediate racial differences in willingness to undergo TKR. Methods: Five hundred fourteen White (WH) and 285 African-American (AA) patients with chronic knee pain and radiographic evidence of OA participated in the study. Participants were recruited from the community, an academic medical center, and a Veterans Affairs hospital. Structured interviews were conducted to collect socio-demographics, disease severity, socio-cultural determinants, and treatment preferences. Logistic regression was performed, stratified by race, to identify determinants of preferences. Clinical and socio-cultural factors were entered simultaneously into the models. Stepwise selection identified factors for inclusion in the final models (p < 0.20). Results: Compared to WHs, AAs were less willing to undergo TKR (80 % vs. 62 %, respectively). Better expectations regarding TKR surgery outcomes determined willingness to undergo surgery in both AAs (odds ratio (OR) 2.08, 95 % confidence interval (CI) 0.91-4.79 for 4th vs. 1st quartile) and WHs (OR 5.11, 95 % CI 2.31-11.30 for 4th vs. 1st quartile). Among AAs, better understanding of the procedure (OR 1.80, 95 % CI 0.97-3.35), perceiving a short hospital course (OR 0.81, 95 % CI 0.58-1.13), and believing in less post-surgical pain (OR 0.73, 95 % CI 0.39-1.35) and walking difficulties (OR 0.66, 95 % CI 0.37-1.16) also determined willingness. Among WHs, having surgical discussion with a physician (OR 1.96, 95 % CI 1.05-3.68), not ever receiving surgical referral (OR 0.56, 95 % CI 0.32-0.99), and higher trust in the healthcare system (OR 1.58, 95 % CI 0.75-3.31 for 4th vs. 1st quartile) additionally determined willingness. Among the variables considered, only knowledge-related matters pertaining to TKR attenuated the racial difference in knee OA patients' treatment preference. Conclusions: Expectations of surgical outcomes influence preference for TKR in all patients, but clinical and socio-cultural factors exist that shape marked racial differences in preferences for TKR. Interventions to reduce or eliminate racial disparities in the utilization of TKR should consider and target these factors. C1 [Kwoh, C. Kent; Vina, Ernest R.] Univ Arizona, Sch Med, Tucson, AZ 85724 USA. [Kwoh, C. Kent; Vina, Ernest R.] Univ Arizona, Arthrit Ctr, Tucson, AZ 85724 USA. [Cloonan, Yona K.; Boudreau, Robert M.] Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Hannon, Michael J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Ibrahim, Said A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Ibrahim, Said A.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Kwoh, CK (reprint author), Univ Arizona, Sch Med, 1501 N Campbell Ave,POB 245093, Tucson, AZ 85724 USA. EM CKwoh@arthritis.arizona.edu OI Boudreau, Robert/0000-0003-0162-5187; Cloonan, Yona/0000-0003-3893-3693; Vina, Ernest/0000-0001-8135-1731 FU NIH/National Institute of Arthritis and Musculoskeletal Skin Diseases [P60-AR-054731]; K24 Mid-Career Development Award from the National Institute of Arthritis and Musculoskeletal and Skin Disorders [K24AR055259] FX This study was supported by the NIH/National Institute of Arthritis and Musculoskeletal Skin Diseases (Grant P60-AR-054731). Dr. Ibrahim is supported in part by a K24 Mid-Career Development Award from the National Institute of Arthritis and Musculoskeletal and Skin Disorders (K24AR055259). NR 44 TC 4 Z9 4 U1 4 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD DEC 3 PY 2015 VL 17 AR 348 DI 10.1186/s13075-015-0864-2 PG 11 WC Rheumatology SC Rheumatology GA CX3YJ UT WOS:000365635100001 PM 26635132 ER PT J AU Hanlon, CA Dowdle, LT Austelle, CW DeVries, W Mithoefer, O Badran, BW George, MS AF Hanlon, Colleen A. Dowdle, Logan T. Austelle, Christopher W. DeVries, William Mithoefer, Oliver Badran, Bashar W. George, Mark S. TI What goes up, can come down: Novel brain stimulation paradigms may attenuate craving and craving-related neural circuitry in substance dependent individuals SO BRAIN RESEARCH LA English DT Article DE Brain stimulation; Functional MRI; Orbitofrontal cortex; BA 10; Caudate ID TRANSCRANIAL MAGNETIC STIMULATION; MEDIAL PREFRONTAL CORTEX; HUMAN MOTOR CORTEX; HF-RTMS SESSION; SYNAPTIC PLASTICITY; COCAINE DEPENDENCE; ALCOHOL DEPENDENCE; CIGARETTE-SMOKING; BASAL GANGLIA; ADDICTION AB Vulnerability to drug related cues is one of the leading causes for continued use and relapse among substance dependent individuals. Using drugs in the face of cues may be associated with dysfunction in at least two frontal-striatal neural circuits: (1) elevated activity in medial and ventral areas that govern limbic arousal (including the medial prefrontal cortex (MPFC) and ventral striatum) or (2) depressed activity in dorsal and lateral areas that govern cognitive control (including the dorsolateral prefrontal cortex (DLPFC) and dorsal striatum): Transcranial magnetic stimulation (TMS) is emerging as a promising new tool for the attenuation of craving among multiple substance dependent populations. To date however, nearly all repetitive TMS studies in addiction have focused on amplifying activity in frontal-striatal circuits that govern cognitive control. This manuscript reviews recent work using TMS as a tool to decrease craving for multiple substances and provides a theoretical model for how clinical researchers might approach target and frequency selection for TMS of addiction. To buttress this model, preliminary data from a single-blind, sham-controlled, crossover study of 11 cocaine-dependent individuals is also presented. These results suggest that attenuating MPFC activity through theta burst stimulation decreases activity in the striatum and anterior insula. It is also more likely to attenuate craving than sham TMS. Hence, while many TMS studies are focused on applying LTP-like stimulation to the DLPFC, the MPFC might be a new, efficacious, and treatable target for craving in cocaine dependent individuals. This article is part of a Special Issue entitled SI:Addiction circuits. (C) 2015 Published by Elsevier B.V. C1 [Hanlon, Colleen A.; Dowdle, Logan T.; Austelle, Christopher W.; DeVries, William; Mithoefer, Oliver; Badran, Bashar W.; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Hanlon, Colleen A.; Dowdle, Logan T.; Badran, Bashar W.; George, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC USA. [Hanlon, Colleen A.; George, Mark S.] Med Univ S Carolina, Ctr Biomed Imaging, Charleston, SC USA. [George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Hanlon, CA (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. EM hanlon@musc.edu OI Dowdle, Logan/0000-0002-1879-705X FU NIH [K01DA027756, R01DA036617, P50 DA015369, P50 AA010761] FX This effort was funded directly by NIH Grants K01DA027756 (Hanlon), R01DA036617 (Hanlon), P50 DA015369 (Kalivas), P50 AA010761 (Becker). Additional assistance was given by the South Carolina Translational Research Institute UL1 TR000062 and R25 DA033680. The authors would also like to acknowledge the Neuroscience Institute at the Medical University of South Carolina, the Neurobiology of Addiction Research Center, the Center for Biomedical Imaging, Truman R. Brown, Jayce Doose, James Purl, Melanie Canterberry, and Kathleen Brady, all of whom provided intellectual support and resources for this endeavor. NR 65 TC 9 Z9 9 U1 1 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD DEC 2 PY 2015 VL 1628 SI SI BP 199 EP 209 DI 10.1016/j.brainres.2015.02.053 PN A PG 11 WC Neurosciences SC Neurosciences & Neurology GA CZ9IV UT WOS:000367412200018 PM 25770818 ER PT J AU Vuong, HE Hardi, CN Barnes, S Brecha, NC AF Vuong, Helen E. Hardi, Claudia N. Barnes, Steven Brecha, Nicholas C. TI Parallel Inhibition of Dopamine Amacrine Cells and Intrinsically Photosensitive Retinal Ganglion Cells in a Non-Image-Forming Visual Circuit of the Mouse Retina SO JOURNAL OF NEUROSCIENCE LA English DT Article DE amacrine cells; dopamine; interneuron; melanopsin ipRGCs; microcircuit; somatostatin ID SUBTYPE 2A EXPRESSION; ROD BIPOLAR CELLS; CONE PHOTORECEPTORS; MAMMALIAN RETINA; RABBIT RETINA; RAT RETINA; RECEPTOR ACTIVATION; CALCIUM-CHANNELS; MELANOPSIN CELLS; CIRCADIAN CLOCK AB An inner retinal microcircuit composed of dopamine (DA)-containing amacrine cells and melanopsin-containing, intrinsically photosensitive retinal ganglion cells (M1 ipRGCs) process information about the duration and intensity of light exposures, mediating light adaptation, circadian entrainment, pupillary reflexes, and other aspects of non-image-forming vision. The neural interaction is reciprocal: M1 ipRGCs excite DA amacrine cells, and these, in turn, feed inhibition back onto M1 ipRGCs. We found that the neuropeptide somatostatin [somatotropin release inhibiting factor (SRIF)] also inhibits the intrinsic light response of M1 ipRGCs and postulated that, to tune the bidirectional interaction of M1 ipRGCs and DA amacrine cells, SRIF amacrine cells would provide inhibitory modulation to both cell types. SRIF amacrine cells, DA amacrine cells, and M1 ipRGCs form numerous contacts. DA amacrine cells and M1 ipRGCs express the SRIF receptor subtypes sst(2A) and sst(4) respectively. SRIF modulation of the microcircuit was investigated with targeted patch-clamp recordings of DA amacrine cells in TH-RFP mice and M1